AD-A181 766

AD



IITRI Project No. L6:21 Study No. 7


DETERMINATION OF THE CHRONIC MAMMALIAN TOXICOLOGICAL EFFECTS OF RDX

Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) in the B6C3F1 Hybrid Mouse

Final Report Phase VI, Vol. 1

Paul M. Lish Barry S. Levine E. Marianna Furedi John M. Sagartz Vladislava S. Rac

April 1984



U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND Fort Detrick, Frederick, MD 21701-5012

> DAMD17-79-C-9161 Contract No.

> > IIT Research Institute 10 West 35th Street Chicago, IL 60616

Project Officer: Jesse J. Barkley, Jr. U.S. Army Medical Bioengineering Research and Development Laboratory Bldg. 568, Ft. Detrick Frederick, Maryland 21701-5010

DOD DISTRIBUTION STATEMENT

Approved for public release; distribution unlimited

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

DISCLAIMER NOTICE

THIS DOCUMENT IS BEST QUALITY
PRACTICABLE. THE COPY FURNISHED
TO DTIC CONTAINED A SIGNIFICANT
NUMBER OF PAGES WHICH DO NOT
REPRODUCE LEGIBLY.

Inclassified SECURITY CLASSIFICATION AUTHORITY DECLASSIFICATION / DOWNGRADING SCHEDULE PERFORMING ORGANIZATION REPORT NUMBER(S) IITRI Project No. L6121 NAME OF PERFORMING ORGANIZATION ADDRESS (Giry, State, and ZiP Code) 10 West 35th Street Chicago, Illinois 60616 NAME OF FUNDING / SPONSORING ORGANIZATION & B. Army Medical Research & Development Command ADDRESS (Giry, State, and ZiP Code) Fort Detrick Frederick, Maryland 21701-5012 NITLE (Include Security Classification) Determination of the Chronic Nammalian Toxicological Effects of RDX P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac In J. W. Sagartz, V.S. Rac In J. W. Sagartz, V.S. Rac In J. D. RESTRICTIVE MARKINGS Approved for public release; distribution unlimited Approved for public release; distribution unlimited Approved for public release; distribution unlimited For Monitoring Organization Report Number(S) 7b. MONITORING ORGANIZATION REPORT NUMBER(S) 7b. ADDRESS (City, State, and ZiP Code) 10 West 35th Street Chicago, Illinois 60616 NAME OF FUNDING INSTRUMENT IDENTIFICATION NUMBERS FOR DAMPINATION NUMBERS FOR DAMPINATION NUMBERS FOR DAMPINATION PROJECT IN SOURCE OF FUNDING NUMBERS FROM PROJECT EMBIL (Include Security Classification) Determination of the Chronic Nammalian Toxicological Effects of RDX P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac In J. Date Of REPORT (Year, Month, Day) 15. PAGE CO 16. SUPPLEMENTARY NOTATION Subtitle: Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Hexahydro— Triazine (RDX) in the 1623F1 17. COSAH CODES 18 MUBBERT TERMS (Continue on reverse if necessary and identify by block of FIELD GROUP SUB-GROUP SUB-G	BER WORK UNIT
DECLASSIFICATION AUTHORITY DECLASSIFICATION / DOWNGRADING SCHEDULE PERFORMING ORGANIZATION REPORT NUMBER(S) IITRI Project No. L6121 Description in Institute S. MONITORING ORGANIZATION REPORT NUMBER(S) IITRI Project No. L6121 Description in Institute S. MONITORING ORGANIZATION REPORT NUMBER(S) IITRI Project No. L6121 Description in Institute S. MONITORING ORGANIZATION REPORT NUMBER(S) J. NAME OF PERFORMING ORGANIZATION IIT Research Institute S. ADDRESS (City, State, and ZIP Code) J. West 35th Street Chicago, Illinois 60616 Description in Institute S. ADDRESS (City, State, and ZIP Code) J. MAME OF FUNDING / SPONSORING ORGANIZATION J. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012 Determination of the Chronic Mammalian Toxicological Effects of RDX J. HITLE (Include Security Classification) Determination of the Chronic Mammalian Toxicological Effects of RDX J. HISH, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac J. TYPE OF REPORT J. DECLASSIFICATION / ADDRESS (City, State, and ZIP Code) J. HILLE (Include Security Classification) Determination of the Chronic Mammalian Toxicological Effects of RDX J. PERSONAL AUTHOR(S) P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac J. DESCRIPTION / ADDRESS (City, State, and ZIP Code) J. HILLE (Include Security Classification) Determination of the Chronic Mammalian Toxicological Effects of RDX J. PERSONAL AUTHOR(S) P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac J. DETERMINED (PROME TO A A A A DATE OF REPORT (Year, Month, Day) J. PAGE CO A A DATE OF REPORT (Year, Month, Day) J. SUPPLEMENTARY NOTATION Subtitle: Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Hexahydro—Triazinc (RDX) in the Majest Terms (Continue on reverse if necessary and identify by block of FIELD GROUP SUB-GROUP SUB-GROUP Chronic toxicity	WORK UNIT ACCESSION NO
Approved for public release; distribution unlimited PERFORMING ORGANIZATION REPORT NUMBER(S) IITRI Project No. L6121 3. NAME OF PERFORMING ORGANIZATION IIT Research Institute C. ADCRESS (Giy, State, and ZIP Code) 10 West 35th Street Chicago, Illinois 60616 3. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command C. ADDRESS (Giy, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012 Determination of the Chronic Nammalian Toxicological Effects of RDX 2. PERSONAL AUTHOR(S) P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac 3a. TYPE OF REPORT 13b TIME COVERED 1- SUPPLEMENTARY NOTATION Subtitle: Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Hexahydro- Triazine (RDX) in the R63F1 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block in fifted GROUP Sub-GROUP RNX GAS PRES. No. 121-82-9 Chronic toxicity 1- Chronic toxicity 1- Contract No. DAMD17-79-C-9161 1- COSATI CODES 1- SUPPLEMENTARY NOTATION 1- SUPPLEMENTARY NOTATION 1- SUBJECT TERMS (Continue on reverse if necessary and identify by block in fifted GROUP Sub-GROUP RNX GAS PRES. No. 121-82-9 Chronic toxicity	WORK UNIT ACCESSION NO
PERFORMING ORGANIZATION REPORT NUMBER(S) IITRI Project No. L6121 3. NAME OF PERFORMING ORGANIZATION IIT Research Institute C. ADDRESS (City, State, and ZIP Code) 10 West 35th Street Chicago, Illinois 60616 3. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command C. ADDRESS (City, State, and ZIP Code) 10. SOURCE OF FUNDING NUMBERS Fort Detrick Frederick, Maryland 21701-5012 10. SOURCE OF FUNDING NUMBERS PROGRAM PROJECT FROM FROJECT FROM FROJECT TASK NO Determination of the Chronic Nammalian Toxicological Effects of RDX 2. PERSONAL AUTHOR(S) P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac 14. DATE OF REPORT 15. PAGE CO 368 16. SUPPLEMENTARY NOTATION Subtitle: Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Hexahydro- Triazine (RDX) in the R623F1 17. COSATI CODES 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block in the Chronic toxicity RDN GAS Reg. No. 121-82-9 Chronic toxicity	WORK UNIT ACCESSION NO
IITRI Project No. L6121 J. NAME OF PERFORMING ORGANIZATION IIT Research Institute C. ADDRESS (City, State, and ZIP Code) 10 West 35th Street Chicago, Illinois 60616 J. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command C. ADDRESS (City, State, and ZIP Code) 10. SOURCE OF FUNDING NUMBERS Fort Detrick Frederick, Maryland 21701-5012 10. SOURCE OF FUNDING NUMBERS FROGRAM FROJECT ELEMENT NO. Determination of the Chronic Mammalian Toxicological Effects of RDX 10. FILLE (Include Security Classification) Determination of the Chronic Mammalian Toxicological Effects of RDX 2. PERSONAL AUTHOR(S) P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac Ja. Type OF REPORT 13b TIME COVERED FROM 2/81 15 SUPPLEMENTARY NOTATION Subtitle: Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Hexahydro- Triazine (RDX) in the RACSF1 18 MUBIECT TERMS (Continue on reverse if necessary and identify by block of the proper in the p	WORK UNIT ACCESSION NO
ADDRESS (City, State, and ZIP Code) 10 West 35th Street Chicago, Illinois 60616 3. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command 3. ADDRESS (City, State, and ZIP Code) 4. ADDRESS (City, State, and ZIP Code) 5. ADDRESS (City, State, and ZIP Code) 6. OFFICE SYMBOL (If applicable) 7. ADDRESS (City, State, and ZIP Code) 7. ADDRESS (City, State, and ZIP Code) 8. OFFICE SYMBOL (If applicable) 8. OFFICE SYMBOL (If applicable) 9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMB Contract No. DAMD17-79-C-9161 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. 3E1- FORD FORD FORD FORD FORD FORD FORD FORD	WORK UNIT ACCESSION NO
IIT Research Institute ADDRESS (City, State, and ZIP Code) 10 West 35th Street Chicago, Illinois 60616 a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command C. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012 10. SUPERSONAL AUTHOR(S) P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac 3a. TYPE OF REPORT 13b TIME COVERED 11c, Supplementary Notation Subtitle: Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Hexahydro-Triazine (RDX) in the ROSF1 17. COSATI CODES 18 UBBECT TERMS (Continue on reverse if necessary and identify by block of RDX) CASP Reg. No. 121-82-9 Chronic toxicity TELD GROUP SUB-GROUP RDX, CASP Reg. No. 121-82-9 Chronic toxicity	WORK UNIT ACCESSION NO
ADDRESS (City, State, and ZIP Code) 10 West 35th Street Chicago, Illinois 60616 3. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command C. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. PROJECT NO. 3E1- Frederick, Maryland 21701-5012 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. Frederick, Maryland 21701-5012 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. SE1- FROM 2/81 TASK NO. A A A A A A A A A A A A A A A A A A A	WORK UNIT ACCESSION NO
10 West 35th Street Chicago, Illinois 60616 a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command c. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. 3E1- FORT Detrick Frederick, Maryland 21701-5012 11. TITLE (Include Security Classification) Determination of the Chronic Mammalian Toxicological Effects of RDX 2. PERSONAL AUTHOR(S) P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac 13a. TYPE OF REPORT 13b TIME COVERED 11c SUPPLEMENTARY NOTATION Subtitle: Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Hexahydro- Triazine (RDX) in the Manual Continue on reverse if necessary and identify by block of the page	WORK UNIT ACCESSION NO
Chicago, Illinois 60616 3. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command Contract No. DAMD17-79-C-9161 C. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012 Determination of the Chronic Nammalian Toxicological Effects of RDX 2. PERSONAL AUTHOR(S) P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac 3a. TYPE OF REPORT 13b. TIME (COVERED 1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1	WORK UNIT ACCESSION NO
ANAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command C. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012 Determination of the Chronic Mammalian Toxicological Effects of RDX P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac 13a. TYPE OF REPORT 13b. TIME COVERED FROM 2/81 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. 3E1- 62720A 62720A 62720A835 00 11. TITLE (Include Security Classification) Determination of the Chronic Mammalian Toxicological Effects of RDX 2. PERSONAL AUTHOR(S) P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac 13a. TYPE OF REPORT 13b. TIME COVERED FROM 2/81 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. 3E1- NO. 3E1- NO. 3E1- NO. 3E1- NO. 3E1- NO. 4A A A A A A A A A A A A A A A A A A A	WORK UNIT ACCESSION NO
ORGANIZATION U.S. Army Medical Research & Development Command Contract No. DAMD17-79-C-9161 C. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012 Determination of the Chronic Mammalian Toxicological Effects of RDX 2. PERSONAL AUTHOR(S) P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac 3a. TYPE OF REPORT 13b TIME COVERED FROM 2/81 TO 4/84 14. DATE OF REPORT (Year, Month, Day) 15. PAGE CO 2 inal, Phase VI. Vol.1 6. SUPPLEMENTARY NOTATION Subtitle: Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Hexahydro- Triazine (RDX) in the Ro23F1 17. COSATI CODES 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block in the Ro23F1 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block in the Ro23F1 17. COSATI CODES 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block in the RDX GAS Reg. No. 121-82-9 Chronic toxicity	WORK UNIT ACCESSION NO
Research & Development Command Contract No. DAMD17-79-C-9161 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. 3E1- 62720A 62720A835 00 1. TITLE (Include Security Classification) Determination of the Chronic Mammalian Toxicological Effects of RDX 2. PERSONAL AUTHOR(S) P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac 3a. TYPE OF REPORT 13b TIME COVERED 14. DATE OF REPORT (Year, Month, Day) 15. PAGE CO- Final, Phase VI. Vol. 1 FROM 2/81 TO 4/84 1984 April 368 16. SUPPLEMENTARY NOTATION Subtitle: Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Hexahydro- Triazine (RDX) in the RO23F1 17. COSATI CODES 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block of the page o	ACCESSION NO
Fort Detrick Frederick, Maryland 21701-5012 Determination of the Chronic Mammalian Toxicological Effects of RDX PROSPRED PROSPRED 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. 3E1- NO. A A HOLDRESS (City, State, and ZIP Code) NO. 3E1- NO. A A HOLDRESS (City, State, and ZIP Code) NO. 3E1- NO. A A HOLDRESS (City, State, and ZIP Code) NO. 3E1- NO. A A HOLDRESS (City, State, and ZIP Code) NO. 3E1- NO. A A HOLDRESS (City, State, and ZIP Code) NO. 3E1- NO. A A HOLDRESS (City, State, and ZIP Code) NO. 3E1- NO. A A HOLDRESS (City, State, and ZIP Code) NO. 3E1- NO. A A HOLDRESS (City, State, and ZIP Code) NO. 3E1- NO. A A HOLDRESS (City, State, and ZIP Code) NO. 3E1- NO. A A HOLDRESS (City, State, and ZIP Code) NO. A A HOLDRESS (City, State, and ZIP City Code) NO. A A HOLDRESS (City, State, and ZIP City Code) NO. A A HOLDRESS (City, State, and ZiP City City Code) NO. A A HOLDRESS (City, State, and ZiP City City City City City City City City	ACCESSION NO
Fort Detrick Frederick, Maryland 21701-5012 1. TITLE (Include Security Classification) Determination of the Chronic Mammalian Toxicological Effects of RDX 2. PERSONAL AUTHOR(S) P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac 13a. TYPE OF REPORT 13b. TIME COVERED 11ab. TIME COVERED 11al. Phase VI. Vol.1 FROM 2/81 TO 4/84 11b. SUPPLEMENTARY NOTATION Subtitle: Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Hexahydro- Triazine (RDX) in the Roe3F1 17. COSATI CODES 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block of the RDX GAS Reg. No. 121-82-4 Chronic toxicity	ACCESSION NO
Frederick, Maryland 21701-5012 1. TITLE (Include Security Classification) Determination of the Chronic Mammalian Toxicological Effects of RDX 2. PERSONAL AUTHOR(S) P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac 3a. TYPE OF REPORT 13b. TIME COVERED 11nal, Phase VI. Vol.1 FROM 2/81 TO 4/84 16. SUPPLEMENTARY NOTATION Subtitle: Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Hexahydro- Triazine (RDX) in the ROCSF1 17. COSATI CODES 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block in the ROCSF1 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block in the ROCSF1 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block in the ROCSF1 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block in the ROCSF1 17 COSATI CODES 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block in the ROCSF1 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block in the ROCSF1 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block in the ROCSF1 19 COSATI CODES 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block in the ROCSF1 19 COSATI CODES 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block in the ROCSF1 19 COSATI CODES 19 COSATI CODES 10 COSATI CODES 10 COSATI CODES 10 COSATI CODES 11 COSATI CODES 12 COSATI CODES 13 COSATI CODES 14 COSATI CODES 15 COSATI CODES 16 COSATI CODES 17 COSATI CODES 18 COSATI CODES 18 COSATI CODES 19 COSATI CODES 19 COSATI CODES 19 COSATI CODES 19 COSATI CODES 10 COSATI CODES 10 COSATI CODES 10 COSATI CODES 11 COSATI CODES 11 COSATI CODES 12 COSATI CODES 13 COSATI CODES 14 COSATI CODES 15 COSATI CODES 16 COSATI CODES 17 COSATI CODES 18 COSATI CODES 18 COSATI CODES 19 COSATI CODES 19 COSATI CODES 19 COSATI CODES 10 COSATI CODES 10 COSATI CODES 11 COSATI CODES 11 COSATI CODES	1
Determination of the Chronic Mammalian Toxicological Effects of RDX 2. PERSONAL AUTHOR(S) P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac 3a. TYPE OF REPORT 13b. TIME COVERED 14. DATE OF REPORT (Year, Month, Day) 15. PAGE CO 16. SUPPLEMENTARY NOTATION Subtitle: Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Hexahydro— Triazine (RDX) in the 8623F1 17. COSATI CODES 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block in the 15 CAS Reg. No. 121-82-9 Chronic toxicity	
Determination of the Chronic Mammalian Toxicological Effects of RDX 2. PERSONAL AUTHOR(S) P.M. Lish, B.S. Levine, E.M. Furedi, J.W. Sagartz, V.S. Rac 3a. TYPE OF REPORT 13b. TIME COVERED 14. DATE OF REPORT (Year, Month, Day) 15. PAGE CO 16. SUPPLEMENTARY NOTATION Subtitle: Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Hexahydro- Triazine (RDX) in the Boc3F1 17. COSATI CODES 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block of the RDX of the RD	
	-1,3,5- number)
Hexahydro-1,3,5-trinitro-1,3,5-triazine, Hepatoc	carcinogen
Hexahydro-1,3,5-trinitro-1,3,5-triazine Hepatoc B6C3F1 hybrid mouse Hepatotoxicity Carcinoma (Continue on reverse if necessary and identify by block humber)	Adenoma
This study was conducted to evaluate the toxicity of the munitions compound hexaly trinitro-1,3,5-triazine (RDX: CAS Reg. No. 121-82-4) in B6C3F1 mice when administed their diet for up to 24 months. RDX purity was established to be 89.2-98.7% with contaminant of HMX. Groups of 85 mice per sex received RDX at doses of 0, 1.5, 7. or 100.0 mg/kg/day. This last dose was reduced from 175 mg/kg/day in Test Week 11 high mortality. Ten mice/sex/dose were killed following 6 and 12 months on test viving animals killed after 24 months of treatment. Toxicologic endpoints include signs, body weights, food consumption, hematology, clinical chemistry, ophthalmology weights, and gross and tissue morphology. The major toxic effects observed during the administration of RDX to B6C3F1 mice in 24 months included hepatotoxicity, possible CNS involvement, and testicular degeneration. In addition, hepatocellular adenomas and/or carcinomas were more prevalent.	ered in the main .0, 35.0 l due to with sur- ed clinical
☐ UNCLASSIFIED/UNLIMITED SAME AS RPT. ☐ DTIC USERS Unclassified 22a NAME OF RESPONSIBLE INDIVIDUAL 22b TELEPHONE (Include Area Code) 22c OFFICE SYMI	41
Mrs. Virginia Milier 22b TELEPHONE (Include Area Code) 22c OFFICE SYM 301/663-7325 SGRD-RMS	valent ov tinued)

19. ABSTRACT (concluded)

for RDX-treated females than for corresponding controls. Whether serum cholesterol levels and/or the incidence of hepatocellular tumors were increased at the 7 mg/kg/day dose level is equivocal. The no-effect level under the conditions of the present study is 1.5 mg/kg/day.

Contract No. DAMD17-79-C-9161 IITRI Project No. L6121 Study No. 7

DERMINATION OF THE CHRONIC MAMMALIAN TOXICOLOGICAL EFFECTS OF RDX

Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) in the B6C3F1 Hybrid Mouse

Final Report Phase VI, Vol. 1

Paul M. Lish
Barry S. Levine
E. Marianna Furedi
John M. Sagartz
Vladislava S. Rac

April 1984

Supported by:

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND Fort Detrick, Frederick, MD 21701-5012

IIT Research Institute 10 West 35th Street Chicago, IL 60616 DTIC COPY INSPECTED

Project Officer: Jesse J. Barkley, Jr.

Faul M. Lish, Ph.D.

Scientific Advisor

Barry S.

Senior To

Life Sciences Research

Barry S. Levine, D.Sc. Senior Toxicologist Life Sciences Research

N 1

Alan M. Shefner Associate Director Life Sciences Research

'y Codes

D

u u∤orcial

A-/

EXECUTIVE SUMMARY

This study was conducted to evaluate the toxicity of the munitions compound hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX; CAS Reg. No. 121-82-4) in B6C3F1 mice when administered in their diet for up to 24 months. Groups of 85 mice per sex received RDX at doses of 0, 1.5, 7.0, 35.0 or 100.0 mg/kg/day. This last dose was reduced from 175 mg/kg/day in Test Week 11 due to high mortality. Ten rats/sex/dose were killed following 6 and 12 months on test with surviving animals killed after 24 months of treatment. Toxicologic endpoints included clinical signs, body weights, food consumption, hematology, clinical chemistry, ophthalmology, organ weights, and gross and tissue morphology.

The administration of 175 mg/kg/day of RDX to male and female B6C3F1 mice resulted in death during the first ten weeks of treatment. This dose was reduced to 100 mg/kg/day in Test Week 11. Subsequently to this, the slope of the survival curves were similar for this treatment group and control animals for the duration of the study. Although these high dose animals showed slight reduction in body weight gains, food consumption was not affected.

Surviving males in this high dose group demonstrated significant skin lesions apparently associated with fighting wounds. RDX is known to induce behavioral changes including hyperreactivity to approach and fighting with cage mates. However, histologic evaluation failed to detect treatment-related lesions of the central nervous system.

Liver injury at 175/100 and to a lesser extent 35.0 mg/kg/day was evidenced by several observations. These included elevated serum cholesterol and triglyceride levels and hepatomegaly. With the exception of hepatocellular tumors (discussed below), histopathologic lesions of the liver were not observed.

At the 6, 12 and 24 month kill, kidney weights were elevated for mice of both sexes administered 175/100 mg/kg/day. Cytoplasmic vacuolation of renal tubules appeared to be more prevalent for RDX-treated males than corresponding control animals after six months of treatment. This lesion was subsequently seen at 12 and 24 months as frequently for control as for treated animals.

Although statistically not significant, an increased incidence of hepatocellular carcinoma was seen in RDX treated female but not male mice. The combined incidences of hepatocellular carcinoma and adenoma were statistically greater for female mice receiving 7.0 mg/kg/day and higher doses than for the concurrent female control group. When historical control

data were included in the statistical analyses, the two top dose levels still demonstrated significant increases in the incidence of combined liver carcinomas and adenomas. When these historical control data were compared to this study data, the incidence values for hepatocellular carcinoma for historical controls fell between the incidence for control and high dose mice.

T

non-statistically significant increase alveolar/bronchio; ar carcinomas was seen in high dose male and female mice. Comparison of study controls to the appropriate incidence controls showed that the historical alveolar/bronchiolar carcinomas and adenomas for study control mice was within the range of incidences of alveolar/bronchiolar carcinomas in both sexes of historical control mice. An additional scatistically significant observation was an increased number of histiocytes in lungs of the female mice receiving 175/100 mg/kg/day.

An additional toxic effect seen primarily at 175/100 mg/kg/day included enlarged hearts without accompanying histologic lesions. Although not statistically significant, increased incidences of testicular degeneration were seen for the male mice at the 175/100 and 35 mg/kg/day dose levels when compared to the concurrent controls or to the historical controls. Absolute or relative testicular weight change failed to accompany this histopathological finding.

In summary, the major toxic effects observed during the administration of RDX to B6C3F1 mice for up to 24 months included hepatotoxicity, possible CNS involvement and testicular degeneration. In addition, hepatocellular and alveolar/bronchial carcinomas and adenomas were more prevelant for RDX-treated mice than for corresponding controls. The incidence of hepatocellular tumors (combined carcinomas and adenomas) was significantly increased at the 7 mg/kg/day dose level. On this basis, the no-effect level under the conditions of the present study is 1.5 mg/kg/day.

FOREWORD

Armv Medical Bioengineering Research and Development Laboratory (USAMBRDL), Fort Detrick, Frederick, MD, has been conducting a research program since 1973 for the purpose of developing the scientific data base necessary for recommending water quality criteria for compounds unique to the munitions industry. A water quality criterion (as defined by the amended Clean Water Act, 1977) is a qualitative or quantitative estimate of the concentration of a pollutant in ambient waters that, when not exceeded, will ensure a water quality sufficient to protect a specified water use. The criterion is a scientific entity based solely on data and scientific judgement. It does not reflect considerations of economic or technological feasibility. Currently, a water quality criterion consists of two separate numerical limits, one for the protection of human health and the other for the protection of aquatic organisms. These numbers, when translated by the appropriate regulatory agency, can be the basis of enforceable discharge or effluent limitations in a point source discharge permit issued under the Clean Water Act.

Since a water quality criterion is to protect designated water uses, a diverse, multidisciplinary research program was developed by USAMBRDL that includes "effects" studies on laboratory and domestic animals, wildlife species, aquatic organisms, plants, and economically important crops. In addition, extensive chemical and biological fate and persistence tests are conducted to provide information on the behavior of a pollutant in the aqueous environment. These kinds of data are especially useful for making site-specific translation of criteria into enforceable discharge limits.

This report represents a portion of the mammalian toxicology data base being developed by USAMBRDL on hexahydro-1,3,5-trinitro-1,3,5-triazine.

In conducting the research described in this report, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (DHEW Publication No. (NIH) 78-23, Revised 1978).

ACKNOWLEDGMENT

This report was prepared at IIT Research Institute, 10 West 35th Street, Chicago, Illinois, 60616, under U.S. Department of Army Contract No. DAMD17-79-C-9161 (IITRI troject No. LO6121) entitled "Determination of the Chronic Mammalian Toxicological Effects of RDX". Mr. Jesse J. Barkley, Jr., Health Effects Research Division, USANDE, served as the Contract Officer's Technical Representative for this program.

The work reported herein was conducted in the Toxicology and Section of the Life Sciences Division, represents a portion of the overall effort of the above named research program. Paul M. Lish, Ph.D., Scientific Advisor, served as Principal investigator. Barry S. Levine, D.Sc., Senior Toxicologist, served as study director and was responsible for the overall conduct of the study. Eva M. Furedi-Machacek, DVM, served as study toxicologist and was also responsible for the mervision of the technical support personnel. DVM Senior Veterinary Pathologist, Bobby R. Collins, Burn. DVM, And Madrislava S. Rac, DVM, M.S., were consecutively respond the for a pervision of gross necropsies. Carol A. Thompson, DVM, A.S., tabulated the gross necropsy data. Drs. Burns and Decime served as consecutive heads of the clinical pathology laboratory, and Samuel Terese, B.S. (ASCP-MT), and Sava, B.S.(ASCP-MT), were responsible for generation of clinical pathology data. Donovan E. Gordon, DVM, Ph.D., Consultan: Veterinary Pathology, was responsible for tabulation and evaluation of histopathology data. Bobby R. Collins, DVM, M.S., and Josegh B. Harder, DVM, served as clincal veterinarians and supervised animal care personnel. Joann M. Hinz, B.S., Renaud, B.S., were responsible for the collection of Dorothy Davis (ASCP-HT) was test data. responsible preparation of histology slides. C. Susan West, DVM, performed the ophthalmic examinations. Josephine M. Reed, M.M., M.S., Supervisor, Quality Assurance, was responsible for the quality assurance program. Robert Remaly, B.S., Senior Engineer, was responsible for preparation of the test article premixes. O'Neill, Ph.D., Manager, Analytical Chemistry, Walter C. Eisenberg, Ph.D., Senior Chemist, and Richard Schonfeld, M.S. and Debra Cunningham, B.S., Assistant Chemists, were responsible for chemical analyses of test articles, test article premixes and test diets. Ms. Jean Graf provided the particle size analyses. Robert D. Gibbons, Ph.D., provided statistical and computational assistance.

QUALITY ASSURANCE STATEMENT

Biological laboratory inspections of critical phases were performed on 25 occasions between January 7, 1981 and May 19, 1983. Data audits were performed between July 21 and 22, 1981, January 21, April 30 to May 3, August 2, 19 and 20, November 4 to 8, 1982, January 12 to 13 and October, 6, 1983, January 11 to 18, and February 20 to March 2, 1984. The final draft report was audited between February 23 and March 3, 1987. Inspections and audits were performed by Josephine M. Reed, Julie McPhillips and Kirit Parikh. The study was found to meet Life Sciences Quality Assurance criteria. Specimens and raw data generated during the study will be retained in the IITRI Life Sciences Archives as specified in standard operating procedures.

Josphine M. Reed

Manager, Quality Assurance

Volume I	I. INTRODUCTION.		TABLE OF CONTENTS	
I. INTRODUCTION. 13 II. MATERIALS AND METHODS. 13 A. Test Article. 13 B. Test Diets. 14 C. Test Animals. 16 D. Experimental Design. 17 E. Statistical Analysis. 22 III. RESULTS. 23 A. Test Diets. 23 B. Food and Water Contaminants. 23 C. Mortality/Clinical Observations. 23 D. Body Weight. 24 E. Food Consumption. 24 F. Hematology. 24 G. Clinical Chemistry. 24 H. Ophthalmology. 25 I. Organ Weights. 25 J. Pathology. 25 J. Pathology. 25 IV. DISCUSSION. 27 V. REFERENCES. 29 APPENDIX I TEST ARTICLE ANALYSIS. 105 APPENDIX II TEI ANALYTICAL CHEMISTRY METHODS. 143 APPENDIX II TEI ANALYTICAL CHEMISTRY METHODS. 143 APPENDIX VI INDIVIDUAL ANIMAL DATA. 153 APPENDIX VI INDIVIDUAL ANIMAL DATA. 153 APPENDIX VI INTRATE, NITRITE AND MERCURY CONTENT OF 5002. 341 APPENDIX IX CHICAGO WATER CHEMICAL ANALYSIS. 343 APPENDIX IX CHICAGO WATER CHEMICAL ANALYSIS. 343 APPENDIX IX CHICAGO WATER CHEMICAL ANALYSIS. 343 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. 345 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. 345 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. 345	I. INTRODUCTION. 13 II. MATERIALS AND METHODS. 13 A. Test Article. 13 B. Test Diets. 14 C. Test Animals. 16 D. Experimental Design. 17 E. Statistical Analysis. 22 III. RESULTS. 23 A. Test Diets. 23 A. Test Diets. 23 C. Mortality/Clinical Observations. 23 C. Mortality/Clinical Observations. 24 F. Hematology. 24 G. Clinical Chemistry 24 H. Ophthalmology. 25 J. Pathology 25 J. Pathology 25 IV. DISCUSSION. 27 V. REFERENCES. 29 APPENDIX I TEST ARTICLE ANALYSIS. 105 APPENDIX II TEST ARTICLE ANALYSIS. 105 APPENDIX II TEST ARTICLE ANALYSIS. 141 APPENDIX II TEST ARTICLE CHEMISTRY METHODS. 143 APPENDIX VI CHINICAL CHEMISTRY METHODS. 143 APPENDIX VI INDIVIDUAL ANIMAL DATA. 153 APPENDIX VI INDIVIDUAL ANIMAL DATA. 153 APPENDIX VII NINITATE, NITRITE AND MERCURY CONTENT OF 5002. 34 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. 345 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. 345 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. 345 APPENDIX XI PATHOLOGY NARRATIVE REPORT. 353 DISTRIBUTION LIST. 364		INDBB OF CONTRIB	
II. MATERIALS AND METHODS.	11. MATERIALS AND METHODS.	<u>Volume</u> <u>I</u>		Page N
A. Test Article	A. Test Article	I. INTRODU	CTION	13
B. Test Diets.	B. Test Diets	II. MATERIA	LS AND METHODS	13
B. Test Diets.	B. Test Diets	д Тез	t Article	13
C. Test Animals. 16 D. Experimental Design. 17 E. Statistical Analysis. 22 III. RESULTS. 23 A. Test Diets. 23 B. Food and Water Contaminants. 23 C. Mortality/Clinical Observations. 23 D. Body Weight. 24 E. Food Consumption 24 E. Food Consumption 24 G. Clinical Chemistry. 24 H. Ophthalmology 25 I. Organ Weights. 25 J. Pathology 25 I. Organ Weights. 25 J. Pathology 25 IV. DISCUSSION. 27 V. REFERENCES. 29 APPENDIX I TEST ARTICLE ANALYSIS. 105 APPENDIX II TEI ANALYTICAL CHEMISTRY METHODS 143 APPENDIX IV HEMATOLOGY METHODOLOGY. 147 APPENDIX V CLINICAL CHEMISTRY METHODOLOGY. 147 APPENDIX VI INDIVIOUAL ANIMAL DATA. 153 APPENDIX VII CHLORTETRACYCLINE CONTENT OF 5002 339 APPENDIX IX CHICAGO WATER CHEMICAL ANALYSIS 343 APPENDIX IX CHICAGO WATER CHEMICAL ANALYSIS 343 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. 345 APPENDIX XI PATHOLOGY NARRATIVE REPORT. 353	C. Test Animals			
D. Experimental Design	D. Experimental Design			
E. Statistical Analysis	E. Statistical Analysis			
A. Test Diets. 23 B. Food and Water Contaminants. 23 C. Mortality/Clinical Observations. 23 D. Body Weight. 24 E. Food Consumption. 24 F. Hematology. 24 G. Clinical Chemistry. 24 H. Ophthalmology 25 I. Organ Weights. 25 J. Pathology. 25 I. Organ Weights. 25 J. Pathology. 25 IV. DISCUSSION. 27 V. REFERENCES. 29 APPENDIX I TEST ARTICLE ANALYSIS. 105 APPENDIX II 5002 CERTIFICATION PROFILE/ANALYSIS. 141 APPENDIX III TEI ANALYTICAL CHEMISTRY METHODS. 143 APPENDIX IV HEMATOLOGY METHODOLOGY. 147 APPENDIX VI CHINICAL CHEMISTRY METHODOLOGY. 151 APPENDIX VI INDIVIDUAL ANIMAL DATA. 153 APPENDIX VI CHLORTETRACYCLINE CONTENT OF 5002. 339 APPENDIX VII CHLORTETRACYCLINE CONTENT OF 5002. 341 APPENDIX VII CHLORTETRACYCLINE CONTENT OF 5002. 341 APPENDIX IX CHICAGO WATER CHEMICAL ANALYSIS. 343 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. 345 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. 345 APPENDIX X I PATHOLOGY NARRATIVE REPORT. 353	A. Test Diets	E. Sta	tistical Analysis	
A. Test Diets. 23 B. Food and Water Contaminants. 23 C. Mortality/Clinical Observations. 23 D. Body Weight. 24 E. Food Consumption. 24 F. Hematology. 24 G. Clinical Chemistry. 24 H. Ophthalmology 25 I. Organ Weights. 25 J. Pathology. 25 I. Organ Weights. 25 J. Pathology. 25 IV. DISCUSSION. 27 V. REFERENCES. 29 APPENDIX I TEST ARTICLE ANALYSIS. 105 APPENDIX II 5002 CERTIFICATION PROFILE/ANALYSIS. 141 APPENDIX III TEI ANALYTICAL CHEMISTRY METHODS. 143 APPENDIX IV HEMATOLOGY METHODOLOGY. 151 APPENDIX V CLINICAL CHEMISTRY METHODOLOGY. 151 APPENDIX VI INDIVIDUAL ANIMAL DATA. 153 APPENDIX VII CHLORTETRACYCLINE CONTENT OF 5002. 339 APPENDIX VII NITRATE, NITRITE AND MERCURY CONTENT OF 5002. 341 APPENDIX IX CHICAGO WATER CHEMICAL ANALYSIS. 343 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. 345 APPENDIX XI PATHOLOGY NARRATIVE REPORT. 345 APPENDIX XI PATHOLOGY NARRATIVE REPORT. 353	A. Test Diets	TTT PESIII.TS		22
B. Food and Water Contaminants	B. Food and Water Contaminants. 23 C. Mortality/Clinical Observations. 23 D. Body Weight . 24 E. Food Consumption . 24 F. Hematology . 24 G. Clinical Chemistry . 24 H. Ophthalmology . 25 I. Organ Weights . 25 J. Pathology . 25 IV. DISCUSSION . 27 V. REFERENCES . 29 APPENDIX I TEST ARTICLE ANALYSIS . 105 APPENDIX II 5002 CERTIFICATION PROFILE/ANALYSIS . 141 APPENDIX II TEI ANALYTICAL CHEMISTRY METHODS . 143 APPENDIX IV HEMATOLOGY METHODOLOGY . 147 APPENDIX VI LINDIVIDUAL ANIMAL DATA . 153 APPENDIX VI INDIVIDUAL ANIMAL DATA . 153 APPENDIX VII CHLORTETRACYCLINE CONTENT OF 5002 . 339 APPENDIX VII NITRATE , NITRITE AND MERCURY CONTENT OF 5002 . 341 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT . 345 APPENDIX XI PATHOLOGY NARRATIVE REPORT . 3553 DISTRIBUTION LIST . 364			_
C. Mortality/Clinical Observations. 23 D. Body Weight. 24 E. Food Consumption. 24 F. Hematology 24 G. Clinical Chemistry. 24 H. Ophthalmology. 25 I. Organ Weights. 25 J. Pathology. 25 IV. DISCUSSION. 27 V. REFERENCES. 29 APPENDIX I TEST ARTICLE ANALYSIS. 105 APPENDIX II 5002 CERTIFICATION PROFILE/ANALYSIS. 141 APPENDIX III TEI ANALYTICAL CHEMISTRY METHODS. 143 APPENDIX IV HEMATOLOGY METHODOLOGY. 147 APPENDIX V CLINICAL CHEMISTRY METHODOLOGY. 151 APPENDIX VI INDIVIDUAL ANIMAL DATA. 153 APPENDIX VII CHLORTETRACYCLINE CONTENT OF 5002. 339 APPENDIX VIII NITRATE, NITRITE AND MERCURY CONTENT OF 5002. 341 APPENDIX X CHICAGO WATER CHEMICAL ANALYSIS. 343 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. 345 APPENDIX XI PATHOLOGY NARRATIVE REPORT. 353	C. Mortality/Clinical Observations. 23 D. Body Weight. 24 E. Food Consumption. 24 F. Hematology. 24 G. Clinical Chemistry. 24 H. Ophthalmology. 25 I. Organ Weights. 25 J. Pathology. 25 I. Organ Weights. 25 J. Pathology. 25 IV. DISCUSSION. 27 V. REFERENCES. 29 APPENDIX I TEST ARTICLE ANALYSIS. 105 APPENDIX II 5002 CERTIFICATION PROFILE/ANALYSIS. 141 APPENDIX II TEI ANALYTICAL CHEMISTRY METHODS. 143 APPENDIX IV HEMATOLOGY METHODOLOGY. 147 APPENDIX VI CLINICAL CHEMISTRY METHODOLOGY. 151 APPENDIX VI INDIVIDUAL ANIMAL DATA. 152 APPENDIX VII CHLORTETRACYCLINE CONTENT 05 5002. 339 APPENDIX VII NITRATE, NITRITE AND MERCURY CONTENT 05 5002. 339 APPENDIX IX CHICAGO WATER CHEMICAL ANALYSIS. 343 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. 345 APPENDIX XI PATHOLOGY NARRATIVE REPORT. 3553 DISTRIBUTION LIST. 364			
C. Mortality/Clinical Observations. 23 D. Body Weight. 24 E. Food Consumption. 24 F. Hematology. 224 G. Clinical Chemistry. 24 H. Ophthalmology. 25 I. Organ Weights. 25 J. Pathology. 25 IV. DISCUSSION. 27 V. REFERENCES. 29 APPENDIX I TEST ARTICLE ANALYSIS. 105 APPENDIX II 5002 CERTIFICATION PROFILE/ANALYSIS. 141 APPENDIX III TEI ANALYTICAL CHEMISTRY METHODS. 143 APPENDIX IV HEMATOLOGY METHODOLOGY. 151 APPENDIX VI UNDIVIDUAL ANIMAL DATA. 153 APPENDIX VII INDIVIDUAL ANIMAL DATA. 153 APPENDIX VII CHLORTETRACYCLINE CONTENT OF 5002. 339 APPENDIX VII NITRATE, NITRITE AND MERCURY CONTENT OF 5002. 341 APPENDIX X CHICAGO WATER CHEMICAL ANALYSIS. 343 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. 345 APPENDIX XI PATHOLOGY NARRATIVE REPORT. 353	C. Mortality/Clinical Observations. 23	B. Foo	d and Water Contaminants	23
D. Body Weight	D. Body Weight. 24 E. Food Consumption. 24 F. Hematology. 24 G. Clinical Chemistry. 24 H. Ophthalmology. 25 I. Organ Weights. 25 J. Fathology. 25 IV. DISCUSSION. 27 V. REFERENCES. 29 APPENDIX I TEST ARTICLE ANALYSIS. 105 APPENDIX II TEI ANALYTICAL CHEMISTRY METHODS. 143 APPENDIX IV HEMATOLOGY METHODOLOGY. 147 APPENDIX VI INDIVIDUAL ANIMAL DATA. 153 APPENDIX VI INDIVIDUAL ANIMAL DATA. 153 APPENDIX VII CHLORTETRACYCLINE CONTENT OF 5002. 339 APPENDIX VII CHLORTETRACYCLINE CONTENT OF 5002. 341 APPENDIX X IX CHICAGO WATER CHEMICAL ANALYSIS. 343 APPENDIX X X CHICAGO WATER CHEMICAL ANALYSIS. 343 APPENDIX X IX CHICAGO WARRATIVE REPORT. 355 DISTRIBUTION LIST. 364			
E. Food Consumption	E. Food Consumption. 24 F. Hematology. 24 G. Clinical Chemistry. 24 H. Ophthalmology. 25 I. Organ Weights. 25 J. Pathology. 25 I. Organ Weights. 25 J. Pathology. 27 V. REFERENCES. 29 APPENDIX I TEST ARTICLE ANALYSIS. 105 APPENDIX II 5002 CERTIFICATION PROFILE/ANALYSIS. 141 APPENDIX III TEI ANALYTICAL CHEMISTRY METHODS. 143 APPENDIX IV HEMATOLOGY METHODOLOGY. 151 APPENDIX V CLINICAL CHEMISTRY METHODOLOGY. 151 APPENDIX VI INDIVIDUAL ANIMAL DATA. 153 APPENDIX VII NITRATE, NITRITE AND MERCURY CONTENT OF 5002. 341 APPENDIX VII NITRATE, NITRITE AND MERCURY CONTENT OF 5002. 341 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. 353 DISTRIBUTION LIST. 364			
F. Hematology	F. Hematology			
G. Clinical Chemistry	G. Clinical Chemistry. 24			
H. Ophthalmology	H. Ophthalmology		minal Chamiatur	
I. Organ Weights	I. Organ Weights			
J. Pathology	J. Pathology			
J. Pathology	J. Pathology			25
V. REFERENCES	APPENDIX I TEST ARTICLE ANALYSIS	J. Pat	chology	25
APPENDIX I TEST ARTICLE ANALYSIS	APPENDIX I TEST ARTICLE ANALYSIS	IV. DISCUSS	SION	27
APPENDIX II 5002 CERTIFICATION PROFILE/ANALYSIS	APPENDIX II 5002 CERTIFICATION PROFILE/ANALYSIS. 141 APPENDIX III TEI ANALYTICAL CHEMISTRY METHODS. 143 APPENDIX IV HEMATOLOGY METHODOLOGY. 147 APPENDIX V CLINICAL CHEMISTRY METHODOLOGY. 151 APPENDIX VI INDIVIDUAL ANIMAL DATA. 153 APPENDIX VII CHLORTETRACYCLINE CONTENT OF 5002. 339 APPENDIX VIII NITRATE, NITRITE AND MERCURY CONTENT OF 5002. 341 APPENDIX IX CHICAGO WATER CHEMICAL ANALYSIS. 343 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. 353 DISTRIBUTION LIST. 364	V. REFEREN	ICES	29
APPENDIX II 5002 CERTIFICATION PROFILE/ANALYSIS	APPENDIX III 5002 CERTIFICATION PROFILE/ANALYSIS. 141 APPENDIX III TEI ANALYTICAL CHEMISTRY METHODS. 143 APPENDIX IV HEMATOLOGY METHODOLOGY. 147 APPENDIX V CLINICAL CHEMISTRY METHODOLOGY. 151 APPENDIX VI INDIVIDUAL ANIMAL DATA. 153 APPENDIX VII CHLORTETRACYCLINE CONTENT OF 5002. 339 APPENDIX VIII NITRATE, NITRITE AND MERCURY CONTENT OF 5002. 341 APPENDIX IX CHICAGO WATER CHEMICAL ANALYSIS. 343 APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. 345 APPENDIX XI PATHOLOGY NARRATIVE REPORT. 353 DISTRIBUTION LIST. 364		MBAM 35MTATM 331571177A	105
APPENDIX III TEI ANALYTICAL CHEMISTRY METHODS	APPENDIX III TEI ANALYTICAL CHEMISTRY METHODS			
APPENDIX IV HEMATOLOGY METHODOLOGY	APPENDIX IV HEMATOLOGY METHODOLOGY. APPENDIX V CLINICAL CHEMISTRY METHODOLOGY. APPENDIX VI INDIVIDUAL ANIMAL DATA. APPENDIX VII CHLORTETRACYCLINE CONTENT OF 5002. APPENDIX VIII NITRATE, NITRITE AND MERCURY CONTENT OF 5002. APPENDIX IX CHICAGO WATER CHEMICAL ANALYSIS. APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT. APPENDIX XI PATHOLOGY NARRATIVE REPORT. 345 APPENDIX XI PATHOLOGY NARRATIVE REPORT. 364			
APPENDIX V CLINICAL CHEMISTRY METHODOLOGY	APPENDIX V CLINICAL CHEMISTRY METHODOLOGY. APPENDIX VI INDIVIDUAL ANIMAL DATA			143
APPENDIX V CLINICAL CHEMISTRY METHODOLOGY	APPENDIX V CLINICAL CHEMISTRY METHODOLOGY			147
APPENDIX VI INDIVIDUAL ANIMAL DATA	APPENDIX VI INDIVIDUAL ANIMAL DATA	APPENDIX V	CLINICAL CHEMISTRY METHODOLOGY	
APPENDIX VII CHLORTETRACYCLINE CONTENT OF 5002	APPENDIX VII CHLORTETRACYCLINE CONTENT OF 5002			
OF 5002	OF 5002	APPENDIX VII	CHLORTETRACYCLINE CONTENT OF 5002	339
APPENDIX IX CHICAGO WATER CHEMICAL ANALYSIS	APPENDIX IX CHICAGO WATER CHEMICAL ANALYSIS			341
APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT	APPENDIX X OPHTHALMOLOGY NARRATIVE REPORT	APPENDIX IX		
APPENDIX XI PATHOLOGY NARRATIVE REPORT	APPENDIX XI PATHOLOGY NARRATIVE REPORT			
DISTRIBUTION LIST				
		DISTRIBUTION 1	JIST	36៤
	8			
	8	,		
	8	•		
	δ	0		
		8		

VOLUME II*		TABLE OF CONTENTS (CONCLUDED) Page	No.
APPENDIX	X	OPHTHALMOLOGY REPORT (COMPLETE)	339
VOLUME III*			
APPENDIX	ХI	PATHOLOGY REPORT (COMPLETE)	595

^{*}Requests for Volumes II and III should be directed to Health Effects Research Division, U.S. Army Medical Bioengineering Research and Development Laboratory, Fort Detrick, Maryland 21701-5012.

LIST OF TABLES

<u>Table</u>		Page
1	Male Actual Doses Received	32
2	Female Actual Doses Received	36
3	Test Diet Concentrations of RDX	40
4	Mean Survival Time	41
5	Male Body Weights	42
6	Male Body Weight Gains	
7	Female Body Weights	48
8	Female Body Weight Gains	
9	Male Food Consumption Measurements	
10	Female Food Consumption Measurements	
11	Male Hematology Values - Test Week 14	
12	Female Hematology Values - Test Week 14	61 62
13 14	Male Hematology Values - Test Week 26	
15	Female Hematology Values - Test Week 26	64
16	Female Hematology Values - Test Week 53	65
17	Male Hematology Values - Test Week 79	66
18	Female Hematology Values - Test Week 79	67
19	Male Hematology Values - Test Week 105	68
20	Female Hematology Values - Test Week 105	
21	Male Clinical Chemistry Values - Test Week 14	
22	Female Clinical Chemistry Values - Test Week 14	
23	Male Clinical Chemistry Values - Test Week 26	72
24	Female Clinical Chemistry Values - Test Week 26	73
25	Male Clinical Chemistry Values Test Week 53	74
26	Female Clinical Chemistry Values - Test Week 53	75
27	Male Clinical Chemistry Values - Test Week 79	76
28	Female Clinical Chemistry Values - Test Week 79	
29	Male Clinical Chemistry Values - Test Week 105	
30	Female Clinical Chemistry Values - Test Week 105	, -
31 31a	Incidences of Cataracts	
31a 32	Incidences of Cataracts (Revised)	
33	Female Mean Relative Organ Weights - Test Week 26	
34	Male Mean Relative Organ Weights - Test Week 53	
35	Female Mean Relative Organ Weights - Test Week 53	
36	Male Mean Relative Organ Weights-Test Weeks 105-106	
37	Female Nean Relative Organ Weights-Test Weeks 105-106 .	
38	Male Mean Organ Weights - Test Week 26	88
39	Female Mean Organ Weights - Test Week 26.,	89
40	Male Mean Organ Weights - Test Week 53	90
41	Female Mean Organ Weights - Test Week 53	91
42	Male Mean Organ Weights - Test Weeks 105-106	92
43	Temale Mean Organ Weights - Test Weeks 105-106	93
44	Statistical Evaluation of Histopathologic Lesions (M)	
45	Statistical Evaluation of Histopathologic Lesions (F)	
46	Statistical Evaluation of Liver Tumors	97

LIST OF FIGURES

Figure	Page	No.
1	Survival Curves for Control and High Dose Males	100
2	Survival Curves for Control and High	100
3	Dose Females	101
3	For Male Mice	102
4	Mean Cholesterol Values	103
4 5	Mean Female Triglyceride Values	104

I. INTRODUCTION

The U.S. Army Medical Research and Development Command (USAMRDC) been directed to evaluate the potential hazards to living systems wastewater discharges from munitions facilities. toxicologic effects to mammalian systems the hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX; Reg. CAS This high explosive is routinely used in filling shells Wastewaters resulting from the loading of this explosive shells are discharged into the environment without significant treatment and are subject to limitations imposed by governmental Evaluation of the potential hazards of these regulatory agencies. wastewaters to human health is therefore a necessary portion of the data-base required to establish comprehensive environmental criteria.

The present study was conducted to aid in this evaluation and assessed the chronic toxicity and carcinogenicity of RDX in B6C3F1 mice when administered in the diet for at least 104 weeks. Information ultimately derived from this comprehensive long-term toxicology study will aid USAMRDC in developing criteria for the establishment of effluent standards and in defining levels of treatment for its pollution abatement program.

The study reported herein was conducted in accordance with the IITRI Quality Assurance Program designed to comply with FDA Good Laboratory Practice Regulations (1). Thus, all terms used in this report, e.g. test article, raw data, specimens, etc., are in agreement with the definitions set forth in the aforementioned document.

II. MATERIALS AND METHODS

A. Test Article

Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX: CAS Reg. No. 121-82-4), batch No. HOL 435-37, 100 pounds, was made available for this study from stocks at the IITRI kingspury Ordnance Plant (KOP) Explosive Facility, La Porte, In. The test article was stored at the facility at ambient room temperature and relative humidity, and in the dark. Upon initiation and at termination of the treatment phase of the study, 30 g samples were taken and stored under conditions similar to those for the batches.

The purity of the test article was determined by high performance liquid chromatography with analytical standards provided by the Sponsor as described in Appendix I. RDX purity was analyzed three times during this study. Results were as follows: May 1981 (91.0 \pm 2.9%), May 1982 (89.2 \pm 8.0%) and April 1983 (98.7 \pm 2.0%). The main contaminant was HMX and represented approximately 3-10% of the sample (estimated concentration on the basis of percent area integration). The other impurities were not determined.

Particle size analyses of approximately 10% premixes were performed in November 1979 and in March 1981 by the Fine Particle Research Section of Chemical Engineering Division of IITRI. The results of premix analyses were as follows:

Date	Nov	vember	1979	No	vember	1981
Size (um)	Number	8	Cummul. %	Number	<u>8</u>	Cummul. %
<22	355	51.7	51.7	105	21.0	21.0
22-44	184	26.8	78.5	216	43.2	64.2
44-66	75	10.9	89.4	92	18.4	82.6
66-110	38	5.5	94.9	41	8.2	90.8
110-220	22	3.2	98.1	38	7.6	98.4
220-330	10	1.5	99.6	8	1.6	100.0
330-440	2	0.3	99.9	0		
>440	1	0.1	100.0	0		

B. Test Diets

Premixes of the test article, (approximately 10% in Purina Certified Rodent Chow No. 5002, Ralston Purina Co., St. Louis, MO., hereafter referred to as 5002), were prepared on a monthly basis in 4 kg quantities at the Kingsbury Ordnance Plant facility by IITRI Chemistry Department personnel. Undiluted RDX was handled in accordance with procedures for explosive and fire hazards. The test article was ball milled with equal parts of 5002 and subsequently diluted with additional 5002 in a twin shell blender to yield approximate 10% premixes.

Each RDX premix was tested for homogeneity, concentration recovery of the test articles by HPLC. Homogeneity testing consisted of analyzing for test article concentration of each batch of premix taken from 6 random locations of its container. Premix stability was established for a period of seven and later for a period of nine weeks by conducting homogeneity tests at the initial and the terminal point of the 7, as previously reported (2), or 9 week period (see below). Recovery tests for premix consisted of adding a known quantity of test article to a weighed quantity of untreated 5002 in a measured volume acetonitrile (the solvent used in the extraction procedure) to achieve the calculated premix concentration. subsequently underwent the identical proce The spiked samples the identical procedures as the actual premixes.

Toxicology Section personnel received the test articles as approximate 10% premixes in 5002. These premixes posed little explosive or fire hazard as previously demonstrated (2). Results of premix analyses were as follows:

LOT NO.	DATE PREPARED	DATE ANALYZED	% COMPOSITE + S.D.*
135-8	1-08-81	1-20-81	10.58 <u>+</u> 0.33
135-9	2-27-81	3-03-81	10.53 ± 0.30
135-12	3-13-81	3-23-81	10.24 ∓ 0.52
135-15	4-16-81	4-27-81	10.65 ∓ 0.40
135-17	5-13-81	5-21-81	9.88 ∓ 0.36
135-21	6-16-81	6-26-81	9.27 ∓ 0.57
135-22	7-08-81	7-22-81	9.44 ± 0.58
135-25	8-12-81	8-27-81	9.53 ± 0.51
163-4	9-29-81	10-02-81	9.99 ± 0.54
163-5	10-19-81	10-28-81	9.46 ∓ 0.61
163-6	11-12-81	11-23-81	10.29 ∓ 0.46
163-7	12-18-81	12-21-81	9.37 ∓ 0.27
163-9	1-18-82	1-27-82	10.29 ∓ 0.79
163-10	2-12-82	2-23-82	10.68 ∓ 0.63
163-11	3-23-82	4-01-82	10.62 ∓ 0.41
163-12	4-26-82	5-05-82	10.52 ∓ 0.36
163-15	6-03-82	6-08-82	10.38 ∓ 0.30
163-15 **	8-06-82	8-17-82	10.04 ∓ 0.37
163-16	7-13-82	7-16-82	10.44 + 0.43
163-17	8-16-82	8-20-82	9.99 ∓ 0.32
163-18	9-10-82	9-20-82	10.79 ∓ 0.45
163-20	10-18-82	10-25-82	10.63 ∓ 0.34
163-21	11-22-82	12-02-82	11.01 ∓ 0.30
163-22	12-20-82	12-29-82	11.06 \pm 0.19

- ** Six sampling locations
- ** Nine week stability test

Following chemical analysis of the premixes to determine article concentration (Appendix I), sufficient quantities were diluted with 5002 in a twin shell blender by toxicology personnel to achieve the concentrations of the test article necessary to administer the required dose levels on a two previous periods' body weight and consumption measurements for each test group by sex wire used to project body weight and food consumption values for the next values, Based on these the desired dietary period. concentrations of the test article was calculated. Ten and later 8 kg of each test diet were routinely prepared on a weekly basis. Unused portions of 10% premixes were returned to KOP for disposal in accordance with instructions for safe disposal of explosives. Surplus and uneaten portions of test diets were incinerated.

Thirty test diet concentrations (2 diets/sampling week) used in Test Weeks 1, 13, 28, 39, 45, 51, 57, 63, 70, 75, 81, 87, 93, 98 and 104 were analyzed for accuracy and homogeneity. In addition, two test diets were monitored for stability under animal cage conditions for one week. First, they were sampled

the day they were placed in the animals' cages and again one week later from the uneaten portion of the diet. Recovery studies of test diets consisted of adding a known quantity of RDX (spiking) to a weighed quantity of untreated 5002 in a measured volume of acetonitrile (the solvent used in the extraction procedure). The spiked samples subsequently underwent the identical analysis as the actual diet samples and the percentage of recovery was calculated.

One sample of 5002, lot March 24 82 G, was analyzed during course of the study by Trace Elements, Inc. Park Ridge Il. (TEI) for those contaminants listed in the 5002 certification as shown in Appendix II. The references to the procedures used by TEI are in Appendix III. On the basis of the analytical results for chlortetracycline content, aliquots from this and three additional reserve samples of 5002 were sent to TEI for analysis. In addition, aliquots from these four reserve samples were sent to Scientific Associates, Inc., St. Mo., Woodson-Tenent Laboratories, Inc. and Harris Laboratories, Inc., Lincoln, Neb. for chlortetracycline analysis. Samples of each 5002 lot used in the study were also analyzed for nitrate, nitrite and mercury content by TEI. The results are shown in Appendices VII and VIII.

C. Animals

B6C3F1 mice obtained from Charles River Breeding Laboratories Wilmington, MA, Portage, MI facility were used for this study. Five hundred and seventy six males and 573 females were received in good condition on January 7, 1981. They were 3 to 4 weeks old upon arrival and random body weights recorded within three days of receipt were 16.5 ± 2.6 g (males) and 14.6 ± 1.6 g (females).

The shipment was housed in two quarantine rooms, one each sex. The animal room conditions during quarantine, pretest and test periods were as follows; 21-25 degrees centigrade, ambient relative humidity (30-70%), and 12 hour light /12 hour dark cycle. No other test animals were in the rooms. The animals were housed five per polycarbonate cage (16.5" x 8"; 8" height) with Ab-sorb-dri bedding (Ab-sorb-dri Inc., Rochelle Park, N.J.) from arrival until their termination. Animals were transferred to clean cages twice weekly. Each animal identified during the quarantine period by a combination of cage number and tail mark. Test animal selection was done at onset of Test Week -2 (2 weeks prior to initiation of treatment). Animals placed on test received a study-unique test animal number (N=850) which appeared as a combination ear punch and toe clip. identifing ears and paws were included with This number appeared on the cage card that also contained the study number, dose level and sex. In addition, the cage cards were color coded as to the dose level and sex.

<u>፟ቔቑዄጚጜዀዄዄቔቔቔዀዀቔጜዹዄጚጚጚዹዄዄዄዀ</u>

Upon arrival at the IITRI animal facility, the animals were held in quarantine for 12 days. During this period, they were observed for signs of disease, general unthriftiness, poor coat, discharge from body openings, abnormal feces, etc. Any animals found to be unhealthy were eliminated from the test animal At the end of the quarantine period, five selection process. At the end of the quarantine period, rive animals of each sex were sacrificed. Extensive gross necropsies were performed under the supervision of the pathologist. Blood samples were collected for measurments of hematology and clincal chemistry parameters (see section II.D.) Results of pretreatment health screen were within normal limits for the mice of the mice of this strain and age. Microbiological examination of the digestive and respiratory system for pathogens, molds yeasts, parasites and Mycoplasma pulmonis was also performed for for the above mice with negative results. Serum antibody titer was determined for the following murine viruses: GD-VII virus, K virus, Mouse Adenovirus, Sendai virus, Reovirus 3, Pneumonia virus of mice, Lymphocytic Choriomeningitis, Polyoma virus, Minute virus of mice, Mouse Hepatitis and Ectomelia. These tests for antibody titers were negative as measured by Microbiological Associates, Bethesda MD.

Animals received 5002 rodent chow from arrival until their termination, except during a 2 to 5 hour fast prior to blood collection and/or scheduled sacrifice. The food was available from powdered diet feeders (Model LC-207/C, Wahman Mfg. Co.). City of Chicago drinking water was available ad libitum from glass or plastic bottles.

D. Experimental Design

Following the quarantine period, test-eligible animals were assigned to five treatment groups by a stratified randomization procedure (blocked by body weight). Following assignment to treatment groups, all animals were randomly assigned test animal numbers as shown below. Body weight ranges at randomization were 16.0-24.8 g (males) and 16.0-18.9 g (females). This procedure was performed at the onset of Test Week -2. The animals were approximately 6-7 weeks old upon initiation of treatment and body weight ranges recorded during Test Week -1 (the most recent data prior to initiation of treatment) were 18.3-28.3 g (males) and 15.4-22.3 g (females). The first day of exposure to the test article was February 9, 1931. Dietary administration continued until Test Week 106 (February 18, 1983).

ᠺᠼᠻᢠ᠙ᠪᡶ᠙ᡓᠻᡠᡊᠪᡉᠻᡚᡚᡚᡚ᠘᠘ᡙᠽ᠕ᠽᠰᠼᡤᢘᡚᠪᡚᡭᠻᡚᢕᡛᠣᠰᡚᠻᡠᡳ᠐ᡮᡠᠰ᠘ᡮ᠘ᡮᡚᠰᡠᠰᡠᠰᡚᠰᡚᠰᡚᠰᡚᠰᡚᠰᡚᠰ᠘᠘᠘᠘ᢢ᠘ᢢ᠘᠘᠘᠘

Treatment Group Allocation:

		Dose Level (mg/kg/day)	Test Animal No. (Males)	Test Animal No. (Females)
Ι.	85	0.0	1- 75, 751-760	76-150, 761-770
II.	85	1.5	151-225, 771-780	226-300, 781-790
III.	85	7.0	301-375, 791-800	376-450, 801-810
IV.	85	35.0	451-525, 811-820	526-600, 821-830
v.	85 1	75.0/100.0*	601-675, 831-840	675-750, 841-850

* The 175.0 mg/kg/day dose level resulted in high mortality for mice of both sexes through Test Week 10. The dose was subsequently lowered to 100.0 mg/kg/day commencing with Test Week 11 (4-20-81).

The appropriate test diets were available to the test animals ad libitum from Test Day 1 until their termination except during a 2 to 5 hour fast prior to either blood collection in Test Weeks 14, 26, 53, 79 and 105 or scheduled sacrifice in Test Weeks 26, 53 and 105-106. Thus, all animals received the appropriate test diet until approximately one day prior to their scheduled sacrifice. Test diets were prepared weekly for each treatment group, by sex, on the basis of projected body weight and food consumption data.

Commencing with Test Week-2 until their termination, all animals were observed once daily in the morning for any pharmacologic and/or toxicologic signs. Afternoon mortality checks were initiated on Test Day 1. Physical examinations which included body weights and palpations for masses were conducted weekly from Test Week -2 until Test Week 13, then biweekly until Test Week 104. Food consumption was measured weekly for each cage of test animals commencing with Test Week -2 through Test Week 13, then biweekly through Test Week 104. Mean daily food consumption per animal was calculated from these data. During Test Week 64 food consumption was measured instead of Test Week 63, when it was inadvertantly omitted and actual doses delivered were not calculated for this period as shown in Tables 1 and 2.

All surviving animals were subjected to ophthalmic examinations during Test Weeks -2, 25, 51, 78 and 103. The examination consisted c indirect ophthalmoscopy and biomicroscopy. Only animals found to be free of clinically apparent lesions in the pretest examination were used in the study.

Blood samples, approximately 0.3 ml, were collected for measurments of hematology and clinical chemistry parameters for 10 randomly selected mice/sex/dose level, exclusive of Test Weeks 14 and 26 when due to errors in randomization the number of

mice/sex/dose level ranged from 8 to 12. During Test Weeks 26, 53, and 105, the selected mice were sacrificed and approximately 1.0 ml of blood was collected prior to necropsy. During Test Weeks 14 and 79, one set of 10 mice/sex/dose level, except as stated above, was randomly selected for hematology tests and a second set of mice was selected for measurments of clinical chemistry parameters. At Test Week 79, blood samples were not collected from the mice at the 175.0/100.0 mg/kg/day dose level. This was done in an attempt to avoid nontreatment-related stress for this group of animals. Blood was collected from each animal via the orbital sinus. The samples were collected and analyzed in a randomized order over a 3 or 4 consecutive day period and the following parameters were measured:

Hematology:

Hematocrit (HCT)
Hemoglobin (HGB)
Mean corpuscular volume (MCV)
Mean corpuscular hemoglobin (MCH)
Mean corpuscular hemoglobin concentration (MCHC)
Erythrocyte count (RBCs)
Leukocyte count (WBCs), total and differential
Platelet count (PLT)

Clinical chemistry:

Glucose (GLU)
Blood urea nitrogen (BUN)
Serum glutamic-pyruvic transaminase (SGPT)
Triglycerides (TRIG)
Total cholesterol (CHOL)
Total protein (T PRO)
Albumin (ALB)
Globulin (GLOB), (calculated value)
ALB/GLOB ratio (calculated value)

Gamma glutamyl transferase (GGT) determinations were not performed due to insufficient blood volume collection. Methods used to measure the above parameters are listed in Appendix IV (hematology) and Appendix V (clinical chemistry).

All animals which were sacrificed in a moribund state or died on test were necropsied regardless of autolytic state. Ten randomly selected animals/sex/dose level, after exclusion of animals designated for blood collection, were sacrificed during each of Test Weeks 26 and 53. At the 175.0/100.0 mg/kg/day dose level during Test Week 26, 12 males and 8 females were sacrificed due to a randomization error. Three hundred and twenty two surviving test animals were sacrificed and necropsied in random order during Test Weeks 105 and 106. Terminal body weights were recorded immediately prior to sacrifice. Euthanasia was

accomplished with carbon dioxide anesthesia followed by exsanguination from the abdominal aorta or the orbital sinus. The necropsy procedure was a thorough and systematic examination of the animal viscera and carcass with collection and fixation of the following tissues:

٩

9

C

-

```
Adrenals
Bone marrow smear
*Brain
Cecum
Colon
Costochondral junction, rib
Duodenum
Epididymes
Esophagus
Eves
Gall bladder
Gross lesions
*Heart
Ileum
Jejunum
*Kidneys
Larynx
*Liver
Lungs and mainstem bronchi
Lymph nodes (mandibular and mesenteric)
Mammary gland
Muscle
Nasal turbinates
Ovaries
Pancreas
Pituitary gland
Prostate
Rectum
Salivary gland
Sciatic nerve
Seminal vesicles
Skin, abdominal
Spinal cord (cervical, thoracic, lumbar)
*Spleen
Sternum, including bone marrow
Stomach
*Testes
Thymus
Thyroids (parathyroids)
Tissue masses
Trachea
Urinary bladder
Uterus
```

^{*}These organs were weighed during scheduled necropsies.

All tissues, except eyes, testes and bone marrow, were fixed at a thickness not exceeding 0.5 cm in 10% neutral buffered formalin (NBF) which was changed 24 hours later. Eyes and testes were fixed in 3% aqueous glutaraldehyde and Bouin's Solution, respectively, for 24 hours. They were transferred to 50% ethanol for 24 hours, then placed in 70% ethanol. Bone marrow smears were prepared from the femur using the "paint brush technique". They were air-dried and fixed in absolute methanol. Lungs and urinary bladder were inflated with NBF prior to immersion in this fixative. The stomach was opened and flattened on paper prior to fixation. All tissues examined microscopically were cut at a thickness of 4 to 6 microns and stained with hematoxylin and eosin.

Tissues from all animals receiving 0.0 and 175.0/100.0 mg/kg/day were subjected to comprehensive histopathologic examination, defined as microscopic examination of the following tissues and/or organs:

Adrenals *Brain (3 sections) Cecum Colon Duodenum **Epididymes** Eyes and optic nerves Gall bladder Gonads Gross lesions Heart Ileum Jeiunum Kidneys Liver Lungs and mainstem bronchi Mammary gland Mesenteric lymph node Pancreas Pituitary gland Prostate Rectum Spinal cord (cervical, thoracic and lumbar) Sternum including bone marrow Stomach Tissue masses Thyroids (parathyroids) Trachea Urinary bladder Uterus

*(1) frontal cortex and basal ganglia; (2) parietal cortex and thalmus; and (3) cerebellum and pons.

STATES OF THE ST

Tissues from all animals receiving 1.5, 7.0 and 35.0 mg/kg/day were subjected to limited histopathologic examination defined as microscopic examination of at least the following tissues and/or organs:

0

(1)

٨

٨

8

*Brain (3 sections)
Gonads
Heart
Liver
**Lungs
Kidneys
Spleen
Spinal cord (cervical, thoracic and lumbar)
Tissue masses

*(1) frontal cortex and basal ganglia; (2) parietal cortex and thalmus; and (3) cerebellum and pons.

**Lungs were examined for mice which died or were sacrificed after 12 months on test.

E. Statistical Analysis

Those variables that were repeatedly measured, e.g. food consumption, and clinical pathology parameters were statistically analyzed using a multivariate analysis of variance (MANOVA) for repeated measurements model. Variables that were measured a single time, e.g. organ weights, were analyzed using both univariate and multivariate analysis of variance procedures. In the presence of significant analysis of variance (ANOVA) results, a series of post-hoc analyses were conducted by Dunnett's test appropriate to a single control for comparison. Frequency data, such as incidences of mortality, organ weights, and histopathologic lesions were compared using log-linear analysis techniques where appropriate. Time to death data were analyzed using Kaplan-Meier and regression analyses. Cox Individual animal data can be found in Appendix VI.

Statistical packages for MANOVA (both fixed-effect and "growth curve" model) were conducted using the computer program MULTIVARIANCE at the University of Chicago and is based on the work of Bock, 1975 (3). Log-linear models which were used for the analysis of "quantel data" were fitted using MULTIQUAL also at the University of Chicago and written by Darrell Bock. This model is equivalent to probit analysis in that the logistic distribution is 1.7 times the normal throughout almost all of its range. Cox regression models were fitted using SAS and Life Table models (Kaplan-Meier estimator) using BMDP. The program used is at the University of Chicago and was developed in the Department of Statistics for tabulations of this kind and has been thoroughly tested for accuracy.

Log-linear models were used to test overall treatment effects. Individual comparisons were obtained by fitting ratios of the maximum likelyhood estimates to their standard errors for individual treatment vs control comparisons (i.e. Wald's test). These estimates are a byproduct of the log-linear model.

The Type 1 error rate was set to 5% (i.e., \leq 0.05) a-priori. Fisher's exact tests were only performed in the presence of a significant main effect of dosage obtained in the log-linear model, therefore the Type 1 error rate of p \leq 0.05 was maintained in spite of the multiple post-hoc comparisons.

To adjust for the problem of multiple comparisons for quantel data analyzed using Fisher's exact test, we used Bonferroni's inequality.

III. RESULTS

A. Test Diets

Doses received by test animals based on their body weights and food consumption, and theoretical concentrations of RDX in the diet are shown in Tables 1 and 2.

Analytically determined concentrations of RDX in test diets were found to be very close to their intended concentrations. The overall percent mean + S.D. for the analyzed/intended ratio was 94.3 + 7.5% (Table 3).

B. Food and Water Contaminants

The TEI analytical results of a 5002 sample for those contaminants listed in the 5002 certification profile (Appendix II) are shown in Appendix III. The results of the repeat testing of 5002 samples for chlortetracycline content are contained in Appendix VII. The three reference laboratories which reanalyzed the 5002 samples following TEI generally reported negligible quantities of chlortetracycline.

A sample from each 5002 lot was analyzed for nitrate, nitrite and mercury content. The results are shown in Appendix VIII. Analytical results obtained from a sample of Chicago water are contained in Appendix IX.

C. Mortality/Clinical Observations

RDX at 175 mg/kg/day was lethal to many male and female mice during the first ten weeks of treatment. At the onset of Test Week 11, this dose level was reduced to 100 mg/kg/day. Although additional deaths were observed in this treatment group for a few weeks following dose level change, survival curves for these

animals were, in general, similar to those for control animals beyond Test Week 12 (Table 4, Figures 1 and 2).

(3)

٩

3

ě)

The incidence of fighting wounds and/or skin lesions was greater for males at the highest dose (175/100 mg/kg/day) than for males in the other treatment or control groups. This was seen primarily during the first part of the study (approximately through the first year). Subsequently, all male treatment and control groups demonstrated high incidences of these observations (Figure 3). A single occurence of convulsions was seen for one male at the 35.0 and one female at the 175/100 mg/kg/day dose level during the last month of the study. Slightly more female than male mice were seen with hair loss. This "barbering effect" was not observed in a dose-related fashion and is common for multiple housed mice of this strain.

D. Body Weight

Reductions in body weight gains were observed for males and females at the 175/100 mg/kg/day dose level. Females at this dose demonstrated reduced body weight gains throughout the entire study. For males, this occurred primarily during the first 12 weeks of treatment which corresponded to administration of 175 mg/kg/day. A slight reduction was also seen for these males from Test Week 93 through study termination.

Sporadic reductions in body weight gains were als: seen for males receiving 1.5 mg/kg/day. As this was not observed for males at the intermediate doses, either 7 or 35 mg/kg/day, this observation was considered to be spurious (Tables 5-8).

E. Food Consumption

Food consumption did not appear to be altered by RDX treatment. Sporadic increases and decreases were observed which were not dose-related and were not, therefore, considered to be biologically significant (Tables 9 and 10).

F. Hematology

Hematology parameters were, in general, unaltered by RDX treatment. Slight reductions in hematocrit and hemoglobin concentration were seen for high dose females at Test Week 53, however, this was not seen at any other sampling time (Tables 11-20).

G. Clinical Chemistry

Hypercholesterolemia was apparent for RDX-treated mice of both sexes. The effect was more pronounced in females. Elevated serum cholesterol levels were seen earlier (Test Week 14) and to a greater extent for this sex. Only 175/100 mg/kg/day-treated

males were affected whereas female mice given 35.0 and 7.0 mg/kg/day demonstrated hypercholesterclemia.

Serum triglyceride levels may have been altered by RDX treatment. They were elevated for females administered 35 mg/kg/day and sampled in Test Week 79 (mice given 175/100 mg/kg/day were not bled at that time) At Test Week 105, mean serum criglyceride levels were higher for RDX-treated females than for controls, however these changes were not statistically significant. This parameter did not appear to be affected for male mice. No other clinical chemistry parameters appeared to be altered by RDX treatment (Tables 21-30; Figures 3 and 4).

H. Ophthalmology

The Narrative Ophthalmology Report is contained in Appendix X. The complete Ophthalmology Report can be found in Vol. II*. Initially, a statistically significant increased incidence of cataracts was seen during Test Week 103 only for the male mice administered 175/100 mg/kg/day, however, when animals used for orbital bleeding were eliminated for the purpose of statistical evaluations, this treatment-related effect was no longer apparent. All other ophthalmologic abnormalities observed occurred in random fashion and were not considered to be treatment-related (Tables 31 and 31a).

I. Organ Weights

Hepatomegaly and increased relative kidney weights were seen primarily for males and females administered 175/100 mg/kg/day of RDX. This was observed at both interim kills and at study termination. For mice given 35 mg/kg/day, hepatomegaly was observed during Test Week 53 (females), and relative renal weights were elevated at study termination (males). In addition, relative heart weights were significantly increased for 175/100 mg/kg/day-treated mice of both sexes after two years of treatment. No other organ weights appeared to be altered by RDX (Tables 32-47).

J. Pathology

The Narrative Pathology Report appears in Appendix XI. The entire Pathology Report can be found in Vol. III*. At the six month kill, red lungs, dark red spleen and liver, and distended red fluid-filled urinary bladders appeared more frequently for mice receiving 175/100 mg/kg/day than for control animals.

^{*}Requests for Volumes II and III should be directed to Health Effects Research Division, U.S. Army Medical Bioengineering Research and Development Laboratory, Fort Detrick, Maryland 21701-5012.

Histopathologic lesions related to these observations, however, were not in evidence. The incidence of renal tubular cytoplasmic vacuolation was greater for males at all dose levels than for the corresponding controls. At the 12 and 24 month kills however, this lesion was observed for control animals as frequently as for animals treated with RDX. No other renal changes were seen in this study.

Throughout the study, histologic evidence of chronic dermatitis and ulcers for RDX-treated males was supported by gross observations. As discussed under Clinical Observations (Section III.C), these lesions were interpreted as fighting wounds associated with RDX-induced behavioral changes. With the exception of fighting wounds, neither gross nor histopathologic lesions related to RDX treatment were apparent at the 12 month kill.

By 24 months of treatment, several histologic changes were ascribed to the administration of RDX. Statistically significant findings for male mice were decreased incidence of hepatocellular adenomas at the 7.0 mg/kg/day and increased incidence of lymphoid hyperplasia in the spleen at the 1.5 and 7.0 mg/kg/day dose levels. However, the biological significance of these changes could not be established. A non-statistically significant increase in alveolar/bronchiolar carcinomas was seen in high dose male and female mice. Incidence of alveolar/bronchiolar carcinomas and adenomas for study controls were within the range of incidences of alveolar/bronchiolar carcinomas in both sexes of historical control mice.

Although statistically not significant, there was an increased incidence of testicular degeneration seen for males mice given either 35.0 or 175/100 mg/kg/day when compared to the corresponding control animals or historical controls (6). Both of these treatment groups demonstrated incidences of approximately 10-11% compared with 0% for control animals and 1.5% incidence in the historical control group.

The incidence of hepatocellular carcinoma showed an increase, however statistically not significant, in female mice receiving either 35.0 or 175/100 mg/kg/day compared to control female mice. Only when combined adenoma/carcinoma data were analyzed, were statistically significant increases observed for both 7.0, 35.0 and 175/100 mg/kg/day females compared to either concurrent or historical control data. This was apparent even though concurrent controls had a significantly lower incidence than historical controls. Historical control data from the National Toxicology Program (5) were subsequently included in the statistical analyses as the female concurrent control group demonstrated a low incidence of liver tumors. When this was

performed, female mice receiving 35.0 mg/kg/day still showed a significant increase in liver carcinomas and adenomas.

An additional microscopic change in the lungs was a statistically significant increased number of histiocytes for females administered 175/100 mg/kg/day. All other lesions observed microscopically were considered spontaneous, naturally occuring degenerative, inflammatory and/or neoplastic diseases which commonly occur in an aging male and female mouse population of the B6C3F1 strain (Tables 44-46).

IV. DISCUSSION

The administration of 175 mg/kg/day of RDX to male and female B6C3F1 mice resulted in death during the first ten weeks of treatment. This dose was reduced to 100 mg/kg/day in Test Week 11. Subsequently the slope of survival curves were similar for this treatment group and control animals for the duration of the study. Although these high dose animals showed slight reduction in body weight gains, food consumption was not affected.

Surviving males in this high dose group demonstrated significant skin lesions apparently associated with fighting wounds. RDX is known to induce behavioral changes including hyperreactivity to approach and fighting with cage mates (3). Histologic evaluation failed to detect treatment-related lesions of the central nervous system.

Liver injury at 175/100 and to a lesser extent 35.0 mg/kg/day was evidenced by several observations. These included hypercholesterolemia, elevated serum triglyceride levels and hepatomegaly. With the exception of hepatocellular tumors (discussed below), histopathologic lesions of the liver were not observed.

At the 6, 12 and 24 month kill, kidney weights were elevated for mice of both sexes administered 175/100 mg/kg/day. Cytoplasmic vacuolation of renal tubules appeared to be more prevalent for RDX-treated males than corresponding control animals after six months of treatment. This lesion was subsequently seen at 12 and 24 months as frequently for control as for treated animals.

Although statistically not significant, an increased incidence of hepatocellular carcinoma was seen in RDX treated female but not male mice. The combined incidences of hepatocellular carcinoma and adenoma were statistically greater for female mice receiving 7.0 mg/kg/day or higher doses than for the concurrent female control group. When historical control data were included in the statistical analyses, the two top dose

levels still demonstrated significant increases in the incidence of combined liver carcinomas and adenomas; however, the actual historical control incidences fell between that of the study control and treated female mice.

0

(3)

۹

non-statistically significant increase alveolar/bronchiolar carcinomas was seen in high dose male and female mice. Comparison of study controls to the appropriate historical controls showed that the alveolar/bronchiolar carcinomas and adenomas for study control mice was within the range of incidences of alveolar/bronchiolar carcinomas in both sexes of historical control mice. additional statistically significant observation was an increased number of histiocytes in lungs of the female mice receiving 175/100 mg/kg/day.

Additional toxic effects seen primarily at 175/100 mg/kg/day included enlarged hearts without accompanying histologic lesions. Although not statistically significant, increased incidences of testicular degeneration were seen for the male mice at the 175/100 and 35.0 mg/kg/day dose levels (11.1% respectively), when compared to the concurent controls (0%) or to historical controls (1.5%) (6). Absolute or relative testicular weight change failed to accompany histopathological finding.

In summary, the major toxic effects observed during the administration of RDX to B6C3F1 mice for up to 24 months included hepatotoxicity, possible CNS involvement and testicular degeneration. In addition, hepatocellular and alveolar/bronchial carcinomas and adenomas were more prevelant for RDX-treated mice than for corresponding controls. The incidence of hepatocellular tumors (combined carcinomas and adenomas) was significantly increased at the 7/mg/kg/day level. On this basis, the no-effect level under the conditions of the present study is 1.5 mg/kg/day.

V. REFERENCES

- 1. Good Laboratory Practice Regulations. Fed. Reg. 21 CFR Part 58. 60013-60020, 1978.
- 2. Levine, B.S., Furedi, E.M., Gordon, D.E., Burns, J.M., and Lish, P.M. Thirteen Week Oral (Diet) Toxicity Study of Trinitrotoluene (TNT), Hexahydro-1,3,5-trinitro-1, 3,5-triazine (RDX) and TNT/RDX Mixtures in the Fischer 344 Rat. Final Report No. L6116/L6121, Study No. 1.
- 3. Levine, B.S., Furedi, E.M., Sagartz, J.W., Rac, V.S., and Lish, P.M. Twenty-Four Month Month Chronic Toxicity/ Carcinogenicity Study of Hexahydro-1,3,5-trinitro-1,3,5triazine (RDX) in the Fischer 344 Rat. Final Report No. L6121, Study 6.
- 4. Reference on NTP historical control data. (i.e., NTP Bulletin 10).
- 5. Bock, R.D. Multivariate Statistical Methods in Behavioral Research. McGraw-Hill, New York, 1975.
- Ward, J.N., Goodman, D.G., Squire, R.A., Chu, K.C., Linhart, M.S. Neoplastic and Nonneoplastic Lesions in Aging (C57BL/6NX C3H/HeN)F1 (B6C3F1) Mice. NCI, Vol. 63, No. 3, 1979.

TABLES

Table 1

IWENTY FOUR MONTH CHROWIC TOXICITY/CARCINGENICITY STUDY OF

BGC3F1 MOUSE	175/100 MG/KG/DAY	85) 166.18 ± 24.06 (85)	85) 197.74 ± 31.39 (85)	85) 174.06 ± 19.78 (84)	85) 192.43 ± 33.43 (79)	85) 242.40 ± 48.42 (71)	85) 175.89 ± 36.13 (67)	85) 142.59 ± 31.00 (67)	85) 172.31 ± 38.76 (67)	85) 158.20 ± 35.04 (64)	85) 185.04 ± 36.89 (60)	85) 87.51 ± 13.38 (55)	85) 108.40 ± 34.21 (54)	85) 108.44 ± 17.17 (55)	85) 89.23 ± 8.85 (55)	85) 106.39 ± 14.44 (55)	85) 108.79 ± 11.99 (54)	85) 92.31 ± 10.75 (54)	84) 104.27 ± 22.67 (54)	84) 105.15 ± 15.76 (54)
IN THE g/day)	35 MG/KG/DAY	34.91 + 5.64 (38.52 ± 5.87 (34.44 ± 6 55 (36.28 ± 4.96 (32.86 ± 5.17 (36.58 ± 5.55 (33.69 ± 5.73 (34.81 ± 5.97 (34.33 ± 5 07 (34.01 ± 4.25 (34.78 ± 3.86 (34.74 ± 4.68 (40.61 ± 4.83 (32.60 ± 4.59 (34.82 ± 3.78 (37.23 ± 3.94 (33.25 ± 3.98 (34.50 ± 5.08 (34 61 ± 4.89 (
.3.5-TRINITRO- MALE DOSAGE [MEAN AND	7 MG/KG/DAY	7.31 ± 1.06 (85)	7.76 ± 1.38 (85)	6.48 ± 0.74 (85)	6.22 ± 0 50 (85)	7.57 ± 0.77 (85)	7,42 ± 0.67 (85)	6.36 ± 0.70 (85)	7.07 ± 0.74 (85)	6.66 ± 0.59 (85)	7.01 ± 0.75 (85)	7.19 ± 0.68 (85)	6.49 ± 0.43 (85)	7.68 ± 0.82 (85)	6.90 ± 0.64 (85)	6.80 ± 0.56 (85)	7.21 ± 0.61 (85)	6.64 ± 0.63 (85)	7.01 ± 0.82 (84)	7.00 ± 0.75 (94)
HEXAHYDRO-1	1.5 MG/KG/DAY	1,44 ± 0,16 (85)	1.68 ± 0.24 (85)	1.30 ± 0.16 (85)	1.50 ± 0.14 (85)	1.59 ± 0.23 (85)	1.65 ± 0.17 (85)	1,44 ± 0,16 (85)	1.47 ± 0.21 (85)	1.63 ± 0.21 (85)	1.49 ± 0.18 (85)	1.41 ± 0.19 (85)	1.44 ± 0.20 (85)	1.65 ± 0.22 (85)	1.47 ± 0.17 (85)	1.42 ± 0.18 (85)	1.59 ± 0.21 (84)	1.37 ± 0.17 (83)	1.43 ± 0.18 (83)	1.57 ± 0.17 (83)
	TEST WEEK	-	2	က	4	រេ	9	7	80	6	10	11	12	13	15	17	19	21	23	25

--- = NO AVAILABLE DATA

0

Table 1 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE DOSAGF MEASUREMENTS (mg/kg/day) {MEAN AND STANDARD DEVIATION (n)}

TEST WEEK	1.5 K MG/KG/DAY	7 MG/KG/DAY	35 MG/KG/DAY	175/100 MG/KG/DAY
27	1.66 ± 0.20 (73)		38.11 ± 4 68 (73)	100.52 ± 21.42 (42)
29	151 ± 0.23 (73)	7.15 ± 0.79 (73)	33.32 ± 3.61 (72)	90.06 ± (6.53 (42)
31	1.52 ± 0.18 (73)	7.24 ± 0.97 (73)	38.56 ± 5.63 (72)	109.98 ± 20.92 (41)
33	1.45 ± 0.14 (73)	6.46 ± 0.69 (72)	32.69 ± 3.24 (72)	106 08 ± 20.07 (39)
32	1.59 ± 0.49 (72)	7.04 ± 0.90 (72)	36.25 ± 3.48 (72)	96.62 ± 13.90 (39)
37	161 ± 0.18 (72)	7.73 ± 0.76 (72)	38.59 ± 5.16 (72)	110.02 ± 19.56 (38)
36	1.41 ± 0.19 (72)	6.52 ± 0.65 (72)	31.38 ± 3.68 (72)	92.12 ± 12.77 (38)
4 1	151 ± 0.21 (72)	6.85 ± 0.71 (72)	37.53 ± 3.63 (71)	101.03 ± 16.17 (38)
43	1.47 ± 0 23 (72)	7.52 ± 0.77 (72)	36.24 ± 3.89 (71)	103.63 ± 45.71 (38)
45	1.69 ± 0.24 (72)	7.08 ± 0.72 (72)	34.42 ± 3.50 (71)	102.82 ± 13.45 (38)
47	1.41 ± 0.28 (72)	6.90 ± 0.86 (72)	35.52 ± 5.24 (70)	93.39 ± 13.38 (38)
49	1.55 ± 0.23 (71)	7.08 ± 0.88 (72)	32.96 ± 3.08 (70)	105.47 ± 16.14 (38)
5.	1.48 ± 0.19 (71)	$6.72 \pm 0.88 (72)$	33.95 ± 3.42 (69)	99.26 ± 20.56 (38)

--- = NO AVAILABLE DATA

Table 1 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE DOSAGE MEASUREMENTS (mg/kg/day) [MEAN AND STANDARD DEVIATION (n)]

	34)	27)	27)	27)	27)	26)	(97	(9;	(9	(9;	(9;	(2)	(2)
λ Α	100.66 ± 34.51 (34)	(05.67 ± 17.49 (27)	94.92 ± 17.38 (27)	· ·	103.18 ± 17.82 (27)	~	101.13 ± 17.27 (26)	123.18 ± 32.19 (26)	86.19 ± 13.94 (26)	104.08 ± 20.82 (26)	106.35 ± 20.60 (26)	114.84 ± 18.64 (25)	104.63 ± 16.06 (25)
175/100 MG/KG/DAY	34.5	17.48	17.38	6.83	17.82	17.63 (7.27	2. 45	3.94	0.83	0.60	8.64	90.9
17 MG/	+1	+1	+1	+1	+1	+1	+1	+1	+1	+1	+1	+1	+1
	30.66	5.67	14.92	100.91 ± 16.83 (3. 18	94.95 ±	1.13	3.18	6. 19	94.08	6.35	4.84	4.63
,	₹	₽	0,	₽	₽	0)	2	7	w	Ç	₽	Ξ	2
	(99	53)	55)	58)	58)	57)	57)	58)	54)	54)	54)	54)	49)
DAY	2	3.93 (53)	4.59 (3.87 (4.45 (5 (6.31 (57)	4	4.12 (54)	4.01 (4.69 (54)	4.23 (54)	9
35 MG/KG/DAY	35.70 ± 3.35 (66)		5.5	3.8	4.4	4.55	6.3	5,54	4.	4.0	4.6		36.03 ± 4.36 (49)
MG	+!	+1	+1	+1	+ i	+1	+!	+1	+1	+1	+1	+1 ∞	+1
	35.7(37.01 ±	36.19 ±	33.31 ±	35.63 ±	32.75 ±	32.77 ±	42.82 ±	31.88 ±	32.99 ±	33.82 ±	35.38 ±	96.03
	.,	.,	•	• • •	.,	.,	.,	•	()	• •	.,	()	()
	(69)	62)	62)	62)	62)	62)	62)	62)	61)	(09	(09	58)	52)
λVQ	ر 8	8	0.79 (62)	0.81 (62)	1.37 (62)	1.51 (62	1.48 (62)	1.56 (62)	1.18 (61)	1.66 (60)	1.04 (60)	1.02 (58)	0.63 (52)
7 MG/KG/DAY	7.16 ± 0.78 (69)	7.37 ± 0.88 (62)	0.7	0.8	1.3	1.5	1.4	τ. Ω	-	-	-	÷.	0.6
MG	+1	+1	+1	+ }	+1	+;	+1	+1	+1	+1	+1	+1	+ i
	7.16	7.37	6.79 ±	6.83 ±	6.90 ±	7 17 ±	6.66 ±	8.48 +	6.25 ±	7.43 ±	7.00 ±	7.21 ±	7.23 ±
,													
	68)	(09	29)	59)	(69	29)	59)	23)	29)	29)	(69	57)	51)
λAζ	0.27 (68)	0.38 (60)	0.23 (59)	<u> </u>	_	· ·	0.24 (59)	~ ~	0.20 (59)	0.31 (59)	0.25 (59)	0.16 (57)	0.20 (51)
1.5 /Y.G/[0.2	0.36	0.2	0.46	0.5	0.26	0.5	0.28	0.20	0.3	0.25	0.16	0.20
MG/	+1	+1	+1	+1	+ }	+1	+1	+!	+ i	+1	+ }	+1	+ 1
	1.48	1.73	1.45	1.49	1.49	1.33	1.47	1.87	1.28	1.66	1.49	1.56	1 61
1.5 MG/KG/DAY													
TEST WEEK	53	22	57	23	61	65	67	69	7.1	73	75	11	79
F- 3													

--- = NO AVAILABLE DATA

(3)

9

0

D

٩

٣

(Ť)

Table 1 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE DOSAGE MEASUREMENTS (mg/kg/day) [MEAN AND STANDARD DEVIATION (n)]

175/100 MG/KG/DAY	98.92 ± 12.39 (25)	101.30 ± 20.60 (25)	121,16 ± 21,93 (25)	97.95 ± 15.36 (25)	108.98 ± 20.73 (25)	99.27 ± 23.76 (23)	104.02 ± 17.14 (23)	96.76 ± 12.39 (23)	101.85 ± 13.69 (22)	98.67 ± 14.26 (22)	100.44 ± 14.53 (22)	90.00 ± 10.62 (22)	91.00 ± 12.32 (22)		175/100 MG/KG/DAY	125.87 ± 46.50 (2378)
35 MG/KG/DAY	34.71 ± 4.15 (54)	34 20 ± 4.16 (54)	35.67 ± 4.33 (53)	33.00 ± 4 13 (52)	36.27 ± 4.73 (52)	36.22 ± 5.70 (49)	33.76 ± 4.59 (46)	34.32 ± 4.18 (45)	35.60 ± 5.06 (45)	34.42 ± 4.84 (40)	35.88 ± 5.26 (39)	31.69 ± 4.53 (38)	33, 19 ± 5,20 (37)	CROSS TIME (mg/kg/day) VIATION (n)]	35 MG/KG/DAY	35.10 ± 5.10 (3874)
7 MG/KG/DAY	7.01 ± 0.81 (57)	6.75 ± 0.71 (56)	7.52 ± 0.79 (56)	6.26 ± 0.79 (56)	7 92 ± C 77 (54)	6.98 ± 0 86 (50)	6.93 ± 0.71 (53)	7.14 ± 1.29 (52)	7.25 ± 1.15 (49)	$6.74 \pm 0.71 (45)$	7.72 ± 0.95 (44)	6.10 ± 0.60 (41)	5.96 ± 0.62 (41)	COMBINED DOSAGE MEASUREMENTS ACROSS TIME (mg/kg/day) [MEAN AND STANDARD DEVIATION (n)]	7 MG/KG/DAY	7.02 ± 0.99 (4000)
1.5 MG/KG/DAY	1.51 ± 0.16 (55)	1.48 ± 0.19 (54)	1.71 ± 0.21 (54)	1.41 ± 0.22 (52)	1.58 ± 0.21 (51)	1.60 ± 0.21 (50)	1.46 ± 0.17 (50)	1.59 ± 0.21 (50)	1.57 ± 0.20 (48)	1.44 ± 0.17 (47)	1.67 ± 0.30 (46)	1.36 ± 0.19 (42)	$1.44 \pm 0.19 (42)$	COMBINE	1.5 MG/KG/DAY	1.52 ± 0.24 (3954)
TEST	8	83	85	87	89	916	69	95	26	66	101	. 103	104		SEX GROUP	MALES

175 MG/KG/DAY (WEEKS 1 - 10)

100 MG/KG/DAY (WEEKS 11 - 104)

101.77 ± 18.51

182.86 ± 25.12

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE DOSAGE MEASUREMENTS (mg/kg/day)

		[MEAN AND STANDARD DEVIATION (n)]	EVIATION (n)]	
TEST WEEK	1.5 MG/KG/DAY	7 MG/KG/DAY	35 MG/KG/DAY	175/100 MG/KG/DAY
-	1.23 ± 0.27 (85)	5.33 ± 1.07 (85)	28.19 ± 5.45 (85)	112.51 ± 16 49 (85)
8	1.20 ± 0.21 (85)	6.05 ± 1.20 (85)	28.85 + 5.36 (85)	130.80 ± 20.14 (84)
ဗ	1.50 ± 0.27 (85)	7.79 ± 1.71 (85)	39.60 ± 6.16 (85)	272.24 ± 60.47 (73)
4	1.61 ± 0.34 (85)	7.08 ± 1.35 (85)	37.87 ± 8.84 (85)	215.28 ± 57.97 (61)
រភ	1.50 ± 0.24 (85)	6.53 ± 0.93 (85)	32.31 ± 7.03 (85)	195.88 ± 51.53 (60)
g	1.32 ± 0.32 (85)	6.36 ± 1.22 (85)	28.65 ± 3.44 (80)	144.60 ± 25.63 (60)
7	1.36 ± 0.22 (85)	7.05 ± 1.21 (85)	35.10 ± 4.89 (85)	137,47 ± 39.04 (55)
ສ	1.35 ± 0.18 (85)	6.31 ± 0.87 (85)	32.97 ± 3.29 (85)	209.36 ± 34.65 (58)
6	1.66 ± 0.24 (85)	6.79 ± 0.77 (85)	34.06 ± 3.58 (85)	147.69 ± 40.24 (53)
0;	1,44 ± 0,23 (85)	7.46 ± 1.33 (85)	34,48 ± 4.94 (85)	170.53 ± 22.51 (53)
Ξ	1.37 ± 0.23 (85)	6.84 ± 0.89 (85)	30.92 ± 2.45 (85)	99.13 ± 27.62 (49)
12	1.45 ± 0.15 (85)	6.58 ± 0.82 (85)	36.29 ± 3.10 (85)	الار 82 + 15 66 (49)
13	1.46 ± 0.15 (85)	7.43 ± 0.81 (85)	36.02 ± 3.14 (85)	94.87 ± 12.21 (49)
15	1.52 ± 0.18 (85)	6.88 ± 0.77 (85)	32.60 ± 2.82 (85)	88.70 ± 11.09 (49)
17	1.48 ± 0.18 (95)	6.70 ± 0.79 (85)	36.44 ± 4.55 (85)	95.46 ± 10.98 (49)
19	1.63 ± 0.19 (85)	8.16 ± 0.83 (85)	34.53 ± 3.28 (85)	110.60 ± 15.43 (49)
21	1,43 ± 0,19 (85)	6.08 ± 0.73 (85)	32.87 ± 3.02 (85)	90 53 ± 13.77 (49)
23	1.51 ± 0.22 (85)	7.46 ± 0.95 (85)	35.34 ± 4.85 (85)	96.40 ± 12.12 (49)
25	1.47 ± 0.22 (85)	6.53 ± 0.80 (85)	39.93 ± 7 93 (80)	101.92 ± 19.13 (49)

- = NO AVAILABLE DATA

Table 2 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE DOSAGE MEASUREMENTS (mg/kg/day) [MEAN AND STANDARD DEVIATION (n)]

7.51 ± 0.87 (75) 6.46 ± 0.97 (75) 7.96 ± 1.20 (74)
6.72 ± 1.08 (74)
7.23 ± 1.23 (74) 6.76 ± 0.87 (74)
7.09 ± 0.98 (74)
0.84 (74)
8.26 ± 2.34 (74)
0.99 (74)
6.62 ± 0.94 (74)

--- = NO AVAILABLE DATA

Table 2 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINGGENICITY STUDY OF HEXAHYDRO-1.3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE DOSAGE MEASUREMENTS (mg/kg/day) {MEAN AND STANDARD DEVIATION (n)}

TEST WEEK	1.5 MG/KG/DAY	7 MG/KG/DAY	35 MG/KG/DAY	175/100 MG/KG/DAY
	1.5: ± 0.23 (70)	7 41 ± 1.28 (71)	35.69 ± 4.32 (70)	93.05 ± 13.78 (38)
	1.55 ± 0.27 (63)	7 C9 + 1.06 (64)	37.84 ± 4.99 (64)	106.53 ± 21.75 (31)
	1 54 ± 0.25 (62)	7.34 \$ 1.11 (64)	34.22 ± 4.03 (64)	1035 ± 14.07 (31)
	1 45 ± 0.23 (62)	7.18 ± 1.01 (64)	37. (4 ± 4.76 (64)	98.80 ± 17.27 (31)
	1.51 ± 0.23 (62)	6.43 ± 0.93 (64)	33.11 2 4.76 (64)	97.94 ± 16.31 (30)
	1.41 ± 0.23 (62)	6.54 ± 0 83 (64)	33.26 ± 4.53 (63)	97.72 ± 18.35 (30)
	1.54 ± 0.35 (61)	7 25 ± 0.88 (64)	35.78 ± 5.14 (63)	87.23 ± 16.71 (30)
	1,70 ± 0.29 (61)	7.34 + 1 08 (64)	41,13 ± 6.01 (63)	117.65 ± 21 73 (30)
	1.36 ± 0.25 (60)	6.73 ± 0.77 (63)	31 79 ± 4.55 (63)	90.05 ± 15.27 (30)
	1.54 ± 0.27 (60)	6.51 ± 0.84 (63)	34.89 ± 5.45 (63)	98.08 ± 17.09 (30)
	1.39 ± 0.22 (60)	7.28 ± 1.16 (63)	33.22 ± 4.65 (61)	100.12 ± 14.69 (30)
	1.58 ± 0 28 (60)	7.41 ± 1.13 (63)	40.11 + 6.09 (61)	105.23 ± 20.79 (30)
	1,55 ± 0.22 (55)	6.99 ± 1.03 (58)	36.72 ± 6.66 (56)	101.63 ± 19.52 (30)

--- = NO AVAILABLE DATA

(3)

3

0

(2)

Table 2 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRIAZINE(RDX) IN THE BEC3F1 MOUSE FEMALE DOSA?F MEASUREMENTS (mg/kg/day) [MEAN AND STANDARD DEVIATION (n)]

175,100 MG/KG/DAY	102.48 ± 17.94 (29)	94.88 ± 15.67 (29)	108.54 ± 25.94 (29)	93.87 ± 19.74 (29)	101.94 ± 19.50 (29)	102.65 ± 20.32 (29)	104.83 ± 28.49 (29)	106.79 ± 18.20 (28)	190.30 ± 19.21 (27)	99.96 ± 14.96 (27)	98.39 ± 14.00 (27)	86.37 ± 13.24 (26)	94.93 ± 20.54 (25)		175/100 MG/KG/DAY	125.87 ± 46.50 (2378)	119.55 ± 48.77 (2380)	122.71 ± 47.75 (4758)		ĺ		
35 MG/KG/DAY	37.04 ± 7.31 (60)	34.40 ± 7.35 (60)	41.11 ± 8.63 (59)	31.90 ± 6.52 (58)	37.20 ± 7.06 (56)	36.36 ± 8.05 (56)	35.03 ± 6.19 (50)	35.51 ± 6.47 (53)	35.08 ± 5.27 (53)	33.15 ± 5.78 (48)	35.86 ± 5.54 (49)	31.99 ± 4.77 (46)	32.03 ± 4.47 (46)	; ACROSS TIME (mg/kg/day) DEVIATION (n)]	35 MG/KG/DAY	35, 10 + 5, 10 (3874)	34.79 ± 5.87 (4086)	34.94 ± 5.51 (7960)	100 MG/KG/DAY (WEEKS 11 - 104)	101.77 ± 18.51	100.25 ± 15.22	100.99 ± 17.03
7 MG/KG/DAY	7.18 ± 1.08 (63)	6.67 ± 1.06 (63)	7.86 ± 1.05 (62)	6.17 ± 0.85 (62)	7.71 ± 1.22 (62)	$6.87 \pm 1.00 (61)$	7.27 ± 1.36 (60)	7.10 ± 1.37 (59)	7.76 ± 1.15 (58)	$6.08 \pm 0.94 (57)$	6.89 ± 1.07 (55)	$6.12 \pm 0.97 (54)$	$6.47 \pm 1.06 (52)$	DOSAGE MEASUREMENTS [MEAN AND STANDARD	7 MG/KG/DAY	7.02 ± 0.99 (4000)	6.95 ± 1.21 (4176)	6.98 ± 1.11 (8176)	175 MG/KG/DAY (WEEKS 1 - 10)	182.86 ± 25.12	166.89 ± 30.65	174.88 ± 29.06
1.5 MG/KG/DAY	1.50 ± 0.29 (60)	1.58 ± 0.30 (62)	1.58 ± 0.33 (60)	1.52 ± 0.31 (60)	1.50 ± 0.27 (48)	1.51 ± 0.27 (60)	1.60 ± 0.33 (57)	1.49 ± 0.30 (54)	1.74 ± 0.28 (52)	1.36 ± 0.23 (48)	1.63 ± 0.29 (47)	1.33 ± 0.24 (45)	1.36 ± 0.22 (44)	COMBINED	1.5 MG/KG/DAY	1.52 + 0.24 (3954)		1.51 ± 0.26 (8024)	71	182	166	174
TEST WEEK	81	83	85	87	89	91	69	98	97	66	101	103	104		SE V GROUP	MALES	FEMALES	COMBINED	S£X GROUP	MALES	FEMALES	COMBINED

والمتالي والمتاري والمتاريخ والمتاريخ والمتاريخ والمتاريخ والمتاريخ والمتاريخ والمتاريخ والمتاريخ والمتاريخ والمتاريخ

TWENTY-FOUR MONTH CHRONIC TOXICITY/CARCINGGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE IN THE B6C3FI MJUSE.

TEST DIET CONCENTRATION OF RDX

A * 100	44	98	73	85	93	90	43	101	44	93	80	102	91		96 (74)*	88	100	96		96 (84)*	84	103	94	103	102	47	102	47	101	001	94.3 ± 7 5
Analyzed % (A)	00399	0.0924	0.00080	0.0224	0.0062E	0.0740	0.00093	0.0247	G. 00524	0.0749	ດ. 0012	0.0340	0.00637	0.0767	0.00096	0.0226	62900 0	0.0837	0.00164	0 0401	29900 0	6660 0	0.00092	0 0276	0.00550	0 0795	0 00173	0 0329	0 00675	0 0796	
INTENDED % (I)	0 0041	0.0947	0.0011	0 0274	9900 0	0 0823	0.0010	0.0245	0.0034	9080 0	0.0015	0 0334	0. 3072	0 0833	0 0010	0 0256	0.0063	0. 0867	0.0017	0 0420	0.0079	8960 0	0 0011	0 0268	0 0054	0. 0820	0. 0017	0 0338	0 0067	0 0793	
SEX	£	Ξ	: և	. և	. Ա	. և	. Σ	Σ	Σ	Έ	i tu	. L L.	. L L	ıŁ	Σ	Σ	Σ	Σ	ů.	LL.	Ŀ	ls.	Σ	Ε	Σ	Σ	Ŀ.	ů.	lı.	L.	
(46p/67/6w)		0.10	o n S) C	7 (0) f) O 80	0 7	0 001) fi) O	0 7	0 001	: £0	: O : n	7 0	100 0	: Đ	0 20	0 /	100 0	£.	0.00	7 0	100 0	n ~	0 00	7 0	0 001	
2 -4 6 6 6 7 7	-	→ +-	٠. ر <u>.</u>	3 5	י מ	ם פי	א ר ס ס	- e	់ ត រ	. 4) -	 	. K	10.00	. 63	63	20	20,	22.	73	. 60	: 6	87	87	6	6	86	85	104	104	MEAN + S D

(4)

Test diets weve held one week in the animal cage prior to sampling. The values in parantheses represent the ratio of the analyzed concentrations for the immediate and subsequent one week sampling periods.

TABLE 4

TWENTY-FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE IN THE B6C3F1 HYBRID MOUSE

MEAN SURVIVAL TIME

DOSE (mg/kg/day)	SEX		SURVIVAL
0.0	M F	98.1 100.9	± 1.8 ± 1.1
1.5	M F		± 2.2 ± 1.7
7.0	M F		± 1.9 ± 0.8
35.0	M F		± 2.4 ± 1.3
175.0/100.0	M F		± 5.1* ± 5.3*

^{*} Significantly different from control group, p< 0.05.

Table 5

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE BODY WEIGHTS (G) [MEAN AND STANDARD DEVIATION (n)]

TEST WEEX	0.0 mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
-2	23.1 ± 1.6 (85)	22.8 ± 1.8 (85)	23.1 ± 1.7 (85)	23.0 ± 1.6 (85)	22.8 ± 1.7 (85)
Ţ	24.2 ± 1.6 (85)	24.2 ± 1.9 (85)	24.1 ± 1.8 (85)	24.5 ± 1.6 (85)	24.2 ± 1.7 (85)
-	25.6 ± 17 (85)	25.8 ± 2.0 (85)	25.7 ± 1.8 (85)	26.0 ± 1.7 (85)	25.3 ± 1.6 (85)
7	26.5 ± 1.6 (85)	26.8 ± 2.0 (85)	26.7 ± 1.6 (85)	27.0 ± 1.8 (85)	26.4 ± 1.6 (85)
ო	27.5 ± 1.7 (85)	27.8 ± 2.1 (85)	27.8 ± 1.7 (85)	28.1 ± 1.8 (85)*	27.2 ± 1.9 (84)
4	28.5 ± 1.8 (85)	28.6 ± 2.2 (85)	28.8 ± 1.6 (85)	28.9 ± 1.9 (85)	28.1 ± 1.9 (79)
r.	29.4 ± 17 (85)	29.3 ± 2.2 (85)	29.7 ± 1.6 (85)	29.6 ± 2.1 (85)	28.9 ± 1.9 (76)
9	29.5 ± 1.7 (85)	30.0 ± 2.0 (85)	30.2 ± 1.7 (85)	30.2 ± 1.9 (85)	29.4 ± 1.9 (67)
7	30.4 ± 1.6 (85)	30.6 ± 2.1 (85)	30.9 ± 1.7 (85)	30.7 ± 2.0 (85)	30.0 ± 2.0 (67)
æ	30.8 ± 1.7 (85)	31.1 ± 2.2 (95)	31.5 ± 1.8 (85)*	31.1 ± 2.0 (85)	30.3 ± 2.3 (67)
თ	31.5 ± 1.8 (85)	31.4 ± 2.2 (85)	31.8 ± 1.7 (85)	31.5 ± 2.1 (85)	31.0 ± 2.0 (64)
0	31.9 ± 1.7 (85)	31.7 ± 2.2 (85)	32.1 ± 2.1 (85)	32.1 ± 2.1 (85)	31.0 ± 2.4 (60)*
Ξ	32.1 ± 1.8 (84)	31.7 ± 2.1 (85)	32.3 ± 1.8 (85)	32.3 ± 2.0 (85)	31.6 ± 2.3 (55)
12	32.4 ± 1.8 (84)	32.3 ± 2.2 (85)	32.7 ± 1.9 (85)	32.7 ± 2.1 (85)	31.7 ± 2.2 (55)
13	32.5 + 1.7 (84)	32.5 ± 2.2 (85)	33.0 ± 2.1 (85)	32.8 ± 2.1 (85)	32.3 + 2.3 (55)
15	33.3 ± 1.7 (84)	33.0 ± 2.2 (85)	33.7 ± 1.9 (85)	33.4 ± 2.2 (85)	32.9 ± 2.7 (55)
17	34.2 ± 2.0 (84)	33.3 ± 2.4 (85)	34.6 ± 2.2 (85)	34.3 ± 2.4 (85)	33.8 ± 3.6 (55)
19	24.6 ± 2.3 (84)	34.4 ± 2.7 (84)	35.1 ± 2.2 (85)	34.6 ± 2.4 (85)	34.4 ± 4.0 (54)
21	35.2 ± 2.3 (84)	34.9 ± 2.5 (83)	35.6 ± 2.2 (85)	35.2 ± 2.6 (85)	35,1 ± 4,1 (54)
23	35.8 ± 2.4 (84)	35.1 ± 2.6 (83)	35.9 ± 2.6 (84)	36.0 ± 2.8 (84)	35.4 ± 3.9 (54)
25	36.0 ± 2.5 (84)	35.3 ± 2.6 (83)	36.2 ± 2.4 (84)	35.7 ± 2.6 (84)	35.8 ± 3.8 (54)
27	36.2 ± 2.7 (74)	35.6 ± 2.8 (73)	36 7 ± 2.7 (73)	36.4 ± 2.6 (73)	35.8 ± 4.5 (42)
58	36.3 ± 2.7 (74)	35.2 ± 3.0 (73)	36.6 ± 2.5 (73)	36.7 ± 2.5 (72)	36.4 ± 4.7 (42)

SIGNIFICANTLY DIFFERENT FROM CONTROL GROUP

--- = NO AVAILABLE DATA

3

٣

Ą)

2

Ē

÷

0

@

4

Table 5 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE BODY WEIGHTS (G)
[MEAN AND STANDARD DEVIATION (n)]

TEST WEEK	0.0 mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
31	36.8 ± 2.8 (74)	35.8 ± 2.6 (73)	37.0 ± 2.6 (73)	37.0 ± 2.7 (72)	36.4 ± 4.7 (41)
33	37.0 ± 2.7 (74)	36.1 ± 2.8 (73)	37.4 ± 2.7 (72)	37.1 ± 2.5 (72)	37.1 ± 4.8 (39)
35	37.2 ± 2.9 (74)	36.3 ± 2.7 (72)	37.7 ± 3.0 (72)	37.5 ± 2.7 (72)	37.1 ± 4.6 (39)
37	37.3 ± 2.8 (74)	36.2 ± 2.6 (72)	37.6 ± 2.9 (72)	37.7 ± 3.0 (72)	37.2 ± 4.6 (38)
39	38.0 ± 3.0 (74)	36.6 ± 2.6 (72)*	38.2 ± 2.9 (72)	38.2 ± 2.9 (72)	37.9 ± 4.8 (38)
41	37.9 ± 3.1 (74)	36.3 ± 2.8 (72)*	37.9 ± 3.0 (72)	37.9 ± 2.8 (71)	37.9 ± 4.7 (38)
43	38.1 ± 3.1 (74)	36.7 ± 2.7 (72)*	37.9 ± 2.9 (72)	37.9 ± 2.7 (71)	37.9 ± 4.9 (38)
45	38.1 ± 3.1 (74)	36.5 ± 2.7 (72)*	37.6 ± 3.0 (72)	37.8 ± 2.6 (71)	38.1 ± 4.8 (38)
47	38.3 ± 3.2 (74)	36.6 ± 2.8 (72)*	37.9 ± 2.9 (72)	37.8 ± 2.7 (70)	38.4 ± 4.8 (38)
49	38.3 ± 3.1 (73)	37.0 ± 2.7 (71)*	38.4 ± 3.0 (72)	38.4 ± 2.9 (70)	38.6 ± 4.9 (38)
51	38.5 ± 3.1 (73)	37.0 ± 2.9 (71)*	38.4 ± 3.1 (72)	38.4 ± 2.9 (69)	38.7 ± 4.6 (38)
53	38.6 ± 3.3 (70)	37.4 ± 3.1 (68)	38.6 ± 3.1 (69)	38.8 ± 3.0 (66)	35.5 ± 4.7 (34)
52	38.8 ± 3.4 (63)	37.2 ± 2.9 (60)*	38.8 ± 3.3 (62)	38.8 ± 3.1 (59)	39.6 ± 5.3 (27)
57	38.6 ± 3.2 (63)	37.0 ± 2.9 (60)*	38.5 ± 3.2 (62)	38.7 ± 3.1 (58)	39.1 ± 4.5 27)
29	38.8 ± 3.0 (62)	37.4 ± 2.9 (59)	38.5 ± 3.5 (62)	39.0 ± 3.1 (58)	39.2 ± 5.2 (27)
61	38.5 ± 3.1 (62)	36.8 ± 2.9 (59)*	38.5 ± 3.4 (62)	38.6 ± 3.3 (58)	39.3 ± 5.4 (27)
63	38.7 ± 3.2 (62)	37.1 ± 3.0 (59)*	38.5 ± 3.3 (62)	38.8 ± 3.4 (58)	39.7 ± 5.7 (26)
65	39.0 ± 3.4 (62)	37.6 ± 3.1 (59)	38.9 ± 3.8 (62)	39.2 ± 3.6 (57)	39.6 ± 5.5 (26)
67	39.0 ± 3.5 (61)	37.5 ± 3.1 (59)	39.4 ± 3.8 (62)	39.0 ± 3.8 (57)	39.8 ± 5.4 (26)

- = NO AVAILABLE DATA

THE STATE OF THE S

Table 5 (continued)

TW""ITY FOUR MONTH CHROWIC TOXICITY/CARCINOGENICITY STUDY OF HEXA: RO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE BODY WEIGHTS (G)
[MEAN AND STANDARD DEVIATION (n)]

TEST WEEK	O.O mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
69	39.2 ± 3.5 (61)	37.3 ± 2.9 (59)*	39.0 ± 3.9 (62)	39.1 ± 3.4 (55)	39.0 ± 5.0 (26)
7.1	39.2 ± 3.5 (61)	37.6 ± 3.1 (59)	39.5 ± 4.2 (61)	39.3 ± 3.6 (54)	39.4 ± 4.0 (26)
73	38.8 ± 3.3 (61)	37.7 ± 3.4 (59)	39.4 ± 4.0 (60)	39.1 ± 3.4 (54)	38.8 ± 3.7 (26)
75	39.1 ± 3.4 (60)	37.3 ± 3.2 (59)*	38.9 ± 3.9 (60)	38.9 ± 3.5 (54)	38.5 ± 3.2 (26)
7.7	39.4 ± 3.5 (60)	37.8 ± 3.1 (57)*	39.4 ± 3.9 (58)	39.4 ± 3.3 (54)	38.8 ± 3.2 (25)
79	39.0 ± 3.4 (53)	37.5 ± 3.2 (51)	39.1 ± 3.6 (52)	39.0 ± 3.4 (49)	38.6 ± 3.0 (25)
81	39.2 ± 4.0 (58)	37.6 ± 3.0 (55)	39.0 ± 3.4 (57)	39.0 ± 3.3 (54)	38.6 ± 3.0 (25)
83	39.1 ± 3.6 (56)	37.7 ± 3.3 (54)	39.2 ± 3.4 (56)	39.3 ± 3.4 (54)	38.6 ± 3.2 (25)
85	38.7 ± 3.5 (55)	37.2 ± 3.2 (54)+	38.7 ± 3 3 (56)	38.5 ± 3.4 (53)	37.9 ± 3.2 (25)
87	38.8 ± 3.9 (54)	37.4.± 3.7 (52)	39.1 ± 3.6 (56)	38.7 ± 3.5 (52)	38.4 ± 3.3 (25)
89	38.4 ± 3.8 (53)	36.9 ± 3.5 (51)	39.0 ± 3.1 (54)	38 0 ± 3.7 (52)	37.3 ± 3.7 (25)
16	38.7 ± 3.8 (52)	37.0 ± 3.3 (50)*	38.8 ± 3.1 (54)	38.0 ± 3.6 (49)	37.6 ± 2.9 (23)
693	38.7 ± 3.7 (52)	36.9 ± 3.4 (50)*	38.7 ± 3.1 (53)	38.2 ± 3.2 (46)	37.2 ± 2.9 (23)
92	38.5 ± 3.6 (51)	36.7 ± 3.9 (50)*	38.8 ± 3.3 (52)	37.8 ± 3.3 (45)	36.8 ± 2.9 (23)*
97	33.1 ± 3.6 (51)	36.6 ± 3.3 (48)	38.2 ± 3.2 (49)	37.8 ± 3.6 (45)	36.9 ± 2.6 (22)
66	38.4 ± 3.7 (49)	36.5 ± 3 2 (47)*	38.6 ± 3.6 (45)	37.2 ± 2.9 (40)	36.8 ± 2.8 (22)
101	38.3 ± 3.8 (49)	36.1 ± 3.6 (46)*	38.2 ± 3.6 (44)	37.2 ± 2.5 (39)	36.4 ± 2.8 (22)*
103	38.0 ± 3.7 (48)	36.3 ± 2.7 (42)*	37.6 ± 3.4 (41)	36.7 ± 2.6 (38)	36.1 ± 3.2 (22)*
104	38.0 ± 3.8 (46)	36.5 ± 2.8 (42)	37.8 ± 3.8 (41)	37.1 ± 2.7 (37)	36.1 ± 3.3 (22)*

* = SIGNIFICANTLY DIFFERENT FROM CONTROL GROUP

= NO AVAILABLE DATA

٩

9

0

0

Table 6

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE BODY WEIGHT GAIN MEASUREMENTS (g) [MEAN AND STANDARD DEVIATION (n)]

1 1.3 ± 0.7 (85) 1.6 ± 1.0 (85) 1.6 ± 0.0 (85) 1.5 ± 0.7 (85) 1.5 ± 0.7 (85) 1.1 ± 0.6 (85) 1.1 ± 0.6 (85) 1.1 ± 0.6 (85) 1.1 ± 0.6 (85) 1.1 ± 0.6 (85) 1.1 ± 0.6 (85) 1.1 ± 0.6 (85) 1.1 ± 0.6 (85) 1.1 ± 0.7 (85) 1.1 ± 0.8 (85) 1.1 ± 0.7 (85) 1.1 ± 0.8 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.8 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7 (85) 1.1 ± 0.7	TEST WEEK	O.O mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
2.3 ± 0.6 (85) 2.6 ± 0.7 (85)* 2.5 ± 0.7 (85)* 2.5 ± 0.7 (85)* 2.2 ± 0.7 (85)* 2.2 ± 0.7 (85)* 2.2 ± 0.7 (85)* 2.2 ± 0.7 (85)* 3.0 ± 0.0 (85)* 3.0 ± 0.0 (85)* 3.0 ± 1.0 € 1.0 € 0.0 (85)* 3.0 ± 1.0 € 1.0 € 0.	_	+ 0.7 (1.0 (9.0 +1	.5 ± 0.5 (+ 0.6 (
3.3 ± 0.0 (85) 3.7 ± 0.0 (85) 3.7 ± 0.0 (85) 3.7 ± 0.0 (85) 3.7 ± 0.0 (85) 4.4 ± 1.1 (85) 3.0 ± 1.0 (85) 4.4 ± 1.5 (85) 3.0 ± 1.1 (85) 3.0 ± 1.1 (85) 3.0 ± 1.1 (85) 3.0 ± 1.1 (85) 3.0 ± 1.1 (85) 4.4 ± 1.5 (85) 3.0 ± 1.1 (85) 4.6 ± 1.1 (85) 4.6 ± 1.2 (85) 4.6 ± 1.2 (85) 4.6 ± 1.2 (85) 4.6 ± 1.2 (85) 4.6 ± 1.2 (85) 5.0 ±	8	9 → 0.6 () 6.0 +	.6 ± 0.7 (.5 ± 0.7 (.2 ± 0.7 (
4.3 ± 0.9 (85) 4.4 ± 1.0 (85) 4.4 ± 1.5 (85) 9.9 ± 1.1 (85) 9.9 ± 1.1 (85) 9.9 ± 1.1 (85) 9.9 ± 1.1 (85) 9.9 ± 1.2 (85) 9.0 ± 1.2 (85) 9.1 ± 1.2 (85) 9.0 ± 1.2 (85)		.3 ± 0.7 (.6 ± 1.1 (.7 ± 0.8 () 8·0 +	1.0 (
5.2 ± 1.2 (85) 5.2 ± 1.0 (85) 5.6 ± 1.0 (85) 6.1 ± 1.0 (85) 6.6 ± 1.2 (85) 6.2 ± 1.2 (85) 6.2 ± 1.2 (85) 6.2 ± 1.2 (85) 6.2 ± 1.2 (85) 6.2 ± 1.2 (85) 6.2 ± 1.2 (85) 6.2 ± 1.2 (85) 6.2 ± 1.2 (85) 6.2 ± 1.2 (85) 6.2 ± 1.2 (85) 6.2 ± 1.3 (85) 6.1 ± 1.3 (85) 6.1 ± 1.3 (85) 6.1 ± 1.5 (85) 6.1 ±	4	3 + 0.9 (.4 ± 1.1 (7 ± 0.9 (.4 ± 1.5 (+ 1.1 (
5.7 ± 1.2 (45) 5.8 ± 1.3 (85) 6.1 ± 1.2 (85) 6.5 ± 1.2 (85) 5.5 ± 1.2 (85) 5.2 ± 1.3 (85) 5.2 ± 1.3 (85) 5.2 ± 1.3 (85) 5.2 ± 1.3 (85) 5.2 ± 1.5 (85) 6.1 ± 1.5 (85) 6.1 ± 1.3 (85) 5.7 ± 1.5 (85) 6.1 ± 1.5 (85)	ស	.2 ± 1.2 (.2 ± 1.5 (.6 ± 1.0 (.1 ± 1.4 (± 1.2 (
6.2 ± 1.1 (85) 6.4 ± 1.2 (85) 7.3 ± 1.2 (85)* 6.6 ± 1.4 (85) 6.1 ± 1.2 (87)* 6.6 ± 1.4 (85) 6.1 ± 2.0 (7.3 ± 1.2 (85) 7.3 ± 1.2 (85) 7.3 ± 1.2 (85) 7.3 ± 1.2 (85) 7.0 ± 1.3 (85) 6.1 ± 2.0 (8.3 ± 1.4 (85) 7.2 ± 1.4 (85) 7.3 ± 1.2 (85) 7.0 ± 1.3 (85) 6.1 ± 2.0 (8.3 ± 1.4 (85) 7.2 ± 1.4 (85) 7.3 ± 1.2 (85) 7.2 ± 1.4 (85) 7.3 ± 1.2 (85) 7.3 ± 1.3 (85) 7.3 ± 1.3 (85) 7.3 ± 1.3 (85) 7.3 ± 1.3 (85) 7.3 ± 1.3 (85) 7.3 ± 1.3 (85) 7.3 ± 1.3 (85) 7.3 ± 1.3 (85) 7.3 ± 1.3 (85) 7.3 ± 1.3 (85) 7.3 ± 1.3 (85) 7.3 ± 1.3 (85) 8.3 ± 1.3 ± 1.3 (85) 8.3 ± 1.3 (85) 8.3 ± 1.3 (85) 8.3 ± 1.3 (85) 8.3 ± 1.3 ± 1.3 (85) 8.3 ± 1.3 ± 1.3 (85) 8.3 ± 1	v	± 1.2 (+ 1.3 (.1 ± 1.2 (.6 ± 1.2 (+ 1.3 (
6.6 ± 1.2 (85) 6.9 ± 1.2 (85) 7.3 ± 1.2 (85)* 6.6 ± 1.4 (85) 6.1 ± 2.0 (7.3 ± 1.2 (85) 7.2 ± 1.7 (85) 7.7 ± 1.2 (85) 7.0 ± 1.3 (85) 6.7 ± 1.6 (8.0 ± 1.2 (84) 7.6 ± 1.3 (85) 8.1 ± 1.4 (85) 8.2 ± 1.3 (85) 6.8 ± 2.3 (8.4 ± 1.2 (84) 8.1 ± 1.6 (85) 8.9 ± 1.6 (85)* 8.3 ± 1.3 (85) 8.1 ± 1.8 (85) 9.1 ± 1.2 (84) 8.3 ± 1.5 (85) 8.9 ± 1.6 (85)* 8.3 ± 1.4 (85) 8.1 ± 1.3 (85) 10.0 ± 1.2 (84) 9.7 ± 1.6 (85) 9.6 ± 1.7 (85) 9.8 ± 1.5 (85) 9.6 ± 3.3 (11.0 ± 1.6 (84) 10.2 ± 1.9 (84) 11.0 ± 1.5 (83) 11.7 ± 2.4 (84) 11.5 ± 2.0 (84) 11.7 ± 1.8 (83) 12.1 ± 2.4 (84) 11.5 ± 2.4 (84) 11	7	+ 1.1 (.4 ± 1.2 (+ 1.2 (1.3 (+ 1.5 (
7.3 ± 1.2 (85) 7.2 ± 1.7 (85) 7.7 ± 1.2 (85) 7.0 ± 1.3 (35) 6.7 ± 1.6 (85) 7.5 ± 1.3 (85) 6.8 ± 2.3 (87) 8.2 ± 1.2 (84) 8.1 ± 1.3 (85) 8.2 ± 1.4 (85) 8.2 ± 1.3 (85) 7.5 ± 1.3 (85) 8.2 ± 1.3 (85) 8.3 ± 1.5 (85) 7.5 ± 1.3 (85) 8.3 ± 1.5 (85) 8.3 ± 1.5 (85) 8.3 ± 1.5 (85) 8.3 ± 1.4 (85) 8.3 ± 1.4 (85) 8.1 ± 1.4 (85) 8.1 ± 1.4 (85) 8.1 ± 1.4 (85) 8.1 ± 1.4 (85) 8.1 ± 1.4 (85) 8.1 ± 1.4 (85) 8.1 ± 1.4 (85) 8.1 ± 1.4 (85) 8.1 ± 1.4 (85) 8.1 ± 1.4 (85) 8.1 ± 1.4 (85) 8.1 ± 1.4 (85) 8.1 ± 1.8 (84) 10.2 ± 1.9 (84) 11.0 ± 1.5 (83) 11.5 ± 1.9 (84) 11.7 ± 1.9 (84) 11.1 ± 1.8 (83) 11.7 ± 2.4 (84) 11.5 ± 1.3 (84) 11.1 ± 1.8 (83) 12.1 ± 2.4 (84) 11.5 ± 1.4 (84)	80	± 1.2 (+ 1.2 (+ 1.2 (+ 1.4 (± 2.0 (
7.8 ± 1.1 (85) 7.5 ± 1.4 (85) 7.9 ± 1.6 (85) 7.5 ± 1.3 (85) 6.8 ± 2.3 (85) 6.8 ± 1.2 (85) 6.8 ± 2.3 (85) 6.8 ± 1.2 (85) 6.8 ± 1.2 (85) 7.4 ± 1.9 (85) 6.8 ± 1.2 (85) 7.4 ± 1.9 (85) 7.5 ± 2.0 (85) 8.2 ± 1.3 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.2 ± 1.4 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.2 ± 1.4 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.2 ± 1.4 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.2 ± 1.4 (85) 8.1 ± 1.9 (85) 8.2 ± 1.4 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85) 8.1 ± 1.9 (85)	6	+ 1.2 (.2 ± 1.7 (.7 ± 1.2 (+ 1.3 (+ 1.6 (
8.0 ± 1.2 (84) 7.6 ± 1.3 (85) 8.1 ± 1.3 (85) 7.8 ± 1.2 (85) 7.7 ± 1.9 (85) 8.2 ± 1.3 (85) 7.5 ± 2.0 (82.4 ± 1.2 (84) 8.3 ± 1.5 (85) 8.6 ± 1.4 (85) 8.2 ± 1.3 (85) 7.5 ± 2.0 (82.4 ± 1.2 (84) 8.3 ± 1.4 (85) 8.6 ± 1.7 (85) 8.8 ± 1.4 (85) 8.1 ± 1.8 (85) 10.5 ± 1.6 (84) 10.2 ± 1.9 (84) 11.0 ± 1.6 (83) 11.7 ± 1.9 (84) 11.0 ± 1.5 (83) 11.7 ± 1.9 (84) 11.0 ± 1.5 (83) 11.7 ± 1.9 (84) 11.0 ± 1.5 (83) 11.7 ± 2.1 (84) 11.0 ± 1.5 (83) 11.7 ± 2.1 (84) 11.2 ± 2.1 (84) 11.2 ± 2.1 (84) 11.3 ± 2.1 (73) 11.8 ± 2.1 (73) 11.8 ± 2.1 (73) 12.3 ± 4.4 (73)	0	+1 +1	.5 ± 1.4 () 9·+ +-	+ +.3 (.8 ± 2.3 (
8.2 ± 1.3 (84) 8.1 ± 1.6 (85) 8.6 ± 1.4 (85) 8.2 ± 1.3 (85) 7.5 ± 2.0 (8.4 ± 1.2 (84) 8.3 ± 1.5 (85) 8.9 ± 1.6 (85)* 8.3 ± 1.3 (85) 8.1 ± 1.8 (10.0 ± 1.2 (84) 9.7 ± 1.6 (85) 10.5 ± 1.7 (85) 9.8 ± 1.5 (85) 8.7 ± 2.3 (11.0 ± 1.6 (84) 10.2 ± 1.9 (84) 11.0 ± 1.6 (83) 11.5 ± 1.9 (84) 11.7 ± 1.9 (84) 11.1 ± 1.8 (83) 12.1 ± 2.1 (84) 11.5 ± 1.8 (84) 11.1 ± 2.1 (73)* 12.5 ± 2.1 (73) 11.8 ± 1.9 (74) 11.1 ± 2.1 (73)* 12.5 ± 2.1 (73)* 12.1 ± 1.7 (73)* 12.5 ± 2.1 (73)* 12.1 ± 1.7 (72) 12.3 ± 4.4 (73)* 12.3 ± 4.4 (73)* 12.3 ± 4.4 (73)* 12.3 ± 4.4 (73)* 12.3 ± 4.4 (73)* 8.2 ± 1.3 (84) 11.1 ± 2.1 (73)* 12.5 ± 2.1 (73)* 12.1 ± 1.7 (72)* 12.3 ± 4.4 (73)* 12.2 ± 2.1 (74) 11.1 ± 2.1 (73)* 12.5 ± 2.1 (73)* 12.1 ± 1.7 (72)* 12.3 ± 4.4 (73)*	_	1.2 (+ 1.3 (.1 + 1.3 (+ 1.2 (+ 1.9 (
8.4 ± 1.2 (84) 8.3 ± 1.5 (85)* 8.9 ± 1.6 (85)* 8.3 ± 1.3 (85) 8.1 ± 1.8 (85) 8.1 ± 1.8 (85) 8.1 ± 1.8 (85) 8.1 ± 1.8 (85) 8.1 ± 1.8 (85) 9.6 ± 1.5 (85) 9.6 ± 3.3 (8.2) 9.6 ±		+ 1.3 (+ 1.6 (.6 ± 1.4 (.2 ± 1.3 (± 2.0 (
9.1 ± 1.2 (84) 8.9 ± 1.4 (85) 9.6 ± 1.5 (85) 8.8 ± 1.4 (85) 8.7 ± 2.3 (10.0 ± 1.2 (84) 9.7 ± 1.6 (85) 10.5 ± 1.7 (85) 9.8 ± 1.5 (85) 9.6 ± 3.3 (10.5 ± 1.6 (84) 10.2 ± 1.9 (84) 11.0 ± 1.8 (85) 10.1 ± 1.6 (85) 10.2 ± 3.8 (11.0 ± 1.6 (84) 10.7 ± 1.6 (83) 11.5 ± 1.9 (8.) 10.7 ± 1.7 (85) 10.8 ± 3.9 (11.7 ± 1.9 (84) 11.0 ± 1.5 (83) 12.1 ± 2.4 (84) 11.5 ± 2.0 (84) 11.1 ± 3.6 (12.1 ± 1.9 (74) 11.5 ± 1. 73) 12.6 ± 2.2 (73) 11.8 ± 1.8 (73) 11.8 ± 4.2 (12.2 ± 2.1 (74) 11.1 ± 2.1 (73)* 12.5 ± 2.1 (73) 12.1 ± 1.7 (72) 12.3 ± 4.4 (+ 1.2 (+ 1.5 (.9 ± 1.6 (.3 ± 1.3 (+ 1.8 (
10.0 ± 1.2 (84) 9.7 ± 1.6 (85) 10.5 ± 1.7 (85) 9.8 ± 1.5 (85) 9.6 ± 3.3 (85) 10.5 ± 1.6 (84) 10.2 ± 1.9 (84) 11.0 ± 1.8 (85) 10.1 ± 1.6 (85) 10.2 ± 3.8 (85) 11.0 ± 1.6 (84) 10.7 ± 1.6 (84) 11.7 ± 2.4 (84) 11.5 ± 2.0 (84) 11.1 ± 3.6 (84) 11.8 ± 1.8 (84) 11.1 ± 1.8 (83) 12.1 ± 2.1 (84) 11.2 ± 1.7 (84) 11.6 ± 3.6 (84) 12.1 ± 1.9 (74) 11.5 ± 1. 73) 12.6 ± 2.2 (73) 11.8 ± 1.8 (73) 11.8 ± 4.2 (73) 12.2 ± 2.1 (74) 11.1 ± 2.1 (73)* 12.5 ± 2.1 (73) 12.1 ± 1.7 (72) 12.3 ± 4.4 (84)		+ 1.2 (+ 1.4 (.6 ± 1.5 (+ 1.4 (.7 ± 2.3 (
10.5 ± 1.6 (84) 10.2 ± 1.9 (84) 11.0 ± 1.8 (85) 10.1 ± 1.6 (85) 10.2 ± 3.8 (85) 11.0 ± 1.6 (84) 10.7 ± 1.6 (83) 11.5 ± 1.9 (84) 10.7 ± 1.7 (85) 10.8 ± 3.9 (84) 11.7 ± 1.9 (84) 11.0 ± 1.5 (83) 11.7 ± 2.4 (84) 11.5 ± 2.0 (84) 11.1 ± 3.6 (84) 11.8 ± 1.8 (84) 11.1 ± 1.8 (83) 12.1 ± 2.1 (84) 11.2 ± 1.7 (84) 11.6 ± 3.6 (84) 12.1 ± 1.9 (74) 11.5 ± 1. 73) 12.6 ± 2.2 (73) 11.8 ± 1.8 (73) 11.8 ± 4.2 (73) 12.2 ± 2.1 (74) 11.1 ± 2.1 (73)* 12.5 ± 2.1 (73) 12.1 ± 1.7 (72) 12.3 ± 4.4 (74)		1.2 (1.6 (± 1.7 (+ 1.5 (3.3 (
11.0 ± 1.6 (84) 10.7 ± 1.6 (83) 11.5 ± 1.9 (85) 10.7 ± 1.7 (85) 10.8 ± 3.9 (8) 11.7 ± 1.9 (84) 11.0 ± 1.5 (83) 12.1 ± 2.1 (84) 11.2 ± 1.7 (84) 11.1 ± 3.6 (84) 12.1 ± 1.9 (74) 11.5 ± 1. 73) 12.6 ± 2.2 (73) 11.8 ± 1.8 (73) 11.8 ± 4.2 (73) 12.2 ± 2.1 (74) 11.1 ± 2.1 (73) * 12.5 ± 2.1 (73) 12.1 ± 1.7 (72) 12.3 ± 4.4 (73)		+ 1.6 (+ 1.9 (+ 1.8 (1.6 (3.8 (
11.7 ± 1.9 (84) 11.0 ± 1.5 (83) 11.7 ± 2.4 (84) 11.5 ± 2.0 (84) 11.1 ± 3.6 (84) 11.8 ± 1.8 (84) 11.1 ± 1.8 (83) 12.1 ± 2.1 (84) 11.2 ± 1.7 (84) 11.6 ± 3.6 (84) 12.1 ± 1.9 (74) 11.5 ± 1. 73) 12.6 ± 2.2 (73) 11.8 ± 1.8 (73) 11.8 ± 4.2 (73) 12.2 ± 2.1 (74) 11.1 ± 2.1 (73) * 12.5 ± 2.1 (73) 12.1 ± 1.7 (72) 12.3 ± 4.4 (84)		+ 1.6 (+ 1.6 () 6.1 ±	+ 1.7 () 6.6 +
11.8 ± 1.8 (84) 11.1 ± 1.8 (83) 12.1 ± 2.1 (84) 11.2 ± 1.7 (84) 11.6 ± 3.6 (12.1 ± 1.9 (74) 11.5 ± 1. 73) 12.6 ± 2.2 (73) 11.8 ± 1.8 (73) 11.8 ± 4.2 (12.2 ± 2.1 (74) 11.1 ± 2.1 (73)* 12.5 ± 2.1 (73) 12.1 ± 1.7 (72) 12.3 ± 4.4 (+1.9 (+ +.5 (± 2.4 (± 2.0 (3.6 (
12.1 ± 1.9 (74) 11.5 ± 1. 73) 12.6 ± 2.2 (73) 11.8 ± 1.8 (73) 11.8 ± 4.2 (12.2 ± 2.1 (74) 11.1 ± 2.1 (73)* 12.5 ± 2.1 (73) 12.1 ± 1.7 (72) 12.3 ± 4.4 (+ 1.8 (+ 1.8 (± 2.1 (+ 1.7 (3.6 (
12.2 ± 2.1 (74) 11.1 ± 2.1 (73)* 12.5 ± 2.1 (73) 12.1 ± 1.7 (72) 12.3 ± 4.4 (+1.9 (₽ +1	+ 2.2 (+ + + (+ 4.2 (
	_	+1	+ 2.1 (± 2.1 (+ 1.7 (+ 4.4 (

--- = NO AVAILABLE DATA

Table 6 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE BODY WEIGHT GAIN MEASUREMENTS (g) [MEAN AND STANDARD DEVIATION (n)]

+ 1.9 (73)* 12.9 ± 2.2 (73) 12.4 ± 1.8 (72) 12.4 ± 4.4 (72) + 1.8 (73) 13.3 ± 2.3 (72) 12.5 ± 1.7 (72) 13.1 ± 4.5 (4.3) + 1.8 (72)* 13.6 ± 2.6 (72) 12.8 ± 1.8 (72) 13.2 ± 4.3 (72) + 1.7 (72) 13.6 ± 2.6 (72) 13.0 ± 2.1 (72) 13.2 ± 4.3 (72) + 1.8 (72)* 13.6 ± 2.5 (72) 13.0 ± 2.1 (72) 13.2 ± 4.3 (72) + 2.0 (72)* 13.9 ± 2.6 (72) 13.2 ± 1.9 (71) 13.9 ± 4.3 (72) + 2.0 (72)* 13.9 ± 2.7 (72) 13.2 ± 1.9 (71) 13.9 ± 4.6 (72) + 2.0 (72)* 13.9 ± 2.7 (72) 13.2 ± 1.9 (71) 14.1 ± 4.6 (72) + 2.0 (72)* 13.9 ± 2.7 (72) 13.2 ± 2.0 (70) 14.4 ± 4.6 (72) + 2.0 (72)* 13.9 ± 2.7 (72) 13.2 ± 2.0 (70) 14.4 ± 4.6 (72) + 1.9 (71)* 14.4 ± 2.6 (72) 13.2 ± 2.1 (70) 14.4 ± 4.6 (4.4) + 1.9 (71)* 14.4 ± 2.6 (72) 13.2 ± 2.4 (59) 14.7 ± 4.2 (4.6) + 1.9 (71)* 14.4 ± 2.8 (62) 14.2 ± 2.4 (59) 14.4 ± 4.5 (6.6) + 2.1 (60)* 14.2 ± 2.8 (62) 14.2 ± 2.4 (59) 15.5 ± 4.5 (6.6) + 2.1 (59)* 14.4 ± 2.9 (62) 14.2 ± 2	E	0.0 mg/kg/DAY	1.5 ng/kg/DAY	mg/k	1	35 9/kg/DA	175/100 19/kg/DAY
$12.0 \pm 1.8 \ (73)$ $13.3 \pm 2.3 \ (72)$ $12.5 \pm 1.7 \ (72)$ $13.6 \pm 2.6 \ (72)$ $12.8 \pm 1.8 \ (72)$ $13.1 \pm 4.5 \ (12)$ $13.2 \pm 4.3 \ (12.5 \pm 1.3 \ (1.2))$ $13.2 \pm 4.3 \ (1.2.5 \pm 1.3 \ (1.2))$ $13.2 \pm 2.3 \ (1.2.5 \pm 1.3 \ (1.3.5 \pm$	12.6	± 2.1 (74)	1.9 (3)* 12.9 ± 2.2	(73)	12.4 ± 1.8 (72)	12.4 ± 4.4 (41)
$12.2 \pm 1.7 (72)$ $13.6 \pm 2.6 (72)$ $13.0 \pm 2.1 (72)$ $13.0 \pm 2.1 (72)$ $13.2 \pm 4.3 (72)$ $12.5 \pm 1.9 (72)*$ $13.6 \pm 2.5 (72)$ $13.0 \pm 2.1 (72)$ $13.2 \pm 4.3 (72)$ $14.0 \pm 4.5 (72)$ $12.2 \pm 2.0 (72)*$ $13.9 \pm 2.7 (72)$ $13.2 \pm 1.9 (71)$ $13.9 \pm 4.3 (72)$ $12.4 \pm 2.0 (72)*$ $13.9 \pm 2.7 (72)$ $13.2 \pm 1.9 (71)$ $13.9 \pm 4.6 (72)$ $12.9 \pm 1.9 (71)*$ $14.4 \pm 2.6 (72)$ $13.2 \pm 2.1 (70)$ $14.4 \pm 4.6 (72)$ $12.9 \pm 1.9 (71)*$ $14.4 \pm 2.6 (72)$ $13.2 \pm 2.1 (70)$ $14.4 \pm 4.6 (72)$ $13.3 \pm 2.1 (60)*$ $14.7 \pm 2.0 (62)$ $14.7 \pm 2.0 (50)*$ $14.7 \pm 2.0 (60)*$ $14.7 \pm 2.0 (60)*$ $14.7 \pm 2.0 (62)$ $14.7 \pm 2.0 (50)*$ $14.7 \pm 2.0 (62)$ $14.7 \pm 2.0 (50)*$ $14.8 \pm 2.0 (50)*$ $14.8 \pm 2.0 (50)*$ $14.9 \pm 2.0 (50)*$ $14.9 \pm 2.0 (50)*$ $14.1 \pm 2.0 (50)*$	12.8	± 2.0 (74)	+ 1.8 (13.3 +	$\overline{}$	+1	+ 4.5 (
$12.5 \pm 1.8 \ (72)* $ $13.6 \pm 2.5 \ (72)$ $13.0 \pm 2.1 \ (72)$ $13.6 \pm 2.0 \ (72)$ $13.2 \pm 4.3 \ (72)$ $12.2 \pm 2.0 \ (72)* $ $13.9 \pm 2.7 \ (72)$ $13.2 \pm 1.9 \ (71)$ $13.9 \pm 4.5 \ (72)$ $13.2 \pm 1.9 \ (71)$ $13.9 \pm 4.5 \ (72)$ $13.2 \pm 1.9 \ (71)$ $13.9 \pm 4.6 \ (72)$ $13.2 \pm 2.0 \ (72)$ $13.3 \pm 2.1 \ (72)$ $13.3 \pm 2.1 \ (72)$ $13.4 \pm 2.8 \ (72)$ $13.8 \pm 2.2 \ (72)$ $14.4 \pm 2.8 \ (72)$ $13.8 \pm 2.2 \ (72)$ $14.4 \pm 4.5 \ (72)$ $13.8 \pm 2.2 \ (72)$ $14.4 \pm 2.8 \ (72)$ $14.2 \pm 2.4 \ (66)$ $14.7 \pm 4.5 \ (72)$ $13.3 \pm 2.1 \ (60)*$ $14.4 \pm 2.8 \ (62)$ $14.2 \pm 2.4 \ (66)$ $15.5 \pm 4.3 \ (72)$ $13.4 \pm 2.1 \ (59)*$ $14.4 \pm 2.9 \ (62)$ $14.4 \pm 2.9 \ (58)$ $15.2 \pm 4.9 \ (72)$ $13.1 \pm 2.2 \ (59)*$ $14.4 \pm 3.2 \ (62)$ $14.1 \pm 2.6 \ (58)$ $15.2 \pm 4.9 \ (72)$ $13.1 \pm 2.2 \ (59)*$ $14.2 \pm 2.1 \ (59)*$ $14.3 \pm 3.2 \ (62)$ $14.3 \pm 2.1 \ (58)$ $15.3 \pm 5.1 \ (72)$ $13.4 \pm 2.2 \ (59)*$ $14.4 \pm 3.2 \ (62)$ $14.5 \pm 2.3 \ (58)$ $15.6 \pm 5.1 \ (72)$ $13.6 \pm 5.1 \ (72)$ $13.6 \pm 2.2 \ (73)$ $14.7 \pm 2.3 \ (73)$ $15.8 \pm 5.0 \ (73)$ $14.8 \pm 3.6 \ (62)$ $14.7 \pm 2.9 \ (57)$ $15.8 \pm 5.0 \ (73)$ $15.8 \pm 5.0 \ (73)$ $14.8 \pm 2.2 \ (73)$ $14.8 \pm 3.3 \ (74)$ $14.8 \pm 3.3 \ ($	13.0	± 2.2 (74)	+1	13.6 +	(72)	+1	± 4.3 (
12.5 ± 1.9 (72)* 14.2 ± 2.6 (72) 13.6 ± 2.0 (71) 14.0 ± 4.5 (72) 12.2 ± 2.0 (72)* 13.9 ± 2.7 (72) 13.3 ± 2.0 (71) 13.9 ± 4.5 (72) 12.6 ± 2.0 (72)* 13.9 ± 2.5 (72) 13.2 ± 1.9 (71) 14.1 ± 4.6 (72) 12.4 ± 2.0 (72)* 13.9 ± 2.5 (72) 13.2 ± 1.9 (71) 14.1 ± 4.4 (72) 12.5 ± 1.9 (71)* 14.4 ± 2.6 (72) 13.8 ± 2.1 (70) 14.4 ± 4.4 (74) 12.9 ± 1.9 (71)* 14.4 ± 2.6 (72) 13.8 ± 2.1 (70) 14.4 ± 4.5 (72) 13.3 ± 2.1 (68)* 14.4 ± 2.6 (72) 13.8 ± 2.1 (70) 14.4 ± 4.2 (72) 13.3 ± 2.1 (68)* 14.4 ± 2.8 (69) 14.2 ± 2.4 (66) 15.5 ± 4.5 (72) 13.3 ± 2.1 (68)* 14.4 ± 2.9 (62) 14.2 ± 2.4 (66) 15.5 ± 4.3 (66) 13.1 ± 2.0 (60)* 14.4 ± 2.9 (62) 14.4 ± 2.9 (66) 15.2 ± 4.9 (66)	13.1	± 2.2 (74)	+ 1.8 (13.6 ±	(72)	± 2.1 (+ 4.3 (
12.2 ± 2.0 (72,* 13.9 ± 2.7 (72) 13.2 ± 1.9 (71) 13.9 ± 4.3 (6) 12.6 ± 2.0 (72)* 13.9 ± 2.5 (72) 13.2 ± 1.9 (71) 13.9 ± 4.6 (8) 12.6 ± 2.0 (72)* 13.2 ± 1.9 (71) 14.1 ± 4.4 (11) 4.4 (11) 4.4 (11) 4.4 (11) 4.4 (11) 4.4 (11) 4.4 (12) 4.5 (12) 13.2 ± 2.0 (70) 14.4 ± 4.4 (11) 4.4 (12) 4.5 (12) 13.8 ± 2.1 (70) 14.4 ± 4.4 (12) 4.5 (12) 13.8 ± 2.1 (70) 14.4 ± 4.5 (12) 13.8 ± 2.2 (69) 14.4 ± 4.5 (12) 13.8 ± 2.2 (69) 14.4 ± 4.5 (12) 14.2 ± 2.4 (66) 15.5 ± 4.3 (12) 14.2 ± 2.4 (66) 15.5 ± 4.3 (12) 13.3 ± 2.1 (60) 14.7 ± 2.9 (62) 14.2 ± 2.4 (59) 15.6 ± 5.0 (12) 14.4 ± 2.9 (62) 14.4 ± 2.9 (62) 14.4 ± 2.9 (62) 14.4 ± 2.9 (62) 14.4 ± 2.9 (62) 14.4 ± 2.9 (62) 14.4 ± 2.9 (62) 14.4 ± 2.9 (62) 14.4 ± 2.9 (62) <td>13.8</td> <td>± 2.3 (74)</td> <td>+ 1.9 (</td> <td>14.2 +</td> <td>(72)</td> <td>1+ 2.0</td> <td>4.5 (</td>	13.8	± 2.3 (74)	+ 1.9 (14.2 +	(72)	1+ 2.0	4.5 (
2.4 (74) 12.6 ± 2.0 (72). 13.9 ± 2.5 (72) 13.2 ± 1.9 (71) 13.9 ± 4.6 (72) 2.5 (74) 12.4 ± 2.0 (72)* 13.6 ± 2.7 (72) 13.2 ± 1.9 (71) 14.1 ± 4.4 (72) 2.6 (74) 12.5 ± 2.2 (72)* 13.2 ± 2.0 (70) 14.4 ± 4.4 (72) 2.5 (73) 12.9 ± 1.9 (71)* 14.4 ± 2.6 (72) 13.8 ± 2.1 (70) 14.6 ± 4.5 (72) 2.6 (73) 12.9 ± 1.9 (71)* 14.4 ± 2.8 (72) 13.8 ± 2.1 (70) 14.6 ± 4.5 (72) 2.6 (70) 13.3 ± 2.1 (68)* 14.4 ± 2.8 (69) 14.2 ± 2.4 (66) 15.5 ± 4.3 (72) 2.8 (63) 13.3 ± 2.1 (60)* 14.7 ± 3.0 (62) 14.2 ± 2.4 (56) 15.5 ± 4.3 (56) 2.5 (63) 13.1 ± 2.0 (60)* 14.4 ± 2.9 (62) 14.4 ± 2.4 (59) 15.2 ± 4.9 (50) 2.6 (62) 13.4 ± 2.1 (59)* 14.4 ± 3.2 (62) 14.4 ± 2.9 (57) 15.1 ± 5.4 (50) 2.8 (62)<	13.8	± 2.5 (74)	+ 2.0 (13.9 +1	(72)	± 2.0 (4.3 (
2.5 (74) 12.4 ± 2.0 (72)* 13.6 ± 2.7 (72) 13.2 ± 1.9 (71) 14.1 ± 4.4 4.4 (2.6 (74) 12.5 ± 2.2 (72)* 13.9 ± 2.5 (72) 13.2 ± 2.0 (70) 14.4 ± 4.5 (4.4 (2.5 (73) 12.9 ± 1.9 (71)* 14.4 ± 2.6 (72) 13.8 ± 2.1 (70) 14.6 ± 4.5 (4.5 (2.5 (73) 12.9 ± 1.9 (71)* 14.4 ± 2.8 (72) 13.8 ± 2.1 (70) 14.6 ± 4.5 (4.5 (2.6 (70) 13.3 ± 2.1 (60)* 14.7 ± 2.8 (62) 14.2 ± 2.4 (56) 15.5 ± 4.3 (5.0 (2.8 (63) 13.1 ± 2.0 (60)* 14.7 ± 2.9 (62) 14.2 ± 2.4 (58) 15.6 ± 5.0 (5.0 (2.5 (62) 13.4 ± 2.1 (59)* 14.4 ± 2.9 (62) 14.1 ± 2.4 (58) 15.1 ± 4.9 (5.0 (2.6 (62) 12.9 ± 2.1 (59)* 14.4 ± 3.2 (62) 14.4 ± 2.9 (58) 15.3 ± 3.0 (58) 15.3 ± 5.1 (2.8 (62) 13.1 ± 2.2 (59)* 14.4 ± 3.2 (62) 14.3 ± 2.9 (58) 15.3 ± 5.1 (5.1 (2.8 (62) 13.7 ± 2.3 (59)* 14.8 ± 3.6 (62) 14.3 ± 2.9 (57) 15.8 ± 5.1 (5.1 (13.9	2.4	± 2.0 (13.9 +	(72)	6. +1	+ 4.6 (
2.6 (74) 12.5 ± 2.2 (72)* 13.9 ± 2.5 (72) 13.2 ± 2.0 (70) 14.4 ± 4.5 (72) 13.8 ± 2.1 (70) 14.6 ± 4.5 (4.6 (72) 14.6 ± 4.5 (72) 14.6 ± 4.2 (72) 14.6 ± 4.2 (72) 14.6 ± 4.2 (72) 14.6 ± 4.2 (72) 14.6 ± 4.2 (72) 14.6 ± 4.2 (72) 14.6 ± 4.2 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 14.7 ± 4.3 (72) 1	13.9		+ 2.0	13.6 ±	$\overline{}$	*1 6.1	± 4.4 (
2.5 (73) 12.9 ± 1.9 (71)* 14.4 ± 2.6 (72) 13.8 ± 2.1 (70) 14.6 ± 4.5 (72) 2.6 (73) 12.9 ± 1.9 (71)* 14.4 ± 2.8 (72) 13.8 ± 2.1 (69) 14.7 ± 4.2 (65) 2.6 (70) 13.3 ± 2.1 (68)* 14.6 ± 2.8 (69) 14.2 ± 2.4 (66) 15.5 ± 4.3 (72) 2.8 (63) 13.3 ± 2.1 (60)* 14.7 ± 3.0 (62) 14.2 ± 2.4 (58) 15.6 ± 5.0 (72) 2.5 (63) 13.1 ± 2.0 (60)* 14.4 ± 2.9 (62) 14.1 ± 2.4 (58) 15.1 ± 4.6 (72) 2.6 (62) 13.4 ± 2.1 (59)* 14.4 ± 3.2 (62) 14.1 ± 2.3 (58) 15.2 ± 4.9 (72) 2.7 (62) 12.9 ± 2.1 (59)* 14.4 ± 3.2 (62) 14.1 ± 2.6 (58) 15.7 ± 5.4 (58) 2.8 (62) 13.1 ± 2.2 (59)* 14.4 ± 3.2 (62) 14.1 ± 2.6 (58) 15.7 ± 5.4 (58) 2.8 (62) 13.7 ± 2.2 (59)* 14.8 ± 3.6 (62) 14.7 ± 2.9 (57) 15.7 ± 5.4 €<	14.1	± 2.6 (74)	± 2.2 (13.9 +	(72)	+ 2.0	4.4 (
2.5 (73) 12.9 ± 1.9 (71)* 14.4 ± 2.8 (72) 13.8 ± 2.2 (69) 14.7 ± 4.2 (69) 14.2 ± 2.4 (66) 15.5 ± 4.3 (72) 2.6 (70) 13.3 ± 2.1 (60)* 14.7 ± 3.0 (62) 14.2 ± 2.4 (59) 15.6 ± 5.0 (72) 2.5 (63) 13.1 ± 2.0 (60)* 14.4 ± 2.9 (62) 14.1 ± 2.4 (58) 15.1 ± 4.6 (72) 2.5 (62) 13.4 ± 2.1 (59)* 14.4 ± 3.2 (62) 14.4 ± 2.3 (58) 15.2 ± 4.9 (72) 2.7 (62) 12.9 ± 2.1 (59)* 14.4 ± 3.1 (62) 14.4 ± 2.3 (58) 15.3 ± 5.1 (72) 2.7 (62) 13.1 ± 2.2 (59)* 14.4 ± 3.2 (62) 14.3 ± 2.7 (58) 15.7 ± 5.4 (72) 2.8 (62) 13.7 ± 2.3 (59)* 14.8 ± 3.6 (62) 14.3 ± 2.7 (58) 15.7 ± 5.4 (72) 2.8 (62) 13.1 ± 2.2 (59)* 14.8 ± 3.6 (62) 14.7 ± 2.9 (57) 15.6 ± 5.1 (72)	14.2	2.5 (+ 1.9 (14.4 +	(72)	1 2.1 (+ 4.5 (
2.6 (70) 13.3 ± 2.1 (68)* 14.6 ± 2.8 (69) 14.2 ± 2.4 (66) 15.5 ± 4.3 2.8 (63) 13.3 ± 2.1 (60)* 14.7 ± 3.0 (62) 14.1 ± 2.4 (58) 15.6 ± 5.0 (6) 2.5 (62) 13.4 ± 2.1 (59)* 14.4 ± 3.2 (62) 14.1 ± 2.4 (58) 15.1 ± 4.6 (7) 2.6 (62) 12.9 ± 2.1 (59)* 14.4 ± 3.1 (62) 14.1 ± 2.6 (58) 15.2 ± 4.9 (7) 2.7 (62) 13.1 ± 2.2 (59)* 14.4 ± 3.2 (62) 14.3 ± 2.7 (58) 15.7 ± 5.4 (7) 2.8 (62) 13.7 ± 2.3 (59)* 14.8 ± 3.2 (62) 14.7 ± 2.9 (57) 15.7 ± 5.4 (7) 3.0 (61) 13.6 ± 2.2 (59)* 14.8 ± 3.6 (62) 14.7 ± 2.9 (57) 15.6 ± 5.1 (7)	14.4		+1 +1	14.4 ±	(72)	± 2.2 (+ 4.2 (
2.8 (63) 13.3 ± 2.1 (60)* 14.7 ± 3.0 (62) 14.2 ± 2.4 (59) 15.6 ± 5.0 (60)* 2.5 (63) 13.1 ± 2.0 (60)* 14.4 ± 2.9 (62) 14.1 ± 2.4 (58) 15.1 ± 4.6 (2.5 (62) 13.4 ± 2.1 (59)* 14.4 ± 3.1 (62) 14.1 ± 2.6 (58) 15.2 ± 4.9 (2.7 (62) 13.1 ± 2.2 (59)* 14.4 ± 3.2 (62) 14.3 ± 2.7 (58) 15.3 ± 5.4 (2.8 (62) 13.7 ± 2.3 (59)* 14.8 ± 3.6 (62) 14.7 ± 2.9 (57) 15.6 ± 5.1 (3.0 (61) 13.6 ± 2.2 (59) 15.3 ± 3.6 (62) 14.5 ± 2.9 (57) 15.8 ± 5.0 (14.5	2.6 (± 2.1 (14.6 +	(69)	+ 2.4 (4.3 (
2.5 (63) 13.1 ± 2.0 (60)* 14.4 ± 2.9 (62) 14.1 ± 2.4 (58) 15.1 ± 4.6 (78) 2.5 (62) 13.4 ± 2.1 (59)* 14.4 ± 3.2 (62) 14.4 ± 2.6 (58) 15.2 ± 4.9 (78) 2.7 (62) 13.1 ± 2.2 (59)* 14.4 ± 3.2 (62) 14.3 ± 2.7 (58) 15.7 ± 5.4 (78) 2.8 (62) 13.7 ± 2.3 (59) 14.8 ± 3.6 (62) 14.7 ± 2.9 (57) 15.6 ± 5.1 (78) 3.0 (61) 13.6 ± 2.2 (59) 15.3 ± 3.6 (62) 14.5 ± 2.9 (57) 15.8 ± 5.0 (78)	14.7	2.8 (± 2.1 (14.7 ±	_	+ 2.4 (+ 5.0 (
2.5 (62) 13.4 ± 2.1 (59)* 14.4 ± 3.2 (62) 14.4 ± 2.3 (58) 15.2 ± 4.9 (5) 2.6 (62) 12.9 ± 2.1 (59)* 14.4 ± 3.1 (62) 14.1 ± 2.6 (58) 15.3 ± 5.1 (7) 2.7 (62) 13.1 ± 2.2 (59)* 14.4 ± 3.2 (62) 14.3 ± 2.7 (58) 15.7 ± 5.4 (7) 2.8 (62) 13.7 ± 2.3 (59) 14.8 ± 3.6 (62) 14.7 ± 2.9 (57) 15.6 ± 5.1 (7) 3.0 (61) 13.6 ± 2.2 (59) 15.3 ± 3.6 (62) 14.5 ± 3.3 (57) 15.8 ± 5.0 (7)	14.5	2.5 (+ 2.0 (14.4 +	(62)	± 2.4 (+ 4.6 (
2.6 (62) 12.9 ± 2.1 (59)* 14.4 ± 3.1 (62) 14.1 ± 2.6 (58) 15.3 ± 5.1 (2.7 (62) 13.1 ± 2.2 (59)* 14.4 ± 3.2 (62) 14.3 ± 2.7 (58) 15.7 ± 5.4 (2.8 (62) 13.7 ± 2.3 (59) 14.8 ± 3.6 (62) 14.7 ± 2.9 (57) 15.6 ± 5.1 (3.0 (61) 13.6 ± 2.2 (59) 15.3 ± 3.6 (62) 14.5 ± 3.3 (57) 15.8 ± 5.0 (14.7	2.5 (± 2.1 (14.4 +	(62)	± 2.3 (+ 4.9 (
2.7 (62) 13.1 ± 2.2 (59)* 14.4 ± 3.2 (62) 14.3 ± 2.7 (58) 15.7 ± 5.4 (2.8 (62) 13.7 ± 2.3 (59) 14.8 ± 3.6 (62) 14.7 ± 2.9 (57) 15.6 ± 5.1 (3.0 (61) 13.6 ± 2.2 (59) 15.3 ± 3.6 (62) 14.5 ± 3.3 (57) 15.8 ± 5.0 (14.4	2.6 (2.1 (14.4 +	$\overline{}$	± 2.6 (± 5.1 (
2.8 (62) 13.7 ± 2.3 (59) 14.8 ± 3.6 (62) 14.7 ± 2.9 (57) 15.6 ± 5.1 (3.0 (61) 13.6 ± 2.2 (59) 15.3 ± 3.6 (62) 14.5 ± 3.3 (57) 15.8 ± 5.0 (14.6	2.7 (± 2.2 (14.4 +	(62)	± 2.7 (± 5.4 (
3.0 (61) 13.6 ± 2.2 (59) 15.3 ± 3.6 (62) 14.5 ± 3.3 (57) 15.8 ± 5.0 (14.9	2.8	+ 2.3 (14.8 +	$\overline{}$	± 2.9 (± 5.1 (
	14.9		± 2.2 (15.3 +	_	3.3 (+ 2.0 (

--- = NO AVAILABLE DATA

3

(2)

9

٥

٥

٩

ð

Table 6 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE BODY WEIGHT GAIN MEASUREMENTS (9)
[MEAN AND STANDARD DEVIATION (n)]

13.3 ± 2.1 (59)*	14 9 4 9 7 (63)	1	
	14:3 + 3:1 (92)	14.5 + 2.7 (55)	15.0 ± 4.5 (26)
13.7 ± 2.3 (59)*	15.4 ± 4.0 (61)	14.7 ± 3.0 (54)	15.4 ± 3.5 (26)
13.8 ± 2.3 (59)	15.3 ± 3.8 (60)	14.6 ± 2.9 (54)	14.8 ± 3.1 (26)
13.4 ± 2.5 (59)*	14.8 ± 3.7 (60)	14.4 ± 3.0 (54)	14.6 ± 2.8 (26)
13.8 ± 2.3 (57)+	15.3 ± 3.7 (58)	14.9 ± 2 8 (54)	14.8 ± 2.6 (25)
13.5 ± 2 4 (51)	15.1 ± 3.3 (52)	14.4 ± 2.9 (49)	14.6 ± 2.4 (25)
13.6 ± 2.3 (55)*	14.9 ± 3.1 (57)	14.5 ± 2.8 (54)	14.6 ± 2.5 (25)
13.7 ± 2.4 (54)*	15.1 ± 3.1 (56)	14.7 ± 2.9 (54)	14.6 ± 2.6 (25)
13.2 ± 2.5 (54)*	14.6 ± 3.1 (56)	14.0 ± 2.9 (53)	13.9 ± 2.7 (25)
13.4 ± 3.1 (52)	15.0 ± 3.3 (56)	14.2 ± 3.1 (52)	14.4 ± 2.9 (25)
13.0 ± 2.7 (51)	14.9 2.7 (54)	13.6 ± 3.5 (52)	13.9 ± 3.2 (25)
13.0 ± 2.6 (50)*	14.8 ± 2.7 (54)	13.5 ± 3.3 (49)	13.6 ± 2.3 (23)
12.9 ± 2.6 (50)*	14.7 ± 2.7 (53)	13.7 ± 2.9 (46)	13.2 ± 2.2 (23)*
12.7 ± 3.1 (50)*	14.8 ± 2.8 (52)	13.4 ± 3.0 (45)	12.9 ± 2.2 (23)*
12.6 ± 2.4 (48)*	14.2 ± 2.7 (49)	13.4 ± 3.3 (45)	12.9 ± 2.1 (22)
12.5 ± 2.3 (47)*	14.7 ± 3.1 (45)	12.8 ± 2.8 (40)*	12.8 ± 2.1 (22)*
12.2 ± 2.5 (46)*	14.3 ± 3.0 (44)	12.9 ± 2.4 (39)	12.4 ± 2.2 (22)*
12.2 ± 2.2 (42)*	13.7 ± 2.9 (41)	12.4 ± 2.6 (38)*	12.1 ± 2.4 (22)*
12.3 ± 2.4 (42)*	13.9 ± 3.2 (41)	12.8 ± 2.7 (37)	12.1 ± 2.6 (22)*
	2 2 2 2 2 2 2 2 2 2 2 2 3 3 4 2 2 3 4 4 6 6 6 6 4 4 6 6 6 7 4 4 6 6 7 4 6 6 7 4 6 6 7 4 6 7 7 7 4 7 <td>2.5 (54)* 14.6 ± 3.1 (3.1 (52) 15.0 ± 3.3 (2.7 (51) 14.9 ± 2.7 (2.6 (50)* 14.7 ± 2.7 (3.1 (50)* 14.8 ± 2.7 (3.1 (50)* 14.7 ± 2.7 (2.4 (48)* 14.2 ± 2.7 (2.3 (47)* 14.7 ± 3.1 (2.5 (46)* 14.3 ± 3.0 (2.5 (42)* 13.9 ± 3.2 (</td> <td>2.5 (54)* 14.6 ± 3.1 (56) 14.0 ± 2.9 (3.1 (52) 15.0 ± 3.3 (56) 14.2 ± 3.1 (2.7 (51) 14.9 ± 2.7 (54) 13.6 ± 3.5 (2.6 (50)* 14.8 ± 2.7 (54) 13.5 ± 3.3 (2.6 (50)* 14.7 ± 2.7 (53) 13.7 ± 2.9 (3.1 (50)* 14.8 ± 2.8 (52) 13.4 ± 3.0 (2.4 (48)* 14.2 ± 2.7 (49) 13.4 ± 3.3 (2.3 (47)* 14.7 ± 3.1 (45) 12.8 ± 2.8 (2.5 (46)* 14.3 ± 3.0 (44) 12.9 ± 2.4 (2.5 (42)* 13.9 ± 3.2 (41) 12.8 ± 2.6 (2.7 (42)* 13.9 ± 3.2 (41) 12.8 ± 2.7 (</td>	2.5 (54)* 14.6 ± 3.1 (3.1 (52) 15.0 ± 3.3 (2.7 (51) 14.9 ± 2.7 (2.6 (50)* 14.7 ± 2.7 (3.1 (50)* 14.8 ± 2.7 (3.1 (50)* 14.7 ± 2.7 (2.4 (48)* 14.2 ± 2.7 (2.3 (47)* 14.7 ± 3.1 (2.5 (46)* 14.3 ± 3.0 (2.5 (42)* 13.9 ± 3.2 (2.5 (54)* 14.6 ± 3.1 (56) 14.0 ± 2.9 (3.1 (52) 15.0 ± 3.3 (56) 14.2 ± 3.1 (2.7 (51) 14.9 ± 2.7 (54) 13.6 ± 3.5 (2.6 (50)* 14.8 ± 2.7 (54) 13.5 ± 3.3 (2.6 (50)* 14.7 ± 2.7 (53) 13.7 ± 2.9 (3.1 (50)* 14.8 ± 2.8 (52) 13.4 ± 3.0 (2.4 (48)* 14.2 ± 2.7 (49) 13.4 ± 3.3 (2.3 (47)* 14.7 ± 3.1 (45) 12.8 ± 2.8 (2.5 (46)* 14.3 ± 3.0 (44) 12.9 ± 2.4 (2.5 (42)* 13.9 ± 3.2 (41) 12.8 ± 2.6 (2.7 (42)* 13.9 ± 3.2 (41) 12.8 ± 2.7 (

- = NO AVAILABLE DATA

Table 7

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF AEXAHYDRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE BODY WEIGHTS (G) [MEAN AND STANDARD DEVIATION (n)]

19.7 ± 1.2 (85) 18.5 ± 1.2 (85) 18.6 ± 1.1 (85) 18.8 ± 1.0 (85) 19.5 ± 0.9 (85) 19.5 ± 0.9 (85) 19.4 ± 0.9 (85) 19.4 ± 0.9 (85) 19.4 ± 1.2 (85) 19.6 ± 1.0 (85) 20.5 ± 1.3 (85) 20.8 ± 1.1 (85) 20.7 ± 1.0 (85) 20.5 ± 1.2 (85) 20.8 ± 1.1 (85) 20.7 ± 1.0 (85) 20.2 ± 0.9 (85) 20.2 ± 1.1 (85) 20.2 ± 1.1 (85) 20.7 ± 1.2 (85) 20.7 ± 1.1 (85) 20.2 ± 0.9 (85) 20.2 ± 1.1 (85	TEST WEEK	0.0 mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
19.4 ± 0.9 (85) 19.4 ± 1.2 (85) 19.6 ± 1.0 (85) 19.5 ± 0.9 (85) 19.5 ± 1.0 (85) 20.7 ± 1.0 (85) 20.7 ± 1.0 (85) 20.7 ± 1.0 (85) 20.7 ± 1.0 (85) 21.2 ± 1.4 (85) 21.2 ± 1.0 (85) 21.2 ± 1.0 (85) 22.0 ± 1.1 (85) 22.0 ± 1.1 (85) 22.0 ± 1.1 (85) 22.0 ± 1.1 (85) 22.2 ± 1.1 (85) 22.2 ± 1.1 (85) 22.2 ± 1.1 (85) 22.2 ± 1.1 (85) 22.2 ± 1.1 (85) 22.2 ± 1.1 (85) 22.2 ± 1.1 (85) 22.2 ± 1.1 (85) 22.2 ± 1.1 (85) 22.2 ± 1.1 (85) 22.2 ± 1.1 (85) 22.2 ± 1.1 (85) 22.2 ± 1.1 (85) 22.2 ± 1.1 (85) 22.2 ± 1.1 (85) 22.2 ± 1.2 ± 1.1 (85) 22.2 ± 1.2 ± 1.1 (85) 22.2 ± 1.2 ± 1.2 ± 1.1 (85) 22.2 ± 1.2 ± 1.2 ± 1.1 (85) 22.2 ± 1.2 ± 1.2 ± 1.2 ± 1.2 ± 1.2 ± 1.2 ± 1.2 ± 1.2 ± 1.2 ± 1.2 ± 1.1 ± 1.2 ± 1.2 ±	7	3.7 ± 1.2 (.5 ± 1.2 (.6 ± 1.1 (.8 ± 1.0 (
20.5 ± 1.0 (85) 20.5 ± 1.3 (85) 20.8 ± 1.1 (85) 20.7 ± 1.0 (85) 20.2 ± 1.2 (85) 21.2 ± 1.1 (85) 21.2 ± 1.1 (85) 21.2 ± 1.1 (85) 21.2 ± 1.1 (85) 21.2 ± 1.1 (85) 21.2 ± 1.1 (85) 21.2 ± 1.1 (85) 21.2 ± 1.1 (85) 21.2 ± 1.1 (85) 21.2 ± 1.1 (85) 21.2 ± 1.1 (85) 21.2 ± 1.1 (85) 21.2 ± 1.2 (85) 21.2 ± 1.2 (85) 21.2 ± 1.1 (85) 21.2 ± 1.2 (85	Ţ	.4 ± 0.9 (9.4 ± 1.2 (.6 ± 1.0 () 6.0 + 5.	19.1 ± 1.1 (85)
21.2 ± 1.2 (85) 21.2 ± 1.4 (85) 22.0 ± 1.1 (85) 21.2 ± 0.9 (85) 22.0 ± 1.1 (85) 21.2 ± 0.9 (85) 22.5 ± 1.1 (85) 22.4 ± 1.4 (85) 22.7 ± 1.2 (85) 22.0 ± 1.1 (85) 22.7 ± 1.0 (85) 22.7 ± 1.0 (85) 22.4 ± 1.4 (85) 22.4 ± 1.4 (85) 22.4 ± 1.4 (85) 22.4 ± 1.5 (85) 22.4 ± 1.5 (85) 22.4 ± 1.6 (85) 22.4 ± 2.1 (85	. -	+ 1.0 (5 + 1.3 (+ 1.1 (+ 1.0 (20.2 ± 1.2 (85)
21.5 ± 1.1 (85) 21.6 ± 1.3 (85) 22.0 ± 1.2 (85) 22.0 ± 1.2 (85) 22.0 ± 1.2 (85) 22.0 ± 1.2 (85) 22.0 ± 1.0 (85) 22.3 ± 1.0 (85)	8	1.2 ± 1.2 (.2 ± 1.4 (.5 ± 1.1 () 6.0 +1	20.6 ± 1.2 (84)*
22.5 ± 1.3 (85) 22.4 ± 1.4 (85) 22.7 ± 1.2 (85) 22.8 ± 1.0 (85) 23.5 ± 1.3 (85) 23.5 ± 1.4 (85) 23.1 ± 1.3 (85) 23.4 ± 1.4 (85) 23.7 ± 1.3 (85) 23.6 ± 1.5 (85) 24.4 ± 1.6 (85) 24.4 ± 1.6 (85) 24.4 ± 1.6 (85) 24.4 ± 1.6 (85) 24.4 ± 1.6 (85) 24.4 ± 1.6 (85) 24.4 ± 1.6 (85) 24.4 ± 1.6 (85) 24.4 ± 1.6 (85) 24.6 ± 1.7 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.9 (85) 25.3 ± 1.0 (85	ဗ	1.5 ± 1.1 (1.8 ± 1.3 (2.0 ± 1.2 (+1.1	21.4 ± 1.1 (73)*
23.5 ± 1.4 (85) 23.1 ± 1.3 (85) 23.4 ± 1.4 (85) 23.1 ± 1.3 (85) 23.2 ± 1.3 (85) 23.1 ± 1.3 (85) 24.0 ± 1.5 (85) 24.1 ± 1.1 (85) 23.2 ± 1.5 (85) 24.1 ± 1.1 (85) 23.2 ± 1.4 (85) 24.1 ± 1.1 (85) 23.2 ± 1.4 (85) 24.1 ± 1.1 (85) 24.2 ± 1.4 (85) 24.1 ± 1.4 (85) 24.6 ± 1.4 (85) 24.6 ± 1.4 (85) 24.6 ± 1.4 (85) 24.6 ± 1.4 (85) 24.6 ± 1.4 (85) 25.1 ± 1.6 (85) 24.6 ± 1.4 (85) 25.2 ± 1.9 (85)	4	.5 ± 1.3 (.4 ± 1.4 (.7 ± 1.2 (1.0 (22.5 ± 1.4 (61)
23.9 ± 1.3 (85) 23.8 ± 1.5 (85) 24.0 ± 1.5 (85) 24.1 ± 1.1 (85) 24.4 ± 1.6 (85) 24.5 ± 1.5 (85) 24.6 ± 1.4 (05) 25.0 ± 1.5 (85) 24.6 ± 1.7 (85) 25.1 ± 1.7 (85) 25.2 ± 1.7 (85) 25.1 ± 1.8 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.3 ± 1.7 (85) 25.2 ± 1.7 (85) 25.2 ± 1.7 (85) 25.2 ± 1.7 (85) 25.3 ± 1.8 (85) 25.3 ± 1.7 (85) 25.2 ± 1.7 (85) 25.3 ± 1.9 (85) 25.3 ± 1.7 (85) 25.3 ± 2.7 (85	ហ	.5 ± 1.4 (.1 ± 1.3 (3.4 ± 1.4 (+ 1.3 (23.0 ± 1.5 (61)
25.0 ± 1.5 (85) 24.4 ± 1.6 (85) 25.1 ± 1.5 (85) 24.6 ± 1.4 (85) 25.2 ± 1.5 (85) 25.2 ± 1.7 (85) 25.2 ± 1.7 (85) 25.2 ± 1.7 (85) 25.3 ± 1.6 (85) 25.3 ± 1.6 (85) 25.2 ± 1.7 (85) 25.2 ± 1.7 (85) 25.3 ± 1.8 (85) 25.5 ± 1.9 (85) 25.5 ± 1.7 (85) 25.2 ± 1.7 (85) 25.3 ± 1.9 (85) 25.5 ± 1.7 (85) 25.2 ± 2.0 (85) 25.0 ± 2.1 (85) 25.3 ± 2.0 ± 2.0 ± 2.0 ± 2.0 ± 2.0 ± 2.0 ± 2.0 ± 2.0 ± 2.0 ± 2	ဖ	+1.3 (1.5 (.0 ± 1.5 (± 1.1 (23.5 ± 1.4 (60)
25.0 ± 1.5 (85) 24.6 ± 1.7 (85) 25.1 ± 1.6 (85) 25.3 ± 1.6 (85) 25.2 ± 1.7 (85) 25.2 ± 1.7 (85) 25.2 ± 1.7 (85) 25.2 ± 1.7 (85) 25.2 ± 1.9 (85) 25.5 ± 1.7 (85) 26.2 ± 2.1 (85) 26.4 ± 2.2 (85) 26.6 ± 1.8 (85) 26.4 ± 2.2 (85) 26.6 ± 1.9 (85) 26.4 ± 2.2 (85) 26.4 ± 2.2 (85) 26.6 ± 1.9 (85) 26.4 ± 2.2 (85	7	1.6 (4.4 ± 1.6 (4.5 ± 1.5 (+ 1.4 (24.0 ± 1.5 (60)
25.2 ± 1.7 (85) 25.1 ± 1.8 (85) 25.5 ± 1.9 (85) 25.5 ± 1.7 (85) 26.2 ± 1.7 (85) 26.2 ± 1.8 (85) 26.2 ± 1.9 (85) 26.2 ± 1.8 (85) 26.2 ± 2.1 (85) 26.0 ± 2.1 (85) 26.3 ± 2.0 (85) 26.4 ± 2.2 (85) 26.5 ± 1.8 (85) 26.4 ± 2.2 (85) 26.6 ± 1.9 (85) 26.4 ± 2.2 (85) 26.6 ± 1.9 (85) 26.8 ± 2.3 (85) 26.7 ± 2.2 (85) 26.7 ± 2.2 (85) 26.7 ± 2.2 (85) 26.9 ± 2.2 (85) 26.9 ± 2.2 (85) 26.9 ± 2.2 (85) 26.9 ± 2.2 (85) 26.9 ± 2.2 (85) 26.9 ± 2.2 (85) 26.9 ± 2.2 (85) 26.9 ± 2.2 (85) 27.3 ± 2.3 (85) 27.7 ± 2.5 (85) 27.1 ± 1.9 (85) 28.2 ± 2.4 (85) 28.2 ± 2.4 (85) 28.2 ± 2.7 (85) 28.6 ± 2.7 (85) 28.2 ± 2.7 (85) 29.0 ± 2.7 (85) 29.0 ± 2.7 (85) 29.1 ± 2.7 (85) 29.7 ± 2.7 ± 2	۵	+ 1.5 (.6 ± 1.7 (5.1 ± 1.6 (+ 1.6 (24.5 ± 1.5 (58)
25.8 ± 2.0 (85) 25.7 ± 2.1 (85) 26.4 ± 2.2 (85) 26.0 ± 1.8 (85) 26.2 ± 2.1 (85) 26.0 ± 2.1 (85) 26.0 ± 2.1 (85) 26.0 ± 2.1 (85) 26.0 ± 2.1 (85) 26.0 ± 1.9 (85) 26.4 ± 2.2 (85) 26.7 ± 2.2 (85) 26.7 ± 2.2 (85) 26.7 ± 2.2 (85) 26.7 ± 2.2 (85) 26.7 ± 2.2 (85) 26.7 ± 2.2 (85) 27.7 ± 2.2 (85) 27.1 ± 1.9 (85) 28.2 ± 2.4 (85) 27.7 ± 2.5 (85) 27.7 ± 2.5 (85) 27.7 ± 2.5 (85) 27.7 ± 2.5 (85) 27.7 ± 2.5 (85) 27.7 ± 2.5 (85) 27.7 ± 2.5 (85) 27.7 ± 2.2 (85) 27.7 ± 2.5 (85) 27.7 ± 2.2 (85) 29.2 ± 2.7 (85) 29.2 ± 2.7 (85) 29.2 ± 2.7 (85) 29.1 ± 2.7 (85) 29.1 ± 2.7 (85) 30.2 ± 2.7 (85) 30.2 ± 2.7 (85) 30.2 ± 2.7 (85) 30.3 ± 2.6 (85) 30.3 ± 2.5 (85) 31.7 ± 2.7 (85	თ	.2 ± 1.7 (5.1 + 1.8 (5.5 ± 1.9 (1.7 (25.1 ± 1.9 (53)
26.2 ± 2.1 (85) 26.0 ± 2.1 (85) 26.4 ± 2.2 (85) 26.5 ± 1.8 (85) 26.4 ± 2.1 (85) 26.7 ± 2.2 (85) 26.6 ± 1.9 (85) 26.8 ± 2.3 (85) 26.7 ± 2.2 (85) 26.6 ± 1.9 (85) 26.8 ± 2.3 (85) 26.7 ± 2.2 (85) 27.1 ± 1.9 (85) 27.4 ± 2.2 (85) 27.3 ± 2.3 (85) 27.7 ± 2.5 (85) 27.1 ± 1.9 (85) 28.2 ± 2.4 (85) 28.2 ± 2.6 (85) 28.6 ± 2.7 (85) 28.5 ± 2.3 (85) 29.0 ± 2.7 (85) 29.1 ± 2.7 (85) 28.9 ± 2.2 (85) 30.2 ± 2.7 (85) 30.2 ± 3.0 (85) 30.3 ± 2.6 (85) 30.5 ± 2.9 (85) 30.2 ± 3.0 (85) 30.4 ± 2.7 (85) 31.2 ± 3.0 (85) 31.1 ± 3.2 (85) 31.1 ± 2.9 (85) 31.7 ± 3.1 (75) 32.1 ± 3.1 (75) 32.7 ± 3.2 (75) 32.5 ± 3.3 (75)	0	+ 2.0 (.7 ± 2.1 (5.9 ± 1.9 (+ 1.8 (24.5 ± 1.7 (53)*
26.4 ± 2.1 (85) 26.3 ± 2.0 (85) 26.7 ± 2.2 (85) 26.6 ± 1.9 (85) 26.8 ± 2.3 (85) 26.7 ± 2.2 (85) 26.7 ± 1.9 (85) 27.1 ± 1.9 (85) 27.4 ± 2.2 (85) 27.7 ± 2.5 (85) 27.7 ± 2.5 (85) 27.6 ± 2.2 (85) 28.2 ± 2.4 (85) 28.2 ± 2.6 (85) 28.6 ± 2.7 (85) 28.5 ± 2.3 (85) 29.0 ± 2.7 (85) 29.2 ± 2.7 (85) 29.1 ± 2.7 (85) 28.9 ± 2.2 (85) 30.2 ± 2.7 (85) 30.2 ± 3.0 (85) 30.2 ± 3.0 (85) 30.3 ± 2.6 (85) 30.5 ± 2.9 (85) 30.9 ± 3.0 (85) 30.4 ± 2.7 (85) 31.2 ± 3.0 (85) 31.1 ± 3.2 (85) 31.6 ± 3.2 (85) 31.1 ± 2.9 (85) 31.7 ± 3.1 (75) 32.1 ± 3.2 (75) 3.1 (75) 32.5 ± 3.3 (75) 3.1 (75)	-	± 2.1 (6.0 ± 2.1 (6.4 ± 2.2 (6.5 ± 1.8 (25.4 ± 1.8 (49)*
26.8 ± 2.3 (85) 26.7 ± 2.2 (85) 26.9 ± 2.2 (85) 27.1 ± 1.9 (85) 27.4 ± 2.2 (85) 27.3 ± 2.3 (85) 27.7 ± 2.5 (85) 27.6 ± 2.2 (85) 28.2 ± 2.4 (85) 28.2 ± 2.6 (85) 28.6 ± 2.7 (85) 28.5 ± 2.3 (85) 29.0 ± 2.7 (85) 29.2 ± 2.7 (85) 29.1 ± 2.7 (85) 28.9 ± 2.2 (85) 30.2 ± 2.7 (85) 30.0 ± 3.0 (85) 30.2 ± 3.0 (85) 30.3 ± 2.6 (85) 30.5 ± 2.9 (85) 30.5 ± 3.0 (85) 30.9 ± 3.0 (85) 30.4 ± 2.7 (85) 31.2 ± 3.0 (85) 31.1 ± 3.2 (85) 31.6 ± 2.9 (85) 31.7 ± 3.1 (75) 32.1 ± 3.2 (75) 32.7 ± 3.2 (75)	12	± 2.1 (± 2.0 (.7 ± 2.2 (+1.9	24.9 ± 1.5 (49)*
27.4 ± 2.2 (85) 27.3 ± 2.3 (85) 27.7 ± 2.5 (85) 27.6 ± 2.2 (85) 28.2 ± 2.4 (85) 28.2 ± 2.6 (85) 28.6 ± 2.7 (85) 28.5 ± 2.3 (85) 29.0 ± 2.7 (85) 29.1 ± 2.7 (85) 28.9 ± 2.2 (85) 30.2 ± 2.7 (85) 30.2 ± 3.0 (85) 30.3 ± 2.6 (85) 30.5 ± 2.9 (85) 30.2 ± 3.0 (85) 30.3 ± 2.6 (85) 31.2 ± 2.0 (85) 30.9 ± 3.0 (85) 30.4 ± 2.7 (85) 31.7 ± 3.1 (75) 32.1 ± 3.2 (75) 31.6 ± 3.2 (75) 32.6 + 3.1 (75) 32.7 + 3.9 (75) 2.5 (75) 32.5 + 3.3 (75)	13	+ 2.3 (.7 ± 2.2 (.9 ± 2.2 (.1 ± 1.9 (25.3 ± 1.7 (49)*
28.2 ± 2.4 (85) 28.2 ± 2.6 (85) 28.6 ± 2.7 (85) 28.5 ± 2.3 (85) 29.0 ± 2.7 (85) 29.2 ± 2.7 (85) 29.1 ± 2.7 (85) 28.9 ± 2.2 (85) 30.2 ± 2.7 (85) 30.0 ± 3.0 (85) 30.2 ± 3.0 (85) 30.3 ± 2.6 (85) 30.5 ± 2.9 (85) 30.5 ± 3.0 (85) 30.9 ± 3.0 (85) 30.4 ± 2.7 (85) 31.2 ± 3.0 (85) 31.1 ± 3.2 (85) 31.6 ± 3.2 (85) 31.1 ± 2.9 (85) 31.7 ± 3.1 (75) 32.1 ± 3.5 (75) 23.7 + 3.9 (75) 23.5 + 3.3 (75)	15	1 2.2 (.3 ± 2.3 (.7 ± 2.5 (.6 ± 2.2 (26.1 ± 2.0 (49)*
29.0 ± 2.7 (85) 29.1 ± 2.7 (85) 28.1 ± 2.7 (85) 28.9 ± 2.2 (85) 30.2 ± 2.7 (85) 30.0 ± 3.0 (85) 30.2 ± 3.0 (85) 30.3 ± 2.6 (85) 30.5 ± 2.9 (85) 30.5 ± 3.0 (85) 30.9 ± 3.0 (85) 30.4 ± 2.7 (85) 31.2 ± 3.0 (85) 31.1 ± 3.2 (85) 31.6 ± 3.2 (85) 31.7 ± 3.1 (75) 32.1 ± 3.5 (75) 32.7 ± 3.6 (75) 32.6 ± 3.1 (75) 32.7 ± 3.9 (75) 2.3 (75) 32.5 ± 3.3 (75)	11	.2 ± 2.4 (8.2 ± 2.6 (.6 ± 2.7 (.5 ± 2.3 (27.0 ± 2.3 (49)*
30.2 ± 2.7 (85) 30.0 ± 3.0 (85) 30.2 ± 3.0 (85) 30.3 ± 2.6 (85) 30.5 ± 2.9 (85) 30.5 ± 2.0 (85) 30.4 ± 2.7 (85) 31.2 ± 3.0 (85) 31.1 ± 3.2 (85) 31.6 ± 3.2 (85) 31.1 ± 2.9 (85) 31.7 ± 3.1 (75) 32.1 ± 3.5 (75) 32.7 ± 3.9 (75) 32.7 ± 3.9 (75) 32.5 ± 3.3 (75)	6	± 2.7 (9.2 ± 2.7 (.1 ± 2.7 (.9 ± 2.2 (27.7 ± 2.6 (49)*
30.5 ± 2.9 (85) 30.5 ± 3.0 (85) 30.9 ± 3.0 (85) 30.4 ± 2.7 (85) 31.2 ± 3.0 (85) 31.1 ± 3.2 (85) 31.6 ± 3.2 (85) 31.1 ± 2.9 (85) 31.7 ± 3.1 (75) 32.1 ± 3.5 (75) 32.7 + 3.4 (75) 32.5 + 3.3 (75) 32.6 + 3.1 (75) 32.7 + 3.9 (75) 7 3.1 (75) 32.5 + 3.3 (75)	21	± 2.7 () 0.8 ± 0.	.2 ± 3.0 (± 2.6 (28.3 ± 2.8 (49)*
31.2 ± 3.0 (85) 31.1 ± 3.2 (85) 31.6 ± 3.2 (85) 31.1 ± 2.9 (85) 31.7 ± 3.1 (75) 32.1 ± 3.5 (75) 32.7 ± 3.1 (75) 31.6 ± 3.2 (75) 32.5 ± 3.3 (75)	23	+ 2.9 (3.0 (9 + 3.0 (± 2.7 (28.7 ± 3.0 (49)*
31,7 ± 3 1 (75) 32,1 ± 3 5 (75) 32,7 + 3, (75) 31,6 ± 3,2 (75) 32,6 + 3,1 (75) 32,7 + 3,9 (75) ? 3,1 75) 32,5 + 3,3 (75)	25	.2 ± 3.0 (.1 ± 3.2 (.6 ± 3.2 (.1 ± 2.9 (28.8 ± 3.1 (49)*
32.6 + 3,1 (75) 32 7 + 3.9 (75) ? 3,! 75) 32.5 + 3.3 (75)	27	.7 + 3 + (.1 + 35 (.7 + 3. (.6 ± 3.2 (29.4 ± 3.0 (41)*
	59	32.6 ± 3.1 (75)	32 7 ± 3.9 (75)	3.1 75)	32.5 ± 3.3 (75)	30.1 ± 3 5 (41)*

F . A CONTROL GROUP = SIGNIFICANTLY L

Y,ATA á **2** "

٩

Ð

(

9

Table 7 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE BODY WEIGHTS (G) [MEAN AND STANDARD DEVIATION (n)]

41)* 31)+ 31)* 31)* 30)* *(08 41)* 41)* 41)* 41)* 41)* 30)* 30)* 41)* 41)* 41)* 38)* 3.4 (41)* J mg/kg/DAY 175/100 5.1 4.1 4.9 က 3.9 4.0 4.6 4 4 4.6 4.8 4 ហ ø N ស N ις. . +1 + [+ ! +1 +1 +1 +1 + 1 + 1 +1 +1 +i +1 +1 +1 +| +1 +1 33.0 33.9 35.7 36.7 31.8 31.8 32.7 33.6 34.2 34.6 34.7 35.2 30.5 32.4 32.8 34.7 33.9 34.3 75) 64) 75) 75) 75) 75) 75) 75) 75) 74) 74) 70) 64) 64) 64) 63 63) 75) 63) _ _ J _ _ mg/kg/DAY 3.8 3.3 3.8 0.4 4.0 4.8 4.0 3.7 3.9 6 4 4.7 Ø 4 ß N ď ល 4 +1 + | +1 +1 +1 + | +1 +1 +1 +1 +1 +1 +! +1 +1 +1 +1 +1 +1 38.5 34.9 35.4 35.5 36.0 36.3 36.8 37.6 38.5 38.7 39.4 40.2 41.2 O 0 38.7 4 38.4 38 32 74)* 74)* 64)* 74)* 74) 64) 64) 64) 64) 64) 64) 74) 74) 74) 74) 74) 74) 74) 71) 4.0 (4.8 (3.6 (4.1 (3.9 (mg/kg/DAY 7 0.4 3.7 4.6 4.6 4 5 4.7 6.9 ø. 3.7 ø. N ល o. +1 +1 +1 +1 + | +1 + | ÷1 +| + [+1 + ! + 1 +1 +! +1 +1 +1 + [37.1 37.0 40.0 40.3 34.5 35.3 36.2 36.6 37.7 39.2 39.7 39.7 40.4 41.3 42.2 ø 38.4 38.9 43.3 62) 62) 61) 74) 62) 62) 62) 75) 74) 74) 74) 74) 74) 63) 74) 73) 73) 73) 20 mg/kg/DAY ល 9.0 8 σ o, ູດ ß ιū ဖ ø ø φ 4.8 0 0 ო 0 φ ထ 4. ທ ß ß B ທ ល +1 +1 +1 +1 +1 +1 + (+1 + ! + } +1 +1 +1 34.2 38.6 39.1 40.3 က 33.5 34.9 35.4 35.5 36.5 37.1 37.5 ď 38.6 39.1 39.2 41.1 0 36.2 38 42 75) 75) 65) 65) 75) 75) 75) 75) 75) 75) 75) 71) 65) 65) 65) 65) 62) 75) 75) _ mg/kg/DAY 6 3.5 4.1 3.8 3.2 3.6 3.6 3.5 3.9 4.2 4.3 9.6 4.2 3.2 ខ 0 4.4 4 e, + + | +1 +1 +! +1 +1 +! +1 +1 +1 +1 +1 +1 +1 +1 +1 + } +1 38.0 33.7 35.3 35.5 38.3 38.8 32.9 33.8 34.8 თ 39.7 ល 35.8 36.1 37.6 38.3 38.6 38.7 41.0 64 36. 53 59 33 35 33 43 45 49 5 63 31 37 4 47 57 61 67

= SIGNIFICANTLY DIFFERENT FROM CONFROL GROUP

- = NO A' NIN E DATA

Table 7 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BEC3F1 MOUSE FEMALE BODY WEIGHTS (G) [MEAN AND STANDARD DEVIATION (n)]

69 40.9 ± 4.4 (65) 42.0 ± 5.9 (61) 43.4 ± 5.3 (64)* 41.0 ± 5.2 (63) 36.2 ± 5.1 (30)* 71 41.9 ± 4.6 (64) 42.7 ± 5.8 (60) 43.9 ± 4.9 (63) 41.4 ± 5.4 (63) 36.1 ± 5.0 (30)* 72 41.5 ± 4.6 (63) 42.7 ± 6.2 (60) 44.0 ± 5.4 (63)* 41.1 ± 5.7 (63) 36.1 ± 5.0 (30)* 73 41.6 ± 4.3 (63) 42.7 ± 6.2 (60) 44.0 ± 5.5 (63)* 41.1 ± 5.4 (61) 36.2 ± 5.0 (30)* 74 41.6 ± 4.3 (63) 42.7 ± 6.4 (60) 44.0 ± 5.5 (63) 41.1 ± 5.4 (61) 36.2 ± 5.0 (30)* 75 41.6 ± 4.3 (63) 42.7 ± 6.2 (60) 44.0 ± 5.5 (63) 41.1 ± 5.4 (61) 36.2 ± 5.0 (30)* 81 41.6 ± 4.7 (58) 43.4 ± 6.0 (55) 43.8 ± 5.6 (59) 41.1 ± 5.4 (61) 36.2 ± 5.0 (30)* 82 41.5 ± 5.0 (61) 43.2 ± 7.0 (60) 44.0 ± 6.2 (63) 41.5 ± 5.6 (60) 36.8 ± 5.2 (30)* 83 41.5 ± 5.0 (61) 43.5 ± 6.8 (60) 44.2 ± 6.2 (63)* 41.1 ± 5.6 (60) 36.2 ± 5.0 (30)* 84 41.6 ± 5.0 (61) 43.5 ± 6.8 (60) 44.2 ± 6.2 (63)* 41.1 ± 5.6 (60) 36.2 ± 5.0 (30)* 85 41.2 ± 5.2 (61) 43.2 ± 7.2 (60) 44.2 ± 6.2 (63)* 41.1 ± 5.6 (59) 36.3 ± 5.2 (29)* 86 42.1 ± 5.2 (50) 43.2 ± 6.8 (60) 44.2 ± 6.3 (61) 41.2 ± 5.6 (59) 36.3 ± 4.1 ± 5.0 (59)* 87 42.1 ± 6.2 (50) 43.2 ± 6.8 (60) 44.2 ± 6.3 (61) 41.0 ± 6.4 (56) 36.3 ± 4.1 ± 5.1 (59)* 89 42.1 ± 6.2 (50) 43.2 ± 6.8 (60) 44.0 ± 6.1 (62) 41.0 ± 6.1 (59) 36.0 ± 5.0 (59)* 80 42.1 ± 6.2 (50) 43.2 ± 6.8 (50) 44.0 ± 6.1 (51) 41.0 ± 6.1 (51) 35.0 ± 4.1 ± 4.1 (59)* 80 42.1 ± 6.2 (50) 43.2 ± 6.8 (60) 44.0 ± 6.1 (62) 41.0 ± 6.1 (51) 35.0 ± 4.1 ± 4.1 (52)* 81 41.0 ± 6.1 (52) 43.1 ± 6.4 (43) 42.5 ± 5.8 (59) 41.0 ± 6.1 (51) 35.0 ± 4.1 ± 4.1 (52)* 82 41.0 ± 6.1 (50) 41.1 ± 6.4 (43) 41.1 ± 6.4 (50) 41.0 ± 6.1 (51) 35.0 ± 4.1 ± 4.1 (51) 35.0 ± 4.1 ± 4.1 (51) 35.0 ± 4.1 ± 4.1 ± 5.1 (50)* 83 41.5 ± 6.0 (51) 41.1 ± 6.4 (43) 41.1 ± 6.0 (52) 41.0 ± 6.1 (51) 35.0 ± 4.1 ± 4.1 ± 6.1 (51) 35.0 ± 4.1 ± 4.1 ± 6.1 (51) 35.0 ± 4.1 ± 4.1 ± 6.1 (51) 35.0 ± 4.1 ± 4.1 ± 6.1 (51) 35.0 ± 4.1 ± 4.1 ± 6.1 (51) 35.0 ± 4.1 ± 4.1 ± 6.1 ± 6.1 (51) 35.0 ± 4.1 ± 4.1 ± 6.	VEEK	0.0 mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
41.9 ± 4.6 (64) 42.7 ± 6.8 (60) 43.9 ± 4.9 (63)* 41.4 ± 5.4 (63)* 41.4 ± 5.4 (63)* 41.1 ± 5.7 (63) 36.9 ± 5.0 (7) 41.6 ± 4.6 (63) 42.7 ± 6.2 (60) 44.0 ± 5.4 (63)* 41.1 ± 5.7 (63) 36.1 ± 5.0 (7) 41.6 ± 4.3 (63) 42.7 ± 6.0 (63) 44.0 ± 5.5 (63) 41.4 ± 6.1 (61) 36.2 ± 5.0 (7) 41.6 ± 5.0 (61) 43.2 ± 6.0 (63) 41.4 ± 6.1 (63) 36.1 ± 5.0 (7) 41.6 ± 5.0 (61) 43.2 ± 6.0 (63) 41.4 ± 6.1 (63) 36.3 ± 5.0 (7) 41.5 ± 5.0 (61) 43.2 ± 6.0 (63) 41.4 ± 6.1 (60) 36.3 ± 5.0 (7) 41.5 ± 5.0 (61) 43.2 ± 6.0 (60) 44.0 ± 6.0 (63) 41.4 ± 6.1 (60) 36.3 ± 5.0 (7) 41.5 ± 5.0 (61) 43.2 ± 6.0 (60) 44.0 ± 6.0 (63) 41.4 ± 6.1 (60)	ø.	40.9 ± 4.4 (65)) 6.3 ‡	+ 5.3 (± 5.2 (+1
41.5 ± 4.6 (63) 42.7 ± 6.2 (60) 44.0 ± 5.4 (63)* 41.1 ± 5.7 (63) 36.1 ± 5.0 (63) 41.6 ± 4.3 (63) 42.7 ± 6.4 (60) 43.5 ± 5.5 (63) 41.1 ± 5.4 (61) 36.1 ± 5.0 (7) 41.6 ± 5.0 (63) 43.5 ± 6.7 (60) 44.0 ± 5.6 (58) 41.1 ± 5.4 (61) 37.0 ± 5.0 (7) 41.6 ± 5.0 (61) 43.2 ± 6.0 (65) 44.0 ± 6.6 (63) 41.1 ± 6.1 (56) 36.9 ± 5.0 (7) 41.5 ± 5.0 (61) 43.2 ± 7.0 (60) 44.0 ± 6.2 (63) 41.1 ± 6.1 (60) 36.1 ± 5.0 (63) 41.5 ± 5.0 (61) 43.2 ± 6.8 (60) 44.2 ± 6.2 (63) 41.1 ± 6.0 (60) 36.1 ± 5.0 (63) 41.5 ± 5.0 (61) 43.5 ± 6.8 (60) 44.2 ± 6.2 (63) 41.1 ± 6.0 (60) 36.1 ± 5.0 (63) 41.2 ± 5.0 (60) 44.2 ± 6.2 (63) 41.1 ± 6.0 (63) 36.1 ± 5.0 (63) 41.2 ± 5.0 (60) 44.2 ± 5.0	~	41.9 ± 4.6 (64)	+ 5.8 (4.9 (+ 5.4 (+1
41.6 ± 4.3 (63) 42.7 ± 6.4 (60) 43.5 ± 5.5 (63) 41.1 ± 5.4 (61) 36.2 ± 5.0 (61) 42.7 ± 5.0 (63) 43.6 ± 5.6 (63) 41.6 ± 5.8 (61) 37.0 ± 5.0 (61) 41.8 ± 5.0 (61) 43.8 ± 6.6 (63) 41.6 ± 5.8 (61) 37.0 ± 5.0 (61) 41.6 ± 5.0 (61) 43.2 ± 7.0 (60) 44.0 ± 6.0 (63) 41.6 ± 6.1 (60) 36.9 ± 5.0 (61) 41.6 ± 5.0 (61) 43.2 ± 7.0 (60) 44.0 ± 6.0 (63) 41.6 ± 5.0 (60) 36.1 ± 5.0 (60) 41.6 ± 5.0 (61) 43.2 ± 6.2 (63) 41.7 ± 6.0 (63) 36.1 ± 5.0 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.2 (63) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.2 (63) 41.1 ± 5.2 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 41.2 ± 5.2 (63) 41.1 ± 5.2 (60) <td>73</td> <td>41.5 ± 4.6 (63)</td> <td>+ 6.2 (</td> <td>+ 5.4 (</td> <td>+ 5.7 (</td> <td>+1</td>	73	41.5 ± 4.6 (63)	+ 6.2 (+ 5.4 (+ 5.7 (+1
41.8 ± 5.0 (63) 43.5 ± 6.7 (60) 44.0 ± 5.5 (63) 41.6 ± 5.8 (61) 37.0 ± 5.0 (63) 41.8 ± 4.7 (58) 43.2 ± 6.0 (55) 43.8 ± 5.6 (58) 41.4 ± 6.1 (56) 36.9 ± 5.2 (41.6 ± 5.0 (61) 43.2 ± 7.0 (60) 44.0 ± 6.0 (63) 41.5 ± 6.0 (60) 36.1 ± 5.2 (63) 41.6 ± 5.0 (60) 36.9 ± 5.2 (63) 41.6 ± 5.0 (60) 36.1 ± 5.0 (63) 41.6 ± 5.0 (60) 36.1 ± 5.1 (63) 36.1 ± 5.1 (60) 36.1 ± 5.1 (63) 36.1 ± 5.1 (60) 36.1 ± 5.1 (63) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36.1 ± 5.1 (60) 36	73	41.6 ± 4.3 (63)	+ 6.4 () S.S 	+ 5.4 (+1
$41.8 \pm 4.7 (58) \qquad 43.4 \pm 6.0 (55) \qquad 43.8 \pm 5.6 (58) \qquad 41.4 \pm 6.1 (56) \qquad 36.9 \pm 5.2 (56)$ $41.6 \pm 5.0 (61) \qquad 43.2 \pm 7.0 (60) \qquad 44.0 \pm 6.0 (63) \qquad 41.5 \pm 5.6 (60) \qquad 36.1 \pm 5.2 (61)$ $41.5 \pm 5.4 (61) \qquad 43.2 \pm 7.2 (60) \qquad 44.2 \pm 5.5 (62) \qquad 41.6 \pm 5.4 (60) \qquad 36.1 \pm 5.1 (61)$ $41.2 \pm 5.5 (61) \qquad 42.8 \pm 7.2 (60) \qquad 44.5 \pm 5.6 (63) \qquad 41.6 \pm 5.4 (60) \qquad 36.1 \pm 5.1 (61)$ $42.1 \pm 5.2 (56) \qquad 43.7 \pm 6.8 (60) \qquad 44.5 \pm 5.8 (62) \qquad 41.7 \pm 5.8 (58) \qquad 36.2 \pm 4.7 (61)$ $42.1 \pm 5.2 (56) \qquad 43.7 \pm 6.8 (60) \qquad 44.0 \pm 6.1 (62) \qquad 41.0 \pm 6.4 (56) \qquad 36.1 \pm 6.0 (56)$ $42.7 \pm 4.4 (54) \qquad 43.3 \pm 6.8 (60) \qquad 43.8 \pm 5.6 (61) \qquad 41.0 \pm 6.4 (56) \qquad 36.1 \pm 4.6 (61)$ $42.0 \pm 4.6 (54) \qquad 43.2 \pm 6.6 (57) \qquad 43.8 \pm 5.6 (59) \qquad 41.0 \pm 6.4 (56) \qquad 35.7 \pm 4.6 (61)$ $40.7 \pm 7.7 (55) \qquad 43.2 \pm 6.6 (57) \qquad 43.6 \pm 5.7 (59) \qquad 41.0 \pm 6.7 (54) \qquad 35.4 \pm 4.6 (61)$ $41.5 \pm 5.9 (53) \qquad 43.1 \pm 6.4 (49) \qquad 42.3 \pm 5.7 (57) \qquad 40.8 \pm 6.1 (51) \qquad 35.4 \pm 4.6 (61)$ $41.5 \pm 5.9 (51) \qquad 41.8 \pm 5.9 (48) \qquad 42.1 \pm 5.8 (55) \qquad 41.0 \pm 5.1 (51) \qquad 35.0 \pm 4.6 (61)$ $41.5 \pm 5.1 (50) \qquad 41.6 \pm 5.8 (45) \qquad 41.6 \pm 6.0 (52) \qquad 41.1 \pm 5.5 (46) \qquad 33.7 \pm 4.9 (61)$	7.7	42.7 ± 5.0 (63)	+ 6.7 (+ 5.5 () 8'5 +	+1
$41.6 \pm 5.0 (61) \qquad 43.2 \pm 7.0 (60) \qquad 44.0 \pm 6.0 (63) \qquad 41.5 \pm 5.6 (60) \qquad 36.6 \pm 5.2 (61) \qquad 64.2 \pm 5.4 (61) \qquad 36.1 \pm 5.1 (61) \qquad 64.2 \pm 5.6 (63) \qquad 41.5 \pm 5.6 (61) \qquad 36.1 \pm 5.1 (61) \qquad 64.2 \pm 5.2 (62) \qquad 41.1 \pm 5.2 (62) \qquad 41.2 \pm 5.2$	6/	41.8 ± 4.7 (58)	+ 6.0 (+ 5.6 (+ 6.1 (ن +۱
$41.5 \pm 5.4 (61)$ $42.8 \pm 6.0 (60)$ $44.2 \pm 5.5 (62)^{*} + 41.1 \pm 5.6 (59)$ $41.2 \pm 5.5 (61)$ $42.8 \pm 7.2 (60)$ $42.8 \pm 7.2 (60)$ $42.1 \pm 5.2 (50)$ $42.1 \pm 5.2 (50)$ $42.1 \pm 5.2 (50)$ $42.1 \pm 6.0 (50)$ $42.2 \pm 4.4 (54)$ $42.1 \pm 6.0 (50)$ $43.2 \pm 6.0 (61)$ $43.2 \pm 6.0 (60)$ $43.2 \pm 6.0 (61)$ $43.3 \pm 6.0 (61)$ $43.4 \pm 6.0 (61)$ $44.5 \pm 6.0 (61)$ $44.6 \pm 6.0 (61)$ $44.7 \pm$	£	41.6 ± 5.0 (61)	+ 7.0 (+ 6.0 (+ 5.6 (+1
$41.2 \pm 5.5 (61)$ $42.8 \pm 7.2 (60)$ $43.6 \pm 6.9 (60)$ $44.5 \pm 5.8 (62)^{+}$ $41.1 \pm 5.6 (59)$ $42.1 \pm 5.2 (56)$ $42.1 \pm 5.2 (56)$ $42.1 \pm 5.2 (56)$ $42.1 \pm 5.2 (56)$ $42.2 \pm 6.8 (60)$ $42.2 \pm 6.8 (60)$ $42.2 \pm 6.8 (61)$ $42.3 \pm 6.8 (61)$ $42.3 \pm 6.8 (61)$ $42.3 \pm 6.8 (61)$ $42.4 \pm 6.8 (61)$ $42.4 \pm 6.8 (61)$ $41.0 \pm$	33	41.5 ± 5.4 (61)	5 + 6.8 (+ 6.2 (± 5.4 (+1
$41.8 \pm 5.9 (60)$ $42.1 \pm 5.2 (56)$ $42.2 \pm 4.4 (54)$ $42.2 \pm 4.4 (54)$ $42.2 \pm 4.6 (54)$ $42.2 \pm 6.6 (57)$ $42.2 \pm 5.6 (59)$ $41.0 \pm 5.7 (54)$ $42.2 \pm 6.1 (52)$ $41.0 \pm 5.7 (54)$ $42.2 \pm 6.1 (52)$ $41.0 \pm 6.1 (52)$ $41.0 \pm 6.1 (52)$ $41.0 \pm 6.1 (51)$ $41.0 \pm 6.1 (51)$ $42.1 \pm 6.1 (51)$ 43.1 ± 6.1	35	41.2 ± 5.5 (61)	2.8 ± 7.2 (+ 5.5 () 9.6 +	+1
42.7 ± 5.2 (56) 43.7 ± 6.8 (60) 44.0 ± 6.1 (62) 41.3 ± 6.0 (56) 36.0 ± 5.0 (56) 36.0 ± 5.0 (56) 36.0 ± 5.0 (56) 36.0 ± 5.0 (56) 36.0 ± 5.0 (56) 36.0 ± 5.0 (56) 36.0 ± 5.0 (56) 36.0 ± 5.0 (56) 36.0 ± 5.0 (56) 36.0 ± 5.0 (56) 36.0 ± 5.0 (56) 36.0 ± 5.0 (56) 36.0 ± 5.0 (56) 36.0 ± 5.0 (56) 36.0 ± 5.0 (56) 41.0 ± 5.0 (56) 41.0 ± 5.0 (56) 36.0 ± 4.5 € <t< td=""><td>37</td><td>41.8 ± 5.9 (60)</td><td>) 6.9 +</td><td>5.8 (</td><td>+ 5.8 (</td><td>+1</td></t<>	37	41.8 ± 5.9 (60)) 6.9 +	5.8 (+ 5.8 (+1
$42.7 \pm 4.4 (54) \qquad 43.3 \pm 6.8 (60) \qquad 43.8 \pm 5.6 (61) \qquad 41.0 \pm 6.4 (56) \qquad 35.7 \pm 4.6 (61)$ $42.0 \pm 4.6 (54) \qquad 43.2 \pm 6.6 (57) \qquad 43.6 \pm 5.3 (60) \qquad 41.0 \pm 5.7 (54) \qquad 35.4 \pm 4.7 (61)$ $40.7 \pm 7.7 (55) \qquad 43.0 \pm 6.8 (54) \qquad 42.5 \pm 5.6 (59) \qquad 41.0 \pm 5.7 (53) \qquad 35.1 \pm 4.5 (61)$ $41.0 \pm 5.7 (54) \qquad 42.3 \pm 6.1 (52) \qquad 41.7 \pm 5.7 (58) \qquad 40.4 \pm 5.7 (53) \qquad 34.5 \pm 4.6 (61)$ $41.5 \pm 5.9 (51) \qquad 41.8 \pm 5.9 (48) \qquad 42.1 \pm 5.8 (55) \qquad 40.8 \pm 5.8 (49) \qquad 34.4 \pm 4.7 (61)$ $41.5 \pm 5.1 (50) \qquad 41.6 \pm 5.8 (46) \qquad 41.6 \pm 6.0 (54) \qquad 41.1 \pm 5.5 (46) \qquad 33.7 \pm 4.9 (41.1) $	62	42.1 ± 5.2 (56)	+ 6.8 (± 6.1 () 0.9 ±	+1
$42.0 \pm 4.6 (54) \qquad 43.2 \pm 6.6 (57) \qquad 43.6 \pm 5.3 (60) \qquad 41.0 \pm 5.7 (54) \qquad 35.4 \pm 4.7 (54) \qquad 40.7 \pm 7.7 (55) \qquad 35.1 \pm 4.5 (54) \qquad 41.0 \pm 5.7 (53) \qquad 35.1 \pm 4.5 (54) \qquad 41.0 \pm 5.7 (53) \qquad 34.5 \pm 4.6 (54) \qquad 41.5 \pm 5.0 (51) \qquad 41.8 \pm 5.0 (48) \qquad 42.3 \pm 5.7 (57) \qquad 40.8 \pm 5.8 (49) \qquad 34.4 \pm 4.7 (57) \qquad 40.8 \pm 5.8 (49) \qquad 34.4 \pm 4.7 (57) \qquad 40.8 \pm 5.8 (49) \qquad 34.4 \pm 4.7 (57) \qquad 41.6 \pm 5.1 (50) \qquad 41.6 \pm 5.8 (45) \qquad 41.6 \pm 6.0 (54) \qquad 41.1 \pm 5.1 (49) \qquad 41.1 \pm 5.1 (41) \qquad 41.1 \pm 5.1$		42.7 ± 4.4 (54)	+ 6.8 () 9.3 7	+ 6.4 (+1
40.7 ± 7.7 (55) 43.0 ± 6.8 (54) 42.5 ± 5.6 (59) 41.0 ± 5.7 (53) 35.1 ± 4.5 € 41.0 ± 5.7 (54) 42.3 ± 6.1 (57) 40.4 ± 5.7 (53) 34.5 ± 4.6 € 41.5 ± 5.9 (54) 43.1 ± 6.4 (49) 42.3 ± 5.7 (57) 40.8 ± 6.1 (51) 35.0 ± 4.6 € 41.8 ± 5.0 (51) 41.8 ± 5.9 (48) 42.1 ± 5.8 (55) 40.8 ± 5.8 (49) 34.4 ± 4.7 € 41.5 ± 5.1 (50) 41.6 ± 5.8 (45) 41.0 ± 5.5 (46) 33.7 ± 4.9 €	33	42.0 ± 4.6 (54)	9.9 7	+ 5.3 (5.7 (+1
41.0 ± 5.7 (54) 42.3 ± 6.1 (52) 41.7 ± 5.7 (58) 40.4 ± 5.7 (53) 34.5 ± 4.6 (6.1 (51) 35.0 ± 4.6 (6.1 (51) 35.0 ± 4.6 (6.1 (51) 35.0 ± 4.6 (6.1 (51) 35.0 ± 4.6 (6.1 (51) 35.0 ± 4.6 (6.1 (51) 35.0 ± 4.6 (6.1 (51) 35.0 ± 4.6 (6.1 (51) 35.0 ± 4.6 (6.1 (51) 35.0 ± 4.6 (6.1 (51) 35.0 ± 4.6 (6.1 (51) 35.0 ± 4.6 (6.1 (51) 35.0 ± 4.6 (6.1 (51) 36.0 ± 4.7 (6.1 (51)	22	40.7 ± 7.7 (55)	3.0 ± 6.8 (+ 5.6 (+ 5.7 (+1
41.5 ± 5.9 (53) 43.1 ± 6.4 (49) 42.3 ± 5.7 (57) 40.8 ± 6.1 (51) 35.0 ± 4.6 € 41.8 ± 5.9 (48) 42.1 ± 5.8 (55) 40.8 ± 5.8 (49) 34.4 ± 4.7 (41.5 ± 5.1 (50) 41.6 ± 5.8 (45) 41.6 ± 6.0 (52) 41.1 ± 5.5 (46) 33.7 ± 4.9 (7.	41.0 ± 5.7 (54)	2.3 ± 6.1 (+ 5.7 (+ 5.7 (+1
41.8 ± 5.0 (51) 41.8 ± 5.9 (48) 42.1 ± 5.8 (55) 40.8 ± 5.8 (49) 34.4 ± 4.7 (41.5 ± 5.1 (50) 41.6 ± 5.0 (54) 41.0 ± 5.7 (46) 33.7 ± 4.9 (41.7 ± 5.1 (49) 41.9 ± 5.6 (45) 41.6 ± 6.0 (52) 41.1 ± 5.5 (46) 33.7 ± 4.9 (6		+ 6.4 (2.3 ± 5.7 (+ 6.1 (+1
41.5 ± 5.1 (50) 41.6 ± 5.8 (46) 41.6 ± 6.0 (54) 41.0 ± 5.7 (46) 33.7 ± 4.9 (41.7 ± 5.1 (49) 41.9 ± 5.6 (45) 41.6 ± 6.0 (52) 41.1 ± 5.5 (46) 33.7 ± 4.9 (=	41.8 ± 5.0 (51)	.8 + 5.9 (+ 5.8 (+ 5.8 (+1
41,7 ± 5,1 (49) 41,9 ± 5,6 (45) 41,6 ± 6.0 (52) 41,1 ± 5,5 (46) 33,7 ± 4.9 (93	41.5 ± 5.1 (50)	.6 ± 5.8 () 0.9 ±	+ 5.7 (+1
	4	41.7 ± 5.1 (49)	1.9 ± 5.6 (+ 6.0 (+ 5.5 (+1

--- = NO AVAILABLE DATA

(4)

9

٨

4

٩

٥

٩

٥

ಿ

Table 8

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE BODY WEIGHT GAIN MEASUREMENTS (g) [MEAN AND STANDARD DEVIATION (n)]

TEST WEEK	0.0 mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
-	1.1 ± 0.7 (85)	1.1 ± 0.6 (85)	1.2 ± 0.8 (85)	1.2 ± 1.0 (95)	1.1 ± 0.7 (85)
8	1.9 ± 0.7 (85)	1.9 ± 0.8 (85)	1.9 ± 0.8 (85)	1.7 ± 0.7 (85)	1.5 ± 0.8 (84)*
ю	2.5 ± 0.6 (85)	2.5 ± 0.7 (85)	2.4 ± 0.8 (85)	2.5 ± 0.8 (85)	2.3 ± 0.8 (73)
4	3.1 ± 0.8 (85)	3.0 ± 0.8 (95)	3.1 ± 0.8 (85)	3.3 ± 0.6 (85)	3.4 ± 1.0 (61)*
ស	4.1 ± 0.9 (85)	3.7 ± 0.8 (30)*	3.8 ± 1.0 (85)	4.2 ± 1.0 (85)	3.9 ± 1.0 (61)
φ	4.6 ± 1.0 (85)	4.5 ± 1.2 (85)	4.4 ± 4.1 (85)	4.5 ± 0.8 (85)	4.4 ± 1.1 (60)
7	5.0 ± 1.1 (85)	5.0 ± 1.1 (85)	4.9 ± 1.0 (85)	5.1 ± 1.1 (85)	4.9 ± 1.0 (60)
80	5.6 ± 1.2 (85)	5.3 ± 1.2 (85)	5.5 ± 1.1 (85)	5.8 ± 1.1 (85)	5.4 ± 1.0 (58)
Ø	5.8 ± 1.3 (85)	5.7 ± 1.2 (85)	5.9 ± 1.4 (85)	6.0 ± 1.3 (85)	6.1 ± 1.3 (53)
01	6.4 ± 1.6 (85)	6.3 ± 1.4 (85)	$6.2 \pm 1.5 (85)$	6.4 ± 1.3 (85)	5.5 ± 1.4 (53)*
* -	6.8 ± 1.7 (85)	6.6 ± 1.5 (85)	6.8 ± 1.7 (85)	7.0 ± 1.4 (85)	6.3 ± 1.2 (49)
12	7.0 ± 1.6 (85)	6.9 + 1.5 (85)	7.1 ± 1.8 (85)	7.0 ± 1.4 (85)	5.9 ± 1 1 (49)*
13	7.4 ± 2.0 (85)	7.3 ± 1.6 (85)	7.3 ± 1.7 (85)	7.5 ± 1.6 (85)	6.3 ± 1.3 (49)*
3	8.0 ± 1.8 (85)	8.0 ± 1.8 (85)	8.1 ± 2.0 (85)	8.1 ± 1.8 (85)	7.0 ± 1.6 (49)*
17	8.9 ± 2.1 (85)	8.8 ± 2.0 (85)	8.9 ± 2.3 (85)	9.0 ± 1.9 (85)	8.0 ± 2.0 (49)*
19	9.7 ± 2.4 (85)	9.8 ± 2.1 (85)	9.5 ± 2.2 (85)	9.4 ± 1.8 (85)	8.6 ± 2.0 (49)*
21	10.8 ± 2.4 (85)	10.6 ± 2.3 (85)	10.6 ± 2.6 (85)	10.8 ± 2.2 (85)	9.2 ± 2.4 (49)*
23	11.1 ± 2.5 (85)	11.1 ± 2.5 (85)	11.3 ± 2.5 (85)	10.9 ± 2.3 (85)	9.6 ± 2.4 (49)*
25	11.8 ± 2.7 (85)	11.8 ± 2.6 (85)	12.0 ± 2.7 (85)	11.5 ± 2.5 (85)	9.8 ± 2.6 (49)*
27	12.3 ± 2.7 (75)	12.8 ± 2.9 (75)	13.1 ± 2.7 (75)	12.2 ± 2.8 (75)	10.4 ± 2.5 (41)*
29	13.2 ± 2.7 (75)	13.4 ± 3.3 (75)	13.8 ± 3.0 (75)	13.0 ± 2.9 (75)	11.0 ± 2.9 (41)*

-- = NO AVAILABLE DATA

Table 8 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENIC17" STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BEC3F' MOUSE FEMALE BODY WEIGHT GAIN MEASUREMENTS (9) [MEAN AND STANDARD DEVIATION (n)]

	3.5 + 2.9 (75)	14.0 + 3.3 (75)	mg/kg/bAY 14.0 + 3.1 (74)	13.4 ± 2.9 (75)	11.4 + 2.9 (41)*
14.6 H G.C	(22)	14.3 ± 3.3 (74)	14.9 ± 3.1 (74)	14.2 ± 3.1 (75)	12.1 ± 3.3 (41)*
14.4 ± 3.2 (75)	(75)	14.9 ± 3.4 (74)	15.7 ± 3.6 (74)	14.9 ± 3.4 (75)	12.8 ± 3.2 (41)*
15.4 ± 2.9	(75)	15.6 ± 3.5 (74)	16.5 ± 3.2 (74)	15.4 ± 3.6 (75)	12.8 2 3.4 (41)*
15.9 ± 3.1	(75)	16.1 ± 3.9 (74)	16.9 ± 5.3 (74)	15.9 ± 3.7 (75)	13.3 ± 3.5 (41)*
16.4 ± 3.2	(75)	16.2 ± 3.9 (74)	17.4 ± 3.6 (74)	16.0 ± 3.3 (75)	13.6 ± 4.0 (41)*
16.1 ± 3.2	(75)	16.9 ± 3.8 (74)	17.5 ± 3.4 (74)*	16.6 ± 3.1 (75)	13.8 + 3.8 (41)
16.7 ± 3.1	(75)	17.2 ± 4.0 (74)	18.1 ± 3.5 (74)	16.8 ± 3.6 (75)	13.9 ± 3.8 (41)*
17.5 ± 3.1	(32)	17.8 ± 3.9 (73)	18.7 ± 3.7 (74)	17.3 ± 3.6 (75)	14.5 ± 4.1 (41)*
18.1 ± 3.5	(75)	18.3 ± 4.2 (73)	19.2 ± 3.8 (74)	18.1 ± 3.4 (74)	14.9 ± 4.6 (41)*
18.6 ± 3.6	(75)	18.9 ± 4.2 (73)	19.6 ± 4.0 (74)	18.6 ± 3.5 (74)	15.2 ± 4.2 (41)*
19.0 ± 3.8 ((11)	19.3 ± 4.1 (70)	20.1 ± 4.1 (71)	19.2 ± 3.8 (70)	15.7 ± 4.5 (38)*
19.2 ± 3.8 ((9)	19.7 ± 4.4 (63)	20.1 ± 4.1 (64)	19.0 ± 3.9 (64)	15.7 ± 4.0 (31)*
18.9 ± 3.5 ((65)	19.3 ± 4.4 (62)	20.3 ± 4.1 (64)	19.0 ± 3.8 (64)	15.0 ± 3.6 (31)*
19.3 ± 3.6 ((65)	19.8 ± 4.8 (62)	20.6 ± 4.0 (64)	19.2 ± 4.2 (64)	15.4 ± 3.9 (31)*
19.4 ± 3.8	3.8 (65)	19.9 ± 4.4 (62)	20.7 ± 4.1 (64)	19.1 ± 4.3 (64)	15.7 ± 4.1 (30)*
20.3 ± 3.5	3.5 (65)	21.0 ± 5.0 (62)	21.6 ± 4.2 (64)	20.0 ± 4 4 (63)	16.3 ± 4.4 (30)*
21.1 ± 3.6 (65)	(9)	21.8 ± 4.9 (62)	22.6 ± 4.3 (64)	20.8 ± 4.5 (63)	16.8 ± 47 (30)*
21.6 ± 4.0 (65)	(65)	22.7 ± 5.3 (61)	23.6 ± 4.4 (64)*	21.8 ± 4.6 (63)	17.8 ± 4.8 (30)*

-- = NO AVAILARLE DATA

Table 8 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINGGENICITY STUDY SF HEXAHYDRO-1.3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE BODY WEIGHT GAIN MEASUREMENT (9) {MEAN AND STANDARD DEVIATION (n),

175/100 mg/kg/DAY	17.2 ± 4.6 (30)*	17.9 ± 4.7 (30)*	17.1 ± 4.5 (30)*	17.2 ± 4.5 (30)*	18.0 ± 4.5 (30)*	13.0 ± 4.7 (30)*	17.7 ± 4.8 (29)*	17.2 ± 4.8 (29)*	17.0 ± 4.3 (29)*	17.3 ± 4.4 (29)*	17.1 ± 4.5 (29)*	16.8 ± 4.1 (29)*	16.5 ± 4.2 (29)*	16.2 ± 4.0 (28)*	15.7 ± 4.1 (27)*	16.2 ± 4.2 (27)*	15.6 ± 4.3 (27)*	14.9 ± 4.5 (26)*	14.8 ± 4.6 (25)*
35 mg/kg/DAY	21.5 ± 4.9 (63)	22.0 ± 5.2 (63)	21.6 ± 5.4 (63)	21.7 ± 5.1 (61)	22.2 ± 5.5 (61)	22.0 ± 5.8 (56)	22.1 ± 5.3 (60)	22.2 ± 5.1 (60)	21.8 ± 5.3 (59)	22.3 ± 5.6 (58)	21.9 ± 5.8 (56)	21.6 ± 6.3 (56)	21.7 ± 5.4 (54)	21.6 ± 5.3 (53)	21.0 ± 5.3 (53)	21.5 ± 5.8 (51)	21.5 ± 5.5 (49)	21.6 ± 5.5 (46)	21.7 ± 5.3 (46)
7 mg/kg/DAY	23 8 ± 4.9 (64)*	24.2 ± 4.4 (63)	24.3 ± 4.9 (63)*	23.8 ± 5.1 (63)	24.3 ± 5.1 (63)	24.1 ± 5.2 (58)	24.3 ± 5.7 (63)	24.6 ± 5.8 (63)*	24.5 ± 5.0 (62)*	24.8 ± 5.3 (62)	24.4 ± 5.6 (62)	24.1 ± 5.2 (61)	23.9 ± 4.9 (60)	22.8 ± 5.3 (55)	22.0 ± 5.4 (58)	22.6 ± 5.5 (57)	22.5 ± 5.5 (55)	21.9 ± 5.8 (54)	21.9 ± 5.8 (52)
1.5 mg/kg/DAY	22.7 ± 5.4 (61)	23.3 ± 5.2 (60)	23.4 ± 5.6 (60)	23.4 ± 5.8 (60)	24.2 ± 6.0 (60)	24.0 ± 5.3 (55)	23.8 ± 6.3 (60)	24.2 + 6.2 (60)	23.4 ± 6.5 (80)	24.3 ± 6.3 (60)	24.4 ± 6.2 (60)	24.0 ± 6.2 (60)	23.8 ± 6.0 (57)	23.7 ± 6.3 (54)	22.9 ± 5.6 (52)	23.7 ± 6.1 (49)	22.4 ± 5.8 (48)	22.2 ± 5.7 (46)	22.6 ± 5.3 (45)
O.O mg/kg/DAY	21.5 ± 4.0 (65)	22.5 ± 4.2 (64)	22.1 ± 4.2 (63)	22.2 ± 3.3 (63)	23.3 ± 4.6 (63)	22.5 ± 4.3 (58)	22.3 ± 4.6 (61)	22.1 ± 5.1 (61)	21.8 ± 5.1 (61)	22.4 ± 5.5 (60)	22.7 ± 4.9 (56)	23.2 ± 4.1 (54)	22.6 ± 4.3 (54)	21.3 ± 7.4 (55)	21.6 ± 5.4 (54)	22.1 ± 5.6 (53)	22.3 ± 46 (51)	22.1 ± 4.7 (50)	22.2 ± 4.7 (49)
TEST WEEK	69	7.1	73	75	7.7	67.	81	83	85	87	88	91	83	92	97	66	101	103	104

^{* =} SIGNIFICANTLY DIFF'RENT FROM CONTROL GROUP

--- = NO AVAILABLE DATA

Table 9

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3.5-TRINITRO-1,3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE FOOD CONSUMPTION MEASUREMENTS (g/day) [KEAN AND STANDARD DEVIATION (n)]

TEST	O.O mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/035
-5	4.2 ± 0.5 (85)	4.4 ± 0.4 (85)	4.3 ± 0.6 (85)	4.4 ± 0.5 (85)	4.6 ± 0.5 (85)*
7	4.2 ± 0.5 (85)	4.1 ± 0.4 (85)	4.2 ± 0.6 (85)	4.0 ± 0.5 (85)	4.2 ± 0.4 (85)
-	5.3 ± 0.8 (85)	4.6 ± 0.4 (85)*	4.5 ± 0.5 (85)*	4.5 ± 0.6 (85)*	4.4 ± 0.5 (85)*
2	5.0 ± 0.7 (85)	4.5 ± 0.5 (85)*	4.7 ± 0.7 (85)*	4.4 ± 0.6 (85)*	4.8 ± 0.7 (85)
ღ	4.8 ± 0.6 (85)	4.5 ± 0.4 (85)*	4.5 ± 0.4 (85)*	4.8 ± 0.8 (85)	4.5 ± 0.4 (55)*
4	4.7 ± 0.5 (85)	4.3 ± 0.2 (85)*	4.4 ± 0.2 (85)*	4.6 ± 0.6 (85)	5.4 ± 0.9 ' 81)*
ស	5.1 ± 0.6 (85)	4.6 ± 0.5 (85)*	4.8 ± 0.4 (85)*	4.7 ± 0.6 (85)*	6.1 ± 1.1 (71)*
ဖ	4.9 ± 0.7 (85)	4.5 ± 0.3 (85)*	4.6 ± 0.3 (85)*	4.7 ± 0.6 (85)*	5.8 ± 1.1 (67)*
7	4.7 ± 0.4 (85)	4.4 ± 0.4 (85)*	4.6 ± 0.4 (85)	4.6 ± 0.8 (85)	5.7 ± 1.1 (67)*
ω	4.9 ± 0.6 (85)	4.5 ± 0.5 (85)*	4.6 ± 0.4 (85)*	4.7 ± 0.6 (85)*	5.4 ± 1.1 (67)*
o)	5 1 ± 0.5 (85)	4.6 ± 0.5 (85)*	4.4 ± 0.3 (85)*	4.5 ± 0.6 (85)*	5.1 ± 1.1 (64)
5	4.9 ± 0.4 (85)	4.7 ± 0.4 (85)	4.6 ± 0.4 (85)*	4.7 ± 0.4 (85)	5.2 ± 1.0 (63)*
=	4.5 ± 0.4 (84)	4.5 ± 0.5 (85)	4.4 ± 0.3 (85)	4.4 ± 0.4 (85)	4.6 ± 0.6 (55)
12	4.8 ± 0.5 (84)	4.6 ± 0.5 (85)	4.4 ± 0.2 (85)*	4.8 ± 0.5 (85)	5.8 ± 1.5 (54)*
13	4.8 ± 0.4 (84)	4.8 ± 0.5 (85)	4.7 ± 0.4 (85)	4.8 ± 0.5 (85)	4.7 ± 0.6 (55)
2	4.7 ± 0.4 (84)	4.8 ± 0.5 (85)	4.7 ± 0.4 (85)	4.7 ± 0.5 (85)	4.4 ± 0.4 (55)*
11	4.7 ± 0.4 (84)	4.8 ± 0.5 (85)	4.6 ± 0.3 (85)	4.6 ± 0.4 (85)	4.3 ± 0.4 (55)*
19	4.9 . 0.4 (84)	4.9 ± 0.5 (84)	4.7 ± 0.3 (85)*	4.8 ± 0.4 (85)	4.7 ± 0.3 (54)*
21	4.5 ± 0.4 (84)	4.8 ± 0.5 (83)*	4.5 ± 0.3 (85)	4.7 ± 0.4 (85)*	4.4 ± 0.4 (54)
23	4.8 ± 0.5 (84)	4.6 ± 0.5 (83)*	4.4 ± 0.4 (84)*	4.6 ± 0.5 (84)*	4.4 ± 0.8 (54)*
25	4.6 ± 0.5 (84)	4.6 ± 0.4 (83)	4.4 ± 0.4 (84)+	4.4 ± 0.5 (84)*	4.6 ± 0.5 (54)

--- = NO AVAILABLE DATA

(2)

(2)

(

0

0

٩

٥

٩

الآية

Table 9 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE FOOD CONSUMPTION MEASUREMENTS (g/day) (MEAN AND STANDARD DEVIATION (n)]

TEST WEEK	O.O mg/kg/DAY	t.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
27	4.8 ± 0.4 (74)	4.9 ± 0.4 (73)	4.7 ± 0.7 (73)	4.8 ± 0.4 (73)	4.6 ± 0.8 (42)
59	4.6 ± 0.5 (74)	4.8 ± 0.5 (73)	4.8 ± 0.4 (73)	4.7 ± 0.4 (72)	4.5 ± 0.6 (42)
31	4.9 ± 0.6 (69)	4.9 ± 0.4 (73)	5.0 ± 0.5 (73)	5.1 ± 0.6 (72)	$4.7 \pm 0.7 (42)$
33	4.8 ± 0.4 (74)	4.7 ± 0.3 (73)	4.7 ± 0.4 (72)	4.8 ± 0.4 (72)	4.9 ± 0.7 (39)
35	4.7 ± 0.5 (74)	4.8 ± 0.4 (72)	4.6 ± 0.4 (72)	4.9 ± 0.3 (72)*	4.7 ± 0.5 (39)
37	4.8 ± 0.4 (74)	5.3 ± 0.5 (72)*	5.0 ± 0.3 (72)	5.3 ± 0.6 (72)*	5.0 ± 0.8 (38)*
39	4.9 ± 0.5 (74)	5.1 ± 0.6 (72)*	4.9 ± 0.2 (72)	4.9 ± 0.4 (72)	4.8 ± 0.5 (38)
41	4.6 ± 0.3 (74)	5.0 ± 0.5 (72)*	4.6 ± 0.3 (72)	4.9 ± 0.4 (71)*	4.6 ± 0.5 (33)
43	4.6 ± 0.3 (74)	4.9 ± 0.6 (72)*	4.7 ± 0.4 (72)	5.0 ± 0.4 (71)*	$4.7 \pm 0.5 (38)$
45	4.6 ± 0.4 (74)	5.1 ± 0.6 (72)"	4.9 ± 0.3 (72)*	5.0 ± 0.4 (71)*	4.8 ± 0.4 (38)*
47	4.6 ± 0.4 (74)	5.1 ± 0.8 (72)*	5.0 ± 0.5 (72)*	5.0 ± 0.6 (70)*	4.6 ± 0.4 (38)
49	4.7 ± 0.4 (73)	5.2 ± 0.6 (71)*	5.1 ± 0.5 (72)*	5.0 ± 0.3 (70)*	4.0 ± 0.5 (38)
51	4.6 ± 0.3 (73)	4.9 ± 0.5 (71)*	4.9 ± 0.5 (72)*	4.8 ± 0.4 (70)*	4.9 ± 0.7 (38)*
53	4.5 ± 0.5 (73)	5.1 ± 0.9 (71)*	4.9 ± 0.4 (72)*	4.8 ± 0 4 (69)*	5.1 ± 1.7 (38)*
52	5.1 ± 0.6 (63)	5.3 ± 1.0 (60)	5.2 ± 0.4 (62)	5.0 2 0.3 (59)	5.0 ± 0.6 (27)
57	5.0 + 0.5 (63)	5.3 ± 0.6 (59)*	5.3 ± 0.5 (62)*	5.2 ± 0.5 (55)	5.0 ± 0.7 (27)
59	4.9 ± 0.4 (62)	5.5 ± 1.4 (59)*	5.3 ± 0.5 (62)*	5.1 ± 0.4 (58)	5.1 ± 0.6 (27)
61	4.9 ± 0.4 (62)	5.4 ± 0.6 (59)*	5.4 ± 0.8 (62)*	5.3 ± 0.5 (58)*	5.2 ± 0.8 (27)*
64	4.9 ± 0.4 (62)	5.3 ± 1.3 (59)*	5.3 ± 0.7 (62)*	5.0 ± 0.4 (57)	5.0 ± 1.1 (26)
65	4.9 ± 0.4 (62)	4.9 ± 0.7 (59)	5.2 ± 0.9 (62)	5.0 ± 0.6 (57)	4.8 ± 0.8 (26)

= NO AVAILABLE DATA

Table 9 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BEC3F1 MOUSE MALE FOOD CONSUMPTION MEASUREMENTS (g/day) [MEAN AND STANDARD DEVIATION (n)]

TEST WEEK	O.O mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
29	4.8 ± 0.3 (61)	4.5 ± 0.6 (59)*	4.8 ± 0.8 (62)	4.6 ± 0.6 (57)	4.6 ± 0.7 (26)
69	4.8 ± 0.3 (61)	5.3 ± 0.7 (59)*	5.2 ± 0.7 (62)*	5.1 ± 0.5 (55)*	5.5 ± 1.4 (26)*
7.1	4.7 ± 0.4 (61)	4.8 ± 0.5 (59)	4.9 ± 0.7 (61)	5.0 4 0.4 (54)	4.8 ± 0.7 (26)
73	4.7 ± 0 3 (61)	4.8 ± 0.6 (59)	48 ± 0.8 (61)	4.7 ± 0.4 (54)	4.6 ± 0.8 (26)
75	4.3 ± 0.2 (50)	4.6 + 0.5 (59)*	4.6 ± 0.4 (60)	4 4 ± 0.4 (54)	4.3 ± 0.8 (26)
7.7	4.4 ± 0.2 (60)	4.5 ± 0.3 (57)	4.6 ± 0.4 (58)*	4.5 ± 0.3 (54)	4.4 ± 0.6 (25)
79	4.4 ± 0.3 (58)	4.6 ± 0.4 (56)*	4.7 ± 0.3 (57)*	4.6 ± 0.4 (54)*	$4.7 \pm 0.3 (25)*$
81	4.7 ± 0.3 (58)	4.7 ± 0.4 (55)	4.8 ± 0.4 (57)	4.8 ± 0.3 (54)	4 6 ± 0.5 (25)
83	4.6 ± 0.3 (56)	4.6 ± 0.4 (54)	4.7 ± 0.4 (56)	4.7 ± 0.4 (54)	4.6 ± 0.9 (25)
85	4.7 ± 0.4 (55)	4.9 ± 0.4 (54)*	4.9 ± 0.4 (56)*	4.8 ± 0.3 (53)	4.8 ± 0.7 (25)
87		4.7 ± 0.5 (52)*	4.6 ± 0.4 (56)*	4.6 ± 0.4 (52)*	4.8 ± 0.7 (25)*
88	4.5 ± 0.4 (53)	4.8 ± 0.3 (51)*	4.9 ± 0.3 (54)*	4.5 ± 0.4 (52)	5.0 ± 0.8 (25)*
91	4.6 ± 0.5 (52)	4.9 ± 0.4 (50)	4.9 ± 0.4 (50)	4.7 ± 0.6 (49)	4.8 ± 1.1 (23)
93	4.5 ± 0.5 (52)	4.9 ± 0.3 (50)*	4.9 ± 0.4 (53)*	4.6 ± 0.4 (47)	4.7 ± 0.7 (23)
95	$4.7 \pm 0.5 (51)$	4.8 ± 0.3 (50)	5.1 ± 0.7 (52)*	4.5 ± 0.4 (45)	4.7 ± 0.5 (23)
97	4.7 ± 0.3 (51)	4.7 ± 0.2 (48)	5.1 ± 0.6 (49)*	4.7 ± 0.4 (45)	4.9 ± 0.5 (22)
66	4.7 ± 0.4 (49)	4.7 ± 0.2 (47)	4.9 ± 0.4 (45)*	4.7 ± 0.5 (40)	4.9 ± 0.6 (22)*
101	4.8 ± 0.4 (49)	4.9 ± 0.4 (46)	5.1 ± 0.6 (44)*	4.8 ± 6.5 (39)	4.9 ± 0.6 (22)
103	4.4 ± 0.4 (49)	4.4 ± 0.5 (42)	4.5 ± 0.4 (42)	4.3 ± 0.5 (38)	4.3 ± 0.4 (22)
104	4.3 ± 0.3 (46)	4.7 ± 0.6 (42)*	4.4 ± 0.4 (41)	4.5 ± 0.5 (37)*	4.3 ± 0.5 (22)

* = SIGNIFICANTLY DIFFERENT FROM CONTROL GROUP

--- = NO AVAILABLE DATA

Table 10

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE FOOD CONSUMPTION MEASUREMENTS (g/day) [MEAN AND STANDARD DEVIATION (n)]

⁼ SIGNIFICANTLY DIFFERENT FROM CONTROL GROUP

- = NO AVAILABLE DATA

Table 10 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE FOOD CONSUMPTION MEASUREMENTS (g/day) [MEAN AND STANDARD DEVIATION (n)]

TEST WEEK	0.0 mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
27	3.9 ± 0.4 (75)	3.6 ± 0.3 (75)*	3.7 ± 0.2 (75)*	3.6 ± 0.2 (75)*	3.8 ± 0.8 (41)
29	3.7 ± 0.5 (70)	3.5 ± 0.6 (75)	3.5 ± 0.4 (75)*	3.6 ± 0.3 (75)	3.7 ± 0.5 (41)
34	3.6 ± 0.2 (70)	3.6 ± 0.5 (75)	3.8 ± 0.4 (74)	3.9 ± 0.2 (70)*	4.2 ± 0.9 (41)*
33	3.7 ± 0.3 (75)	3.7 ± 0.3 (74)	3.9 ± 0.4 (74)*	3.7 ± 0.2 (75)	3.9 ± 0.4 (41)*
35	3.7 ± 0.2 (75)	3.7 ± 0.3 (74)	3.8 ± 0.3 (74)*	3.8 ± 0.3 (75)*	3.7 ± 0.4 (41)
37	3.7 ± 0.3 (75)	3.8 ± 0.3 (74)	3.9 ± 0.5 (74)*	3.8 ± 0.2 (75)	4.0 ± 0.4 (41)*
39	3.8 ± 0.3 (75)	3.6 ± 0.3 (74)*	3.8 ± 0.2 (74)	3.8 ± 0.2 (75)	4.0 ± 0.6 (41)*
41	3.8 ± 0.3 (75)	3.7 ± 0.4 (74)	3.8 ± 0.2 (74)	3.7 ± 0.3 (75)	3.7 ± 0.4 (41)
43	3.6 ± 0.3 (75)	3.6 ± 0.2 (74)	3.8 ± 0.2 (74)*	3.6 ± 0.1 (75)	3.8 ± 0.3 (41)*
45	3.5 ± 0.2 (75)	3.5 ± 0.2 (74)	3.6 ± 0.2 (74)*	3.7 ± 0.3 (75)*	4.0 ± 0.7 (41)*
47	3.6 ± 0.3 (75)	3.7 ± 0.3 (73)	4.1 ± 1.0 (74)*	3.7 ± 0.3 (75)	3.8 ± 0.5 (41)*
49	3.8 ± 0.3 (75)	3.8 ± 0.3 (73)	3.9 ± 0.2 (74)	3.8 ± 0.3 (74)	3.7 ± 0.4 (41)
51	3.5 ± 0.2 (75)	3.6 ± 0.3 (73)*	3.7 ± 0.2 (74)*	3.6 ± 0.2 (74)*	4.0 ± 0.4 (41)*
53	3.6 ± 0.2 (75)	3.6 ± 0.2 (73)	3.8 ± 0.3 (74)*	3.6 ± 0.2 (74)	3.9 ± 0.3 (41)*
55	3.5 ± 0.3 (65)	3.7 ± 0.4 (63)*	3.8 ± 0.3 (64)*	3.8 ± 0.2 (64)*	3.9 ± 0.6 (31)*
57	3.7 ± 0.4 (65)	3.9 ± 0.3 (62)*	4.0 ± 0.3 (64)*	3.8 ± 0.2 (64)	4.1 ± 0.4 (31)*
20	3.9 ± 0.4 (65)	4.0 ± 0.3 (62)	4.2 ± 0.4 (64)*	4.0 ± 0.4 (64)*	4.0 ± 0.4 (31)
61	3.8 ± 0.3 (65)	3.9 ± 0.3 (62)	3.9 ± 0.3 (64)*	3.8 ± 0.3 (64)	4.0 ± 0.4 (30)*
64	4.1 ± 0.2 (65)	4.0 ± 0.2 (62)	4.1 ± 0.2 (64)	3.9 ± 0.2 (63)*	4.1 ± 0.5 (30)
65	3.7 ± 0.3 (65)	3.8 ± 0.2 (62)*	3.8 ± 0.2 (64)*	3.6 ± 0.2 (63)	4.1 ± 0.5 (30)*

^{* =} SIGNIFICANTLY DIFFERENT FROM CONTROL GROUP

- = NO AVAILABLE DATA

G

8

0

4

4

Ċ

Table 10 (continued)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3.5-TRINITRO-1,3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE FOOD CONSUMPTION MEASUREMENTS (g/day) [MEAN AND STANDARD DEVIATION (n)]

had hall to the defendence of the other process are the sea are

TEST WEEK	O.O mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
67	3.9 ± 0.3 (65)	3.7 ± 0.5 (61)	3.8 ± 0.1 (64)	3.5 ± 0.3 (63)*	3.6 ± 0.5 (30)*
69	3.7 ± 0.3 (65)	3.9 ± 0.4 (61)*	3.9 ± 0.3 (64)*	3.9 ± 0.3 (63)*	3.8 ± 0.4 (30)
7.1	3.8 ± 0.3 (64)	3.8 ± 0.3 (60)	3.9 ± 0.2 (63)*	3.7 ± 0.2 (63)	3.8 ± 0.3 (30)
73	3.5 ± 0.3 (63)	3.6 ± 0.3 (60)	3.6 ± 0.1 (63)	3.5 ± 0.3 (63)	3.5 ± 0.3 (30)
75	3.4 ± 0.2 (63)	3.4 ± 0.2 (60)	3.5 ± 0.3 (63)	3.2 ± 0.3 (61)+	3.4 ± 0.3 (30)
7.7	3.6 ± 0.3 (63)	3.5 ± 0.2 (60)	3.7 ± 0.3 (63)	3.4 ± 0.3 (61)*	3.6 ± 0.4 (30)
79	3.4 ± 0.3 (63)	3.7 ± 0.2 (60)*	3.8 ± 0.3 (63)*	3.6 ± 0.4 (61)*	3.7 ± 0.5 (30)*
81	3.8 ± 0.2 (61)	3.7 ± 0.3 (60)	3.9 ± 0.2 (63)*	3.8 ± 0.4 (60)	3.8 ± 0.4 (29)
83	3.6 ± 0.2 (61)	3.7 ± 0.3 (60)*	3.8 ± 0.4 (63)*	3.7 ± 0.6 (60)	3.7 ± 0.3 (29)
82	$3.7 \pm 0.2 (61)$	3.8 ± 0.2 (60)*	4.0 ± 0.2 (62)*	3.9 ± 0.5 (59)*	4.0 ± 0.6 (29)*
87	3.4 ± 0.3 (60)	3.8 ± 0.3 (60)*	3.8 ± 0.3 (62)*	3.6 ± 0.5 (58)*	3.9 ± 0.6 (29)*
89	3.7 ± 0.2 (53)	3.8 ± 0.3 (48)	3.9 ± 0.2 (62)*	3.6 ± 0.5 (56)	$3.7 \pm 0.5 (29)$
91	4.0 ± 0.3 (54)	3.8 ± 0.3 (60)*	3.8 ± 0.3 (61)	3.9 ± 0.4 (56)	3.9 ± 0.5 (29)
93	3.7 ± 0.3 (54)	4.0 ± 0.4 (57)*	3.9 ± 0.5 (60)*	4.0 ± 0.4 (50)*	4.0 ± 0.8 (29)*
36	4.0 ± 0.4 (54)	3.9 ± 0.3 (55)	4.0 ± 0.6 (59)	4.0 ± 0.4 (53)	4.1 ± 0.4 (28)
97	4.1 ± 0.3 (54)	4.2 ± 0.4 (52)	4.4 ± 0.4 (58)*	4.1 ± 0.3 (53)	4.2 ± 0.6 (27)
66	4.0 ± 0.2 (53)	4.1 ± 0.3 (49)	4.2 ± 0.4 (57)*	3.9 ± 0.4 (48)	4.2 ± 0.3 (27)
101	4.2 ± 0.3 (51)	4.2 ± 0.4 (49)	4.3 ± 0.4 (55)	4.2 ± 0.3 (49)	4.1 ± 0.3 (27)
103	3.9 ± 0.3 (51)	3.9 ± 0.4 (46)	3.7 ± 0.4 (54)	3.8 ± 0.2 (47)	3.6 ± 0.5 (26)*
104	3.9 ± 0.2 (50)	4.0 ± 0.4 (46)	3.9 ± 0.4 (53)	3.8 ± 0.4 (46)	3.9 ± 0.5 (25)

* = SIGNIFICANTLY DIFFERENT FROM CONTROL GROUP

--- = NO AVAILABLE DATA

Table 11

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE HEMATOLOGY VALUES - TEST WEEK 14 [MEAN AND STANDARD DEVIATION (n)]

HEMATOLOGY VALUES	O O mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
WBC × 103/mm3	7.7 ± 1.2 (8)	8.3 ± 2.0 (11)	7.8 ± 1.4 (10)	7.5 ± 2.0 (8)	7.5 ± 1.5 (9)
RBC > 10*/mm3	9.80 ± 0.58 (8)	9.95 ± 0.37 (11)	9.88 ± 0.39 (10)	9.84 ± 0.52 (9)	9.71 ± 0.85 (9)
HGB g/d1	16.8 ± 0.7 (8)	16.8 ± 0.4 (11)	16.9 ± 0.5 (10)	16.6 ± 1.1 (9)	16.5 ± 1.2 (9)
HCT %	45.9 % 3.2 (8)	46.1 ± 2.5 (11)	46.5 ± 2.4 (10)	45.5 ± 2.6 (9)	44.9 ± 4.3 (9)
MCV Um	47 ± 1 (8)	46 ± 1 (11)	47 ± 1 (10)	46 ± 1 (9)	46 ± 2 (9)
мсн ра	17.5 ± 0.5 (8)	17.3 ± 0.4 (11)	17.5 ± 0.4 (10)	17.3 ± 0.8 (9)	17.4 ± 0.7 (9)
MCHC g/dl	37.3 ± 1.4 (8)	37.3 ± 1.5 (11)	37.2 ± 1.4 (10)	37.4 ± 1.5 (9)	37.7 ± 1.4 (9)
PLT x103/mm3	883 ± 472 (8)	907 ± 385 (11)	959 ± 259 (11)	1056 ± 232 (9)	1035 ± 246 (9)
Im N×10³/mm³	0.01 ± 0.04 (8)	0.00 ± 0.00 (11)	0.09 ± 0.30 (11)	(6) 00.0 7 00.0	0.02 ± 0.06 (9)
Ma N×10¹/mm¹	1.50 ± 0.52 (8)	1.69 ± 1.07 (11)	6.81 ±15.37 (11)	4.63 ± 6.40 (9)	1.57 ± 0.91 (9)
Lym ×103/mm3	6.12 ± 0.96 (8)	6.55 ± 1.36 (11)	9.23 ±12.25 (11)	13.07 ±24.73 (9)	5.88 ± 1.13 (9)
Mon x 10³/mm³	0.06 ± 0.03 (8)	0.07 ± 0.07 (11)	0.07 ± 0.06 (11)	0.04 ± 0.10 (9)	0.02 ± 0.04 (9)
Eos ×10'/mm'	0.01 ± 0.02 (8)	0.00 ± 0.00 (11)	0.02 ± 0.06 (11)	0.05 ± 0.07 (9)	0.00 ± 0.00
Bas x101/mm1	0.00 ± 0.00 (8)	0.00 ± 0.00 (11)	0.00 ± 0.00 (11)	0.00 ± 0.00	0.00 + 0.00
NRBC/100 wbr	(8) 0 70	0 + 0 (11)	0 ± 0 (11)	(6) O + O	(6) 0 + 0

--- = NO AVAILABLE DATA

(2)

Table 12

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE HEMATOLOGY VALUES - TEST WEEK 14 [MEAN AND STANDARD DEVIATION (n)]

175/100 mg/kg/DAY	6.8 ± 3.4 (9)*	9.39 ± 0 63 (10)	16.4 ± 1.1 (10)	44.0 1 3.0 (10)	47 ± 1 (10)	(01) 2.0 ± 6.71	38.2 ± 2.0 (10)	975 ± 296 (10)	0.00 ± 0.00 (10)	3.66 ± 5.29 (10)	12.34 +24.83 (10)	0.01 ± 0.02 (10)	0.10 ± 0.32 (10)	0.00 ± 0.00 (10)	0 + 0 (10)
35 mg/kg/DAY	4.3 ± 1.3 (11)	9.92 ± 0.50 (11)	17.3 ± 0.5 (11)	46.7 ± 2.6 (11)	47 ± 1 (11)	17.9 ± 0.6 (11)	37.9 ± 1.5 (11)	900 ± 281 (11)	0.02 ± 0.04 (11)	0.66 ± 0.32 (11)	3.62 ± 1.09 (11)	0.01 ± 0.02 (11)	0.00 ± 0.02 (11)	0.00 ± 0.00 (11)	0 + 0 (11)
7 mg/kg/DAY	5.0 ± 0.6 (10)	9.83 ± 0.39 (11)	17.2 ± 0.5 (11)	46.4 ± 2.5 (11)	47 ± 1 (11)	17.9 ± 0.5 (11)	38.0 ± 1.5 (11)	957 ± 137 (11)	0.00 ± 0.00 (11)	2.36 ± 5.20 (11)	11.27 ±23.46 (11)	0.02 ± 0.03 (11)	0.00 ± 0.00 (11)	0.00 ± 0.00 (11)	0 + 0 (11)
1.5 mg/kg/DAY	4.5 ± 1.1 (10)	9.91 ± 0.43 (11)	17.2 ± 0.6 (11)	46.8 ± 2.5 (11)	47 ± 1 (11)	17.8 ± 0.7 (11)	37.6 ± 1.9 (11)	736 ± 192 (11)	0.01 ± 0.01 (11)	1.43 ± 2.86 (11)	11.56 ±25.37 (11)	0.10 ± 0.30 (11)	0.09 ± 0.30 (11)	0.00 ± 0.00 (11)	0 + 0 (11)
O.O mg/kg/DAY	4.0 ± 0.6 (7)	9.54 ± 0.39 (9)	16.8 ± 0.8 (9)	45.0 ± 1.~ (9)	47 ± 1 (9)	18.0 ± 0.6 (9)	38.2 ± 1.6 (9)	855 ± 238 (9)	0.01 ± 0.02 (9)	8.79 ±19.79 (9)	16.39 ±28.11 (9)	0.12 ± 0.33 (9)	0.00 ± 0.01 (9)	(6) 00.0 7 00.0	(6) 0 7 0
HEMATOLOGY VALUES	WBC ×10'/mm'	RBC ×10*/mm3	HGB g/d1	HCT %	MCV Um,	мсн ра	MCHC g/d1	PLT ×10'/mm'	Im N×10'/mm'	Ma N×10'/mm'	Lym ×10'/mm'	Mon ×10'/mm'	Eos ×10'/mm'	Bas ×10'/mm'	NRBC/100 wbc

* = SIGNIFICANTLY DIFFERENT FROM CONTROL GROUP

-- = NO AVAILABLE DATA

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3.5-TRINITRO-1,3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE HEMATOLOGY VALUES - TEST WEEK 26 [MEAN AND STANDARD DEVIATION (n)]

HEMATOLOGY VALUES	0.0 mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
WBC ×10'/mm'	10.9 ± 2.4 (10)	11.9 ± 1.4 (8)	11.9 ± 1.6 (10)	11.8 ± 1.8 (10)	10.5 ± 2.2 (12)
RBC ×10"/mm1	8.41 ± 1.41 (10)	9.03 ± 0.34 (10)	8.62 ± 0.98 (10)	8.82 ± 0.39 (10)	8.61 ± 0.46 (12)
HGB €/a1	15.1 ± 2.5 (10)	16.2 ± 0.4 (10)	15.5 ± 1.5 (10)	15.9 ± 0.4 (10)	15.3 ± 0.9 (12)
HCT %	38.7 ± 6.2 (40)	41.5 ± 1.7 (10)	40.0 ± 3.7 (10)	41.0 ± 1.4 (10)	39 7 ± 2.2 (12)
MCV Um¹	46 ± 0 (10)	46 ± 1 (10)	46 ± 1 (10)	46 ± 1 (10)	46 ± 1 (12)
мсн ра	18 5 ± 0.4 (10)	18.4 ± 0.3 (10)	18.5 ± 0 4 (10)	18.5 ± 0.4 (10)	18.2 ± 0.4 (12)
MCHC g/d1	40.3 ± 0.9 (10)	40.4 ± 1.6 (10)	40.0 ± 0.9 (10)	39.9 ± 0.6 (10)	39.7 ± 1.2 (12)
PLT ×10'/mm'	1135 ± 275 (10)	1071 ± 200 (10)	1311 ± 256 (10)	1115 ± 340 (10)	1390 ± 326 (12)
Im N×10'/mm'	0.00 ± 0.00 (10)	0.14 ± 0.33 (10)	0.03 ± 0.06 (10)	0.00 ± 0.00 (10)	0.03 ± 0.09 (12)
Ma N×10'/mm'	2.15 ± 0.85 (10)	5.80 ± 6 56 (10)*	2.67 ± 1.32 (10)	2.18 ± 0.83 (10)	2.58 ± 1.57 (12)
Lym ×10'/mm'	8.65 ± 2.33 (10)	23.34 ±30.19 (10)*	9.12 ± 1.74 (10)	9.47 ± 1.26 (10)	7.80 ± 1.29 (12)
Mon ×10³/πm³	0.11 ± 0.08 (10)	0.25 ± 0.62 (10)	0.05 ± 0.10 (10)	0.13 ± 0.18 (10)	0.03 ± 0.05 (12)
E.os ×10°/mm³	0.02 ± 0.08 (10)	0.02 ± 0.05 (10)	0.00 ± 0.00 (10)	0.03 ± 0.06 (10)	0.03 ± 0.05 (12)
Bas ×10'/mm'	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (12)
NRBC/100 Wbc	0 + 0 (10)	(01) 0 7 0	0 + 0 (10)	(01) 0 70	0 ± 0 (12)

--- = NO AVAILABLE DATA

9

(2)

٩

Ť

0

Table 14

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE HEMATOLOGY VALUES - TEST WEEK 26 [MEAN AND STANDARD DEVIATION (n)]

HEMATOLOGY VALUES	0.0 mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	3£ mg/kg/DAY	175/100 mg/kg/DAY
WBC ×10³/mm³	6.9 ± 2.4 (10)	6.1 ± 1.4 (10)	7.4 ± 1.5 (9)	6.9 ± 1.7 (10)	8.0 ± 1.5 (8)
RBC ×10*/mm	9.29 ± 0.29 (10)	9.20 ± 0.52 (10)	9.37 ± 0.35 (9)	9.11 ± 0.53 (10)	9.22 ± 0.33 (8)
HGB 9/41	17.0 ± 0.4 (10)	17.1 ± 0.6 (10)	17.2 ± 0.4 (9)	16.9 ± 0.4 (10)	17.1 ± 0.4 (8)
HCT %	43.2 ± 1.2 (10)	43.1 ± 2.0 (10)	44.1 ± 1.3 (9)	42.7 ± 2.2 (10)	43.5 ± 1.6 (8)
MCV Um	46 ± 1 (10)	47 ± 1 (10)	47 ± 1 (9)	46 ± 1 (10)	46 ± 2 (8)
MCH pg	18.7 ± 0.3 (10)	19.1 ± 0.8 (10)	18.8 ± 06 (9)	19.1 ± 0.9 (10)	19.0 ± 0.5 (8)
MCHC g/dl	40.4 ± 0.7 (10)	40.9 ± 1.4 (10)	40.1 ± 1.1 (9)	40.8 ± 1.6 (10)	40.5 ± 1.1 (8)
PLT ×10'/mm'	953 ± 225 (10)	1122 ± 279 (10)	1062 ± 290 (10)	1051 ± 223 (10)	1080 ± 167 (8)
Im N×10'/mm'	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	(0: 00:0 7 00:0	0.00 ± 0.00 (10)	0.00 ± 0.00 (8)
Ma N×101/mm1	0.96 ± 0.39 (10)	0.90 ± 0.35 (10)	1.93 ± 2.52 (10)	1.29 ± 0.46 (10)	1.22 ± 0.73 (8)
Lym ×10'/mm'	5.85 ± 2.14 (10)	5.19 ± 1.20 (10)	14.58 ±26.89 (10)	5.53 ± 1.56 (10)	6.77 ± 1.16 (8)
Mon × 10³/mm³	0.02 ± 0.03 (10)	0.03 ± 0.04 (10)	0.02 ± 0.04 (10)	0.02 ± 0.04 (10)	0.03 ± 0.07 (8)
Eos ×101/mm3	0.02 ± 0.05 (10)	0.01 ± 0.03 (10)	0.05 ± 0.08 (10)	0.03 ± 0.04 (10)	0.00 ± 0.00 (8)
Bas × tO¹/mm¹	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (8)
NRBC/100 wbc	(01) 0 7 0	(01) 0 + 0	(0) 0 + 0	0 + 0 (10)	(8) 0 + 0

--- = NO AVAILABLE DATA

Table 15

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE HEMATOLOGY VALUES - TEST WEEK 53 [MEAN AND STANDARD DEVIATION (n)]

175/100 mg/kg/DAY	10.4 ± 2.1 (10)	8.76 ± 0.51 (10)	15.1 ± 0.5 (10)	39.5 ± 1.5 (10)	45 ± 2 (10)	17.3 ± 0.6 (10)	38.5 ± 1.1 (10)	1045 ± 188 (10)	0.00 ± 0.00 (10)	1.50 ± 0.75 (10)	8.63 ± 1.61 (10)	0.26 ± 0.17 (10)	0.05 ± 0.10 (10)	0.00 ± 0.00 (10)	0 + 0 (10)
35 mg/kg/DAY	11.0 ± 1.6 (10)	9.21 ± 0.45 (10)	15.5 ± 0.8 (10)	40.7 ± 2.3 (10)	44 ± 1 (10)	16.9 ± 0.5 (10)	38 5 ± 0.8 (10)	1074 ± 196 (10)	0.00 ± 0.00 (10)	1.55 ± 0.47 (10)	9.00 ± 1.55 (10)	0.42 ± 0.25 (10)	0.08 ± 0.10 (10)	0.00 ± 0.00 (10)	(01) 0 7 0
7 mg/kg/DAY	11.0 ± 3.0 (10)	8.00 ± 2.87 (10)	15.1 ± 1.4 (10)	39.8 ± 3.3 (10)	44 ± 1 (10)	16.9 ± 0.5 (10)	38.4 ± 1.0 (10)	936 ± 138 (10)	0.00 ± 0.00 (10)	1.30 ± 0.54 (10)	9.30 ± 3.02 (10)	0.29 ± 0.14 (10)	0.07 ± 0.08 (10)	0.00 ± 0.00 (10)	0 + 0 (10)
1.5 mg/kg/DAY	11.4 ± 1.7 (10)	9.15 ± 0.50 (10)	15.6 ± 0.6 (10)	41.6 ± 2.3 (10)	45 ± 2 (10)	17.1 ± 0.8 (10)	37.8 ± 1.2 (10)	966 ± 202 (10)	0.00 ± 0.00 ((0)	1.92 ± 1.17 (10)	9.16 ± 2.42 (10)	0.32 ± 0.19 (10)	0.04 ± 0.08 (10)	0.00 ± 0.00 (10)	0 + 0 (10)
0.0 mg/kg/DAY	10.9 ± 2.3 (10)	9.07 ± 1.08 (10)	15.2 ± 1.9 (10)	40.2 ± 4.6 (10)	44 ± 1 (10)	16.8 ± 0.3 (10)	38.2 ± 0.8 (10)	946 ± 113 (10)	0.00 ± 0.00 (10)	1.33 ± 1.33 (10)	9.22 ± 1.55 (10)	0.23 ± 0.23 (10)	0.10 ± 0.08 (10)	0.00 ± 0.00 (10)	0 + 0 (10)
HEMATOLOGY VALUES	WBC ×10'/mm'	RBC ×10 4/mm3	HGB g/dl	HCT %	MCV Um	мсн ра	MCHC g/d1	PLT ×10³/mm³	Im N×10'/mm'	Ma N×10³/mm³	Lym ×10³/mm³	Mon :10³/mm³	Eos x101/mm1	Eas ×10¹/mm³	NRBC/100 wbc

--- = NO AVAILABLE DATA

٨

Table 16

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE HEMATOLOGY VALUES - TEST WEEK 53 [MEAN AND STANDARD DEVIATION (n)]

HEMATOLOGY VALUES	0.0 mg/kg/DAY	1.5 mg/kg/DAY	mg/kg/DAY	as mg/kg/DAY	175/100 mg/kg/DAY
WBC ×103/mm3	6.8 ± 1.2 (9)	1.9 + 1.4 (10)	7.6 ± 2.5 (10)	7.7 + 2.3 (10)	7.8 ± 1.5 (10)
RBC ×10'/mm'	5.51 + 4.98 (9)	5.91 + 4.94 (10)	5.75 ± 4.85 (10)	8.64 ± 3.00 (10)	8.58 ± 2.89 (10)
HGB g/d1	17.0 ± 0.5 (9)	16.9 ± 0.4 (10)	16.7 ± 0.6 (10)	16.6 ± 0.4 (10)	16.4 ± 0.6 (10)*
HCT %	44.0 ± 1.0 (9)	44.3 ± 1.4 (10)	43.4 ± 1.6 (10)	43.9 ± 1.6 (10)	42.4 ± 1.4 (10)*
MCV Um	44 ± 1 (9)	44 ± 1 (10)	15 + 1 (10)	45 + 1 (10)+	44 ± 1 (10)
MCH pg	17.1 ± 0.6 (9)	17.1 ± 0.3 (10)	17.2 ± 0.5 (10)	17.3 ± 0.4 (10)	17.2 ± 0.4 (10)
MCHC 9/d1	38.8 ± 1.0 (9)	38.3 ± 0.8 (10)	38.8 ± 0.6 (10)	38.1 ± 1.0 (10)	39.0 ± 0.8 (10)
PLT ×10'/mm'	813 ± 74 (9)	809 ± 104 (10)	767 ± 105 (10)	893 ± 140 (10)	941 ± 129 (10)*
Im N×10'/mm'	(6) 00 0 7 00.0	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)
Ma N×10¹/mm¹	0.76 ± 0.34 (9)	0.69 ± 0.20 (10)	1.01 ± 0.90 (10)	0.63 ± 0.30 (10)	0.77 ± 0.28 (10)
Lym ×1G³/mm³	5.78 ± 1.28 (9)	6.94 ± 1.34 (10)	6.42 ± 2.21 (10)	6.69 ± 1.85 (,)	6.80 ± 1.42 (10)
Mon x tO¹/mm¹	0.18 ± 0.09 (9)	0.18 ± 0.12 (10)	0.14 ± 0.14 (10)	0.33 ± 0.32 (10)	0.20 ± 0.12 (10)
Eos ×10'/mm'	0.06 ± 0.07 (9)	0.06 ± 0.07 (10)	0.05 ± 0.06 (10)	0.03 ± 0.05 (10)	0.05 ± 0.07 (10)
Bas ×10,/mm,	0.00 ± 0.00	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)
NRBC/100 wbc	(6) 0 + 0	0 + 0 (10)	(01) 0 7 0	(01) 0 7 0	0 + 0

-- = NO AVAILABLE DATA

Table 17

TWLNTY FOUR MONTH CHRONIC TOXICITY/CARCINUGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE HEMATOLOGY VALUES - TESY WEEK 79 [MEAN AND STANDARD DEVIATION (n)]

HEMATOLOGY VALIJES	0.0 mg/kg/DAY	1.5 mg/kg/DAY	7 / / wa/kg/, / /	35 mg/kg/DAY	175/100 m::/kg/DAY
WBC ×101/mm2	10.8 ± 1.9 (10)	10.5 ± 2.4 (10)	9.8 ± 2.7 (10)	11.2 ± 2.4 (10)	(o) 0.0 +
RBC ×10'/mm'	9.65 ± 1.30 (10)	9 00 ± 0.32 (10)	9.23 ± 0.80 (10)	9.35 ± 1.78 (10)	(0) 00.0 7
HGB 9/d1	16.1 ± 1.3 (10)	15.2 ± 0.7 (10)	15.6 ± 0.9 (10)	15.9 ± 2.4 (10)	(0) 0.0 7
HCT %	43.4 ± 3.5 (10)	41.4 ± 1.6 (10)	42.5 _ 2.5 (10)	43.1 ± 7.1 (10)	(0) 0.0 +
MCV Um³	44 ± 2 (10)	45 ± 1 (10)	45 ± 1 (10)	45 ± 1 (10)	(0) 0 +
MCH pg	16.9 ± 0.7 (10)	17.1 ± 0.4 (10)	17.1 ± 0.6 (10)	17.3 ± 0.7 (10)	(0) 0.0 +
MCHC g/d1	37.8 ± 0.8 (10)	37.5 ± 0.9 (10)	37.6 ± 0.6 (10)	37.6 ± 1.3 (10)	(0) 0.0 7
PLT ×10'/mm'	797 ± 301 (10)	338 ± 222 (10)	842 ± 196 (10)	848 ± 186 (10)	(0) 0 +
Im Nx10³/mm³	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	(0) 00.0 7
Ma Nx:01/mm1	1.98 ± 1.17 (10)	2.74 ± 1.60 (10)	2.62 ± 1.73 (10)	2.98 ± 1.40 (10)	(0) 00.0 7
Lym ×10°/mm'	8.66 ± 1.54 (10)	7.47 ± 1.09 (10)	7.06 ± 1.86 (10)*	8.04 ± 1.91 (10)	(0) 00.0 7
Mon ×10³/mm³	$0.14 \pm 0.19 (10)$	0.21 ± 0.20 (10)	0.20 ± 0.33 (10)	0.13 ± 0.10 (10)	(0) 00.0 7
Eos ×10'/mm'	0.00 ± 0.00 (10)	0.04 ± 0.07 (10)	0.03 ± 0.05 (10)	0.01 ± 0.04 (10)	(0) 00.0 7
Bas ×10'/mm'	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	(0) 20.0 7
NRBC/100 wbc	(01) 0 7 0	0 + 0 (10)	0 + 0 (10)	(01) 0 70	(0) 0 +

--- = NO AVAILABLE DATA

(3)

(2)

9

٩

0

٥

٩

٧

Table 18

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINGGENICITY STUDY OF HEXA.HYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE HEMATOLOGY VALUES - TEST WEEK 79 [MEAN AND STANDARD DEVIATION (n)]

HEMATOLOGY VALUES	0.0 mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
WBC ×10'/mm'	5.9 ± 1.1 (10)	5.7 ± 1.5 (10)	7.2 ± 4.0 (16)	5.7 ± 0.8 (10)	(0) 0.0 7
RBC ×10*/mm1	9 43 ± 0.36 (10)	9.48 ± 0.44 (10)	9.19 ± 0.42 (10)	9.07 ± 0.31 (10)*	(0) 00.0 +
HGB 9/d1	16.3 ± 0.6 (10)	16.2 ± 0.4 (10)	16.0 ± 0.8 (10)	15 8 ± 0.5 (10)	(0) 0.0 7
HCT %	43.7 ± 1.2 (10)	44.2 ± 19 (10)	42.2 ± 2.0 (10)	42.4 ± 1.6 (10)	(0) 0.0 7
MCV Um'	46 ± 1 (10)	46 ± 1 (10)	46 ± 1 (10)	46 ± 1 (10)	(0) 0 +
мсн ра	17,5 ± 0.4 (10)	17 3 ± 0.6 (10)	17.6 ± 0.5 (10)	17.6 ± 0.4 (10)	(0) 0.0 7
MCHC g/d1	38.0 ± 0.7 (10)	37.7 ± 1.2 (9)	38.1 ± 0.8 (10)	38.2 ± 0.8 (10)	(0) 0.0 7
PLT ×10'/mm'	728 ± 115 (10)	736 + 95 (10)	(01) 111 (10)	720 ± 64 (10)	(0) 0 +
Im N×10'/mm'	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (16)	(0) 00.0 7
Ma N×10'/mm'	1.40 ± 0.55 (10)	1.03 ± 0.40 (10)	1. 9 ± 0.56 (10)	0.83 ± 0.24 (10)*	(0) 00.0 7
Lym ×10'/mm'	4.46 ± 0.88 (10)	4.63 ± 1.66 (10)	5.89 ± 3.60 (10)	4.84 ± 0.78 (10)	(0) 00.00 7
Mon × 10 1/mm	0.05 ± 0.06 (10)	0.05 ± 0 06 (10)	0.09 ± 0.18 (10)	0.04 ± 0.06 (10)	(0) 00.0 7
Eos x10'/mm'	0.00 ± 0.00 (10)	0.01 ± 0.03 (10)	0.01 ± 0.03 (10)	0.01 ± 0.02 (10)	(0) 00.0 7
Bas ×101/mm1	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	(0) 00.0 +
NRSC/ 100 Wbc	(01) 0 7 0	(01) 0 7 0	(01) 0 70	0 + 0 (10)	(0) 0 +

--- = NO AVAILABLE DATA

COCK TEXASTER TO CONTINUE TO C

Table 19

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE HEMATOLOGY VALUES - TEST WEEK 105 [M-AN AND STANDARD DEVIATION (n)]

HEMATOLOGY VALUES	O.O mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
WBC ×10'/mm'	12.6 ± 4 7 (10)	11.0 ± 6.8 (10)	11.6 ± 3.7 (10)	10.6 ± 2.7 (10)	8.8 ± 1.9 (10)
RBC ×10*/mm1	8.21 ± 2.25 (10)	7.86 ± 2.55 (10)	8.47 ± 1.67 (10)	7.94 ₹ 7 43 (19)	9.36 ± 1.78 (10)
HGB 3/41	13.9 ± 2.7 (10)	13.1 ± 4.0 (10)	14.3 ± 2.2 (10)	13.2 ± 3.1 (10)	15.2 ± 1.4 (10)
HCT %	38.3 ± 6.7 (10)	36 7 ± 10 5 (10)	39.5 ± 4.9 (10)	36.7 ± 7.7 (10)	41.9 ± 6.9 (10)
MCV Um,	48 ± 9 (10)	47 + 7 (10)	17 + 6 (19)	46 ± 5 (10)	44 ± 1 (10)
мсн ра	17.8 ± 3.2 (10)	17 2 1 1 7 (19)	17.3 + 16 (10)	17 1 ± 1.7 (10)	16 6 ± 1.2 (10)
MCHC 9/d1	36.9 ± 1.2 (10)	36.2 ± 2.4 (10)	36.9 ± 1.6 (10)	36.7 + 1.1 (10)	37.3 ± 2.4 (10)
PLT ×10'/mm'	549 ± 195 (10)	729 ± 384 (10)	598 ± 269 (10)	667 ± 167 (10)	697 ± 122 (10)
Im N×10'/mm'	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)
Ma N×10'/mm'	4.76 ± 4.46 (10)	4.32 ± 5.24 (10)	4.94 ± 3.66 (10)	3.91 ± 2.67 (10)	2.40 ± 2.07 (10)
Lym ×10'/mm'	7.55 ± 1.94 (10)	6.49 ± 1.82 (10)	6.55 ± 2 57 (10)	6.44 ± 2.71 (10)	6.33 ± 1.88 (10)
Mon × 10'/mm'	0.28 ± 0.30 (10)	0.16 ± 0.27 (10)	0.08 ± 0.10 (10)	0.22 ± 0.24 (10)	0.03 ± 0.07 (10)*
Eos ×10'/mm'	0.02 ± 0.05 (10)	0.02 ± 0.06 (10)	0.04 ± 0.07 (10)	0.06 ± 0.10 (10)	0.04 ± 0.07 (10)
Bas ×10'/mm'	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)
NREC/100 wbc	(01) 0 7 0	0 + 0 (10)	0 + 0 (10)	0 + 0 (10)	(0,) 0 7 0

- SIGNIFICANTLY DIFFERENT FROM CONTROL GROUP

-- = NO AVAILABLE DATA

(

Ø

٩

٩

٩

0

٥

Ó

Ù

Table 20

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE'RDX) IN THE BGC3F1 MQUSE FEMALE HEMATOLOGY VALUES - TEST WEEK 105 [MEAN AND STANDARD DEVIATION (n)]

175/10C mg/kg/DAY	5.7 ± 1.4 (10)	8.74 ± 0.67 (10)	15.0 ± 0.4 (10)	40.5 ± 1.3 (10)	46 ± 2 (10)	17.4 ± 1.0 (10)	38.0 ± 1.0 (10)	492 ± 95 (10)	0.00 + 0.00 (10)	1.02 ± 0.6 (10)	4.60 ± 1.00 (10)	0.08 ± 0.12 (10)	0.00 ± 0.00 (10)	0.00 ± 0.00 (10)	(0) 0 70
35 mg/kg/DAY	7.3 ± 2.4 (10)	8.92 ± 0.43 (10)	15.3 ± 0.5 (10)	41.4 ± 1.5 (10)	46 ± 1 (10)	17 3 ± 0.6 (10)	37.8 ± 0.9 (10)	473 ± 194 (10)	0.00 ± 0.00 (10)	1.01 ± 0.46 (10)	6.08 ± 2.60 (10)*	0.16 ± 0.10 (10)	0.02 ± 0.03 (10)	0.00 ± 0.00 (10)	(01) 0 7 0
7 mg/kg/DAY	7.9 ± 2.2 (10)*	7.89 ± 1.57 (10)	13.7 ± 2.0 (10)	37.6 ± 5.3 (10)	47 ± 5 (10)	178+17(10)	37 2 ± 1.1 (10)	437 ± 72 (10)	0.00 ± 0.00 (10)	2.20 ± 2.05 (10)	5.55 ± 1.31 (10)	0.13 ± 0.15 (10)	0.02 ± 0.04 (10)	0.00 ± 0.00 (10)	(01) 0 70
1.5 mg/kg/DAY	6.4 ± 1.6 (10)	8.79 ± 1.29 (10)	15.1 ± 1.9 (9)	41.3 ± 50 (10)	46 ± 2 (fc)	17 5 ± 1 1 (10)	37.4 ± 2.0 (10)	405 ± 135 (10)	0.00 ± 0.00 (10)	1.09 ± 0.58 (10)	5.29 ± 1.57 (10)	0.04 ± 0.06 (10)	0.01 ± 0.02 (10)	0.00 ± 0.00 (10)	0 + 1 (10)
0.0 mg/k ₃ /DAY	5.7 ± 1.7 (10)	8.49 ± 0.63 (10)	14.8 ± 0.9 (10)	40.1 ± 2.4 (10)	47 ± 1 (10)	17 7 + 0 4 (10)	37.7 ± 0.5 (10)	470 ± 139 (10)	0.00 ± 0.00 (10)	1.28 ± 0.80 (10)	4.31 ± 1.33 (10)	0.07 ± 0 08 ' 10)	0.01 ± 0.03 (10)	0.00 ± 0.00 (10)	0 + 0 (10)
HEMATOLOGY VALUES	WBC ×10'/mm'	RBC ×10*/mm	HGB g/d1	HCT %	MCV Um'	мсн ра	MCHC g/d1	PLT ×10'/mm'	Im N×10'/mm'	Ma N×10¹/mm¹	Lym ×10'/mm'	Mon ×10³/mm³	Eos ×10³/mm³	Bas ×10'/mm'	NRBC/100 wbc

* = SIGNIFICANTLY DIFFERENT FROM CONTROL GROUP

--- = NO AVAILABLE DATA

A THE STATE OF THE PROPERTY OF

Table 21

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BEC3F1 MOUSE MALE CLINICAL CHEMISTRY VALUES - TEST WEEK 14 {MEAN AND STANDARD OEVIATION (n)}

	175/100 mg/kg/DAY	136 ± 17 (11)	20 ± 4 (11)	32 ± 21 (11)	124 ± 41 (11)	5.4 ± 0.4 (11)	2.8 ± 0.2 (11)	129 ± 9 (11)	2.6 ± 0.4 (11)	1.1 ± 0.2 (11)
	35 mg/kg/DAY	126 ± 14 (11)	19 ± 4 (11)	36 ± 23 (11)	110 ± 22 (11)	5.8 ± 0.5 (11)	3.0 ± 0.2 (11)	131 + 19 (11)	2.9 ± 0.4 (11)	1.0 ± 0.1 (11)
MEAN AND STANDARD DEVIALION (11)	7 mg/kg/DAY	132 ± 13 (9)	16 + 3 (9)	54 ± 48 (9)	98 ± 24 (9)	5.5 ± 0.4 (-9)	29+03(9)	124 ± 13 (9)	2.7 ± 0.3 (9)	$1.1 \pm 0.2 (9)$
MEAN AND	1.5 mg/kg/DAY	127 ± 16 (9)	21 ± 11 (9)	36 ± 22 (9)	122 ± 35 (9)	(t.) 4 0 ± 9 5	2.8 1 0.2 (7)	121 ± 12 (9)	2.8 ± 0.3 (9)	1.0 ± 0.1 (9)
	0.0 mg/kg/DAY	136 ± 16 (12)	17 ± 2 (12)	18 ± 21 (12)	122 ± 34 (12)	5.6 ± 0 5 (12)	2 9 ± 0.2 (12)	122 ± 15 (12)	2.8 ± 0.4 (12)	1.1 ± 0.1 (12)
	CHEMISTRY VALUES	GLU mg/d1	BUN mg/d1	SGPT 1u/1	TRIG mg/dl	T PRO 9/41	ALB 9/6.	CHOL mg/d!	GL08 g/d1	ALB/GLOB

--- = NO AVAILABLE DATA

9

(3)

(4)

Table 22

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE CLINICAL CHEMISTRY VALUES - TEST WEEK 14 [MEAN AND STANDARD DEVIATIGA (n)]

CHEMISTRY		0.0		i, c	1.5) Em	7 ma/ka/DAY		/bш	35 mq/kg/DAY		171 /gm	175/100 mg/kg/DAY	
VALUES	/bm	mg/kg/UAY	:	+ 44 +	118 + 16 (6	124 +	124 + 18 (9)	6	128 +	128 + 17 (9)	6	128 ±	9 (10)	6
GLU mg/d1	124 +	124 ± 5 (11)	<u>:</u>	·	·		1	•		1	1	6	9	*(01)	*
BUN mg/d1	4 +1	2 (11)	.	1 5 +1	2 (6	15 +1	<u>-</u>	6	+1 9	- m	6	+ I 20 20	-	
SGPT Iu/1	22	12 (11)	Ξ	+i 00	7 (6	35 +	25 ((6	27 ±	15 (6	3 1	33 (10)	ô
TR16 mg/d1	+ 66	99 + 27 (11)	Ξ	95	23 ((,	+ 26	35 (-9)	6	+1	111 + 44 (6	87 ±	25 (10)	6
T PRO 9/41	56104(11)	9 0	=	د د د	5 0	:	ه د د	561036	ê	56+ 0.3 (0.3 (6	5.4	0.4 (10)	6
1 1 2 3 C 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	· · ·	32 + 0 1 (11)	Ξ	r	 - c	;	33100	° °	ç	€ 7 +1	3 4 + 0.1 (6	3.2 +	0 2 (10)	6
CHO! ma/d!	; + 00 -	100 + 10 (11)	Ξ	110 +	110 + 011	6	15 +	15 ± 14 (9)+	÷(6	125 ±	125 ± 14 (+(6	132 ±	10 (10)*	*(0
GIOE mg/ C.	2 3 + 1	2.3 + 0.4 (11)	11)	2.5	0.4 (6	2.2 +	2.2 ± 0.1 (9)	(6	2.2 +	2.2 ± 0.3 (6	2.2 +	0.3 (10)	<u>(</u> 0
ALB/GLOB	1.4	1.4 ± 0.2 (11)	11)	1.4 ± 0.2 (9)	0.2 (6	+. 51	1.5 ± 0.1 (6	1.5 +	1.5 ± 0.2 ((6	1.4+	0.2 (10)	<u>6</u>

--- = NO AVAILABLE DATA

Table 23

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDPO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE CLINICAL CHEMISTRY VALUES - TEST WEEK 26 {MEAN AND STANDARD DEVIATION (n)}

175/100 mg/kg/DAY	137 ± 28 (11)	18 ± 3 (11)	14 ± 4 (11)	125 ± 29 (11)	5.4 ± 0.2 (11)	3.3 ± 0.2 (11)	158 ± 11 (11)*	2.2 ± 0.1 (11)	1.5 ± 0.2 (11)
35 mg/kg/DAY	151 ± 70 (10)	19 ± 3 (10)	16 ± 5 (10)	105 ± 31 (10)+	5.4 ± 0.3 (10)	3.2 ± 0.2 (10)	125 ± 19 (10)	2.1 ± 0.2 (10)	1.5 ± 0.2 (10)
7 mg/kg/DAY	145 ± 34 (10)	18 ± 2 (10)	21 ± 14 (10)	130 ± 27 (10)	5 5 + 0.3 (10)	3.2 ± 0.2 (10)	133 ± 20 (10)	2.3 ± 0.2 (10)	1.4 ± 0.1 (10)
1.5 mg/kg/DAï	185 ± 79 (10)	17 ± 2 (10)	44 ± 64 (10)	109 ± 25 (10)+	5 4 1 0 4 (10)	3 2 ± 0.2 (10)	122 ± 19 (10)	2.2 ± 0.3 (10)	1.5 ± 0.2 (10)
0.0 mg/kg/DAY	211 ± 134 (10)	17 ± 2 (10)	28 ± 15 (10)	149 + 38 (10)	5.3 ± 0.6 (10)	3.1 ± 0.4 (10)	136 ± 17 (9)	2.1 ± 0.3 (10)	1.5 ± 0.1 (10)
CHEMISTRY VALUES	GLU mg/dl	BUN mg/dl	SGPT 10/1	TRIG mg/d1	T PR0 g/d1	ALB g/d1	CHOL mg/dl	GL08 g/d1	ALB/GLOB

* = SIGNIFICANTLY DIFFERENT FROM CONTROL GROUP

- = NO AVAILABLE DATA

Ģ

9

@

٩

٩

٥

ŝ

Table 24

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINGGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINJTRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE CLINICAL CHEMISIRY VALUES - TEST WEEK 26 [MEAN AND STANDARD DEVIATION (n)]

	8)	8	8)	8)	8)	8)	8)*	8	8
175/100 mg/kg/DAY	136 ± 18 (8)	2 (8)	4 (8)	45 (8)	0.4 (8)	0.2 (8)	159 ± 30 (8)*	1.8 ± 0.2 (8)	0.2 (8)
17 //6m	136 +	16 +	15 +	125 ±	5.5	3.7 +	159 ±	+1 8: +1	2.1+
	10)	10)	(01	10)	10)	10)	10)	10)	(0)
35 mg/kg/DAY	20 (3 (10)	4 (10)	42 (0.2 (0.1 (25 (0.1 (0.1 (
W/bm	128 ± 20 (10)	+5 +1	12 +1	131 ± 42 (10)	5.5 ± 0.2 (10)	3.8 ± 0.1 (10)	139 ± 25 (10)	1.8 ± 0.1 (10)	2.1 ± 0.1 (10)
	10)	(01	to)	10)	to)	10)	10)	10)	(0
7 mg/kg/DAY	25 (3 (10)	2 (10)	30 (10)	0.4 (0 1 (16 (0.3 (0.5 (
mg/k	139 ± 25 (10)	+i	12 +	+1 61 +	5 3 ± 0.4 (10)	3.6 ± 0 1 (10)	113 ± 16 (10)	1.6 ± 0.3 (10)	2.3 ± 0.5 (10)
	10)	(0)	(0)	10)	10)	(0)	10)	10)	10)
1.5 mg/kg/DAY	29 (3	32 (10)	20 (0.3 (0.1 (23 (0.2 (0.2 (
mg/k	137 ± 29 (10)	14 ± 3 (10)	22 4	114 ± 20 (10)	5.4 ± 0.3 (10)	3.7 ± 0.1 (10)	117 ± 23 (10)	1.7 ± 0.2 (10)	2.1 ± 0.2 (10)
	(01	10)	6	10)	6)	(6	6	(6	(6
0.0 mg/kg/DAY	80 (ິນ	21 (42 (0.2 (0.1 (21 (0.1 (0.2 (
0 A/gm	148 ± 80 (10)	17 ± 5 (10)	18 ± 21 (9)	131 ± 42 (10)	5.5 ± 0.2 (9)	3.7 ± 0.1 (9)	115 ± 21 (9)	1.8 ± 0.1 (9)	2.1 ± 0.2 (9)
CHEMISTRY VALUES	GLU mg/d1	BUN mg/d1	SGPT IU/1	TRIG mg/dl	T PR0 g/d1	ALB 9/41	CHDL mg/d1	GL08 g/d1	ALB/GLOB

- = NO AVAILABLE DATA

Table 25

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINUG-NICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE CLINICAL CHEMISTRY VALUES - TEST WEEK 53 [MEAN AND STANDARD DEVIATION (n)]

175/100 mg/kg/DAY	142 ± 27 (10)	17 ± 3 (10)	29 ± 8 (10)	134 ± 86 (10) ·	5.6 ± 0.3 (10)	3.3 ± 0.2 (10)	152 ± 31 (10)*	2.4 ± 0.2 (10)	1.4 ± 0.1 (10)
35 mg/kg/DAY	147 ± 37 (10)	16 ± 3 (10)	49 ± 34 (10)	122 ± 48 (10)	5.5 ± 0.3 (10)	3.2 ± 0.2 (10)	134 ± 14 (10)	2.4 ± 0.2 (10)	1.3 ± 0.1 (10)
7 /Ar' 24/2m	124 ± 51 (10)	16 ± 3 (10)	33 + 6 (10)	110 ± 45 (10)	5.6 ± 0.3 (10)	3.1 ± 0.2 (10)	126 ± 11 (10)	2.5 ± 0.3 (10)	1.2 ± 0.2 (10)
1.5 mg/kg/DAY	126 ± 25 (10)	16 ± 4 (10)	34 + 7 (10)	105 ± 34 ' 101	5.5 ± 0.4 (10)	3.0 ± 0.2 (10)	120 ± 19 (10)	2.5 ± 0.3 (10)	1.3 ± 0.2 (10)
0.0 mg/kg/DAY	153 ± 48 (10)	16 ± 3 (10)	36 ± 13 (10)	116 ± 30 (10)	5.5 ± 0.5 (10)	3.2 ± 0 3 (10)	129 ± 20 (10)	2.4 ± 0.4 (10)	1.4 ± 0.2 (10)
CHEMISTRY VALUES	GLU mg/dl	8UN mg/d1	SGPT Iu/1	TRIG mg/dl	T PRO g/d1	ALB g/d1	CHOL mg/d1	1p/6 8019	ALB/GLOB

--- = NO AVAILABLE DATA

(

0

0

٩

3

٩

9

Ť

Table 26

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE CLINICAL CHEMISTRY VALUES - TEST WEEK 53 [MEAN AND STANDARD DEVIATION (n)]

--- = NO AVAILABLE DATA

Table 27

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINGGENICITY STUDY OF HEXAHYDRO-1.3,5-TRINITRO-1.3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE CLINICAL CHEMISTRY VALUES - TEST WEEK 79 [MEAN AND STANDARD DEVIATION (n)]

O 점	0.0 mg/kg/DAY mg/k	1.5 mg/kg/DAY 134 + 12 (10)	7 mg/kg/DAY 137 + *5 (10)	35 mg/kg/DAY 136 + 18 (10)	175/100 mg/kg/DAY + 0 (0)
		2 (10)	17 ± 2 (10)		(0) 0 +
78 ± 120 (10) 50 ±		29 (10)	49 ± 28 (10)	61 ± 45 (10)	(0) 0 7
125 ± 34 (10) 109 ±		26 (10)	112 ± 19 (10)	135 ± 30 (10)	(0) 0 7
6.2 ± 1.3 (10) 5.9 ±		0.8 (10)	5.9 + 0.9 (10)	5.6 ± 0.9 (10)	(0) 0.0 7
3 4 ± 0.7 (10) 3.2 ±		3.2 ± 0.5 (10)	3.3 ± 0.4 (10)	3.1 ± 0.4 (10)	(0) 0.0 7
138 ± 51 (10) 122 ±		32 (10)	134 ± 39 (10)	134 ± 32 (10)	(0) 0 7
2.7 ± 0.7 (10) 2.7 ± 0.6 (0.6 (10)	2.5 ± 0.5 (10)	2.5 ± 0.6 (10)	(0) 0.0 7
1.3 ± 0.2 (10) 1.2 ± 0.3 (0.3 (10)	1.3 ± 0.1 (10)	13 ± 0.2 (10)	(0) 0.0 7

- = NO AVAILABLE DATA

(

٩

(

٩

٩

٥

٣

0

Table 28

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRINZINE(RDX) IN THE BGC3F1 MQUSE FEMALE CLINICAL CHEMISTRY VALUES - TEST WEEK 79 [MEAN AND STANDARD DEVIATION (n)]

0.0 mg/kg/DAY 123 ± 10 (10) 14 ± 2 (10)
48 +
5 4 + 0 2 (-0)
34+0165
114 ± 16 (10)
2.0 ± 0.2 (10)
18 ± (.2 (10)

--- = NO AVAILABLE DATA

intercom excessors and and an experience of the company of the com

Table 29

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3,5-TRINITRO-1.3,5-TRIAZINE(RDX) IN THE BEC3F1 MOUSE MALE CLINICAL CHEMISTRY VALUES - TEST WEEK 105 [MEAN AND STANDARD DEVIATION (n)]

CHEMISTRY VALUES	1/6ш	0.0 mg/kg/DAY		1 5 mg/kc/DAY	1 5 /ks/DAY		1/6W	7 mg/kg/DAY		/bw	35 mg/kg/DAY		T mg/	175/100 mg/kg/DAY	>	1
G10 mg/d1	139 ± 48 (10)	18 (10)	125 ± 26 (10)	36 (10)	123 ±	123 ± 26 (10)	6	130 ±	130 ± 26 (10)	10)	135 ±	135 ± 36 (10)	(0)	_
BUN mg/d1	19 +1		5 (10)	24 +	24 ± 12 (10)	10)	21 +	4 (10)	(0	18 +1	3 (10)	10)	22 +		6 (10)	_
SGPT IU/1	31 +	20 (10)	10)	25 +	8 (10)	10)	48 +	76 (10)	6	20	82 (10)	10)	52 +		76 (10)	_
TRIG mg/d1	161 ± 151 (10)	151 (10)	195 ± 238 (10)	338 (10)	128 ±	58 (10)	6	177 ± 121 (10)	121	10)	120 ±		26 (10)	
T PRO 9/d1	6.1 ± 08 (10)	08(10)	5.7 ± 0.3 (10)	0.3 (10)	+1 0.9	6.0 ± 0.8 (10)	6	5.9 ± 0.6 (10)	0.6	10)	6.4 +	1.2	1.2 (10)	_
ALB 9/d1	3.4 ± 0.4 (10)	0.4	10)	3.1 ± 0 4 (10)	0 4	(0)	3.4	3.4 ± 0.3 (10)	(0	3.4 ± 0.3 (10)	0.3 (10)	3.7 ±	0.5	0.5 (10)	_
CHOL mg/d1	127 ± 39 (10)	39 (10)	141 ± 60 (10)) 09	10)	113 +	113 ± 34 (10)	6	133 ± 31 (10)	31 (to)	176 ±	176 ± 116 (10)	(01)	_
GLOB g/d1	2.7 ± 0.5 (10)	0.5 (10)	2.6 ± 0.2 (10)	0.2 (60	2.6 ±	2.6 ± 0.5 (10)	6	2.6 ± 0.5 (10)	0.5 (10)	2.7 ±	2.7 ± 0.7 (10)	(01)	_
ALB/GLOB	1.3 2 0.2 (10)	0.2 (10)	1.2 ± 0.2 (10)	0.2 (10)	+1 6	1.3 ± 0.2 (10)	6	t.3 ± 0.3 (10)	0.3 (10)	4.4	1.4 ± 0.2 (10)	(0)	_

= NO AVAILABLE DATA

4

()

Table 30

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE CLINICAL CHEMISTRY VALUES - TEST WEEK 105 [MEAN AND STANDARD DEVIATION (n)]

	10	(0)	10)	(0 1	10)	10)	10)	10	10)
175/100 mg/kg/DAY	17 (4 (10)	19 (10)	74 (10)	1.3 (10)	0.5 () 9/	0.8 (0.2 (
175 mg/k	126 ± 17 (10)	£ +1	33 +	149 +	+1 6.9	3.9 ± 0.5 (10)	153 ± 76 (10)	2.4 ± 0.8 (10)	1.7 ± 0.2 (10)
5 /DAY	13 (10)	17 ± 3 (10)	25 ± 5 (10)	40 (10)	.4 (10)	.2 (10)	37 (10)	.3 (10)	.2 (10)
35 mg/kg/DAY	131 ± 13 (10)	17 ±	25 ±	164 ± 40 (10)	6.0 ± 0.4 (10)	3.8 ± 0.2 (10)	139 ± 37 (10)	2.1 ± 0.3 (10)	1.8 ± 0.2 (10)
	10)	10)	to)	10)	10)	10)	10)	to)	10)
7 g/DAY	21 () 6	17 (51 (1.1 (0.7 () 99	0.5 (0.3 (
7 mg/kg/DAY	117 ± 21 (10)	20 ± 9 (10)	28 ± 17 (10)	149 ± 51 (10)	5.5 ± 1.1 (10)	3.5 ± 0.7 (10)	128 ± 66 (10)	2.0 ± 0.5 (10)	1.7 ± 0.3 (10)
>	(01)	(01)	(01)	(01)	(01)	(01)	(01)	(01)	(01)
1.5 kg/DA	24	17 ± 2 (10)	27 ± 8 (10)	54	0.5	0.3	56	0.3	0.5
1.5 mg/kg/DAY	125 ± 24 (10)	£ 21	27 ±	155 ± 54 (10)	5.9 ± 0.5 (10)	3.8 ± 0.3 (10)	118 ± 26 (10)	2.1 ± 0.3 (10)	1.8 ± 0.2 (10)
!		10)	10)	10)	10)	10)	10)	10)	10)
0.0 mg/kg/DAY	25 (3 (10)	9 (10)	40 (10)	0.3 (0.3 (30	0.3 (0.3 (
D mg/k	130 ± 20 (10)	17 +	25 +	116 +	5.9 ± 0.3 (10)	3.8 ± 0.3 (10)	111 ± 30 (10)	2.1 ± 0.3 (10)	1.8 ± 0.3 (10)
CHEMISTRY VALUES	GLU mg/d1	BUN mg/d1	SGPT Iu/1	TRIG mg/d1	T PRO 9/41	ALB g/d1	CHOL mg/d1	CL08 9/d1	ALB/GLOB

- = NO AVAILABLE DATA

TABLE 31

TWENTY-FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5,-TRIZINE IN THE B6C3F1 HYBRID MOUSE

andra kanala kanala

INCIDENCES OF CATARACTS

DOGE			TEST W	EEK	
DOSE (mg/kg/day)	SEX	<u>25</u>	<u>51</u>	<u>78</u>	103
0.0	M	0/84	2/73	2/58	4/49
	F	0/85	0/75	0/63	3/51
1.5	M	0/83	2/71	3/57	7/42
	F	0/85	2/73	1/60	2/46
7.0	M	0/84	0/72	0/58	0/41
	F	1/85	1/74	0/64	9/55
35.0	M	0/84	1/70	1/54	3/38
	F	1/85	0/74	0/61	0/46
175/100	M	1/54	1/38	2/25	6/20*
	F	0/49	0/41	0/30	1/26

^{*} Significantly diferent from the appropriate control group, $p\!<\!0.05$

TABLE 31 A

TWENTY-FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY ()F HEXAHYDRO-1,3,5-TRINITRO-1,3,5,-TRIZINE IN THE B6C3F1 HYBRID MOUSE

DOSE			TEST W	EEK	
(mg/kg/day)	SEX	25	<u>51</u>	<u>78</u>	103
0.0	M	0/5.4	0/71	0/56	2/47
	F	0/3%	0/75	0/63	2/50
1.5	M	0/83	0/69	0/54	2/41
	F	0/85	0/71	0/59	1/37
7.0	M	0/84	0/72	0/58	0/4 <u>1</u>
	F	0/84	0/73	0/64	6/52
35.0	M	0/84	0/69	0/53	2/37
	F	0/84	0/74	0/61	0/46
175/100	M	0/53	0/37	0/23	2/16
	F	0/49	0/41	0/30	1/26

^{*}Animals with cataract where the eye was used for blood collection were eliminated from the statistical analysis

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BEG3F1 MOUSE MALE MEAN RELATIVE ORGAN WEIGHTS - TEST WEEK 26 [(g ORGAN WT / g BOD' WT) x 100] [MEAN AND STANDARD D[" ion (n)]

	0.0	1.5	7	35	175/100
ORGANS	mg/kg/ŋAY	mg/kg/DAY	mg/ kg/ DA I	120/64/6::	20/20/20
BRAIN	1.33 ± 0.06 (10)	1.35 ± 0.07 (10)	$1.37 \pm 0.11 (10)$	1.41 ± 0.10 (10)	1.38 ± 0.07 (10)
HEART	0 57 ± 0.05 (10)	0.56 ± 0.04 (10)	0.56 ± 0.05 (10)	₹ 58 ± 0.06 (10)	0.57 ± 0.06 (10)
KIDNEYS	1,85 ± 0,18 (10)	1.90 ± 0.24 (10)	1.89 ± 0.20 (10)	1.83 ± 0.09 (10)	2.04 ± 0.13 (10)*
LIVER	5.57 ± 0.51 (10)	5.50 ± 0.41 (10)	5.50 ± 0.51 (10)	5.37 ± 0.62 (10)	6.24 ± 0.51 (10)*
SPLEEN	0 30 ± 0.02 (10)	0.33 ± 0.04 (10)	0.39 ± 0 12 (10)+	0.32 ± 0.03 (10)	0.30 ± 0.04 (10)
GONALS	0 10 ± 0.03 (10)	0 71 ± 9 03 (10)	0.71 ± 0.06 (10)	0 72 ± 0.04 (10)	0.71 ± 0.03 (10)

= NO AVAILABLE DATA

@

@

(

0

4

٥

٩

Ĝ

*

Ī

Table 33

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE MEAN RELATIVE ORGAN WEIGHTS - TEST WEEK 26 [(g ORGAN WT / g BODY WT) X 100] [MEAN AND STANDARD DEVIATION (n)]

175/100 mg/kg/DAY	1.75 ± 0.17 (10)	0.53 ± 0.08 (10)	1.47 ± 0.13 (10)	5.97 ± 0.63 (10)*	0.34 ± 0.04 (10)	(0) 00.00 +
35 mg/kg/DAY	1.68 ± 0.12 (10)	0.51 ± 0.05 (10)	1.38 ± 0.11 (10)	5.65 ± 0.53 (10)	0.37 ± 0.07 (10)	(0) 00.00 7
7 mg/kg/0AY	1.55 ± 0.19 (10)	0.47 ± 0.07 (10)	1.23 ± 0.10 (10)*	4 98 ± 0 44 (10)	0 32 + 0 05 (10)	(0) 00.0 +
1.5 mg/kg/DAY	1.65 ± 0.15 (10)	0.49 ± 0.05 (10)	1 39 ± 0.08 (10)	5.36 ± 0 54 (10)	0 34 ± 0 05 (10)	(0) 00'0 7
0.0 mg/kg/DAY	1.59 ± 0.25 (10)	0.51 ± 0 07 (10)	1.48 + ^ 33 (10)	5 40 ± 0 68 (10)	0 34 ± 0.06 (10)	0.70 ± 0 06 (2)
ORGANS	6R4IN	HEART	KIDNEYS	LIVER	SPLEEN	GONADS

--- = NO AVAILABLE DATA

Table 34

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE MEAN Relative organ Weights - Test Week 53 [(g organ Wt / g body Wt) x 100] [(g organ Wt / g body Wt) x 100] [MEAN AND STANDARD DEVIATION (i)]

ORGANS	0.0 mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
BRAIN	1.27 ± 0.12 (10)	1.31 ± 0.10 (10)	1.32 ± 0.10 (10)	1.31 ± 0.11 (10)	1.28 ± 0.14 (10)
HEART	0.54 ± 0.05 (10)	0 56 ± 0.06 (10)	0.56 ± 0.04 (10)	0.54 ± 0.02 (10)	0.56 ± 0.06 (10)
KIDNEYS	1.88 ± 0.25 (10)	1.88 ± 0.14 (10)	1.84 ± 0.20 (10)	1.92 ± 0.16 (10)	2.17 ± 0.19 (10)*
LIVER	5.05 ± 0.32 (10)	5.20 ± 0.39 (10)	5.26 ± 0.35 (10)	5.35 ± 0.38 (10)	5.85 ± 0.49 (10)*
SPLEEN	0.30 ± 0.08 (10)	0.30 ± 0.05 (10)	6.32 ± 0.13 (10)	0.26 ± 0.04 (10)	0.27 ± 0.05 (10)
GONADS	0.62 ± 0 05 (10)	0.65 ± 0.04 (10)	0.63 ± 0.08 (10)	0.62 ± 0.04 (10)	0.61 ± 0.10 (10)

--- = NO AVAILABLE DATA

Table 35

rest direction of transfer of the second of

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYURO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE MEAN RELATIVE ORGAN WEIGHTS - TEST WEEK 53 [(g ORGAN WT / g BODY WT) X 100] [MEAN AND STANDARD DEVIATION (n)]

	0.0	1.5	•	35	175/100
ORGANS	mg/kg/DAY	mg/kg/DAY	mg, : g/DAY	mg/kg/DAY	mg/kg/DAY
BRAIN	1.39 ± 0.18 (10)	1.34 ± 0.12 (10)	1.30 ± 0.21 (10)	1.30 ± 0.11 (10)	1.37 ± 0.22 (10)
HEART	0 41 ± 0.03 (10)	0.39 ± 0.04 (10)	0.40 ± 0.06 (10)	0.41 ± 0.03 (10)	0.43 ± 0.05 (10)
KIDNEYS	1.24 ± 0.10 (10)	1.18 ± 0.11 (10)	1.24 ± 0.18 (10)	1.23 ± 0.08 (10)	1.33 ± 0.16 (10)
LIVER	4.52 ± 0.45 (10)	4.33 ± 0.21 (10)	4.53 ± 0.42 (10)	4.95 ± 0.40 (10)*	5.64 ± 0.52 (10)*
SPLEEN	0.30 ± 0.06 (10)	0.28 ± 0.07 (10)	0.29 ± 0.06 (10)	0.32 ± 0.08 (10)	0.29 ± 0.05 (10)
GONADS	(0) 00.0 +	(0) 00.0 7	(0) 00.00 +	(0) 00.0 +	(0) 00.0 7

= SIGNIFICANTLY DIFFERENT FROM CONTROL GROUP

= NO AVAILABLE DATA

Table 36

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE MEAN RELATIVE ORGAN WEIGHTS - TEST WEEK 105 [(g ORGAN WT / g BODY WT) X 100] [MEAN AND STANDARD DEVIATION (n)]

ORGANS	0.0 mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
BRAIN	1.35 ± 0.14 (44)	1.40 ± 0.15 (41)	1.38 ± 0.15 (40)	1.38 ± 0.13 (36)	1 42 ± 0.12 (21)
HEART	0.60 ± 0.11 (44)	0.64 ± 0.12 (41)	0.63 ± 0.09 (40)	0.63 ± 0.08 (36)	0.68 ± 0.13 (21)*
KIDNEYS	1.91 ± 0.22 (44)	1.96 ± 0.21 (41)	2.02 ± 0.24 (40)	2.12 ± 0.20 (36)*	2.42 ± 0.26 (21)*
LIVER	5.91 ± 1.29 (44)	7.82 ± 4.29 (41)+	6.64 ± 1.95 (40)	$6.72 \pm 1.93 (36)$	8.64 ± 4.45 (21)*
SPLEEN	0.47 ± 0.38 (44)	0.59 ± 0 47 (41)	0.62 ± 0.51 (40)	0.42 ± 0.25 (36)	0.37 ± 0.22 (21)
GONADS	0.57 ± 0.05 (44)	0 22 7 (08 (40)	0.58 ± 0.06 (40)	0 56 ± 0.10 (36)	0.56 ± 0.08 (21)

--- = NO AVAILABLE DATA

(B)

(3)

(2)

٧

Table 37

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAL:YDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BEG3F1 MOUSE FEMALE MEAN RELATIVE ORGAN WEIGHTS - TEST WEEK 105 [(g ORGAN WT / g BODY WT) x 100] [MEAN AND STANDARD DEVIATION (n)]

175/100 mg/kg/DAY		1.58 ± 0.23 (25)*			7.83 ± 3.57 (25)*		()) 00.00 =
35 mg/kg/DAY		1.30 ± 0.18 (43)	$0.49 \pm 0.09 (43)$	1.37 ± 0.17 (43)	6.36 ± 2.47 (43)	0.62 ± 0.32 (43)	(0) 00.0 +
7 mg/kg/DAY	and the same of th	1.32 ± 0.22 (49)	$0.50 \pm 0.11 (49)$	1.35 ± 0.28 (48)	5.81 + 1.95 (49)	0.86 ± 0.83 (49)	(0) 00.0 =
1.5 mg/kg/DAY		1.29 ± 0.19 (44)	0.47 ± 0.11 (44)	1.36 ± 0.27 (44)	5.72 ± 2.48 (44)	0.78 ± 0.69 (44)	(0) 00.00 +
0.0	1 NO /24 /5III	1.34 ± 0.19 (48)	$0.47 \pm 0.07 (48)$	1,34 ± 0,19 (48)	5.39 ± 1.17 (48)	0.75 ± 0.62 (48)	(0) 00.0 7
4000	ORGANS	BRAIN	HEART	KIDNEYS	LIVER	SPLEEN	GONADS

--- = NO AVAILABLE DATA

87

Table 38

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE MEAN ORGAN WEIGHTS (g) - TEST WEEK 26 [MEAN AND STANCARD DEVIATION (n)]

ORGANS	0.0 mg/kg/DAY	1.5 mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/CAY	175/100 mg/kg/DAY
BODY WT.	L V	34.2 ± 1.7 (10)	34.6 ± 2.3 (40)	32.8 ± 2.2 (10)*	34.6 ± 1.2 (12)
BRAIN	0.47 ± 0.02 (10)	0.46 ± 0.01 (10)	0.47 ± 0.03 (10)	0.46 _ 0.01 (10)	$0.47 \pm 0.02 (12)$
HEART	0.20 ± 0 02 (10)	0 19 ± 0.02 (10)	0.19 ± 0.02 (10)	0.19 ± 0.03 (10)	0.20 ± 0.02 (12)
KIDNEYS	0.65 ± 0 08 (10)	0 65 ± 0 09 (10)	0 66 ± 0 08 (10)	0 60 ± 0.06 (10)	0.71 ± 0.05 (12)
LIVER	1.96 ± 0.24 (10)	1 88 ± 0 20 (10)	1 90 + 0 20 (10)	1.77 ± 0.28 (10)	2.17 ± 0.17 (12)
SPLEEN	0.11 ± 0.01 (10)	0.11 ± 0.01 (10)	0.13 ± 0 04 (10)+	0.11 ± 0.01 (10)	0.10 ± 0.01 (12)
GUNADS	0.25 ± 0.01 (10)	0.24 ± 0.01 (10)	0 25 ± 0.02 (10)	0.23 ± 0.02 (10)	0.25 ± 0.01 (12)

--- = NO AVAILABLE DATA

(3)

(

٨

٩

٥

9

٨

ANTERIOR METALLICIA CONTROL CO

O

Table 39

TWENTY FOUR MINTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE FEMALE MEAN ORGAN WEIGHTS (9) - TEST WEEK 26 [MEAN AND STANDARD DEVIATION (n)]

29.7 ± 3.8 (10) 29.7 ± 1.7 (10) 0.48 ± 0.02 (10) 0.15 ± 0.01 (10)
0 37 + 0 03 (10)+
01 0 + 0 01 (10)

-- = NO AVAILABLE DATA

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3.5-TRINITRO-1,3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE MALE MEAN ORGAN WEIGHTS (g) - TEST WEEK 53 [MEAN AND STANDARD DEVIATION (r)]

		MEAN AND	MEAN AND STANDAND OUT THE STANDAND		
			7	35	175/100
	0.0	ð. .	> 4 G/ ~ 1/ ** **	mg/kg/DAY	mg,'kg/DAY
8 6 1	\\U\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	mg/kg/DAY	mg/kg/na	the same and the s	
CIRGANS	763 /60			(01) 0 0 . 0 20	37.0 + 3.6 (10)
1	(01) 9 6 4 9 66	36.8 + 35 (10)	36 5 ± 2.2 (10)	37.8 2 2 3.75	1
BODY WI	(S) - O - O - O - O - O - O - O - O - O -	1		0, 102, 40, 015, (-10)	0.169 +0 024 (10)*
	(01) 010 01 387 0	0 479 +0 015 (10)	0 479 ±0.016 (10)	2000 07 27 10	
BRAIN	20.01	I	(0)) 0:0 0	(01) 910 01 000 0	0 206 +0.019 (10)
	01 0 200 01 800 0	0 208 +0 035 (10)	0.203 ±0.017 (10)		
H AK			(0) 7 700 0: 120	0 725 +0.068 (10)	0.805 ±0.120 (10)
U. A. L. A.	0 721 +0 087 (10)	0 695 40 108 (10)	0.671 40.064 (10)		
KIONETS			(01) 001	2 018 +0 175 (10)	2.168 ±0.331 (10)
	1 030 +0 186 (10)	1,918 40 270 (10)	1.916 (0.13% (10)	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	ı
L1VE K	200 01 000 -	•		(0)) (10 0) 000 0	0.097 +0.018 (10)
,	(0) / 200 0: 1:: 0	0 110 +0 023 (10)	0 116 10.041 (10)	0.038 10.01	
SPLEEN	0 115 10.021 0			(01) 610 0: 100 0	0, 221 +0.020 (10)
	(01) 210 01 966 0	0 237 +0 019 (10)	0 230 70 050 (10)	0.744 10.014 10.0	1
SOVNOS					

--- - NO AVAILABLE DATA

0

4

9

٩

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYORO-1.3.5-TRINJTRO-1.3.5-TRIAZINE(RDX) IN THE BEC3F1 MOUSE FEMALE MEAN ORGAN WEIGHTS (g) - TEST WEEK 53 [MEAN AND STANDARD DEVIATION (n)]

175/100 mg/kg/D4V		36.6 ± 5.3 (10)	0.490 ±0.012 (10)	0.155 ±0.014 (10)	0.182 ±0.060 (10)	2.048 ±0.215 (10)*	0.105 ±0.016 (10)	(0) 000.07
35	ma/ka/out	38.6 ± 3.7 (10)	0,498 ±0 025 (10)	0.157 ±0 009 (10)	0.474 ±0.054 (10)	1 907 ±0.205 (10)*	0 121 ±0 026 (10)	(0) 000 07
7	mg/kg/DAT	38.5 ± 4.6 (10)	0 493 ±0 016 (10)	0.154 ±0.014 (10)	0.472 ±0.048 (10)	1,731 ±0 165 (10)	0.109 ±0.020 (10)	(0) 000.0+
±.5	mg/kg/DAY	36.2 ± 4.1 (10)	0.482 ±0.018 (10)+	0 142 ±0.014 (10)	0.127 ±0.060 (10)	1.575 ±0.251 (10)	0.102 ±0.022 (10)	(0) 000'07
0	mg/kg/DAY	36 6 ± 4,1 (10)	0.502 ±0.023 (10)	0 150 +0 013 (10)	0.451 +0 044 (10)	1.650 ±0.216 (10)	0 111 +0.030 (10)	(0) 000 07
	ORGANS	BODY WT.	BRAIN	HEART	KIDNEYS	LIVER	SPLEEN	CONADS

- SIGNIFICANTLY DIFFERENT FROM CONTROL GROUP

--- = NO AVAILABLE DATA

Table 42

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXALIYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE REC3F1 MOUSE MALE MEAN GRGAN WEIGHTS (g) - TEST W'EK 105 [MEAN AND STANDARD DEVIATION (n)]

ORGANS	O.O mg/kg/DAY	1 5 Mg/kg/DAY	7 mg/kg/DAY	35 mg/kg/DAY	175/100 mg/kg/DAY
800Y WI	36 8 ± 2.7 (44)	35 6 ± 3.4 (41)	36.3 ± 3.7 (40)	36.3 ± 2.9 (36)	34.7 ± 3.2 (21)*
BPAIN	0.495 ±0.028 (44)	0 494 ±0 029 (41)	0 498 +0 030 (40)	0.499 ±0.032 (36)	0 490 ±0.022 (21)
HEART	0 218 ±0.033 (44)	0 227 ±0.031 (41)	0,227 ±0 030 (40)	0.228 ±0.028 (36)	0.234 ±0.035 (21)+
KIDNEYS	0 703 ±0 094 (44)	0 677 ±0 086 (41)	0 131 +0 081 (40)	0 768 ±0 084 (36)	0 840 ±0.124 (21)+
LIVER	2.169 ±0.463 (44)	2 774 ±1 567 (41)+	2, 101 10 670 (10)	2 421 ±0.614 (36)	2.923 ±1 256 (21)
SPLEEN	0, 173 ±0, 139 (44)	0 215 ±0 186 (41)	0,227 ±0 195 (40)	0 155 ±0 107 (36)	0 125 ±0 073 (21)
GONADS	0 208 10 014 (34)	0 195 ±0 028 (40)	0.208 ±0.020 (40)	0 204 ±0 034 (36)	0.196 (0.031 (21)

--- = NO AVAILABLE DATA

9

٩

٩

٥

ø

Table 43

this extense. The entry west and the secretary was to extense and the entry to be a second as attended to the

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINF(RDX) IN THE RGG3F1 MOUSE FEMALF MEAN ORGAN WEIGHTS (g) - TEST WEEK 105 (MEAN AND STANDARD DEVIATION (n)]

= SICHIFICANTLY DIFFERENT FROM CONTROL GROUP

-- = NO AVAILABLE DATA

TABLE 44

TWENTY-FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE IN THE MALE B6C3F1 NOUSE

Statistical Evaluation of Histopathologic Lesions

Dose (mg/kg/day)	0.0	1.5	7.0	35.0	175/100
SKIN ^b , Chronic De	rmatitis 26/63 41.3%)	21/23***	25/26***		16/27 (59.2%)
SKIN ^b , Ulcer		5/23* (21.7%)			
LUNG, Alveolar/Br	3/63	Carcinoma 6/60 (10.0%)	3/62 (4.8%)	7/59 (11.9%)	5/27 (18.5%)
LUNG, Alveolar/Br	6/63	Adenoma 5/60 (8.3%)			
LUNG, Alveolar/Br	9/63	Carcinoma 11/60 (18.3%)	8/62	14/59	6/27
LUNG, Histiocytos	2/63	1/60 (1.7%)	0/62 (0%)	2/59 (3.4%)	3/27 (11.1%)
KIDNEY, Malignant	1/63	2/60 (3.3%)			

^aStatistical analyses were conducted on the combined data collected from animals which either spontaneously died or were sacrificed in a moribund state following the 12 month sacrifice and from animals at the 24 month scheduled sacrifice.

bSkin and eyes were microscopically examined for animals at the 1.5, 7.0 and 35.0 mg/kg/day dose level only when a gross lesion was noted at necropsy.

⁼ Significantly different from the control group, p < 0.05. = Significantly different from the control group, p < 0.01.

^{*** =} Significantly different from the control group, p < 0.001.

TABLE 44 (conta)

TWENTY-FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1, 5, 5-TRINITRO-1, 3, 5-TRIAZINE IN THE MALE B6C3F1 MOUSE

Statistical Evaluation of Histopathologic Lesions^a

Dose (mg/kg/day)	0.0	1.5	7.0	35.0	175/100
EYE ^b , Subcapsular	Cataract 4/63 (6.3%)	0/1	0/0	1/1	3/27 (11.1%)
LIVER, Malignant	0/63	1/60 (1.7%)	4/62 (6.4%)	5/59 (8.5%)	0/27 (0%)
LIVER, Hepatocell	ular Carc	inoma	16.60	10 (50	e 10.7
·	13/63	20/60 (33.3%)	(25.8%)	18/59 (30.5%)	(22.2%)
LIVER, Hepatocell	ular Adend	oma	1 (60)	7 (50	7 (07
(8/63 (12.7%)	(10.0%)	1/62** (1.6%)	(11.9%)	(25.9%)
LIVER, Hepatocell					12/27
(21/63 (33.3%)	(43.3%)	(27.4%)	(42.4%)	(48.1%)
SPLEEN, Lymphoid	Hyperplas:	ia			
	6/63 (9.5%)	18/60**	17/62* (27.4%)	9/59 (15.2%)	1/27 (3.7%)
TESTES, Degenerat					
	0,′€3 (0%)	2/60 (3.3%)	2/62 (3.2%)	6/59 (10.2%)	3/27 (11.1%)

^aStatistical analyses were conducted on the combined data collected from animals which either spontaneously died or were sacrificed in a moribund state following the 12 month sacrifice and from animals at the 24 month scheduled sacrifice.

bSkin and eyes were microscopically examined for animals at the 1.5, 7.0 and 35.0 mg/kg/day dose level only when a gross lesion was noted at necropsy.

- = Significantly different from the control group, p < 0.05
- = Significantly different from the control group, p < 0.01
 * = Significantly different from the control group, p < 0.001</pre>

TABLE 45

TWENTY-FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5 TRINITRO-1,3,5-TRIAZINE IN THE FEMALE B6C3F1 MOUSE

Statistical Evaluation of Histopathologic Lesions^a

DOSE (mg/kg/day):	0.0	1.5	7.0	35.0	175/100
LUNG, Alveolar/B	3/65	Carcinoma 1/62 (1.6%)	3/64 (4.7%)	3/64 (4.7%)	4/31 (12.9%)
LUNG, Alveolar/B	4/65	Adenoma 2/62 (3.2%)	5/64 (7.8%)	9/64 (14.1%)	3/31 (9.7%)
LUNG, Alveolar/B	7/65	Carcinoma 3/62 (4.8%)	8/64	12/64	7/31
LUNG, Histocytos	1/65	1/62 (1.6%)	3/64 (4.7%)	3/64 (4.7%)	9/31** (29.0%)
LIVER, Hepatocel	0/65	rcinoma 4/62 (9.7%)	3/64 (4.7%)	6/64 (9.4%)	3/31 (9.7%)
LIVER, Hepatocell	1/65	enoma 1/62 (1.6%)	6/64 (9.4%)	6/64 (9.4%)	3/31 (9.7%)
LIVER, Hepatocel	1/65	rcinoma and 5/62 (8.1%)	9/64*	12/64*	6/31*

Statistical analyses were conducted on the combined data collected from animals which either spontaneously died or were sacrificed in a moribund state following the 12 month sacrifice and from arimals at the 24 month scheduled sacrifice.

^{* =} Significantly different from control group, p < 0.05

^{** =} Significantly different from the control group, p < 0.01

TABLE 46

TWENTY-FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5 TRINITRO-1,3,5-TRIAZINE IN THE FEMALE B6C3F1 MOUSE

Statistical Evaluation of Histopathologic Lesions a
Versus Historical Controls

DOSE (1	ng/kg/day):	0.0	1.5	7.0	35.0	175/100	Historical Controls b
LIVER,	Hepatocellu	lar Ca	rcinoma				
•				3/64	6/64	3/31	101/2469
		(0%)	4/62 (6.4%)	(4.7%)	(9.4%)	(9.7%)	(4.1%)
LIVER,	Hepatocellu	lar Ad	enoma	a	نہ		
	-	1/65	1/62	6/64 ^u	6/64 ^u	3/31	98/2469
	(1.5%)	1/62 (1.6%)	(9.4%)	(9.4%)	(9.7%)	(4.0%)
LIVER,	Hepatocellu	lar Ca	rcinoma ar	nd Adenoma	(Combine	ed) .	
·	Hepatocellu	1/65	5/62	9/64 ^c	12/64 ^{c,c}	6/31 ^c ,d	199/2469
	(1.5%)	(8.1%)	(14.1%)	(18.8%)	(19.4%)	(7.9%)

^aStatistical analyses were conducted on the combined data collected from animals which either spontaneously died or were sacrificed in a moribund state following the 12 month sacrifice and from animals at the 24 month scheduled sacrifice.

b NTP Technical Bulletin No. 10.

 $^{^{\}rm c}$ Significantly different from control group, p < 0.05

 $^{^{\}rm d}$ Significantly different from historical control, p < 0.05

FIGURES

Figure 1

Hexahydro-1,3,5-tr	,3,5-trinitro-1,3,5-triazine (RDX) in The B6C3F Survival Curves for Control and High Dose Males	Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) in The B6C3F1 :lybrid Mouse Survival Curves for Control and High Dose Males
CUMULATIVE PROPORTION SURVIVING	C = CONTROL	T = HIGH DOSE (175/100 радку/day)
.********	,,,,,,,,,,,,,,,	·
17		00000000000000000000000000000000000000
- +- +- +- - · · ·		
7500 + T		ວ ວນວນ
11111 1 1 1 .6250 + 11		
TT	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	
. 5000		1111111
3750 +		
.2500 +		•
. 1250 +		• {
00.00		•
6.0 18. 30. 0.0 12. 24.	36. 48. 54. 60.	

Survival Time (Weeks)

(

Figure 2


Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) in The B6C3F1 Hybrid Mouse Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Survival Curves For Control and High Dose Females

	000 +1171666	· . * · · · · * · · · · * · · · · * · · · · * ·	*******************************	
175 • 177 • 0000000000000000000000000000000	⊬ ⊢ ⊢ i	0000000000000000000000000000	יככככככ יייי	***************************************
1750 • 17 1711 • CCCCCCCC 1711 • CCCCCCCC 1711 • CCCCCCCC 1711 • CCCCCCCCC 1711 • CCCCCCCCCC 1711 • CCCCCCCCCCCC 1710 • CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	- i		ວວວວວວວວ ວວວວວວວວວ	້ວວວວ:
1750 • 1	<u>_</u>			0000 0000
150	3750 + T			ວັດວວ
11	- j-			ວ້ວວວວ
5250 • 17	111	 }		ລນລວລວລ
5250 • TITITITE THE TITITITE TH	7500 +	7. *		ວັວວວ
.5000 •		· 		ຸວ
+				
	5250 +	1111111111		
			. * * * * * * * * * * * * * * * * * * *	
			TTTTT	
	. +			
				TTTTT
				-
• • • • • • • • • • • • • • • • • • • •				
. 1250 +	3750 +			
	• •			
• • • • • • • • • • • • •				
	\$ 0057			
• • • • • •	•			
	1250 ÷			
•				
	+ 000			


Survival Time (Weeks)

CONTROL 0400 **Ø**0 Twenty-Four Month Chronic Toxicity/Carcinogenicity fudy of Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) is the B6C3F1 Hybrid Mouse **(E)** O∕**©** ⊲ **♦**1310 Ø Incidence of Fighting Wounds and/or Skin Lesions, for Male Hice 0 D TEST WEEKS **^** 4 Figure O 0 0 4 ∞ 4 **B**1 00 < 0 ◊ INCIDENCE × 100%

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B6C3F1 MOUSE MEAN CHOLESTEROL VALUES (MG/DL) VS TIME MALES AND FEMALES COMBINED



TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B6C3F1 MOUSE MEAN FEMALE TRIGLYCERIDE VALUES (MG/DL) VS TIME



APPENDIX I
TEST ARTICLE ANALYSIS

ANALYSES OF THE RDX TEST ARTICLE

⊗:

0

3

SCOPE

- 1.1 The procedure describes the analysis of the RDX test article for purity.
- 1.2 This method is recommended for use only by experienced analysts familiar with High Performance Liquid Chromatography (HPLC) or under close supervision of such qualified persons.

INTERFERENCES

2.1 Solvents, reagents, glassware and other sample processing hardware may yield discrete artifacts and/or elevated baselines causing misinter-pretation of chromatograms. All of these materials must be shown to be free from interferences under the conditions of the analysis by running method blanks.

EQUIPMENT

- 3.1 Higher Performance Liquid Chromatography
 - · constant flow, isocratic pumping system
 - reverse phase column, 10 μ 3.9 mm x 30 cm μ-Bondapak C₁₈ column
 - ultraviolet detector capable of monitoring $\lambda = 254$ nm
 - strip chart recorder and electronic integrator capable of measuring peak areas and performing an internal standard calculation.

REAGENTS

- 4.1 Propiopnenone, an internal standard, Aldrich Chemical Company (Purity 99%)
- 4.2 Methanol, Actronitrile, and Water, HPLC Grade or equivalent
- 4.3 RDX. Standard Army Reference Material (SARM), supplied by Sponsor, (Purity 99.8%).

CALIBRATION

5.1 Calibration standards were prepared from stock solutions containing 200 µg RDX, and propiophenone pe. ml acetonitrile so as to bracket the working range of the chromatographic system. These concentrations were: 2 µg/ml, 10 µg/ml, 20 µg/ml, and 40 µg/ml.

- 5.2 A constant injection volume of 15 μ l was employed for all measurements.
- 5.3 In order to determine the precision of the HPLC system, a series of 6 replicate injections of the 20 µg/ml solution were made.
- 5.4 Retention times should remain relatively constant (within + 5% day to day) with RDX being 3.7 minutes, and propiophenone 7.3 minutes under the specified conditions. If the retention times are not within + 5%, supervising chemist should be informed prior to the analysis and corrective action should be taken.

QUALITY CONTROL

- 6.1 Before processing any samples, the analyst should demonstrate through the analysis of a blank that all glassware and reagents are interference free.
- 6.2 In a typical sample set, a minimum of one blank and five samples will be analyzed.
- 6.3 The analyst will follow each step in an analytical protocol without deviation or improvisions in order to accurately assess the performance of the method. Prior to making any changes in the procedure, analyst will consult the supervision chemist and the supervising chemist and Q.A. officer will review and approve all the changes.

SAMPLE PREPARATION

- 7.1 The test article will be spread on a sheet of paper, and five samples will be takin from different areas. Each sample shall have a weight of ~150 mg. The samples will be collected in amber vials and stored at refrigerator temperatures in the dark until analysis.
- 7.2 A portion of the sample (100 mg) will be weighed and transferred to a 100 ml volumetric flask. The internal standard will be added and it will be diluted to volume. It will be further diluted to a concentration of 20 µg/ml and analyzed by high performance liquid chromatography.
- 7.3 If the sample is not analyzed immediately it will be stored at refrigerator temperatures in the dark

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

8.1 Each sample was analyzed by reverse phase HPLC using the conditions described below: Column, 3.9 mm x 30.0 cm μ-Bondpak C₁₈; Solvent System, methanol:water (55%:45%, v/v); Flow Rate, 1.5 ml/min; Detection, UV at 254 nm; Sensitivity, 8.1 AUFS. the retention times

- of RDX and propiophenone were 3.7 and 7.3 minutes, respectively. The limit of detection was 2 μg RDX/ml acetonitrile and is defined by 5x the background nouse. The representatibe chromatogram is Figure 1.
- 8.2 The chromatographic system was calibrated daily with a minimum of two injections of one standard representative of chromatographic range.
- . 8.3 An injection volume of 15.0 µl was used for each sample. If the peak area exceed the linear range of a sample it was diluted and reanalyzed.

CALCULATIONS

9.1 Determine the concentration fo RDX using the formula:

% RDX in Sample =
$$\frac{(Ax) \text{ (Wis) } \times D \text{ X } 100}{(Fx) \text{ Ais (Ws)}}$$

Where

Ax = Area (X) where x is RDX

Ais = Area (internal standard)

$$F_{X} = \frac{\text{Area } (x) \times \text{Weight (is)}}{\text{Area (is)} \times \text{Weight (Wx)}}$$

Wis = Weight of the internal standard

Ws = Weight of the sample

D = The dilution factor

Wx = Weight of component x is RDX

9.2 The results should be reported in percent RDX. Where replicate samples are analyzed, all data should be reported. All results were recorded in standard IITRI logbooks and these plus chromatograms and data tapes are retained in the Chemistry Division Q.A. files.

ANALYSIS OF RDX IN DIET PREMIXES

SCOPE AND APPLICATION

- 1.1 This method covers the determination of RDX in diet premixes.
 at 10% and 50% levels.
- 1.2 The sensitivity of this method is usually dependent on the level of interferences present in the samples, rather than the instrumental limitations.
- 1.3 This method is recommended for use only by experienced analysts familiar with High Performance Liquid Chromatography (HPLC) or under close supervision of such qualified persons.

SUMMARY OF THE METHOD

2.1 A weighed quantity of the premix was stirred with 50 ml of acetonitrile for 30 minutes. The suspension was filtered through a porous glass filter and the filtrate was transferred with washings to a volumetric flask. Propiophenone, the internal standard was added to the filtrate or a portion, thereof and this solution was diluted to its final volume. The samples were analyzed using reverse phase high performance liquid chromatography. Each was eluted on 3.9 mm x 30.0 cm μ -Bondapak C_{18} column with methanol:water (55%:45%) and the eluant was monitored with an ultraviolet absorption detector at λ = 254 nm.

INTERFERENCES

- 3.1 Solvents, reagents, glassware and other sample processing hardware may yield discrete artifacts and/or elevated baselines causing misinter-pretation of chromatograms. All of these materials must be shown to be free from interferences under the conditions of the analysis by running method blanks.
- 3.2 Interferences coextracted from the samples will vary considerably from source to source, depending on the type of animal feed used in the study.

MATERIALS

- 4.1 Erlenmeyer flasks, 125 ml
- 4.2 Filtering apparatus, vacuum flask, 125 ml; fritted glass filters, porosity M, ASTM 10-20 microns.

EGUIPMENT

- 5.1 Mettler Grammatic Analytical Balance, No. 1-9:0
- 5.2 Corning Hot Plate Stirrers, BC 351
- 5.3. Buchi Evaporator, Model R
- 5.4 Sample Clarification Kit, Organic (Water's Associates)
- 5.5 Higher Performance Liquid Chromatography
 - · constant flow, isocratic pumping system
 - reverse phase column, 10 μ 3.9 mm x 30 cm μ-Bondapak C₁₈ column

1

- ultraviolet detector capable of monitoring $\lambda = 254$ nm
- strip chart recorder and electronic integrator capable of measuring peak areas and performing an internal standard calculation.

REAGENTS


- 6.1 Propiophenone, an internal standard, Aldrich Chemical Company (Purity 99%)
- 6.2 Methanol, Acetonitrile, and Water, HPLC Grade or equivalent
- 6.3 RDX, S.A.R.M., supplied by the sponsor (Purity 99.8%)

CALIBRATICN

- 7.1 Calibration standards were prepared from stock solutions containing 200 µg RDX, and propiophenone per ml acetonitrile so as to bracket the working range of the chromatographic system. These concentrations were: 2 µg/ml, 10 µg/ml, 20 µg/ml, and 40 µg/ml.
- 7.2 A constant injection volume of 15 μl was employed for all measurements.
- 7.3 In order to determine the precision of the HPLC system, a series of 6 replicate injections of the 20 µg/ml solution were made.
- 7.4 Retention times should remain relatively constant (within \pm 5% day to day) with RDX being 3.7 minutes, and propiophenone 7.3 minutes under the specified conditions. If the retention times are not within \pm 5%, supervising chemist should be informed prior to the analysis and corrective action should be taken.

QUALITY CONTROL

- 8.1 Before processing any samples, the analyst should demonstrate through the analysis of a blank that all glassware and reagents are interference free. Each time a set of samples is extracted or there is a change in reagents, a method blank should be processed as a safeguard against laboratory contamination.
- 8.2 Standard quality assurance practices were used with this method. A minimum of 6 replicate spiked samples were analyzed to validate the accuracy of the method. If doubt should arise concerning the identity of the peak on a chromatogram, confirmatory techniques such as mass spectrometry should be used.
- 8.3 In a typical sample set, a minimum of one blank and scheduled samples will be analyzed. A control sample will be prepared by adding a known concentration of RDX to the sample. The concentration will be in the working range of chromatographic system as determined by calibration experiment.
- 8.4 The analyst will follow each step in an analytical protocol without deviation or improvisions in order to accurately assess the performance of the method. Prior to making any changes in the procedure, analyst will consult the supervising chemist and the supervising chemist and the Q.A. officer will review and approve all the changes.
- 8.5 The typical analysis will consist of the following samples shown in the diagram. One blank sample, 6 premix samples as is, 3 spiked samples.



SAMPLE COLLECTION

9.1 Samples are collected and stored prior to analysis according to SOP 81-sample collection (TNT & RDX Premix)

SAMPLE EXTRACTION

the second of the second deposits of the second deposits of the second o

- 10.1 The appropriate amount of sample is weighed into a 125 ml Erlenmeyer flask using standard operating procedures. The sample amount for both the 10 percent and 50 percent premix is one gram. Approximately 50 mls of acetonitrile is added to the flask and it is stoppered. The sample is extracted by stirring for 30 minutes at room temperature.
- 10.2 Following extraction, the sample was filtered through a medium porosity fritted glass filter. In this operation the extraction mixture was swirled to form a uniform suspension and immediately poured into the glass funnel. A stirring rod was used to drain the last drop of liquid from the flask.
- 10.3 The extraction flask was rinsed with three portions of acetonitrile of approximately three mils each, and the rinse is poured into the funnel. This procedure is repeated three times, then the vacuum is reapplied and the washing process is completed.
- 10.4 The filtrate is transferred via a short-stem funnel into a volumetric flask. The filtering flask is rinsed three times, with approximately 6 ml portions of acetonitrile, and the rinses are added to the volumetric flask. The size of the volumetric flask and the subsequent treatment of the sample depend on the initial RDX concentration in the sample. The dilution for sample is shown in Table 1.
- 10.5 An aliquot (approximately 10 ml) is filtered using a Water's Organic Sample Clarification Kit using 0.5 µm filter. The sample is now ready for analysis for HPLC.

STORAGE OF SAMPLES

- 11.1 All samples including premixes and blank feed will be stored in the dark at refrigerator temperatures.
- 11.2 If the sample preparation procedure is stopped at any point during the working day, the samples should be stored in stoppered vessels in the dark at refrigerator temperatures.

TABLE 1. DILUTION SCHEME FOR SAMPLE EXTRACT

Premix Concentration	10%	50%
Original Extract Volume	100 m1	500 ml
Secondary Dilution	l ml extract plus l ml I.S. to volume of 50 ml with acetonitrile	<pre>l ml extract plus l ml I.S. to volume of 50 ml with acetonitrile</pre>

- 1. I.S. solution concentration is ~ 1000 µg/ml
- 2. In the case of a sample analyzed by the method of standard addition 1 ml of the original extract was diluted with 50 ml acetonitrile, and 1 ml of the extract added to 1 ml of the spiking solution of known concentration was diluted with acetonitrile as above.
- 11.3 Samples that are ready for HPLC analysis will be stored in the dark at refrigeration temperature.
- 11.4 Similarly, RDX and promipphenone standards and all standard solutions will also be stored in the dark at refrigerator temperatures.

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

- 12.1 Each sample was analyzed by reverse phase HPLC using the conditions described below. Column, 3.9 mm x 30.0 cm μ -Bondpak C₁₈; Solvent System, methanol:water (55%:45%, v/v); Flow Rate, 1.5 ml/min; Detection, UV at 254 nm. The retention times of RDX and propiophenone were 3.7 and 7.3 minutes, respectively. The limit of detection was 2 μ g RDX/ml acetonitrile and is defined by 5x the background noise. The representative chromatogram is Figure 1.
- 12.2 The chromatographic system was calibrated daily with a minimum of two injections of one standard representative of chromatographic range.
- 12.3 An injection volume of 15.0 μ l was used for each sample. If the peak area exceed the linear range of a sample it was diluted and reanalyzed.

Best Available Copy

12.4 Following the completion of an analysis or set of analyses, a gradient going from initial solvent conditions to 100% methanol in 15 minutes will be used to elate polar compounds from the column. Elution at 100% methanol will be continued for at least 1 hour.

(

CALCULATIONS

13.1 Determine the concentration of RDX using the formula:

%RDX in Sample =
$$\frac{(Ax)(Wis) \times D \times 100}{(Fx) \text{ Ais (Ws)}}$$

Where

Ax = Area(X) where x is RDX

Ais = Area (internal standard)

 $Fx = \frac{Area(x) \times Weight(is)}{Area(is) \times Weight(Wx)}$

Wis = Weight of the internal standard

Ws = Weight of the sample

D = The dilution factor

Wx = Wt of component x is RDX.

13.2 The results should be reported in percent RDX composite. This is the RDX actually used in the toxicity study. Where replicate samples are analyzed, all data should be reported. All results are recorded in standard IITRI logbooks and these plus chromatograms and data tapes are retained in the Chemistry Division Q.A. files.

SAFETY

14.1 Safety regulations will be followed at all times especially with regard to the handling of toxic materials. When the premix samples are being handled, a lab coat, gloves and a mask will be appropriate attire. When solutions as extracts are being handled, a lab coat and gloves should be worn when there is the change of direct contact with these materials.




Figure 1. Chromatogram of RDX (1) Propiophenone (2) Standard, 20 $\mu g/m \mathcal{L}$

ANALYSIS OF RDX IN DIETS

SCOPE AND APPLICATION

- 1.1 This method covers the determination of RDX in diet samples at 0.0005% to 0.100% level.
- 1.2 The sensitivity of this method is dependent on the level of interferences present in the samples, rather than the instrumental limitations.
- 1.3 This method is recommended for use only by experienced analysis familiar with High Performance Liquid Chromatography (HPLC) or under close supervision of such qualified persons.

SUMMARY OF THE METHOD

2.1 A weighed quantity of the diet was stirred with 50 ml of acetonitrile for 30 minutes. The suspension was filtered through a porour glass filter and the filtrate was transferred with washings to a volumetric flask. Propiophenone, the internal standard was added to the filtrate or a portion, thereof and this solution was diluted to its final volume. The samples were analyzed using reverse phase high performance liquid chromatography. Each was eluted on 3.9 mm x 30.0 cm μ -Bondapak C_{18} column with methanol: water (55%:45%) and the eluant was monitored with an ultraviolet absorption detector at λ = 254 nm.

INTERFERENCES

- 3.1 Solvents, reagents, glassware and other sample processing hardware may yield discrete artifacts and/or elevated baselines causing misinter-pretation of chromatograms. All of these materials must be shown to be free from interferences under the conditions of the analysis by running method blanks.
- 3.2 Interferences coextracted from the samples will vary considerably from source to source, depending on the type of animal feed used in the study.

Ö

MATERIALS

- 4.1 Erlenmeyer flasks, 125 ml
- 4.2 Filtering apparatus, vaccum flask, 125 ml; fritted glass filters, porosity M, ASTM 10-20 microns.

EQUIPMENT

- 5.1 Mettler Grammatic Analytical Balance, No. 1-910
- 5.2 Corning Hot Plate Stirrers, BC 351
- 5.3 Buchi Evaporator, Model R
- 5.4 Sample Clarification Kit, Organic (Water's Associates)
- 5.5 Higher Performance Liquid Chromatography
 - · constant flow, isocratic pumping system
 - reverse phase column, $10 \mu 3.9 \text{ mm} \times 30 \text{ cm} \mu \text{Bondapak C}_{18} \text{ column}$
 - ultraviolet detector, capable of monitoring $\lambda = 254$ nm
 - strip chart recorder and electronic integrator capable of measuring peak areas and performing an internal standard calculation.

REAGENTS

- 6.1 Propiophenone, an internal standard, Aldrich Chemical Company (Purity 99%)
- 6.2 Methanol, Acetonitrile, Water HPLC grade or equivalent
- 6.3 RDX, S.A.R.M. Supplied by sponsor (Purity 99.8%)

CALIBRATION

- 7.1 Calibration standards were prepared from stock solutions containing 200 µg RDX, and propiophenone per ml acetonitrile so as to bracket the working range of the chromatographic system. These concentrations were: 0.5 µg/ml, 2 µg/ml, 10 µg/ml, 20 µg/ml, and 40 µg/ml.
- 7.2 A constant injection volume of 15 µl was employed for all measurements.
- 7.3 In order to determine the precision of the HPLC system, a series of 6 replicate injections of the 20 $\mu g/ml$ solution were made.
- 7.4 Retention times should remain relatively constant (within \pm 5% day to day) with RDX being 3.7 minutes, and propiophenone 7.3 minutes. If the retention times are not within \pm 5%; supervising chemist should be informed prior to the analysis and corrective action should be taken.

QUALITY CONTROL

8.1 Before processing any samples, the analyst should demonstrate through the analysis of a blank that all glassware and reagents are interference free. Each time a set of samples is extracted or there is a change in reagents, a method blank should be processed as a safeguar against laboratory contamination.

9

- 8.2 Standard quality assurance practices were used with this method. A minimum of six replicate spiked samples were analyzed to validate the accuracy of the method. If doubt should arise concerning the identity of the peak on a chromatogram, confirmatory techniques such as mass spectrometry should be used.
- 8.3 In a cypical sample set, a minimum of one blank and scheduled samples will be analyzed. A control sample will be prepared by adding a known concentration of RDX to the sample. The concentration will be in the working range of chromatographic system as determined by calibration experiment.
- 8.4 The analyst will follow each step in an analytical protocol without deviation or improvisions in order to accurately assess the performance of the method. Prior to making any changes in the procedure, analyst will consult the supervising chemist and the supervising chemist and Q.A. officer will review and approve all the changes.
- 8.5 The typical analysis will consist of the following samples, one blank sample, 6 diet samples as is, 3 feed samples spiked for the recovery determination at the diet concentration.

TABLE 1. DILUTION SCHEME FOR RDX DIET SAMPLES

Diet Level %	Extract Volume (ml)	Extract Diluted (ml)	Propiophenone (IS) Added	Final Volume (ml)
0.0005	100	-	l ml, 50 μg/ml	100
0.0050	100	-	. 1 ml, 500 μg/ml	100
0.0100	100	-	l ml, 1000 μg/ml	100
0.0500	100	10	1 mì, 500 μg/ml	25
0.1000	100	10	l ml, 1000 μg/ml	50

SAMPLE COLLECTION

9.1 Sampler are collected and stored prior to annalysis according to SOP 81-sample collection (TNT and RDX diet samples).

()

٧

SAMPLE EXTRACTION

- 10.1 The appropriate amount of sample is weighed into a 125 mi Erlenmeyer flask using standard operating procedures. The sample amount for the diet mixture is ten grams. Approximately 50 mls of acetonitrile is added to the flask and it is stoppered. The sample is extracted by stirring for only 30 minutes at room temperature.
- 10.2 Following extraction, the sample was filtered through a medium porosity fritted glass filter. In this operation the extraction mixture was swirled to form a uniform suspension and immediately poured into the glass funnel. A stirring rod was used to drain the last drop of liquid from the flask.
- 10.3 The extraction flask was rinsed with three portions of acetonitrile of approximately 5 mls each and the rinses are poured into the funnel. The vacuum is reapplied and the washing process is completed.
- 10.4 The filtrate is transferred via a short-stem funnel into a volumetric flask. The filtering flask is rinsed three times, with approximately 5 ml portions of acetonitrile and the rinses are added to the volumetric flask. The size of the volumetric flask and the subsequent treatment of the sample depend on the initial RDX concentration in the sample. The dilution for various sample levels is shown in Table 1. Diet samples will be diluted to a volume that places them in the working range of the chromatographic system.
- 10.5 An aliquot (approximately 10 ml) is filtered using a Water's Organic Sample Clarification Kit using 0.5 µm filter. The sample is now ready for analysis for HPLC.

STORAGE OF SAMPLES

- 11.1 All samples including diet and blank feed will be stored in the dark at refrigerator temperatures.
- 11.2 If the sample preparation procedure is stopped at any point during the working day, the samples should be stored in stoppered vessels in the dark at refrigerator temperatures.
- 11.3 Samples that are ready for HPLC analysis will be stored in the dark at refrigerator temperature.
- 11.4 RDX and propiophenone standards and all standard solutions will be stored in the dark at refrigerator temperatures.

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

- 12.1 Each sample was analyzed by reverse phase HPLC using the conditions described below: Column, 3.9mm x 30.0cm u-Bondpak C₁₈; Solvent System, Methanol:Water (55%:45%, v/v); Flow Rate, I.5 ml/min; Detection,UV at 254 nm. The retention times of RDX and propiophenone were 3.7 and 7.3 minutes, respectively. The limit of detection was 0.2 ug RDX/ml acetonitrile and is defined as 5x the background noise. The representative chromatogram is Figure 1. For levels at and below 0.005% RDX, the chromatographic conditions have to be changed, since UV absorbing compounds interfere with the RDX quantitation. The eluting solvent in these cases is Methanol:Water (45%:55%, v/v) at a flow rate of 1.5 ml/min.
- 12.2 The chromatographic system was calibrated daily with a minimum of two injections of one standard representative of the chromatographic range.
- 12.3 An injection volume of 15.0 ul was used for each sample, except at or below 0.0010% level. The injection volume at 5 & 10 ppm was 25.0 ul. If the peak exceeds the linear range of a sample it was diluted and reanalyzed.
- 12.4 For levels of 0.005% and below the retention times are 4.8 and 12.9 minutes for RDX and propiophenone respectively.
- 12.5 Following the completion of an analysis or a set of analyses, a gradient doing from the initial solvent conditions to 100% methanol in 15 minutes will be run and the column will be eluted with 100% methanol for at least one hour.

CALCULATIONS

13.1 Determine the concentration of RDX using the formula:

% RDX in Sample =
$$\frac{(Ax)(Wis) \times D \times 100}{(Fx) \text{ Ais (Ws)}}$$

Where

Ax = Area(X) where x is RDX

Ais = Area (internal standard)

 $Fx = \frac{Area(x) \times Weight(Wx)}{Area(is) \times Weight(Wx)}$

Wis = Weight of the internal standard

Ws = Weight of the sample

D = Dilution factor

Wx = Wt of component x is RDX

13.2 The results should be reported in percent RDX composite. This is the RDX actually used in the toxicity study. Where replicate samples are analyzed, all data should be reported. All results are recorded in standard IITRI logbooks and these plus chromatograms and data tapes are retained in the Chemistry Division Q.A. files.

SAFETY

14.1 Safety regulations will be followed at all times, especially with regard to the handling of toxic materials. When the diet samples are being handled, a lab coat, and gloves will be appropriate attire. When solutions or extracts are being handled, a lab coat and gloves should be worn when there is the chance of direct contact with these materials.




Figure 1. Chromatogram of RDX (1) Propiophenone (2) Standard, 20 $\mu g/mL$

STANDARD OPERATING PROCEDURES FOR THE PREPARATION OF THE AND RDX DIET PRE-MIXES

OBJECT

The object of this <u>Standard Operating Procedure</u> (SOP) is to set down procedures which, when followed, will assure quality from lot to lot of the subject pre-mixes. It also provides a guide to safe practices in the handling of these explosives materials.

HEALTH AND SAFETY

The materials (TNT and RDX) being handled in these feed preparations are not only explosive but are also toxic. It would appear that the greatest risk is incurred by the covert inhalation of the aerosolized finely divided powders produced by filling and emptying the ball mill and the V blender. Accordingly the following rules are hereby promulgated.

2.1 When charging or emptying the ball mill or "V" blender a respirator mask, and gloves must be worn. The 3M "Dust and Mist Respirator," 09910 is available to the Chemistry Storeroom and is recommended. Surgeons gloves are recommended for use when handling these materials. They are also available in the storeroom.

The above are considered disposable and will therefore be discarded: the respirator mask at the end of the day and the gloves immediately after they are removed. They will be incinerated along with all other expendable materials at the end of the work day. This will be done by the resident staff at KOP. These people should be made aware of the nature of the material to be burned.

- 2.2 Safety glasses, with side shields supplied by IITRI will be worn at all times in the operating areas.
- 2.3 Cleanup of contaminated surfaces will be accomplished with damp wipers, by washing or wet mop. Dry sweeping is not permitted.

Spills will be cleaned up immediately. The spilled material should be discarded and not returned to the processes. Spilled material should be placed in an appropriate container, given to the KOP staff, with explanation of its nature, for disposal.

General cleanup will be performed between mixes, i.e., say after preparing a TNT pre-mix and before starting on an RDX pre-mix.

All work surfaces, the ball mill, "V" blender, and balance will be cleaned at the end of each work day.

- 2.4 Only a sufficient amount of explosives material for immediate (one or two days operation), will be removed from the explosives magazines to the work area. This will be done by the approved resident KOP staff. Overnight storage of explosives is permitted only in designated areas within the facility. Explosives material will be stored and transported in appropriate "Velostat" containers. Explosives in proper containers should be kept on the bench top, not stored in drawers.
- 2.5 After the pre-mixes have been prepared and further work is not planned for the following day, residual bulk explosives will be returned to the storage area. This will be done by KOP resident staff.
- 2.6 Hands, forearms, and face will be washed upon leaving the work area.
- 2.7 Eating and drinking in the work area is strictly prohibited.

3. GENERAL

3.1 Logbooks

All activity and supporting data will be recorded in the approved IITRI laboratory logbook.

· 3.2 Sample and Lot Designation

Samples or lots of pre-mix are designated by a number relating it to a logbook and page as follows:

NNN-nn.j

where

"NNN" is the last three digits of logbook registration number,

"-nn" is the page number in that logbook and

".j" is the sample number.

For example: Sample 838-14.5 would be described on page 14 of IITRI Logbook 24838 and would be the fifth sample on that page.

"PRE-MIXES" prepared for the feeding program will be designated as "PRE-MIX" using a similar code. For example: TNT PRE-MIX 838-13.1.

3.3 Data Format

The data regarding the preparation of the pre-mixes shall be kept in the logbook in a prescribed manner. The format proposed is shown in Figure 1.

3.4 Labeling

TNT pre-mixes, contained in "Velostat" bags will be identified with yellow tape and with a label as:

10% TNT PRE-MIX Wt Kg Lot No. (see 3.2) Date: mm/dd/yy

Initials of the preparer

RDX pre-mixes contained in "Velostat" bags will be identified with \underline{blue} tape and with a label as:

10% RDX PRE-MIX Wt Kg Lot No. (see 3.2) Date: mm/dd/yy

<u>Initials</u> of the preparer

4. PREPARATION OF THI OR RDX/FEED PRE-MIXES

4.1 Introduction

Animals are to be fed the test materials (TNT or RDX) at very low doses. This requires that gram quantities of these materials be dispersed as uniformly as possible among large quantities of feed. In order to accomplish this the test materials are first dispersed at a concentration of 10% in feed. This is known as the <u>PRE-MIX</u>. Appropriate quantities of the PRE-MIX are then blended into large quantities of feed to attain the required dosage level. The correct preparation of the PRE-MIX is the subject of this SOP.

TNT is a soft waxy substance with a low melting point which is difficult to grind. The starting material is TNT flake which must be reduced in particle size to meet the needs of this program. This cannot be done by ball-milling the TNT without a "grinding aid". The aid used in this sudy is the certified feed material; an animal feed in the form of a finely divided meal. Equal portions, i.e., 50/50 by weight of TNT and feed, are ground in a ball mill to form a TNT CONCENTRATE. This 50/50 CONCENTRATE is subsequently blended with more feed in a P-K "V" blender for form the 10% PRE-MIX.

The same procedure is followed for the preparation of the RDX PRE-MIX.

While it was not necessary to ball mill the RDX with feed as a grinding aid this procedure was followed to avoid introducing another variable in the feeding programs.

Thus the preparative procedure is the same for the FNT and the RDX PRE-MIXES.

4.2 Preparation of TNT Pre-Mix

The required amount of materials are shown in Table 1. The following stepwise procedure is to be followed for the preparation of a 10% TNT PRE-MIX.

Table 1
MATERIALS REQUIRED

For Pre-mix <u>Wt (kg)</u>	FEED CONC Ball THT (1) +		>-	PRE-MIX Blend With Feed (g)
1	10ú	100		800
2	200	200		1600
3	300	300		2400
4	400	400		3200
5	500	500		4000
6	600	600		4800

- 4.2.1 Determine the appropriate quantities of feed and TNT (from Table 1) to be weighed out to prepare the 50/50 TNT/feed concentrate.
- 4.2.2 Weigh out the appropriate amount of TNT and feed.
- 4.2.3 Examine the ball mill jar and balls to be sure they are clean. The ball charge should weigh approximately 3.8-3.9 kg and is a mixture of 3/4" and 1/2" balls. (See logbook C24838 pg. 3).
- 4.2.4 Place the balls in the jar, pour in the weighed feed and then the TNT. Firmly fasten the jar cover and place on the mill. Turn the mill on and record the time.
- 4.2.5 Ball mill for 40 minutes. Record the exact time in the logbook. Remove and open the ball mill jar. Sift the powdered feed/TNT from the balls onto a large piece of paper. (Use the large hardware cloth basket provided to separate the balls and powder.) Weigh this feed concentrations and record in the logbook.
- 4.2.6 Weigh out the larger amount of feed into an appropriate bucket. Record the weight.
- 4.2.7 Open the blender top on each leg of the "V". Put about 1/3 of the concentrate into the blender (i.e., at the point of the "V"). Pour about 1/2 of the feed into the blender. Put another 1/3 of the feed, in the blender, dividing it between the two legs of the "V". Pour the rest of the feed into the blender (1/2 into each leg) and divide the rest of the concentrate between the two legs of the "V". Close the blender.
- 4.2.8 Run the blender for 15 minutes without the intensifier bars on. Turn the intensifier bars on for 15 min. Turn off the blender. Note and record the total blender time.
- 4.2.9 Open the cover at the apex of the V and dump the content of the blender into a Velostat bag. Make sure the blender is completely empty. Seal the bag and label (see 3.4).
- 4.2.10 Clean the blender by running with about 2 kg of feed material only. Repeat this twice. Discard the feed material. Disconnect the blender from the wall outlet, clean the blender with damp wipers.

Clean the ball mill by a similar procedure, i.e., milling feed only, repeated twice followed by a damp wiping.

- **4.2.11** Notify the proper individual that the PRE-MIX is available and expected date of shipment to the Chicago laboratory.
- 4.2.13 The PRE-MIX procedures will be witnessed by second indiviual and second individual will sign the logbook as witnessed.
- 4.3 Preparation of RDX PRE-MIX

The required amounts of materials are shown in Table 2. The following stepwise procedures are to be followed for the preparation of a 10% RDX PRE-MIX.

4.3.1

entering the second of the second second

- about one kg of alcohol wet RDX is placed in a wide mouth gallon jar containing ½ gal of distilled water
- the jar is agitated for five minutes by rolling on the ball-mill or by shaking
- the RDX water-slurry is decanted through a 60 mesh or finer seive muslin cloth. The crystal cake is drained to remove excess water
- the water wet crystals are then returned to the jar and the above procedure repeated two more times
- after the final wash the crystals are spread on paper toweling and let dry overnight or dried in oven at approximately 100°F overnight
- 4.3.2 Determine the appropriate quantities of food and the washed and dried RDX (from Table 2) to be weighed out to prepare the 50/50 RDX/feed concentrate.
- 4.3.3 Weigh out the appropriate amount of RDX and feed.
- 4.3.4 Examine the ball mill jar and balls to be sure they are clean. The ball charge should weigh approximately 3.8-3.9 kg and is a mixture of 3/4" and 1/2" balls. (See logbook C24838 pg. 3)
- 4.3.5 Place the balls in the jar, pour in the weighed feed and then the RDX. Firmly fasten the jar cover and place on the mill. Turn the mill on and record the time.

Table 2
MATERIALS REQUIRED

For Pre-mix	FEED CONG Ball RDX (g) +	Mill Feed (g)		PRE-MIX Blend With Feed (g)
1	100	100		008
2	200	200		1600
3	300	300		2400
4	400	400		3200
5	500	500		4000
6	600	600		4800

4.3.6 Ball mill for 40 minutes. Record the exact time in the logbook. Remove and open the ball mill jar. Sift the powdered feed/RDX from the balls onto a large piece of paper. (Use the large hardware cloth basket provided to separate the balls and powder.) Weigh this feed concentrate and record in the logbook.

- 4.3.7 Weigh out the larger amount of feed into an appropriate bucket. Record the weight.
- 4.3.8 Open the blender top on each leg of the "V". Put about 1/3 of the concentrate into the blender (i.e., at the point of the "V"). Pour about 1/2 of the feed into the blender. Put another 1/3 of the feed, in the blender, dividing it between the two legs of the "V". Pour the rest of the feed into the blender (1/2 into each leg) and divide the rest of the concentrate between the two legs of the "V". Close the blender.
- 4.3.9 Run the blender for 15 minutes without the intensifier bars on. Turn the intensifier bars on for 15 min. Turn off the blender. Note and record the total blender time.
- 4.3.10 Open the cover at the apex of the V and dump the contents of the blender into a Velostat bag. Make sure the blender is completely empty. Seal the bag and label (see 3.4).
- 4.3.11 Clean the blender by running with about 2 kg of feed material only. Repeat this twice. Discard the feed material. Disconnect the blender from the wall outlet, clean the blender with damp wipers.
 Clean the ball mill by a similar procedure, i.e., milling feed only, repeated twice followed by a damp wiping.
- 4.3.12 Notify the proper individual that the PRE-MIX is available and expected date of shipment to the Chicago laboratory.
- 4.3.13 In the first four months of this program 8 kg of the RDX PRE-MIX will be required each month. This exceeds the capacity of the available ball mill and blender The following procedure is to be used.
 - 4.3.13.1 Prepare two (2) 4 kg pre-mixes by following steps 4.3.1 through 4.3.10 above. This will result in two sub-batches for the final lot, identified as sub-batch 1 and 2.

- 4.3.13.2 Blend one-half of sub-batch 1 with one half of sub-batch 2 in the "V" blender for 10 minutes with the intesifier bar "on". Repeat with the remaining halves of the sub-batches. These become two new sub-batches. Repeat the procedure.
- 4.3.13.3 Combine the results by alternately dumping portions of the resulting sub-batches into the large Velostat bag. Periodically shaking the bag and mixing the contents. Proceed with steps 4.3.11 and 4.3.12.
- 4.3.13.4 The premix procedure will be witnessed by second individual and second individual will sign the logbooks as witnessed.
- 4.4 Any deviation from this procedure must be first cleared with the project leader and must be recorded as an addendum or revision to the SOP.

Record any unusual occurrence in the logbook and advise the project leader immediately.

In cases of uncertainty contact Robert Remaly, ext. 4309 or Barry Levine, ext. 4901 before proceeding.

4.5 Transmittal Record

Transmittal record will be initiated by the person who is preparing the premix. All the pertinent information must be filled. The test article premix record must accompary the premix. Copies of the transmittal record can be obtained from the Principal Investigator.

.SAMPLE COLLECTION AND STORAGE (TN: AND/OR RDX PREMIX SAMPLES)

Scope.

1.1 This procedure covers the collection and storage of TNT and RDX premix samples prior to analysis.

Materials and Equipment

- 2.1 Small scoop
- 2.2 Powder funnel
- 2.3 Amber vials with plastic screw cap

Sample Collection

3.1 Personnel of the Life Sciences Division will inform the supervising chemist and the analyst when they receive TNT or RDX premixes. The analyst will collect 6 samples from the Velostat bag container, one from each of four corners and two from the middle. At least 5.0 gram quantities of premix will be collected in order to permit the extraction and analysis steps to be performed in duplicate. All samples will be identified according to the Chemistry Division identification system. All detailed information will be placed in the sample identification logbook immediately.

The sampling procedure for the premix will be performed as follows: One sample is removed from the center of the storage bag with a small scoop which will permit the removal of a 5.0g quantity. The second sample will also be removed from the center of the container in the same manner as the first sample but at a deeper level.

After center sampling, the surface of the premix is restored by leveling and four additional samples will be removed with a small scoop from each of the four corners of the bag at gradually increasing depths by lifting the corners of the bag. The 6 samples will be labeled and placed in amber vials with plastic screw caps. The label will contain Date Sampled, Sample Number, Premix Identification, Lot Number and Sampled by Initials.

Sample Storage

- 4.1 All samples will be stored at refrigerator temperatures in the dark prior to analysis. This includes feed that will be used for blanks and control samples. Every three months (from manufacturing date) feed will be changed. This manufacturing date will be supplied by Life Science Transmittal Record
- 5.1 Transmitted record will be completed by responsible personnel. A copy of Test Article Premix (T.A.P.) and/or T.A.P. Sample Transmittal (or custody) record is attached.

Sample Disposal

6.1 Samples or parts of samples will be returned to the Safety Officer for disposal.

TEST ARTICLE PREMIX (T.A.P.) AND/OR T.A.P. SAMPLE TRANSMITTAL (OR CUSTODY) RECORD

Project No Study No(s).	T.A.P
Lot No T.A.P. Prepared	(K.O.P.) Date/By:
Intended Concentration: % Quantity	
Logbook No./Page No Storage	Conditions of T.A.P. (K.O.P.):
T.A.P. Received (L.S.R.) Date/By:	Logbook No./Page No.:
Storage Conditions of T.A.P. in L.S.R.:	······································
T.A.P. SAMPLING AND ANALYSIS	
T.A.P. Sampled Date/By:	Logbook No./Page No.:
Witnessed By/Date: Storage	Conditions of T.A.P. Sample by Chemistry
Personnel:	
Extraction Performed By/Date:	
Analysis Performed By/Date:	Logbook No./Page No.:
Data Reviewed & Approved By/Date:	
Analytical Report Prepared By/Date:	Checked By/Date:
Quality Assurance Check By/Date:	
Analytical Report Received (L.S.R. Supervis	
T.A.P. First Used By/Date:	T.A.P. Last Used By/Date:
Excess T.A.P. Submitted to K.O.P. Personne	I for Disposal by Burning By/Date:
Quanti+ (kg)	
Excess T.A.P. Received By/Date:	
Key	
K.O.P. = Kingsbury Ordinance Plant, La Por 5002 = Purina Certified Rodent Chow 5002	te, IN.

SAMPLE COLLECTION AND STORAGE (TNT AND/OR RDX DIET SAMPLES)

Scope

1.1 This procedure covers the collection and storage of TNT and RDX diet samples prior to analysis.

Materials and Equipment

- 2.1 Small scoop
- 2.2 Large scoop
- 2.3 Powder funnel
- 2.4 Amber vials with plastic screwcap

Sample Collection

3.1 Personnel of the Life Sciences Division will inform the supervising chemist and the analyst when the TNT or RDX diets are available. The analyst will collect 6 samples from the plastic tub container, one from each of four corners and two from the middle. The tubs receiving the rat diets are rectangular with a capacity of 42 liters. The tubs receiving the mouse diets are square with a capacity of 27 liters. At least 30.0 gram quantities of diet will be collected in order to permit the extraction and analysis steps to be performed in duplicate. All samples will be identified according to the Chemistry Division identification system. All detailed information will be placed in the sample identification logbook immediately.

The sampling procedure for the diets will be performed as follows:

One sample is removed from the center of the storage container at the surface of the diet. This sample will be removed with a small scoop which will permit the removal of a 30.0g quantity. The second sample will also be removed from the center of the container about half the distance to the bottom after toxicology personnel have exposed the sampling site by shifting the

diet toward the side of the container using a large scoop. After this sampling, the surface of the diet will be restored by leveling. Four additional samples will then be removed with the small scoop, one from each of the four corners of the container at gradually increasing depths within the container, again using the large scoop to expose the sampling sites. The 6 samples will be labeled and placed in amber vials with plastic screw caps. The label will contain Date Sampled, Sample Number, Diet Identification and Lot Number and Sampled by Initials.

Sample Storage

4.1 All samples will be stored at refrigerator temperatures in the dark prior to analysis. This includes feed that will be used for blanks and control samples. Every three months (from manufacturing date) feed will be changed. This manufacturing date will be supplied by Life Science Personnel.

Transmittal Record

5.1 Transmittal record will be completed by responsible personnel. A copy of transmittal record for diet sample analysis is attached.

Sample Disposal

6.1 Samples or parts of samples will be returned to the Safety Officer for disposal.

TRANSMITTAL RECORD FOR DIET SAMPLE ANALYSIS

	Species	Test Week
Test Article	Lot. No.	% Conc. of Premix
Diets calculated by:	. Date•	
Premix weighed by:	Date;	
Diet prepared by:	Date:	5002 Lot No.(s)_
		_
Dose level:	_mg/kg/day sex:	
Dose level:	_mg/kg/day sex:	T.W intended conc. mg/g
Diets Stored in the Refr		
	s Fynnsume to the Diet.	
First Day of Test Animal		
First Day of Test Animal:		
Dict Samples Taken By/Da	te	Loghook No./Page No
Dict Samples Taken By/Da Witnessed By/Date:	te	
Dict Samples Taken By/Da Witnessed By/Date: Storage Conditions of Dic	teet Samples in Chemistry	Loghook No./Page No
Dict Samples Taken By/Dar Witnessed By/Date: Storage Conditions of Dic Extraction Performed By/D	teet Samples in Chemistry	Loghook No./Page No Division
Dict Samples Taken By/Dar Witnessed By/Date: Storage Conditions of Dic Extraction Performed By/D	teet Samples in Chemistry	Loghook No./Page No Division Logbook No./Page No
Dict Samples Taken By/Dar Witnessed By/Date: Storage Conditions of Dic Extraction Performed By/D	et Samples in Chemistry Date:	Loghook No./Page No Division Logbook No./Page No
Dict Samples Taken By/Da Witnessed By/Date: Storage Conditions of Dic Extraction Performed By/Dar Analysis Performed By/Dar	teet Samples in Chemistry Date:te:	Logbook No./Page No DivisionLogbook No./Page No Logbook No./Page No Logbook No./Page No
Dict Samples Taken By/Dar Witnessed By/Date: Storage Conditions of Dic Extraction Performed By/Dar Analysis Performed By/Dar Results Calculated By/Dar	et Samples in Chemistry Date: te: ed By/Date:	Logbook No./Page No Division Logbook No./Page No Logbook No./Page No Logbook No./Page No
Dict Samples Taken By/Da Witnessed By/Date: Storage Conditions of Dic Extraction Performed By/Da Analysis Performed By/Da Results Calculated By/Da Data Reviewed and Approve	et Samples in Chemistry Date: te: ed By/Date:	Logbook No./Page No Division Logbook No./Page No Logbook No./Page No Logbook No./Page No

APPENDIX II
5002 CERTIFICATION PROFILE

Certified Rodent Chows 5002



Maximum

ertified Rodent Chow is a controlled onstant nutrient rodent diet recommended in life cycle feeding of rats, mice and amsters. A sample of this product has sen assayed for certain environmental ontaminants. Maximum diet control is obieved by pre-analysis monitoring of key utrients and certain contaminating obstances. Diet control helps minimize ariables in research studies.

Quaranteed Analysis

rude protein, min	20.0%
rude fat, min	4.5%
rude fiber, max	
sh, max	8.0%
dded minerals, max	

ertification Profile

ased on analysis of a composite sample, ach package contains not more than less maximum concentrations of the illowing substances.

cavy	MIZZIMUM
ietals Co	oncentration
rsenic	1.0 ppm
admium	5 ppm
28d	
Sercury	2 ppm
flatoxin	10 ppb
hiprinated Hydrocarbons	and PCB
ldim	05 ppm
ີເ eໄວ ຕຸກ	05 ppm
ndrin	
leptachlor	
leptachlor Epoxide	
indane	
hiordane	
DT Related Substances	
CB	15 ppm
rganophosphates	
himet	5 ppm
Plazinon	5 ppm

Disultation	.5 ppm
Methyl Parathion	.5 ppm
Malathion	.5 ppm
Parathion	
Ethion	
Trithion	.5 ppm

Drugs and Estrogens — This product is manufactured in a plant where antibiotics and synthetic estrogens are strictly prohibited. Routine monitoring for over a decade has not shown any detectable levels of these substances. No drugs or synthetic estrogens are permitted in manufacturing, storage or warehousing to avoid any contamination of Lab Chows diets.

Other Contaminants — If additional contaminants assays are needed, these can be obtained by ordering such analyses prior to manufacture. Cost of these additional assays will be charged based on current analyses rates at time of assay.

Ingredients:

Ground extruded corn, soybean meal, ground oat groats, dried beet pulp, wheat germ meat, fish meat, brewers' dried yeast, dehydrated alfalfa meal, cane molasses. dried milk products, meat and bone meal, wheat middlings, animal fat preserved with SHA, calcium carbonate, dicalcium phosphate, salt, animal liver meal, calcium iodate, vitamin By supplement, methionine hydroxy analogue calcium, calcium pantothenate, choline chloride, folic acid, riboflavin supplement, thiamin, niacin, pyridoxine hydrochloride, ferrous sulfate, vitamin A supplement, D activated animal sterol, vitamin E supplement, iron oxide, manganous oxide, cobait carbonate, copper uxide, zinc oxide.

Chemical Composition* Nutrients**

Protein %								,			20.0
Arginine %									٠		1,13
Cystine %											
Glycine %											.86
Histidine %											.49
Isoleucine %											
Leucine %				٠.							1.58
Lysine %											
Methionine % .											
Phenylalanine 9											
Threonine %											
Tryptophan % .											
Valine %											

Fet %	4 5
Fiber %	4 (
TDN %	77.0
NFE (by difference) %***	55 1
Gross Energy, KCa gm	41
Ash %	5.6
Calcium %	62
Pnosphorus %	70
Potassium %	86
Magnesium %	21
Sodium %	.30
Chiorine %	47
Fluorine, ppm	
Iron, ppm	180.0
Zinc, ppm	52 4
Manganese, ppm	63 0
Copper, ppm	133
Cobalt, ppm	.€
lodine, ppm	1,2
Vitamins	
Carotene, ppm	5 €
Monadione (added), ppm	
Thiamin, ppm	133
Riboflavin, ppm	8 3
Niacin, ppm	60 (
Pantothenic Acid, ppm	17,0
Choline, ppm x100	180
Folic Acid, ppm	4 (
Pyridoxine, ppm	60
Biotin, ppm	13
B-12, mcg/lb	9 (
Vitamin A, IU/gm	17.6
Vitamin D, IU/gm	22
Alpha-tocopherol, IU/ib	30 (
Ascorbic Acid, mg/gm	_

Feeding Directions

Feed ad libitum to rodents. Plenty of fresh, clean water should be available to the animals at all times.

Rats — Adult rafs will eat 12 to 15 gran a of diet per day Feeders in rat caged should be designed to hold two to three days supply of feed at one time.

Mice — Adult mice will eat 4 to 5 grams of pelleted ration daily. Some of the larger strains may eat as much as 8 grams per day per animal. Feed should be available on a free choice basis in wire feeders above the floor of the cage.

Hamsters — Adults will eat 10-14 grams per day.

Best Available Copy



APPENDIX III
TEI ANALYTICAL CHEMISTRY METHODS

TELANALYTICAL, INC. 460 SOUTH NORTHWEST-HIGHWAY - PARK RIDGE, ILLINDIS - 80068 - 312/696-2070

October 29, 1982

LABORATORY REPORT

19166

Page 1 of 2 pages

Dr. Marianna Furedi IIT Research Institute 10 West 35th Street Chicago, Illinois 60616

P.O. #16092

Sample rereived June 9, 1982

[TEI-14080] Rodent Chow #5002 - March 24-822G

	Result in ppm	* <u>Method</u>
Nitrate Nitrogen	19.0	7.030
Nitrite Nitrogen	0.24	7.03 0
Hercury	< 0.05	25.103
Arsenic	0.014	JADAC 60.813
Cadmium	< 0.05	25.(`^
Lead	0.61	25. 058
Penicillin	< 10	Snell & S Colorimetric of Analysi. Vol IVAAA, p. 221
внт	< 1.0	JBOAC 60,505
вна	< 1.0	JAOAC 60,505
Total Estrogen	not detected	39.000
Chlortetracycline	to be reported at a la date	ter -
Aflatoxin B ₁	< 0.005	26.003
Aflatoxin B ₂	0.01 - 0.02	26.003
Aflatoxin G ₁	< 0.005	26.093
Aflatoxin 62	< 0.005	26.003
Dieldrin	< 0.001	29.000
Endrin	< 0.001	29.000
Aldrin	< 0.001	29.000
Heptachlor Epoxide	< 0.001	29.000
BHC .	< 0.001	29.000

e. marks

TEI ANALYTICAL, INC. 460 SOUTH NORTHWEST HIGHWAY - PARK RIDGE, ILLINOIS - 60068 - 312/696-2070

LABORATORY REPORT

October 29, 1982

#9166

Page 2 of 2 pages

Dr. Harianna Furedi IIT Research Institute 10 West 35th Street Chicago, Illinois 60616

P.O. #16092

Sample received June 9, 1982

[TEI-14080] Rodent Chow #5002 - March 24-8226

	Result in ppm	* Method
Lindane	< 0.001	29.000
DDT Total	< 0.001	29.000
hethoxychlor	< 0.001	29. 15
Chlordane	< 0.001	29.0
Nirex	< 0.001	29,000
Toxaphene	< 0.001	29.000
Strobane	< 0.001	29,000
НСВ	< 0.001	29.000
PCE	< 0.001	29,000
Polychlorinated Dioxins	< 0.006	28.128
Parathion	< 0.001	29.000
Nethyl Parathion	< 0.001	29.000
Enthion	< 0.001	29.000
Carbophenothion	< 0.001	29.000
Malathion	< 0.001	29.000
konnel	< 0.001	29. X 0
Diazinon	< 0.001	29.000
Disulfeton	< 0.001	29.000
Phorate	< 0.001	29.000

^{*}Official Methods of Analysis of the Association of Official Analytical Chemists.

Tracker

ANALYTICAL PROCEDURES USED BY TEI ANALYTICAL, INC. PARK RIDGE, IL TO ANALYZE PURINA CERTIFIED RODENT CHOW NO. 5002 FOR IMPURITIES

	Limit of	1
Procedure	Detectability	References
Chlorinated Pesticide Screen	10 ppb	A.O.A.C. 29.000
Phosphated Pesticide Screen	50 ppb	A.O.A.C. 29.000
Polychlorinated Biphenyls (PCBs)	100 ppb	A.O.A.C. 29.000
Hexa-, hepta-, octachlorodibenzo-p-d		
Heavy Metals	• •	
Arsenic	1.0 ppb	J.A.O.A.C. 60.813
Cadium		A.O.A.C. 25.026
Lead		A.O.A.C. 25.058
Mercury		A.O.A.C. 25.103
Nitrates	<1.0 ppm	
Nitrites	<1.0 ppm	
Aflatoxins		A.O.A.C. 26.003
Penicillin	<2.0 ppm	
		Colorimetric Methods
		of Analysis Vol IV
		AAA, pg. 221
Chlortetracycline	10.0 ppm	Snell and Snell,
,	• •	Colorimetric Methods
		of Analysis Vol IV
		AAA, pg. 184
Butylated hydroxytoluene	1.0 ppm	· · · · · · · · · · · · · · · · · · ·
Butylated hydroxyanisole	1.0 ppm	
Estrogens		A.O.A.C. 39.000

A.O.A.C. - Official methods of analysis of the Association of Official Analytical Chemists.

APPENDIX IV
HEMATOLOGY METHODOLOGY

Hemoglobin

Cyanmethemogiobin method
Coulter Counter Model S System

Hematocrit

Indirect method; calculated value based on erythrocyte count and mean corpuscular volume

Coulter Counter Model S System

9

♦

٣

Erythrocyte Count

Electronic Counting Procedure
Coulter Counter Model S System

Leukocyte Count

Electronic Counting Procedure
Coulter Counter Model S System

Mean Corpuscular Volume (MCV)

Electronic Sizing Procedure
Coulter Counter Model S System

Mean Corpuscular Hemoglobin (MCH)

Indirect method; calculated value based on erythrocyte count and hemoglobin

Coulter Counter Model S System

Mean Corpuscular Hemoglobin Concentration (MCHC)

Indirect method; calculated value based on hematocrit and hemoglobin Coulter Counter Model S System

Leukocyte Differential Count

Neutrophils - Immature
Neutrophils - Mature
Monocytes
Basophils
Lymphocytes
Eosinophils
Wright stain procedure
Schalm, O.W., Jain, N.C. and Carroll, E.J.
Veterinary Hematology, Color Plates Chapter,
3rd Edition, Lee and Febiger, 1975.

Nucleated RBCs

Wright stain procedure
Schalm, O.W., Jain, N.C. and Carroll, E.J.
Veterinary Hematology, Color Plates Chapter,
3rd Edition, Lee and Febiger, 1975.

Platelet Count

Direct Method
Schalm, O.W., Jain, N.C. and Carroll, E.J.
Veterinary Hematology, p. 69, 3rd Edition,
Lee and Febiger, 1975.

Ü

APPENDIX V

CLINICAL CHEMISTRY METHODOLOGY

Glucose

Hexokinase method

Centrifichem Centrifugal Analyzer System
Neeley, W.E. Clin. Chem. 18. 509. 1972.

6

ţ

Urea Nitrogen (BUN)

Modified urease technique Centrifichem Centrifugal Analyzer System Karmen, A. J. Clin. Invest. 34, 131, 1955

Glutamic-Pyruyic Iransaminase (SGPI)

Modified Wroblewski and LaDue technique Centrifichem Centrifugai Analyzer System Henry, R.J., Chiamori, N., Golub, O.J., and Berkman, S. Am. J. Clin. Path. 34, 381,1960.

Total Protein

Biuret technique Centrifichem Centrifugal Analyzer System Failing, I.F., Jr., Buckley, M.W. and Zak, B. Am. J. Clin. Path. 33, 83, 1960.

Albumin

Bromocresol green method
Centrifichem Centrifugal Analyzer System
Rodkey, I.L. Clin. Chem. 11, 478, 1965.

<u>Irialvcerides</u>

Tetrazolium salt reduction method
Centrifichem Centrifugal Analyzer System
Klotzsch, S., Serricchio, M. and Furedi, R.
Advances in Automated Analysis
Vol. 1, Mediad Inc., Tarrytown, N.Y. p 111, 1973.

Cholesterol

Cholesterol esterase-cholesterol oxidase method Centrifichem Centrifugal Analyzer System Roseschlaw, P., Bernt, E. and Gruber, W. Z. F. Lin. Che. u. Klin. Biochem. 12, 226, 1974. APPENDIX VI
INDIVIDUAL ANIMAL DATA

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B₆C₃F₁ MOUSE SURVIVAL RATE DATA

A N I M A	T R			' ,	
Ľ	G			E	1
AT.	R	C	D	V	
N	O U	S E	A T	E N	
•	P	x	Ē	T	T University
001	1	М	03/22/82	0	
002	ī	M	02/07/83	1	Í
003	1	М	07/29/82	0	
004	1	М	02/11/82	1	
005	7	М	11/29/82	0	i
006 007	<u>.</u> 7	M M	02/07/83 02/07/83	<u> </u>	
008	า	M	02/07/83	ì	İ
009	זֿ	M	02/07/83	י ז	1
010	ĵ	M	02/07/83	î	
011	ī	M	02/07/83	<u>ז</u>	
012	ī	M	02/07/83	ī	İ
013	1	М	01/28/83	Ō	
014	1	М	02/09/82	1	
015	Ţ	М	12/30/81	0	
016	1	M	09/20/82	0	
017	l	M	02/07/83	1	
018	ļ	M	09/06/82	Ō	
019	Ì	M	02/02/83	0	
020	1	M	05/14/82	Ó	14
021	7	М	02/10/82	j	Ì
022 023	÷	М	02/07/83	j	1
023	<u>.</u> 7	M	01/27/83 02/07/83	0	
025	ī	M M	02/0//83	j	ļ
026	<u>.</u>	M	02/10/82	7	
027	1	M	02/07/83	3	
028]] :	M	02/07/83	1 1 1 0 1	
029		М	02/07/83	ī	i
030	1	М	02/07/83	1	
031	1	M	02/07/83	1	i
032	1	М	02/07/83	1	į
033	1	M	10/07/82	0	1
034	1	M	02/07/83		
035	1	M	02/07/83	1	i
036	1	M	04/19/81	0	
037	i ,	M	02/07/83	ļ	1
038 039	j	M	02/07/83	1	;
039	J.	M M	02/07/83 02/07/83	1	
040	÷ 7	M M	12/27/82	0	
1 027	-	171	14/41/04	U	i

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B.C.F. MOUSE SURVIVAL RATE DATA

A N I M A L N O	Ţ R G R O U P	S E X	D A T E	', E V E N T	
042 043 0445 0445 0447 0449 049 0512 0554 0556 0556 0556 0556 0661 0667 0669 071 072 073 075 077	P 111111111111111111111111111111111111	X M M M M M M M M M M M M M M M M M	E	111111111111111111111111111111111111111	
078 079 080 081 082	1 1 1 1	F F F F	02/07/83 12/30/82 02/09/82 02/07/83 02/07/83	1 0 1 1	; ;

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control

 \odot

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B₆C₃F₁ MOUSE SURVIVAL RATE DATA

A N I M A L N O	T R G R O U P	S E X	D A T E	E V E N T	6
083 084 085 086 087 088 089	1 1 1 1 1		02/07/83 02/07/83 02/07/83 02/09/82 02/07/83 02/07/83 02/11/82	1 1 1 1 1	•
090 091 092 093 094	1 1 1 1	444444	02/07/83 02/07/83 02/07/83 02/07/83 02/07/83	1 1 1 1	6
095 096 097 098 099 100	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	मममममम	02/09/82 02/07/83 02/07/83 02/07/83 02/07/83 02/07/83	1 1 1 1 1	•
101 102 103 104 105 106 107	년 년 년 년 년 <u>년</u>	444444	02/09/82 10/06/82 02/07/83 02/07/83 10/20/82 02/07/83 02/07/83	1 0 1 1 0 1	3
108 109 110 111 112	1 1 1	F	02/07/83 02/07/83 02/11/82 02/07/83 02/07/83	1 1 1 1	6
113 114 115 116 117 118 119	1 1 1 1 1	पं म म म म म म म म म म म म म म म म	06/18/82 10/11/82 02/07/83 02/07/83 02/07/83 02/07/83 02/10/82	0 0 1 1 1 1 1 1	
120 121 122 123	1	, F F F F	02/07/83 12/15/82 02/07/83 02/07/83	0	i 3

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B,C,F, MOUSE SURVIVAL RATE DATA

A N I M A L N O	T R G R O U P	S E X	D A T E	E V E N T	
124 1256789012345678901234567890121131333456789012456789012456789012456789012456789012456789012456789012456789012456789012456789012456789012456789012456789012456789012456789012456789001245678901245678901245678901245678901245678901245678901245678900124567890124567890100000000000000000000000000000000000	494944444444444444444444444444444444444		02/07/83 12/29/82 08/10/82 02/07/83 10/02/82 02/07/83 02/07/83 02/11/82 02/07/83 06/04/82 10/17/82 02/07/83	100101111001111011110111111111111111111	
163 164	2	M M	07/26/82 02/10/82	l	•

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B₆C₃F₁ MOUSE SURVIVAL RATE DATA

A N I M A L	T R G R		D	E V	
И	O U	S E	A T	E N	
	P	X	E	J.	
165 166	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	M M	08/14/82 02/07/83	0 1	
167	2	М	01/17/83	Ō	
168	2	М	02/09/82	1	
169	2	М	02/17/82	0	
170	2	M	02/07/83	l	
171	2	W	02/07/83	1	
172	2	M	02/07/83	1	
173	2	M	01/13/83	0	ì
174	2	M.	12/03/82	ō	
175	2	M	02/10/82	7	
176	2	M	12/30/82	0	
177	2	M	12/17/82	0	
178 179	2	M	09/06/82	0	
180	2	M M	02/07/83 02/07/83	7	
181	2	M	12/02/82	Ō	
182	2	M M	02/07/83	1	
183	2	M	08/08/82	Ō	Br. 15. 44
184	2	×	02/07/83	1	i
185	2	M.	09/28/82	ō	i
186	2	M	09/30/82	Ö	1
187	2	М	02/07/83	ì	1
188	2	M	02/07/83	1	ŧ
189	2	M	02/07/83	1	
190	2	M	02/07/83	1	
191	2	M.	02/10/82	1	1
192	2	M.	07/27/82	0	
193	2	M	06/19/81	0	!
194	2	M	10/05/81	0	
195	2	M.	02/09/82	1	1
196	2	М.	12/31/81	Ü	
197	2	M.	02/07/83	1	} •
198 199	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	M.	02/07/83	0 1 0	1
200	2	M M	06/11/81 10/10/82	0	
200	2	m M	02/07/83		1
202	2	г. Ж	02/07/83	<u> </u>	ř
203	2	м. М	02/07/83	1.	
204	2	M.	02/07/83	1 1 2 2	;
205	2	M M	02/07/83	ī	

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control; $2 = 1.5 \, mg/kg/day \, RDX$

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B₆C₅F₁ MOUSE SURVIVAL RATE DATA

A N I M A L N O	T R G R O U P	S E X	D A T E	E V E N T
206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 232 233 234 235 237 238 239 231 232 233 234 235 237 238 239 231 232 233 234 235 237 238 239 231 232 233 234 235 237 238 239 230 231 232 233 234 235 236 237 238 239 239 239 239 239 239 239 239 239 239	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		02/07/83 02/07/83 02/07/83 02/07/83 02/07/83 02/07/83 01/21/83 02/10/82 01/23/83 02/07/83 02/11/82 02/07/83	

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B.C.F. MOUSE SURVIVAL RATE DATA

A				•	{
N				,	
- I	${f T}$				9
M	Ř				
Ä	*				
	C			77	
L	G			E	į
	R	_	, D	V	
Ŋ	0	S E	A	E	6
O	U	E	T	N	39
•	P	X	E	Ţ	
247	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	F	02/07/83	1	1
248	2	F	02/07/83	1	
249	2	F	02/07/83	1	
250	2	F	02/07/83	1	9
251	2	F	12/27/82	0	
252	2	F	02/07/83	ì	
253	2	F	05/07/82	Õ	
254	2	ŕ	11/23/82	0	l
	2		11/23/02	7	
255	2	F	02/10/82	1	8
256	2	F	02/07/83	٨	9
257	2	F	02/07/83	1	ļ
258	2	F	02/67/83	1	
259	2	F	02/11/82	1	
260	2	F	02/07/83	1	
261	2	F	02/07/83	7	
262	2	F	02/02/83	Õ	9
263	2	F		י	
	2		02/07/83	7	1
264	2 2 2 2 2 2 2 2	F	02/07/83	1	
265	2	F	02/07/83	1	
266	2	F	02/07/83	1	i
267	2	F	02/07/83	1	Ì
268	2	F	02/07/83	1	3
269	2	F	09/21/81	0	
270	2	F	02/07/83	j	Ì
271	2	F	02/09/82	วิ	!
272	2	F		1 1	1
		-	02/07/83	<u>.</u>	i
273	2	<u> </u>	02/07/83	Ţ	
274	2	F	02/07/83	1	<u> </u>
275	2	F	12/16/81	0	
276	2	F	02/07/83	1	
277	2	F	02/07/83	1	
278	2	F	02/07/83	1	İ
279	2	F	02/07/83	J	I I
280	2	च	12/27/82	J 0	- 9
281	2	- ਜ	02/07/83	1	9
282	2	÷	11/11/82	0	
	2	Σ •••	TT/TT/05	U 3	ļ
283	2	<u>+</u>	02/07/83	Ţ	į
284	2	F	02/07/83	1	1
285	2	4	02/01/83	C	1
286	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	ज 'च च च च च च च च च च च च च च च	02/07/83	1	එ
287	2	F	02/07/83	1 C 1	
	_	-	,,		

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B.C.F. MOUSE SURVIVAL RATE DATA

A N I M A L N O	T R G R O U P	S E X	D A T E	E // E N T
288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 307 308 309 310 311 312 313 314 315 317 318 319 321 322 323 324 325 326 327	222222222223333333333333333333333333333		02/11/82 02/07/83 01/11/83 02/07/83 02/07/83 12/15/82 02/09/82 12/03/82 02/07/83 02/11/82 11/06/82 02/07/83 02/07/83 02/07/83 02/07/83 02/07/83 12/27/82 02/10/82 02/07/83 12/27/82 02/11/82 02/07/83	1 1 0 1 1 1 0 1 0 1 1 1 0 0 0 0 1 1 1 0 0 0 0 1 1 1 1 0 0 0 0 1 1 1 1 0 0 0 0 1 1 1 1 1 0 0 1
328	3	M	07/25/82	0 ;

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B,C,F, MOUSE SURVIVAL RATE DATA

A				s 1	1
Ŋ	m				
I M	T R				Į.
A	1(
Ĺ	G			E	į
	R	_	D	V	THE STATE OF THE S
Й	O U	S	A	E N	
0	P	E X	T E	T	
329	3	M	02/07/83	1	1
330 331	3 3	M M	02/07/83 02/07/83	1 1	
332	3	M	02/07/83	i	•
333	3	M	02/07/83	ī	Ì
334	3	М	02/11/82	1	
335	3	M	02/07/83	1	
336 337	3 3 3	M M	02/07/83 02/09/82	1 1	
338	3 3	M M	02/03/82	i j	
339	3	M	07/06/81	Õ	
340	3	M	08/06/82	0	
341	3	M	02/07/83	ļ	
342 543	3	М	02/07/83	1	
344	ง ว	M M	02/07/83 06/29/82	1 0	!
345	3	M	02/07/83	ĭ	
346	3	M	02/07/83	1	;
347	3	M	02/07/83	j	
348	3 3 3 3 3 3 3 3 3	M	02/07/83	1	
349 350	3	M M	02/07/83 02/07/83	1	
351	3	M	02/07/83	i	4
352	3	M	01/17/83	0	1
3 53	3	M	02/07/83	1	1
354	3	M	02/16/82	1	
355 356	3 3	M M	02/09/82 02/07/83	1	!
357	3 3 3	M M	02/07/83	i	,
358	3	×	02/07/83	ī	:
359	3 3 3	М	02/07/83	1	1
360		M	11/29/82	0	†
361	3 3	M	02/07/83	1	1
362 363	3 3	M M	02/09/82 10/08/82	Ô	1
364	3	M M	10/18/82	ŏ	•
365	3	M	02/07/83	1	ï
366	3	M	01/03/83	0	•
367	3	M	02/07/83	1	•
368 369	3 3	М М	12/04/82 12/12/82	0 0	
303	J	171	12/12/02	0	

Event code is: 0 = Diea or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B,C,F, MOUSE SURVIVAL RATE DATA

 A N I M A L N O	T R G R O U P	S E X	D A T E	Έ V E N T	
370 371 372 374 375 3778 3789 381 3883 3886 3890 3990 3990 401 402 403 404 405 407 407 408	<u> </u>		12/15/82 02/07/83 09/14/81 02/10/82 02/07/83		
409 410	3 3		11/28/82 02/07/83	0 1	

Event code is: 9 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B,C,F, MOUSE SURVIVAL RATE DATA

A N N						
N	N I M A	R			1	
N O S A E T NN . P X E T NN . P X E T NN . P X E T NN . 12/19/82	L			_		
O U E T N E T N A	M		c			ļ
411 3 F 12/19/82 0 412 3 F 02/07/83 1 413 3 F 02/07/83 1 414 3 F 02/07/83 1 415 3 F 02/07/83 1 416 3 F 02/07/83 1 417 3 F 02/07/83 1 418 3 F 02/07/83 1 419 3 F 02/07/83 1 419 3 F 02/07/83 1 420 3 F 02/07/83 1 421 3 F 02/07/83 1 422 3 F 02/07/83 1 422 3 F 02/07/83 1 423 3 F 02/07/83 1 424 3 F 02/07/83 1 425 3 F 02/07/83 1 426 3 F 02/07/83 1 427 3 F 02/07/83 1 428 3 F 02/07/83 1 429 3 F 02/07/83 1 429 3 F 02/07/83 1 430 3 F 02/07/83 1 433 3 F 02/07/83 1 443 3 F 02/07/83 1 429 3 F 02/07/83 1 430 3 F 02/07/83 1 431 3 F 02/07/83 1 432 3 F 02/07/83 1 433 3 F 02/07/83 1 434 3 F 02/07/83 1 435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 02/07/83 1 438 3 F 02/07/83 1 439 3 F 02/07/83 1 431 3 F 02/07/83 1 432 3 F 02/07/83 1 433 3 F 02/07/83 1 434 3 F 02/07/83 1 435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 02/07/83 1 438 3 F 02/07/83 1 439 3 F 02/07/83 1 440 3 F 02/07/83 1 441 3 F 02/07/83 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 444 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 444 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 448 3 F 02/07/83 1			2			
411 3 F 12/19/82 0 412 3 F 02/07/83 1 413 3 F 12/03/82 0 414 3 F 02/07/83 1 415 3 F 02/07/83 1 416 3 F 02/07/83 1 417 3 F 02/07/83 1 419 3 F 02/07/83 1 419 3 F 02/07/83 1 420 3 F 02/07/83 1 421 3 F 02/07/83 1 422 3 F 02/07/83 1 422 3 F 02/07/83 1 424 3 F 02/07/83 1 425 3 F 02/07/83 1 426 3 F 02/07/83 1 427 3 F 02/07/83 1 428 3 F 02/07/83 1 429 3 F 02/07/83 1 427 3 F 02/07/83 1 427 3 F 02/07/83 1 428 3 F 02/07/83 1 427 3 F 02/07/83 1 427 3 F 02/07/83 1 427 3 F 02/07/83 1 427 3 F 02/07/83 1 428 3 F 02/07/83 1 427 3 F 02/07/83 1 428 3 F 02/07/83 1 427 3 F 02/07/83 1 428 3 F 02/07/83 1 429 3 F 02/07/83 1 430 3 F 02/07/83 1 431 3 F 02/07/83 1 432 3 F 02/07/83 1 433 3 F 02/07/83 1 434 3 F 02/07/83 1 437 3 F 02/07/83 1 438 3 F 02/07/83 1 439 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 02/07/83 1 438 3 F 02/07/83 1 449 3 F 02/07/83 1 441 3 F 02/07/83 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 444 3 F 02/07/83 1 444 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1	0					
412 3 F 02/07/83 1 413 3 F 12/03/82 0 414 3 F 02/07/83 1 415 3 F 02/07/83 1 416 3 F 02/07/83 1 417 3 F 02/04/83 0 418 3 F 02/04/83 0 418 3 F 02/04/83 1 419 3 F 02/04/83 1 420 3 F 02/07/83 1 421 3 F 02/07/83 1 422 3 F 02/07/83 1 422 3 F 02/07/83 1 422 3 F 02/07/83 1 423 3 F 02/07/83 1 424 3 F 02/07/83 1 425 3 F 02/07/83 1 426 3 F 02/07/83 1 427 3 F 02/07/83 1 426 3 F 02/07/83 1 427 3 F 02/07/83 1 428 3 F 02/07/83 1 427 3 F 02/07/83 1 428 3 F 02/07/83 1 429 3 F 02/07/83 1 430 3 F 02/07/83 1 431 3 F 02/07/83 1 432 3 F 02/07/83 1 433 3 F 02/07/83 1 434 3 F 02/07/83 1 435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 02/07/83 1 438 3 F 02/07/83 1 439 3 F 02/07/83 1 440 3 F 02/07/83 1 441 3 F 02/07/83 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 444 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1						'
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3	F		0	-
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3				
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3			0	
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3	F		1	
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3			1	t
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3	<u>F</u>		_	
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		<u>ತ</u>	F.		-	
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3	7		-	
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3	r			į
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3	r ਜ਼ਾ			
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3	F			,
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1	423	ž	<u>-</u> ਜ			
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3	F		ī	į
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3		02/07/83	ī	
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3	F	02/07/83	ī	1
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3		02/07/83	l	
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3		02/07/83	1	
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3				į
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3				i 1
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3				
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3			1	
435 3 F 02/07/83 1 436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/11/82 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3		02/07/83	1	
436 3 F 02/07/83 1 437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/07/83 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		3			1	
437 3 F 09/02/81 438 3 F 02/09/82 1 439 3 F 02/07/83 1 440 3 F 02/11/82 1 441 3 F 02/11/82 1 442 3 F 02/07/83 1 443 3 F 02/07/83 1 444 3 F 02/07/83 1 445 3 F 02/07/83 1 446 3 F 02/07/83 1 447 3 F 02/07/83 1 447 3 F 02/07/83 1 448 3 F 02/07/83 1 448 3 F 02/07/83 1 449 3 F 02/07/83 1 449 3 F 02/07/83 1		<u>ა</u>	F.			
			•	02/07/83	1	
		ડ ૧	r r		3	į
		3	र म			
		3	F		י ז	!
		3	F		วิ	1
		3	F		<u> </u>	
		3	F		Ō	:
		3			ì	1
		3	F		_	!
	446	3	F		1	
	447	3	F	02/07/83	1	i
		3	F		1	,
		3	F		1	i !
M = 12/19/82 = 0						
	451	<u> 4</u>	M	12/19/82	0	

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day; 4 = 35.0 mg/kg/day

RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B,C,F, MOUSE SURVIVAL RATE DATA

A N				n yer an die das des ges des des des des des f	
I M A	T R				
Ĺ	G R		ם	E V	
N C	o U	S E	A T	E N	
·	P	X	E	T 	
452 453	<u>4</u>	M M	02/07/83 02/10/82	1	
454 455	4 4	M M	02/07/83 02/09/82	1	
456 457	4	M M	02/07/83 02/07/83	1	
458	4	M	02/07/83	1	
459 460	4	M M	02/07/83 02/07/83	1	na v e mile
461 462	₹ ₹	M M	02/07/83 02/11/82	1 1	
463 464	<u>4</u>	M M	10/27/82 02/07/83	0 1	
465 466	<u>4</u>	M M	02/09/82 02/07/83	<u>1</u> 1	
467 468	<u>.</u> 4	M M	02/07/83 02/07/83	l l	e-in-pagente u
469 470	<u>.</u>	M M	02/07/83 08/03/·1	1	
471	4	M	11/15/82	0	; ;
472 473	<u>4</u>	M M	10/21/82 02/07/83	0	
474 475	<u>د</u> د	M M	02/07/83 02/07/83	1 1	:
476 477	<u> </u>	M M	02/07/83 10/20/82	1 0	!
478 479	<u>4</u> 4	M M	04/21/82 02/11/82	0 1	;
480 481	۲ ۲ ۲	M M	02/07/83 02/07/83	1	•
482 483	4 4	M M	05/27/82 02/07/83	0	i .
484 485	4 4 4	M M	02/07/83 02/02/83	1 0	1
486	4	M	02/07/83 02/07/83	i	
487 488	4 <u>4</u>	М М	12/17/82	0	1
489 490	<u>4</u>	M M	12/24/82 02/07/83	0	:
491 492	Ž Ž	M M	11/16/82 01/22/83	0 0	ı

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B.C.F. MOUSE SURVIVAL RATE DATA

N J	T			١,	9
M A L	R G R		D	E V	
и О •	O U P	S E X	A T E	E N T	a
493 494 495	<u>4</u> 4 4	М М М	02/09/82 12/24/82 02/07/83	1 0 1	
496 497 498	4 4 4	М М М	02/10/82 12/29/82 03/04/82	0 0	9
499 500 501	<u>4</u> 4 4	М М М	11/09/82 02/07/83 12/27/82	0 1 0	
502 503 504	र् र र	М М М	01/26/82 10/01/82 09/13/82	0 0 0	
505 506 507 508	4 4 4	м м м	02/07/83 02/07/83 02/11/82	1 1 1	0
500 509 510 511	₹ ₹ ₹	М М М М	06/11/82 02/07/83 11/28/82 02/07/83	0 1 0	
512 513 514	₹ ₹	м М М М	02/01/83 02/11/82 08/06/81 02/07/83	1 1	6
515 516 517	ج ج ج	м М М	02/07/83 02/07/83 02/10/82	1 1 1	
518 519 520	۲ ج ج	М М М	02/07/83 02/07/83 02/07/83	1 1 1	0
521 522 523	₹ ₹	М М М	11/09/81 12/17/81 05/20/82	0 0 0	
524 525 526	ر ر ق	M M F	01/30/83 08/24/81 09/26/82	0 0 0	6
527 528 529 530	र द द द	F- F- F- F- F- F- F-	02/07/83 02/07/83 02/07/83 02/07/83	1 1 1	
531 532 533	<u>.</u> 4 4	H 19 H	02/07/83 02/07/93 02/10/82	1 2 1	Ö

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B,C,F, MOUSE SURVIVAL RATE DATA

A N I T M R A L G R O U P	S E X	D A T E	', E V E N T	
534 535 536 537 538 539 541 542 544 544 544 544 544 544 544		02/07/83 12/29/82 07/02/82 02/07/83 02/11/82 02/07/83 02/07/83 02/07/83 01/18/83 01/01/83 12/17/82 12/21/82 02/07/83 02/07/83 02/07/83 10/16/82 02/11/82 10/07/82 02/07/83	1000111110100001101101011101010111010101	

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice

TR Group 1 = Control: 2 = 1.5 mg/kg/day PDV: 3 = 7.0 mg/kg/day PDV:

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX

3

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B.C.F. MOUSE SURVIVAL RATE DATA

SURVIVAL RATE DATA						
· A N I M A L	T R G R O U P	S E X	D A T E	E V E Ñ	 G	
575 576 577 578 579 580	4 4 4 4 4 4	F F F F F	02/07/83 01/20/83 04/16/82 02/07/83 02/07/83 02/07/83	1 0 0 0 1 0	4	
581 582 583 584 585 586	द द द द	F F F F F F	02/07/83 02/07/83 02/07/83 02/09/82 02/07/83 02/07/83	1 1 1 1 1	•	
587 588 589 590 591 592	4 4 4 4	म म म म म	02/09/82 02/10/82 11/12/82 02/07/83 02/07/83 02/10/82	1 0 1 1	•	
593 594 595 596 597 598	주 주 주 주	4 4 4 4 4	11/21/82 02/07/83 02/07/83 02/07/83 02/07/83 02/07/83	0 1 1 1 1	ć	
599 600 601 602 603 604	4455555	F F M M M M	02/07/83 01/05/82 04/19/82 02/09/82 02/26/81 02/07/83	1 0 0 1 0 1	đ	
605 606 607 608 609 610	4 ភេ ភ ភ ភ ភ ភ ភ ភ ភ ភ ភ	M M M M M	04/15/81 02/09/82 12/10/82 03/03/81 03/03/81 02/07/83	C 1 0 0 0 1	*	
611 612 613 614 615	55555	м м м м м	03/11/81 02/07/83 03/12/81 03/12/81 03/11/81	0 1 0 0	<u> </u>	

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B₄C₃F₁ MOUSE SURVIVAL RATE DATA

ar give day give dan gan ann gan dan dan dan dan sair enn sair ann ann dan dan dan ann ann ann ann ann	jage ange ang tred gang diath ange dian dans tres anne 1970 bing dans Plan		
A			1
N	_		
	T		
	R		
A	•		_
	G	_	E
	R	D	V
	O S U E	A	E
i		Ţ	N
	P X	E	T i
616	5 M	02/10/82	1
617	5 M	03/02/81	0
618	5 M	02/07/83	i l
619	5 M	02/15/82	ō
620	5 M	02/27/81	Ö
621	5 M	02/09/82	ì
622	5 M	10/10/81	0
623	5 M	02/10/82	i !
624	5 M	03/08/81	0
625	5 M	02/07/83	i
626	5 M	03/13/81	0
627	5 M	02/09/82	1
628	5 M	08/04/81	1
629	5 M	02/07/83	1
630	5 M	02/07/83	1
631	5 M	07/22/82	0
632	5 M	04/02/81	0
633	5 M	02/07/83	1
634	5 M	03/12/81	0
635	5 M	04/17/81	0
636	5 M.	09/10/81	0
637	5 M	10/29/82	0 .
638	5 M	02/11/82	1
639	5 M	02/07/83	1
640	5 M	02/07/83	1
641	5 M	03/04/81	0
642	5 M	02/07/83	ì
643	5 M 5 M	06/06/81	0
644		08/05/81	l
645	5 M	04/14/81	О .
646	5 M	04/01/81	0
647	5 M	02/07/83	1
648	5 M	08/04/81	1
649	5 M	04/14/81	0
650	5 M	03/11/81	0
651	5 M	02/07/83	1
652	5 M	02/07/83	1
653	5 M	02/07/83	1
654		02/07/83	1
655	5 M. M. M.	02/07/83	1
656	5 M	10/27/82	0

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

3

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B,C,F, MOUSE SURVIVAL RATE DATA

A				,	1
N					
I	${f T}$				
М	R				1
A					
L	G			E	1
	R		D	v	}
N	0	S	À	E	1
0	U	E	T	N	-
•	P	X	E	${f T}$	ļ
657	5	M	02/10/82	1	
658	5	M	03/16/81	0	1
659	5	M	02/07/83	1	}
660	5	M	02/07/83	ļ	1
661	5	M	04/15/81	0	İ
662	5	M	02/07/83	1	-
663	5	M	09/16/81	0	!
664	5	М	04/11/81	0	ļ
665	5	M	03/12/81	0	-
.5	5	M	08/06/81	1	
667	5	М	09/15/81	0	
668	5	M	02/11/82	1	;
669	5	M	08/04/81	1	
670	5	M	08/04/81	1	
671	5	M	02/11/82	1]
672	5	M	04/20/81	C	
673	5	M	02/07/83	l	
674	5	M	02/24/81	0	
675	5	M	02/07/83	1	!
676	5	F	02/07/83	1	
677	5 5	F	04/01/81	0	
678	5	F	02/07/83	1	
679	5		02/24/81	0	
680	5	Ŧ	02/28/81	0	
681	5	P F	11/30/82	0	
682	5	F	02/07/83	ĺ	
683	5	F	02/07/83	1	
684	5 5	F	02/07/83	ī	į
685	5	F F F F F F	03/02/81	ō	
686	5	F	08/05/81	ì	1
687	5	F	02/28/81	ō	į
688	5	F	04/06/81	Ŏ	ì
689	5	F	02/07/83	ĭ	i
690	5	F F	08/16/82	Õ	1
691	5 5 5	F	02/07/83	ĭ	:
692	5	F	02/07/83	ī	
693	5	F	02/07/83	i	1
694	5	F	02/07/83	i	
695	5	F	02/07/03	Õ	i .
696	5	ŗ	02/22/81	0	t
697	5	F	03/01/81	Ö	
	<u> </u>		03/01/01		•

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B.C.F. MOUSE SURVIVAL RATE DATA

		. كام يتين حيث حيث عند كام الله عند عام عام عام عام عام عام عام عام عام عام	****
M A L N O	T R G R O S U E P X	D A T E	E V E N T
698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738		02/27/81 02/07/83 02/07/83 01/14/83 02/10/82 03/03/81 08/06/81 02/07/83 02/07/83 04/01/81 08/05/81 02/25/81 02/25/81 02/10/82 04/16/81 03/31/81 02/10/82 02/10/82 02/10/82 02/10/82 02/10/82 02/10/82 02/24/81 02/07/83 03/04/81 02/07/83 03/04/81 02/07/83 04/05/82 04/19/81 02/25/81 04/05/82 04/19/81 02/07/83	011010101001001000000111111111111111111

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B.C.F. MOUSE SURVIVAL RATE DATA

A N I M	T R	an ain ain ain an ain ain ain ain ain ai		1,	
A L N O	G R O U P	S E X	D A T E	E V E N T	•
739 740 741 742 743 744	5 5 5 5 5 5	F F F F	02/07/83 02/07/83 02/11/82 02/11/82 02/07/83 08/06/81	1 1 1 1 1	
745 746 747 748 749 750	5555555555	,	02/25/81 02/24/81 01/28/83 02/07/83 02/24/81 02/09/82	0 0 0 1 0	4
751 752 753 754 755 756	1 1 1 1	м м м м м м	08/05/81 08/05/81 08/04/81 08/06/81 08/05/81 08/04/81	1 1 1 1	
757 758 759 760 761 762	1 1 1 1 1	M M M M F F	08/04/81 08/06/81 08/06/81 08/06/81 08/06/81 08/06/81	1 1 1 1 1	
763 764 765 766 767 768	1 1 1 1	F F F F F	08/04/81 08/05/81 08/05/81 08/06/81 08/05/81 08/06/81	1 1 1 1	
769 770 771 772 773 774	1 1 2 2 2 2	F F M M M M	08/05/81 08/04/81 08/05/81 08/05/81 08/06/81 08/04/81	1 1 1 1	
775 776 777 778 779	2 2 2 2 2 2 2 2 2 2	M M M M M	08/06/81 08/06/81 08/04/81 08/04/81 08/05/81	1 1 1 1 1 1 1 1	

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B,C,F, MOUSE SURVIVAL RATE DATA

A					i
N					ļ
Ĭ	${f T}$				Ì
M	Ř				Ì
	R				
A				~	
L	G		_	E	
	R	~	D	v -	
, N	0	S E	A	E	1
0	ប		${f T}$	N	į
•	P	X	E	Ţ	Ì
780	2 2	М	08/06/81	1	
781	2	F	08/06/81	1	I
782	2 2 2	F	08/05/81	1	i
783	2	F	08/04/81	1	1
784	2	F	08/04/81	1	ļ
785	2	F	08/06/81	ì	İ
786	2	F	08/04/81	ī	İ
787	2	F	08/04/81	ว ์	į
788	2	F	08/05/81	ז	
	2			7	ı
789	2	F	08/05/81	7	1
790	2	F	08/06/81	1	
791	3 3 3 3	M	08/04/81	1	
792	3	M	08/04/81	1	ļ
793	3	M	08/06/81	1	i
794		M	08/03/81	0	ļ
795	3	M	08/05/81	1	Ì
796	3	М	08/06/81	1	1
797	3	M	08/05/81	1	
798	3	M	08/04/81	้า	
799	3	M	08/05/81	7	j
800	3	M	08/05/81	ī ī	, ,
	3			3	
801		F	08/05/81	1	
802	3	F	08/04/81	Ţ	,
803	3	F	08/05/81	1	į
804	3	F	08/06/81	1	·
805	3	F	08/04/81]	1 1
806	3	F	08/05/81	1	į
807	3 3 3	F	08/06/81	1	•
808	3	F	08/06/81	1	
809	3	F	08/05/81	1	, !
810	3	F	08/06/81	1	
811	ā	M	08/04/81	้า	ļ
812	Â	M	08/04/81	้ำ	;
813	V	M M	08/05/81	<u>.</u>	
814	<u>ቱ</u>	M.	08/06/81	T	
	4			<u>.</u>	
815	4	М	08/06/81	7	
814	4	M	08/05/81	1	
817	4	М	07/13/81	Ü	
818	4	М	08/05/81	1	i
819	4	M	08/04/81	j	
820	4	М	08/04/81	l	

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4.= 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B,C,F, MOUSE SURVIVAL RATE DATA

A N I M A L N O	T R G R O U P	S E X	D A T E	E V E N T	
821 822 823 824 825 826 827 828 831 832 833 833 835 837 838 838 839 841 842 844 844 845 847 848	444444444555555555555555555555555555555		08/06/81 08/04/81 08/06/81 08/05/81 08/05/81 08/05/81 08/05/81 08/05/81 08/04/81 08/06/81 03/04/81 04/17/81 04/17/81 04/14/81 08/04/81 08/04/81 08/05/81 08/05/81 08/06/81 08/06/81 08/06/81 08/06/81 08/06/81 08/06/81 08/06/81 08/06/81 08/06/81 08/06/81 08/06/81 08/06/81 08/06/81 08/06/81	1 1 1 1 1 1 1 0 0 0 1 0 1 0 1 0 1 0 1 0	
849 850	5 5	F F	02/20/81 02/19/81	0 0	i 3 1

Event code is: 0 = Died or moribund sacrifice; 1 = Scheduled sacrifice

TF Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX;

4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (g)

ഇ		997-
1	0.00 0.	38. 38.
27	aurumnouum-440auuunouunrnon-m8400-a-r	
	0000000400000000000000000000000000000	0 10 O 10
25		
	$\begin{smallmatrix} 1\\1&0&0&0&0&0&0&0&0&0&0&0&0&0&0&0&0&0&0&$	n n n n
8		
*	0 0 0 0 0 0 0 0	ოოოო
	1 - 0 - 4 - 0 0 0 2 - 0 0 0 - 4 0 0 0 0 4 4 - 0 0 0 0 0 0 0	
o i	10	0000
	20000000000000000000000000000000000000	35. 30.
17	uu-040000000000000000000000000000000000	စ် က ် ဝ
		4 W O W
2		
İ	1 - 2 2 2 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	0000
# 3		
8		ω ω (v α
~	- d 0 - n 4 n d 0 d d n 0 4 n 0 4 d - 4 0 d 0 d d 0 - 6 0 - 6 d 0 - 4 -	
-	04	0 C 4 0
	**************************************	34. 28. 29.
ž č	1	-0
	1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	30 33
	929 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	0000
ω	000000000000000000000000000000000000	υ υ υ υ υ υ υ υ υ υ υ υ υ υ υ υ υ υ υ
	· · · · · · · · · · · · · · · · · · ·	
	28 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	တ်တယ်ဆ
ဖ	On # 4 On # 6 # 8 # 8 # 8 # 8 # 8 # 8 # 8 # 8 # 8	മനത
	229 229 227 229 229 230 230 230 230 230 230 230 230 230 230	40140
ស	44400-40044-0-0000000000-4446400000-0-0-	
	288 200 200 200 200 200 200 200 200 200	28 28 25 27
	N	
	2009 200 200 200 200 200 200 200 200 200	
	$\begin{array}{c} 1 \text{0} \text$	9 2 4 4
	0	
	222 22 22 22 22 22 22 22 22 22 22 22 22	25. 24.
	wa n u m u w w - O w n w - n G 4 4 - w 2 2 2 2 2 2 2 2 2 2 3 3 4 4 4 4 4	
	486888864986648868848888888888888888888	25 25 21 23
1	@@@@a@a@@@uuraa-O@-@an@@@a@@eunan@a	
	64-64-64-64-64-64-64-64-64-64-64-64-64-6	22 23 23 23 23 23 23 23 23 23 23 23 23 2
2	$\begin{array}{c} 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 $	
		9 12 12 14 14 14 14 14 14 14 14 14 14 14 14 14
νшх		EEEE
+¤ @¤o⊃¢		
ASHEAT SO .		37 38 39 40
	F .	

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX*---No data available (died) TR Group 1 = Ii

<u></u>	40000m00m-6m000mm4-2mn6m0mm/mmm-m00m::::::	
77		
72		
I.		
? ;	80 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0)
2	4 to O to to to to to to to to to to to to to	,
· ·	 യൈഎന്നയാഗരസം ഗര്ഷസ്ഷരസം — ഠയതയാഗയം — ഷത്രീഗയരുരുയത്തുന്നത്തെ യുധുയ്യുയ്യുള്ള വെള്ള വെള്ള വെള്ള വെള്ള വെയുന്നത്ത്	,
2	0 m 0 m m = 2 L L 4 0 4 m m G 4 m m G 4 m G 4 4 m m 4 4 G m G 8 m 8 m	;
- 1	rv rv rv rv rv rv rv rv rv rv rv rv rv r	•
1	60000000000000000000000000000000000000	,
17	+ r r r 4 r r r - r r r r r r r 4 r r r r	;
ĺ	+ 04 0 00 0 0 0 0 0 4 4 4 0 0 0 0 0 4 0	
- 1	23 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	3
6 ;	$ \begin{array}{c} n \otimes o \cup o \otimes o \otimes n + \otimes c \otimes a \otimes o + \otimes c \otimes o \otimes c + c \otimes o \otimes o \otimes c \\ \end{array} $	
t		?
- 1	0.45 0.00 0.45 0.00 0.00 0.45	
i I	। ଜିଉଁ ରଚିତି ନିର୍ଦ୍ଦିନ ରଚିତି କରି ନିର୍ଦ୍ଦିନ କରି ନିର୍ଦ୍ଦିନ କରି ନିର୍ଦ୍ଦିନ କରି ବିଜିତି ନିର୍ଦ୍ଦିନ କରି କରି କରି କରି କର ।	2
# # # # # # # # # # # # # # # # # # #	k is no santo is a notis of a filos for illustration and notice of table at the contration	;
+ ← - ←		
TES	9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	5
ர :	1 + W + + 4 W B O + O B + W O B O 4 W + 4 W W O B B O W O C W O + + + O W B + 4	•
1	トーーーーーーーーーーーーーーーーーーーーーーーーーーーーーーーーーーーー	-
1 1	33. 33. 33. 33. 33. 33. 33. 33. 33. 33.	3
~	mmm4+m>0>m+>0mmmm0m4m4m4m4m4mm>04mm>00	מ
1	2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	5
- 1	0 - 0 - 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	•
	I ᲠᲝᲠᲝᲝᲝᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠᲠ	7)
	000000000000000000000000000000000000	
4	O - O 0 4 4 7 7 7 - O 0 0 0 7 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0	າ <i>ເ</i>
	227 227 227 227 227 227 227 227 227 227	
က	000-40000004-00-00-0-00000040000400	
	0	52
	1	
	$\begin{array}{c} 1 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\$	
	1 4 0 ± 0 ± 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ກ
	no-uunn-unncoannema-nuon-ouunnoramumaa	
'	$\begin{array}{c} 1 & 0.00 $	
	8-04-8-1-0-08-4-0-0-08-00-04-1-0-08-4-0-08-4-0-08-4-0-08-4-0-08-4-0-08-4-0-08-4-0-08-4-0-08-4-0-08-4-0-08-4-0	•
	0000000401200202020202020202020202020202	23
		_
νm×	XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	Æ
⊢α 0α0⊃α	*	-
	44444444444444444444444444444444444444	TU.

= Control; $2 = 1.5 \cdot g/kg/day \; RDX$; $3 = 7.0 \; mg/kg/day \; RDX$; $= 35.0 \; mg/kg/day \; RDX$; $5 = 175/100 \; mg/kg/dey \; RDX$ *---No data available (sacrificed) TR Group 1

٨

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGG3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

	. !									_		۔. ہ		. <i>.</i> _							_							_	 .	٠.	. ~					
	29	í		1	i	4	. 0	m	-	8	ω,	4.		. 6	ы	æ.	ö	ö	m	• د	; o	, <u>, , , , , , , , , , , , , , , , , , </u>	-	4	<u>ن</u> د	, .	29.7	ė	4.	4 (. 4	36.3	·σ	0	
	27	! !	: 1	ļ	:	Ľ	S	တ	8	ø	٠,	ء و	2 4	က	ស	0	0	0	<u>ص</u> (٠ بو	ی -	2 6	0	0	φ, •	- 41	9	ო	φ.	N *	- 6	٠,	ν. (N II	0	
		* *	4		ړ ب	: 6	29	9	ဓ္ဓ	37	27	9 6	0 0	36	35	28	33	ဓ္ဗ	93	5 6	3 6	34	9	32	32	N (C	88	63	CV	., (36	V (1)		36		
	25										-					-												•			-		•		• •	
	23	- (۰ ۲	; c	۶ اد	. c	0	0	0	o,	φ.	ه د	ى ز	1 0	0	æ.	<u>ه</u>	. ب	4.	ه زه	ی و	9 0	4	4	٠. ٥	, c	O	۲.	ო (ص ر	ء د	. m	- 1	·	9	
	1	9	יז ני	י כ	3 () (T	0	Ö	n	n	CV I	(n)	J (10	n	0	က	C)	e (n (ט נ	40	10	က	ო (7 C	3 (4	က	2	n c	<i>N</i> C	4 (C)	36	<i>.</i>	\$ CV	
	2	ю· -		٠,				. n	or.	Ť.	o .	÷.	n ~	. 4	6	7	ů.		ó		, o		6	Ξ.		٠ د		ė.	8	σ, σ	. o	. 6	33,3	ن ن	, IO	
	6	<u>ښ</u> د	o u	٠.	- <	. c	90	n	1	۲.	9	0	א נ	9	0	Ξ.	o.	8	- (o c	n 0	י ני	٠-	٣.	ب ا	<u>ء</u> ڊ	4	<u>ه</u>	- :	<u>ه</u> د		i u	ល	n in	9 09	
		(C) (י) ני	3 (2	,	3 6	10	n	B	N I	m :	7 (10	C	0	က	N	0	m (7 (40	10	8	e (7 (i (n	~	ο c	. V	40	9 31	<u>ო</u> ი	10	
	17											٠						•	•					•	•			•	•	•						
	5	N, I	٠.	۰ ۲	t	9 0	9		4	۲.	o.	œ i	٠ .	9 0		₩.	æ	-	٧.	- •	4.0	۰,	ະທ	œ	٠, ٥	ρ, c	i Ri	۲.	æ	4 1	•	- 1	σ,	ci n	? 6	
	9	(C)	3 (, c	9.3	٠,	10	. 0	N	m	CV.	0	× 6	4 2	N	4	G	N	N	Ö (7 (4 0	1 (1	7	ci c	7 (3 6	C	0	0	20	10	6 28	α (4 (4	
	-	8	<u>.</u> ,		· -	ص-	0 3	٠ 🕳	ω.	6	വ	اه	ດ ພ	. (1)		4.	ö	ທີ	ω.	÷.	. 0	۰,	. 6	7.	œ (u o		8	ė	۲.	٠, د	4 G	27.	<u>.</u> ن		
	5				٠												•	•	•		•				•	•			•	•	•		8.8	•		
	-	6.0	रू स	יר פרו	יי יי	ີ ເ	5 K	2 10	. 6	8	3	0 (0 (0 C	v c	7	7 2	9	9	7 7	0 ·	4 n	, c	9 00	6 2	7	, c	4 EU		2	0 I	~ L	א ט א	10	0 C	9 69	
E E	- !		٠, ر	٠.		v u	0 4	· σ.	ın.	8	4.	œ :	· 0	o u		4	ä	4.	5	٠ ا		, -	. ه	ß.	ف	υ, n		တ်	o.	٠ ي	4 (25.	ر ا	, c	
W TS	₽												-							•										•	-		7.6			
1	6	60	m (, c	າເ - ເ	, ,	, c) a	· ~	3	+ 2	6	0 C	ν c 0 σ) E	2	2	5	8	ເນ .	- (9 Y D Q	9 C	2	0	0 C	0 C	10	C	CV ((,	74 C	: C	~ 0	A (A	
	1	31.	9 8		\neg) t	2 5	• 10	·	ന	4	~ '	ਰ :	. a	10	*	8	~	4	ന	10 (ο τ	t in	ഥ	ED.	9 (2 6	. ~	25.	26.	25	22.	76.	25.	22	
	æ	<u>.</u>	ö	·,	- 6	5 6	٠,	: "	. 4		9	6	4 (າ o		4	7.	ი	4	ش	φ,	4 1	0 4	΄ ω	4	٠,	4.	ف	9	<u>ن</u>	4 (ນີ້	5.8	4.	9 0	
	7	8										0		0 <		4	-		n	N.	- 1	ດ ເ	v 0		13:								_		א נט א	
		1										56	4 6	3 C	200	23	30	23	23	27	25	2 2	2 12	24	26	23									2 2	
	;	8.0	ნ.	(5 . (٥,	ລເ	V U	. 4	ູເຄ	4,	4	4.1		. 4		9	ი	Ċ	7	4,	. (9 4	Э	ω.	4.		. ic	6	₹.	4 (ni r	. .	₹.	ŋ	
		0.								0	4	0		N '				က	ø	9	-	4 0	ο σ	00	æ	0		, n	m							
		ñ	N	m i	Ñ		Š	, ,	Ó	N	N	N	מי נ	Ŋ Ĉ	'n	1 (1	'n	N	Ň	Ñ	O I	7	10	N	N	0	4 6	i	c	7	C)	S C		C) I	7 7	
	1	29.9	۲.	0	٠.	~ (٠.	٠.	8	4.	∴ ,			;	7	-	÷.	ъ.	4	, i	ر د د	. 6	Э.	₽.		. 4	С	ε.	8	ά,	4 4	ĸ.	~ -	
	6	8.9	-	(C)	on e	~ i	ο ,	- c			ED.	~	r 1	n •	- 10	. N	· Ien	N	0	0	<u>.</u>	.	ი თ	•	ιΩ	ហ	~ c) N	. (5)	80	-	co (מוכ	ω.	- დ	
		0 28	₩.	C ·	C) (· (~ (γ c	1 C	10	N	CA	C)	~ 0	ч с	10	2	10	C	N	C)	(4)	A C	1 (1	N	C	אנ	4 (7		C	(4	CA C	4 (1	(4)	. W .	
	1	28.	. ق	თ	ر ا	ه و	N (n -	· _	: -	c.	-	÷,	٠.	, +		, m	· •	÷.	'n	<u>.</u>	o o	د د	; -	ö	ċ	o o	; , ;		8	'n	ö٠	- 0	o.		
		7.7			٠	٠				•																•					•				6 6 8 9	
	-	2 2	24	0	6	C (2	- (4 C	• •	,		-	0	ν ς	٠ -	. 4	! (7	ď	8	7	O E	3 6) 12 	0	8	e .	- 1- - 0	1 (4	0	8	CV C	7 (1	ď	C 0	
	1	26.	24	26.	~	23.	200	, o	, a	200	18	20.	8	9 6	α	σ.	20	8	1 8	21.	20	⊕ :	<u> </u>	9	0	6	<u>.</u>	n C	202	20	<u>6</u>	ω :	2 2	9.	5 2	
		4.4	ď	9	ċ	· .	o:	- 0	D a	o o	. ດ	6	8	ພ່າ	- a	o «			œ	o.	ó			5 6	8	œ.	თ. ი	÷ •		6	8	ω.	ກຸກ	-		
		18	7	8	~	0	٠ ٢٧			_	_	-	-	- (N =			. —	-	2	C4		- •	- ~	-	_		- 0	-	_	_	·- ·		-	 •	
S	ın ×	2	Σ	Σ	Σ	Σ	ابد	L L	L	L LL	,	L.	_	<u>.</u>	L	L U	. 11	. 4	u	Ŀ	ı	u, i	ır u	_ 11	. 44	LL.	LL E	LL	. 1		Ŀ	LL 1	ı (v	<u>.</u>	<u> </u>	
0 & O :	ے د	-	-	-	-	_	 .	.				—	_	. .			٠.		-	_	_	.	. .			_	- •				_	.		-		
				* ^	т.	^	10 .		m -	<i>~</i> ~	٠.	~		.	n	n -	. ~	. ~		-	~	Ε.	* - 14	· "	. ~	m	m /	~	. ~			ю. '	o	er.	ത ന)
	0 ·	756	75	756	758	767	~ 1		~ ~	. 6	စ်ထ	8	ĸ	άö	ž d	δά	ä	ĕ	6	6	ò	တ်	ф.,	ó	6	6	<u>წ</u>	Š	ò	Ę	Ö	Ď.	<u> </u>	õ	ĕΞ	•

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX*---No data available (sacrificed)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASENTS (9)

Group 4 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2

∢Z⊢Σ∢

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINNGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

		29		1 1	!!!	1 4	5.	່ ຕ ແ	 	. ~	4 6	6.	Ox	6.6	in a			. CO L	 	٠. ن.	9 1	- 4
		27]		1 0	- ~		- m	0 0	0 0	80 C	000	9 0	00 1	. 10 -	- 10 1		4 4	വ	. .	- 0
		25	* * * *	44.44.	* * * - O -	% C)	9 4	. ന r) (D)	0 10 10 10	4 10 10 4	OR	900		. O «		າຕເ ວພ•	. O	ים ממ	o G	ლ (4 44 3 63
		9		000	70 4 10 50 61 60	3 35	6 35	5 32	6 37	2 38 1 33	7 35 6 38	9 34	29 0	0 4 6	888	2 37	36	27.	5 36 5 36	4 33 33	7 36	- 5 34
		2		000	n 0 0	0 m	ოო	. CO C	ימי	ოო	ი ი	(C) (C)	. m m	40	(C) (C)	ימי	າຕເ	3 64 6	ים מי	ოო	m c	ים פ
		2			0 - 4	œ 10	4.0	4 I	· ·		4.	ω r	· 4	œ -	in 4		9 10 6	. ~ 1		. 6	٠ 1 عا	. 4
		49		27.4	28.08 20.08	27.6	34.3	33.2	32.0	31.9	34.4	34.5	8.02	37.6	24.0	7.7	. 0. A	9.09	34.5	36.0	35.0	33.8
		17	4446	~~	- ~ @	m in	0.00	0 11	. **	mm	- 10	0	110 0	m a	10.10	. ~ 0	י יוי	- 10 (0 10		~ -	n m
		15	4200	00	e	o. +.	ი. ი	4	- 01 I	.υ. 	4.6	ric a	46	46	40	່ທີ່ເ	, 4 4		2 G	, 4.	ю. •	- m
		<u>ဗ</u>	0000	100	~ ~ ~	24 00	ი ი	en c	00	6 4	ი ი	0 0	200	000	(m)	900	יטוי	2 63 6	. n	ო ო	(C)	າຕ
			28.	N = 1		4.0	- <			4 6	4	e c				 ! 			2 6	∻ ⊹	· ·	
			28.5 27.4 30.1	. C. 4.1	C 4 8	40	- C	2 10	. 4	40	4	നാ) - (0 C	,	- 40	າຕເ	200	NO	~ 5	2	4 (7)
	Ä	Ξ	21.12	ر ب ان عا	- n u	4.0	1-0	9 4	4	N 10	œ, 0	α α	, eo -	'nν		دري	0 10 0	<u>ه -</u> د	20	o	٦.	4 6
	ST WE	_	0.000		O 10 0	2 0	ი ო		າ ຕ _່	6 6 6 6	m m	. — -	200) (C) (C	, m r) m c	າ ຕ ເ 	200		ო ო	ල (ກຕ
	TES		7 28 (0 28. 9 28. 3																			
				. d m	4 4 W	4.0	0-	0,	· 67 ·	÷. ∞.	0 6	ci c	; æ c				, m		×-:	۰. o	ó	ý -
		œ	29.7 26.8 26.8	- m	. e o	e -	60		; .	٠. د	0.0	+		4.0	. N +		, - ,		٠ - د	- 0	0	
		7	n a r c a r c c	. च्या	ນ ດ ທ	2.5	6.4	0.6	1.7	0.0	- 6		8.6	a		4.0	9 60 6	9 69 6		÷ 0.0	9.6	4.0
		9	0000	44	000	- 6	46	- u	, eo	0 60 60 60	0.0	0.4	.04		100	. 4. c	3 4. ¢	4 to .	~ (O	ω 4 ω ω	ω (ນ ຄຸນ ລະດ
		ស	9 25 1 25 7 23 25 25 2																			
			24.	, -	w v, 4	00	ω C		60	0	80 6	00		. m a			900		, o	0 8	· •	- o
			23.7 23.5 22.3	- 6 -	~ - ~	0 6	600		·	۲. 4	6	6		.0.	. a	- c			. o	o ·∹	ω.	29.3
		က	3.7.4	4.6	4 0 0	- 4	w c	٠, ٥	. n	40	ن 4	ល	iric	, c , c	د د د	0,0	ာ ဆ	خ متن	4.1.	o ، ۲-	φ,	၁ ဖ
			2000	4 - 0	~ ~ ~	200	900	900	2 to 10	0 U	84	. 64	- 60 +	. 61 c	. C. +	- - - c	2 CO C	101 101	9 2 2	22	4	9 CC
			1 22 9 22 0 21 0 21 2		20 23	202	24	4 6	27	26	25	27	23,	287	28	360	27	22	26	27	26	27
			200.5	. 6	- 0 -	0 6	, n u		. 6	ი თ. თ.	4 4	60.3	; -			 . o r			. ·	ω 4	6	9 0
		•	20.4 19.0 18.9	့ မေ က	ဝစ်င	o io			0.10	4. O	60	 			 		 	 	 m w	٠. ×	₹ .	
		?	0.00	- 22	6 6 6 6 6 6	6.6	- α	4.1	9.0	0 0 7	2. 4	4.1	, eo e	. .	9.00	່ເບັ	. 4	9.7	4.8	e -	5.5	3.5
			7 = = =		~ ÷ ₹	رة مــ ا	1010	100	7 (7)	α ∓	00	i ci c	4 ← 6	'nò	i W.	v čí č	N 61 6	N ~	N Ñ	0 0	2	NÄ
	សធ	u ×	; ; ; ; ;	. L. LL	L. LL LL	. L. Z	ΣΞ	Σ:	EΞ	ΣZ	¥ 2	Œβ	E 2	2 2	E 2	E 2 :	ΣΣ:	E E	ΣΣ	ΣΞ	Σ:	ΣΞ
ت 2	0:	٥ م				0	000	100	7 77	0 0	00	000	400	4 () (900	v 27 (200	N 61	n n	0 0	8	7 7
ب :	2 5		761 762 763	ဗမ	ဖြစ္ဖ	F 15	ពេល	15.4	156	153	159	161	163	165	167	9 6 6	275	173	174	176	178	179 180

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX*---No data available (sacrifices)

			7	() (.,	,,,	., (3 6	, (,	(7)	(3	., 4	7 (7)	,	(C) (r	35.	n	į	ָה ה	34	4.	98.	32.	32.	2 6	38.	33	37.	34	3 6	5 6	39.4	9	33.
			27	36.5	٠,	n c	, ,		. ~	ID.	N I	ם כ			٠	ט פ	35.2	RJ.		n ee		.			e .	, 6	38.5	e,			iσ		40.3	٠,	35.4
			25	34.8	٠,	٠,	;	·σ	. 4	4	- ;	. כ	m		r,	D 4	35.4	'n				•						•	•	•			39.0		
			23	0.	- (? 6	. u	, «	. ~	0	4	4 -	. m	: :	٠. ٥	7 6	, W	0	: 3	e un	-	ų,	ຄຸຕ	ø	<u>ه</u> و	, ,		-	٠. ۱	α	- «	٦ (· w	w c	10
			21			ם מ	, 0	, r	60	6	6	N +	- 00	1	~ (" –		0		t o	0	m (p (*)	o o	ភ (ο σ	7	m	9 (x 0	n -		3 39	ທ່	υ
			. i	es c	י ני	ין ר ר	יין נ	0 00	32	33	0 1	מ מ	000	ا ⊀د	98	ים מי	32	36	ו ע ע	9 6	34	66	5 6	3	င္က င	, E	38	32	33	32	2 6	3 8	9 37	37	34
			-	-	, 0 •	• c) =	, r oc	, i	e.	o i			8	ю. •		; _	4.	١,	, 60	6	ö.			- ,		; -	÷.	4.	-		. ~	36.9	œ •	4
			17	10		, .		· α	Ŕ	e.	o's	÷ ,	. 6	6	4 (<u>.</u>	4	٠.	, e	i	<u>.</u>	ຫໍອ	-	.	<u>.</u> ,	, IU	- :	e.	-	. א	i u	35.8	ທ່ ເ	່ຕ
			15	7.5	- (9 6	, ,	. r		. .	9	- 6	. ~	6.	7.5	p 4	9 00	6.6	m •	• 10	8.	۲.	9 1	6.0	= 1			7.5	ص ا	E C	יי נית	, 0	9	8 (2.0
			3	6	. c		- 4 5 C) (T	7 3	5	4	ט מיק) m	8	μ. (ים מים	3 W	8	თ. თ. (n n n	8	4 (6 n 10 c	. m	က က (ი ი ე ი) (0	, 9	(7)	n G		ים פ) L	α (C) (, 6. . 6.
			2		4 6	ה ל ה	, נ	א ה	3 6	31	53	99	9 17	31	32	5	8 34. 28.	33	<u>.</u>	ה היי	9	32	39	မ္	ဓ္ဓ	9 6	35	29	33	29	28	ט ני מע	9 34	31	32
			7																														33.0		31.
	E	;	-				4																						•				33.1		30.4
	ST WE		0	4	N, C	י פ	• •	ņu) œ	ø	-	φ 0	n C	0	m I	v c	u O	7	œ, ·	- v	4	۲.	ທ໌ ເ	4 65	6	7 0	n w	6	7	ហុ	ω n	n u	0	<u>ن</u>	ກຸ່
	TEST		6	η.	4 (٠ و	- (۰.	ی .	'n	6	۲. ر	ى رە	9	ır.	- (و م	'n	ဖ	m +	n	ı.	oo c	9	۲.	٠. (ე	ı.	œ,	~	ס ָי	٧.	3 00	ဖ	. 2 30
			c o				2 6	ק	300	30	28	32	ט ט ט	32	3 32	ခွ <u>ရ</u>	233	31	31	2 C	200	35	37	29	3 28	28	32	28	31	5 29	3 27	2 i	3 CC	33	99
			1		٠.			٠,											•	•									•	•		•		•	8 8
			7	2	e.	- O (5 6			0	7	٠ ا	ה כ	; -	_ .	6		-	,			4	<u>ن</u> ن		6	œ (9 6	7	ó	æ 1	۲.	, ,	2 6	'n	30.2 29.9
			ဖ	6	-	٠ ا ب	ų (, כל ב	r cc	n	œ	9	ח ע	0	7	ທຸເ	ō 4	0	0	n u	-	-	4 (0 7	-	٥ı	ດທ	7	ı	œ	٠,١	- 0) 4	6	40
																														~	'nÒ	= :		Ñ	32
			J.	-	۱,	'n.	٠, ١	٠. ١	΄. Τ	٠.	٧,	٠: ١	٠, ٠			٠,			•			•				•		٠.	æ	9					6; -
					6	28	5		, ,	29	26	E (ם כ	29	23	53	32	29	90 1	4 28	27	32	8 6	27	28	7	3 6	26	29	7 27	1 26.9	1 31.2	3 31.4	32.8	28
			4	31.8 32	30.9 31	27.8 28	28.8 30	27.6.78	29.0.21	28.6 29	26.5 26	31.5 31	32.5 33	29.6 29	29.3 29	28.9 29	25.0.25	28.6 29	29.7 30	27.4 28	27.1 27	30.8 32	33.5 34	27.1.27	26.6 28	25.9 27	30.1.31	29.7 26	28.4 29	26.7 27	26.1 26.9	26.1 31.2	31.3 31.4	31.8 32.8	28.0 28 27.4 28
			4	1.4 31.8 32	0.2 30.9 31	7.2 27.8 28	8.0 28.8 30	6.121.678	7 6 29 0 21	7.7 28.6 29	5.4 26.5 26	0.1 31.5 31	2.2 32.5 33	8.1 29.6 29	7.8 29.3 29	7.8 28.9 29	9.6 31.0 32 4.7 25.0 25	8.3 28.6 29	8.7 29.7 30	6.6 27.4 28	6.5 27.1 27	0.5 30.8 32	2.5 33.5 34	5.8 24.1 23 6.4 27.1 27	6.0 26.6 28	4.9 25.9 27	6.5 27.4 28 0.2 30.1 31	4.6 29.7 26	8.0 28.4 29	6.2 26.7 27	5.6 26.1 26.9	8.8 26.1 31.2	2.3 32.4 31.8 0.6 31.3 31.4	0.7 31.8 32.8	28.0 28 27.4 28
			£	0.7 31.4 31.8 32	8.7 30.2 30.9 31	6.1 27.2 27.8 28	5.9 28.0 28.8 30	5.7 26.7 27.6 78	9.8 30.3 32.0 31 6 7 27 6 29 0 21	7.1 27.7 28.6 29	4.9 25.4 26.5 26	8.5 30.1 31.5 31	0.5 32.2 32.5 33 6 0 7 6 70 0 70	7.3 28.1 29.6 29	6.8 27.8 29.3 29	6.2 27.8 28.9 29	7.7 29.6 31.0 32 3.7 24.7 25.0 25	6.8 28.3 28.6 29	8.1 28.7 29.7 30	5.6 26.6 27.4 28	5.3 26.5 27.1 27	9.5 30.5 30.8 32	1.5 32.5 33.5 34	5.5 26.4 27.1 27	5.4 26.0 26.6 28	4.3 24.9 25.9 27	5.9 26.5 27.4 28 8.6 30.2 30.1 31	3.9 24.6 29.7 26	6.9 28.0 28.4 29	5.7 26.2 26.7 27	4.7 25.6 26.1 26.9	8.2 28.8 26.1 31.2	9.7 30.6 31.3 31.4	9.5 30.7 31.8 32.8	5.1 27.2 28.0 28 5.3 27.0 27.4 28
			2 3 4	.2 30.7 31.4 31.8 32	.9 28.7 30.2 30.9 31	6 26.1 27.2 27.8 28	1 26.9 28.0 28.8 30	2 25.7 26.7 27.6 78	9 28.8 30.3 32.0 31	4 27.1 27.7 28.6 29	.6 24.9 25.4 26.5 26	.0 28.5 30.1 31.5 31	.3 30.5 32.2 32.5 33	.6 27.3 28.1 29.6 29	.3 26.8 27.8 29.3 29	.5 26.2 27.8 28.9 29	.6 27.7 29.6 31.0 32 .6 23.7 24.7 25.0 25	.0 26.8 28.3 28.6 29	.1 28.1 28.7 29.7 30	.9 25.6 26.6 27.4 28	.0 25.3 26.5 27.1 27	.3 29.5 30.5 30.8 32	.5 31.5 32.5 33.5 34	.7 25.5 26.4 27.1 27	.5 25.4 26.0 26.6 28	5 24.3 24.9 25.9 27	.4 25.9 26.5 27.4 28 .5 28.6 30.2 30.1 31	.8 23.9 24.6 29.7 26	.3 26.9 28.0 28.4 29	.7 25.7 26.2 26.7 27	0 24.7 25.6 26.1 26.9	.8 28.2 28.8 26.1 31.2	.9 31.1 32.3 32.4 31.8 .6 29.7 30.6 31.3 31.4	.1 29.5 30.7 31.8 32.8	.8 26.1 27.2 28.0 28 .0 26.3 27.0 27.4 28
			1 1 2 3 4	29.2 30.7 31.4 31.8 32	27.9 28.7 30.2 30.9 31	24.6 26.1 27.2 27.8 28	25.1.26.9.28.0.28.8.30	24.2 25.1 26.1 21.6 78	26 6 29.6 30.9 32.0 31 26 9 26 7 27 6 29 0 21	26.4 27.1 27.7 28.6 29	24.6 24.9 25.4 26.5 26	28.0 28.5 30.1 31.5 31	28.3 30.5 32.2 32.5 33	25.6 27.3 28.1 29.6 29	26.3 26.8 27.8 29.3 29	25.5 26.2 27.8 28.9 29	3 26.6 27.7 29.6 31.0 32 5 23.6 23.7 24.7 25.0 25	6 26.0 26.8 28.3 28.6 29	3 27.1 28.1 28.7 29.7 30	24.9 25.6 26.6 27.4 28	24.0 25.3 26.5 27.1 27	28.3 29.5 30.5 30.8 32	29.5 31.5 32.5 33.5 34	24.7 25.5 26.4 27.1 27	24.5 25.4 26.0 26.6 28	23.5 24.3 24.9 25.9 27	27.5 28.6 30.2 30.1 31	22.8 23.9 24.6 29.7 26	26.3 26.9 28.0 28.4 29	24.7 25.7 26.2 26.7 27	24.0 24.7 25.6 26.1 26.9	26.8 28.2 28.8 26.1 31.2	29.9 31.1 32.3 32.4 31.8 28.6 29.7 30.6 31.3 31.4	25.1 29.5 30.7 31.8 32.8	8 26.1 27.2 28.0 28 0 26.3 27.0 27.4 28
			-1 1 2 3 4	28.0 29.2 30.7 31.4 31.8 32	26.6 27.9 28.7 30.2 30.9 31	23.1 24.6 26.1 27.2 27.8 28	23.6 25.1 26.9 28.0 28.8 30	22.2 24.2 25.7 26.7 21.6 78	26.8 28.8 29.8 30.9 32.0 31 23 E 25 9 26 7 27 6 29 0 21	24.9 26.4 27.1 27.7 28.6 29	23.9 24.6 24.9 25.4 26.5 26	26.2 28.0 28.5 30.1 31.5 31	26.8 28.3 30.5 32.2 32.5 33	24.8 25.6 27.3 28.1 29.6 29	24.8 26.3 26.8 27.8 29.3 29	23.4 25.5 26.2 27.8 28.9 29	25.3 26.6 27.7 29.6 31.0 32 23 5 23 6 23 7 24.7 25.0 25	24.6 26.0 26.8 28.3 28.6 29	25.3 27.1 28.1 28.7 29.7 30	22.7 24.9 25.6 26.6 27.4 28	22.9 24.0 25.3 26.5 27.1 27	26.5 28.3 29.5 30.5 30.8 32	27.8 29.5 31.5 32.5 33.5 34	23.4 24.7 25.5 26.4 27.1 27	22.9 24.5 25.4 26.0 26.6 28	21.4 23.5 24.3 24.9 25.9 27	24.2 25.4 25.9 26.5 27.4 28 25.9 27.5 28.6 30.2 30.1 31	24.7 22.8 23.9 24.6 29.7 26	20.9 26.3 26.9 28.0 28.4 29	23.9 24.7 25.7 26.2 26.7 27	22.1 24.0 24.7 25.6 26.1 26.9	25.3 26.8 28.2 28.8 26.1 31.2	26.9 28.6 29.7 30.6 31.3 31.4	27.2 25.1 29.5 30.7 31.8 32.8	23.0 28.8 26.1 27.2 28.0 28 23.3 25.0 26.3 27.0 27.4 28
			-2 -1 1 2 3 4	5.5 28.0 29.2 30.7 31.4 31.8 32	4.8 26.6 27.9 28.7 30.2 30.9 31	1.5 23.1 24.6 26.1 27.2 27.8 28	2.4 23.6 25.1 26.9 28.0 28.8 30	0.8 22.2 24.2 25.7 26.7 21.6 78	5.5 26.8 28.8 29.8 30.3 32.0 34 5 4 53 E 55 9 26 7 27 6 59 0 24	3.7 24.9 26.4 27.1 27.7 28.6 29	3.4 23.9 24.6 24.9 25.4 26.5 26	4.8 26.2 28.0 28.5 30.1 31.5 31	5.1 26.8 28.3 30.5 32.2 32.5 33	3.2 24.8 25.6 27.3 28.1 29.6 29	3.8 24.8 26.3 26.8 27.8 29.3 29	1.9 23.4 25.5 26.2 27.8 28.9 29	4.0 25.3 26.6 27.7 29.6 31.0 32 2 4 23 5 23.6 23.7 24.7 25.0 25	3.2 24.6 26.0 26.8 28.3 28.6 29	4.2 25.3 27.1 28.1 28.7 29.7 30	1.3 22.7 24.9 25.6 26.6 27.4 28	3.8 23.8 28.1 28.4 30.2 30.4 32 1.9 22.9 24.0 25.3 26.5 27.1 27	5.1 26.5 28.3 29.5 30.5 30.8 32	4.0 27.8 29.5 31.5 32.5 33.5 34	1.9 23.4 24.7 25.5 26.4 27.1 27	1.6 22.9 24.5 25.4 26.0 26.6 28	9.8 21.4 23.5 24.3 24.9 25.9 27	2.6 24.2 25.4 25.9 26.5 21.4 28 4.7 25.9 27.5 28.6 30.2 30.1 31	9.6 24.7 22.8 23.9 24.6 29.7 26	3.5 20.9 26.3 26.9 28.0 28.4 29	2.6 23.9 24.7 25.7 26.2 26.7 27	0.0 22.1 24.0 24.7 25.6 26.1 26.9	3.3 25.3 26.8 28.2 28.8 26.1 31.2	5.5 27.7 29.9 31.1 32.3 32.4 31.8 4.4 26.9 28.6 29.7 30.6 31.3 31.4	4.8 27.2 25.1 29.5 30.7 31.8 32.8	23.0 28.8 26.1 27.2 28.0 28 23.3 25.0 26.3 27.0 27.4 28
			-2 -1 1 2 3 4	5.5 28.0 29.2 30.7 31.4 31.8 32	4.8 26.6 27.9 28.7 30.2 30.9 31	1.5 23.1 24.6 26.1 27.2 27.8 28	2.4 23.6 25.1 26.9 28.0 28.8 30	0.8 22.2 24.2 25.7 26.7 21.6 78	5.5 26.8 28.8 29.8 30.3 32.0 34 5 4 53 E 55 9 26 7 27 6 59 0 24	3.7 24.9 26.4 27.1 27.7 28.6 29	3.4 23.9 24.6 24.9 25.4 26.5 26	4.8 26.2 28.0 28.5 30.1 31.5 31	5.1 26.8 28.3 30.5 32.2 32.5 33	3.2 24.8 25.6 27.3 28.1 29.6 29	3.8 24.8 26.3 26.8 27.8 29.3 29	1.9 23.4 25.5 26.2 27.8 28.9 29	4.0 25.3 26.6 27.7 29.6 31.0 32 2 4 23 5 23.6 23.7 24.7 25.0 25	3.2 24.6 26.0 26.8 28.3 28.6 29	4.2 25.3 27.1 28.1 28.7 29.7 30	1.3 22.7 24.9 25.6 26.6 27.4 28	3.8 23.8 28.1 28.4 30.2 30.4 32 1.9 22.9 24.0 25.3 26.5 27.1 27	5.1 26.5 28.3 29.5 30.5 30.8 32	4.0 27.8 29.5 31.5 32.5 33.5 34	1.9 23.4 24.7 25.5 26.4 27.1 27	1.6 22.9 24.5 25.4 26.0 26.6 28	9.8 21.4 23.5 24.3 24.9 25.9 27	2.6 24.2 25.4 25.9 26.5 21.4 28 4.7 25.9 27.5 28.6 30.2 30.1 31	9.6 24.7 22.8 23.9 24.6 29.7 26	3.5 20.9 26.3 26.9 28.0 28.4 29	2.6 23.9 24.7 25.7 26.2 26.7 27	0.0 22.1 24.0 24.7 25.6 26.1 26.9	3.3 25.3 26.8 28.2 28.8 26.1 31.2	5.5 27.7 29.9 31.1 32.3 32.4 31.8 4.4 26.9 28.6 29.7 30.6 31.3 31.4	4.8 27.2 25.1 29.5 30.7 31.8 32.8	1.2 23.0 28.8 26.1 27.2 28.0 28 2.3 23.3 25.0 26.3 27.0 27.4 28
			x -2 -1 1 2 3 4	M 25.5 28.0 29.2 30.7 31.4 31.8 32	M 24.8 26.6 27.9 28.7 30.2 30.9 31	M 21.5 23.1 24.6 26.1 27.2 27.8 28	M 22.4 23.6 25.1 26.9 28.0 28.8 30	M 20.8 22.2 24.2 25.7 26.1 21.6 78	M 25.5 26.8 28.6 29.6 30.9 32.0 31	M 23.7 24.9 26.4 27.1 27.7 28.6 29	M 23.4 23.9 24.6 24.9 25.4 26.5 26	M 24.8 26.2 28.0 28.5 30.1 31.5 31	M 25.1 26.8 28.3 30.5 32.2 32.5 33	M 23.2 24.8 25.6 27.3 28.1 29.6 29	M 23.8 24.8 26.3 26.8 27.8 29.3 29	M 21.9 23.4 25.5 26.2 27.8 28.9 29	M 24.0 25.3 26.6 27.7 29.6 31.0 32	M 23.2 24.6 26.0 26.8 28.3 28.6 29	M 24.2 25.3 27.1 28.1 28.7 29.7 30	M 21.3 22.7 24.9 25.6 26.6 27.4 28	M 21.9 22.9 24.0 25.3 26.5 27.1 27	M 25.1 26.5 28.3 29.5 30.5 30.8 32	M 24.0 27.8 29.5 31.5 32.5 33.5 34	M 21.9 23.4 24.7 25.5 26.4 27.1 27	M 21.6 22.9 24.5 25.4 26.0 26.6 28	M 19.8 21.4 23.5 24.3 24.9 25.9 27	M 22.6 24.2 25.4 25.9 26.5 27.4 28 M 24.7 25.9 27.5 28.6 30.2 30.1 31	M 19.6 24.7 22.8 23.9 24.6 29.7 26	M 23.5 20.9 26.3 26.9 28.0 28.4 29	M 22.6 23.9 24.7 25.7 26.2 26.7 27	M 20.0 22.1 24.0 24.7 25.6 26.1 26.9	M 23.3 25.3 26.8 28.2 28.8 26.1 31.2	M 25.5 27.7 29.9 31.1 32.3 32.4 31.8 M 24.4 26.9 28.6 29.7 30.6 31.3 31.4	M 24.8 27.2 25.1 29.5 30.7 31.8 32.8	M 21.2 23.0 28.8 26.1 27.2 28.0 28 M 22.3 23.3 25.0 26.3 27.0 27.4 28
ர	œ c		P X -2 -1 1 2 3 4	M 25.5 28.0 29.2 30.7 31.4 31.8 32	2 M 24.8 26.6 27.9 28.7 30.2 30.9 31	2 M 21.5 23.1 24.6 26.1 27.2 27.8 28	2 M 22.4 23.6 25.1 26.9 28.0 28.8 30	20.8 22.2 24.2 25.1 26.1 21.6 78	2 M 25.5 26.8 28.6 29.6 30.3 32.0 31	2 M 23.7 24.9 26.4 27.1 27.7 28.6 29	2 M 23.4 23.9 24.6 24.9 25.4 26.5 26	2 M 24.8 26.2 28.0 28.5 30.1 31.5 31	2 M 25.1 26.8 28.3 30.5 32.2 32.5 33	2 M 23.2 24.8 25.6 27.3 28.1 29.6 29	2 M 23.8 24.8 26.3 26.8 27.8 29.3 29	2 M 21.9 23.4 25.5 26.2 27.8 28.9 29	2 M 24.0 25.3 26.6 27.7 29.6 31.0 32	2 M 23.2 24.6 26.0 26.8 28.3 28.6 29	2 M 24.2 25.3 27.1 28.1 28.7 29.7 30	2 M 21.3 22.7 24.9 25.6 26.6 27.4 28	M 21.9 22.9 24.0 25.3 26.5 27.1 27	2 M 25.1 26.5 28.3 29.5 30.5 30.8 32	24.0 27.8 29.5 31.5 32.5 33.5 34	2 M 21.9 23.4 24.7 25.5 26.4 27.1 27	2 M 21.6 22.9 24.5 25.4 26.0 26.6 28	2 M 19.8 21.4 23.5 24.3 24.9 25.9 27	22.6 24.2 25.4 25.9 26.5 21.4 28 2 20.5 30.1 31	2 M 19.6 24.7 22.8 23.9 24.6 29.7 26	2 M 23.5 20.9 26.3 26.9 28.0 28.4 29	2 M 22.6 23.9 24.7 25.7 26.2 26.7 27	2 M 20.0 22.1 24.0 24.7 25.6 26.1 26.9	2 M 23.3 25.3 26.8 28.2 28.8 26.1 31.2	2 M 25.5 27.7 29.9 31.1 32.3 32.4 31.8 2 M 24.4 26.9 28.6 29.7 30.6 31.3 31.4	2 M 24.8 27.2 25.1 29.5 30.7 31.8 32.8	21.2 23.0 28.8 26.1 27.2 28.0 28 22.3 23.3 25.0 26.3 27.0 27.4 28

*---No data available (died) TR Group I = Control; 2 = 1.5 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MGNTH CHRONIC TOXICITY/CARCINGGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGG3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

7	100000-11111111114004-00000-00004-0000-00004	
72		۲.
ດ	00448-0000-0000000000000000000000000000	
a	220 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	D
6	22222222222222222222222222222222222222	9
2	$ \square $	6
თ	084-0000-070-4000000000000-4040000-0000-	4
₩-	40 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	4.
-	60 60 60 60 60 60 60 60 60 60 60 60 60	
r.	4084044868448846444648-44646486	- -
	COOP F O O D P C O D	CA
-	-0000-00000000000000000000000000000000	4
-	1	T
· · -	40,4404	m.
W.E.E.	1 - 0	23
F +	$\begin{array}{c} : \ \ \ \ \ \ \ \ \ \ \ \ \$	
- o	100-00004400004-04-6000004-44-44-6000000	'
80		
-		0
•	222 22 22 22 22 22 22 22 22 22 22 22 22	
ဖ	40004466666666666666666666666666666666	
	40004444.000000000000000000000000000000	တ
		~
	7.07.22.22.22.22.22.22.22.22.22.22.22.22.22	o
	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	o
8	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	ď
	1 9 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	<u>0</u>
•	04800000000000000000000000000000000000	6 0
Ţ		
		_
•	22222222222222222222222222222222222222	17
νш×	 - 	u_
@ # D D #		8
47 ZO ·	.	o
	2224 2224 2227 2227 2227 2227 2223 2233 223	25

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX*---No data available (sacrificed)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

	53	ם נים				•			•			•						•								•	•			•				•	
	1		34	32	29	4 c	200	9	6	6 1	(T) <	ព្រ	4	4	S	ID.	D.	•	യറ	200	-	3	0	უ თ	•	10	60 4			* *		\sim	(9 t	5
	7	ن رہ		N	7	ლ ი	7 6	ာ တ	4	٥.	- c	v m	0	0	IJ	8	ω.	.	~ ~	ر د	ı o	6	0	ກແ	4	8	ព ព	2 0	٠,	; C.	4	6	ເກ (٥,	_
	8	លីα	(7)	6	8	თ :	p c	. α	4	<u>.</u>	4 C	. 0	ģ	9	ċ	ຜ	-	္ပဲ	<u>.</u>	. 0		œ.	4		С	ري ا	<u>.</u> ر	ق	, , .	٠ ر	4	4	6	9 1	
	!																															;			
	Ni	24 G								•																	•								
	į	8 6	ö	28	က	4 6	2 6	7 %	<u>ь</u>	2	0) m	က်	ဗ	က	'n	8	ë	2 2	2 %	'n	ဗ	ě	ĕ ë	8	ë	ě	28	× 0	י ה	2	ä	23	m d	รั
	23	•	٩	เก	-	φ, (ء م	i R	0	ا -		- 10							0.0	o c	2	ı.	۲.	- v	, ro	φ	ល់ (N (۶ ج	7	7	æ	ဖ	න ර	7.
	`` i	30	333	27	27	38	υ C	25	3	8	2 6	3 8	93	33	31	92	32	62	9 8	- σ	38	53	33	2 2	9	32	33	9	2 5	- 7	35	ဓ္ဓ	9	93	2
	- 1	- r																																	
	8	4,0	io	S.	<u>.</u>	۲.	o c		ົ. ຄ	ω.	0 0	;	.	8	ნ	υ.	÷.	o i	· ·		· •	80	Ö.	- 6		ď	്. ന	·.	ກໍຕ	ບັນ		о О	6.	٩,	.
	_																																		
	- 1	80 6	٠.		•	•	•			•	•					•		•				•	•	•		•	٠		•	•		•		•	
	!		S	26	26	37	2 6	4 %	29	28	8	2 6	8	29	29	23	29	58	255	3 6	9	29	9	28	27	6	္က	28	2 6	3 6	် က	9	27	m (<u> </u>
	4		4	4	Ŋ	4.	N a	ំ ស	ĸ.	V	4. *	- @	n	4	ιū	4	ល	Φ.	4.4	į	9	7	ស	∞ α	တ	ω.	o, i	m l	ຄຸ	o r	4	က	o,	4	×O.
	Í	27	9 8	25	25	34	ກຸດ	2 2	29	52	28	2 6	8	29	27	74	28	28	2.5	2 6	28	27	28	9 2	38	30	53	27	7 5	` . F	28	27	27	32	9
	lo i	r 4																																	
	- !	٠. ٥	, œ	ີ ທີ	4.	ლ ს	ກ່ອ	. 4	9	ئ	ن ف		ω.	ω.	œ.	4.	9	7	ر ا ب	. ب	ω,	ιυ	8	ໝ່ວ		6	60 I	ເກີເ		o c	ດ	8	ق		D
	_																																		
	₽ !				•	•	•		-	•	•			•	•	•		٠	•	•		•	•			•	•	•	٠					•	
	i	27	, 6	2 2	23	8	2 6	4 6	26	2	2 .	1 6	8	2	26	8	2	2	2 2	4 C	26	28	2	2 6	4 C	30	2	4 6	2 6	א ני	2 5	23	2	2	
	2	~ 0	9	ω.	Ŋ	ر ا	9,0	4	4	ဖ	o e	9		Ψ,		რ	ဖ	o.	O G			9		io i	2 0	Τ.	ထု	ص (n :	- α	, m	0	₹,	٠. (9
	į	27	22	24	24	3	2 6	2 4	26	24	28	2 0	27	28	26	23	25	25	20 10	א ני	26	24	27	5	ال ا -	7	so .	2 2	2 K	0 0	, 'A		56		
	i	~ 0									- 4	9 0	ω	œ	C	0	ω.	_	0 4	ກແ	8	ın	្រ	n u	7	4	- 1	٠,	~ (> -	. n				
쯌		r- r	ی	4	ė.	₹ :	4 n		9	4	C I	n w	8	æ	ß	3	4	S	4 1	0 4	9	ໝ	-	5	- 4	9	9	រ ល	s c	9 0	·φ	വ	4	0	20
≥	. !																																		
ST	¥ ;		•			•	•		•	•	•	•				•	•	•	٠				-	•		•	٠	•	•				•	•	•
Ĕ	į	2,2	, 6	3	8	ĕ	2 2	Y CY	2	ň	2 2	2 2	ัก	'n	8	ñ	2	ຸ	8	, c	3 6	26	7	2, 12	, 4	3	2	2, 0	2 6	¥ (Š	ñ	6	3	ñ
•	6	• `				•			•	•	•	•				•	•	•					•											•	•
	1	26	. 55	25	23	29	2 2	2 4	26	23	24	A 6	26	26	26	22	24	23	24	2 6	25	24	25	25	24	25	26	23	2 2	2 2	2.4	23	24	26	7
	80	ω (٠	٠ ۵	8	4	ω 0	o	က	7	- (2 4	-	រប	g	8	0	~	φ.	- (, α	រូវ	ស្រ	o c	۵ 4	6	_	4.	4 (7 0	4	6	8	<u>.</u> .	ব
	į	25.) ~	· ro	2	-	4 C	א כי	₹	3	♥ ₹	T LC	വ	ß	4	2	3	D	4 4	† •	t w	**	ED .		၁ က	4	10	C) (N 4	* 0	၁၈	~	е.	ഗ	Ω
	_ :	r 4																																	
	Ì	4.4	. ~		ς.			-	4	÷	٠.	o uc		₹.	ε,	ĸ.	Ε.	œ.	٠,		. 4	'n.	ε.		. n	ıΩ.	₹.	e.	~ ·	ຸ ຄ		ω.	e.	ر ا	o.
	1	C) C	8	N	8	Ñ.	N C	V C	2	Ň	Ň	40	10	N	N	8	Ö	Ň	Ċ C	v c	'nŇ	Č	0	N C	10	7	Ň	0	N	ν ς	10	0	8	3	N
	1	ω, ς			•	•	•		•	-	•	•			•	•		•	•				•	•		•	•	•	•				•	•	•
	:	23	, 6	4	22	26	22	4 6	24	22	23	3 6	2	2	25	22	22	23	23	3 6	2 6	22	2	2 6	9 6	24	24	23	2 3	7 [. 4	23	24	23	28
	រោ	∞.∠	α	7	-	E)	9 6	. 4	m	۵.	ų,	n œ	9 (7)	ဖ	o,	~	4	œ	۲.	<u>.</u> c	4 1	ល	Τ.	ų,	. w	6	o.	ကျ	r i	÷ <	ı ıc	Ø	æ	4	ı.
	į	23	20	: 0	8	9	3 (1)	7	2	က	2	4 (4	က	CV	~	2	က	20	יו פי	2 4	~	9	en c	2	6	3	0	- (7 0	9	2	-	œ٠	24
	- 1	.1 <									- .	. ~) ц.	N	-	60	_																		
	ļ	6	· -	. 6	ö	Š,		- 0	2	-	٠. ن	7 6	2	(7)	C	*	-	N	0.0	N C	v 4	N	N	ن) -	3	3	2	o e	, c	o c	· —	- -	6	2
	_ :	64.6																																	
		2.3					•																-												
	1	24.0	40	1 (1)	8	2	CV C	V	7	8	~	40	1 (N	N	8	8	(1	0	, c	4 (4	2	CA	(4 (4 (4	6	7	0	0	N C	40	S	7	~	0
	2 1	ω. ο																																	
	!	22	3 5	22	20	25	æ (2 0	2	20	21	7 0	. 5	2	2	20	19	7	21	3 5	2 2	2	22	21	200	20	5	20	6;	7 7	. 0	2.5	20	2.	2.4
		4,0	να	۸ ر	4	4	ហ	pφ	Ø	ø	N O	N C) m	8	80	4	-	n	6) (ם מ	טון פ	6		٠. د					٠,		n ex			-	-
	i	22	ο σ	0	6	2	o (5 80	0	6	0	> -		0	0	O	0	-	0	a	0	0	0	- (v O	0	-	0	<u> </u>	~ r	o o	m	m.	2	22
	1	- 0							0	N	0	vα		0	6	0	_	₹	0	n +	٠ م														
	' 1	٠. ر	> «	. 6	ю.	-		۲,	0	ω.	თ	α	. 0	6	8	8	ნ	თ	0	ກ່ວ	; -	6	ö	ص د		ο.	ė,	ю.		D •	· σ				
		ומו	4	-	-	N.		_		-	- '		-	_	-	_	-	_	α.		- ~	: 0	0	T (٧	_	_	_	-	- 0	٧ -	_	_	_	C
	7	8.0								•									•																
	1	5	7 K	2 2	#	7	- :	- 4	5	7	φ :	- 4		18	5	#	#	2	8 (٠ د	- 5	8	8	ω (₹ ₩	1	48	18	9	2	1,	+	Ġ	<u>~</u>	ñ
		i i																																	
	i	į																																	
Ωπ	×į	1 11 1	L	. 1	4	T.	u i	ı lı	u	ı	u. 1	. u	ш	. Ľ	ш	14	Ľ.	Ľ	LL I	L U	L	. 44	ш	Lι	·	u	ш.	LL I	u i		Lu	. 11	ij.	!!	Ľ.
		!																																	
0 & O :	ים כ	. 64	4 0	4 (4	8	2	0 0	2 6	2	~	0	2 6	40	1 (2	C	Ç	C	81	N :	. ~	2	N	0	N (V	8	7	7	0	.4 (40	2	8	2	2
	. !	! ! 						~ ~				. -					_	_								_	_		~					_	_
t_1 Z C	• •	251	กเ	מנ	S	S	ល រ	ດະເ	Ó	æ	9	o u	PΨ	ဗ	9	ဖ	9	~	1	-	- 1	٠.	-	- 1	- 1	8	8	8	œ	X) (X	οα	8	S	æ	თ
	,		• •	4 (4		.,	•••		. (4	**	(4)	. 4 6				CA	(A	.4	(4)		1 ()	. (7	(4			(4	.4	(4)	. 4 (4 ()	. (4	(4	. 4	٠, ۲

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; $\frac{1}{4}$ ~ 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHROHIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE B6C3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUKEMENTS (g)

	29		0 2 2 2 4 2 0 0 0 8 2 4 2 2 2 0 0 0 1 2 2 2 2 1 1 1 1 1 1 1 1 1
	27	<i>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</i>	u044α0α-πανοαΟ _γ υυυυ4υυυυυυ4υ
	1) 0 0 0 0 0 0 0 0 0 0 4 4 4 4 4 4 4 4 4	482444444444444444444444444444444444444
	25	22222 22222222222222222222222222222222	477507975567088
	23	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	∠ #000000004- ∠ ⊬
	_	1 W F B O B - F O B C O B C O B C O B C A O C O C O C O C O C O C O C O C O C	
	2	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	407700004504-68
	19	22222222222222222222222222222222222222	-000000004040040
	17		ñ. τ â â ν ν ω α ω α α 4 ν O −
	D.	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	
	#	22 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	+ 10 4 4 L 4 4 10 4 4 5 10 L 10 0
	13	- x x 2 C x c x x x x x x x x x x x x x x x x x	0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4
	7	00-00-00000 -0 -040000000000000000000000	4 - 0 4 8 8 9 U 0 - 4 - 6 F 4
	-	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	
)	<u>.</u> = :	- 450-6880-648-688-688-688-688-688-688-688-688-688	
3	. O	> x x x x x x x x x x x x x x x x x x x	
101	u	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	000000000000000000000000000000000000000
٠	ົ ຄ	0 - 5 0 7 0 0 0 0 0 1 1 1 0 0 0 1 7 1 1 0 0 0 1 7 1 1 1 0 0 0 0	-44-64-64-66-466
	œ	; o c = - 4 - c - c o o o o o o o o o o o o o o o o	2000-14014014000
		2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	0.0000000000000000000000000000000000000
	7	22222222222222222222222222222222222222	
	9	io-reo4oriuojoi-o4uoju4uojua nvv-vvuuuuuuuuuuuuuuuuu	20-1-08-1-01-01-4
		9 3 9 9 7 5 7 5 7 5 7 5 7 5 7 5 7 5 7 5 7 5	800000000000000000000000000000000000000
	ស	785	2-60-0-0-0-600.
		0 6 7 - 7 0 0 0 0 - 7 8 - 0 0 0 0 7 7 - 0 0 0 4 O 0	w0w40@@w00-4@@r
		0 0 0 - 8 0 8 0 0 0 0 - 8 0 0 - 8 0 0 0 0	
		22222222222222222222222222222222222222	000-1-000000000000000000000000000000000
		0 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
		2	
	- 1	22	0.0144001010000000000000000000000000000
	-2	i	RON849880870+N-
	,	c r o 4 to o a o r a a a a a a a a a a r o r 4 + O to c	
	A V		******
נ עש:	20 ·	29 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	3008 3008 3008 3008 3008 3008 3008 3008

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX *---No data available (sacrificed) TR Group 1 = 9

N	33 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
27	048668888-084808888 0480840888880 0141887878
25	
23	
-	8 0 1 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0
	4 1 35 5 1 2 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3
	0 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
-	1.4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
-	3300.5.2.2.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3
12	0-70000004464444-040-000000448040444000000-
퐈 =	0 + 6 0 8 0 0 0 4 4 + + 4 0 0 + 0 0 0 0 0 0 0 0 0
ST WE	
- 6 I	4 m u u n o o m 4 u 4 m + m u u u u u u o 4 o m m + + u m 4 m u u u u u u u
Į.	228 23 23 23 23 23 23 23 23 23 23 23 23 23
4	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
ω	00000000000000000000000000000000000000
	22 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	228
v	22222222222222222222222222222222222222
	222
8	6 8 7 4 4 6 6 7 9 7 6 8 8 8 4 7 8 8 7 4 8 7 7 8 8 8 8 8 8 8 8
-	เมื่อ ดัก และ เก้า หาย กาย เก้า ค. เก้ () 4 กาย เก้า ค. เก้า () 4 กาย () 4 ก
+	
7	no
	222222222222222222222222222222222222222
wm×	ZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZ
רמ טמטטם	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
i	000 000 000 000 000 000 000 000 000 00

Control; 2=1.5 mg/kg/day RDX; 3=7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5=175/100 mg/kg/day RDX*---No data available (died) 11 li TR Group

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BEC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

⊢ α:

42 W # 4

		თ	! 4	_		~	_			~ 1	_	•	_				_																						_	_
		8	1 -	ທີ	0	ເກ	6	R	'n	ß.	ė.	38.2	œ	ص	<u>.</u> ما	٠.				1	1	!	i		1	1	١,	٠. د		, - -	Θ.	₩,	φ.		ი,	œ ,	<u>,</u> ,	i r	ີ ຕ	۲.
		27	16															Į	!	1	7	;	1	1	į	ľ														
			4	36	37	38	4	33	32	35	35	38	38	33	96	38	36	i «	į	i *	i *	i *	; *	i *	i	i X	i (25	36	ဓ္ဌ	30	39	36	3	32	၉ ရ	9 6	37	33	35
		C			•		•			•	•	•	•			•										•														
			5 4																							37														
		7	io	ĸ.	8	7.	6	6	2	IJ.	ė.	έ.	ė.	o	ا ما	٠.		ლ	'n.	ი	υ.	4.	œ.	ю.	e.	37.0	· •	<u>.</u> .	. 4	6	8	œ.		o.	<u>.</u>	o	٠,	, .o	_:	6
		21	,										ω	ω.			- (9	σ.	0	ස	α	-	o	N	લું લ		20 <	t (N	4	4	8	c	ın ı	ரை (۰.	ח כ	o 0	æ	7
			37	34	38	35	38	32	32	35,	34.	37	C)	6 0 1	ו מו	0	(2)	N.	₹	G)	m	6	£D.	*	N	35.	0 6	n c	3 (2)	m	co.	œ	N.		ر ـپ	ന	00	3.4	-	
		0		•	•	•	•	•	•		•	•	•	•	•	•	•	٠		•		•	•	•		ú,	•	•					•	•		•	•			
			16	G	n	n	က	n	က	က	n	C	n	CO I	(D)	(C)	m ((C)	G.	n	(C)	က	B	n	m ·	35		N :) (C)	3	4	ന	(C)	0	0	N C	, c	4 C	7	e
		-	6.4	Θ.	œ.	œ.	ľΩ.	Ξ.	Ψ.	4.	4.	œ.	₹.	œ (· .	ص		œ.	ς.	•	ë.	'n.		n e	٠.	: 0	in	œ.	۲.	<u>.</u>	· ·	∹,				Ť.	Ċ
			5 3	₩ •	8	4	2	4 3	4	7 3	е 2	က ဝ	ය .	ල :	(N)	(C)	ი ი	ლ : ი :	ල :	ຕ ຕ	ന ന	ო ი	ຕ ຕ	6	თ ი	ი (ים ימ	9 6		0	9	e C	ر ري	2	en e	N O	9 Y	, C	2	7
		-	٦.	ď	۲.	~	6	- :	ö	ε.	e.	IJ.	က်	<u>.</u>	έ.	. .	e (i.		īÙ.	ω.	ä	ö	е. С	<u>.</u>	34.				6	.0	ς.	.		٠.				Ċ.	m.
		-	8	9	?	٧.	Ю.	σ.	. 7	Ŋ	Ŋ	8	<u>س</u>	e i	ı, e	N (٠	4	0	ιņ.	e.	-	ø.	-	α.	m .	- 1	- •	. 0	ω	4	8	œ.	- (φ (φ (ى د	4 (4	က	۲.
			1 1	~	_	œ	ゼ	0	o	~	9	٠	~	ഗ ഷ	4 (უ •	4	O :	Ν.	₹	~	_	-	\sim	n	93	t t	0.0	a	10	10	\circ	ന	in i	N 1	0 1	2	\sim	_	10
		_	7.0																		-		-		_	2 : 2 :		_				_	-	_	-	-			-	
			1 0	.,	.,	.,	.,	•		(·)	(,)	(-)	Ç-3	(-)	.,	י ני		(')	(')	(-)	(°)	,,	(*)	۲,	C)	(r) ("	A C	4 (1	64	N	C	co ·	C4 (٠, (46	v m	N	C
	EEK	_	36.5	ċ	₹.	ä	'n.	6	თ	'n	'n	ص	ĸ.	<u>.</u>	<u>.</u>	, i		ά.	÷.	e.	ä		ς.	ä	<u>.</u>	9.5			'n		'n	نہ		· .	٠.			·		m
	3	0		_	m	C4	ın	₹	0	7	m	<u>ا</u>	-	.	o 1	~ (.		0	m	~	**	_	10	_	ω, c	n .	_ 10	· ~		6	و	ın .	٠.	4 (0 (νa	တ	ဖ	-
	resi		1 10	0	TO.	c	ນ	О	0	က	S	ͺ	•	♥ 1	70 (N (77	a	0	∾ .	_	റ	N	(n)	\circ	32	72 1	n a	3 (0	4	₹	~	m ·	et (0		7 16	28.	10	m
	_	6	35.3	9.	_	.3	. 7	8.	5	Ţ.	0	<u>-</u>	េ	- 1	e (N (0.0	0	0	0	-	S	0	4	0	0,0			ິທ	8.	4.		ල <u>1</u>	۲.	٠.	N C	o n	90	4	6
			,	.,	.,	.,	(-)	•	•	.,	.,	(-2	(-)	(7)	.,	.,,	.,		(-)	(')	C	(1	(.)	(·)	(')	(') (, (" (1	CA	N	CA.	CA I	CA I	CA (CA C	46	4 (4	C	n
		æ	33.8																							54 G														
			1 2	ď	-	9	ល	0	œ	0	~	-	6	0	o o	5	0.0	ا ما	m i		က	œ	~	ın.	m	10 (o t	- 0) (0	ın	ß	6	60	(O 1	n I	0 +	- (, ,	_	
			33.	0	က	0	3	0	8	2	-	2	0	с	- (N	2	50 (0	ດ າ	0	∞ .	3	•	Ġ.	e	٧,	t u	່ເຄ	₹	4	-	۰ ون	4	♥ '	*	2	10	ın	24
		9	-			•	4		•	•		•																												
			1																							စ္က ဗ														
			2.3	Ψ.		Ÿ.	Ÿ.	w.	Ľ.	Ξ.	Ÿ.	i.	٠.		ς.	÷.	∹.		ά.		٠.	ά.	ς.	ς.	~	~ .	∹.	<i>-</i> -	:	_	_:	.:	٠.		٠.	<u>.</u>	: _	: _:	_:	<u>.</u> :
		4	933			2	7	9	4	7	9	ဖ	o i	- 1	٠.	- (0 (m .																						
			1 .	80	0	6	œ.	۲.	7	ċ	ъ.	ö		<i>-</i> ,	m	n	י	٠.	en 1		o. :		o	m i		o .	, ,		. ~	ς.	ď		ın ı	~:	<u>.</u>	٠.	- ^	. ~	**	~
			6	o.	۲,	Ψ.	0	0	ı,	4	۲.	6	®	۲.	4.	၁ (٠ ,	- 1	2	α.	មា	۲.	۲.	œ	- (, c	א א		ဖ	ເນ	ហ	4	ص <u>ا</u>	'n.	÷. 6	ė c	9 19	۲.	4
			10	C	n	ď	C	N	7	(1	N	C	C I	က	2	3 6	7	7	CV I	N	N.		N	C,	C)	ရှိ ရ	.1 (. v	1 (C	0	N	~	0	0	2	A C	10	0	8
			8.6	ė	α.	7	۲.	ß.	ė	æ.	7		•	0		20 (201	٠ ا	٠.	6		Ď.	0	0	10	o	٠,	<u>.</u> .		Ξ.	ö	ż	<u>.</u>	<u>.</u> .	÷.	d.	· .	: -	Ť.	<u>-</u>
			1 8	C	C	c.	N	CA	C	CA	C	C	2	CV (~ (N (2	C)	C	CI .	C	C	N	~	(V (N 6	, C	1 (~	~	N	C)	0	2	C) C	A C	10	~	0
			27.3	vo.		ဖ	~	₹	œ	_	-	6 0 1	9	α (Ωŧ	- (۰ و	9 (וכט	וכט	c o⊓	m	7	~ 1	ഥ	on (0 (າ •	- റ	റ	*	m	•	n.	- 4	TO C	7	\sim	-	-
			1 6				œ	6	ໝ	ო	ល		4	ت ا	ກເ	20 t	٠,	η.	- 1	7	0	ტ .	13	4	_		٠,	~ 0	, -	1	80	4	7			۰ -	- պ		6	-
			24	24	26	25	25	21	24	26	25	2.4	25	56	e 1	Ω,	ď	- 1	m 1	(1)	in i	2	10	to ·		► •	* 1	D (m	•	70	-	\sim	6	<u></u>	9 5	2 0	0	O)	20
		-2					•	•	•			•														თ. თ.														
			Ä	ĸ	Ċ	Çį	Ň	7	N	Ñ	Ň	Ñ	ći i	Ň	N (Ň	N i	ĭ ;	ri i	ลั	N	ă	ń	Ŕ	~	20, 5		~ ¥	: #	7,	#	ผ	~	₩;	χ;	~ 5	- 4	· +	¥	¥
			<u>i</u>																																					
	υu	× τ	Σ.	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ:	Σ:	Σ:	Σ:	ε:	ε:	Σ:	Σ	Σ	Σ:	Σ	X :	≆ :	₹ :	Σ:	٤١	<u>. u</u>	. 1	4.	u.	u.	L I	L 1	L 1	L L	يا ـ	. L	Li.	L.
ت ع	0 :	ο α .	6	က	m	m	က	က	က	က	e	ტ :	(7)	ი (·> c		n (က (m I	m	က	es .	က	m i	က ၊	(n)	າ ເ	יז ני	က	က	ო	(C)	ල :	ო (m (.	י ני	п	က	ო
ب	zc		161	32	53	7	ស្ត	99	7.	9.	6	<u>و</u>	- !	2 5		4 1	ნ :	_ :	2 1	<u>س</u>	7 !	ស្ល	ဖွ	<u>,</u>	æ	စ္က (۶ <u>د</u>	٠ و	· έα	6	õ	=	2	ლ :	<u> </u>	v i	0 1	. go	g)	0
			: ĕ	ř	36	ř	ĕ	36	ĕ	ř	ř	က	in i	m i	2 6	<u>ب</u> د	, ,	~ 1	37	3/	2,	2,	2	2,	32	5 6	ŏ (ה ה ה	9 6	37	38	36	ဗ္ဗ	8	<u>ښ</u>	200	מ מ	386	38	36

fR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; h = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX *---No data available (sacrificed)

Sec. 25.

				_ !	! _							_	_							_			_									_		_	_	_	_								
				29	(0)	რ	'n.	છ	ö		œ.	7.	œ.	Ψ.	თ	9	ນ	Ġ.	ლ	ئ	ო	7	ω.	÷.	ις.	÷.	4.	÷.	ω.	ö	ó	ლ	:		٠,		E	e .	÷	-	4	ö	'n		
				27	ю.	'n	4.	ė.	÷.	ö	Ģ.	9	ъ.	┷.	œ.	4.	ю	œ	÷.	┿.	ä	4.	60	ö	ლ	ö	ö	ö	œ.	ش	o.	34.5	, i	n	, ,	ά,	<u>.</u>	.	'n	÷	რ.	თ	4		
				25	0.2	0.0	3.0	5.6	8.9	5.9	4.9	5.6	5.	1.2	9.9	5. 1.	4.4	÷.	1.6	3	9.0	3.1	9.5	0.2	5.9	6.0	8.8	2.8	4.	6. 0.	7		9.	9.0	9	- (9	9	0.0	9.4	8.	4 :	5.	0.0	
				23	.23	, 3	ю. С	ь С	0	۔ ع	.42	e 6	ь. 2	.23	₽.	ი ი	.2	ი ი	. J	.7 3	.23	.7 3	.3	.63	.63	.53	9.	. 1 3	4.2	.8	, 9	e.	7	, k	4.	ლ. ლ. (e .	8 8	ນ. ຄ	. 1	. ع	8	e T.	ო - .	
				21	6	ന	G	က	0	N	N	n	ç		r w	E	B	က	N	က	7	က	N	က	က	4	7 2	7	8 2	4	ල :	8 31	უ (უ (ლ ი ი	7 P	ר ((C)	CI I	က	N	n	CI :	က	8	
					5 30.	N	n	n	N	C	N	m	N	N	23	33	33	က	0	N	3	က	8	n	က	a	29	ဓ္ဓ	56	27	23	3 28	7	34	87	3	α,	(7	~	N	က	C4	က	N	
				- !	29.	28.	29.	31.	26.	28.	24.	33.	24.	29.	35.	32	30.		29	30.	28.	32.	26.	27.	30.	26.	27.	27.	28	27.	28	27.	77		7 .	9	90	29		29.	29.	28.	29.	27.	
				- 1	8	Θ.	÷.	÷	œ.	œ.	რ	÷.	4	۲.	÷	ö	6	6	œ.	8	89	.	œ.	ö	ö	ω.	7.	ď.	ĸ,	'n,				o i	'n.	ᆣ.	<u>.</u>	0	œ.	7	ö	7	ω.	œ.	
				±		7.93	28.2	29.4	25.2	30.3	23.4	30.2	24.5	9.92	31.5	30.5	0.0	8.63	6.63	6.9	6.4	7.08	38.5	7.73	80.9	0.93	9.9	16.1	24.4	6.0	7.0	8.8	56.5		. c	6.8	27.4	26.7	27.1	52.8	8.0	8.9	27.5	27.4	
				43	ø.	۳.	ø,	4	6	Ψ,	7	۲.	o	ω.	4	ď	-	Ç	o.	'n	7	œ.	ø.	o.	ď	o.	Ņ	<u>.</u>	ເດ	Ŋ	ທ		80 (ლ (و	ص <u>.</u>	ص ·	-	ဖ	ω.	ເນ	۲.	- -	ø.	
				- 1	.3 2	ь. 2	0.	7.3	2	.6	.3 2	.62	.62	0.	4.	6	7	4.	.8	.5	.8	.0	.6 2	0.	.8.2	.8	9.	9.2	4	2	2	9	0.1	, ,	.3	0,	9	4.	.6	.2	.2	9	.6	9.	
		V			7 27	7	0	8	2	1 2	0	12	8	8 2	4	3	9	9	3	9 2	3 2	9	9 2	8 2	2	3 2	3	9 2	5 2	2	2	0	5	20	9	ດ: ດ:	3	0	8	0	N	N	C	0	
		VEE		į		C	25	27	24	26	23	28	22	24	29	29	56	27	56	24	25	29	24	25	26	25	27	56	24	25	22	26	25	S	22	29	2	C	C	CA	0	N	7	7	
		TEST			27.	24.	25.	28.	23.	25.	22.	27.	22.	25.	27.	28.	27	27.	25.	29.	26.	27.	25.	25	29.	25.	24.	26.	24.	24.	25.	27.	24.	26.	24.	28	25	4	24.	24.	24.	24.	25	25.	
				ď	26.7	ë	۲.	7.	ε.	4.	~	7	ς.	ic.	ö	·	7	<u>.</u>	₩.		"	7	₹.	10		=	'n	٠.	Ε.	œ.	'n			٠.			m.	Ε.	.	÷		'n	ıc.	<u>۰</u>	
				1	25.5	۳.	تا	9	ლ	7.	ά,	2	6	4.	6	œ.	യ	Ġ	4.	<u>ي</u>	ъ.	9	ı,	S.	ω.	4.	رى كا	Ω	4.	е Э	വ				ь. С	ر. س	ف	.	<u>.</u>	'n	₹.	4.	છ	ري ريا	
					4.8	4.2	5.1	5.3	2.4	3.8	2.8	5.1	1.3	5.9	6.0	5.6	6.4	0.9	6.4	4.7	3.4	4.8	4.2	4.5	4.9	3.6	4.8	5.0	3.4	3.1	4.7	7.0	9.	9.1	3.5	4.4	ม ม	4.4	7.	2.4	3.5	3.2	4	8.8	
				9	4 5 2	œ.	٥.	7	۲.	9.	٩.	- -	ω.	o.	۲.	ø.	ω.	-	o.	е.	α.	7	0	æ	0	9	ø.	Ŋ	₿.	د .	. 7		ı.	ლ (œ.	۲.	<u>ත</u>	0	ဖ	9	₹.		Φ.	œ.	
				i	2 2	2	ď	~	5 2	7 2	0 2	8 2	0 2	S	1 2	7 2	7	←	5	9	8 2	6.2	7 2	3 2	1 2	9	9	6 2	3 2	9	5	0	7	9 .	4	0	7	2	8 2	1.2	2	4	7	6.2	
				1	3 24	Ċ	8	26	2	23	21	23	22	23	27	23	25	24	23	22	23	24	23	22	24	<u>. 4</u>	24	9 22	9 22	4 22	6 24	5 23	22	25	24	58	23	22	22	22	22	23	23	23	
				1	2 23.	N	N	N	N	N	0	8	0	~	N	~	R	N	ผ	R	22	23	ď	23	0	N	4	22	C	7	24	23	N	0	2	C	0	7	C	N	Ŕ	~	S	0	
				1	22.	ლ	Ť.	n	ö	_	ö	÷.	ö	- :	Э.	ö	ω.	4.	Э.	б.	٠.	ά.	Ť.	. .	6	ö	ά.		ö	ö	е С	ю Ю	'n		ი.	ä	'n	÷	÷	ö	÷.	Ξ.	e,	.	
					22.5	-	ö	ε.	-	Ξ.	6	ö	8	÷.	ς.	4.	4	ო	ä	÷	- :	ď	ö	<u>.</u> :	~	-	÷.	-	ó	ö	'n	. .	.	რ.	÷	'n	ä	Ť.	÷.	ö	. .	∴	÷.	<u>.</u> .	
				;	22.2	o	o.	ď	о О	_	ъ.	ó	ω.	<u>_</u>	ď	Ġ.	Ť.	e.	ó	+:	<u>_</u> .	-	ď	Ö	÷.	ö	Ö	÷.	ċ	ď	m.	_	Ψ.	d.			÷	ċ	ď.	•	^	ċ	. .	œ.	
				-	1 6	9.1	9.5	6.0	4.8	٠.٠	6.7	8.8	7.4	-	1.5	9.7	6.0	1.7	0.0	8.0	න භ	0.	9.5	6.8	1.6	0.6	0.0	8.6	9	8.3	ص ص	9.0	ص ص	9.	10	7.0	9.0	8. 13.	₽.	6.7	3.6	9.3	9.6	7.8	
				-2	.9.2	4.	.6	5 2	2.	.0	6.	+.	0.	.3	4.	.2	.3	. 2	4.	.62	9.	5 2	4.	-	.2	.3	4.	-	1	4	ıs.	. 1	4	r.	4.	.8	. 7 2	;;	8.	₽ 6.	.6	.6	2	- 0	
				1	19	<u>~</u>	18	5	18	45	16	18	16	# ₩	19	18	50	20	\$	18	19	18	17	10	19	19	48	200	17	17	5	19	80	<u>დ</u> :	8	6	18	18	17	17	17	17	5	₩	
		S	ш	×	! ! ! !	ı.	u	iL.	ĮL.	ı.	u	Ŀ	ŭ.	u	LL_	u.	Ŀ	u.	u	u.	IJ.	u.	u	ų.	u	u.	L	ij.	ഥ	u.	L.	u.	u,	u.	u	L	u.	ıL	u.	u.	ų.	u.	u	LL.	
O	œ	0	>	a		က	ෆ	ო	၉	၈	6	၉	က	က	ო	က	က	က	က	ო	က	ო	က	n	ო	ო	က	ო	က	ო	ო	ო	က	က	က	က	က	ო	ო	က	က	ო	က	က	
ك)	,	z	٥	- 1	391	ത	ത	O	ത	ത	ത	ന	ത	റ	റ	O	O	\circ	റ	O	റ	റ	റ	-	_	_	_	_	-	-		_	-	~	2	N	N.	\sim	2	\sim	\sim	2	N	6	

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group 1

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDY) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

⊢ ∝

< Z - Z < J

	29	ដល់ប៊ុនដល់សំដាល់លំង់ក្តីប៉ុស្តែសំអ៊ីងីលីកំរុ រ ្រុ រ ្រុ ស្រីប៉ុស្ស ৮ 4 6 មិនម	
	27	ωωνασω4 πο 0 0 ω 0 0 ω π π α κα κα κα κα κα κα κα κα κα κα κα κα κ	
	25	u L u u u d o u d u u d u d u d u d d d d d d d d	
	23		
		wœwdwœ-uouaewincoauorewaeauauauauaeaeaeaeaeaeaeaeaeaea	
	19	WW-10-WW-010-01-01-01-01-01-01-01-01-01-01-01-01	
	17	พิดีตัดและ พิดีตัดและ พิดิตตัดและ ิตตัดและ พิดิตตัดและ พิดิตตัด พิดิตตัด พ พิดิตตัดและ พิดิตตัดและ พิดิตตัดและ พิดิตตัด พิดิตต	
		OR DOO JORD DA LA LER LORD LORD DE LA LA LA LA LA LA LA LA LA LA LA LA LA	
	3	80-4-4000-040-048-000-0-0-444	
	- !	44.7.7.4.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8	
	i	24 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	
VEEK		22222222222222222222222222222222222222	
EST V	0	460222222222222222222222222222222222222	
-	1	22222222222222222222222222222222222222	
	æ	000404044440008000000040404040404040++++0i *0.4 00048404800000000000040+++04804004004400+4	
	7		
	9	- 0.00	
	ស		
	4	n·n·- v·- v·- oʻu v·- a a v·- oʻu v·- oʻu v·- a a v·- oʻu v·- oʻu v·- a a v·- oʻu v·- oʻu v·- a a v·-	
	б	2000 0 1 0 4 8 0 0 0 0 0 4 4 0 0 0 0 1 0 0 0 0 0 0 0 0	
		00000000000000000000000000000000000000	
	-	24	
		0 0 4 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
	ı	8 2 3 2 3 2 3 2 3 2 3 2 3 2 3 3 3 3 3 3	
	1		
.0	1.1 52	! 	
2 نـ ۵	o .	4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	
		1444 1444444444444444 200000000000000444444444	

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

*---No data available (sacrificed)

TEST WEEK

0 20

29	37.7	ن ن	· .	9	ó	ب	9	1,		j.		, ,	٠,	i e	! ((α		34.5	θ.	ю	œ	.	ς. Θ	i.	<u>.</u> .	10x	٠,	٠.	4 (> u	ດຸມ	ດ ຜ		
27	17.1	۲ ر 4 م	0 0	8	0	2	o.	;	4 6		1 1					9 6				. T.	4.5	3.0	Ð. 1	9.		- 1	7.5	יי ני	n (9 (9.0	2.0	9 1		 		; ;
25	7.2	œ. o	0 0	2.7	e O	2	7.2	G	o .	- c	n (N 10	, ,	, c	היי	, ,	, c	0		90	3.6	3.0	7.7	7.	2	8 .	9 1	- 0		9 (0.0	ا ت ا ت		יי פופ	о и И		:
23	6.9 3	ល់ឲ	٦.	N	۲.	Ψ,	- - 1	ស រ	٠. ۱		ņ.	- u	•	- <		- r	. 4	L	•	. ~	Ŋ	6.	ທຸ	ဖ	<u>ه</u>	ω.	4.0	٠,٠	4. 1	۱ ج	ĸ.		4.0	٠ .		٠,	
21	6.13	ن د د	6 6 6 6	7.3	8.3	ر د	က (၀	е С	ක් ය	ص	4 . D (_ a) () C	. o	ο α) T	9 0	in.	.63	.3	.6	ا	ය. ය	0 ا	ون د	8. 4 8. 4	4 I		ю. Ю.	4 4	 	_ c	ນ (ນ (י פיר) !
19	8 3	—`π ω ι	. 4 . 6	. . .	9	ල. ල	က (၁		ين دن د	ი. ი.		5 c			, c		ט ני ס ני) (. w	53	.63	.7 3	о О	٠. ص	4 . E	ω. ω.			ω. ω.	. 7	ල : ල :	 	ი (5 c	, L	
1	6.9	4.4	3 m	. 2	9.	9	o.	၀ က	0.1	 	ກຸເ	ລຸດ ລຸດ) t	. c	я п	הני	, π , υ) (*	· α	90	4.3	.7 3	.7 3	о. С	6. G	. 7	ည်း က (٠. و ر		0	e :	E /	ი. ი.		ο (ο (פנ	ų į
1	.2 34 .0 34	ඩ 4 ය ර	. c	3.5	.2.3	<u>-</u> ی	œ. Θ	٠. ص	ස ය	ب ب	υ.	o	ة. د	5 c	9,6	? C	4 4 5 6	יים רכ	, ,	, 6	8	.63	4.3	0.	ο ω	က က	ည (က (دی و		က ((၁)	ر ا	7	4. 6.	10 (d)		ے د	9
13	.5 34	α, α	ייי סמ	4.	8	.7	<u>ဖ</u>	сі Сі	ص ص	ක් ක (า กูย	ນ ເ	יי ייני		4. G	, 6) C	2 6	-	6.	6.	œ.	.7	ω. ω	67 I	ص ص	ים יים	ю (С)	ю :	in in	ص ص	ມ່າ ພ		າ ເ - ບ	N D
12	.7 33	io G	o D	3 7	7 3	8	0	0	ස ස	က (က (თ. თ. მ	οι 10 τ	, ,	20 C	מני	י יי	ט טני		, 4	, L	9	-	-3	6	က (၁	က က	ල (ල	ნ. დ.	4 i	m :	m 	4	ლ. (ن دى د	ان در	הנ	3
Ξ	9 33	32	2 6	8 32	2 35	2 31	6 32	3 33	1 32	32	34	37 to 100	, c	- C	, c	ָ קרי קרי	מ מ מ	7	7 0	30.	30	8 31	8 35	5 29	4 34	9 32	2 33	5 34	8 33	() ()	e G	4	ម ព្រ	in i	.,, (יי ספ	` >
2	4 33. 9 32.	0 1	ט ה מני	9 (0	9	ຕ ດ	2	ဗ	ල :	က ၊ က ၊	(A) 1	ກເ	יני פיני	4 (3) (אנ מנ	יי יי	ა (ა (, c	י יי	; 	e C	ص ص	9	~	2	4 (C)	י מ	ന ((N)	က က	n G	ار د	က (က (in in	יי כי	າ ເ ໑ (V
	0 32 3 33	33	2 6	33	35	30	9 31	9	4 31	1 33	2 34	9 6	25.0		- C - C - C	2 C	ນ ເ ລັດ	7 6	, c	, to	90	4 31	3 34	2 27	1 33	30	33	6 34	8 33	32	31	9	32	35		2 0	V
80	3 32. 4 33.	m (ים כי	, m	m	30	3	29	<u>ب</u>	34	33	(T) (2 6	9 6	2 6	2 6	2 6	2 6) (8 4 5 6	1 29	3	5 33	28	33	9	33	33	32	n	ო	က	m i	ო (m :	א ני	٧
7	0 31.	9	, C	90	ල ල	9	0	2	7 1	ر ا	ස 1 ස 1	n: n:	. (ກ ເ ວ •	ກ ເ - (ກ ເ ວ່າ		, c	, ,	2 6	7 28	8 29	9 33	~	2	8	က (၁	က : က :	e -	ი	S C	ი ი	က က	₩ (, d	9 C	v >
9	6 32.				0	0	ဖ	ဖ	Φ:	ω :	o	φ (20 (9 0	5 6	٠,	٠,	- ر	٠ د	ى -		0	0	ø	4	ဖ	_	o ·		0	C	0					
	2 31. 5 32.	η.	۰ -	٠-	9 33	8	8 30	9 30	8 29	31	9	3 29	300	8 29	200	. ·	٥ (, c	7 0	200	c	1 28	6	1 27	0 31	9 28	1 30	8 31	90	3 32	-	8 32	2	. ي	4 (
	7 31.	30.		30.	3.	29.	29.	29.	28.	31.	.	23	30.	28	200	32.	3 3	2 6	, ,	, K	2 6	28	60	27.	31.	27.	31.	34.	23	32	29.		30	29.	29.		0
	4 29.	28.	9 8	29.	31.	27.	28.	28.	28.	30	3	28	29.	27.	58	30	S		9 6	2 2 2		27.	30	26.	29.	27.	29.	35.	29.	31.	28.	31.	2ر	28.	28.	28.	. 44
	28.	27.	230	, 8 7 8 7	30	26.	28.	28.	26.	29.	29.	27.	28	27.	77	28	788	9 8	200	26.	200	26	29	25.	29.	27.	29.	30.	28.	E	26.	30	28.	27.	28.	27.	7.4
	27.2	27.	27.	26.	29.	25	27.	27.	25.	28.	29.	26.	27.	25.	26	28	28.	. 6	9 0	98	, L	25.	28.	24	28.	26.	28.	29.	27.	30	25.	30.	27.	26.	27.	23.	5
	26.2	26.	26.	24.	28.	25.	26.	26.	25.	27.	28.	25	27.	25.	26.	27	27.	9 0	7	2, 5 7, 5 8, 7		25	27.	23.	28.	25.	27.	28.	26.	27.	24.	28.	26.	52	25.	25.	
,	123	24.	22	2 6	26.	23.	25.	25.	23.	25.	26.	24	25.	23	24	26.	23.	ָ אַ נ	0.0	2 23	. 40	23	26.	22	26.	23.	25.	26.	24.	26.	22.	26.	24.	24.	24	24.	-
1	ina		4.	÷ ÷	'n	'n	4	4	ς.	ъ.	u	· 5	4	. ი	N.	4	٠.	•	4 (άς	; ,	; -	. 4	-	4	÷.	8	ъ.	4	4.	ö	ນ ເ	'n	ä	ლ	ლ,	Ġ
ъ ш ×	ΣΣ	Σ	E 1	EΞ	Œ	Ξ	Σ	Σ	Σ	Σ	Œ	Œ :	Σ	Σ	Ξ:	Σ	Σ:	Σ:	Ξ	Σ 3	: S	: 2		æ	Σ	Σ	¥	Σ	Æ	Σ	Œ	Σ	Σ	Œ	Σį	Σ:	Σ
	44																																				
. 0	61	e .	4 1	ດຜ	· ~	- α	6	0	.	~	ო	4	ស	ı و	7	ထ	ග ්	٠,	- 1	۰، د	, ,	t tr	, w		8	0	0	_	2	ဗ	4	យ	9	7	&	ص (0
	144	4	(+ è	4 4	₹	4	4	4	4	4	4	4	4	4	4	4	4	4 ,	4	4 5	7	4	4	₹	4	4	4	4	4	4	4	4	‡	4	4	₹ 1	S.

TR Group 1 = Control; 2 = 1.5 mg/kg/day RUX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX*---No data available (died)

(3)

0

(3)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (g)

29	4 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	
27	nna4wwna4~804v1~na0ua8na40aw1111111111111110vwu	
25	ພົກບົຽ-ກໍລັກບົນລີສືພິພິລະກົບຄົລີລີພິພິລະພິລີພົກປະລີ ກິບລະບວດວັນ	
23	807-0-44600440460474	
2.	®№4®+644466644+44№690000+460044+6₽₽ОООООО	
- 1	044004-4644446+44464-4446446-4446086	
47		
1		
1 3	, ,	
- 1	. www.nr-4wu-roamaaun-ounar-uau-runnananunon	
× =	, 	
T WE	mm = v = o = v = o q m q = m m q q m m = 4 m o q = m q m q m m m n = m q	
1ES		
ω	200 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
,	44 45 45 45 45 45 45 45	
ဖ	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
i		
	1	
	4 4 4 4 5 5 6 6 6 7 4 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6	
	0 0 4 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
	0 0 0 4 4 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
ı		
+		
νm×		
⊢α 0α0⊃ <i>σ</i>	 	
	501 502 502 502 503 503 504 504 505 504 505 505 507 507 507 507 507 507 507 507	

! = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX;35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

**---No data available (sacrificed) *---No data available (died)

li

TR Group

		_!				_													_									_			_	_						_		
		29	-	ċ	e .			·· (o i			, .			-	4	η.	÷.	e.	'n	.	o	.	o		ດ ເ		o a	. 4	о О	8	oi (. .	0 -	- ~	٠,	4	. .	
		27		•				•	•	•							•			•			•		•	•														
			C) (") ((D)	က ၊	ල	co ((C)	? ?	უ (-	יז כי	, (1 (2)	(7)	n	N	n	ന	G	N	m ·	m ·	(C)	ი (י ני) (r)	8	က	(C)	וכו	ო (n (4 CO	n	n	
		25	8	,	'n.	<u>,</u>	'n.	. ,	0	ai e	'n,	. c			Ö	ó	7	ö	÷	ö	æ.	ö	ó,	ö	4.0		- د			7	6	о О	D	ö	4 (. m	6	e,	
		23	Oi	Ω (6 0 1	o i	n.	60 (o (o (D 6	N C		۰ ۵	ω .	m	ល	ĽΩ	_	a	Ø	6 0 :	ا 20	.	c o (· ·	, ,	4 ~		80	a	រ ខា	י מו	ლ -	+ (יי מ	0	80	o)	
		"	_	g S	5	53	<u>.</u>	÷ (28	22	4	5 6	5 6	34	30	29	28	29	3	30	ဗ္က	36	33	28	32	9	ဒ္ဌင္	ָ מַ מַ	9 6	26	33	23	28	29	, ,	2 6	35	ဓ္ဓ	53	
		7	8.6	•	•		٠.		•	•	•	•	•					-			•	•	٠	•	•			•			•	٠	•	-	•	•		•	•	
		6		(C)	(C)	(C)	n.	co (2	C4 (~ (יז כי	3 6	1 (7)	~	n	N	ო	N	က	~	n	~	C 1	(C) (.D	7	; (י ה	~	0	0	~	ო (3 6	4 CO	က	က	
		7	29.	· •		ю О	÷	۲.	æ .	ن ن	n	5	- u	; -	8	8	ů.	80	ö	7	7.	Ġ.				ກໍ	ກ ພ		, . .	9	÷	-	٠.	0	o ı		; -	œ.	ė.	
		17	0,	ا جو	۲.	ဖ	-	9	0	ဖ	9 1	ō a	. 0		ភ	~	<u>م</u>	9.	₹.	o.	ဖ	۲.	o.	ب ا	ဖ ့	n. •	- •	- ^	. ~	-	ເນ	œ.	o.	æ (ກຸເ	ų c	٠.	4	9	
				5 0 1	σ.	æ	0	0	(O)	8	- (1 C	٠ ٢		~		ဖ	æ	R	0	~	G	~	ο.	- (n (1 P	- c	0	-	-	0	_	ម្រា (N	~ ປ	n 0	28	28	
		5	6	٠ ت	ω.	თ	ω.	9	œ.	4 1	٠.	, 02	: ພ	· c	(c)	יי	ທ	8	7.	7	۲.	ښ ب	ທີ		თ (ກ່າ		0 C		6	æ.	8	φ.	٠ ن	50 I	٠,		7	7.	
		9		٦,	4	Ci	មា	<u>.</u>	₹.	4	x 0 (30 C	,	ο α	4	~		7	-		ហ	8	N	ທ	<u>د</u> ر		N (s	- ო	00	9	6	σ.	(י ת	4 11	י א		_	
		-	25.		•	ø.	**	6 0 1	in i	ın ı	m i	22	٠.	٠.	. 10	ED	*	ш	8	26	æ	~	(0	-	ത	m 1		7 0	30	60	0	10	ın:	io i	20 I	0 <	* C	27.	27.	
		2							•	-	•	-							-				•			•							•		•					
				N	~	C	N	~	(4	()	N (4 (4 C		! (7	C	N	N	u	N	e	N	c4	0 1	.1	N ε	י ני	3 C	~	က	~	N	(7)	~ (. Y C	40	N	<u>~</u> :	
	Ä	-			ó	г. С	ت	œ ·	٠.	4.	. 0	٠. د		. σ	. r	. 4	4	7	ζ.	Ġ.	ω.	ä	0	6	(i)					ū	œ.	6	٠.	ب ا ب		ກ່ເ	ເກີ	ı,	Ġ	
	¥.		2																					თ	ص ا	20 1	ω (ט פ	0 00	~	Ci	ø								
	rest		25	7.7	28	22	27	24	22	24	24	26.	9 0	2 6	7.	25	24	27.	27.	28.	25	ဓ္ဌ	24	S	8	9	n ·	- 0	9	ທ	O	ស្វា	25.	23	27.	5 7	10	25	26	
	_	6	6.9	٠		•			•				•									•	•									-	•	•	•					
		1	8	N	N	N	8	2	0	0	2	0	4 (40	, 0	10	N	N	R	N	N	N	N	N	CV I	C4	W (n c	10	1 (4	N	8	N	0	7	C4 C	40	2	~	
		i	24.8	s.	ω.	ın.	ις. Ο	ır.	4.	'n.	4 1	, L	· <		, 4	4	4	6	9	ω.	7.	8	₩.	4.	ស់ រ	٠.	٠,				~	œ.	ω.	ص	60 (2	6	ε.	
		~ :	_ n	-	m		CD.	~	(0	0	_		- •		. ~	m	-	~	_	m	6	"	~	< +	**	-	m	· ·	. ~	. ~	0	т.	₹	.	m	0.0	0		0	
		1	23.	26	27	25	24	2.4	23	25	2	24	, ,	2 4	, C	23	23	25	2,	24	24	င္ထ	23	Ż	25	20	1 5	~ (0 K	23	25	24	₹	23	7	2 0	3 6	23	24	
		ı	3.9	₹.	ლ	4	4	4.	;	ص	٠ ا	ນີ້ ເ	; (. ⊿	. 4	. c	, m	S.	4	4	e.	7.	е Э	ຜ	4	'n.	4 (u	. 4		3	4	4.	'n		n c	, 4	6	5	
		5	5 2										ŧ u	י כי	ט כ	, ,		-	9	8	લ	_	8	ø	o i	0	CV (ν (
		1	23.	24.	24.	23.	23.	23.	23.	23.	23	24.															23		۵ د د د	23	26.	24.	23.		23	55	- นั	23.	22.	
			6	٠	•	•	٠	•	•	•	•	•	•		•				•	•		•	•	•	•	•		•				•	•	•		•	•		-	
		ļ	22	ď	0	~	~	8	0	C	~	CA C	V (4 0	10	10	: 0	N	CA	ď	0	ď	~	6	7	N	CV (N	× 0	10	(4	0	~	~	2	CV C	, c	1 (4	4	
		1	21.2	с. С	₩.	ς.	ς.	ς.	÷.	÷	8	ლ,	- 6	; -		: +		6	ď	ö	ς.	4	÷:	÷	ĸ.	ε.	⊹.		i c		6	ż	ä		<u>.</u>	. .			÷	
		- 1	9.	ω.	-	8	ņ	0	o.	4	0	ທຸດ		ף פ	· c	α	۲.	ı.	ø	9	o.	ស	ო	-	က	o.	٠.	- 0	n 0	0	0	9	æ	-	<u>س</u>	* 0	ی ن	. 60	80	
			20	2	22	2	2	20	20	2	2	2	2 6	2 6	4 6	, 0	200	2	7	2	7	23	20	2	7	2	22	5 6	2 5	5	23	22	7	7	7	200	2 6	2	20	
			်ဝ	~ .	÷.	ö	ö	ė.	o,	o.	ö	င်	ś		· •		Ġ	d	<u>.</u>	6	- :	ä	e.	o.	င်	÷.	<u>.</u> .	. .			· -	ς.	÷.	ö	o.	റ്		. 0	_	
		1	3	7	7	3	12	-	0	7	9	8 .	2 C	9 C) C) L	. 60	0	2	~	~	4	-	_	N	N	(4)		- 6	10	10	C	~	N	Ŕ	Ġ (N C	. (~	
		' ;	.	0	O)	σ	0	6	0	8	σ	<u></u>	7) (D G	0	σ) CO	0	-	0	0	-	ø	8	<u>6</u>	0	o	٠- (α	0	0	σ	æ	Ð	o (xo -		19.	
		1 1	4	•		•						•	•															•												
		1	18	5	0	₽	5	17	48	#	2	<u>⊕</u> :	D :	- 0	9	2 4	. 8	8	5	5	5	2	17	+	#	20	<u>₽</u> :	6 9	ο α - τ	σ.	2	2	8	48	9	- 6	2 6	4 6	18	
		1	:																																					
	ωn	×		ıŁ	ш	щ	u.	L	ı.	u.	u.	L	. 1	LU	L	L LL	. u	. ::	li.	LL.	Ŀ	11	U.	u.	u.	u	L	4. 1	L U	. u	. 4.	14.	Ŀ	ĻĻ.	u.	L I	ı U	. 14.	ш,	
0 b	2 O E	۵.	4	4	4	4	4	4	4	4	4	₹ '	4 4	4	7 <	7	4	4	4	4	4	4	4	4	4	4	₹ .	4 .	4 4	7	4	マ	4	4	4	4.	4 <	4	4	
1 —	z	٠ د	531	532	533	534	535	536	537	538	539	540	140	242	24.0	מ מ מ מ	546	547	548	549	550	551	552	553	554	552	556	557	55 55 55 55 55 55 55 55 55 55 55 55 55	יוני מער	561	562	563	564	565	566	190	569	570	

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group 1

0

٩

\$

A Z H Z A J

		,																																			
		29	7		· σ	4	ı,	٠,	φ,	0	ຫໍແ	; - -	က်	÷	6	თ ი	u œ			6	ū.	o	٠.	27.6	6	6	ლ.			1	1	1	1	1 1	 		
		27		ם מ	·	- 0	_	ເດ	_	e0 1	n r	. m	on.	-	_	on 1	n a		~	-	E		- 1	· 0	(0	**	₩ (~		ļ	1	1	1		i		
			27	2 6	3 6	32	26	ë	6	6	7 6	3 8	29	8	6	26	2 6	5 6	9 6	33	9	27	7	282	28	27	ဗ္ဗ မ		 < -}	ا ; -;:	ا :-::	ा - ३८	ا لا:	। %•	: :< -	K 4	:
		25	80.0	9 4 5 +	5 4	7.7	7.1	4.6	5.2	7.8		, e	0.5	6.0	* 1	9		י ע	7	€.	9.0	8 6	9 6) Q	8.0	7.6	O .	ລຸດ ວຸດ	פיק	7 0	. 0	7.4	4.7	0.0	9.0	שא	
		_ !																						? (V													
		133	0.7					•																													
		-	6 27	v +	٠ ر	8	4	រប	ლ .	₹ 1	ກຕ	0	4	-	ហ	ο,	4 N	ς α	v	N		in i	•		LC.	ល	on s	ກເ	ם מ		0	(7)	~				
		2	27.	-	_		_	_	-	-			-	-	-		-	_				_	-			-	_		-					-	_	-	
		6	6	, C	4 F	. ~	4	6	6	ω (∞ C	o	σı	N	-	ဖ	n <		ıω	0	ස	ω,	٠.	- m	6	N	-	5 1	ה כ	vσ	9	~	8	დ .	4 (n c	
			9 1	٠ د	v u	0	4	6	on ·	4	o c) h	0	-	~ I	~ :	n c	v (*	1	-	8	(O I	- 1	26	· co	B	10 0	20 0	n d	n or	·	~	0	∞ 1	~ (א כ	3
		17	က္၊	٠, «	. 4	0	ဖ	-	-	ų,	ល ០	9	σ.	۲.	æ,	۱.۵	n •		4	4	-	4. (oj e	ာ o		-	9	ų.	- a	ه و	. 0			9	٠ ج	4 C	?
		i	10 (٥٠٥	7 (. დ	10	0	ın ·	OΙ	n +	- 00	Ø	€	-	- 1	n c) C	0	œ	~	LO I	n t	72	ID.	ဖ	9	O t	• •	- a			2	-	9	א מ	•
		ŧ	ល់រ	ស្ត	ם נ	90		~	Ŋ	œ,	4 4	. (7)	Ŋ		œ .	<u>ه</u> و	N -	٠,	9	6	o.	æ (æ c	7 0	0	۲.	4.	4	- 0	, ,	. ~	4	œ.	- 1	n.	ن د	?
		į	25	7 6	3 6	27	23	54	56	23	24	27	29	29	29	25	3 6	, C	27	27	29	56	22	25	23	23	26	28	> 0	25	2,	27	59	27	27	2 2	7
		6	o.	4 +	- α	. 6	ဖ	∞.	80	ص (o n	yφ	8	9	2	<u>ه</u> و	x, <	ŗσ	8	ı.	_	N I	٠. ١	u œ	ø	o	0		ى د				۲-	ın o	o e	4 6	v
		i	ະກ	1 0	٠ د	·	マ	-	9	n :	s a	o ~	ID.	8	6	ω,	*	10	10	œ	യ	TU.	77 (2 6	· RD	4	32	~ 1	~ 0	n u	o co	to	27	38	2 4	- 0	0
		2	0	<u>ء</u> ڊ		, 6	o,	0	R)	١ بې	ល ផ	φ	1	9	φ.	- (9	• •	ဖ	មា	œ	O I	~ 0	9 15	φ	- .	- (ق	4.6	4 O	, -	(0)	c,	4	<u>ص</u> و	pς	Y
		į	24	n u	ט כ	o co	-	Ø	2	ο,	4 1	- 10	S	B	-	•	4	- c) ဖ	œ	9	S) I	ט נ	0 4	4	*	រ ល	n (1 0	·	ט נ	S	-	D.	4 (ט פ	3
	¥	=	4	ی و	, c		-	αį	ω.	ا بی	m a	9 0	σ.	-	<u>ص</u>	- (o, c	, .	i o	Φ.	۲.	N (ו פּט	v 4	N	-	- (۰.	ج د	- ب	. ~	N	<u>د</u>	φ.	٠,	ب ر	P.
	H	•	97	200	9 0	24	24	27	56	25	24	200	26	26	56	24	200	ט ע ע	38	27	25	27	24	72	24	24	52	23	1 0	ָ ע כ	26	26	3	24	23	9 10	V
	3	£ :		•	•			•	•		•			•	٠	•	•					•					•			•	• •				•		•
	ES	!	24	מ מ	2 6	25	22	27	53	22	24	26	24	24	2	2	22	λ C	27	27	24	25	2 2	2 2	24	24	24	26	מ מ	2 4	25	25	27	24	24	2 6	y V
	•	o i		•	•		•	•		•	•		•	•	•	•	•	•			•	•	•			•	•	•	•						•	4	
		1	N	N 6	4 0	4 (C	C	2	0	04 C	4 (1	~	3	~	0	2 6	4 (2	~	ď	9	2	2 6	2	~	C) (2	7 0	40	1 (1	N	Ñ	CV I	~	, c	٧
		Φ :	4		9 0	'n	3	ς,	<u>ن</u>	0,	o .	4	0	٣.	0	ĸ.	4 (i, c		Ö	4	0	Ņ	Ŋ -	Θ.	ο.	<u>ه</u>	æ (٠ ? ح	. "	4	-	6	œ.	4.1	- 0	D.
		1	24	מ ני	0 6	25	22	27	25	24	2 6	2 6	36	4	2	2	1 7	4 6	28	27	25	24	26	2 6	23	23	23	25	א כ	2 6	25.1	4	25	24	22	2 5	ţ
		7	•	•	•		•	•	•	•	-	٠ -	•	•	•	•	•	•		•	•	•	•	7 1-		•	•	•	•	•	•	٠.	•	•	•		.
			2	÷ è	, ,	, 6	~	26	23	2	2 2	26	8	26	2	2	5	7 6	2 6	25	25	2	2 6	2 6	8	22	2	2 0	200	, ,	4 5	24	27	23	20	, c	,
			3.2	•						•				•		•							•				•	٠		•							
		i	2	2 6	4 0	* 0	8	8	N	24	~ ~	4 (7	C	C	•	CI I	CV C	A C	10	C	N	a	~ (3 C	10	N	CI I	2	7 (4 5	4 (10	8	~	0	W (7
		S !		•						-						•	•			•	•		•	5 C													
			2	.,	4 (4 0	7	2	8	~	C4 C	4 (1	~	7	8	~	~ 0	4 6	1 (1	8	3	0	0	<i>N</i> 0	3	~	0	0	N (4 6	40	1 (7	0	R	0	η τ	•
		1	2.5	•				•	•	•	•	٠.	٠.	•		•		•	٠,		-		•				•		•			٠.			•		
		į	3	(V)	, ,	. ?	=	7	2	×	0,0	, v	~	8	2	2	N 0	, ,	1 2	4	č	7	'n	0 0	N	ö	8	2		4 0	4 6	12	2	2	7	2 5	v
		က	21.4	ກ ເ	 	9 9	4.	.3	5	ი ი	φ. r	9	4.	4.	Ξ.	8	ຕຸ		9 6	4.	<u> </u>	0	თ. <u>.</u>	2 0	. 0	₹.	e	9	9 0	י ני	3 (2)	0	9.	4.			٥.
		i	Ŕ	ĭ	'nò	, ,	, <u>~</u>	4	3	¥.	۲ ۲	, ,	N	%	ĭ	~	ă	46	3 %	7	N	ä	0	7 6	10	N	0	6	7 6	i c	4 6	6	5	'n	<u>ج</u> ز	7 0	٧
			7.7																				•									٠.		-			
		1	20																																		
			-	•					•																												
			2																																		
		1 1	Q.9	•											•	•		•		•	•		•				•			•						-	•
		1	-	- (7 -	- 0	-	~	-	-			_	-	-	-	* (A C	4 6	-	~	-	-		-	-	-	ο.	~ (7 -	- 0	4	Ø	-	Ψ.	- (`
			7.2	•	•	•			-	•	•	•			•	•	•	•			•	•	-	80 F			•	•	•	•	•				•	-	•
			-	- :		- #	=	#	Ŧ	_	∓ ₹	2 2	=	¥	=	₹ :	¥ :	- +	· +	ă	-	=	≠ ′ :	~ +	. ₩	-	≃ :	¥ :	≓ ₹		= =	: 4	7,	÷	- :		Ĭ
			! !																																		
	S a	υ×	1 LL	u ı		. "	. Ŀ	u	ш	ш	u. L	L 11	L	ı	LL.	LL.	L I	Lu	L LL	11	u.	u	LL 1	և և	. 4	L.	u.	<u>. </u>	u i	L U	LL	. u	Ŀ	ᄔ	u.	L	_
© a	0	ے د	4	4 •	4 4	1 4	4	4	4	4	47 4	4 4	4	4	4	4	4.	4 4	4	4	₹	4	4	4 4	4	4	4	4	4 .	7 4	1 4	4	4	4	4	₹ ₹	4
د ;	z		i -	~ (7 5	t LC	9	7	80	6	۰,	۰ -	B	4	S.	9	٠,	o a	0	-	~	ဗ	4 1	ពេធ	, -	ထ	6	0	- (N 6) u	ı ıı	ဖ	7	œ i	on C	5
			571	57	ני ני	. ני ני	57	57	57	57	28	20 00	58	58	58	58	80	מ מ מ	o G	59	59	53	29	00 00	50	59	59	Ö	85	9 6	2 6	8 6	82	82	82	827	Š

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX*---No data available (sacrificed)

		29	4	ĸ.	ļ (Ŋ	: 1	ល	o		1 :	۲.		ri.		i		•				ŧ			N :		ı				0 0							w r			
			34	32	1 (33	' '	(C)	က		1	36	1	36	ı	•		35	1 (37	4	1 6	8 8	n (י ני	37	1	33	1	00	32	3	1 6	ş							
		27	32.0	'n	, ,	36.5	, ,	•	4	1	1	35.8	1	•	i	1	1		ļ.		0	! (٠	ų.	ر ا ا		1	4.	1	4 1	35.8		ŀ		1	! (ó	57.4		. و	~
		25	0	₹.	; .	-	1 1	ų,	۲.	1	,	•		•	1		1	ო.	١.	4	Ŋ	L	ហៈ	٠, ١	0 1	ω.	1	ผ	ĸ.	ı İ	~ (Ņ				! (G	ı,	ກຸ່ດ		C
		8	0 35	m	(n	1	ומ	n			9 35		C				n	1	ო .	4	•	2	"		n		က	n	(C)	- 1 0 0 0 0	י	C	מ		•	က I	 	N (וכי	ď
		8		•		•	ı	•	•	•	1		i	33.	į	į	į	•	1	•		1						35.	35.	33	35.4	7.	֚֚֡֝֝֝֓֓֓֓֝֝֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓	ģ.	i	i ;		56.8	א ני	33	-
		21	Ψ.	æ	1 4	6	!	4.	₹.	i	t I	N	ł	ល	l l	i	!	- -	i	o	-	; (ų,	ه و	N !	80	1	ო.	9	'n.	c	Y	; •	-		1	<u>ه</u>	ص 1	ກຸ		ď
		6	C	က	1	n		(C)	က			93		n				e C	1	(C)	ਲ ਦ	. '	ი (n (3	n		က	n	(C)	2 32	יי	C	7		1	က၊	7 57	N (י פי	٣.
		-		ů,	1		:		ė.	1	1		l			ì	i	•	1	•	ω.	١,		4.	. 1		1	e.	4	6	46.0	;	1				C) (56	٠,	,	-
		4		æ.	1	•	1		ر س	!	1	2. 4	!	9.	1	i	1	8.8	!	0		1 (7		. i	1.5	1	. 7	9.6	6.	- c	9.	! :	-	!		٠	ω : ω :	٠	•	
		:C	4	4 6	. 1	რ -1		က ၊	n			n	1	0	,	ı	ı	4 6	1	(C)	က	(ტ ((C)	7)	က	i	O	E)	(C)	2 2	V	•	7		1	(C)	ព ព	2 1	3	ď
		- !		ς.	١,	•	1	•	- -	1	1	33	1	•	1	•	1		∦.		ď.	١.	•	ກ່ເ	ا			÷ :	Э.	ó.	E 6	,	١,			١,	ς.			<u>.</u>	c
		5		•	t		ı		•	•	1	4.0	l l	0.	!	1 1	1	Э. Т					•	•			. 1			•	0 0	•			t		•	S (•	•	
		2	က	n		m	•	(C)	n			က		n			ı	9		m	8	1 1	ច ខ	o (5 1	~	1	ຜ	n	0	4. 06.	5	. 2	n		1	m I	0	N C	"	"
		- !	£.	3	;	34.	!	33	3.	!	1	33.	1	30.	;	1	!	3+.	1		9	1 (93		33	1	<u>ج</u>	2	-	8	٥	1 (97	1		က ၊	6	۰و	- 1	С
Ä	í	=	0.7	7.	! !	ص ص		. a		1	1	2.3	; i	9.7	! ! !	1	:	1.3	}	- 1	4.5	1 4	د ر	ص ص	2	2.2		0.8	2.0	-	29.3	9	1 6	9	1	!	ċ	0 t		<u>.</u>	σ
X E E E		٥	R)	.7 3		æ .	ا بر ا	G :	ເກ	ı	1	8	!	0	!	:	!	so.	:	0	N	٠.	4 (N (0	0	!	4	m	ហ	٠, ح	3		7)		יי פס	N 1	រ ខ	œ ·	_	¢
TEGT	3	-	30	ဗ္ဗ	1	32	င္က	7	ဗ္ဗ	1	i	32.	i	30.	i	!	1	31.		3.	32.	: 1	33	(C)	35	32	:	0	0	σı ·		מ	: (97	i	23	ن ج	<u>ب</u>		5	ç
•		o i	ö	ö	! :	ლ ('n	ი ი	ö	1	1	-	1		1	ı	i	÷	1	о О	9	!	ά,	ď.	- ¦	2		6	ς.	င်	O (,	!		1	ö.	. .	4 1		٠ د	Ø.
		8		8	!	•	<u>.</u>	ω.	-	ł	!	ع	!	0	f	:	:	S	1	7	ლ.	1	თ. თ.	O .	ກ - ¦	4		0	6.3	ر د	4 c	N .	ָ קאָ	n		C	က (က (ω (אוני פוני	رن ص	•
		1	(C)	30	•	33	6	33	9	1	1	32	ı	ဗ္ဂ	•	•	ı	ç	1	33	ဗ္ဗ	1	3	8		33	•	ဓ္ဓ	3	29	2.9	7	9 6	9	1 ((2)	CO I	က (N (c
		7	30.7	Ø		32.0	_	3	0	1	ŧ	32.1	!	30.3	1	! ! !	ı	0	1	o ₁	n	5 (N I	N (0 1	(1	0	0	Φ:	4.0	- (ار و	D	1 (σ ·	0	0	٠ (x	-
		9	7	-	1	۲.	ဖ	٠.	œ.		:	-	- 1		1	•	1		ŀ	4		! (•	ס ו	n i		1	0	6	~	ω, α ω (٥.	m (2	. (თ. ·	4		v i	S	-
			29	28	•	(C)	္က	9	28	ł	1	91	1 -%	e.	ا ع: ،	! 水·	ا -::	29	1	28	32	1 7	3	ဓ္ဗ	20	32	ا ا	29	28	28	27	7	9 6	2	i (29	ဓ္က	29	23	28	S
		5				•					•								•				<u>.</u> .	<u>.</u>							25.2										
		4	9	æ	į.	3	ល	œ	4	:	1	ı,	ဖ	Ŋ	<u>ه</u>	œ	۲.	σ,	!	۲.	4	: (0	សុរ	ກີ	òc	4	o,	N	o.	Φ,	٠ بد	4 (n (<u>ه</u> و	က	က	e i	~ 4	~	~
			29	.51	! **	27	27	29	26	*	ا *	28	27	9	56	27	ဗ္ဗ	27	*	27	ë.	; (29	29	27	, C	29	26	27	56	24	9 1	28	2 1							
		(2)	27.5	œ.	4	<u>ن</u>	œ.	œ.	n.		7	В.	œ.	ó	'n.	œ.	σ.	ζ.	œ.	œ.	o.	თ	١٠.	m			. n	ιο.	7.	ın.	٠.						m.	m ı			ıc
		~	Ψ.	4	o.	რ.	œ.	9	۵.	ω.	6	Ξ.	Ö	٩.	0	9	۲.	8	۲,	4.	- ;	ທຸ	o.	- , ·	4.	- 4	6	-	ი.		0 1	v.	ه وه	æ :	œ, ι		۲.	9	7	œ.	c
		¦	3 27	C	N	CV ·	ď	~	C	N	~	C	~	~	N	N	N	~	2	N	~	CV I	C)	~	~ (, C	2	~	~	0	0	N (2	.71	C 1	0	0	0	C, (C	c
		-	25.8	ď.	'n	₹.	ë.	ທີ	6	ď.	4.	ιΩ	4	œ.	ω.	6	6	'n	œ.	4.		۲.	4.	n ·	. .		. י	4.	īυ.	e.	÷.			<u>.</u>	÷.		7	٠. ش	ς.		
		+	6	۲.	Τ.	<u>ن</u>	<u>ه</u>	o.	ø.	Τ.	ø.	æ	o.	۲.	9	6	۲.	8	æ.	۲.	ល	<u>ص</u> (co :	<u>.</u>	4 (م و	0	6	4	o.	o٠	٠,	- (20 1	٠.	9	<u>ق</u>	ص ا	ហ	e.	Œ
		!	3 25	N	C	0	N	N	N	ď	C	~	~	~	N	~	0	ď	0	0	0	0	C	~	20	40	10	N	N	C	24 (N .	-	0	N	C	~	3	~	¢
		- 5	4	ε.	- -	ď.	Ψ.	e.	Ť.	e.	ö	4	Ψ.	4.	ó	÷.	₩.	ĸ.	₹.	ä	₹.	₩.	₹.	તં.	÷.	- स		6	.	ö		÷.	<u>.</u>		٠.	~	₩.	<u>.</u>	<u>.</u>	ς.	,
		į	••	••	••	. •	- •	••		•	••	••	••	••	••	••	••	••	••	. •	• •	•	•••				4	• • •	••	••	•••	• •	• •	» —		٠,	. 7	.,	'	. *	•
U	ט דה	×	Σ	Σ	Σ	Œ	Œ	Œ	Σ	Σ	Σ	Σ	Œ	Σ	Σ	Σ	Σ	Σ	Œ	Σ	Σ	Σ	Σ	Σ:	Σ:	ε ≥	.	Σ	Σ	Σ	X :	Σ	Σ:	Σ:	≅ ∶	Σ	Σ	≆ :	Σ:	Σ	2
			ស	រប	ເກ	ស	ល	u:	'n	រ	īΟ	ro O	រា	ស	រប	វិប	ស	S.	ເດ	r D	r.	ıD:	ហៈ	י מו	i D	ט זע	טז (ı.	TC	ហ	ıo ı	י ט	י מו	in:	ស ៈ	ហ	T.	ម្នា	י מו	מו	15
α c	د ر		٠.														•					'	'	'	٠. ٠						(1	1		1			1	1	-•	_
	2 0	;									_				_						_	_																			

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; t_1 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

*---No data available (died)
**---No data available (sacrificed)

4

4

8

AND THE STATE OF T

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINGGEN.CITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

σ α

	ç	23	1	33.7	1	ļ	į t	1	32.4	1	:	í		2 6	20.00	9 4	2.5	4.6	38.6	í	37.2	Ģ.	1 1	37.7	33.5	! !			9.0			7 26	1	33.2	1	38.7	! !	-	:	1 	
	t	27	 	34.3	! !	1	1	1 6	32.3	i	1		D (- t		4 C	9 C) (9.7		4	2.	1	35.6	o.	ı		1 (u	; !	32.5	i	37.0	1	!!!	1	1	
	į	22	1	33.8	į ; į,	٠,	} ;	1 (32.2	36.4	i	1 6	m 1	- 1	0 · 0	- 1		21	6.7	1 1	37.9	6.4	1 1	37.1	ж Э	! !	!	- 0		מיל	34. 10	i c	2	31.4	1	36.0	1	1	1 1	33.4	! !
	ć	53	i i i	34.2	; {	35.2	i t	1	33.2	7		1 1	· ·	- c	5.00	9 0	, c		5.4	1 1	N	0.9	1	m, i	7.9		1 (8.6	י זינ		٠ ح	•	7 ! • ! • !	30.4	1	34.1	!	1	1 1	32.8	i i
	č	21	i i	33.8	!		1	1 (?	5.9	1	,	4.6	4. r			2 .	<u>ه</u> . ه	6.5	1 (<u>.</u>	5.6	1 1	m i	ъ.	1	١,	4 (. و	•	• +	: !	27.3	1	31.4	1 1 1	1	1 1	31.8	i L
	9	19	1	G)	*	35.1	1	: .	31.5	4.	1				36.0						•	34.7	1	•	ω.	!!	:	4 (N (9 t		٠,	· 1			32.1	!	1	1	31.4	! !
	!	11	1	2.8	ű	ر دن	,	1		4.		1		٠,	92.6	; t	٠,	j,	4	1	٠	ю	ŀ	•		1	١.	₹ (ή,	4 1	•	o c	34.5	28.3		31.4	!	!	!	30.4	f l
	ļ	- 12	{ }	32.4	28.4	33.6	!	1 1	30.4	33.7	!	1	34.1	. c.	94.0		25.0	30.4	34.0	1 1	35.4	33.1		33.7	35.5		1 1	32.8	32.1	33.7	2 10	יי פיי	9 1	27.4	1	29.8	1	1	1 1	29.5	1 1 1
		<u>:</u> ع	1			33.5		1 1	30.8	34.0	1	1 1	33.8	9.6	0.0	5 6	34.6	30.7	33.4	١.	34.9	ö	1		S	1	1 1	33.2	31.3	33.5	. u	 	5 1	26.6	1	29.1	1	1 ! !	1	28.6	1
	:	12	1	ó		32,5	1	1	30.4	CV.	3	1 1	34.3	9.4	31.7	2 6	33.7	30.2	32.3	! !	•	÷	! !	•	Α.	ŧ		-					÷ ;		1	27.2	1	1	1	28.9	i ! !
WEEK	,	= !	1	3	٠	33.1	1	1	29.2	ς.	1	1	34.1	ή.	31.6	ċ٤	a	ö	'n	1	35	32.	 	34	33.	1	1	'n.	- (٠. ص (9 6	, c	ډ. ۲	26.		•	1	ı	1	29.5	1
TEST		2 ;	1	31.	28.	32.2	! ! -::	1 1	27.7	<u>.</u>	 	!	34	99	32.7	9 6				1	32.	9	33	34	93	! *	1	9	ဓ္ဗ	35		? ? ?	200		. !	27	i	33.		29.5	
		6 1	1	÷.	9	33.3	. .	1	28.4	ö	60	;	4	'n.	31.5	n	32.4	30.3	31.7	1	ö	ò	32.5	Ţ.	e.	.	1.	. .	ö	ტ.	- (i c	23.0		: 1	26.	-;:	33.	ς.	. 29.1	
	,	80 !	1	<u>ო</u>	~	7 31.0	~	~	~	ന _	~				30.4			_					31.3	_	_	_			.				יים מאמי			26.	~	33.	3 30.8	~	1
		9	:		25.	1 29.7	30.	27.	27.	9.	29.	1	9	3	29.	787	31.	29.	4 29.5	1	3	29.		9.	<u>წ</u>	9	l	29.	99			7 0	200	900	; ;	26.	26.	32.	30.	28.	i :
		2	1	ö	ໝ	ö	ნ	7	7	ö	ö	1	ö	ö	53	28.	30	53	28	1	3 30.	. 62 9	9 31.	7 31.	31.	3 28.	1140	1 28.	28.	93.	7 29.		200		: 1	26.	26.	31.	31.		i
		4	* 9												29	28.	30	28.	27.	27.	30.	28.	30.	29.	3.	28.	28.	28.	28	29		2 :	7 0	, v	; ;	26.	25	30.	30.		8 %
			26	ני	23	28	28	25	27	္က	28	7 31	6 29	30	28	28	6	28	27	56	53	56	3	7 29	30	7 27	8 29	9 26	8 27	6 27	9 28	4 1 2 2	מ מ מ מ	מ מ מ) I	4 26	2	30	28	25	5
		2	3 25.	C	C	~	ď	N	←	~	8	4 29	0	8 29	0	N 1	n	N	7	0	~	8	C	0 25	9 27	2 25	7 27	26	78	56	27	7 7	יי אנ	1 0 t	ئد ر (3 26	7	0	~	2	0
		1	. 1 24	C	7 2	ó.	4	1 2	1 25	7 27	92 0	9 29	9 28	5 26	9	÷ 5	~	8	9	9 26	9 27	2 26	9 28	7 27	0 28	3 26	9 26	4 26	7	6 6	2 6	8 (8	2 6	1 1 2 2 2	200	5 26	7 23	N	0	8	C.
		1	8 24	C	21	26	56	23	4	26	27	26	27	56	25	24	27	25	25	24	56	28	56	25	27	25	24	25	22	20.	52	20	2 6	א כ מ	3 6	25.	22	~	C	~	N
			3 22																					_																	
		İ	21.	23	-61	23	23	50	21.	24	24	24	25	22	23	20	23	22	23	22	22	23	27	23	23	22	22	22	22	22	23	23	2.5	3 6	2.4		202	24.	24	6	2
S	ш	×	Σ	Σ	¥	Σ	¥	Σ	Σ	Σ	Σ	Σ	Z	Σ	Œ	Σ:	Œ	Σ	Σ	Σ	Σ	Z	Σ	X	Σ	Σ	Σ	Σ	Σ	Σ	Σ:	Σ:	E 3	E 2	Ξ	3	Σ	Ξ	Σ	Σ	Σ
0	⊃	٦	ស	ល	រេវា	ស	រោ	ស	٠.	ល	ល	ល	ល	ໝ	ល	ស	ល	ស	ໝ	ເດ	ß	យ	ເກ	ល	נת	ស	ល	ស	ស	ស	ស រ	ម ប	in ii	ក រេ	ט ר	ហ	ព	ស	ល	ເດ	ស
z	0	• 1	641	642	643	644	645	646	647	648	649	650	651	652	623	654	655	656	657	658	629	99	661	662	663	664	665	999	667	668	699	670	671	770	674	275	83.4	832	833	834	835

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXavailable (sacrificed) *---No data available (died) **---No data TR Group 1 =

= 7.0 mg/kg/day RDXmg/kg/day RDX RDX; = 175/100= 1.5 mg/kg/day(sacrificed) S 35.0 mg/kg/day RDX; *---No data available (died) ~ available Control data H Group 1 **---No

8

₩

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (g)

(0)

63

(<u>i</u>)

-		ı																																	
	Či i	60	1 1		۱ ۲ -	١.	-	10		- 1	•	7	1	4	ė.		1 1	7	8	-	٠.	o n	; ;	-	١.	+ u		ູນ	2	i	1 1	5	9.0	1	9.6
ŗ	_	0	1) 4) (s)	1	ლ ლ	1 F		í	1	8		~ (€)		,	,					4 4 9 0		+ 3				9		1			9 6		9
C		37.	1	. 6	ംമെ		29,	1 6	4)	1	}	25.	•	33	S)	1	,	ம	-	0	LD 1	26. 26.)]	8	1 -	- 6	່ວ	•	8	1	;	· C	22	1	27.
	N	5.4	i			1	•	1		1	1		1	-		1	1	•		•				•	•			8			1 1	7.4		1	<u>و</u>
r	_	9.35		C	0		N	C.	•			N		(D)	N			N	N	က	01	<i>M</i> C	ł	n	•	י ני	1 (7)	n	0	N		C	1 (1)		2
ŕ			,	່ດ		1	•		. ,	1			į	•	S.	1 1	,	ı,	8	6	0	•	; ;	•	10	v u	 	7	•	۲.	1 1	9		1	28.
-	21	.3	;			5 1		1					1			• •	1				•			•	1					4	1 1	8		•	-
o		ເຕ)	c	0	'	~	ני	' '			4		က (N			N	a	n	0	22.5	•	~	c	4 6	1 (2)	G	C)	n		0	1 (1		2 28
Ť	<u> </u>		1 1	: œ		1 1	•	1	: !		1	•	1		4	1		S	9	6	ن ی	25	. !	•	1 0	0 <	4	N		œ.	1 1	9	22	i	27.
2	~ !		1	,		ı	•	ı			- 1	•	•	•	٠	1 1	. 1	9	۲.	o.	ო (Ŋσ	1	æ	1 1	. u	, m		٠. ١	<u>ო</u>	1 1			1	•
10	į	i g	1 1	~	10		~	C.	•			ĸ		(n)	~			8	64	8	0	NO	i	N	•	, c	1 (2)	G	0	0		0	1 (4		0 26
~	- 1		1	9	٠,	1 1	•	1	. !	- 1	ı	•	ŀ	•		1 1	٠,	3	ĸ.	۳.	e,	2.4	1	•	1 .	٠,		6		ഡ	1 1	6	٠.	1	27.0
ā	5	0.9	1 1		-	1 (o.	1 1	: :	1	1	8.	!	0.9		!!	. !	ø.		e.	<u>ه</u> و	ž ~	1	. 7	! <	, t-	មា	6	0	o.	!!	8	0	!	-
		2 26	1 1	~	. (7)	' '	C.	e	ş			N		0 27	7			N	1 24	0	(1)	9 6 9 6	ı	~	•	7 C	10	8	8 27	N			S		3 26
÷	i		ŧ i	່ເກ			7.4	,	. I	1	1		-	•	6	1 (- 1	'n	B	π.	4. 0		: :	•	! 1		6	6	•	2		6		1	26.
EK	- 1	7.5	1 1	8.7	4.	: :	-	6	:	1	1	9.9	1	- 6	6.3	1 1	!	4.4	3.5	9.		4 -	1	Ţ.	! *		9	2.	ر د د	2.7	1 I 1 I	8.	9	!	9.6
≱	. 1	! ∾.	∷ UC I	رن در		•	, 0	υα ∷	<i>,</i>	ı	,	4	,	0 (N . N 1	* - 1	,	5	52	8	4 t	0 G	;) [23	10	υ C 4 C	. O	5	CV (2		5	~		;; 0
TEST	ר ני	1 .	ای	່ເ		1 1	រ ព		. !	- 1			1	•		. 1	1	6	ω.	4.	ი ი		1	ö	! <	. (*		~		4	1 1	6		1	27
	ກໍ	١.	8.1	١.		1		•	. 1	ı	1	-	ı		•		•		-	•	•	9 6		•	1	*	٠.	•	•	•	1 1	9.1		1	ır.
α	ו ו ס	1 8	ر د ه	. N	0			n ∝	, 4: C		1	**	1	4 (9 F	יא הומ	*	4	8	4	(N (- C	1	2	1 0	4 α 4 υ) -	1 2	51	2	1 1	2	-	1 (7 D
	1	26.	9,	25.	4	;	: C	2, 2	. (7)	1	1	24	1	23	NI	n ı	24	(1)	3	ທ	4,	23.6	, 1	22	1 1	7	٠,	S	24.	₹	1 1	n	22.	1 1	24
	į		ານ ກ ແດ່ດ			•				. 1	1	8	1	•		. 1			•					•	1	-		•	5.5		1 1	٠.		1	•
u	ן ו	. ~	~ c ω c		ب	, (,	טונ טי	: 0	· 1	ı	5	ı	5 C	N €	и Э 1	8	20	2	6	0 1 0 1	4 4 4 6		~	10	9 C	9	0	01	9	ı t	8	8	:	8
	1	25,	24	2,6	~	;	4 6	8 K	(C)		1	ď	1	8,5	- (7) 1	+	E	~	2	2	2 2	1	4	1 0	3 (ဖ	25.	N	; ;	N	20.	ı	23
វេ	1	i 😎	ი ი	. ~	΄ς'	ί.	ή,	3.0	(0)	;	1	Ψ.	ì			. !	~	<u>,</u>	Τ,	ri.	ĸ,			ю	; c	•	4	4	e. ('n	, ,		8		•
4	4	5 2	מ מו	n w	0	. 1	រា ព		'n	,	!	-	1		ه م	ָי כ	æ	8	~	8	m (į	- 0	9	מו		m		4		!	
	1	23	2,5	23	23	;	7 6	2 2	2	i	i	2	23	22	7 6	7	22	22	20	22	2 2	2 6	i	23	i	- 6	23	23	24.	, 72	 	20	#	i	2
r.	1	1.8	٠. د			1.	⋰,		٠.	•	1	ö	~	Ļ,	٠.		: -	-	œ.	٠.	Ŀ.		1	~	! ~	٠.	: _:	m	<u> </u>	٠.	-	Ċ		1	-
~		8 2																																	
	1	22	<u>.</u> .	, C	2	23	25	2 5	20	20	19	19	2	2 :	2 0	÷ 6	0.00	20	18	50	2,5	20.2	19	22	2 6	- 0	2	20	20	200	2 5	20	5	18	20
-		20.9	-				•	* 1			•	•	•			•				-	•														
Ţ	- !	Ó	ល់ផ	. 4	ເຄ	- (، ب	٦ .		6	o	æ	4	ú	ņ (י מ	? ?	4	Ŋ	ტ.	٠. (ی م	-	0	œ, α	, r	(1)	0	ص و	ກຸ	N C	0	80	9	۲.
	1	21	מנ	4 (4	0	C4 .			_	-	_	_	-	•		- *	-	_	_	-	٠.		-	CV ·	C +	•	G	-	÷ .	- 1		-	-	-	
,	۱ ;	20.0	o (6	ö	r (, œ	8	8	6	7	60	ດີເ		0 C	٠,	7.	Ġ.	•	•		7	6	•		Ö	7	œ 1						
	1	 ! !	•	•		٠٠,										•		- 1				•	•		. • •	•	. *			,	•		•		•
υш×	, ,) ! ! !!! !	نا سا	- LL		u.	. L	L II.	u	LL.	Ŀ	L	u.	u i	ı.	LL	. u.	u.	u.	u.	u. u	L IL	L.	u.	L. U	. 1	. ند	i.	u i	LL	LU	. u.	Ľ.	u.	u.
+ w w a ⊃ a	,	្រ	ព្រះ	מו כ	ır.	י מי	ומ	ព្រ	מו	īρ	ស	ស	ហ	ស្នា	יו מ	ם ור	10	ı,	TO.	ហ	וו מו	טוט	ın.	n.	יו עו) IC	מני	ID.	י מו	יי מ	ט וע) ID	ED.	ម្នា	ro N
	1	1 																							-		_								
AZHZAJ ZO	1	711	-	•	•				~	~	8	2	S	\sim	N (1 C	1 C	G	3	0	ω (36	3	(C)	es c) 4	4	4	4 .	• •	4 4	4	4	4	ທ

195

**---No data available (sacrificed)

TR Group 1 =

ti

*---No data available (died)

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINGGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

THE PROPERTY OF THE PARTY OF TH

		مد
	29	23.7 24.0 22.1 23.8 23.3 23.3 23.9 24.7 23.9 25.7 25.1 26.8 26.1 27.7**
	27	
	25	34. 4%
	23	23.7
	21	29.5 23.7 24. ### 26.8 26.1 27. 7## 29.9 31.3 31.5## 24.6 30.2 26.2## 24.6
	19	22.7 : 25.4 : 333.1 : 27.7 : 27.7
	17	25.7
	15	22.0 24.0 23.9 25.7 27.9 30.8 24.1 26.1
	5 6 7 8 9 10 11 12 13 15 17 19 21 23 25 27 29	20.1 20.2 20.9 20.8 21.0 21.4 21.2 21.2 22.4 22.0 24.0 22.7 23.5 23.7 24.4***
	12	1.00 1.00 1.00 1.00 1.00
EK X	1	23.7.3
TEST WEEK	9	411 62 62 62 63 63 63 63 63 63 63 63 63 63 63 63 63
F	o i	21.0 23.8 22.7 26.6 25.9
	8	23.0
	7	20.09
	ဖ	22.22.22.22.22.22.22.22.22.22.22.22.22.
	យ	23.00.00
	4	4 16.7 17.8 17.4 19.3 20.1 8 20.7 21.9 22.9 %
	က	2222.23
	8	22 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	-	20.05 20.09 20.09 20.09 20.09 20.09
	Ŧ	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	۲	2.48 8.88 9.85 9.85 9.85 9.05 7.00 7.00 9.77
		t 8 8
	m×	
ר א סאט	، م	
· •	_	844 844 844 844 845 846 848 848 850

9

(3)

0

	65 67	10) i	œ,	:	9	<u>.</u>	4	ဖ	o,	41.5 42	4.	4 44	w.	1		-	_	10	$\overline{}$	~		-	~	37.1 38.2	į (Ν (י פ		,	- 0	2 0	י מ	۷ 0	n (٥.		x 0 (. و	4	0
	63	1 6		٠	Ł						40.5				1	!	39.	39.	36	34.	38.	1	38.	38	38.	1	6 1	37.	9				5 6	, (9 6	9	,	4 (37.8	(n)	C)
	9	1.) ·	'n	!	о О	7		36.0	7	40.4	ლ	40.9	6	1	1	39.8	38.4	37.4	35.2	38.8	1 1 1	37.6	37.3	36.9	1 1	38.8	37.3	4.75	. t	9.0	200	2.6		200	9.75	1 1	43.0	36.7	35.0	37.9
	53	-}; C			1	38.	39.	41.	36.	38	39	42.	40	32	I	!	38.5	38.8	36.9	35.9	38	1	33	96		1	40.5	36.8	38.0	y	- 0	0.00	36.00 20.00	0.00	36.2	8	1 (42.9	38.	35.3	38.2
	57	33.9	٥,	4	1	39.5	38.1	43.1	37.1	39.0	40.1	42.6	40.3	32.8	1		38	37		33	38	1	9	99	38.6	1	(C)	36	37.5	3 t	מ מ	1 0	2. 4. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6.	: u	2 6	D	1 1	42.2	38.6	35.3	38.6
	32	33.9	4.00	34.9	**	39.4	38.9	42.9	36.7	37.5	40.0	42.3	4-	36.1	1	1	39.1	37.9	37.1	35.8	39.1		38.6	39.1	7 37.8		38.8	35.8	37.1		4.05	1 (200	, (36.0	39.1	1 1	42.2	37.7	34.4	37.1
	53	34.5	9 6	34.9	39.2	39.6	39.3	44.9	37.0	39.2	_:	_:	39.5		XX	1	38.9	37.4	36.9	35.5	38.8	35.2	38.7	39.5	38.7	38.5	38.7	36.4	37.7	. 44.	35.0	5.0	9.90	, ,	3.00.00	38.9	1 1	41.4	37.3	34.1	36.0
VEEK	5.1	33.9	•		•								38.2			!	40.1	38.5	36.1	34.8	39.4	35.5	39.7	38.4	37.9	38.6	38.1	35.3	35.9	. 64	36.0	200	20.00	, ,	9.6	38.6		٠	38.6	•	•
TEST 1	49	35.3	9.00	36. 7	40.4	39.1	38.2	41.2	37.0	37.9	40.0	40.8	38.8	35.2	37.5	! ! *	39.8	38.1	36.5	35.6	39.6	34.9	38.7	38.7	36.8	36.9	39.0	37.0	37.7	50.00	2.0	0 0	30.8	, ,	36.3	38.8	1 1	<u>.</u>	36.	4	9
	47	34.5		•				•		-				•	•	•	•	•	•		•			•	36.3	•	•										1	ö	37.9	₹.	9
	45	33.3							•															-					37.4	5. C	36.2	000	6.00	200	4.1	37.7	1	40.8	37.7	34.3	35.4
	43	34.5																	٠.																-	٠.					
	41	34.4	•			-		-				•	•	•	•				•	•	•		•	•					•	•		•					:	39.6	38.1	33.8	37.8
	က	34.8	٠,	Ω.	ნ	6.	7	-	9	7	თ	ö	- -	n.	۲.	₹.	Θ.	ω.	ဖ	'n.	о О	ıc:	υ.	ъ.	9	ö	ω.	₹ 1	9	· ·	4 (Ω :	ά.	:	ດ	LO.	ė	Ġ
	37	33	٠.	4	7	ω.	7.	ö	ß,	7	7	æ,	œ.	4.	ζ.	ä	æ.	ė.	ري ري	5	7	4	œ,	Θ.	ທີ	ω.	۲.	4.	<u>ن</u> و			٠,	ء ف	;	4.	80	1	ω.	છ	რ.	ທີ
	35	34.0	٠.	₹.	7	Τ.	9	8	ä	œ.	9	o o	÷.	4	۲.	6	ი	7	4	г. С	7.	θ.	છ	7	₹.	ω.		6	œ i		4 1	٠,	٠.	• (1	œ		е Н	7
	33	33.4	ġ.	₹.	7	σ,	7	6	4	7.	9	o.	ö	ю.	Ġ.	6	æ.	œ.	ς.	ın.	æ.	6	8	ω.	'n	ω.	9	4	٠. س	ς.	4 (9	ς,	₹.	B	i	7		ю	4.
	31	33.2	، و	2	œ.	o.	7.	6	ß,	9	7.	ω.	æ.	ო	9	ö	6	7.	S.	S.	æ,	ი	7.	7	θ,	۲.	ġ.	4	4.		ი ი	D (วเ	ŝ	œ	1	۲.	. 9	6	7
v	ш×	Σ: Σ:	Ε	Σ	Σ	Z	Σ	Σ	Σ	Σ	Σ	Σ	X	I	Σ	Σ	Ξ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Ξ	¥:	Ξ	Σ:	ε:	Ξ:	Ε:	Σ	Σ	Σ	Σ	Σ	Σ	Σ
0 x 0			~ .	-	-	5	-	7	8	-	- 0	<u>-</u>	2				6								-					ຫ [,]		- (0.0	η,			9				

TR Group 1 = Cont ol; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX **---No data available (sacrificed) *---No data available (died)

TWENTY FOUR MONTH CHRONIC TOX .ITY/CARCINGFFNICT; STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) .N THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASURFMEN:S (g)

Same of the same of the same

*																																						
	67	35.9		i c	; o	9	1	١,	, .	, r	33.8	6	o,	ö	ທີ	i i i	١,	ກ່ເ	35.3		LC	-	ė,	o; 6	38.3		6	ė.	ó		et (,	; -	43.9	1		
	65	36.6	თ ი	i c	; 0	ė.	1	! ,	4 C	າ ຜ		6	ά	ö	4.	1	1		. i	1 1	Δ	0	Ġ.	٠. د			6	о О	ö		ທີ່ ເ		í			- 1		
	63	36.2	40.7	000	40.4	45.8	1	1 9	2 5	, to	33.5	37	37.9	39.3	35.1	1	1 6	9.0	33.0		43.5	39.5	46.1	43.8	39.4 4.0	34.3	40.3	39.2	40.9	36.6	32.7	40.2	1 0	0.00	40.4	1		
	F.1	36.2	٠. د	i o	່ຕໍ	ıc.	1	١,	٠. د			7	œ.	6	ı.		١,		o.	1 1	. 4		'n.	ف				ö	÷.		<u>.</u> د	Ď.	1 1 t	- 0				
	59	-	o c	o o	6	ທ	1	١,	N C	v u	33.9	ω,	6	ó	9	1	;	33.6	ا و		C	ö	ı.	 0	39.8	, 4	0	о О	o :	ഡ	ເນ ເ	ς.	! (38.0			
	LO I	36.2	38.6	30.5	39.3	44.7	1 5 1	! (52.5	7 6	34.0	38.0	38.9	41.5	35.8	! !	! !	0.68	36.0	t	41 4	38.4	44.3	49.2	40.3	34.2	41.6	40.7	41.4	36.1	37.6	46./	1 0	000	42.0	1		
	55		9. cc	50.00 0.00	40.2	45.6	1 1	; (! ; (2. c	2 4 . 0	33.6	38.2	39.0	41.5	36.8	**	· · · · · · · · · · · · · · · · · · ·	38.4	35.7	! ! ! !	244 5	40.9	46.2	51.3	39.5	34.2	41.6	41.0	39.1	36.6	36.5	4 °	1 0	0 0	0 10	; ; ; ;		
	53	~ (η.	- α	0	4.	!	4 (אַ פֿל	. u	ט ני	ω,	7	7	ω.	- (φ, ι	ه و	7	ָ י	, d	4	~	9	ص •	0	<u>.</u>	ω.	n.	_	4.0	N (Y (0	: :		
EK	51	3".1																																				
EST WE	61	36.0	m s	• a		10	.		· .	V 0	· -	6	8	o.	ις.	س	<u>.</u>	o i		• (-		.	င်				b.	÷	ω.			n.		o o			
_	~ .																																					
	45	35.9																•						•								•					•	
	43	35.4		N 0	ით	_:	œ :	N	0			ဖ	8	ö	വ	9	. ,	ω.	٠.	4 (o	. ω	4.	ö	٠. د ه	: u		6	8	Ġ	9	٠ ا	ان		ດີ ປ	· c		
	4.1		œ (· a	. o	- :	о О	ري	÷,	- u	, 6		7	6	2	9	ó.	ω.	4.	4 (4	0		; <		6	ö	۲.	٠ .	٠.	٠.		ບໍ່ບ	. α	0	
	39	35.1	o (· a			8	<u>.</u>	. .	1 C	: -		7	œ.	œ.	w	ó	ໝ່າ	ນີ້ ເ	m		· -	ω.	ດ	_	. u	; _~	σ.	6	છ	. ·	₹ :	٠.	N :	- 15) เร		
	37	٠.		i a	. 60	_	7.	ព		:			ω.	ω.	υ. Ω	2	ö	<u>.</u>	4 ('n.	٠,		Ψ.	8	œ •	† U	·	6	6	ω.	<u>.</u> ف	4	٠.		. u		, n	
	35	34.7	ω·	- a	o «		Ŋ.	ທ.	٠.	ت د	-	. 6	9	α.	ū.	4.	o.	œ.	4 (x	0	-	8	۲.			8	8	ъ	<u>.</u>	4	4 (ġ,	- c			
	33	35.2	ت	. a	. œ		S.	4.	. 0	J. (م و		7	8	10	9	о О		ۍ. کا	- 1	٠,		ö	9	۲,	; <		-	ö	9	<u>.</u>	₹.		4 1	ນີ້ດ			
	3.		ъ.	- 0			₹.	÷.	<u>.</u>		÷ c	. 4		œ.	œ.	'n.	о О	œ.	ب ب	ά,	0 0	. u	-	œ.	ω,	· •		6	7	ın.	10	ω,	ທ່າ					
	י ו א ע	•	.	c: -	- -		~	5	5 '	•	ç -	. =	•	•	ŗF	*	\$	÷	-	·	-		•	•	.		. =	-	•	=	~	~			,	,.		
		-	~ .			. ~	~	~					_	•	-	-	_	-	-	•			-	_	*			•	-	_	_	~	_				•	
+α 0¤0:	oa i	-				-	•	-		- 1	- +	-		-	-	₹.	-	**	-	Ψ.			-	-	-	- +	-	-	_	•	-	-	Ψ.		- +	- *	•	
.HΣ∢¬ ∑(}	4 1	4.	4 4	2 T	46	47	48	49	င္သ	นิว	3 6	54	52	56	21	28	23	9	9	2 6	8 8	65	99	67	9 0	202	7	72	73	74	75	76		9 6	0 0	2	

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX*---No data available (sacrificed)

0

0

(2)

(

٩

٣

AND THE PROPERTY OF THE PROPER

ð

٣

198

< 2

		7	- (•							1	•					1							•		•		Ņ.											<u>ه</u>		i	n.
		9 :	ë.																																							
		65	37.2		x	6	0	1	37.3	- -	ŀ	40.8	e.	e,	œ.	'n	!	ເດ	თ	36.7	ö	ó	1	œ.	'n		4	39	<u>.</u>	ó	6	1	ζ.	39.8	რ.	4	œ.	œ.	4.	ò	ī	43.4
		63	38.8	<u>.</u> ,		٠.	4	i		ö	;		е	÷		6	1	÷	o.		9	æ.	:	E,	÷	6	<u>.</u>	•	ю	ه	÷	1	۲.		რ.	- :	æ.	ß.	ιυ	÷.	1	40.8
		19	36.3	40.1	36.2	38.4	44.7	1	34.4	50.7	1 1 1	39.7	44.2	43.9	33.5	37.2	1	40.4	40.1	32.5	36.1	36.0	1	34.1	39.5	36.3	33.5	36.8	42.6	40.9	39.7	1	32.1	38.0	42.6	40.4	37.2	36.5	42.7	42.1		43.2
		59	36.2	42.3	35.9	36.9	45.0	1	34.7	50.4	1	41.4	41.4	4.0	35.9	37.5	:	39.9	39.8	35.0	37.9	35.8	k E E	37.2	39.4	37.3	31.6	36.8	42.5	38.1	4. 3.	!	37.2	39.	42.2	42.6	37.5	34.4	45.0	41.6	1	41.1
		57	37.0	m 1	1.1	2 9	5.1	1	ıs.	9.5	!	- .	2.8	9.4	6.9	9.9	1	в.э	8.9	7	5.1	7.4	t 1	5.7	7.8	7.0	-2	o.	7.	-	e. O	1	ъ. В	-	2.3	1.6	9.9	4.4	5.0	2.7	:	40.2
		55	4.1	01		၈ မ	9.9	1	0.0	2.5		3.7	9.9	S		9.		7.6	6:	<u>ه</u>	g.6	5.5	1	÷.	ю. С	ю.	6.0		4.	۲.	4.	1	9.	რ.	4.	ღ.	9.6	3.4	3.1	6		0.5
		53	7.9								•	9.5																														9.7
		-	4	₹ (9	្រ :	ω	თ						_	ហ	a	o o		~	7		_		7	4		ო	cv	-		N	4	~	_	m	a	თ	8	ស		7	
	VEEK	3	33	38	36	32	4	41						38	34	38	36	37	4	34	36	36		37	9	37	9	36	43	38	37	30	37	37	42	42	33	38	44	39	43	
	TEST	49	33.9	40.7	35.4	36.7	43.3	39.3	35.9	46.5	33.1	37.8	41.1	41.2	36.8	35.9	35.2	38.5	41.0	33.3	36.9	35.1	43.4	34.4	39.9	34.9	29.5	34.7	4	41.0	35.9	32.4	37.2	37.0	41.2	39.9	36.7	34.3	41.8	40.3	41.9	37.4
		47	S	٠	٠			•		•		•	•	•						•		•		•	•		•	•					•	•								
		45	31.7	ω.	4	Ċ.	რ.	۲.	'n	2	რ.	9	ö	ω.	е.	ري ري	ε.	θ,	ω.	. :	വ	ø.	თ	ė.	۲.	4	٠ ق	4,	ζ.	ė.	S.	6	6	6	о О	σ,	4	ъ.	7.	ö	8	ų.
		43		37.1	34.3	33.0	41.9	37.2	31.5	44.9	32.6	36.4	39.6	38.8	32.5	34.3	32.4	36.7	38.1	31.3	34.2	31.3	37.5	33.2	37.0	37.6	31.5	34.3	37.6	35.9	33.1	29.9	37.0	33.8	40.1	38.6	37.6	33.0	40.8	37.0	38.9	35.3
		41	30.4				٠.		٠.		٠,		٠.	٠,		•					Ξ.	٠.	٠.		٠,	٠,										٠,						
		39	.7	9.9	٦. ت	2.7	.	7.5	3.4	6.5	-:	9.9	8.8	8.7	4.6	4.4	4.4	5.2	8.9	9.7	3.5	4.7	8.4	3.0	8.4	2.9	0.2	4	6.9	6.1	7.9	6.6	8.3	3.7	0.3	0.6	6.5	2.3	7.2	0.9	8.8	6.0
		-	0	<u>رن</u>	4	о .	4	9	9	o	8	4	ស	4	80	0	ស	80	80	N	7	r.	e,	9	<u>ب</u>	₹.	ທ	r.	80	o.	ς.	o	7	_	9	6	Q	<u>و</u>	ល	6	-	c o.
		į,	.7	<u>ب</u>	m.	۲.	o.	0	9.	0.	0	0	9.	4.	6	-	6	8	6	-	ω.	<u>ه</u>	۲.	₹.	0	က	Ċ	<u>-</u>	0	ლ.	o.	4.	œ	9.	6	-	ω.	e,	70	o.	ø.	₩.
		9	.4	9.	က (၁	о. О	ල ල	0.	ь 6	0.	8.	.5	0.	e 6	.2	4.	8.3	8.	4.	.7	6.	.2	.3	e. 6.	9.	e. 9.	- 2	9	e T.	හ ලා	. A.	6	4.3	9.	ь Э	.8	.3	3	.8	6	6.	.7
		3		က	C	n	က	n	m	4	~	ന	က	က	n	n	n	ന	n	C	n	ო	n	n	ന	က	~	n	n	(C)	က	N	က	က	ო	က	n	ო	n		n	es .
		3+	8	ი.	ö	ი ი	ი ი	9	o,	o.	8	ς.	ů.	ς.	ď	4	<u>.</u> .	9	r	6	α.	Ö	æ	. .	4	ς.	Ġ.	4.	7	4	ö	8	e,	8	8	ق	6	6	ິຕ		-	e.
	νu	×		Ŀ	ıL	i.	ц.	u.	u.	u.	u.	li.	Ľ	LL.	u.	L.	u.	u.	LL.	u.	ш	u.	u.	L	u	Ŀ	u.	u.	u.	u.	u.	u	ᄔ	Ŀ	ij.	L.	Ľ	LL.	u.	. L-	ıL	L
७ ∝	0 =	اے	-	- -	-	-	-	-	-		-		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ب	zc) · i	81	82	83	84	82	86	87	88	83	90	91	93	93	94	95	96	97	98	66	9	101	102	103	104	5	106	107	108	109	100	111	112	113	114	115	116	117	118	119	120

TR Group 1 = Control: 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; t = 35.0 mg/kg/day RDX; t = 175/100 mg/kg/day RDX*---No data available (sacrificed)

d Z

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F! MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

	. !	6.	4	6	-	ហ	~	ი :	თ (0	o O	!	თ	۵	04	4	ဖ	8	ო		-	ဖ	۲-	0	ဖ	ស រ	ព ព	ຫ ^ເ	4 1	ກເ	n r	- α	σ) 1	-	- u	o e	0 01	o o	7	٠
	67	5	**	O	σο ∙	n	6	•	ເກເ	9	vo .	1	0	4	n	œ	-	ທ	o	1	₹	TO.	ത	R	ന	—	┯ .	9 1	រា ព	20 2	O II) r	- α	וכ	. 0	•	42	100	- 200	~	
	65	മ	e,	o.	'n.	÷	₹.	ö	<u>.</u> ف	e .	ω.	;	'n	ນ.	ю	4,	œ.	ö	ä	1	'n	е С	7	ei S	ش		ċ	42.8	T 1		. u	0 a		٠ :	σ	; ;	42.4	. ω	œ,	4	
	63	43.5	Ť,	7	4	- -	ä	ຫ	ζ,	4	ω.	i	ω.	რ.	. :	4	ιυ	. .	6	1	Α.	е Э	თ	ö	თ	Ġ	ó.	٠,		٠,	, D 14	· -		: :	α	o			ω.	е,	
	9	(1)	6	Ľ.	'n.	ö	<u>.</u>	٠.	4	<u>.</u>	۲.	1	ö	e,	ö	e,	4.	7.	ö	1	ä	ď.	7	œ.	ó.	ω.	ó.	<u>.</u>	٠.	٠,	• 1		٠,	: !		٠,	40.5		7	ď	
	59	41.2	O	~	ro ·	-		•	ימ	~	φ	1	,	*	o	n	က	o	7	•	ď	4	^	•		О.	- 1	∞ ≀	7) 8	~ L	กเ	οα	oσ) 1	σ) 0	40.0	S (C	-	~	
	57	39.7	۲.	ທ	ı.	ö	ຄ	9	6	ö	ю. С	1	œ.	4.	о О	ю	4	8	8	1	.	'n	ů.	ю О	œ.	œ ·	. ,	თ (٠,	; (• a		. ;	α	o	h -		7	θ.	
	55	45.3	Ψ.	რ.	4.	ö	ص	ω.	₹.	<u>.</u>	ω.	1	ó	ö	ö	ö	e,	ζ.	ψ.	1	'n	÷.	о О	÷		.	o.	٠.	· .		0 u		. a	: !	-		4 - 4 0 - 4		7.	ε.	
	53	43.7																	ល																						
ብ አ	51	44.0	9	ε.	ໝ	о О	- ;	S.	ن		ف	ю	ω.	ä	6	ä	ς.	Θ,	ιņ.	4.	÷	ż	Ω.	œ.	œ.	ó	o.	ᆣ.	- ,	٠,	. .						- a			Ψ.	
EST WE		46.0	۲.	4.	ю.	÷.		کا		_	4.	'n	ω.	ω.	o.	ä	ς.	ω.	ö	œ.	÷.	ς.	Α,	6		÷.	6	ċ		٠.	שני		D G			· .	30.7			~	
-	47	80	œ.	ö	.	α.		ტ.	· 5	o.	د	4.	S.	ö	o,	ö	÷.	ω,	o.	4.	ნ	÷.	7.	7	۲.	ω.		· .	ກໍ	0			- 1-				, a			<u>-</u> :	
		41.0	œ.	τ.	<u>.</u>	о О	ြဲ	ċ		<u>,</u>	ĸ.	- -	ω.	ď	œ.	o.	₩.		ın.	٠.	œ.	e.	'n	7.		о.	m	٠.			• •			•		1				_	
	43	0	4.	Ξ.	თ	ω.	٠.	ю	ö	е В	e,		រា	Ψ.	۲.	ö	÷.	7	ო	4	ö	ö	4	œ,	ū.	ö		ö	ġ,	· ,	• e			- 11	5 a			· ·		Ψ.	
	41	4		•			•																																		
		0																																							
	37	38.4	4	6	ö	7	ъ.	ö	ດ	'n	-	'n.	₩.	e.	ω,	m m	ς.	ıņ.	₩.	٠.	ტ.	,	₩.	·	ıo.	٠,	m		n	n (٠.	• "					ö	•
	35	36																																	_		_			_	•
	33	-	Θ.	ö	۲.	EÜ.		6	თ.	ó	- .	.	ö	7	~	æ,	.	4.	ď	ë.	Ψ.	œ.	ë	Ε.	Ξ.	ıÖ.			·	٠.	÷.,	n ::							ς.	φ,	
	31	36.4	÷.	7	ė.	ຜ	ς.	ġ	о О	ö	о О	6	ი	ζ.	7.	φ.	8	Θ.	9	4	8	7	- :	Э.	ო	ري ري	ທີ	ما	و و	٠. د د	- t	٠,	D a		:	: -	- a	. 4	ın.	Ö	
	w×:	4-		•-	•,					٠.	••	•			••		•-		•		•-				•		• 4	•.												_	
	!																																								
⊢ α 040	ָם בּין	-	-	_	-	_	-	-		•	-	-	-	-	_	-	-	-	_	-	_	-	-	_	-	-	_	-	-	-	- (У С	4 6	4 (y (۷ (4 C	4 (· (~	C	
₩¥U Z	o · !	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	5	ָר בי בי	70.	0.0	1 U	ת ה ה	100	158	159	160	

#---No data available (died)
##---No data available (sacrificed)

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX: 5 = 175/100 mg/kg/day RDX TR Group 1 = 4 =

٩

9

3

ð

0

		67	35.6	: ,	Ċ	1	ö		7.]]	•	38.8	œ		ດ			39.3		-		36.9											1	•	1	1 1	1		40.0	. 1	27.4	
	!	65	34.8	٠.	ψ.	:	ö		ö	1	1	40.5	α,	ი ი	0	7	ł	œ	۲.	ص.	e,	37.4	ო.	89	7	9	ņ	က	o	ဖ	ဖ ု	ırı	1	•	1 1 I	!!!		11	•			•
		63	4 .	- 1	ر. د	1	9.6	-	0.0	1	i	ი ი		6.	ი ი	7.2	1	8.5	4.7	7.6	8.6	5.7	8.2	7.5	5.3	7.5	4.	4.4	6.7	6.4	4 . 4	7.3	!	7	ı	t 1	1 1 1		38.4	8.7		
		61	2.2	ຄຸ	7	1	ල ල	5.	ි ල' ල	÷	!	39.6	o.	4	7	9.	ŀ	. 7	œ.	0	7.		-	æί	- .	8	4.	4.7	7.2	6.2	5	7.1	1	٣.	1 1	! !	1 1 1	!			C	· ·
		59	4.6	٠	2	t 1	-	4.	9.5	•	1	9.5	0.6	8.6	9.0	6.7	1	9.7	4.5	. .	9.3	6.2	8.6	8.2	7.5	6.5	4.5	O	7.2	ω.	ه. دن	7.4	1	6	1 1		1 1	! !	0.0	9 1		, ;
		57	⊕	9.	2.8	! !	න ග	₹.	7.9	1	1	O	8.7	6.8	0.6	ი ი	!	8.6	4.9	6.7	8.2	6.4 3	9.6	8.7	5.5	₩.	4.6	4.4	6.8	6.3	9.4	0.8	!	•	1 1	!!	1 1	1	8.1	to !	7	•
		55	4.0	ر ن	B	;	د	მ	е 6	1	1	÷.	ය. ස	e.	6,	e. e.	!	.a	e 6.	.4 3	.43	.4 3	9.	.3	.7	9.	9	4	. A.	හ ස	ص ص	و. ص	!	.2	1	1	! !	;	დ. დ.	, t B	, ,	? *.
		53	3.9 34		۵.	o O	7	o	e,	:	₹ 7	ထ	ທຸ	ω.	4	œ	<u>4</u> K	œί	7	9	5	ı,	۲.	-	œ	7	ស	-	0	_	Ŋ	က	9	-	i	1	!	t i	6. 6.	ان. ا	7	:
		+ 1		-	0	-	c	<u>ත</u>	<u>.</u>	 	۲.	4.	o.	ໜຸ	۷.	-	₹.	4.	<u>.</u>	∞.	. 7	ش	<u>ب</u>	₹.	r.	4	9	9	o.	æ.	ø.	e e	۲.	o.	:	:	, v	:	98 99	ю. ;		-
	2 11 11	9 5	.6 34		ი. ი	က က	. .	ල ල	.2	G	.2	e -	9	٠.	e. 2	6. G	e +	.7	3	.6	.o	.1	ь 6	.2	ъ. В	.7 3	е. О	.6	Б	9	4. B	ъ.	ъ. 4	e. e.	1	!		!	96 36	9.	ָ עו	
į	E2	4 1 1 1	2 35									38	38	38	29	36	37	38	34	37	38	35	5 38	38	36	36	5 34	42	35	35	33	38	4	33	1	1	35	۱ *	(7.)	S i		c
		47	5 34.																			35	37			37	34			0 35.					;	:	G	28	96.0	37	i	יי
		45	34		35	30	ę,	33	37.	36.	0	38.	36.	38.	28.	37.	36.	37.	34	37.	36.	34.	37.	38.	36.	37.	35.	43.	36.	35.	33.	37.	42.	33.	•	i	2	'n	•	7.		•
		43	34 3																										٠.						i	1	ທ່	÷.		37.9		•
		41	34.2		~	in.	ö	~	~	5.	ö	6	6	œ	ω.	છ	ζ.	7	4.	œ.	۲.	4	e,	7	4.	ω.	4.	ä	ıΩ	ď.	32.7	36.7	41.2	D	1	1	ທີ	œ.	35.2	۲.	1 4	
		39	34.4	80	_	œ.	œ	3	-	æ	0	38.5	~	38.0	6	ø	7	6	S	37.5	(O	33.8	-	37.8	35.2	4	34.5	N	10	ហ	32.3	LD.	N	35.6		1	32.0	33 8		36.1	! ! L	33.0
		i co	34.2	S)	~	S	0	3	-	LO.	0	O	Œ	œ	O	~	1	8	4	~	-	4	-	~	₹	ø	4	0	4	ß	_	ø	-	S	i		9	2		ဖ	i	
		33	33.4	m	_	10	œ.	m.	~	.0	ď	m.	7	œ.	œ.		ιο.	ζ.	₹.	7	~	w.	w.	w.	"	in	Ψ.	ö	, i	'n	w.	ζ.	φ.	'n	!	į	ζ.	·.	<u>.</u> .	٠.	! L	
		33	34 0	,	o	4	6	c	ė	4	6	8	7.	7.	o,	7	œ.	7.	ς.	ø	9	4	8	7	ъ.	4.	4.	φ.	4	4.	ŝ	9	ä	4	1	7	7.	е.		9	! ! !	
		9.1	34.3		Ξ.		w.	Ε.	~		w.	7	10	ζ.	œ.	ιö.	'n.	ς.	Ε.	~		Ψ.	ω.	Ψ.		١.	w.	S.		~	٣.	'n.	ä	Ξ.	1	'n	٠.	~	15		١,	
		1					•																			••	•	•	•	••	•		•	•••		•	•	•		,	•	
1	N M	×	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Ξ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	æ	Σ	Σ	Ε
0 α	0 0		! !																																							
ٔ ب	20	• 1	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	159	200

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX*---No data available (died)
**---No data available (sacrificed)

•		
67	4 0 0 0 4 0 0 0 0 4 0 0 0 4 4 0 0 0 0	
ស	4 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
Ü	4 0 0 4 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	55.6
	4 1 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	51.2
9 9	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	52.7
57	1 4 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
ស ប	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	52.2
53		. ro
E E S	4 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
3 ⊢ 6:	4 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
47	4 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0	· -
45	6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	: 20
43	4 0 4 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
4	8 8 8 4 6 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	
39	4 84 4 4 8 8 2 8 8 8 8 8 8 8 8 8 8 8 8 8	. ω
37	4 64 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	
35	4 6 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	
33	4 0 4 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
-	4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
		LL
-α 0α00a	 	7 C
H E 4 J ZO ·	22222222222222222222222222222222222222	2 Q

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/dav RDX **---No data available (sacrificed)

*---No data available (died)

9

9

٩

4

Ö

3

۷Z

⊢ ≃

42 - E 4

TEST WEEK 11 3 39 35 37 39 41 43 45 46 47 53 48 53 55 55 57 59 61 61 63 66 68 12 4 5 51 5 51 5 51 5 51 5 51 5 51 5 51			06.60	0.887.838 0.886.887.	9 9 9 9	- 1 0 0 0 4 4 6 5 12 1	8 084 6-8-
TEST WERK 1			!				
TEST WEEK N 0 0 S N 0 S N 0 S N 0 S			1				
TEST WERK N 0 0 S 1 13 3 35 35 37 39 41 43 45 53 47 49 51 65 15 51 55 57 59 61 2 1 1 2 2 F 31.3 39.0 31.4 32.9 31.7 39.4 31 43 53.4 31.8 31.7 39.7 39.7 39.7 39.7 39.7 39.7 39.7 39			ြုံပဲမှုကို		r. ω ω r. 4.	4.08.2.	
TEST WEEK N 0 5 S N 1 3 3 3 3 5 3 7 3 9 41 4 34.5 35.4 47 49 51 55 51 53 55 57 59 N 1 2 S 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3		61	1 0 6 67	4000000	0401-0	1 46.0000-67	6 9 9 9 9 9 9 9 9 9
TEST WEEK N 0 0 0 N 0 0 0 0 0 0 N 0 0 0 0 0 0			1 6 6 10 1	-098797	u-m m u	1 - 64 - 66 66 - 1	R1000-1800-
TEST WEEK 1 0 5 5 1 3 3 3 5 3 7 39 41 43 6 45 47 49 51 53 55 56 5 36 5 37 37 37 39 41 43 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5		7		- 0 2 2 2 4 2	4 60	. ! க்-ல்ஸ்ஸ்ங்க்க்க்!	4 6 4 2 4 4 - 8
TEST WEEK 1		ນາ	!				4 666 6646
TEST WEEK 1		ณิ	13 0044	3 3 3 3 3 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	4 4 4 4 4 5 5 6 6	,	4 4 6 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
TEST WEEK 1		53	62297		044406	, r r r r r r r r r r r r r r r r r r r	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
TEST N D S N D	×	ស	ပြောလ်ထာတ်င	. + 80.08 -	v. o. o. o. o. ←	4 - 9 - 8 0 0 6 4 6	+ 0 0 4 4 1 0 8 4 4 0 0 0 0 1 4 1 0 8 4 4
T C C C C C C C C C C C C C C C C C C C		ø	47.67.0	úri 4 w m - 4	ထထြေလာက်မှစ်	, w u 4 4 w 0 0 0 0 w 0 1	40040 0846
L G S S S S S S S S S S S S S S S S S S	1			à ໝ ໝ ∸ ൹ ൹ ฃ ∡ ພ ພ ພ ພ ພ ທ ฬ			4 8 8 8 8 1 1 1 C C L
N N S N S N S S S S S S S S S S S S S S			10004	4 6 6 6 6 7 4	34 9 3 9 4 4 5 5 6 4 5 6 6 4 6 6 6 6 6 6 6 6 6 6	344 344 344 344 344 344 344 344 344 344	934 394 395 397 37 397 397
L G N R N C N C N C N C N C N C N C		4	ព្រះជ្រួលពេ	5 4 2 2 4 9 5 5 6 5 6 5 6 5 6 5 6 5 6 5 6 5 6 5 6	84641-		_ ຎ ຎ ຎ ←
N 0 S		4	14.4.80	9.66.69.69	84-600		F444+68FOR
N 0 S		41	1			· · · · · · · · · · · · · · · · · · ·	
T C C C C C C C C C C C C C C C C C C C		6	1 80 7 10 7 1	0044040	# N B B O B	x-x-40x-00x:	0-24085724
L G N N C N N C N N C N N C N N C N N C N N C N N C N C				2000004	400040	200000000040	<u></u>
L G N N C N N C N N C S C C C C C C C C C C C C C C C C C		37	1 23.5.7.1		~ w ~ ~ ~ ~	. 6 6 8 9 9 9 9 9 9 9	r-64r6r464
7 1 2 2 2 2 2 2 2 3 3 2 3 3 2 3 3 3 3 3 3			- 460	06-897-	~ e e e e e		0 4 4 - 4 0 10 10 0 c
7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7		33	1				
ND - 1 - 1 - 1 - 2 - 2 - 4 - 2 - 4 - 4 - 4 - 4 - 4 - 4		_	i waani	m / m m + + m	തെവവയര	7 10 0 0 10 17 4 0 18 18 0 18 18 18 18 18 18 18 18 18 18 18 18 18	
O N O D D D D D D D D D D D D D D D D D		6	32 32 36 36	300 33 300 33 300 33 300 33	34 34 30 41 41	2 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	, a a a a a a a a a a a a a a a a a a a
	S	ш×	<u> </u>		ասև		
: 4 4 4 4 4 4 4 4 4 4 11 11 11 11 11 11 1	0 x 0	⊃	0000	~ ~ ~ ~ ~ ~ ~ ~	000000	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	10000000000
	z د،	ο .	: 4 4 4 4 4	4474480	រលលលលលល		0~~~~~~~~

TR Group 1 = Control; $Z = 1.5 \, \text{mg/kg/day RDX}$; $3 = 7.0 \, \text{mg/kg/day RDX}$; $4 = 35.0 \, \text{mg/kg/day RDX}$; $5 = 175/100 \, \text{mg/kg/day RDX}$ **---No data available (sacrificed) *---No data available (died)

		3		_	_	_	_	_			_						_		_		_	_							_				_		_					_	_		
		67	7.	က်	ю О	е •	4	7	•	!	7	55	ó	œ ·	₹.	ď.	1		e,	1	ö	ä	۲.	37.8	о О	6	1			43.2	1	œ	έ.	:	7	ю.	ယ	ių,	Ť.	47.3	÷		
		65									•																													46.7		1	
		63	7.	თ	8	ö		7.	ö	1	'n.		0	œ.	4	÷	1	_	٠.	1	ď.	е В	œ.	-	7	ω.	1	ທີ		ö	1	_	ζ.	۲.	7	6	7.	4.	ö	46.1	_	!	
		61		•	•	•		•	•	1							1	•																						46.7	-	(; 1	
		59	Θ.	: :	7	ď.	•	7	Ġ	1	4.	•		4.	Ö		!		ω.	i	÷	œ.	7.		6	ó	1	Ġ		.	1 1	ري ري	ω.		ω.	ري ري	œ.	4,	ö	46.4	ö	1	
		57	6	ຜ	œ.	ö	45.0	2	7.	;	6	48.4	ß.	4	ö	ö	;	27.8	œ.	ľ	ლ.	ö	ė.	37.2	8	о О	ł	S.	39.4	ó	!	S.	œ.	7.	œ.	ഡ	7.	ß.	ö	47.1	41.6	1 1	
		55	ď	7	7.	ဂ	6	æ.	œ.	ļ	ω.	- :			'n	<u>.</u>	1	œ.	æ	i	<u>-</u> :	ď	ä	7.	ó	ö	1	ιο.	÷	ф	1	'n	ä	en.	ъ С		7	10	Ċ	5.9	4.] i 1	
		53	65	œ	က	6	ıs.	4	ı.	o,	Φ.		9	œ.	o.	<u>ص</u>	;	o	<u>س</u>	-	o	o.	_		æ	Ŋ	ဖ	ဖ	ဖ	_	-	7	N	ဖ	ø	ເນ	ល	4	~	ď	_	1	
		-	-	7	~	œ	6	9	o.		Ŋ	ო	0	ω.	۲.	o.	æ	o,	o.	0	o,	ស	_	4	ø.	4	9	4	ဖ	Ŋ	~	m	9	8	o.	0	ď	<u>م</u>	80	.8 .46	S.		
	_ VEEK	9															9		က																			80	_	4 46	D.		
	TEST	45															33	56	38																			34	39	9 45.	33	'	
		47	42.	34	33.	37.	44	33.	36.	35.	42.	45.	33.	35.	30.	29.	<u>.</u>	26.	39.	37.	37.	39.	46.	37.	37.	38.	36.	35.	38	40.	6	4 31	37.	37.	37.	35.	36.	35.	38.	43.	38.	1	
		45		•				•		•	-	•				•		•		•		-				•				-				٠.						43.7	٠.	3	
		43																-				- 2	-						-			-				-		-	- 1	42.9			
		4 1				-						-					•													-		٠.						٠.		44.2	-		
		39	-	ď.	ო.	ß.	ö	ė.	ი	4	ö	÷	4.	÷.	ö	8	<u>.</u>	ů.	υ.	4	S.	'n.	œ.	7	œ.	ö	īυ.	7	œ	en.	6	'n	7	7.	ъ.	'n.	ω.	÷			œ.	1 1	
		37	.7	5	2.2	8.7	1.0	3.3	5.5	1.7	ი ი	6.3	5.5	2	დ. დ.	ი ი	2.0	3.6	9.6	3.8	3.7	÷.	3.2	5.2	ر. تع	3.7	5.3	و. ق	9.0	9. 6.	8	9.	9.8	1.7	0.7	5.7	5.7	3.7	5.5	3.8	6		
		35	7.0	Ð.	4.6	3.8	6.6	3.3	5	4.4	9.7	6.0	1.7	2.7	6 6	8.0	2.5	0.0	0.4	ري دي	5.7	9.9	9.6	6.0	6.6	5.5	. .	5.8	 	2.5	3. S	1.3	7.4	ر. ي.	7.1	8.1	0.7	3.5	-	6	0.		
			9	9	е 6	ю. С	8	ი ი	е С	.7	6	7.4	6	4. G	9	2	6 6	8	2	2	8	0	4	e -	9	4	හ භ	3	9	2	e	₁ 0	9	9	9	د	1	2 3	9	4	9	•	
			.4 37	CA	(,)	O	0	ณ	e	9	9		9	(T)	8	8	-	7	n G	5	e -	7 3	4	n	r C	2	8	9	e +	9	e e	13 4	9	e +	7	-	9	9	3	~	3	,	
		(1)	38	29	9	32	O	4	N	ĽΩ	ω	0	O	O	~	S	O	IJ	Ø	4	ĽΩ	3	₹	LO.	E	8	4	iO	ന	8	~	•	~	~	10	10	10	(10	40	10		
	ωш	·×	ıL	ı	Œ	Ŀ.	ᄔ	Ŀ	Ŀ	L	Ŀ	Ŀ	Ľ	Ŀ	ᄔ	u.	Ľ.	Ų.	L	ų.	u.	u.	¥	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Œ	Σ	Σ	Σ	Σ	Σ	Σ	Œ	Σ	
ο α	0 >	اء	8	7	0	7	0	7	ς;	(4	7	64	ч	~	n	7	7	7	8	8	Cŧ	Q	ဗ	e	က	ო	с	က	ო	၉	ო	က	ო	ო	ო	ო	ဗ	е	6	က	e	က	
J	z 0		281	282	283	284	285	286	287	298	299	290	291	292	293	294	295	296	797	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX *---No data available (sacrificed) TR Group 1 = 4 =

9

0

3

ø

99			;	;		;	;			Ε,		꿆			r	C U	ā		ប	7.3
2 0 0 15	33	33	÷	35	37		41	43	43	_ :	43	51	53	55	o i	52		9 1	וְ פּ	ופ
5. 4 3.5.7	32.3 32.	8		N	6.1	N I	6	ю :	ر ا	0	7.4	5.9	<u>.</u> ,		20	ر س		4.0	 :: u	10 1
7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7	.2 34.	G 1:		s: u	٠, د	0 >		έα		- ^	v -	9.			0 00				; ~	∙ α
9. 4. 1 3.4. 6 3.4. 7 3.6. 6 3.6. 7 3.6. 9	. 50			2	۲.			ی .		o	5.3	8			S)	6		6.	œ.	~
0. 6 40.9 41.2 40.7 36.7 36.7 36.8 38.8 6 39.2 37.8 \$\frac{3}{3} \text{3} \	.3 32.	8		œ.	4	4	4	4	4.	ဖ	2	5.3	9.4	32.	4	4		9	6	ယ
9.5 39.6 40.1 40.2 40.2 10.1 39.3 39.3 39.4 39.7 39.8 89.7 39.7 39.8 40.3 39.7 39.8 40.3 39.7 39.8 40.3 39.7 39.8 40.3 39.7 39.8 40.3 39.7 39.8 40.3 39.7 39.8 40.3 39.7 39.8 40.3 39.7 39.8 40.3 39.7 39.8 40.3 39.7 39.8 40.3 39.8 39.8 40.3 39.8 39.8 40.3 39.8 39.8 40.3 39.8 39.8 39.8 39.8 39.8 39.8 39.8 39	.5 39.	о О		ö	ċ	- :	ö	9	ω.	œ :	9.9	ณ เ	ω.	<u>;</u> ;	iı	! .		: (١,	1 6
3.7 41.0 47.1 47.2	.9 39.	6		6	о О	ö	ö.	o i	വ	m e	ຫຼາ ຫຼາ	٠.٧	· ·		n t			يا ف	В	1 a
41.0 42.0 43.0 42.1 42.2 42.2 42.1 42.1 42.2 42.2 42.2 42.1 42.2 <td< td=""><th> S</th><td>Ö</td><td></td><td> (</td><td><u>.</u>,</td><td>. .</td><td></td><td>٠.</td><td>· .</td><td>N =</td><td>~ c</td><td>• •</td><td>٠,</td><td></td><td>~ C</td><td>, r</td><td></td><td>n α</td><td></td><td>-σ</td></td<>	 S	Ö		(<u>.</u> ,	. .		٠.	· .	N =	~ c	• •	٠,		~ C	, r		n α		-σ
5.6 3.6 <th>0.</th> <td></td> <td></td> <td></td> <td>- ,</td> <td>4 4 2. 0 4 0</td> <td><u>.</u> .</td> <td></td> <td>n c</td> <td>- α</td> <td>, a</td> <td>- c</td> <td></td> <td></td> <td>) œ</td> <td></td> <td></td> <td></td> <td></td> <td>0</td>	0.				- ,	4 4 2. 0 4 0	<u>.</u> .		n c	- α	, a	- c) œ					0
5.6 36.7 36.7 35.3 36.1 36.6 36.7 36.6 36.1 36.6 36.7 36.6 36.1 36.6 36.7 36.6 36.7 36.6 36.7 36.6 36.7 36.6 37.1 36.6 36.7 36.6 37.2 36.6 37.3 36.6 37.3 36.6 37.3 37.8 37.9 36.6 37.3 37.8 37.9 37.8 37.9 37.8 37.9 37.8 37.9 37.8 37.9 37.9 37.9 37.9 37.9 37.9 37.9 37.9 37.9 37.9 37.9 37.7 38.9 37.9 37.7 38.9 37.9 37.7 37.8 37.9 37.7 38.9 37.7 38.9 37.7 38.9 37.7 38.9 37.7 38.9 37.7 38.9 37.7 38.9 37.7 38.9 37.7 38.9 37.7 38.9 37.7 37.7 37.8 37.7 37.8 37.7	- 6	- œ		· ~	, c	2	; 6			o O		7.2	٠		-1	9		7	7	. α
8.5 36.4 38.0 38.4 36.8 35.9 35.1 37.1 36.9 36.5 37.1 36.4 36.5 36.8 37.8 36.6 37.8 38.6 38.9 38.0 38.5 38.0 38.5 38.4 36.7 37.2 36.6 37.3 37.8 36.6 38.5 38.0 38.5 38.2 37.8 36.7 37.2 36.6 37.3 37.8 36.6 38.8 37.8 38.6 38.2 38.2 38.2 38.2 38.2 38.2 38.2 39.4 37.2 36.8 37.3 37.8 36.6 38.8 38.6 39.9 37.0 38.5 38.2 39.8 39.8 39.8 39.8 39.8 39.8 39.8 39.8	35.	מו		'n	4	9	6	ω.	ı,	(7)	6.1	9.9			ĽΩ	9		ė.	ū,	ဖ
1.8	.5 36.	9		8	9	Ø	8	ė.	ις.	-	7.1	6.9	.5	37	ဖ	9		7	9	7
0.5 38.0 38.7 38.7 36.7 37.2 36.6 37.3 37.8 36.6 37.3 37.8 36.6 37.3 37.8 36.6 37.3 37.8 37.9 34.6 37.3 37.8 37.8 37.9 34.6 37.3 34.6 37.3 34.6 37.3 34.6 37.9 34.6 37.9 34.6 37.9 34.6 37.9 34.6 37.9 34.6 37.9 34.6 37.9 34.6 37.9 34.6 37.9 34.6 37.9 34.6 37.9 34.6 37.9 34.6 37.9 34.6 37.9 34.7 37.0 38.6 37.9 34.7 37.0 38.6 37.9 34.7 37.9 37.9 34.7 37.0 38.6 37.9 34.7 37.0 38.6 37.9 34.7 37.0 38.6 37.9 34.7 37.0 38.6 38.9 34.7 37.0 38.6 38.9 34.7 37.0 38.6	.64 8.	ö		÷.	Ť.	3	Θ.	Ť.	6	o,	9.4	6.9	9.0	٠,٠	i i	1	t	1	1 (1 1
2.8 33.9 33.4 33.9 33.4 33.6 33.4 33.6 33.6 34.6 <th>.5 36.</th> <td>9</td> <td></td> <td>Ε.</td> <td>ω.</td> <td>9</td> <td>ω.</td> <td>ω.</td> <td>7</td> <td>۲.</td> <td>8.9</td> <td>7.7</td> <td>٠.</td> <td></td> <td>~</td> <td>•</td> <td>•</td> <td>۲.</td> <td>0</td> <td>∞ .</td>	.5 36.	9		Ε.	ω.	9	ω.	ω.	7	۲.	8.9	7.7	٠.		~	•	•	۲.	0	∞ .
8.1 37.2 38.4 37.3 38.2 37.8 39.0 38.5 38.2 ************************************	.4 33.	ლ		ä	3	3	ë.	ტ.	8	<u>س</u>	ຕ :	1.4	~·		4	ю		4	ю	4
4.1 37.0 38.4 39.3 38.6 40.2 37.7 38.6 39.8 39.9 40.2 40.7 41.0 42.0 42.0 42.0 42.0 42.0 33.6 33.6 33.8 33.9 34.9 34.7 33.6 34.8 33.9 34.9 34.7 33.6 34.8 33.9 34.9 34.7 33.6 34.8 33.9 34.9 34.7 33.6 34.8 33.9 34.9 34.7 33.6 34.8 33.9 34.9 34.7 33.6 34.9 34.9 34.7 33.6 34.9 34.9 44.7	.3 35.	'n.		8	7.	B	7	ω.	٠.	0	8 9	8.2	١.		i	١.		١,	١,	1 (
38.6 33.6 34.9 34.7 34.9 34.9 34.9 34.7 34.9 34.9 34.7 34.9 34.9 34.7 34.9 34.9 34.7 34.9 <td< td=""><th>.8 35.</th><td>9</td><td></td><td>₹</td><td>7</td><td>€</td><td>Ď.</td><td>8</td><td>ö</td><td>۲.</td><td>ဖ ဗ</td><td>8.6</td><td>Ψ.</td><td></td><td>0</td><td></td><td></td><td>7</td><td></td><td></td></td<>	.8 35.	9		₹	7	€	Ď.	8	ö	۲.	ဖ ဗ	8.6	Ψ.		0			7		
9.6 39.0 37.7 39.3 37.8 37.0 38.0 37.9 38.9 37.9 38.9 37.9 38.9 37.9 38.9 38.9 38.9 38.9 38.9 38.9 38.9 38	1 1	:		1	1	: (! !	! (ŧ	: (! (! ;	1 •	, ç	it	ו ועו		, ,	۱ ۰	١,
33.6 33.9 34.1 33.9 34.1 33.9 34.1 33.9 34.1 33.9 34.1 41.2 41.2 42.1 41.2 42.1 42.1 42.1 42.1 42.1 42.1 42.1 42.1 42.1 42.1 42.1 42.1 42.1 42.1 42.1 42.1 42.1 42.2 42.3 42.2 42.2 42.2 42.3 42.2 42.3 42.2 42.3 42.2 42.3 42.2 42.3 <td< td=""><th>.2 39.</th><td></td><td></td><td>Ö</td><td>თ ი</td><td>0</td><td>٠,</td><td>ກໍເ</td><td></td><td>د د</td><td>00</td><td>٠,</td><td>- 0</td><td>30.5</td><td>9 4</td><td>n =</td><td></td><td></td><td>٠,</td><td>; ,</td></td<>	.2 39.			Ö	თ ი	0	٠,	ກໍເ		د د	00	٠,	- 0	30.5	9 4	n =			٠,	; ,
9.6 38.4 41.4 41.5 42.6 41.6 43.4 42.8 44.9 45.3 44.2 45.0 43.9 45.2 45.3 44.7 46.7 47.7 47.7 47.1 42.8 44.9 45.3 46.2 46.7 47.7 43.7 43.7 43.7 43.7 43.7 43.7 43.7 43.7 43.2 42.2 42.3 42.3 42.7 43.7 43.7 43.2 42.2 42.3 42.7 43.7 43.7 43.7 43.7 42.3 42.7 43.4 42.7 43.7 43.7 43.7 44.7 44.5 42.7 43.7 43.7 42.7 44.7 42.7 44.7 46.7 47.3 47.3 47.3 47.7 46.7 46.7 47.2 47.3 47.3 47.7 46.7 47.7 46.7 47.7 47.3 47.3 47.3 47.3 47.3 47.3 47.3 47.3 47.3 47.3 47.3 47.3	. 4				າ a		÷ C	• •		p (5	• •	· -	0 1-	42.7	-				. ຕ	. 4
9.6 58.4 39.2 40.0 40.4 40.9 41.2 42.1 41.7 42.3 43.4 42.7 43.7 43.2 42.2 42.2 42.3 42.3 42.3 42.2 42.3 42.3 42.3 42.3 42.3 42.2 42.3	, C	. c		. c	ċ	ċ	; -	· -		·ω	9.7	. ~	6.9	45.3	4	ູເດ		4	9	7.
34.6 36.2 36.6 36.6 36.6 36.6 36.6 36.6 36.6 36.6 36.6 36.7 37.7 37.1 37.1 37.1 41.1 43.1 41.7 41.5 41.3 40.7 42.2 44.1 41.3 40.7 42.2 44.1 40.7 36.9 36.1 39.1 39.1 39.1 39.1 30.1 30.3 36.9 36.3 36.4 34.1 36.9 36.7 36.9 36.1 36.9 <td< td=""><th>.4 37.</th><td></td><td></td><td>6</td><td></td><td>ົດ</td><td>0</td><td>0</td><td></td><td>N</td><td>2.1</td><td>÷.</td><td>2.3</td><td>43.4</td><td>2</td><td>ε.</td><td></td><td>'n</td><td>2</td><td>8</td></td<>	.4 37.			6		ົດ	0	0		N	2.1	÷.	2.3	43.4	2	ε.		'n	2	8
42.0 40.6 42.2 40.5 41.7 36.0 40.0 41.6 41.1 43.1 41.7 41.5 41.3 40.7 42.2 43.1 41.5 41.3 40.7 42.2 40.1 39.1 39.1 31.6 39.1 31.2 36.2 36.4 35.7 36.9 36.3 36.3 36.9 36.9 36.3 36.3 36.4 37.7 36.8 36.7 37.8 36.7 37.8 36.7 36.9 36.9 36.3 36.3 36.7 37.8 36.7 36.7 36.7 36.2 36.4 37.7 36.8 36.7 36.7 36.7 36.7 36.7 36.7 36.7 36.7 36.7 36.7 37.7 37.8 36.7 37.8 36.7 37.7 37.8 36.7 37.8 36.7 37.8 36.7 37.8 38.1 38.9 38.1 38.8 38.1 38.8 38.1 38.8 38.1 38.8 38.1 38.2 <th< td=""><th>.5 34.</th><td>4</td><td></td><td>4</td><td>₩.</td><td>9</td><td>ທ</td><td>ė.</td><td></td><td>-</td><td>7.1</td><td>ġ.</td><td>9.9</td><td>37.5</td><td>9</td><td></td><td></td><td>0</td><td>٠ و</td><td>۲.</td></th<>	.5 34.	4		4	₩.	9	ທ	ė.		-	7.1	ġ.	9.9	37.5	9			0	٠ و	۲.
1.9 40.3 42.6 38.4 38.1 33.2 40.4 38.6 40.1 39.1 39.3 39.1 37.0 37.9 37.9 37.9 37.9 37.9 37.9 37.9 37.9	.9 39.	6		·.	ö	0	ö	÷.		0 •	ب ب و	- (43.	- (÷.		o e	N 0	
5.1 35.1 35.7 34.2 34.7 31.3 35.7 35.1 36.2 35.1 35.7 35.7 35.7 35.7 35.7 35.7 35.7 35.7	. 44.	<u>.</u> .		. .	Ö	NI		ġ.		4.	ه د د		- 0	5 c	ט מ	٠,		0 เร	0 u	> u
37.1 36.7 38.5 37.2 37.6 33.7 38.4 38.5 39.5 39.5 39.4 38.5 39.5 41.3 40.1 39.3 32.5 33.6 33.5 33.7 33.7 33.7 33.5 33.8 34.5 34.6 33.7 33.6 34.1 33.9 37.2 37.2 37.1 38.3 38.5 39.1 38.5 39.1 38.7 38.7 38.6 38.7 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.7 38.7 38.7 38.7 38.7 38.7 38.7 38.7 38.7 38.7 38.7 38.7 38.7 38.7 38.7 38.7 38.6 38.7 38.1 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.8 38.8<	. a.e.	4 R		ນີ້	. ພ	ກແ	4 4	4 L		- 6	- E	ی :	. . .	36.6	מור			; ;		. 6
2.5 33,6 33,5 33,6 33,5 33,6 33,5 33,6 33,7 33,6 33,7 33,6 34,1 33,7 33,7 33,6 34,1 33,7 33,6 34,1 33,7 33,6 34,1 33,7 33,6 34,1 33,7 33,6 34,1 33,7 33,6 34,1 33,7 38,1 39,1 40,2 40,2 40,2 40,2 40,2 40,2 40,2 40,2 39,2 39,1 39,1 40,2 40,2 40,2 39,3 40,2 39,3 40,2 39,3 40,1 40,0 39,3 40,1 40,0 39,3 40,1 40,0 39,3 40,1 40,0 39,3 40,1 40,0 39,3 40,1 40,0 39,3 40,1 40,0 39,3 40,0 40,1 40,0 39,3	98.9					, α				~	8	6	9.5	39.5	6	ω.		÷.	ö	6
7.2 37.3 37.7 36.8 37.1 38.3 38.3 38.1 39.1 38.5 39.1 39.3 39.2 39.1 38.2 38.1 38.7 38.6 38. 6.9 37.0 37.1 37.2 37.9 38.1 38.6 36.7 38.8 38.8 38.1 \$\frac{1}{3}\times\frac{1}{3	33	. n		. ~		(1)	G	6		-	3.7	ю	3.5	33.8	4	4,		ю	4.	ε.
7.4 36.7 37.0 56.5 38.2 38.5 37.6 39.2 38.8 38.6 38.5 39.9 40.2 40.2 40.2 40.5 40.8 39.6 6.9 37.0 37.1 37.2 37.9 38.1 38.6 36.7 38.9 $38.1 \% \% =$.4 36.	9			7	7	9	7		6	8.1	о О	8.5	39.1	6	о О		ω.	ω.	ω.
6.9 37.0 37.1 37.2 37.9 38.1 38.6 36.7 38.9 38.1 \$\psi^{	4 37.	_		۲.	9		9	8		ဖ	9.2	œ	8.8	38.5	6	ó		ö	ö	თ
34.9 33.9 34.3 24.6 35.0 34.4 34.7 35.0 35.5 ***	5 37.			9	7	~	7.	۲.		9.	6.7	8	8.1%	:::::::::::::::::::::::::::::::::::::::	i i	1		1	1	!
38.1 39.7 39.5 40.0 33.8 40.2 38.6 39.4 40.8 39.6 40.4 40.0 39.3 40.2 39.6 40.1 40.0 39.3 35.7 35.5 35.8 36.2 35.5 35.8 36.6 38.9 35.0 35.7 35.5 35.8 36.2 35.5 38.6 38.6 38.8 38.7 39.1 40.0 39.8 40.9 41.4 42.3 32.7 33.4 33.9 34.0 33.7 34.3 34.7 35.1 36.7 35.2 35.1 35.9 35.5 35.5 36.3 37.5 37.6 38.3 37.8 37.8 37.8 38.2 36.9 37.2 37.6 38.3	.3 34.	4		4	ω.	4	4	ъ.		7	5.0	ე ე	*	1	1 1			•	1 1	t i
34,3 35,0 35,7 35,5 35,5 35,8 36,2 35,5 35,8 36,6 38,9 28,9 39,0 39,8 39,1 39,4 39,5 38,6 38,6 38,8 38,7 39,1 40.0 39,8 40,9 41,4 42,3 32,7 33,4 33,9 34,0 33,7 34,3 34,7 35,1 36,7 35,2 35,1 35,9 35,5 35,5 36,3 37,5 37,6 38,3 37,8 37,8 37,8 38,2 36,9 37,2 37,6 38,	.7 39.	6	ເຄ	8	6	6	ó	ε.		9	9.4	ó	9.6	40.4	0	•			수 -	40.5
38.9 28.9 39.0 39.8 39.1 39.4 39.5 38.6 38.6 38.8 38.7 39.1 40.0 39.8 40.9 41.4 42. 32.7 33.4 33.9 34.0 33.7 34.3 34.7 35.1 36.7 35.2 35.1 35.9 35.5 35.5 36.5 36.1 36.2 36. 34.3 36.2 37.3 35.8 36.5 36.3 37.5 37.6 38.3 37.8 37.8 37.8 38.2 36.9 37.2 37.6 38.	.7 34.	4	8	4	ທ	រេ	ъ.	ຜ		٥.	5.5	ż,	9.9	1	1	1		!	١.	1
32 7 33,4 33,9 34,0 33,7 34,3 34,7 35,1 36,7 35,2 35,1 35,9 35,5 35,5 36,1 36,2 36, 34,3 36,2 37,3 35,8 36,5 36,3 37,5 37,6 38,3 37,8 37,8 37,8 38,2 36,9 37,2 37,6 38,	.9 39.	6	~	8	8	39 0	6	6		ıs.	8.6	8	8.8	38.7	0	ö		ö	<u>.</u>	
34,3 36,2 37,3 35,8 36,5 36,3 37,5 37,6 38,3 37,8 37,8 37,8 38,2 36,9 37,2 37,6 38,	2 33.	6		7	6	33.9	4	ë		.7	5.1	9	5.2	35.1	S	کا		ف	9	9
	.6 35.		_	4	9	37.3	S.	9		<u>س</u>	7.6	œ	7.8	37.8	^	ω.		۲.	۲.	œ.

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX *---No data available (died)
**---No data available (sacrificed) TR Group 1 =

0 × 0

- 4	- 4	!	33	LC I		6 7		43	10.1	47	ST 49	X 21-	61.5	IO I	57	O t	61	63	65	
M 38.6 39.9 39.9 41.	. 6 39.9 39.9 . 2 38.2 37.2	8.2 37.2	ە د <i>ا</i> د	37	4 œ i	37.9	38.3	37.7	38.4	38.6	38.7	39.7**	2 % 4 2	0 1 0	0 1 0	e i e	7 1 0		44.2	er i u
40.2 38.9 39.0 38. 36.6 57.7 37.2 37.	. 2 38.9 39.0 38. .6 37.7 37.2 37.	8.9 39.0 38. 7.7 37.2 37.	2 37.		- 6	4.		. 1.8		- 6	. 8	ນ ນີ້		יט יַּט		, .a		٠.	٠.	37.6
42.5 43.0 44.2 45.	.5 43.0 44.2 45.	3.0 44.2 45.	.2 45.		٠.	6		7.4		χ.	8	7.7		8.0	6.9	8.8	9.8		6	÷,
33.5 34.4 33.9 33	5 34.4 33.9 33	4.4 33.9 33	93			ص د		۰,۰		ນີ້ນ	. ພ	ი - ი -		2. 2.5	ໝູນ	ທຸດ	8.6	5.	ú,	. α
36.2 37.7 36.4 37	2 37.7 36.4 37	7.7 36.4 37	. 4 37			- 0		2.9				. 6		7.7	6.2	9.7	9.7	. 60		6
37.1 37.4 37.2 36.	.1 37.4 37.2 36.	7.4 37.2 36.	.2 36.			4		7.6		8	8	9.3	7	8.7	9.7	9.6	6.9	თ	ej.	e.
38.4 39.0 38.9 40	.4 39.0 38.9 40	9.0 38.9 40	9 40			۲.		- (- ;	ö	∞ c		4.4	ب- د دن د	- t	4.6	რ ი	ď,	. ი
31.6 36.6 31.6 36.	.6 36.6 37.6 36.	6.6 3/.6 36.	. a.			٠.		١		•	6	2	: 1	7	0 1	7	. !	· 1	٠ :	. !
38.7 25.7 35.7 35.7 35	7 36 1 36 7 35	5 1 36 7 35 5 1 36 7 35				٠, ٥		ی د				2.6	9		1 1		L		1	1 1
38.2 38.2 38.4 37.	2 38.2 38.4 37.	8.2 38.4 37.	9			, w		ဖ		ω,	6	6.4		39.8	3.2	ø.	41.9	6	œ.	ó
36,6 36,9 37,0 37.	6 36.9 37.0 37.	6.9 37.0 37.	.0 37.			0		(7)		6	7.	7.3	€.	-	6.3	-	37.9	Θ.	iė	8
31.8 33.2 32.6 34.	.8 33.2 32.6 34.	3.2 32.6 34.	.6 34.			₽.		e		7	6	2.3	ت	က	8.7	80.	40.0		ω.	. .
35.0 35.0 37.2 37.	.0 35.0 37.2 37.	5.0 37.2 37.	.2 37.			4		0		ò	6	9.5	o.	- -	2.6	o.	42.4	4	Ü.	9
37.1 37.4 39.9 39.	.1 37.4 39.9 39.	7.4 39.9 39.	.9 39.			<u>ق</u>		7		÷	3	0.5	4.	ا ب	ල - -	- .	39.3	.	ლ :	რ.
35, 1 33, 1 34, 1 36, 2	.1 33.1 34.1 36.2	3.1 34.1 36.2	. 1 36.2	7	•	ر و		<u>ن</u>		œ ·	ດ ເ	.	0 1	ဖြ	0.	- (38.5	m 1		÷.
30.8 31.9 30.9 33.4	8 31.9 30 9 33.4	1.9 30 9 33.4	9 33.4	4.	.,	o i		φ,		4.0	ი.		۰. ه	æ (4.4		6.00 60.00	٠ •	~ +	د ف
36 2 37 K 39 D 38 9	9 37 K 39 D 38 9	7 5 39 0 38 9	- 0	- 0	•	- (*	n -	, C		· -		- m	. 00	9 6	. 6	٧ ٢-	45.6	. 4	- 10	
27.7 29.7 28.8 33.8	7 29.7 28.8 33.8	9.7 28.8 33.8	8 33.8	8		· -	ស	8.0		0	; - :	5	ın.	ب	3.5	ဖ	32.4	4	Э.	6
35.9 35.2 37.8 39.	.9 35.2 37.8 39.	5.2 37.8 39.	.8 39.			o,	_	8.2		о О	Ξ.	2.0	œ.	6	2.7		42.8	4.	e .	4
30.3 29.1 28.9 33.	.3 29.1 28.9 33.	9.1 28.9 33.	.9 33.			4	6	₽.		٠. ص	₹.	2.5	ص •	_	77	ri.	32.2	₹.	₹ :	۲.
28.7 29.2 33.0 30.	7 29.2 33.0 30.	9.2 33.0 30.	.0			o .	α:	® (ö٠	o. 6	ص ر د	- -	٠,	. t	თ -	32.2	4.0		ف د
30.5 31.0 32.2 36.	.5 31.0 32.2 36. + 38 8 38 3 39	38.2.36.	96 30			- v	0 0	0 0				- (7	43.2	43.3	44.1	44.5	45.2	44.9	47.9	48.2
33.5 33.0 38.2 36.	5 33.0 38.2 36.	3.0 38.2 36.	2 36.			-				0	6	5.0	*	: !	1	!	;	•		ł
36.1 37.3 36.7 40.	.1 37.3 36.7 40.	7.3 36.7 40.	.7 40.			7	v	~		ຕ່	4.	- 9	ស	ဖ	5.1	4.2	4.8	۲-	7	6
34 2 34.4 36.8 37.	2 34.4 36.8 37.	4.4 36.8 37.	.8 37.			ø	0	7.5		7.	ó	2.7	₹.	_	4	0.0	- 1	ä	G.	م
33.9 34.4 37.3 35.	.9 34.4 37.3 35.	4.4 37.3 35.	.3 35.			7	œ	4.		4	œ.	7.2	ထ	o.	4	-	۲.	•	·.	•
34.9 38.8 36.5 38.	.9 38.8 36.5 38.	8.8 36.5 38.	.5 38.			ø.	œ	6.7		٠. س	o.	9.6	œ	4	0.6	0.0	æ.	ω.	•	. :
38.7 41.4 40.1 41.	.7 41.4 40.1 41.	1.4 40.1 41.	.1 41.			0	-	2.4		ົ. ເດ	'n.	5.7	ď	ņ	7.2	8.7	ຄ.	0.6		œ.
32.0 32.9 32.2 33.	.0 32.9 32.2 33.	2.9 32.2 33.	.2 33.			N	_	4.6		Ŋ.	ω.	5.3	r.	₹.	7.0	7.8	5.5	8.6	-:	о О
32.1 33.4 33.6 35.	.1 33.4 33.6 35.	3.4 33.6 35.	.6 35.			ø.	0	6.4		ω.	ທີ	7.1	ŀ		1 1	1	1	į 1	İ	!
27.4 26.3 27.9	A 26.3 27.9 27	6.3 27.9 27	.9 27	27.		R)	ស	9.0		6	Β.		ω.	٠.	9.6	.7		ö	٠.	•
38.5 38.1 41.9 40.	.5 38.1 41.9 40.	8.1 41.9 40.	.9 40.		6	7	7	0.		ö	ı.	2.7	4	46.4		15.2	ໝ	47.6	46.5	œ.
26.1 26.8 27.3 27.	.1 26.8 27.3 27.	6.8 27.3 27.	.3 27.			<u>ص</u>				ω.	0	7.8	*: 'E			1 1	1	ı.	1	١,
32.1 32.4 30.9 33.	.1 32.4 30.9 33.	2.4 30.9 33.	.9 33.			c				4	e.	ທ		34.3	33.3	33.9	34.5	36.1	36.3	•

9

0

4

0

0

٩

ð

Đ

٣

0

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 1/5/100 mg/kg/day RDX

available (sacrificed)

**---No data TR Group 1 = 4 =

*---No data available (died)

-			- 1	9.4					. 1				•	•	•		•			l l			•	1	<u>ب</u> د				•		- 4			8.	1	•	n ا		
			9 !	0 57	7	4	4	4.4	₹	4	4	4	4	4	♥ 1	n e	ი •	4 4	4	٧	; (T)	n	4		4 t	3 4	· m	4	4 (י פי	20	4	ຕ	4		•	5 47		
			65	55.0		4	₹ (ف	; i	œ	43.8	α.	e,	ö	- 1		(0 t	m	· 1	U	36.8	0	ä	1	43.			0	<u>ن</u> .	ı	:-		7	7.	į	1	46.		
			63	51.5	; -	6	.	- (α		7.	÷	ີ. ດ	്. ഗ	٠. ا		ന	מ	-		ດ	<u>.</u>	1				υ.		٠,	ے د			7	1	!	. 1		
			61	•	v c	· 6	8	ö	. i	Ľ		ري ري	Ψ.	ნ	6	۲.	₹.	. .	מ		· 6	ω.	6	1					6	20 (20	ه د	, <u>-</u>		7	1	:			
			59		; ~	7	0	က်း	- :	α	0	ις.	τ.	о О	ω:	ا	(0)	ი :	0	Ľ	34.5	7	6	!	40.3	o o		€.	۲,	4 (α	o	ູ່ເ	9	!!!	1 .	44.3		
			57	6.0	0.00	4.4	9.7	- ·		0	. rv	7.8	8.	8.9	7.9	 	2.5	0 0	× × ×		0	, e	8.2	1 1	u c	, 6	5.1	4.2	7.3	ر د د	. v		7.5	6.2	1	!			
			55	8.6		0.0	ī.	د ر	100 t 100 t 100 t	C	6.0	5.5	5.6	1.		0.	۲.	ص - د	-	,	, e	4.	- 6	!	6. 6.	. a		9.6	8.8	Б. 1	. o	, ~	8,7	5.6	ŧ	1 1 1	6.1		
			C I	n-	- ac	?	7	ဖ (o +	- 0	ဖ	-	-	ល	œ	٠.	ω, ι	œ و	1 0	: - <	÷ (5	-	ø.	α	- u	ņ	ម	ø.	<u>ن</u>	۳. ·	4 c	. 0	, r.	0	1	!	7. 4.4.8.	:	
			1 1 1	4.4	: =	4	4.	۲,	e -	י פי) M	4	4	ന	m	က ⁽	e,	4 (י כי	2 4	יו ל	4	4	က	en c	שע	6	4	(C) ((n)	יו מי	4	'n	4	:	* *	40	,	
	1	EEK	51	48.											•																				t				
	!	TEST W	49	- •											•															•							42.8		
			47	•																																	35.2		
			45			•									•	٠		٠	•					•	•	•					•				1	Ŋ.	40.9	;	<u>~</u>
			43	~ 0	ກແ		E 1	ر ا ا	ر در در		0	8.	9.7	5.2	3.2	6.3	4.4	8.1			- E		9.9	6.7	2 1	ט טיר	. 6	0.2	6.4	ທ	9.6	9 0	7.	3.5	1	6		•	ı study
			- 1	~ ~	÷ 6	, ~	c.	ព	ω υ	ې و		4	z.	ლ.	~	۲.	ဖ	ıŭ.	4 (ء د	υr	9 (5	. ~	۲.	ָם סָי	p, c	v æ	6	0	-	۰ ز	, r		-	:	۲.	e e		from
				œ (، د	<u>,</u> 0	0	21	ភ ប	ņ <	, 0	0	(0)	. 7	-	۲.	-	ლ :	- (×.		. œ	0	ø.	ဖ္ဖ	<	4	6	<u>ب</u>	-	۱ ش	- ("			ı	?	ហួច	<u>:</u>	nated
			37	œ. c	Y 0	o ო	ಬ	<u>س</u> ا	o, c	. c	۰ د	4	~	-	-	بع	۲.	4.1	٠. ۱	N C	ۍ د		. α	0.	0.6	אָ כּ	4 4	ιυ.	٣.	~	0.4	- o) c	ဆ	i	6	ص ح		el imi
			!	1					о ·	1 1	٠,	ı o	រា	80	80	_	LO	₹ :	n i	N 0	ກະເ	o C	. 4	G	- :		v C	D	ω	m	ლ (วะ	3 0	ı w	ı	_	9 37	v	_ e_
			35	44.	٠ د	37	37	34	to c	0 +	٠ د	8	-	3	2	N	3	~	•	₹ ₹	- C	ט כ	6	4	32	N 0	7	4	O	n	Oι	7	7	. 0		7	39	3	ilab
			(C)	1 0 1		 	~	7 .						÷.	÷	ò	ä	o.	٠,	D (D U	, io	ري. دي	4		. ~		ε.	e.	<u>.</u> ,	 - u		ò	- [ď.	-	;	a ava
			31	41.2	•				٠.	٠.	٠.	• •			•		•	-		٠.	•	•			٠	٠	•		•	•	•	•	•	٠.	ı	•	36.2		dat
			,																																ш				No
		ωu	×	1 LL 1 	i. U	. 11.	L	ti.	L 1		LU	. u.	<u>.</u>	u.	u.	ıL	ıL	ш.	LL I	L L	L U	L U	. 11	ш	L	LL L	L LL	. L L	u.	ıL	u. 1	Lts	. u	. 1	¥.	ш.	և և	-	ú
- α	OR	0 =	a	(n)	יו מי	າຕ	n	(C)	ကျ	י) ני) (T) (C	n	n	n	C	က	n	n i	n	יו פי	י מ) (C	n	(C)	n r	າຕ	n	n	က	ကျ	י ר	א ני	ი	က	ო	en e	,	
∢ 2∺\$∢	د ،	zc		401	\circ	\circ	. 0	0	0	\supset	> -	•	-	-	_	-	-	-	-	- (2 12	у С	10	3	~	(7)	1 C	10	က	$^{\circ}$	ෆ (7 (א כ	າຕ	က	C	439	;	

**---No data available (sacrificed)

*---No data available

(died)

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; h = 35.0 mg/kg/day RDX; S = 175/100 mg/kg/day RDX

TEST WEEK

S

	67	1	α.	46.6		1	•	÷.	44.6	•	<u>.</u> ص	ς.	38.2	1	٠.	1	37.2	ი		39.5		თ	1	3	•	1	რ	4.	•	38.2	1	S	_	ω.	ω.	ω.	35.3	4	1	1 .	44.3	
	65	1	•	43.3	4.	t			41.9		50.3	•	37.0	ŧ	42.3		37.0		42.1	38.3		٠.		43.8	•	j	ä	44.4	œ.	7	!	₹:	٠.	о О	٠.		35.3	ιυ	1	! (43.3	
	63	1 1	-	•	e.	:	n	60	マ	 -	47.5	ö	7	1	•	1	37.0	.	42.0	38.6	₹.			·	•	l	<u>-</u>	42.8	n.	7	1	٠. د	ά,	თ	۲.	o	32.0	2	36.4	;	42.7	
	61		41.1	42.4	ς.	1	ش	39.5	ნ	39.4	•	-		1	٠.	į	٠.	34.8		38.7	42.4	39.1	t		42.3	! !	40.8	42.9	9	~	1	້. ທ	ი .	ö	ω,	ω.		ທ່າ	7	1	42.6	
	59		41.9		ნ		ö	7	•	ω.	ω.	0	-			ŀ		4.	.	38.8	ς.	ω	1	41.4	٠,	1	'n	e:	•	37.3	1	•	o.	Ψ.	о О	о О		6	7	1,	42.2	
	57	!!!	о О		51.2	1	ς.	6	တ်	ω.	•	6	35.4	1	39.4	i	Ġ	35.3	'n	39.4	്. ന	œ.	ı	40.2	₩.	1	Ť.	•	ın.	37.4	1	Ġ	о О	ς.	37.3	თ	34.5	35.4	9	Ĺ	42.4	
	55		40.2	•	ö	1	•				44.4	•			39.0	1	36.7	34 9	41.7	38.5	42.6	38.4		40.4	40.7	l j	39.9	43.2	36.2	37.0	} } !	37.5	0	٠			35.5	•		ì	43.4	
	53		37.9	~	7	:	ω.	o.	ស	6	ო.	e.	۲.	~ ~	8. 8	1	6.5	4.4	6.	9.4	2.8	8.8	8.4	ı.	5.5	1	7.0	2.6	7.1	8.5	!	4	<u>ن</u>	ø.	4	Ŷ	œ.	Ξ.	₹.	ا بى	. 1	
	51	2.9	41.6	5.8	9.5	2.6 🚓	3.3	6 6	8.8	8.6	6.1	9.6	4.4	9.0	8.3	0.2 %	0.9	ე. მ.	1.7	8.4	٥.	8.9	6.0	5.6	0.7	7.7%	٥.٦	4.2	6.9	8.2	F (6.8	4.4	-2	7.8	9.4	4.8	6.8	7.3	ب د	3.6	
	49	1.6	7.4	- .		۲.	6.	8	ω.	ပ	0	-	. 7	6	8	რ	۲.	9.	<u>ر</u> د	۲.	0	0.	8		٠ 0	•	4	о О		٠.	!	Ŋ		0	8.	0		r.	6.4	- .	<u>ن</u>	
	47	4	36.0 3	æ	9.	0.	0.	- .	0.	- .	۲.	e.	9.	۷.	-	æ.	ıs.	4	- .	ი.	S.	<u>.</u>	o.	۲.	8	<u></u> ق	e,	8.	7	₽.	:	œ.	6.	ო.	4.	e.	- .	6	6 9	6.8	a. +	
	45	6	38.7 3	æ	7		~		σ	9	ဖ	8	۲,	ស	ı.	₹.	e,		-	<u>س</u>	؈	ر	R.	9	<u>د</u>	ı.	۲.	ιυ.		o.	?	9	က	89.	o.	ທຸ	6	₹.	7	<u>~</u>	۲.	
	43		7.4 3	6	۲.	~	-	۱.	J)	σ:	- .	٧.	7	œ.	6.	تا	۲.	ت	0	∞.	تا	₩.	7	9.	4.	-	<u>.</u>	o.	<u>ن</u>	5.	1	ღ.	8	۲.	æ.	₿.	0.	9	-	7	œ	
	<u>.</u>	6		6.4	5.5	.7 3	ъ, С	2	6	.7	0.	е С	9.	.4	ღ 9.	3	.2	0	0.	. . .	4.3	۳ ۲.	е 0.	4	.5	.43	9.	.a	5	e 6.	:	ъ. Б	5.	و	В	3	8	8.		.2	ه. م	
	т П	-	.7 33	. 7	6	۲.	9	æ	Ø	۳.	0.	o,	~	6	۲.	۲.	0	o.	۲.	8	ω.	0.	7	ღ.	4.	- .	m.	4	9	۲.	!	æ	<u>.</u>	-	0	0	۲.	6	۲.	ī.	۲.	
	7		o	0	ល	٣.	₹.	<u>ب</u>	.7	9	6.	9.	9	e.	o.	<u>و</u>	۲.	<u>ه</u>	Ŋ	۲.	80.	7.	-	4	ω.	ღ.	0	80	8	۲.	!	9	ri.	0	0	9.	ღ.	۷.	0	₹.	-	
	n	A 37	, C	5	ਵ	8	C	8	က	n	4	е 0	S	4	6 38	5 38	4 35	8 32	9 41	4 38	6 40	7 38	4 38	40	7 40	7 38	9 37	6 39	9 35	36	•	3 36	7 41	40	S S	9	ო	က	က	e G	4	
	_E	75. 57	9 6	37	4	39	27	34	n	n	4	37	32	0 37	0 36	5 38	3 35	1 33	1 40	2 39	2 40	1 37	3 38	8 38	6 40	7 36	9 37	2 40	4 35	4 36		38	3 42	1 39	3 36	2 38	e -	n	37	37	4	
	Ö		n	n	4	n	7	n	n	e	4	က	က	36	36	38	34	34	38	m	39	38	38	n	40	37	37	40	35	က	1	က	40	39	n	38	34	e	က	(T)	4	
	31	: 5	3 6	8	C	6	~	N	ιŋ	0	0	~	6	~	ß	ဖ	Ľ	(7)	0	1	0	8	~	6	٥	7	9	O	B	ß	1	ဖ	•	6	-	8	3	ß	7	~	0	
) LI	u ×	i ! ! !	. LL	· LL	ii.	<u></u>	Ŀ	Ľ.	- -	u.	L	Σ	Σ	æ	Σ	Σ	Σ	Œ	Œ	Σ	Ξ	Σ	Σ	Œ	Σ	Σ	Σ	Σ	Ξ	Œ	Σ	Œ	Σ	Σ	Œ	Σ	Σ	Σ	Σ	Σ	Σ	
> =	ه د	10	о С	· п	n	С	6	n	C	n	6	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	7	4	4	4	7	4	7	7	4	4	
: c	٠.	444	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX**---No data available (sacrificed)

*---No data available (died)

9

9

3

0

4

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

AZHEA1

	7	1 00 0	5 4	~	ø.	æ	۲.	8	9	6	ω.	œ	1 (10	י כ	c		0	6	Ŋ	!	۱ ج	- a		!	o	o, e	N O) !	!	-			!	o,	
	9	64	ព្រ	ເນ	ന	О	תו	O)	ຫ		_	ຫ	1 1	35	ព	39		N	32	∞	•	01	37.) r	1	0	,	. 6	4 1	i	LD.	4	33.	•	35.	O
	65	40.8	0 10		₹.		₩.	ö	'n.	ω.	- -	40.2	1	35.0	4 1	39.1	1	Ξ.	35.2	6		ö	39.4 4.0		1	0	۲.	40.4 26.4	; ;	! !	7.	7.	34.5	ŀ	36.0	თ
	63	39.3	96.0	35.6	34.4	41.1	34.4	10.9	35.3	36.2	 	39.1	1 1	35.7	8.71	39.5		41.0	34.8	16.4	!	40.4	38.6 7	36.7	1	39.4	36.8	5 K	2 !	!	96.9	ເນ	34.3	[36.7	8
	61	38.6	÷ (c	ω .	4	4	Ŋ	ស	6	CV.	4	o,	! !	20 (ו פ	o,	:	e	80	-	!	<u>ن</u> و	N U	, -	1	~	٠,	א פ	2 1	!	6	9	7	!	7	o o
	6	! ! ** 0	^ -	. ~	~		_	٠,	_	~	_	_		_ ,	٠.	~		~	••	_		~ , ,	~	. ~		_	<u>.</u>	~ -			•	"	_		_	_
	1 2	8 40.			_																															
	57	40.8	35	35	34	40	35.	40.	35.	37.	40.	38	1 1	32.	4	38	*	40.	35.	44	1	 ရေ	38.7	36	1	41	37.	5 6	· i	į	36.1	35	34.	i	37.	38.
	55	1 - 0	່ເກ	'n	ις.	Ψ.	ιĊ.	۲.	4	٠.	ö	ω.											39.8								_		_			
	53	39.7	 	5.2	14.4	3.5	9.0	17.1	14.7	7.5	0.2	2.0	ا ا ا ا بارا		4 C		17.9	8.6	15.7	9.5	!	+ i	7. 6 8	7.3	. 6. L	0.0	0.0	יי אַכ	. 4 . 10 . 10		7.1	7.3	4.3	8.3	6.3	7.8
	-		- 6	0	Į,	r.	D.	0	ß	4	ស្ទ	8	4 (ه م	າແ	2	0	m	0	o,	į	ស (9 6	4	4	9	φ.	4 0	2 0	1	ø	n	8	6	0	m
VEEK	ו ו ו	88 38	ວເດ		0	0	ത	~	~	~	.	- 1			- u	. ~	10	0		~	₹7 :	_	m +	. 10	₹	-		n +			"	*			~	_
TEST	49	39.	34.	35.	35,	41.	34.	41.	35.	38	4.	39	4 .	32.	44.	36	37.	4	34.	45.	34	37.	39	36.	35.	39.	37.	, K	3.0	; ;	35.	35.	33.	37.	36.	38
	47	39.3			•												-	-			-				-	-	-	-					_	_	-	
	45	40.4			•																	-					-				9.98		_	_	-	
	6	8	-	_	RJ.	4	ນ	9	~	e .	ဖ	4 (٠ بى		- ~	y Up	-	_	80	0	©	۰. (n α	8	ო	~	80 •	٠, د	v cc	!	80	_	9	6	80	0
	4 1	5 38			ស	_	ဖ	ဖ	-	7	n.	<u>ن</u> س	_	N (ກອ	· 0	~	ເດ	TO .	LO.		- (~ =	o co	6	80 ·	- (ט ע	3 5		10	ហ	R	ဖ	_	σ
	4	39.																																		
	33	39.4	- 10		ď.	6	e.	6	ນ		ö	6			- c		6	e.	4	₩.	iC.	m			ïÖ.	e i				: :	9	S.	ε.	9		7
	- 1	39.3			•	-		-	-		-		-	-			_	-	-	_	-	-			_			-	_							
	10.1	. S.	i IU	2	ო.	9.	7	œ	ဖ	بي	<u>ල</u>	ص <u>.</u>	æ. ·	- •	- c	· ^	ო.	0	ω.	ស	ლ.	ص ا	- u		0.	6.	ď.	4.0	5 4	. !	o.	4	7	0	0	7
	1	ioor	4 /	. 6	3	7	3	7	6	ල :	3	က ၊ ထ ၊	ю. С	.	ა ი ა ი) M	ີ ຕ	2	ල ල	4	ب ص	ი : ი :	0 u		ຕ	ED :	е е	~ o) C)	Ö	က	ო	m	က	C
	8 1	39.	. 4	4	4.	o.	'n	æ.	4.	ທີ່	о О	۲.			n o	. 6	6	7.	ri.	.	ċ	<u>.</u> .			ω.	e :		٠,		: :	9	ري	8	-		8
	= !	37.6		<u> </u>	Ψ.	Ψ.	ς.	~	<u>.</u>		.:		<u>.</u>	٠.		٠.				.:		٠.	<u>.</u>	: .:		_:	٠.	٠.	:	: !			_:		:	.:
	; ; !																																			
	ш×	! ! !																																		
	ے ا ۵ ا	(1																																		
Z	0 . 1	481	36	84	85	86	87	88	83	90	9	92	6	2 C	0 0	97	98	99	8	5	8	ဗ္ဗ (Q C	90	0	90	<u>ල</u> :	2 :	5		4	5	16	17	18	5

*---No data available (died)
**---No data available (sacrificed)

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

						67	1	! !	48.6	1 (د د	40.04	ω.	8	0	9	1	42.7	- (י) רי	; ;	ហ	7	44.8	၈ ၊	٠,٠	วถ		S	4 1	~ 0	0 1	C	41.0	7	7	ŧ		N a	0 C	
						65	! !	١,	48.8	!	. (2.0	. 6	6	6	ė.	!	38.8	ກໍເ	, o	. !			43.1	ın.	₹.	- 6		e.	÷.	٠,	: i	_	40.9		8	1	57.2	٠.	٠,	
-						63		: -	47.7			-													_																_
						61	1	1 (47.3	1 (3 17	33.00	• 0	9	6	S	1	თ •	- 1	4 (9 1		0	42.0	ທ	က၊	40	4	O	- (3 C	- 1	σ	38.2	(2	ဖ		54.3	თი	∞ o	η.
						59		1 (46.5	1.	4.	43.0		0	7.	9	1	38.9	- (1 (1)	: :	c		40.0	ς.	٠. د		. 4	Ψ.	ö		: :	o	37.2		ณ	-	9	50.3	ກ່ວ	'n
ISE						57	•	1 0	47.5		· 1	4 C C C C C C C C C C C C C C C C C C C	. œ	7	7.	7.	i	39.2	o o	. 10	: :	-	0	39.5	Ġ.	4.0	0 0	. e	ö	ص		9 1	U	38.4		6	1	53.8	ص	· 0	ć
IF 1 MOU						55	ı		43.3												. 1	•											ŀ						•		
IE 86C3						53	!	١,	45.7	1	N (Ö	6	7	'n	o .	ه ۱		ם מ	; c		39.8	4	ლ (٠ د	. 4	ω.	ó.	ö	u a	, a	σ	· -	7.7	80	б.	o o		ė
IN TH				į	Ä	51	- 1		44.0		-	_				-		_			_																				
ZINE(RDX) EASUREMENT				; ;	EST WE	49	1	١,	43.8	!	ი (o r	· σ		9	2	6	7	ი	٠.	4 4		o	40.0	ς.	o e	n o	32.1	8	ω.	o ı	u	, ,			7	8	6	7	o u	ດ
-TRIAZIN GHT MEAS				1	-	47	1	1 6	4.1.8	i	-																														
.3.5						45		თ (40.7		ന	നം	0 5	10	•	~	$^{\circ}$	മ	ന	ന	ກເ	Vα	າດ	39.4	\sim	- 1	ם מ	\circ	_	LD.	en 1			o n			ι.	49.3	ın (40.4	31.1
JITRO-1						43	-	ლ (40.8	1	.	10		. 4		ı,	۲.	7	Ġ.	<u>.</u> ن	4 (o c	· ^		4.	ά.	4.0	. .	n,	œ.	Ċ,	4.0	, c	• •	: α			ဖ	0		
3.5-TRINIT						41			43.7	!	29.6	36.0	34.0	36.96	33.9	33.2	38.6	35.5	37.9	34.5	34.1	30. s	37.0	38.8	32.4	39.2	35.0	29.7	35.7	36.6	37.0	35.4	45.	. ac.	37.0	26.4	36.7	45.9	43.1	37.5	32.4
0-1						39	30.9	2.0		: :	٠. ھ						æ,	7.	ı,	÷ :	n	N B	י. סנג		ö	ö.	. .		6	e.		D		о п	D @			œ	ي	m	<u>-</u>
HEXAHYDR						37	33.9												•							•	•				•										
Ĭ						35	32.	4	O 4	٠.	0	ഥ	ים פי	א כי	3 4	. 44	O	œ	CO.	(C)	ומו	20 3	צו ל	35.2	~		4 I	n or	4	מנ	~	ന	\sim 0	N 5	* 0) 4	. 4	_	C	r .	-
						8	3.3			: ;	о О	₹.	о и			. ~	۲.	ω.	ď.	4.		. ,			0	7	₹,	• a		ъ.	Ċ.	'n.	- (n c		- u			÷.		ó
						-	33.2	m.		; ;	ë.	10 .		;	: ^	: ~:	٠,	10	₹.		<u>.</u>	D 1		 V IO	6	7	. ·		. 4	ς.	ä	<u>.</u>	<u>.</u>			• 10			m.	٠.	o.
					10 ··	×:	=	~	· ·	: =					1.		1,	ŧ,	L	11	t : 1	h. 1	. 1	, 1,		b	ı. •	. 10	ļ.	ν	u	12. 1	ta. I	ı.,		_ 1.	_ t,		D.	ıı.	L.
		⊢ α	G		0 =		 		4 4	-																															
	∢ 2	? ∺ ∑ <	د ۲	ì	zc	· •	521	522	523	525	526	527	528	223	72.5	532	533	534	535	236	537	538	5 C	54.0 54.1	542	543	544	545 545	547	548	549	550	551	552	500	1 1 1 1 1	220	557	558	559	560

 $\begin{array}{c} \textbf{i} & \textbf{$

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX**---No data available (sacrificed) *---No data available (died)

Q

9

0

٨

0

٩

67		24 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
ស	. 04 1 4 1 8 4 8 9 8 9 4 4 8 4 8 4 8 4 8 9 9 9 1 1 1 4 8 4 8 9 8 9 9 9 1 1 1	
63	TO 1 8 1 8 4 8 4 8 4 8 4 9 4 4 4 4 1 9 7 7 7 9 7 9 7 9 9 7 1 1	339.7 339.7 339.7 339.7 339.7 339.7
19	ww.io.io.woo-r-raachaer-raira ww.io.io.woo-r-raachaer-raira ww.io.io.woo-r-raachaer-raira ww.io.io.woo-r-raachaer-raira ww.io.io.woo-r-raachaer-raira ww.io.io.woo-r-raachaer-raira ww.io.io.woo-r-raachaer-raacha	
59 9	4519186677777478865698719711	
57	14	
១ឧ	44. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.	4 6 4 % 8 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
93 93	######################################	400007789007
W	04000000004-0000000	
S1 49	4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	5 0 0 0 4 10 0 1 - 10 0 1 1 1 1 1 1 1 1 1 1 1 1 1
47	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	6.8 + 5.3 + 5.5 5.6 6.0
45	7.7.7.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9	000044700000
43	32.2 32.2 33.3 34.4 35.3 36.4 36.4 36.4 36.4 36.4 36.4 36.4 36	0464+6804+48
	4 6 6 6 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	44-30.5325.769
39	8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	38.6 34.3 38.2 31.9 31.7 31.7 31.7 31.7 31.7 31.7 31.7 31.7
75	8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	497798
32		86700004800
33	938 93 93 93 93 93 93 93 93 93 93 93 93 93	920082-0220g
£	0.00 0.00	
νш×	, , , , , , , , , , , , , , , , , , , ,	<u> Ասսսնննն ան</u>
+¤ ©¤0⊃₫	; 	*********
42⊢2< → 20 ·	5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	. & O O O O O O O O O O O O O

Control; 2 = 1.5 ... $\frac{1}{3}$ /kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX **---No data available (sacrificed) *---No data available (died) TR Group 1 = Iŧ

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (g)

		39.8		4 . 0	89.8			35.2	!	! ! ! !	!!	89.9	!!	35.8	36.3	34.9	! !	51.7	3.3	9 98
9	1 1 1																		2.3	4
e 6		39.7 3																		. w
																			. ~	.5
	8 39.1																			8 35
	37.8																			33.
	39.2																			35
ប្រ	38.8	39.5	9 1 1	37.6	40.4	! !	*>	37.4	!	1 1	1 1 1 1 1 1 2 2	39.5	1 1	36.0	37.4	34.5	t i i	61.7	44 4	35.4
53	38.8	40 4	2 ! !	39.5	40.1	! !	38.83	37.4		! ! ! ! ! !	35.93	38.9	*	36.3	36.4	32.9	! ;	60.6	36.8%	34.3
WEEK 51	38.0	433								7.			-:-					61.2	36.1	34.8
. EST WE	37.5	38.3 40.2	7 1 1	39.0	38.9	1 i 1 i 1 i	38.3	37.5	- (31.2	34.0	38.4	35.9	35.2	36.2	32.9	1 1	61.4	35.5	34.1
¥ 7.4	37.3																		50.0	9.0
52	l É	39.85 5.00-5																	6.9	
	35.0 3																		n r	7.
-	i I																		5. 34 2. 34	.2 33
₹	5 33.8	r 1 m (D 1 1	o i	្រ រ	, ,	4 1	. o c) i	- 1	8 1	о ;	6 0 I	10 (മ				34) (t)
39	37.	38	7 1	38.	37.	1 1	36.	35	. !	. i	34.	38.	36.	33.	35.	33.	;	61.	34.	33.5
37	36.2	39 6	7 1 1	. 1		1 1			:	-:		- 1		4.			1 1	1 6		. n
35	34.7			7.	. 1	: :			: !		<u>ا</u> ي	. :	1	ر ا				- 6		
33	33.9	8 1 7.	. 1 1	9;		1 1	. 1		:		e: 1			ري. د			1 4	10		
n	33.3	38.4		~ 1	(O i		மை	ເທື	~ i	~ 1 0	₹ 1	~ 1	₹ 1	***	0.00			നന	~ a	ດຕ
	!	**	નલ્લ	40	水 -	* 4	4	ĸ	*		-}¢	:	*		•	* +	< ⊰:			
+ a a a a ⊃ v m ×	EEE																			
47H54J 70 ·	601 602 603	æ 10 t0 t	~ m m	~	~ ~	TT 10	(0.5	- m r		- ~	m ↔	- 10 (1	· ~ "		o -	~ m	~ 10	(C N	സർ	n ()
	. 600	ωφω	စကာဏ	φφ	φφ	9 0	9 (υQU	y O	φφ	ယယ	יטי	y OD (00	ဖဖ	տ დ	ယ ယ	ယေ	G (υ (υ

**---No data available (sacrificed) TR Group 1 = Control; $2 = 1.5 \, \text{mg/kg/day RDX}$; $4 = 35.0 \, \text{mg/kg/day RDX}$; $5 = 175/100 \, \text{mg/kg/day RDX}$ *---No data available (died)

3

(

Ø

(3)

•

TWENTY FOUR MONTH CHRONIC TOX:CITY/CARCINDGENICITY STUDY OF HEXAHYDFQ-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B6C3F1 MOUSE INDIVIDUAL BODY WEIGHF MEASUREMENTS (9)

	67		9		!	1	o.	!	t i		yα			80.	0	1	(N 60	1	9.	!!		!	1	1 !		1	1	8	! (æ. a) i	٥.	!	!
	i																																		
	65	1 6	. i	1	i	1	36.	t i	1			ת ה	34.	42	37.	1	1		1	39.	1		ļ	1	1	1 1	1	1	37.	1 1	45	. 1	40.	;	i •
	63	1 9	40.4		1	1	36.2	1	1			2 4	34.4	42.0	36.2	;	! !	36.8	1	40.0	! !	† 	1	1 1	i i	1 1	1	1 1 1	37.1	1 1	44.6	0.1	42.9	1	! ! }
	61	1 6	39.4		1	1	35.1	; ;	!	1 4	4 C 4 C 4	37.4	35.2	42.3	36.6	1	1 1	37.8	1	39.8	 	1 1	i i	!	!!	1 ! 1 !	1	1 1	36.6	() 	43.3	3.1	39.6	1	1
	59	; 6	38.9		1 1	! !	34.9	1 1	1	1 0	40.45 20.40 20.41	25.0	34.1	42.4	37.0	! !	1 1	37.7	;	39.4	1	 	1	!	!	1 1	ł	1	36.7	!	43.2	1 . 10	37.4] 	! !
	57																																		
	55																																		
	53																																		
X.	51																																		
TEST WEEK	49																																		
F	47																																		
	1	;																																	
	- 1																																		
	43																																		
	4-	;	36.0	!	;	į	34.0	1	i		38.	. 60	ກຸດ	40.4	35.6	39.6	i	38.0	3	38.8	1	; ;	į	į	38.7	į		2	34.6	;	42	37.	38.		İ
	39		36.0	1 2 4	! ! ! ! ! ;	1	33.5	;	1	1	37.9	44 0.10	7.76	39.6	35.4	39.4	í i i	38.5	0 1	38.1	!!!		; ;	1	40.1	1	1 0	0 1	34.4	:	41.8	35.7	35.9	1 1	
	37	-	35.2	1	1 1	1 1	33 6	1	;	!!!	38.0	42.7	36.8	0.00	35.2	39.6	!!!	39.4		38.0	 	1 1	1 1	1	38.4	1	1 4	1 1	34.0	!	40.2	33.6	35.7	; ;	; ; ;
	35		34.8	! ! !	; ; ; ;	l l	33.5	1 1 1	1	1	38.2	43.0	36.9	- 65	34.2	39.2	1 1	38.7	7 : 1	38.2	1	1	1 1	ì	39.4	!	1 6	5 1	33.8	1	40.1	35.9	34.8	1 1	t t
	33	 	35.0	1	1 1		34.0	1	;) []	38.2	44.3	38.6	25. TA	33.9	39.66	1	39.5	0 1 0	38.6	{ 1 i	1		1	39.4	! ! !	1 6	0.00	34.2	1	40.1	34.2	33.1	. 1	!
	31	!																39.1																	
		水 		*	-34 -3	< -10	Í	*	*	4:			,				*		40		*	-;< ·	* +	K		¥	¥.	4	•	-K		ų		4:	**
v	ш×	: : :	Σ	Σ	Σ:	EΣ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Ε 2	Σ	Σ	Σ	Σ:	Ε 3	Ξ	Σ	Σ:	EZ	Ξ	Σ	Σ	Σ	£ 3	Σ	Σ	Σ	LL	L LL	. "	L
+¤ ©¤0	5 C	ខ	ູນ	ស	נט נו	กเ	ល	រោ	ន	ស	ល	រភ រ	រោ ប	מ מ	, ru	ល	ហ	លេ	ט מ	וט ל	ß	សេរ	ם מ	ດທ	ល	ល	រ ល	ពម	מי	เก	ស	ហ	១មា	ເລ	ស
Z FSSHZP	0 .	641	642	643	644	645	647	648	649	650	651	652	653	604 888	656	657	658	629	200	662	663	664	000	669	899	699	670	673	673	674	675	676	678	679	680

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX**---No data available (sacrificed) *---No data available (died) TR Group 1 = 4 =

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

	1	o (o •	J L	n	1 1	ı	ļ		œ •	.) (າ ເ	v 0	0	ı	1	ı	ı	<u>.</u>	- (m	ı	1	1 :	0 (0		,			l 1	ı	:	1	1	ı		1	ı	ı
	67	43.9	9 1	2 6	36.	1	•	1	1 (36.	5 6	3.5	? ?		3	!	1	į	!	36	34	38.	1	1	1 :	38	38.	1	1	1		! ! ! !	t	;	1	1	1	1	!	ŀ	1
	65	41.5	200	5.00	χ. Σ.	1) 	1	1	34.4	9 1	31.5	0 (1 (2 (2 (5.0	i i	1 1	1 1	1	33.2	32.0	36.4	1	1	1 1	35.7	36.0	† ! !	! ! }	t !				t 1 1	! ! }	1	į	1	1		1 1 1
	63	42.6	36.0	36.1	34.	i i) 1 1	1	t :	33.4	2.0	30.7	ני	0,0	0.00	l !	! ! !	1	1	32.7	30.7	34.4	1 1 1	1 4	1	33.8	37.4	i i ì	1 J 1	! !	1	1	l 1 !	1	1	1	1	1	1	1	1
	61	40.1	33.3	33.4	36.9	1	:	2 1 1	1	34.7	33.6	29.6	2 c	28.5		† - -	! !	1	! !	31	31.3	34.6	1	ł 	1	32.8	35.4] 	1 1	t 3 i	! !	i !	1 1 1	i i	1	1 1	1	l ;	1 1	! !	! !
	59	40.1	33.8	33.7	34.3) ! ;	1 3 1	:	:	35.3	32.6	29.7	32.7	36.5		1 1	1	1	1	32.2	30.6	35.4	} ! !	! !	1 1	34.2	38.5	! !	ŧ ;	1 1 1	! !	! ! !	ŧ •	1		i i	:	1	ł	1 1 1	! !
	57	39.4	31.3	32.1	۳ ا	1	:) 	t I	31.1	32.7	29.6	31.2	35.4	5	1	! !	!	1	31.3	29.9	34.9		1	:	32.9	37.0	l !	!	! !	1 1	! ! !	!	1	1	! !	1	1	! !	t s	! !
	55	39.9	٠. ۱	ص ا	<u>ئ</u>	:	ļ	:	1 2	32.8	2	٠,	٠ .	٠.	4	ļ	1	1		31.0	318	35.1		1	1	34.6	37.8) !	! ! }	:	! ! !	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	; ;	!		٤ ١	;	1	1	****	! :
	53	40.9	32.2	32.8	۳. ج	•	;		; ;	31.3	32.4	28.3	30.7	35,4	41.1	1	; ;	1																					!	9	!
EΚ	51	38.9	æ. 1	σ. :						30.9																												35.0%	!	39.8	! !
TEST WEEK	49	39.8	32.1	31.7	۳ ک					30.4																															
 	47	6	~	n	~					30 7																															
	45		•							30 +																															
	43	36.1	ص ص	ر د	ر د						~	_	~	_	~					~	•	~	_			~	~					_			_			m		_	
	41	38.2	ď	_	c.	1		,		29.1																															
	39	36.2		•		,		,		31.2	၉	0	ი.	- .	0	!	į	į	į	6	8	8	9	!	:	е	er.	Į.	;	:	:	₹.	:		0	ဖ	: !	9	: :	۳.	;
	37	35.9								29.9							! !	1	1			32.0			:	30.4	37.0		!	1	! !	41.7	1	1	35.4	28.4		30.9		35.8	i i 1
	35	33.2	29.0	30.5	30 -	;	•	;	:	27.6	33.5	29.5	30.8	31.8	33.1	!	1 1	1	1	29.0	28.0	31.6	35.3	1) 1 1	33.2	34.1	ŧ 1	1	!	1	40.9	1 1	1	37.4	28.7	. ! . ! . !	31.3	; ; ; ;	36.9	!
	33			_	_		,		,	28.4		.	ς.	_	മ	,		,		(0	~	10	~			_	_	,	,		,	<u>_</u>			m	~	, ,	~		_	
	_	33.0	29.5	29.4	30.0	!	*	1	!	29.6	30.7	26.9	26.6	31.0	32.9	1	1	!!!	1 1 1	26.8	27.3	31.2	32.4	1		29.5	33.1	1 1		!		38.2	! ! !		34.0	27.4		20.00	1 1	34 0	1
		! ! !				**	**	-::	: -::							4:	-40	. 40	-*					**	**			**	7.	75	7.		が	7.			7,6		7		•
v	w ×	<u> </u> u	LL.	L .	L	tı.	L	L	LL.	·	LL.	LL.	Ŀ	L.	L	Ŀ	u.	ij.	Ľ	. LL	. Li	u.	щ	ıL	L	. L	ı	ш	L	t.	Ŀ	Ŀ	Ŀ	ı	<u>u</u>	ts.	. Li.	. 14		. ti.	L.
α O	ے م	5	IJ	ស	ເດ	S	Ŋ	ß	ល	ល	ល	ល	ល	ល	ស	ស	ល	ß	Ľ	П	ល	r.	Ŋ	ស	R	L)	ល	ស	ស	ស	រេ	ល	ស	it.	ហ	យ	ď) LC	ប	n,	ស
Z	o .	681	682	683	684	685	989	687	688	689	690	691	692	693	694	695	969	697	808	669	200	701	702	703	704	705	106	707	708	709	7 10	711	7:2	713	714	7 15	7 6	717	7 18	7 19	720

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXavailable (sacrificed) H **----No data TR Group 1 =

*---No data available (died)

(1)

(2)

9

0

0

٩

٥

٥

29	1 1 1 1 1 1 1	1	28.9	1 (14.2	í t	1	(1	35.0	38.4	41.8	25.3	30.3	!	!!	5.5	1 1	40.2	30.6	1 1 1		38.	1	1	1	34.6	26.0	} }	; } !	
ស	i		28.0																								_	24.7			
63	1 1	1	27.2	1 1	42.5	i i	i	} !	1	32.8	40.6	38.9	25.4	30.5	t 1 1	1 (39.3	1 1	40	30.2	1 1	1 (38.0	1	! !	1	34.5	25.1	1	!!!	
-		3	27.4		4 - 3	! ! !	i i i	1 1 1	t 1	33.8	38.7	39.5	29.6	28.6	ì i	1 1	37.3	1	38.8	29.7	! ! !	1 (38.6	1	i i	1	33.5	24.7	1	;	
89		1	27.0	1	40.0	27.8	t I I	!	ŧ t	34.1	39.1	39.8	29.0	29.0	1	1 1	36.8	!	39.5	29.0	!!!	1 1	38.1	1	! !	!	33.1	24.7	!!	1	
57	; ! ! ! ! ! !	t t j	29.0	† 1	38.9	28.4	1 1	1	!!!	32.3	38.4	38.3	31.8	29.1	i ! !	1 1	37.5	!	38.4	29.2	 	1 1	37.8	!	1	 	31.7	25.1	!	!	
ង	1 1 1) } }	27.7	;	42.8	27.0	1	i !	! ! !	35.7	38.4	41.1	32.3	28.1	**	! ! ! } !	37.8	!	39.6	30.0	111 %	ا ا ا	37.5	1 1	!	!	32.4	25.0	 	t ! !	
53			27.7																												; 8
WEEK 5 t	1 1 1 1 1 1 1 1 1	1	27.4	1 1	40.7	26.1	! !	1	1	31.9	36.6	39.3	30.5	27.6	24.2	-	38.6	1	37.1	29.3	42.4	40.0	36.9	1 1	!	1	35.0	25.5	1	33.3%	;
TEST W	1 1 1 1 1 1	1	27.2	! !	40.8	96.9	1	1 1	} f 1	30.7	38.2	36.4	28.1	28.6	22.8	; !	39.5	1 1	36.9	28.8	42.0	39.0	35.4	ŧ ŧ	1 ! !	!	32.5	24.9	1	36.1	:
4	1 ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !	i i	96.8	1	39.7	25.3	1 1 1	! !	! ! !	32.1	36.1	39.1	28.7	28 3	22.7	! !	36.6	1	38.2	20.8	41.5	37.3	32.0	i i	!	1	29.8	26.2	!!!	34.C	
45	1 1 1 1 1 1 1 1 1	1	28.3	! !	37.0	20.e	! !	i	1	30.0	36.6	37.6	28.1	28.9	22.6	!!	35.1	1	37.1	27.7	39.8	37.9	31.7	! !	1 1 1	! !	31.2	25.2	1 1 1	33.3	•
43	1 1	\$ \$ \$	26.5	!	37.3	25.9	1	! !	1 1	31.3	34.0	36.4	31.0	29.7	20.5	1	38.5	1	35.6	27.5	41.1	35.7	33.7	1	!	1 1	30.7	25.9		33.5	
4	1 1	,	27.0	;	38.9	25.6	1	1	1 1	28.8	35.4	34.8	27.7	29.4	23.9	1 1	36.5	1	37.1	28.5	40.9	38.8	34.4	1	!	1	30.4	25.2	1	32.7	ced)
99	1 1 1		26.2	1 1			!	!!	1		34.3	-	28.4	27.1	27.3	1	34.9	;		27.8			╼.	1		1	30.2	N	!	31.7	ied) acrifi
37	1 1	: t	27.0	1	36.4	23.8	!	1	1	30.7	31.3	36.0	27.5	27.9	27.1	:	36. 1	1	35.8	28.3	39.2	36.4	34.4	1	1	l l j	29.0	24.8	1	29.5	le (d
35	1 1		25.3	1																									1	32.2	ailab ailab
33			28	1	35.	24	1	1	;	29.	31.	34.	27.	25.	27.	1	31.	i	33.	27.	37.	36.	32.	1	i	;	28.	23.	:	28.	ata av
Т		: ->	27.1	1 1 *	37.9	C	***			CA	30.8	33.2	26.8	27.6	a	*	31.4	**	32.5	26.5	36.5	34.2	m	×	*		27.6	24.4	*	29.6	No da
υш×		LU	ـ انـ	Ŀ	Ľ.	L.	u.	li.	U.	ī	IL.	ŭ.	u	L	u	Ų.	ഥ	Ľ	u.	ц.	u	u.	u	ıL	ų.	ĸ	u.	۱L	ıı	LL.	* *
+ a a a o o o o	1 1	០ ជ	າທ	ស	ស	ហ	ស	ហ	រប	ស	រ	ស	S	ល	រប	ល	ស	ນ	ស	ស	ល	ល	រប	ស	ល	ស	រ	ស	ស	R	
42 H E 4 J Z O ·		127	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	149	750	

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group 1

ST WEEK 87 89 91 93 95 97 99 101 103 1	7 37 2 35.8 36.1 35.8 34.7 35.1 35.1 35.8 36.1 35.8 36.1 35.8 36.1 35.8 36.1 35.8 34.7 35.1 35.8 36.1 35.8 36.1 35.8 36.1 35.8 36.1 35.8 36.1 35.8 36.1 35.8 36.1 35.8 36.1 35.8 36.8 36.8 36.8 36.8 36.8 36.8 36.8 36	mg/kg/day RDX; av RDX
# #	8	= 7.0 /kg/d
		/day RDX; 3 : = 175/100 mg
7.7		d) rificed) .5 mg/kg
73 75	38 1 38 3 3 4 4 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	lable (die lable (sac rol; 2 = 1
17 69	23 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	data avai data avai p 1 = Cont
		*No **No TR Grou
AZHZAJ ZD	- 2 C C C C C C C C C C C C C C C C C C	

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

-	103	1	39.3	34.8	39.4	39.3	37.1	1	1 1 1	44.5	41.8	36.5	32.7	39.1	37.8	1 ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !	33.6	!	1	38.9	34.3	1	1	1 1 1		1		34.8	34.2	33.3	33.0	}	38.3	!	36.5	48.2	I I	44.5	40.9	1
ţ	101		40.4	_		10				10	_	~	-		.		_			2 39.3	34	•							34.6							7	ı	80	_	6
Ö	66	*	8 40.1	34	9	8 40	1 37		1																	45			2 34.4											
0.0	97	. 39.	39.1	33,	40.	40.	37.	;												38.7									34.2						33.	48.	;	43.	43.	27.
0	95	36.2	40.7	32.5		41.	37.1	;																					34.4						34.4	48		44.8	43.6	33.7
C	93		40.6					1 2 1	1	44.3	43.2	37.1	32.5	39	37.7	36.0	34.7	i i	!	39.5	34.3	! !	1	!	-	39.0	1 :	39.5	33.9	9 .	37.4	1	39.7	l l t	33.7	48.3	1	42.5	43.7	41.7
ā	91	36.8	40 8	32.1	4	4.1.	38.1	1	:	44.7	42.9	37.3	33.	33.4	37.3	36.8	34.3	1	1	39.7	34.7	!	1	!	1	45.6	1	39.1	33.7		38.	*	40.0	t t	34.5	48.5	1	44 0	43.9	45.2
WEEK	89	36.0	40.9	32.8	41.4	40.4	38.2	1 1 1	;	44.5	43.5	37.2	33.7	38.4	37.6	36.1	34.8	1	1	38.9	32.0	1 1	1	i i	1	45.0	!	39.1	34.1	33.6	38.2	31.2	40.0	1	34.0	47.2	1	43 9	44.0	46.5
1	87	35,8	40.9	33.8	41.4	39.9	39.5	1	!	45.0	43,6	37.6	34.1	39.5	38.0	38.2	34 0	i j l	1 1 1	39.0	34.8	1 1	1	1	 	46.4	1	39.3	34.2	34.2	39.4	34.4	39.3	1	34.4	47.2	i i	45.8	44.0	47.7
	85	36.1	40.5	32.5	40.7	39.3	39.6	1	1	44.3	43.1	37.3	33.0	39.1		37.6	35.1	1] 	39.6	34.6	1	;	1	37.5	46.8	1	39.5	34.6	33.5	38.9	36.4	39.0	1	34.1	46.7	1	44.3	44.4	46.8
ç	83		40.7	•	•		•	1	1	44.8	43.3	37.4	34.8	38.9	37.6	37.7	32.1	1 1	1 1	40.1	35.3	1	1	1	40.9	48.0	1	40.1	35,3	33. E	39.2	38.6	39.4	! ! *	34.5	46.7	;	43.1	45.9	47.7
ā	31	34 9	40.0	32.2	39.5	37.8	39.4	1	:	4	ლ.	ស	7	38.8	ı.	œ	o.			40.1	34.7	1	;	;	41.1	47.2	1	39.5	34.6	34.0	33.8	39.7	38.4	54.0	34.6	46.4	!!	40.7	44 5	46 2
9	79		39.6		1	37.8		1	1	44.0	44.3	1 	33.6	40.1	37.8	38.2	32.0	1	1	40.8	35.6	:	!	1114	41.1	46.9	t 1	38.7	34.9	34.3	38.9	40.3	38.2	45.2	34.1	45.9	1	44.3	44.6	46.4
,	77	7	-	ю	ς.	Ġ.	c	1	ł	6	5	۲.	Θ.	•	۲.	თ	ıc.	ı	\$ #	•	e.			ς.		8	ŀ	7		4	٠,	ກ		თ	ທີ	9	1	'n		S.
	75	36.5	ю О	6	- -	о О	ω.	i	1	θ.	4	7	4.	39.7	ω.	о О	S.	1	1	40.8	ທ	1	!	~	40.9	:	!	თ	34.9	ش	ნ 1	ά.	ش	7	4.	9	1	ö	44.2	₹.
		35	0	S	0	œ	ທ	- 1	1	က	G	^	4	39.4	∞ .	ത	യ	1	1	40 0	ທ	1	1 1	n	0	ဖ	Ø	~	35.0	m	- 1		1	~	S	~	•	0	43.6	Φ
	7.1	36.2	39.3	32.8	41.2	40.1	45.7	1	1	44.1	44.9	37.0	35.3	39.7	38.5	39.6	36.0	!	:	40.0	35.7	1	1	44.9	41.1	46.4	39.8	39.9	36.5	34.1	40.0	40.1	40.6	38.1	35.5	46.8	1	44 3	45.9	46.3
	69	-	38.8	33.1	39 4	40.6	46.4	11144	**	44.1	44.0	37.1	34.4	39.8	38.8	40.4	35.7	11144		40.1	35.5		**	44.7	41.2	46.5	41.5	39.8	35.8	34.9	40.0	37.7	38.8	36.8	35.4	46.2	11144	39.6	43 1	42.4
ω ir .	~	i	Σ	Σ	Σ	Z	Σ	Σ	Σ	Σ	Σ	Σ	₹	Σ	Σ	Σ	Σ	Σ	Σ	*	Ī	Σ	Σ	Σ	Σ	Σ	Σ	Σ	ž	Ξ	Σ	Ξ	Σ	Σ	Σ	Σ	u	ښا	ıL	ů.
x 0 ⊃ 0	۵	-	-	-	-	~	 -	-	_	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		-	-	-	-		-	-		-	-	-	-	-	-

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; mg/kg/day RDX = 175/100**---No data available (sacrificed) 35.0 mg/kg/day RDX; *---No data available (died)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGG3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

		104		უ ც		י מ		١,	31.4	'n	١.	44.8		م	ė,	ö	!	'n	- .	ė.	43.7	S.	l - -	1	41.7	Θ.	1	'n	ω.	43.6	ċ	١,	÷	42.4	1	1	ä	4	45.4	4	7 77	;
		103	38.8	N	n	1 C	`		31.3	S)	1	44.7	N 1	Ľγ.	•	0	1	2	_	9	40.2	က	1 1		42.2	-	1	B	~	42.6	ത	1	41.1	~	1	1	n	9	45.7	2	7 7 7	
		101	39.4	۳,	. 0		5	!		4.	1	•	₹ :	ئ	÷.	ó	!	'n	ö	ė.		e.				7.	ŧ	4.	8	٠	ö	1	•	·	1	1	ä	9	•	4	ı	•
		66	ω.	4 1	ر ا	o o	æ	;	32.1	7.	1	N I	2.7	9	ი ი	2.0	1	2.3	0.5	5.1	8.5	4.8	!!	!!	2.7	6.9	1	9	~	42.5	ö	۱,	41.7	- -	! !	1	÷	4.	44.6	4	ו ני ני) ;
		7	8.4	0.1	9.	7.1	1.1	F 1	0	S. 4	1	4	4 : W :	ນ ນ	3.4	8.0		1.4	9.0	3.6	6	6.2	1		÷	8.4	!	7.3	7.3	3.0	0.	1	ص ص		j	ì	0.	1.8	0.	7. 12.	; <	,
		95	ю. 	- -	ıŭ i	iù (o.	1	6.4 6.4	-	!	3.0	α.	N.	ល	4	!	ω.	ص	9	7.2 3	₹,	!!!	:	ď	8.9	:	'n	o.	4.0 4	-	:	1.7 4	e e	:		2.6	6.7	4			P.
		93	9	7		ω, 4.	9		က ထ	B	!	ь. Д	8	4	7	2.	:	.5	.3	.2	.4	о С	1	1	8.	ь 6	1	د ۳	.6	.6	.7 4	;	9.	4. B	;	1	4 4.	9.	4	ь. Б		D.
				C -	e e	- 1	7		e e	យ		2	۵ 4	4	8	9	,	7 4	3	9	9	5		1	9	4		4	8	79	4		10 4	4			6	6	4	0		,
			7 3	~	(C)	< '	4		n	មា		4	4	4	4	4		4	4	(C)	n	(C)			4	n	<u>ئ</u> :	n	4	4	4		ব	4			4	m	7	. 2 43	•	ग
	WEEK	8	œ	4	r:	.	7	1	3 33	9 55	1	4.2	3 46	7 44	4 42	7 41		3 44	6 41	35	7 39	5 38	•	י * ס	5 44	8 39	7 27	5 40	4 46	6 42	0 40	1	8 4	3 41	!	1	42	5 38	0 46	9 45	: 0	4
	TEST	87	5 38.	~	m	~	יי		1 33	စ က	1	4	47	45	43	42	•	44	4	36	42	40	1	31	43	n	<u>.</u>	4	46	43	42		42	4	•	е С	4	က	45		i (₹
		85	36.	43.	33	č.	7	•	33	55.	1	44	46.	44.	41.	41.	1	43.	40.	33.	38.	38.	1	37.	42.	38.	30.	40.	46.	43.	42.	1	41.	42.	ŀ	32.	41.	36.	48.	44.	1 4	40
		83						;	33.0	55.2	!	42.9	45.8	44.2	42.2	40.1	1	43.3	41.7	34.3	41.9	38.6	1	37.1	43.0	38.0	30.0	40.C	45.7	43.C	42.7	;	40.8	42.	1	31.6	40.5	37.3	47.1	44.4		48.0
		81				40 4					•																													44.2	•	46.3
		79	37.	ŀ	œ	•	~		~	•	;	Ċ,	;	ë	ö	1	;	6	Ö	ın.	0	8	ł	8	4	6	ლ	ö	ຜ	ς.	ď	ŀ	ε,	Ψ.	ŀ	Ö	6	မ	7.	46.4	;	44.4
		7.7		42 8	38.5	39.6	47 2	1	34.8	2 99	1	44.2	46.5	46.8	41.5	43.0	;	44.8	42.8	34.4	40.8	40.9	1	41.1	43.9	40.4	32.5	40.5	48.1	42.5	46.9	1	41.2	41.8	l I	41.8	43.8	40.4	45.7	45.9	!!!	•
		75	37.2	m	8	å	ي.	!	ß	÷.	1	ď	υ.	4.	6	43.0	;	ς.	<u>-</u> :	ဖ	Ö	ω,	i	9	6	39.7	2	-	ın	9	2	;	Ψ.	8	,	Ψ.	-	ω,	48.8	45.8	۱.	45.2
		73		Э.	ნ	o,	۰.	;	4	•	į	Ť.	9	6	8	-	1	3	0	m			1	ی			_	0	L.	CA	ς.	1	ó	-	1	c				6	1 1	•
		_	36.9		-			•			- 1																						σ	n	α	,	σ	٦.	8	80		
			7.1	9.8	7.9	0.0	69	!	5.4	2.3	!	1.5	4.5	2.4	7.2	3.5	!	4.4	i.	9 9		. 60	· ·	ď		2.2	0	2	4	-	-	[}	6.0	9.	C.) a	-	4	-		1 '	α .
			! ! ! !					-\$*			-30						*						بزد	•								*									*	
	S) I	ш×	! !! !	Ŀ	Œ	14	<u>.</u>	Ľ.	LL.	щ	4	ı	u.	ŭ.	ш	u.	L	. 14.	ш.	. u	. u	. 14	. L.	. 11.	. 11	. u	. 44.	. LL	. 14	ш,	u	L	ш		щ	. u	. u	. 44.	ш	L	u . 1	u.
¢α	0	⊃ ¢	-	-	-	-	-	-	-	-	-	-	•	-	-	-	-	-	-	-		-	•	•		-	-	-	-	-	-	-	-	-	-	• ••	٠ 🕶		-	-	4-	-
۳.	2	· œ	8	82	83	84	85	86	87	88	83	06	6	65	63	94	P. C	9 6	6	8	0 0	5	2	Š	100	10.5	, C	900	100	108	109	10	-		7		4	7	117	118	119	120

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX**---No data available (sacrificed)

*---No data available (died)

6

9

(3)

(

٩

218

A Z w ff A J

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3,5-TRINITRO-1.3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL RODY WEIGHT MEASUREMENTS (9)

 α

 $AZ \vdash Z A \bot$

				~		_		,	,,						,		٠.		_				_			٠,	_					_	_						_		_
		104	1	44.9	2	4.	1	1	•	1	38.7	છ	1	•	1		37.2			- 2	!		34.1								0 1			36.3		39.8	39.4	39.6	39.5	36.7	5.
		103	1	45.5	52.2	44.9) 	1 1 1	52.1	1 1	38.1	36.5	1 1	42.2	1	1	37.0	34.3	44.0	30.7	i) 	33.7	1	45.5	37.4	41.2	1 1	45.9	9 0	0 1	34.6	38.0	36.3	1 1	40.3	41.4	39.5	35.8	37.2	S S
		101	;	45.9	6	7	1	1	50.3	1	38.7	38.5	1 1	42.7	1	! !	36.9	34.9	44.2	40.0	1	;	34.0	1	42.4	37.5	40.8	33	46.0	. u		34.3	39.1	36.5	1	40.0	ö		რ:	38.4	
		66	1 1	46.6	53.8	47.6	42.4	1 1 1	52.0	ļ	4	0	!	7	}	1	۲.	۲.	-	6	1	!	0	:	<u>ن</u>	m.	ម ខ	١.	4 (, ,	: !	9	ω.	9	1	ស				37.9	
		97	•	45.5	'n	9	45.1	1	50.7	1	36.3	38.8	i t	41.6	1	!!!	37.9	33.4	43.6	39.3	!	1	32.6	1							200						т.			37.7	-
		95	23.8	46.0	52.3	47.6	45.6	1	51.	1	37.2	40.2	i i	43.0	1	1	37.3	36.7	42.7	42.0	1	:	34.2	; ; ;	43.2	37.0	40.3	4.6	46.3	, ,	5			39.2						38.2	
		93	34.7	45.8	53.2	46.1	45.8	t 	48.9	1 1	34.1	36.7	1 1 1	41.8	! !	1 :	38.1	35.7	41.8	43.3	1	1	34.0	:	46.1	37.2	41.0	0.65	45.0	10		35,5	38.9	39.3	1	39.6	38.5	40.8	33.9	38.0	7.19
		91	39.3							1	38.4	40.6	1	42.3	1	;	38.2	37.2	45.8	40.5	1	!	34.9	! !	44.2	38.3					7 1			39.9						39.2	
	X.	88		ស	C)	₹.	Ŋ	•	ဖ	ļ	_	-	!	_	!	!	īυ.	0	0	6	!	0	80	!	8	ဖ	۰.	4 1	۰, د	ه د	٠.	0	ဖ	æ	!	4	e.0	1.7	2.7	37.9	٠. د
	TEST WEI	87																																			39.9	42.1	28.6	38.6	42.1
	-	85	9.6		3.4	7.2		1	æ.		7.2	e. 6	1 1			7.7		6.4	3.2	2.0			3.1		3.9		ر ان					6.2	6.0	9.6	!	9.4	٠.	6.0	6.3	37.8	٠. ت
		83		•								37.8			 - 	32.6	38.6	38.2	41.4	41.8	t 1	27.0	33.9	1	42.5	37.1	43.0	41.1	46.8	Y 0	35.3	37.1	41.9	39.4	1	40.9			_	37.4	
		81	က	ග	~	-	4	į	က	0	æ	σ,	!	~	:	9	0	7	-	7	!	7	4	!	Ŋ	<u>ග</u>	4 (~	ם סי	4 (> σ.	0.	တ	ဖ	į	6	œ	_	ල :	37.6	7
		79	46.6	رن	-	-		က	7	٩.	₹.	o.	1	ø.	ŀ	Φ.	Б.	!	9	4	i	1	o.	<u>ه</u>	₹.	۲.	(i)	ا ھ	o. •	٠, ٠	2 C	0	4		ŀ	ທຸ	6	O	7	38.7	0
		77		44.8	52.8	48.6	44.8	42.0	53.3	38.3	34.7	39.0	!	43.8	;	38.1	36.9	39.1	44.9	41.9	\$ 1	33.2	33.4	54.2	41.7	39.2	43.4	5.5	47.1		ກ <i>ຕ</i> - ເຕ	37.2	40.6	39.1	1	40 7	40.5	12 4	35.3	38.3	43 C
		~ 1	~	₹	~	on .	ന	_	N	:0	₹	on.		43,1	!!	6.1	B	-	1.1	6.0	1	5.8	5.3	8.8	5.1	7.6		7.7	ار ا	p (, tr	0.3	2.5	!	٥. ١	٥. ت	3.2	5.7	01	3.e
		73	43.4																																						
		7.1		0.	0.0	0.3	. 2	0.	3.0	7.8	5.5	ю. В	1 1	2.2	!	3.8	3.	9.S	2.3	7.0	!	6.2	6.3	7.0	0.	1.9	6.	0	44 T		, u	. IC	1.0		ŧ !	9.6	9.3	2 3	0.0	(O)	9.7
			2.3	න ල	5. 1	7.4	2.8	9.9	9.7	0.0	9.0 0.0	38.7	111	2.8	1.7	3.8	4.5	8.7	1.4	1.4	1	4	4.	7	₹	ö	က်				. ~		6	m	1	m	œ.	÷	ı.	36.9	2
	,.	1											∹ :								삯														*						
	υnu	× :		<u></u>	ıŁ	ı			u	ш.	u.	u.	u.	ij.	u		ı	ш	LL.	Ŀ	11.	Ŀ	-	ш	u.	11.	LL !	_	u. l	L. 1	LU	. ≥	Σ		Σ	Σ	Σ	Σ	Σ	æ :	Ł
םט	602	۵.	-	-	-	-	-	-	-	•-	- -	-	-	-	-	-	-	-	-	-	-	-	-	-	-	•-	-	_	- 1	۰ ۹			. ~	8	~	8	8	63	7	0	~
4 -1	zc	· ·	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	139	139	140	141	142	143	144	143	146	147	148	2 T	12.5	152	153	154	155	156	157	158	159	160

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX **---No data available (sacrificed) *---No data available (died)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRD-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE IND;VIDUAL BODY WEIGHT MEASUREMENTS (9)

STATES TO STATES AND S

		104	31.9	35.3	i i	t : :	1 6	33.0] 	1	1 1	37.7	34	32.0	} ! [i i i	l l l	} 	!	1	37.1	36.6	1	37.9	1 1	36.8	! !	! !	5. t	0. r	2 0	0.00	· ;	. !	1	1	•	1 1	37.1	37.7	l ;	! !	
		103	32.2	33.1	! !	! !	1 6	34.0	1 1 3%	! !	1 1 1 1	37.7	34.2	32.3	!!!!	!	i i		:	t i t	37.2	36.1	! !	37.9	1	36.4	!	; ;	0.00 0.10 0.10	35.7	0 0	S			!		1	1 1	37.2	37.7	1	! ! !	
		101																																									
		- 1	~																																								
		- 1	32.9																																								
		1	33.4																																								
		93																																					"	37.8			
		9 }																																									
	×	89	7.																											36.1													
	EST WEEK	87	æ.	ς.	:			35 5 3	^																					36.8													
	T	85	6		1 1					i ,																				36.5 3												2.7	
		83	33 4 3	ı C				 ت	~																					36.0 3												6. 6.	
		81	<u>س</u>	မ				et -																						36.4 3									₩.	9.	1	o.	
		1	32.8 33				•																							37.0 36										7.9 38			
		i		m			_	۳.				_	_	_	m	~		_	~	_	"	10	~	10		10	_	_	.	et i	_		,					,	_		ı		
		7	33	36	к	•	3.7	35	42	t	i	40	40	40	29	36	1	38	34	38	39	36	40	39	34	37	33	43	37	36	35	38		*	1	i	ŧ	ı	38	38		37	
		75	34.5														ı										•			36.4			1			1		ı		36.9	ŀ	•	
		73	34.7	۲.	е	;	-		_	,	1	ö	6	ໝ	6	7.	1	7	ريا د	σ.	6		ó		'n.	œ,	4	ω.	7	•	ıņ.	7	1	•	1		1		7	•	!		
			33 5	7	ς.	į	0		0	•		o.	6	σ,	o.		;	7.	4	7	6	c	6		រប	9	4	8	4		2	ė.	i		•		í		8	40.0	•	•	
		C D 1	1 🐨	7	32.	ŀ	_:	Ψ.	₹.	:	1	39.	7	æ	6	ιο.	1	38	ıΩ	<u>.</u>			6		ın.	10	Ψ.	Ε.		-	**	36.	ļ	₹.	1	ļ	1	; ; -;:	ιD.	8	ļ	7	
	ر د د	ш×	 \S	Σ	Σ	Σ	Œ	Σ	Σ	Σ	Œ	Σ	Σ	Σ	æ	Σ	Σ	Σ	Σ	Ξ.	•	: <u>1</u> 2	.	Ξ	Œ	Ξ	Œ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Z	Σ	
0 0	x 0 :	۵ د	2	8	~	~	^	0	%	6	2	0	0	8	0	8	0	0		. 0	, 0	10		. 0	0	i (4	7	0	8	8	6	7	0	8	~	7	7	~	8	7	0	8	
لہ ۵	Z		161	162	163	154	165	166	167	168	169	170	171	172	173	174	175	176	177	178	7.0	5 2	18	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	

**---No data available (sacrificed) TR Group 1 = Control; $2 = 1.5 \, \text{mg/kg/day RDX}$; $4 = 35.0 \, \text{mg/kg/day RDX}$; $5 = 175/i00 \, \text{mg/kg/day RDX}$

4

9

3

*---No data available (died)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

	104	89.48.93.49.49.49.49.49.49.49.49.49.49.49.49.49.	
	103	E & E & B & B & E & E & E & E & E & E &	
	101	89.39.39.39.39.39.39.39.39.39.39.39.39.39	
	66	33 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	
	16	2000	
	95	24 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	
	66	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	
	91	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0)
WEEK	83	4 6 6 6 6 6 6 7 7 7 8 7 8 7 8 7 8 7 8 7 8	; ;
TEST W	87	4 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	; ;
	85	0480	
	83	4 8 6 4 4 6 6 6 6 6 6 6 7 6 7 7 7 7 7 7 7 7	!
	8	4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	í
	79	2. 1	; ; ;
		0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	•
		046.00	•
	7	41.8 33.9 33.9 33.9 33.9 33.9 33.9 33.9 34.0 35.0 36.0 37.0 38.0	`
	7	$\begin{array}{cccccccccccccccccccccccccccccccccccc$)
	69	4 8 8 4 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	١.
v	ш×	**************************************	
ဖထဝ) D Q	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	;
(J Z	· o	2001 2002 2003 2003 2004 2004 2007 2006 2007 2008 2009 2009 2009 2009 2009 2009 2009)

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX **---No data available (sacrificed) *---No data available (died) TR Group 1 =

ئ س	ပ																				
Z	x 0 :	S									-	EST WE	EK								
	⊃ •	ш ×	69	7.1	73	75	7.7	19	81	83	82	87	0	6		95	7	66	ç	03	104
241		;	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	 	1 1 1 1 1 1 1 1 1	1 1 1 1 1 1 1	: : : : : : : :	! ! ! ! ! ! !	; ! ! ; ! !	1 1	! ! ! ! !	1 1 1 1 1 3 1 1	! ! ! ! ! !	! ! : ! : ! !	! ! ! ! ! ! !	1 1 1 1 1 1	 	; ; ; ; ; ; ; ;	; ; ; ; ; ;	
ਢ	8	LL.	44.4		4	2	4	44.5		c.		6.2	ın	T.	42.9	6	9.4	w.	യ	1	1 1
*	0	ů.	•		40.6	*		39.2		က	ເນ	4		42.0	418		-	٠	41.2	41.2	O
4	8	u,	•	ς.	7	8	G	4G B		o,	-	9 6	6	Œ	49.6	7.	2 2	m.	O.	6	48.7
~	8	Ŀ	•	o.	о О	ċ	_	50 3		್ಷ	ທ	3 9	m	ď	49.6	÷.	9.0		\sim	÷.	-
₹	8	ıL		4	Э.	ς.	6	34.0		ω	0	0 /	~	œ	38.5	æ	9.5	Ψ.	0	ļ	1
₹	7	u	•	6	ς.	Ö	Ξ.	39.1		က	٣.	ນ ຄ	œ.	O	39.9	ö	6.6	۲.	0	o.	O
マ	7	Ŀ		7.	ις. ·	ນ	9	38 1		6.	-	7.5	o.	æ	38.6	7	7.2	~	ശ	4	រូប
₹	2	Li.		₹.	4	ε.	ις.	44.3		9.	~	5.3	10	က	44.1	ຜ	4.0	"	ശ	6.	w
· LO	0	. u.		6	<u> </u>	6	6	1		7.	4	6.4	₹.	4	33.9	4	0.4		4	4	34.4
L.	10	. U .			. 6		ີ່ເຂ	45.9		က	-	8.8	<u>_</u> :	•	41.8	6	2.7	!	- 1	1	•
) LC	, 0	. 14	•	יט		4		45.6		. 7	æ	1.2	7	_	47.1	4	4.3	Ψ.	43.0	39.1	40.1
រប	10	. 11	. 1	; ;	; ;	· 1	, ;	1 0		: 1) [: !	: !		:			: !	1	1	
) LC	, 0	. u .	7		86	L.	œ	7.98		æ	4	7		38.0	40.1	ŀ	- 1	- 1	1	1	!
) II	, ,	. u	: !	; ;	; ;	; ;	; ;	· ! · ! · !) <u> </u>	:	. !	:	1		i	- 1	- 1	;	1	!
) L	, ,	. u	ŭ	α	c	-	-	109		α	0	6	-	С	60 1	æ	7	8	LC:	4	4
าย	۷ (. 4	•			. ພ		- 0	_	. ע		. α	. α	"	7		٠,	α	່ແ	ی	. Г
ם מ	ч с	LU	•		0.00	•	•			9 0	yα	, ,	•	7 - 7		٠.			o		
n t	٧ (Li	;				,	¥ .	- 1				. !	٠ ١		; ;	, ,	; ;	וו	; ;) 1
n t	N C	ı. L		! ! L	! ! (! !	! ! t			֓֞֜֜֜֜֜֞֜֜֜֞֜֜֜֞֜֜֜֜֜֜֜֜֜֜֜֜֜֓֓֓֓֜֜֜֜֜֜֜				. 0	1 0		י וני		٠,	۱ ر	
0 1	74 (_ 1	· ·	ς. Ω·		٠,	٠.	40.4 0.0	-	7		7 (C	, 0 (0(5 T	ກ່ຽ	0 (- 4) (
10	~	L i	•	•	40.9	٠		9.6		- (4 (9.0 0.0	46.1	•			250	. t	5.0 0.0
ഥ	0	L.	6	ຫຼ		œ ·	o	40.7		0.0		- 0	ກໍ	Э (. 66.	:	x) t	x	D t	٠,	ס נ
to.	~	LL.	4.	کا	ლ	4	و	44.5		9 .	ю.	0.0	ο,	ω,	48.3	æ •		έ,	~ (x 0 ·
CD.	7	u.	÷	რ.	ю	ω.	е.	! ! }		9.	4	ල ල	4	4	44.5	4	ا	4	N 1	4	4
(C	7	L.	4	س	4.	ä	6	1		7.0	4	6.2	21	₹	45.5	ι.	S.	9	ഥ	4	r o
ťΩ	7	u.	ю.	4.	ς.	ъ.	ь	46.2		ช.	9	4. S	4	₹	46.0	ū.	ო	4.	က	ო	4
tO	7	u.	4.	ω.	ъ.	4	4	45.2	-	7.6	4	4.9	വ	ທ	44.1	r.	რ.	4	4	ლ	マ
tD.	8	u.	29.	о С	7	7	ά.	1	-	7.9	<u>ო</u>	თ. დ	ω.	œ	28.6	ω.	ω.	ω.	∞ -	7	_
LO.	~	<u>.</u>	;	1	1	;	i	1		1 1	•	1	:		! !	ŀ	i	1		1	
~	8	ıL	48.		47.2			50.3		.,	ທ	6		49.3	49.9		•		47.4	46.9	47.8
^	7	u.	ŧ		! !	1	1	1		1	!	1	!	1	1	1	;	!		ŀ	ı
^	7	ш			÷			42.4		<u>.</u>	Ŋ	ღ.		43.9	42.4				41.7	41.3	41.8
~	8	Ľ.	7	۲.	7.	ნ	٦.	38.9	-	7	4	6.7	œ.	~	36.3	۲.	ι.	7	9	છ	!~
~	C1	u	43.	n.	42.9	ي	4.	44.3	-	ĸ.	ب	8.0	г. Э	Q	46.5	9	4.	S.	ø	9	~
-	8	u	1	!	÷	1	•	1		1	1	1		1	1 1	1	!	1		1	ì
~	7	u.		2	4	9	7	47.1		6	. 7	8.5	8	ထ	48.0	ė.	•	•	0	38.3	38.3
~	8	ĮL,	е.	ი	с С	ი	4.	42.8		œ	9	7 5	7	4	35.3	4.	4.	ص	3	ς.	က
-	8	u	9		48.2			510		4	0	5		50.6	49.3		α,	8	48.3	7.	0
~	0	u.	4	0	6	~	4	42.1		-	G	4.9	9	ဖ	45.2	4.	4	2	4	ري ري	S
٠ α		. u	α	. 5	o	. c	٠,	. 02		4	C	6		C	48.0	7	6			1	
	v	•		,	;	,	,	2))	:	,			ì				
			-		-	•	•														
		1 1 	0		ap	ø	_														
		**	¥	ava]ab]e	(sacr	ifice	(

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; h=35.0 mg/kg/day RDX; f=175/100 mg/kg/day RDX

A Z M Z A J

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYORD-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (g)

イΖーミベレ

		1 8	,	₹ :	0	1 (ω,	~	1	7	1	~	6	8	;	,		ប	•	1	თ	G		9	1	ı	8 0 (ထ			מכ	:	9	ო	ဖ	,	,	,	េ	m	•
	104	45.		Q.						īU		41.2															38.8			1	ກ					i		}	40	37.	i 3
	103	47.2	1	40.2	44.8	29	4	47.1	1	52.8	1	40.5	37.5	34.6	1	1	1	37.2	t t	1	40.6	45.9	1	38.9	1	1	38.1	39.8	! !	1 1	C. / 4	1	36.9	39.4	35.1	1	!	i ! *	43.8	37.2	!
	101	47.4	!	40.9	45.2	28.4	39.6	46.9	1	52.9	1	40.9	36.7	34.0	1	1	1	38.8	1	i L	41.8	46.3	38.1	39.1	1	! !	37.7	40.3	! ! ;	1 1	42.8	1	37.5	39.1	35.3	1 1 3	:	37.8	43.3	39.8	1
	66	49.4	1	-	9	8.7	C.	47.8												1	45.4	46.3	37.0	38.7	 	1 1	37.4	40.7	! ! *	1 1	43.3	:	36.1	38.6	35.2	!!!	:	42.2	44.7	41.2	; !
	26	47.5	1	39.	44.6	32.7	41.0	47.0		•	^		ın	10	•			_	,	,	_	_	~	0	•		37.0	m	ın		~		m	_	10	,	1	39.7	44.5	41.7	:
	95	48.4	!	37.6	44,5	46.3	40.4	46.8	! ! !	51.3	67.9	41.6	40.6	36.6	32.5	;	21.8	41.9	1	! !	£3	45.8	37.9	38.2	41.8	1	37.1	60.3	36.8	1 1	39.7	i i	37.2	38.3	35.7	;	1	39.6	46.3	43.0	} }
	63	51.1	1 1 1 1	40.5	44.0	48.5	40.3	46.7	{ ! !	50.6	62.2	40.9	39.9	33.4	31.2	;	27.8	41.5	!	1	42.5	46.0	38.0	38 0	41.4	1	37.3	41.3	36.3	;	39.4	1 1	37.3	38.3	32.6		£	38.6	44.8	42.3	1
	91	i	•																								37.3											40.4	46.3	43.0	1 8
EX	89	1.1	6	æ :	رن ا	₹.	B .	חו		51.2	m	~	~	~	ın	i	0	6		10	6	m		.	39.0		œ.						ņ	37.7	9.	۲.	;	ღ.	46.3	ღ.	; ; ;
TEST WEEK		51.3	39.9	39.9	46.2	49.2	42.6	_						_								_	_	_	_		38.4		_			_					1	41,4	46.8	43.1	t †
<u>-</u>	85	ì	~	_	_	_	_	~	,	m	_	ın	ın	10	0		~	ın									38.5														
	83	ì	∞.	۲.	o.	0.1	n)	ဖ	ŧ	6	₹	₹	Œ	თ	0		7	80	1	₹	6	0	4	-	7		38.9	ເດ	m	1 1	47.3	1	38.7	o.	36.0	- -	;	<u>.</u>	17.5	o.	ŧ
	81	6.0	2.4		3.9		8.8		!	0.2		1.4	9.0		6.4			3.5		ጠ	~	_	m	_	_		38.1	_	(0	. 1			~	m	_	38.9	1 1	11.6	17.7	12.5	1 1
	79	!														1			1								38.1						o.	7	e,	-	1	41.3	~	42 7]
	-	. 7	9	o.	9	0	S.	7	i	۲.	'n	۲.	ď	æ	۲.	i	6	ຜ	ŧ	4	6	4	īύ	3	'n	;	6	o.	o.	!	0	1	o.	ឆ	80,	0.	!	5	0		
	75	-	7.6	ი 6	4 0	8.4	o.	2.4	! !	<u>.</u>	5.1	9.8	8. 1.	6.7	3.4	!	7.	4.6	1	4.2	9.0	6.3	7.4	7.4	۲.	!	- .	3.6	3. 8	!	o.	1 1 1	9.9	8.2	5.7	7.2	4.0.4	6.1	٠,	3.4	i
	73	8	-	ဖ	<u>ب</u>	0	٠	œ	!	<u>س</u>	נט	رب د	_o	-	ល					9	8	R	Ŋ	8	C.	!	39.0	4	0			:	80	0	ø	7	8	8	ις.	9	
	7.1	6	7	80	-	ņ	ω.	<u>ත</u>	į	o.	۲.	œ.	<u></u>	<u>თ</u>	9.	1	9.	4	1	0	œ.	r.	0	9	4	!	7	o.	7	!	تا	:	9	- .	<u>م</u>	~	0	0	4.	<u>ه</u> .	:
		7.3	3.5	4.	2.5	0.6	<u>.</u>	7.4		6	3.7	3,1	8.6	1.8	3.3	!	6.0	8.0	!	3 7	4.6	9.7	9.0	8.6	0.0	!	3.7	.		!	.5	. 1	٠. د.	4.7	0.5	9.6	5.5	6.	9.6	9.	į
		1	•	(7	7	`	7	•	** **	•	υ,	•	.,	.,	• •	**	.,	`	**	•	.,	`	•	•	7	*	ĕ	7	•	* *	4	(-)	(7	(')	(,)	(,,	.,	7	7	7	**
U	m ×	! 4	4،	u.	L.	Ŀ	u.	L	Ŀ	ш	u.	u	u.	ı	u	۱.	LL.	ų.	u.	Ŀ	L	Z	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ
œ 0	200	2	64	8	8	8	8	N	7	8	8	0	8	7	6	6	8	8	8	8	8	ო	n	က	၉	n	ო	က	က	၉	n	က	က	က	က	က	ဗ	ဗ	၈	n	n
Z	· O	281	282	283	284	282	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	305	303	304	302	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX**---No data available (sacrificed) *---No data available (died)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASURFMENTS (9)

	03 104	;	.3 36.	1	1 1 1	.5 34.	1	.9 38.	1	.3 40.6	.0 40.	.9 36.	.0 33.	.6 34.	1 10 0		٠. د		.5 33.	!	1 1	.6 32.	.3 37.	.2 47.	1 1	.2 36.	7 41.	.5 40.	. 8			. 92.			1	1	.0 35.	1	- ·	. 1 34.	!
	101 10	'								38.0 39																						•	;			!	-	:	36.7 36	m,	i i
	66									38.8																										1	37.7	; ! ;	36.4	34.0	† 1 1
	97		34.9	40.7	1	35.5	1	36.5	1	37.7	39.6	36.1	34.0	35.7	! L	5.00 10.00	30.3	;	34.3	1	1 1	32.4	38.6	44.0	!	36.1	43.1	40.9	39.4	9.6	200	7 7	6. 0.0	39.1	! !	t	٠		35.9	•	1
	95	39.5	32.0	40.6	!	35.1	1			38.8					•			Ł	•		t				1	•		•	•							ŀ	•	ļ	38.1	₹	1
	63	38.6	34.2	38.0	1	35 1	1	37.7	!	39.7	40.6	37.1	34.9	35.9	: :		35.8	! !	35.9	1	!	32.1	39.9	43.7	!	37.1	43.0	9.0	39.7	ر ا ا	7.65	. e	7.7	40.0	} ! !	! !	39.6	1 1	41.3	35.3	34.2
	16	41.6	35.2	40.5	! !	36.4	! !	37.4	!	38.8	37.8	37.1	34.9	36.1	: (0.70	36.3	:	36.5	1	!!!	32.8	39.5	44.7	1	36.5	44.5	41.8	40.0	7.00	9.00	5.0	7 6	41.0	1 1 1			ı	41.0	•	•
WEEK	88	41.8	34 6	38.6		36.0	•	38 4	(;	38.8	38.5	37.2	35.1	36.0	! (9.0	36.8	:	37.8	1 1	! !	32.8	39.3	43.2	1	36.8	44.9	40.8	39.3		7.00	33.0	36.6	40.2	1	1	39.3	1 1	41.7	35.5	36.0
TEST W	87	38.0							1	40.0	•				•		36 1	!	39.3	1	!	32.7	39.4	46.0	1 1	37.3	45.2	41.4	39.6	20.00	D 0	33	9.75	40.7	1	1	39.8	 	41.8	36.3	37 1
	85	34.7	Ľ	~	:	35.4	1	35.9	i	36.1	37.5	37.5	35.6	37.1	1 0	5.75	36.9	1	39.6	1	1	32.8	39.4	46.4	1	37.5	40.6	39.5	37.6	37.4	39.9	32.9	37.2	39.9	; !	1	39.4	1	41.4	T.	_
	83	35.0	•					37 6	:	39.1	38.6	37.9	36.0	36.8	: 0	30.0	35.6	1 1 1	42.1		1	33.7	39.5	46.6	1 1	38 4	44.7	40.1	99.9	38.5	39.7	33.8	37.8	40.5	! !	i i	40.2	i i	42.4	36.3	37.9
	8 1	34.2		•				37.1		38.6	39.3	36.2	35.8	36.6	1 6	36.9	35.4	1	41.4	!	-	33.2	39.8	45.6	1 1	37.1	43.9	40.	39.0	38.7	40.3	32.6	37.1	39.8	!	1 1	38.8	1	41.4		
	79	33		1			3		ı	38.6							36.1	!	42.5	1 1	*	33.6	40.0	47.0	;	37.1	43.1	41.1	38.8	38.2	40.3	33.6	38	39.9	1 1	! !	39.6	l l	40.2	;	37.6
	- 1	4.6	10	8	-	œ		œ	1	39.5	n	~	ທ	~	1 1	37.9	LO.	1 1	44.4	! !	œ	က	40.0	ဖ	1	~	ທ	*	40.1	o	0	(2)	∞ .	0	i i	!	39.8	1	41.8	œ	_
	75	34	35.6	36.5	37.4	34.9	!	37.0	36.3	39.3	38.4	38.4	35.9	38.6	1 1	38.6	34.0	1	43.7	1	29.1	33.2	40.0	46.2	1	36.2	43.5	41.7	39.4	38	41.1	33.0	38.4	40.0	!	1	40.2	1	41.5	w	_
	73	35.0	9	7	8	ဖ		8	ဖ	39.6	O	œ	ဖ	~	1	38.0	4	!!	44.2	1	О	က	39.7	~	1	~	(7)	O	38.7	8	0	m	∞	0	t i t	i i	40.4	1 1	~	G	36.6
	-	33.7	ъ.	7	۲.	œ	;	-	ω.	6	ö	80	ις.	7	!	φ.				i	σ.	IJ.	4.	æ	- :	œ	Ť.	7		ω.	ó.	4.	ω.	ö	1	- 1	•	1	Ε,	7	•
	69	i no	œ		00	· cc		36	w	39.2	o	~	w	96.		~	35		43		-	₹	3	O	*	~	~		ഥ	∞ .	ത	3	፟	39	ı	*	6	1	N	œ	_
v	ш×	Ξ	Σ	Σ	Σ	Ξ	Σ	: 72	Σ	Σ	Σ	Σ	Σ	Œ	Σ	Σ	Σ	Σ	Σ	Ξ	Σ	Σ	Σ	Ξ	Σ	Σ	Σ	Œ	Σ	¥	Σ	Σ	≆	Σ	Œ	Σ	Σ	Σ	Σ	Ξ	Σ
αO	⊅ €		n	n	ෆ	'n	· m	ני) ו	m	6	E	၉	က	ო	ო	က	ო	က	က	က	ღ	e	ო	က	ო	ဗ	ო	ო	က	ო	ო	က	က	၉	၉	က	6	m	က	ო	က
z	D ·	321	322	323	324	325	326	327	328	329	330	331	332	333	334	332	336	337	338	339	340	341	342	343	344	345	346	347	348	349	320	351	352	353	354	355	356	357	358	359	360

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX**---No data available (sacrificed)

*---No data available (died)

₩

42HE4J

TWENTY FOUR MONTH CHRUNIC TOXICITY/CARCINDGEMICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B6C3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

7	ឆ្នា 1 1	8 80	6.1	401-0	9 60	0.00 0.00 1.7.00
Õ	38 1 1	38 1	n	ww 44	10 4040	**
103	37.0	9 8 9	38.6	36.8 36.8 48.0	39.74	38.7.7.2.3.3.4.4.4.3.3.3.3.3.3.3.3.3.3.3.3.3.3
101			1 - 1 1	38.2 37.0 37.9 48.0	38.6 38.6 47.3 34.2 34.6	233 4 4 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
66		! !			39.9 39.9 47.5 35.1	110-060001-010
26	S 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	87.61	8.80 I I	ا د ن ن ن ن ن ن	8 6 6 4 4 6	1 0 0 1 0 0 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0
35	39.4	40.8 40.9 47.2 41.2	38.0	38.2 36.7 41.8 48.0	46.6 34.9 34.2	31.7.4 46.9 46.3 43.2 38.7 38.7 38.7 31.2 44.3 31.2 31.2
6	80 1 1 0 1 1	20 - E C	9.0	64.00		187 0.40 44 18 18 18 18 18 18 18
6	.			~~~~		**************************************
× 88	6 1 1 1	66.7 60.0 40.0 40.0 40.0 40.0 40.0 40.0	8.4 9	9.7.4	. 4 1 0 4 9 4 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	4 4 4 4 4 4 4 6 6 4 6 6 6 7 6 7 6 7 6 7
ST WEE!	~	0 10 10 0 m	0	- m m - i		
ir 	- 1 - 10	N 10 10 10 10 10	~ + 1 :	. r e c c c		10 T O 1 T 10 10 10 10 10 10 10 10
œ i	4 00	40004	ເວເລ	00444	ta amuau	
83	40.0 31.6 39.3	36.5 39.7 39.4 40.7	39.5	39.7 37.1 41.2 46.8	50.24 50.24 37.29 36.69	
20	41.2 32.1 38.6	36. 1 38. 1 38. 6 39. 9	37.2	38.6 37.5 40.4 47.0	42.3 48.0 34.3 35.0	30.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
61	1 1 7 80	. 6	39.8	38.9 41.3 45.2	4-14-4104	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
7.7			- 6 1 1	. a.o.a. r		237.4 239.6 247.1 247.1 248.9 248.9 24.0 251.8 38.6 34.0
75			- 6	-864-		335.9 444.6 55.6 55.1 73.3 73.3 8.9 8.9
e e	6 . 6 . 6 . 6 . 6 . 6 . 6 . 6 . 6 . 6 .	4 4 0 12 10 10 10 10 10 10 10 10 10 10 10 10 10	9.09	- 80 0 c	40 1 80 0 0 2 4 0 8 1 4 12 12 0 12	1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	9.7	0.000 0.000 0.000	1 9 4	- 8 - 10 c	0.04.0.0	0.0000000000000000000000000000000000000
o o	0.140			0.4 - 7 -	- C C + C C C C C C C C C C C C C C C C	000 000 + 00 + 1 0 + 1 + 2 + 1 + 2 + 2 + 2 + 2 + 2 + 2 + 2
	4 . 9 . 9	ัติต _์ ติดั	₹ 9	×4004	<u> </u>	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$
ωm×	EEEE	EEEEE	ZZZZ	ESSurra		
⊢α 0α0⊃α	0000		ოოოო	, , , , , , , , ,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
∢Z∺ ₹∢」 ZO ·	361 362 363 364	365 367 368 368	370 371 372	374 375 376 377	381 381 381 383 384	386 388 388 390 391 391 392 393 396 396 398 398 398 398 398

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; t_1 = 35.0 mg/kg/day RDX; t_2 = 175/100 mg/kg/day RDX **---No data available (sacrificed)

*---Nc data available (died)

T WEEK 7 89 91 93 95 97 99	9.3 58.9 57.1 59.0 58.6 68 8 4 47.6 47.8 45.3 44.2 44.2 9.3 58.9 57.1 59.0 58.6 68 9.3 10.7 40.7 46.8 44.4 36.8 36.9 47.2 47.2 48.7 48.7 48.7 47.2 48.9 47.2 48.7 48.2 48.2 48.3 48.7 48.2 48.3 48.7 48.2 48.3 48.7 48.3 48.7 48.3 48.7 48.3 48.7 48.3 48.3 48.7 48.3 48.3 48.3 48.3 48.3 48.3 48.3 48.3	RDX
TES 83 85 8	60.1 58.6 60.0 58.9 58 31.0 27.7 27.0 %	; 5 = 175/100 mg/kg
71 73 75 17	58.4 59 4 58.9 60.7 47.6 48 8 49.4 49.4 47.6 48 8 40.7 46.9 48.1 48 9 40.7 46.9 48.1 48 0 40.9 46.7 41.7 40 8 42.1 43.7 41.7 40 8 42.1 43.7 43.3 8 44 7 44.6 46.3 43.4 41.2 40.9 42.1 43.7 44.3 44.3 38.2 38.9 37.3 38.5 38.2 38.9 37.3 38.5 38.2 38.9 37.3 38.6 40.6 42.2 43.4 44.3 44.3 44.4 45.9 47.9 49.8 45.7 47.9 49.1 44.3 48.9 48.4 48.5 51.0 48.9 48.4 48.1 44.8 48.9 48.4 48.1 44.8 48.9 48.4 48.1 44.8 48.9 48.4 48.1 44.8 48.9 48.1 48.1 44.8 48.9 48.1 48.1 44.8 48.9 48.1 48.1 44.8 48.9 48.1 48.1 44.8 48.9 48.1 48.1 44.8 48.9 48.1 48.1 44.8 48.9 48.1 48.1 44.8 48.9 48.1 48.1 44.8	35.5 mg/kg/day RDX
⊢ α ७αο⊃α		

Q

(

	104			! ! L																		42.7	_	38.8		- 1	•				34.0				
	103	1 1	۲,	,	او	-		7	۲.	4 1		1	•	١,	0		. σ	Ö	ъ.	1	١.		ö		ດ໌ແ	; i	- 1	ŀ	œ (<u>.</u>	•	, ;	ı		40.7
	101		ლ.		- 1	-	42.7	7.	ភ ខា	. i	7	1	40.6	!	٠.	13 0	o c	; -	36.3	!	! (42.6	o.	38.0	ນ ດ	; ;	1	1	φ,		37.3	. !	1 { 1	1	40.8
	66		ن	j,		+		6	8	e		;		!	ö,	4 a	. c	ი		1	١,	43.6			ů,	: :		1	9	د		: 1	1	ŧ	40.7
	97	1	47.2	57.0	57.3	300	42.1	47.6	40.8	51.7	38.5	!	41.5	! !	39.3	34.3	7 - 0	45.4	36.8	:	1 .	1 1 1 1	40.8	39.2	35.8		1	1	37.9	36.9	36.7	? ! ? !	t 1	: :	40.3
	95	ŧ	48.4	1.53 1.53 1.53	55.6		4.2.2	48.8	39.5	53.9	38.4	1	43.1	!	39.9	33.8	. C.	46.5	37.1	i i t	(97.6	40.6	39.6	32.0 20.0	0.1.0	!!	1	38.1	37.3	3.96	. 1	! ! !	1	40.2
	93	1 1 1	48.6	<u>.</u> ,	9	ן מ		7	<u>-</u>	ທ່ ເ	38.0	1	42.7	!	ດ ເ	33.9	0 C	; ;	8	; ; ;	1 (0.8	- -	39.6	٠ و	: l	*	1	6	٠.	37.1	:	:	1	41.4
	91	!	49.2	44.4	53.9	. 0	44.0	47.6	42.0	56.6	38.8	1	42.9	!!	39.9	34.4		47.3	38.8	} ! !	ļ. :	44.6	41.1	39.6	36.1 26.6	0.00	ဖ	•	O	~ 1	38.1	7 1	,	1	41.5
Ä	88	; t	48.6	45,1	57.9		42.1	47.2	42.7	57.3	38.5	1	42.2	1	39.7	34.6	45.6	47.1	38.1	1	40.5	44.6	40.8	40.2	35.5	0.10		•						:	•
EST WEE		1	ហៈ	7	~		מ פ	o,	æ,	4 () m	!	9	į	Ψ,	œ 0	ם מ	٦,	N	!	4 1	- 1	7	σ,	u, n	9	0	₩.	9.	o,	o c	۰ ج	. ;		
۰	282	1	7	9	Ø		\circ	9	4	۲,	37.		~	1	σ.	4 (າ ເ	o G	38.0	1	44.1	4 1	ಂ	39.3	S (ρı	*	9	0	8	o <	t a	•	1	42.6
	83		50.4	50.5	58.6	, ,	4 6. 50 4	44.7	43.2	58.2	38.7	. 1	43.9	1	39.4	34.6	- 4	7 2 2	39.4	1 1	44.4	45.2	41.2	40.5	36.8		33.3	37.1	40.3	39.5	40.4	5.00 5.00 7.00	, i	1 1	43.6
	81	!!!	۲.	o,		1 0	הית	۲,	رى رى	α.	•	; ;	•	;	ດ່	4. (, u		ŀ	•	e.	ļ .	•	٠.	: ;	ω.	7	6	6	•	, ,	:	•	•
	79	- 1	ö		•	! (د		4	۲.		, ,	Ю.	1	ю О	4.	:: (ي د		1	•	ဗ ၂	0		1 1		(5)	7.	6	8	•	٠	: ;	•	
	77	í							4	٠. ا		. :	ω.	!	ຫ	4 (N •	٠.		1	о С		-		6	9 1		7	6	თ	6 (٠.	0 1	1	•
	75	1	7			: :	٠, ٣	. 4	2	6		; ;		ŀ	æ.	ი	m	2 L		i	•	რ	1 0		0	. :	4		6	8	•		. !	t	
	73	1																				44.1				. 1							. 1		
	7.1	1 1	9	9	ın.	1	· +	- ო	7	2		: :	7	1	7	4.				1	ຜ		¦ -			ا	4	. 60	6	ω.	0	ف د	. !		
	69	1 1	6	Ġ,	54.	1 1	٠ د		-	÷		: :	42.	- 1	7.	e.	- ,	, c		1	44	43.8	֝֟֝֓֓֓֓֝֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓		<u>.</u>				60	7.	œ :	n	. i	- 1	4 .
ν	ш×	, , , ,	u.	ц.	LL I	LL .	LL LL	. L .	. 11	ı	E:	E 3	Ξ	Σ	Œ	Σ	Æ :	ΣΞ	EΞ	Σ	Œ	Σ:	£Ξ	Σ	Z :	¥:	EΞ	Ξ.	Σ	Σ	Σ	Σ:	ΞΞ	Σ	Σ
⊢ α ७α0	۵ د	6	က	က	n	n i	ကျ	n (1	e 6	6	4 4	; <	4	4	4	4	4	4 4	1 4	4	4	4	4 4	4	4	4 •	7 4	4	4	4	₹.	4 1	4 4	4	4
⊢≅ <j th="" z<=""><th>o ·</th><th>441</th><th>~</th><th>~</th><th>℧</th><th>4</th><th>♥ ₹</th><th>3 7</th><th>4</th><th>ß</th><th>ום מו</th><th>יש ה</th><th>) IU</th><th>מניי</th><th>LD.</th><th>ro.</th><th>ហា</th><th>ΩL</th><th>o co</th><th>· w</th><th>ம</th><th>6 (</th><th>O U</th><th>O (C</th><th>o ·</th><th>uo t</th><th>~ ~</th><th>٠.</th><th>٠.</th><th>~</th><th>~</th><th>~ *</th><th></th><th>- 1~</th><th>œ</th></j>	o ·	441	~	~	℧	4	♥ ₹	3 7	4	ß	ום מו	יש ה) IU	מניי	LD.	ro.	ហា	ΩL	o co	· w	ம	6 (O U	O (C	o ·	uo t	~ ~	٠.	٠.	~	~	~ *		- 1~	œ

35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; **---No data available (sacrificed) *---No data available (died)

3 = 7.0 mg/kg/day RDX;

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

TEST WEEK

0 20

	104	38.2	-	35.4	35.6	30.8	38.7	32.6	1	:	35.2	1	1	1	1	36.0	1	1	!	1	37.6	1 1	1 ;	1	1	40.1	35,6	! !	1	35.2	!	35.3	\$!	1	34.3	33.0	34.3	:	36.3	37.9	39.5
	103	37.1	1	36. 1	32.0	32.3	38.2	32.7	1	1	34.9	1		1	1	36.3	1	1	1	1	36.9	1	1	!	1	40.3	35,4	1	1	34.8	!	34.8	1 []	1	35.1	33.4	34.0	1 1	35.9	39.0	37.8
	101	38.8	l l	37.4	35,4	33.0	38.4	33.2	t 1	1	36.1	1 1	38.6	1 5 F	!!	37.2	i	! !	1	1	35.4] } 	1		1	40.6	35.0	!	1	32.0	1	35.3	t ; 1	1 1 1	34.7	33.8	34.2	!!	36.3	39.0	37.2
	66	39.1	! ! !	36.9	35.2	33.3	38.5	31.4	*	: : : : : : : : : : : : : : : : : : : :	35.5	!	37.0	l t s		37.9	1 1 1	32.3	!!!	1	35.2	1 1 4	:	1	1 1	41.5	35.3	i i i	1	35.8	1	33.4	} 1 1	1	34.8	32.0	34.0	!	35.3	37.9	37.4
	97	38.7	1	35.6	35.1	32.9	38 6	33.2	50.6	33.9	35.3	!	35.8	!	43.8	38.3	1 1 1	34.0	1 1	1	34.9	42.6	1	; ;	!!!	42.2	35.3	1	1	35.7	: 	35.3	!	i i	34.6	34.2	34.1	; ;	35.8	38.1	38.0
	95			36.4																																					
	93	39.8																																							
	i	38.6																		•																					
	89																																								
	87			3583																																					
•	82	ŀ																																							
	i	i																							•																
	83	40.0	;	35	35.	E	-	35	39.	34.	38.	40.	40	;	37.	43.	l	37.	1	41	36.	44	į	39	37.	46.	36.	i	1	36.	41.	35.	1	;	36.	37.	34	1	37.	39.	39.
	81	40.5	1	35 1	35 5	S. CE	40.4	34.9	38.8	33.6	38.1	41.1	40.2	;	36 5	42 8	!	36.6	!	41.6	36.1	44.6	į ;	40 +	38.8	46.2	36.6	!	i	36.1	40.9	35.5	! !	1	36.4	37.8	34.2	!	35.9	39.2	39.
	79	39.5	;	34.0	34 B	34 1	40 4	34 0	39 (33.7	38 0	41.5	39.3	:	37.3	1	!	36.6	:	41.6	36.1	44.1	1	1	39.5	46.6	36.2	1	:	36.5	40.8	35.4	! !	1 1	1	37.4	:	!	36.9	40.0	38.5
		40.5	!		ហ	۲.	æ	ω.	8	6.	- .	ø.	۲.	1	ស	₩.	!	۲,	1	2.2	9	5.5	!	6,4	8 4	ω.	7.1	:	1	-	7.	6.3	ļ	1	7 6	ស	5. 15	1	37.5	٣.	-
	75	39.7	. 1	34.9									40.1	i	36.8	44.2	1	36.8	i	41.9	35.1	46.7	1	39.0	38.0	46.0	36.6	!	!	35.7	41.2	35.0	1	ŧ !	ω	•	34.1	•	36.8	•	
	73			35.9				•			37.4	41.5	41.1	1			1	•	•	•			ι	39.7				1	1	36.4			1	1	7.	•	34.4	1	37.6	39.6	•
	7 ;	40.3	1	6.7	5.1	3.4	9.3	4.7	8.6	5.3	o.	2.3	0.5	!	4.	છ. 4	!	ņ	!	2.2	9	7.5	!	9.6	3.0	10	7.0	-	1	7		5.1	1	:	9	ر. س	33.4	ı	۲.	٠.	
	69	0.3		80	ဖ	9	8	7	0	m	ιυ.	80	-		~	o.		~		N	<u>ص</u>	9		80	o,	·-	w	!	ry.	∞	ø	-			8	7	6		-	0	0
	:	4	∹∺	35	n	c	7	n	m	က	n	4	4	**	e	4	*	က	*	4	6	4	- ;<	6	n	7	e.	* *	4	က	4	n	**	*	e	E)	က	** **	က	4	က
u	×	. ≨	Ξ	Σ	Σ	Σ	Σ	ž	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Z	Σ	Œ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ
=) <u>o</u>	7	~	4	4	4	4	4	4	4	4	4	4	4	₹	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	7	4	4	4	4	4	4	4
: c	, .	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	156	197	198	199	000	501	502	303	504	505	909	507	508	909	510	511	5 12	513	514	515	516	517	5 18	5 19	520

9

0

٩

٩

٩

٩

٨

Ö

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; t_1 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

**---No data available (sacrificed)

*---No data available (died)

TWFNTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

< Z - ∑

E 4 📙 🤅	χ (O α (,								F		}								
20	۽ د ه	v ш ×	7.1	7.3	75	11.	79	8	83	85	.ς e	Х. 89	91	66	95	97	6	101	103	104
	. <				1 1	; ; ; ; ; ; ; ;	; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;	:	1	 	;	!	:	1 1 1 1 1		1 1 1 1 1 1 1 1 1 1	1 1	1 1 1 1 1	; !	
200	. 4	: : -:	,	!	1	ij	!	1		i i	ŧ		:	1	1	1	!	l l) ; 1	i i
523	7	; ; ; -;;	i	1	- 1	•	1	1		1	ļ		ť	1 1	! !	1	1	1	1	1
524	4	47.	47.	47.4		45 9	45.9	~		43.6	0		ĸ.	43.2	41.4	39.1	39.1	35.4	31.7	1114
525	4	;	1	;	1	; ;	:	,			1		;	:	i i	;	1	Į 	1 1	1
526	4	33.	34.	33 4	Э.	m	33.2	<u>د</u>		۲. ب	1		!	1	1	1 1 1 1	1 1	! !	1 1	1
527	4	43	44.	44.3	ŝ	44.8	46.0	6		o,	6.2		c,	45.2	46.1	46.8	48.	46.6	46.7	46.0
528	ব	43.	45.	42.8	8	0	44.4	0		- (4.7		- (45.0		44.2	46.9	45.8	44.9	45.0
529	4	42	9	41.6	ნ	01	42.3	<u>ر</u> د		0, 0	- c		ب به	43.0	n	43.43	43.7	9.70	25.50	27.0
230	4	44.	0 :	40.	o o	ത	18.	n (2 0 C	- (ຄຸ	5 . C	٠,	33.6	7.70	5 6	9 0	0.0
531	4 4	40.	9 45.0	5, 0 0, 0	40.5 40.6	42.5 9.7 9	40.5 7.7		38.2	38.2	ى بو	30.4	- 8	- 6	40.8	0.00	4 10	90.00	40.0	4.4.
25 R	; <		. !	0.10	: :	• 1	: :	. !		: !	. 1		? !	2 1	; ;	1 1	1))	
1000	1 4	66	42	41.2	6	Ţ.	40.5	~		4	5.4		۲.	33.4	ი	32.9	32.5	32.9	32.6	33.3
535	4	42.	44	43.7	43.8	44.0	45,2	4		<u></u> ဘ	0		2	42.6		40.8	34.1	! ! ! *	1	!
536	4	32.	32	27.2		1	1	ļ		:	!!!		1	1	-	1 1 1	1	i i	1	1
537	4	43.	40.	41.6	6	43.3	38.6	80		e.	ĸ.		е.	40.3		40.4	39.6	37.6	37.6	36.0
533	4	1 4 4 4	i	1	1	1	1	!		,	1		ļ	!	1	!	1 1 1	1	!	1
539	4	43.	42.	45.1	ь	Ç	44.7	ı,		ဖ	5.9		-	44.6	4	44.4	44.4	₹ 1	44.2	45.3
540	4	44.	45.	43.9	ი	4	42.8	4		က	4.6		ψ.	43.1	e. ۱	42.6	42.6	N I	43.2	43.7
541	4	45.	40.	44.6	7	9	44.8	φ,		-	0.9		٠,٠	47.7	9	46.0	48.1	ומו	45.8	46.1
542	4	38.	37.	38.2		-	37.4	<u>س</u>		4.	7.6		ص •	36.5	19	36.3	36.2	· I	ļ. (1 1
543	4	46.	45	46.9	6	CO t	49	- (m r			N 0	4.7.4	٠,	4 . 6	2 . c	• (40.4	2.0.5 U II
544	4 .	43.	46.	44.6	8.2	45.6	1 5	i c		ი -	<u> ر</u>		א ה			9 0	0.00	7 ! Y !!	2:1	? !
242	* *	. 44 C	4 G	4 C	5 ਵ	* 6	1 0	40		- c	0.4			30.00		37.5) !) !) **		1	!
547	1 4	. 6	43	44	. 4) 4	44.2	ι α		មា	2.0		o.	40.8	7	35.4	1	1	į	1 1
548	ব	4	43.	42.8	6	4	43.4	8		~	5.5		ιū	44.6	4.	42.6	43.1	41.1	41.4	40.7
549	4	38.	38.	40.3	œ.	9	37.6	80.		~	5.0		<u>ه</u>	42.6	е Э	42.5	45.0	42.4	40.4	40.7
220	4	37.	39.	37.2	ö	37.4	39.9	ဖ		Ŋ	7.2 ;		!	!	1	! !	 	1	\$ 1 \$ 1	1
521	₹ '	! 생생 생	i	! .	: (1 (. •			י י י		1 1	; ; ; ;		1 1	 			
552	4 .	42.		2 .	ກໍເ	7 (n .	; (, n	? 0		c	7 00	a	27.2	27 5	95	98	26.35
553	4 4	. 88	5 4	7 0	ກ່ປ	y c	70.7	, d		9 4	9.0		۶α	40.4		48.8	48.8		47.8	45.1
10 10 10 10 10 10 10 10 10 10 10 10 10 1	1 4	29	27.	27.5	26.7	28.4	27.3	ဖ		. 63	<u>ا</u> ۳		0) 	; ;	1		1	1	-
556	4	***	!	1 1	1	- 1	! ! ;	!		:	1 1		;	! !					!	1
557	4	57.	57	58.4	7	0	59.6	-			ır.		evi	58.4	•	57.3	59.4	57.3	54.9	55.6
558	4	54.	57.	57.8	4.	59.0	57.8	ស		80	8.1		ဖ	54.5	₹.	θ,	54.1		54.0	54.0
529	7	32	31.	33.0	1114	;	1 1 1	!		:	-	ı	į	-	! !	ł	1 1 1	ŧ	;	1
260	4	41.	43.	39.8	÷	42.3	42.4	o.		40.4	44.4	, 6.21	ო.	42.2	•	40.4	40.5	42.2	42.4	43.4
		P 0N*	data ava	available	_	(died)														
		•				•	•													

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX**---No data available (sacrificed)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCIANGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGG3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

		104	39.4	1 1	41.7	1	1 4	40.4	45.5	39.3	32.9	33.9	1 6	אט ה ה		!	46.9	38.4	41.1	43.6	39.6	4.6	40.5	36.6	1 !	 	1 0	2.00	1 1		38.4	40.7	37.0	34.7	31.7	45.1
		103																						36.8				٠ ۲				٠.		34.8	m ·	_
		101	ຸ່ເຄ																																	
		95 1(40.4																																	
		8 :																																		
		6	8 40.4																												. 6	י פר	36	35	£ ;	4
		95	39.8																																	
		93	39.0																																	
		91	39.1	:	42.0	1	: :	7.08	ה ה	42.5	33.9	38.5	48.3	27.0	9 6	. !	46.6	40.1	40.0	45.8	41.7	43.5	7 + 0	38.4	1	! ! !	29.4	37.5	40.6		38.4	ט ה ה	38.	36.9	34.2	45.7
	WEEK	83	40.1		42 3	•	, (32.0	40.07	41.7	33.3	41.1	48.	28.5	2.0 2.0 10.0	1	44.9	40.0	39.4	45.6	40.8	42.9	. 0	38.1	1	1	42.2	38.8	40.1		38. 10.	ος סיר	37.0	38.6	33.9	43.9
	TEST W	87	38.1		5 CF		, 1	37. 10. 10.	2 7 7	42.9	35.0	40.2	48.3	28.4	20.00	. !	46.4	40.8	40.9	44.1	39.7	43.4	; ;	40.5	1	 - -	51.0	38.5	41.1	1 1	38.0	0 F	17.0	37 2	34	43.5
	-	35	1 1 0																																	
		83	0 8																																	
		- ;	40																					38.6												
		6	42.2 42 38.7 40																																	
		7 7			7	1	ın:	ın (e c	· -	- 🕁	₹	60	- (ο :	ď	െ	LC.	0	~	_	, (2 4 6		ı	ID.	.	0	,	σ. :	ກເ	V (v 60	ស	0
		7	42 33	1	7	!	29	35	4 4	1 4 7 4	6	39	47	င္က !	4 (2	4	40	4	48	43	43	١;	- 6) :	•	47	ဗိ	6	•	36	38	4 C	66	33	4.
			42 37		~		n	ი.	4 4	* 4	7 (7)	4	4	n,	4 (י	7	r en	4	4	4	4	•	4 4			4	ro ·	n		rs c	י פי	4.6	3 (2	(1)	4
		73		i		;	ë	е.			່ະທ		80	<u>.</u>	٠ س					7	-	ċ	1.		: !	- 1	7.	ö	•	1	- 0	o	<u> </u>		4	Ψ.
		7.1	1 1- 0	1	43.6	!	35.2	35.0	45.7	27.0	3.4	40.8	46.0	31.7	46.8	32.	707	38.4	40.8	46.8	42.8	41.6	; ;	4 2 . c 4 . c 5 . c 5 . c 5		1	46.4	41 5	40.8	1	37.9		4. v.	39.7	34.4	42.9
		69	48.7		42.3		39.9	33.3	44.2	4.0	2 C	40.4	47.4	31.6	42.5	ກ. ກໍ	1 4	200	42.4	45.5	42.4	41.3	***	39.0)	1111次次	43.6	40.1	41.8		36.4	38.6	42.7	37.5	32.6	41.1
			! ! !																																	
ن ن			4.																																	
	_	٠ .	561 562	. ~	. 😝	ıO	(D	7		m (5 +	- ~	(n)	4	ពេះ	.	~ c	0 0	, 0	,	~~	6	4	in a	۰, ۵	- α	၈	0	- -	8	6	₹ 1	ن د	9 1-	- 60	, G ,

**---No data available (sacrificed) TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX*---No data available (died)

42-54J

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX; IN IHE BGC3F1 MOUSE INDIVIOUAL BODY WEIGHT MEASUREMENTS (9)

< Z - Z < J

81 83 85 87 89 91 93 95 97 99
85 87 89 91 93 95 97
93 95 97
93 95 97
95
;
2 1 1 1
101 103 104
41111

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; t=35.0 mg/kg/day RDX; t=175/100 mg/kg/day RDX **---No data available (sacrificed) *---No Jata available (died)

ją. Proma i mosposowy na rozpowyczna manastropowy mposposi mposposi mparostropowy i meskoskowy w posposi posposi i pospo

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX} IN THE BGC3F1 MGUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

z	< O :	ΩII									_	TEST WEEK	EK								
	٠.	×	69	7.1	73	75	77	79	81	83	85	87	83	91	93	95	97	66	101	103	104
641	ស			; ;	! !	1 1	1 1	1	1		1 1										1
642	r,		47.4	41.0	39.4	38.6	39.9	39.7	39.6	39.4	38 6										35.9
643	ហ			1 1	:	1 1	1	:	1		•										1 1 1
644	ល			:	:	*	:	,			•										1
645	ro.			:		•															1
646	ហ			;	: :	:															1
647	S			36.3	36.0	35.9	36.2	ř. «			/ LL										33 8
648	ហ			!	;	1 1	• !	1			;										!!
649	ល			;	!	1	:	:			;										1
650	ល			i : :	!	1	1 1	! !			;										1 1
651	ល			41.7	41.9	40.5	47.2	41.7			40.6										41.6
652	ល			44.5	44.4	42.8	42.4	42.4			42.3										42.2
653	ជា			38.3	37.5	36.1	38.6	38.2	_		37.1										38.4
654	រ ខា			34.5	34.3	34, 5	35.0	34.8			34.4										33.8
655	r S			42.2	42.5	4.1	41.8	41.5			40.2										39.2
656	ល			34.9	34.0	33,3	34.6	35.1			34.4										1
657	ស			1	1	!!!	!	! !													1
658	ល			1	1 1	1	1	!			1										1 1 1
629	ស			42.6	40.5	40.1	39.6	39.1			36.9										34.2
099	ប			37.2	37.1	36.7	36.8	36.7			36.3										33.B
661	មា			!	1	1	1	1			1										1
662	ល			40.6	40.6	39.5	40.4	39.3			38.6										36.8
663	S)			1 1 1	1	1	1	1 1			1 1										1 1
664	ស			!	1	 	!!	1			!										:
665	ស			l !	1	:	1	1			! ! !										1
999	ល			1	t s i	! !	 	1			1 1										!
667	ល			1	ł ł	1 1	:	• • •			:										! !
668	ល			!!	!	1	1 1	:			!!!										1 1
699	ល			1	i !	! !	t t	ŧ 1			 										! !
670	ល			: : !	1	1 1	!	1			! !										1
671	ស			!!	 - -	1	1	 			1 1										i !
672	ល			1	:	1	1	! !			1 1										!!!
613	ស			38.5	37.6	37.6	37.8	38.0			36.9										36.6
674	ıc:			1	1	! !	!	1			!										1
675	ស			13.5	43.9	43.7	43.0	43.0			41.9										38.4
9/9	ır.			10.5	39.3	40.0	40.9	40.9			39.6										33.3
677	IJ			1	!	! !	! !	1 1			# 										i i 1
678	rv			11.9	42.0	39.3	43.0	43.3	40.0	42.4	39.0										43.0
619	ស			:	:	1	:	:			!										} 5
680	ល			1 1	;	1 1	1	:			1 1										1

(4)

9

()

٩

٥

٩

W

Ö

6

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

*---No data available (died)
**---No data available (sacrificed)

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCIMOGENICITY STUDY OF HEXAHYDRO-1,3.5-TRINITRO-1.3.5-TRIAZINE(F.DX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

		104		34.6	9. v	D 1	1	!	; ; t	36.5		30.7	7.00	23.7	: !	;	1 1	1 2	28.4	29.7	i :	!		35.9	34.9	:	1 1	1 1	! !	l			1 1	1 1 1	!	!!!	1	! !
		103	; ;		0.0 6.0	7 : 4			!		1	٠.٠	4 (0.0				9									!	t t	!	1 1	: !	
		101		34.7	36.2	رة 1. د	1	:	1 2 1	36.0	1 (30.6	- 1	- C) !	1	1 (1 1		•	34.6	: : : :	1 1	36.8	35.0	1	! !	t I	1 1		1 1		1	1	1	! !	!	! !
		66																															ŀ	:	1	; 1 1	1	\$ 1 1
		97	i i																														1	1	1 1	1 1	:	1 1 1
		95																																		ı	1 1	! !
		93																																		!!	1 1 1)
		0)	35.6	36.6 1	37.5	5 · · · ·	!	1 1	1 !	32.2	1 1	30.8	0.0	7 0		1 1	1	;	27.9	31.8	37.6	\$ 1 8 1	 	36	38.0	1 1 1	;	1	!	í ! !			1	:	1	!	1 1	! !
	F.F.	88	40.0	35.6	38	5. 'S	:	1 :	; ; t	31.8	1 1	3. T	32.7	40.0 2.0		1	;	1	28.8	ю (9. ve	t 1	: :	37.9	36.9	1	1	!	;	! !			;	:	1	1	;	1 1
	TEST WE	87	40.3	37.1	37.7	D. 15	1	: :	! ! !	33.3		31.6	5	40.0 20.0	7 1	} ! !	!	!	28.9	32.1	36.4	1	; ; ; ;	8	40.2	1	!	1	1	! !			1	;	1	1 1	1	1
		85	42.6	36.6	38.3	38 2	1	1	1 1	33.7	!	32.4	32.2	50		1 1 2	1	1	29.3	31.0	37.1	! !	;] i !	39.7	40.0	:	6 1 1		i i i	t 1 1	i		1	1 1	1	;	1 1	!
		83	44.6	35.6	37.6	9.19	1 1	1	! !	32.2) 	30.5	32.1	9.5) ! !	1	:	1	31.2	31.0	37.3	i :	1 ! 1 !	38.1	40.8	1	1	l i	:	!	! ! ! !		!		;	} ! !	1	!
		8 1	45.8	36,3	37 5	۵. / ۲ ۱ . ۱ . ۲	1	;	1	33.1	1	31.2	32.0	5. u	0 1	!	!	:	32.7	32.2	37.8	1 1	! ! ! ! ! ;	38.2	40.6	!	! ! !	1	1 1 t	! !			1 1	1	1	1	1	!!!
		32	, ,	36.4	37.2	5.75	1	1	1	35.2	45.0	30.5	34.	9.00	P 1	1	1	1	33.3	32.0	37.7	1 2 3	t 6 t 1	27.2	40.6	1	1	} 	; ; !	1				:	:	! !	1	5 1 1
		77	44.0	ទ	٠.		;	ì	;	6	4			288	- ;	- [1 1	I t I	4.	31.4	D.	1	1 1		44.3	1 1	1	1	!	! ! !		; ; ; ;	1 1	1 1	1	!	1 1	!
		75	43.8	ທ :	ف	. i	1	1	:	ď,	e.	<u>.</u>	'n	ж. ш	. !		- 1		e,		7		1 1	ı u	٠.		1	1	1	1		! ! ! ;	1	1	1	!	1	1
		,	4	35.6	36.5	37.2	;	1 1	1	33.0	42.8	30.6	31.6		44.0	:	1	f I 1	32.7	30.5	36.6	! !	} 	200	40.1	! ! !	1	! !	!	! !	!	; ;		1	1 1	:	! !	1
		-	44.7	w	w :	ועג	:	l i	!	เขา	_	_	♥ I	39.4	ગ ા	-	1	1	C	33.0	ເນ	1	1 1		39.7	;	1	:	1	:	! !	1 1 1				!		
		•	. 60																						33.3													
	ις	.×																																				
⊢ α	¢ 0 =) <u>a</u>	5	រេ	ស្រ	ស ព	ı ru	נו	D.	ខ	IJ	ស	ល	ព្រ	ດແ	ט ני	ល	ស	ជា	ល	ម រ	וה ו	បដ	ם מ	ល	ស	Ŋ	ស	ល	n ı	n r	ប្រ	ם נו	n n	ខ	ខ	ព	ស
42H 2 4J	20	· •	681	682	683	684	686	687	688	689	069	691	692	693	6 0 0 0 0	969	697	869	669	700	701	702	207	704	206	707	108	109	7 10	711	7.7	9 - 1	1 7	716	7117	7 18	7 19	720

*---No data available (died)
**---No data available (sacrificed)

TR Group 1 ==

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRD-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL BODY WEIGHT MEASUREMENTS (9)

		104	1 1 1	1 (29.0	1 1	37.9	1	! !	i k	1 (2.6	40.0	36.8	31.2	29.9	i S Į	 	!	t t	34.6	29.8	i t	1 1	4	! !	! !	! !	1 1	24.1	1	! !
		103	1												_													. •	·			
		0	 																													
		86																												24.8 2		
		1																														
		97																												8 24 6		
		95	1																													
		93	1	!	28.4	1	39.5	1	1	1	1	33,2	40.5	39.7	32.8	30.2	1	i i	39.7	1	40.8	31.8	1	1	38	1	1	1	34.7	25.5	1	,
		91	1	!	28.8	;	39.3	1	1 1	1 1	!	33.5	40.8	40.4	30.4	30.6	!	1	38.8	-	40.0	31.6	1	i t	39.6	!	1	1	35.7	26.0	1	1
į	WEEK	89	! !	1	29 0	í f	, 0			t 1	i ! !	33.3	40.8	40.:	30.1	30.1	!!!!	:	36.7	1	41.8	31.8	t •	!	39.9		1	!!!	32.6	25.6	! ! !	! !
	EST WE	87	1	! !	29.3		40.4		:	! !	1	90.4	40	40.0	28.7	30.4	1 1	1	36.8	1 1	41.5	32.3	:	;	40.5	1	ŧ i	!!!	35.5	26.4	1	1 1
	_	85	1 1	:	7 60	:	93.0	1	1	:	! !	32.9	10.7	39.6	28.6	31.0	1 1	:	35.2	1	38.8	30.9	i	1	39.8	1 1 1	1 1	1 1 1	35.4	55.6	1 1	!
		83																												26,9		
		-																												27.4 2		
		8																														
		79																												26.8		
		77	!	1	29.7	;	.12 6		!	1 6	!!	34 2	41.3	417	28.0	30.8	1	1	40.5	1	43.0	32.4	l l s	!	39.5	1	1	1	35.2	26.6	1	l I
		75	: ! {	!	28.6	1	40.5	†	1	i i	1	32.0	40.5	40,5	27.5	29.3	1	1	38.8	:	39.2	31.0	!	† ! !	38.1	1	1	!	33.6	26.3	i	1
		73	1	1 4 5	28.7	1	43.4	! !	; ; 1	1	1 1 1	32.9	39.4	38.8	26.8	30.8	! !	1 1	41.6	1	41.4	30.5	!	!	37.6	!	1	1	34.8	26.5	1	į
		7.1		;	29 4	:	44.6	;	:	; ;	; !	35.4	41.8	39.1	27.	30.5	!	1	41.2	1	41.4	30 8	:	1	38.0	1	1	1	35.3	26.0	1	1 1
		69																	_													
		- 1 1 1	** 	*	7	-;:	~	-;<	- ;:	*	*	e	n	4		ı m	*	∹:	. 4	-3:	. 4	ິຕ	**	**	က	**	⊹ ∶	4:	, M	C	*	ポポ
	νm	×	 14	Ŀ	L.	L	L	Ľ	ıŁ	<u>. </u>	LL.	u.	ų.	ı.	. u.	. L L	4		. 14.	. L	. t.	. ц.	ш.	ъ	:1	ш	u.	Ŀ	. ц	ــا .	L	u
ල ස	0 0	اما	5	ιυ.	ស	ល	ល	ល	ល	ប្រ	ស	ເດ	ហ	ប	មា	ព	ហ	r.	ហ	ď	e un	ហ	ស	ıŋ	រះ	ស	រប	រប	េ	ល	ល	ស
ب	Z C		721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	427	739	740	741	742	743	744	745	7.46	747	748	749	750

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX**---No data available (sacrificed) *---No data available (died)

()

(3

8

٣

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINGGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (9/day)

	25				•		•		•	٠	•		•	٠	•		٠	٠	٠.	•			•			5.1		1	. 4 . 8	•	
	23	4 4 6.9							•	•	•		•	•	•				٠.	•	•		•	•	•		•	1		•	
	21	4.4	4.4	- -	9.4	4.6	9.6	4 4 5 4	4	4.	4.4	4.	4.4	4.4	4.4	. 4	4.3	4 . G (4 4 5 6	5.7	. r	5.7	5.7	4.6	4 4 5 A	9.4	4.6	4	4 0.0	9.0	D
	19	4.4								•					•					•				•		٠.	•	1		-	
	17	2.4			•	٠.	•		٠.	•	-, -		•	•	•		•	•	• .		•		•	•	•		•	1	. r.		
	15	4 4 R R	4 4 10 11	• •	•	٠.	•		· •	•	•		•	•	•		•	•		•	•	• •	•		•		•	1			
	13	4.4	4.4	•			•			•	•				•			•					•	•				1			•
	12		. .		•		•			•	•			٠	•	٠.					•		•		•		•	3			٠
	-	4 4 6 6		•	•		•		•	•			•	•	•	٠.		•		•	•		•	•	•		•			•	•
,	, Ç		10 m				•		٠.	•	•			•			• •	•			•		•	٠.	•		٠.			_	٠
¥ 99 14		0 S			•		•					•		•	•	• .	٠,	•	•		٠		•	•	•				• •	•	•
TEST	,		1				•			•	•	•		•	٠			•	•		•		•	•	•		•			•	•
	7	20.0		-	•	٠.	•	•	٠.	•	•			•	٠			•					•	٠	•		•	•		•	-
	φ		ຸ ທີ່ ເບີ				•			•	٠				٠			•	•		•		•		•			•	ດທ	5.	n
	ນ		900				•		٠.	•	•			•	•			•	•					•	•		•	•			5.
	4	1	4.	ਰ ਹ ਰ	4.	4	4	4	4	4	4 4	. 4	4	4	4.	4.4	4	4	4 4	ı,	ທ໌ ພ	ຸດ	ທ	4	4.4	. 4	4	ب ا		ທ່	S.
		4.2					•			•	•			•	•	•		•	•	• •	•		• •	-	٠		٠.	•	-		•
		4.7	4	4 4	រប់ រ	ກ່ຽ		ທ. 4	4	4	4.4	4	4	4	4.	4.4	4	4	4.4		ທ່າ	ດີທີ		4	4, 4	4	4	<u>ن</u> ن	ဖ် ဖ	ဖ်	6
		10.R	່ທີ່	ທ ທ	4.	4 4	4	4.4	4	4	4,4	4 R	ຸທ	ស	ເບ ເ	ກ່ ແ	. ທ	ស	ນ່ໝ		6		6	4	4.4	3 4	4	ហ	വ	ທ	വ
	'	i 4 4	4.	4 4	4.	4. 4.	4	4 (n	რ	რ (m	က်	က်ဖ		4	4	4.4	ູນ	ល រ	n n	ູນ	4	4.4	1 4	4	က်	m m	က်	က်
	-2	5.00	100	•	•		•	•		•		•			•	•		•	•		•			•	•	•					٠
v	o m ×	Σ 2	E 3 E 3	ΣΣ	Œ:	Σ.Σ	Σ	E 3	E E	Σ	I:	X 2	Ξ	Œ	X:	£ 3	E 3E	Ξ	E 3	. .	æ;	ΣΣ	Œ	Σ	Z:	ΣΣ	Σ	E :	¥ Z	Œ	₹
+ x 0 x c)) 2		- 🕳		· •		_			-	. .			-	-			_			- .			-			-	- .		_	_
42m24J 2	20 .		N W	4 R	9 1	~ &	· 61	₽;	- 2	£	4 :	ັນ ຊ	1.0	18	19	50	22	23	24	5 2	27	8 6	ခိုင္တ	31	33	5 G	35	36	37 38	36	40

Control; $2=1.5 \, \text{mg/kg/day RDX}$; $3=7.0 \, \text{mg/kg/day RDX}$; $35.0 \, \text{mg/kg/day RDX}$; $5=175/100 \, \text{mg/kg/day RDX}$ H 11 Group 1 **T**R

25		
m !	00000rrrrrmmmmrrrrr444440000000	000
21	44444666664444444444444444444444444444	4 4 4 0 0 0
- [លលល
-	44444WWWWWA444444444444444444444444444	4 4 4
- !	6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	4 4 4
£ .	\mathbf{n} \mathbf{n}	8, 6, 6,
- 1	$\begin{array}{c} FFFFF = 8888888666666444444666666666666666666$	• • • • • • • • • • • • • • • • • • • •
- 1	$\begin{array}{c} 0.0000024444444444444444444444444444444$	0 0 0
•	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
. ×	$\begin{array}{c} 1 \\ \text{Impure} \\ Impur$	
TE 7	8 8 8 8 8 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1004
ဖ	44444000000000000000000000000000000000	1444
4	44444000000000000000000000000000000000	2000
		4444
	4 4 4 4 4 R R R R R R R R R R R R R R R	4 4 4 4
	n n n n n n n n n n	יםיםיםים
1	4444444444444444 NUNUNUNOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO	0000
2	$\begin{array}{c} \begin{array}{c} & \text$	ហល់លំហ
<i></i> ம ய >	×	ZZZZ
⊢ α ७α ૦ ⊃¤		
SZHEAJ ZO		752 753 754 755

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 hg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group 1

Ū

ان

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

25	$\frac{1}{1}$	
23		
-	4444466666666666666666666666666666666	စ် က်
0		
17		10
1		44
ū		ာ် ယ
5		
=	000000000000000000000000000000000000	ā <u>ā</u>
ō	1	. o
EEK 9		· .
EST W		ဖ် က
7		ບ່ານ
ဖ		ဆင် ဆ
ល		üü
4		က် က
ო		
	00000000000000	۲, ۲-
-	$\begin{array}{c} 2 \\ 2 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\$	တ တ
Ţ	$\begin{array}{c}$	w w
		ω ω
	; የነው የነው የመመመመመመመመመመመመመመመመመመመመመመመመመመመመመመ	4 4
νшх	\$\$\$\$\$#################################	ı. tı.
+¤ @¤0⊃¢		
ASHEAT SO .	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	109

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

	•	
25	$\begin{array}{c} 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 $	• •
23	$ \begin{array}{c} \mathbf{u} \ \mathbf$	
21	1 + 4 + 4 + 4 + 6 + 6 + 6 + 6 + 6 + 6 + 6	
-	444444444446666666666666666666666666666	. .
17		4
<u>2</u>	$\vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\$	
<u>e</u>		
n		
-	mmmmm 4 4 4 4 4 6 6 6 6 6 6 6 6 6 6 6 6	າ ຕ
▼	[www.www.www.www.www.www.www.www.www.ww	
ō	$\begin{array}{c} \omega\omega\omega\omega\omega\omega_{4} + 444\omega\omega\omega\omega\omega\omega\omega\omega\omega\omega\omega_{4} + 44\omega\omega\omega\omega\omega\omega\omega_{4} + 444\omega$	4 4
w	4444444400000000000444440000000000000	•
1EST 8	4444444444444444 nnnnnn0000000000000000000000000000000	
	$\frac{1}{1}$ $\frac{1}$	
ဖ		ດທ
	្រុ ប្រភពពេលមេសាធាមានក្រុមពេលមេសាធាមាធាមាធាមាធាមាធាមាធាមាធាមាធាមាធាមាធា	າຕ
	$\begin{array}{c} \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots $	
ო	4 4 4 4 4 4 m m m m m m m m m m m m m m	
И	4444444444444444000000000000000444440000	
	44444444400000044444400000044444444444	
	14444400000000000000000000000000000000	
9	\(\phi \phi \phi \phi \phi \phi \phi \phi	
	; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;	9 Q
wш×	 	L U L
⊢¤ ©¤⊙⊃¢	 ***********************************	
4ZHE4J ZO .	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	150

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

(3)

(3)

SACTOR SECTIONS THE SECOND SACTOR SECTION SECTION SECTION SECTIONS SECTIONS.

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

23	888888888888888
19	
47	ως ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο
25	COOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO
**	$ \begin{array}{c} 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 $
	$\begin{array}{c} \omega \omega \omega \omega \omega 4 4 4 4 4 $
Õ	1 1
ST WEEK	$ \begin{array}{c} 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 $
169	लिलिलिलिलिकिकिकिकिकिकिकिकिकिकिकिकिकिकिक
φ	ι ου ου ου ου ου ου ου α α α α α α α α α
ស	
ω 4	$\begin{array}{c} \cdot \cdot \cdot \cdot \cdot \cdot \cdot \cdot \cdot \cdot \cdot \cdot \cdot \cdot \cdot \cdot \cdot \cdot \cdot$
	00000mmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmm
**	ι πιπιπιπιπιπιπια α α α α α α α α α α α
:	1 4444400000000000044444444444444444444
ų	 rrr rr rr rr rr rr rr rr rr rr rr rr r
wω×	
+ α α α ο ⊃ σ	
AZHZAJ ZO ·	761 762 763 765 765 766 766 766 766 767 768 768 768 768 768

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX TR Group 1

25						
23	00000) 	ים מונו מומי		พ.พ.พ.พ.พ.พ.พ.พ.พ.พ.พ.พ.พ.พ.พ.พ.พ.พ.พ.	-
	տ տոսոտ տո	מומומומומים	.សស! សស@ 44 44	20 20 1 20 20 20 20 20 20 20 20 20 20 20 20 20	00	•
2	ம்ம்ம்ம்	ເບຸນ ເບຸນ ເບຸ	चित्रं विचेत्र	4414000	000 4 4 4 4 4 4 4 4 4 4 4 4 4	•
			444440		n n n n n n n n n n n n n 4 4 4 4	
17					000000000000000000000000000000000000000	•
3					~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	•
<u> </u>					44000000444444444 00000000000000000000	•
-	ທ່ ເ ທ່ ເ ທ່ ເເ	idddd	் ஐ ை ஐ ை வ	ท่างกับเก๋ส์ 4	4444444000004444	
0			់ស់សំសំសំសំ	ニ ーニー で の の o	100000000000000004444	4
¥ 6			, 1)	
ST WE	 	1 4 4 4 4	44444	~ ~ ~ ~ ~ ~ ~ ~	4400000000000000000444	
w :		4 4 4 4 4 - ri ri ri ri ri	,	444444		4
					i a a n n n n n n a a a a a a a a a i n n u u u u u u a a a a a a u u u u	• •
ψ	4444				440000004444444 000000000004444	
'n			<i>.</i>		. 4 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	٠.
4	4444. 66666				00000000000000000000000000000000	. 4 . 6
m	1	ຊ ຊ ຊ ຊ ຊ ຊ ພ ຕ ຕ ຕ ຕ ຕ			. 4 4 N N N N N A 4 4 4 4 4 4 4 4 4 4 4 4	
7	,					
-		~ ហេលហេហ	ուսասա	n n n n n o o o	o o o vi vi vi vi vi o o o o o o o o o o	n on
		4 4 4 4 4	44444	44444		1 4
1		o 4 4 4 4 .	4. မ. မ. မ. မ. မ.			י אי
7	1 7 7 7				4 4 4 N N N N N N 4 4 4 4 4 N N N N N 1 i i i i i i i i i i i i i i i i i i i	

+					,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	1					
AZHEAJ ZO ·	1 2 2 2 2 2	<u> </u>	<u> </u>	<u> </u>	202 204 204 205 205 205 205 205 205 205 205 205 205	55

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; t_1 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINGGENICITY STUDY OF HEXAHYDRO-1,3,5-TRIMITEC-1,2,7 TOTAZINE(RDX) IN THE BGC3F1 MOUSE CONSUMPTION MEASUREMENTS (g/day)

25	4444444444	4 4 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	44446666666666666	0.0
23		ப் ப் ப் ப் ம் ம் ம் ம் ம் ம்	44444000000000000000000000000000000000	က္က
. 2	00000444444	4446666	14444444444	1.
.		1000		
	\mathbf{n} \mathbf{n} \mathbf{n} \mathbf{n} \mathbf{n} \mathbf{n} \mathbf{n} \mathbf{n} \mathbf{n} \mathbf{n} \mathbf{n} \mathbf{n} \mathbf{n} \mathbf{n}	* 4 4 4 8 8 8 8 8 8		
· w		0 10 10 10 11 11 11 11 11 11 11 11 11 11		00
6	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~		. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4.	
-	4 4 4 4 4 4 4 4 4 4	4 4 4 4 6 6 6 6 6		ю ю
<u>+</u>	4 4 4 4 4 4 4 4 4 4 4	4 4 4 4 6 6 6 6 6 6		
=			, , , , , , , , , , , , , , , , , , ,	
01			. 4. 4. 4. 4. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6.	
WEEK			. 4 4 4 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	
1EST 8			i 4 4 4 4 u u u u u u u u u u u u u a 4 4 i a a a a a ii n ii n ii n ii i n ii n	
۲			, w w w w w w w w w w w w w w w w w w w	
φ				
. ທ			u n n n n a 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	
4	00000000000	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	,	် က က
п		ωωωω	******	000
N			, , , , , , , , , , , , , , , , , , ,	
-				44
-	0000011111		, o o o o o o o o o o o o o o o o o o o	തെ
		4444000000		44
Ÿ				
ហម	******	*********		. 14. 14.
			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
ZHZ4J ZO	22222222222222222222222222222222222222	25 25 25 25 30 30 30 30 30	2232 2232 2236 2236 2242 242 243 246 246 248	2 Q
		auau	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	100

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TEST WERK 1	25	$ \begin{array}{c} 1 \\ 1 \\ 1 \\ 2 \\ 3 \\ 3 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4$	
7		\$	
### ### ### ### ### ### ### ### ### ##			
### ### ### ### ### ### ### ### ### ##			
THE THE THE THE THE THE THE THE THE THE	17		•
######################################	-	4	
TEST WEEK TO DE STATES TO DE	Ē	.	•
ANTERNAL MANAGE STATE AND	5	1	
ANN NAME		4	
NO No No No No No No No No No No No No No	5	1	
ANN NA NA NA NA NA NA NA NA NA NA NA NA	ង 6	4 , , , , , , , , , , , , , , , , , , ,	
N N N N N N N N N N	ш	1	
7 N N N N N N N N N N N N N N N N N N N		4	• •
7. A A A A A A A A A A A A A A A A A A A	φ	1	
7. 1		1	
7.7	4	1	
7 N N N N N N N N N N N N N N N N N N N		1	
7 N N N N N N N N N N N N N N N N N N N			, .
AN I MA I NO I SUSTAIN A STAIR OF STAIR AND IN IN IN IN IN IN IN IN IN IN IN IN IN	**		
AN H M A 1		1	
AN - M A J	1		
0	wш×		. L
00000000000000000000000000000000000000	⊢ ¤ ७≈०⊃₫		N 64
	42m24J ZO ·		ဘတ

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; t_1 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

(2)

. 25 1 25		
e :	$[\begin{array}{c} 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 $	
21		
6		
11	>> 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
<u>z. </u>	000000000000000000000000000000000000	
<u>~</u>	$[\omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega$	
27		
-		
0	$\begin{bmatrix} \omega \omega \omega \omega \omega + 4 + 4 + 4 + 4 + 4 + 4 + 4 +$	• •
WEEK 9	00000044444000000000000044444444444444	
w i	$\begin{array}{c} \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega $	
7		
ဖ	$\begin{bmatrix} \omega & \omega & \omega & \omega & \omega & \omega & \omega & \omega & \omega & \omega $	
ហ	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 0 0 0 0	л . т
	00000 x x x x x x x x x x x x x x x x x	
	$[\begin{array}{c} 4444444444444444444$	
	$\begin{array}{c} 44444 \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ $	
~	$\left\{\begin{array}{llllllllllllllllllllllllllllllllllll$	
ī		
2	$ \begin{array}{c} 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 &$	
1A 111 S	; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;	£ 2'
+a 0ao⊅a		
42∺ ∑4J ZO·	2991 2992 2993 2994 2996 2996 3904 3909 3909 3909 3909 3909 3911 3912 3913 3914 3913 3914 3913 3914 3914 3915 3916	318 320

Control· 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX 11 TR Group

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

25				ৰ্ব্ <u>ব্</u> বিহেছে।	ઌ૽ઌ૽ઌ૽ઌ૽ઌ૽ઌઌઌઌ	ယ် ယ် လ က် က် က် က်
•	. 44444) 4 4 4 4 4	ययय। ययय	nnn00000	
6	1					
8					4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	
20					₩₩₩ 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	
←	1		<i></i>		44466666666	
	1			<i></i>	44466666688	
. 6		idddd	,00000	7777755	พพพตตตตต	
	1				0,000	2222222
	1				800	4444444
Ξ	4444				444444444	
5					4444444444 www44444ww	
WEEK 9	1			<i>.</i> .	4 4 4 W W W W W 4 4	
TEST 8	1		· · · · · ·		R R R R R R R R R R R R R R R R R R R	
۲-	1				999999999	
ø	1				444444444	
ıΩ	1					
	4444	ເທີທີ່ທີ່ຕອ	04444	លេលលេល44	444444444	4444444
4	1				44466666444 4446699999999	
ю	6 6 6 6 6					4444444 7
8	1				4444444444 @ @ @ 0 0 0 0 0 0 0 0 0	<i></i>
-	1				4446666644 3567777768	
7		ဆတ် လက် လုံ	ယ်ဝဝ်ဝဝ ် ဝ) อุดฺตฺตฺตฺตฺหฺหฺ		00000000
7	1		00000		 	
1	60000	w 4 4 4 4 .		14444400	ကြောက်လုံလုံလုံလုံလုံလုံလုံ	
w m ×	2255	5 5 5 5 5 5	EEESSS	EZZZZZZZ	ERREFFERRE	EFFEREE :
						, -
47454 L 70	1 2 2 2 2 3	25 25 26 26 26 26 27	5 - 5 E E E E	25588525 255885252	. 4 4 4 4 4 4 6 6 6 6 6 6 6 6 6 6 6 6 6	
AZHZAJ ZO	1 8 8 8 8		6 8 8 8 8	, w w w w w w		ดัติตัติตัติตัติ

#---No data available (died)
C.oup 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX;
4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

P

Q

9

+- ∝

∢Z × Σ

		រូវ	1 4	4	4	4	4 4	4 .	4 4	•	1 4	-		_	-	-	က	ෆ ්	က	ල :	(C)	is i	.	yo e	o u) (4	.	4.	4 6	י מי	າຕ	6	က	0	0 :) () C	,
		8	i :						•	•	•					•	٠	•	•	•	٠	•	•	•	•		'n		•		•			•	•	-	٠	•	•
		23	1 -	•	•	٠	•	•	•	•	•			•	•	•	•	•	٠	•		•	٠	•	•		3.8		•	•	•				•	•	•	•	
		21			•		•	•		•								•			•	•					3.7		•		•			•	•	•		•	•
		19		٠	٠		•	٠			•						٠	•	•	•	٠	•		•	•		0.0		•					•	•	•	•	•	
		17				•	•			•				•	•		•	•	•	٠	•		•	٠			3.5	•			•	•		•	•	•			
		15		•	•	٠.	•	-	•	•	•			•		•	•	•	•			-	•	•			3.7	•			•		٠.	•	•	•	•	•	•
		13		•	•	•	•	•							•	٠	•			•		•		•	•		4		٠	•	•	•			•	•	•		•
		42	1 .	-	•	•				•		•	٠.	-	-	•	•		•			•		•	•	•	3.6	٠.	-	•	•					•		•	•
		=	4.2	•		•	•	•						•				•	-	•	•			٠	•		3.5	•	•	•	•		. ,					 - c	
		ð	1 .	•		•	•	•			•		٠.	Τ.	٠,	٠.	•	•	•	٠.	•	•				• -		-:	-:	•			. –,	٠.		•	•	•	٠
	WEEK	6	-	-	-	-	- 1	ומו	ល់គ	י נ	ບ ແ	. [9 (7)	е	<u>و</u>	е. С	-	-	-	-	-	o.	0	0	0,0	۶ ۲-	. ~	.7	<u>,</u>	٠, ۵	ם ת	ם נו	. 10	ស	ю.	<u>ښ</u> (3
	EST W	æ	1						0 i										4	•			-) რ ე დ												
	Ŧ			•	•	•	•	•	•	•	•	•			•	•		•		•	٠	•	•	•	•	•	. n	•	•		•	•			•		•	•	•
		7																	•				٠				œ.												
		ø	1 .		•	•	•	٠.	-	•	•							•	•	•	•		•	•		•	, e	•	•		•			٠.		•		•	•
		ເດ	ŧ -				•		10 t				• •			•	•		•	•	•	4.1	4.	4.1		•	. 4 . 5	•	•	•	•	•			•	•	•	•	•
		4	4.4	4.1		•		•	7 1	٠	•	•	•			•		•								•	. 4 . 6	•	•		•	•				•	•	•	•
		ю		4.1	٠.	4	•	•	•	٠		•	-			•	•	•	•	•	•	•			•	•	3.7.	•	•	•	•	•	•		-	•	•	٠	•
		8	4.0			•	•	•	•	•	•	•	•	•		•	•	•	٠	•		•	•		•	•	, c	•	•	٠	•	•	•			•		•	•
		-	4.0																								3.7												
			3.7		•		•	•	•	•		•					•			•			•	•	•						•	•				•	4.1	4.	
		-2	3.7					•	-	٠	•	•	•		•		•	•		•		•	•	•	•			•	•	•		•	•				•	•	•
					•			-					•		•	•	•	•	•	•	•	•	•		•				-						•	•	•		•
	s	ш×	Σ	Σ	Ξ	Σ	Σ	Σ	Σ	Σ	Σ:	E 3	E 3	Σ	Σ	Σ	Σ	Σ	2	Σ	¥	Σ	¥	Œ	æ:	ΞĽ	L 1L	ш	u.	u i	ı. ı	L E	ւս	. "	u.	u.	L I	ı	L
0 0	, D	5 a	. 6	m	က	၉	6	က	က	r)	ი ი	י ני	ים כי	o m	ල	n	n	6	ღ	ღ	n	ო	ო	ຕ	က	m c	າ ເາ	က	က	(C)	ကျ	m c	י ני) (C)	က	6	က	ი (ກ
ר א	z	o ·	361	362	363	364	36.5	368	367	368	339	3 6	1 / 5	373	374	375	791	792	793	794	795	196	797	798	729	800	377	378	379	380	381	382	000	385	386	387	388	383	225

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE B6C3F1 MGUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

the second of the second secon

;	ev -			•						•	•				٠		•	•	•			•																	
	23	3.6	٠	•	٠			•	٠	٠	•	•	•	•	•	•	•	•	•	•	•	•	٠.	•	•	•	•	٠	•	•	•	•		•		•	•	•	
,	21	3.4	٠	•	•	•		•	•	•	•	•	٠	•		•	•	٠	•	•	•	•			•	•	•	٠	•	•	•	•			•	•	•		
	19	3.7	•	•	•	•	•	•	•	•	•	•	•	٠	•	•	•	•	•	٠	٠	•			•	•	•	•		-	•	•			•	٠	•	•	
!	17	2.6	•	•	•	•		•	•	•	•	•	•	•		•	•	•	•	•	٠	٠				•		•	•	•	•				•	٠	•	-	
!	15	3.7	٠	•	•			•	•	•	•	•	•	•	٠	•	•	•		•	•	•			•	•	•	•		•	•	•	٠.		•		٠	•	
ı	13	3.2	•	-	•	•		•	•	•	•	•	•	•	•	•	•	٠	•	•	•	•			•	•	•	-	•	•	•	•			•	•	•	•	
	12	6.6	•	-	•			•	•			•					-		•		٠			٠.		•								٠.	٠.				
	-		•	•	•	•		•	•	•	•				•				•	•						•	•	•									•	•	
:	2	ອ. ທີ່	•	٠	•	•			•	•	•	•	•	•	•	•	•	•	•	•	•					•	•	•	•							•	•	•	
XEEK	6	9.4	•	•	-	•		•	•	٠	•	٠	•	•	•	•			•		•	•		٠.		•	٠	•	•		•	•					•		;
TEST	t	4.6	•	•	•					•	٠		•	•	•	٠		٠	•	•		•			•	٠	•	~		•		•				•		•	
		0.0			٠						•	•	•			•	•		•	•																		•	
	9	9.9	•	•	•				•	•	•	•			•	•	٠	•	•	•	•					٠	•	•	•		•								
	5. 5.	3.4	•	•	•	•		•	•		•	•	•	•	•		•	•	•	•	•	•	•		•	٠		٠	•		•	•						•	
	4	3.5	٠	٠		•	•	•	٠	٠	•	•		•		•	٠	•	•	٠	•	•	•		•	•	•	•	•	*		•							
	1	3.2	•	•	•	•		•	•	•	•	•	-	•	•	•	•	٠	•	•	•	•	•		•	٠	•	•	•		•			•				•	
	2	9.5	•	٠	•				•	•	•	•	•	-	•	•	-	•	•	•					•	•	٠												
	1	9	e .	က်၊	m c	, <	. 4	4	4	4	რ	ю	ლ	რ	ო	4	4	4	4.	4	4.	4 4	4 4	4	6	Ö	ල ₍	ر ن		n ı	ກ່ມ	ก น	n u	. 4	4	4	4	4	
	, ,	4	•	•											•	•	•	•	•	•																			
	1 1	5.6	•	•	•													•	•																				
υш	×	! ! !	ш.	1	ᄔ	L U	LU	. u.	ш	ш	u.	LL.	L.	ıL	ш	u.	L.	u.	LL I	L.	u. 1	ا با	L U	_ 11_	. 11	u_	u_ :	ш. 1			L Li	. u	. 11	·	·	Ŀ	
⊢ α ७α页⊃	۵	9	က	n :	ကျ	י מ	วเ	က	က	က	က	က	က	က	6	ლ	ო	က	ღ :	ო	n I	ლ (יז כי	n (1)	· е	ღ	m ·	n i	ლ (m (n (י פי	י פ	י כ) с	m	n	е	
∢S∺≅∢ ∃ ZO		391	⊙	о	თ (D C	ο σ	ത	ന	0	0	0	0	0	0	0	0	0	ο.	•	,	* 4	- +		-	-	•	-	Ň.	N	V (N C	40	10	10	11	C	(1)	

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group 1

٠

9

3

1 25 1 55						444 6 6 6 6 6 7 7 7 7 7 7
23	00000			~0000	იფლლლლ <u>ი</u>	+++000007777
2.1	សល់សល់ស)		∠ ღღღღ	87777799	0 0 0 0 4 4 4 4 4 0 0 0 0 0 0 0 0 0 0 0
₹ * !	***	ရောက် ရောက်	ပ်ထဲထဲထဲဆဲ	ខាល់លល់ ស	សេចខេត្តទាក់ក	0000444444
17	លល់សល់ស		9444	4	- 0 0 0 0 0 0 4 4	. 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
ν Σ		00000) 4 4 4 4	_4 ល ល ល ល •		1.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
8) 4 4 4 4 4	10000			. 4 4 4 m m m m m m m m m m m n m m u 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
				. w w w w	00000000	000044444000000
12						000044444000000 0000000000000000000000
-						
0						
¥ EEK						0 0 0 0 4 4 4 4 4 0 0 0 0 0 0 0 0 0 0 0
1 ES 4						្រុក ភាព ភាព ភាព ភាព ភាព ភាព ភាព ភាព ភាព ភាព
F- !	ល់ល់ល់ល	်ထဲထဲထဲထဲ ေ	04444	4444	4 ထဲ ထဲ ထဲ ထဲ ထဲ က က	หเทเงอยอยอย่นหน่นหน
i !		របាលបាយប				0000000000000000
Ψ I I I				· · · · ·		44466600000000000000000000000000000000
ហ i ! !			<i>.</i> .			,
4						> 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
n						,
8						្ចេស
-					· · · · · · ·	0 0 0 0 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
.	<u> </u>) 	- 4 4 4 4	4 0 0 0 0	ល់ ហេ	ာ် ကု ကု ကု ကု ကု ကု ကု တဲ့ စာ တဲ့ စာ
2						
) i		•	4444			44446666444444 GQ
νшχ	<u> </u>				<u> </u>	,
רמ ממטטי	00000		, , , ,			> w w w a a a a a a a a a a a a a a a a
AZHEAJ ZO.	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	7 4 4 4 4 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6	1 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	450 801 803 804 805 805	8808 8008 8008 810 810 810 810 810 810 8

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY UF HEXAHYDRO-1,3.5-TRINITRO-1,3.5-TRIAZINE(RDX) IN THE BGC3F1 MQUSE INCIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

N	 m m m m m m m m m m m a a a a a a a a	4
	के के के के के चंच चंच चं के के के के के चंच चंच चंच चंच चंच चंच चंच चंच चंच चं	4
24		•
2	ηνηνηνησα α α α α τηνηνηνα α α α α τηνηνηνης α α α α α α α α τηνηνην η ο ο ο ο ο ο τηνηνηνην α α α α α α α α α α α α α α α α	•
₹-	nnnnnnnnnnn4444444444nnnnn44444444444	•
2	n n n n n n n n n n n n n a 4 4 4 4 4 4	
-	mnnnn44444444444444nnnnn44444444444444	
5	NON NO NO 4444444444444	ე. 1
-	4 4 4 4 4 6 6 6 6 6 4 4 4 4 4 4 4 4 4	4 .
9		
Ē		ci.
EST 8		n
r -		7
φ		
ស	$\begin{array}{c} \bullet & \bullet & \bullet & \bullet & \bullet & \bullet & \bullet & \bullet & \bullet & \bullet $	_
4	ι α α α α α α α α α α α α α α α α α α α	ល
	nnnnnnooooommmmmunnnnnnnn	
	<u> </u>	ស
		٧.
1		
1	4444466666666666666666666666666666666	
+ x Q x O D T	;	
.HX47 50 ·	: 444444444444444444444444444444444444	0

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; t_i = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

∢ Z

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENJCITY STUDY OF HEXAHYDRO-1.3.5-TRINITRD-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (9/day)

i	in i	r r	~ ~	. [-	19 19	ာတ	6 6	9 0	າຕ	က	en e) C	101	<u>ر</u>	N 6	4 L-	7				m	n m	ო	4	1 4	, «	1 4	~	20	4 C	10	
	1 12	44	•	• •		• -		•		•				•			٠.	•	• •	• •	•			•	1	•		•		•		
	18	44			•		•	•		•	•			•	•		•	•			•		•	•	1	•		•	•	•		
	21	44	•		•		•	•		•	•		• •	•	•		•	•			•		•	•	•	•				•		
	19	ဖဖ			•			•		•	•	•		•	•			•			•		•	٠	•	•		•	•	•		
	7	44								9																						
	S	00 44		-	•		-	•		4	4 4	•		_						-			-	-	_		-					
	7	44	•		•		•	•		•	•	•		•	•			•	•		•	•		•	•	•		•	•	•		
	13	4.6	•					•		•	•	•		٠	•			•	•			•		•	•	•		•	•	•		
	12	4.4 ถัง	•		•						•			•	•			•	•			•		•	٠	•	•		•	•		
		4 4 G G			•						•			•	•			•						•	•					•		
	0	44				٠.	•	•		•	•	•		•	•			•	•	٠.	•	•		•	•	•			•	•		
WEEK	6	66							-						о		, m	<u>ල</u>	יז פיז	າຕ			່ຕ		က၊	-						
ts.	80 1	6 6 4 4	•				Ť	-		·								-	-		-		-	-								
7.E	1	4.4										ທ ≺			4	4 4	·	4		1 4												
	7	44		4	•		•	•	•		-	٠			•	•			•			•			•	•	٠		•		, m	_
	9				•			•			•	•	٠.			•	٠.	٠	٠	•		•			•	•	•	; ;	1	1	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	ighing
	2	4.6			•	•										•			•			•			•	•		'n	'n	ល់ ព	ດທ	weig
	4	9.4	•		•		٠.	•	•		•	٠			٠	•			•	•		•		•	•	•	•		•	•		ore
	8	ω ω	00	ρω	-		-	-	4 4	43	4	4 (ים ני	e	ო.	س ر	, m	6	ຕຸເ	? 0	0	0,0	90	N	8	ų.	i, c	. 6	9	ဖ	ဖ်က်	bef
	2	ស 4 4																													4 4 w 6	j.ed
		66 44	•	•		•		•					•		•••			•				•		_	_	_				•		empt
	1	4.4	4.	4.4	4	4.4	4	4	ນ ່ໝ	່ ເກ	ທ	'n,	4 4	4	4	4.0	, w	6		ب م	4	4.	. 4	6	Ö.	ø.	(e e	(1)	က်	က်က်	٧-(
	-	0.4		٠.	•	•		•	•			•	•		•	•	•		•	•		•	•		•	٠	•	•		•	ю 6 4	enta
	-2							•								•					٠.	•					•			•		cid
	1																															od ac
ហយ	×	ΣZ	Œ	E E	Œ	E 2	EΣ	X	X 3	E 3	Œ	≨ :	E 3	Ξ	Ξ	¥ :	E 2	: :	Æ :	ΣΣ	Œ	£;	ΕZ	Œ	Œ	¥	E 3	Eu	. ц.	ц.	L L	P ₀
בסמט א	۵	4 4	4	4 4	4	4 4	1 4	4	4 4	1 4	4	4	4 4	4	4	₹ ₹	1 4	4	4	♥ ₹	1 4	v •	4 4	4	4	4	₹ ₹	7 4	*	4	4 4	*
ASHWAN ZO		100	0	00	0	00	20	*	* *	~ -	•	•	~ +	- +-	•	N	4 C	10	2	(1 -					*	•	- (40	10	~	529 530	

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; t = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE B6C3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

	25		٠.	•	•	•		•	*	٠	•		٠	•	•	•	٠	•	٠.	•	•	•	•	•	٠		•	•	•	•	•			•
	23												ຕ	m	ල <u>.</u>	က (ח פ	, r		7	-		9							ი •				•-
		n n																																
	1	64 C																																
	- 1	6,6		е.	ლ (n m	, m	ю	က်	m c	າ ຕ		რ	ю	რ (m (m	<u>დ</u>	က်	, m	ю С	რ (m r	, m	Ю	ю	က	ب ب	י) ני		ю С	ю.
	17	3.5		•	•	•		•	٠	•			•	•		•	•		٠.	•	•	•		•	•	• •		•	•	•				•
	5	6. c		٠	•	•		•	•	•	•	٠.		•	•	٠				•	٠			•			•		•	•	•			
	13			•	•	•	٠.	•		•			•	•	•	•		•			•			•	•			•	•	•				
	- i	6.6		٠	•	•		•	•	•			•	•	•	•	•		٠.		•			•	•			•	•	•				•
	- 1	4.6		•					•	•	•		•	•	•		٠	•			•	•	•	•	•			•	•	•	•			•
	9	លិក	ຸທຸ	ស	ن ا		-	-	-	4.	. d	. ₹	4	4.	4.	4	4.4	. LC	יא י	r.	រប់ រ	n œ	. α.	ω,	ထုဏ	~	^	۲.	۲.	_	ກຸດ	n o	6	ە
<u>ж</u> ш	6	R) II											-	•									-	•										-
3		7 3							-							_) 4	4	4	4	ប្រ	ល								•			-
<u>u</u>	· !	7 3.														(D)) C	n	က	ෆ 1		n											
	; ; ;			ю	mi (n n) (n)	က်	ტ.	4.4	4	4	4	က်	က်	m (m r	י ני	m	'n	ю (ω 4	4	4	4.4	r es	С	რ	С.	ر د			ю (რ
	φ i i	4 4							•	•	•		•	•	•	•	٠	•		•	•	•		•	•	•		•	•	٠	•			•
	5	ю 0	٠.				•	•	٠	•			•	•	•	•	•	•			٠			•	•	•	•	•	•	•	•			•
	1	2.4 R) R	٠ .			•		•	٠	٠	٠			•	4	4.	4 4			•	•			•	٠			•	•	•	•		٠.	•
	1	ក ព្រំព			•		-	•	٠	•	•			•	•	-		•			•			•	-			•						
	2	5.7					•		•		•	٠	•								٠.	•		•				•	•			`, -,		٠.
	-	80.0		ω.	œ. ι	o u	9	9.	ا بی	ຕຸເ	າຕ	, נט	m	.7	١.٦	٠,	۲.	· α	0 00	æ	ω,	ب م م	2	C)	ci c	ı L	'n	ı,	S.	ທຸ	ກຸດ	ņ		<u>ه</u>
	- i	77																-					_			, -		_	_	 (20 0		ω	
	1	5 7	-											-					. 4	4	•	_	-			> 4	4	4	4	4.	4 4	1 4	4	•
	, , , ,	n, n	מוי	ູເນ	ı,	4.4	4	4	4	4.4	3 4	4	4	4		4	4. <	ď	מו ה		ល់	ດີທ	ູເດ	ر ب	ທີ່ພ	'n		რ	e,	ю·	4.4	4	4	4
v	хшх	ս. ն	. u.	ш,	L I	ı. u	. L L	LL.	u. i	u. L	L W	. Ա	u.	Ŀ	u.	L I	L U	_ 14	. u.	ıL	u. i	. u .	. L.	ш. 1	L L	. u	. li.	LL.	u.	LL t	ı lı	L W	. 11.	u.
⊢ α 0α0	200	47	1 4	4	۵,	4 4	4	4	4	4.	4 4	1 4	4	4	4	4	₹ ₹	7	1 4	4	4	4 4	4	4	4 4	1 4	4	4	4	4,	4 4	1 4	4	4
Z LÞZHSÞ	: O ·	000) ຕ	3	m (77 C	n	3	4	*	す 5	7	4	4	4.	4	すば	צו ר	່ານ	ß	10	υr	ED (IO I	រោ ប	o co	· w	9	ဖ	o t	ט פ	စေ	9	7
	'	មេល	מוני	E.	លេ	ນດ	מני	ស	រភ ।	ເດະ	ល ល	משים	ល	ល	មា	មា 1	ម មា	ט ר	מונ	ល	ומו	ກແ	ព	ស	រ ល	ט וני	ល	ល	ស	ល់	រ ជ	រ ព	ស	מו

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TETABLICA DE LA PRINCIPA DE SENTENCIA DE LA COMPANSA DE LA PRINCIPA DE LA PRESENTA DEL PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DEL PRESENTA DE LA PRESENTA DEL PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DE LA PRESENTA DEL PRESENTA DE LA PRESENTA DEL PRESENTA DE LA PR

ķ

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRD-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MQUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

21 23 2	$\begin{bmatrix} & & & & & & & & & & & & & & & & & & &$	
17 19	$\begin{array}{c} 1 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\$	
2	о со со со со со со со со со со со со со	
£ 13		
5		
=	\$\$\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\	
∓		Y O
ñ	ြုံးမှုလုံလုံလုံလုံလုံလုံလုံလုံလုံလုံလုံလုံလုံ	day r
'n	444440000000000000000000000000000000000	/ĸg/
ဖ	$\begin{array}{c} \\ $	Ō
ស		1/5/1
4		ν li
ო		Š
N		/day
-	44444606666666666666666666666666666666	mg/kg
7		5.0
?	0 0 0 0 0 0 4 4 4 4 4 4 4 4 4 4 0	li
wш×	Group Groups	
⊢ α ७α०⊃⊾	444444444444444444444444444444444444	
OZ LÞZHÍÞ	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE B6C3F1 MOUSE INDIVIDUAL FOND CONSUMPTION MEASUREMENTS (g/day)

25	44 4 44 44 41 41 41 44 40 40	ນ ເບ ລັດ
8	4 4 4 4 1 4 1 1 1 1	
		•
-) 	o ĸ.
-	44 4 44 44 64 14 44 66 66	
	144 4 4 4 4 6 4 44 44 4 44 44 44 44 44 4	۲. ۲.
		တတ္
-		ဖဖ္
	44	ស. ស.
ç	44 44 44 44 44 44 44 4	- -
WEEK 9	44 44 60 0 4 44 44	
TEST 8		
σ		
ស	(((((((((((((((((((
4	00 00 00 00 00 00 00 00 00 00 00 00	
ю	N N N N N N N N N N N N N N N N N N N	
0		
-	444440000044444444444444444440000004444 	
	-	
	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	
	×	
+ a a a o ⊃ o	្នុក ឧត្តម្ភាក ស្ត្រក្រុង ស្ត្រក ស្ត្រក ស្ត្រក ស្ត្រក ស្ត្រក ស្ត្រក ស្ត្រក ស្ត្រក ស្ត្រក អ្នក អ្នក អ្នក អ្នក អ រុ ម្ភាស់ ស្ត្រក្រុង ស្ត្រក ស្ត្រក ស្ត្រក ស្ត្រក ស្ត្រក ស្ត្រក ស្ត្រក ស្ត្រក ស្ត្រក ស្ត្រក ស្ត្រក ស្ត្រក អ្នក អ្នក អ្នក អ្នក អ្នក អ្នក អ្នក អ្ន	
ASHZAN SO .	00000000000000000000000000000000000000	60 4

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX TR Group 1

ا و

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGEN(CITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BEC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

ŭ		4.4			!!	•		1	•	. 4	4	4.1	•	•	•	1	•	- 1			1	1	יו סכ			•	•	1	. 1	3.7	 - -		7	. !	
ç	3	4.4	1	4 .		4.5	7.5	1	* *		-	4.1	4.1	ъ.	4 ن	1 (m (۳ ا ا د	5.3	ص د	!	! .	9 (7	<u>ب</u>	ه. ع	٠. د .	3.4	 	† 1 • 1	3.4	!	1	1 (7		
•	- ! - !	. 9	Į į	œ.	! !	ω.	ø.	I I	<u>ו</u>	i c	! 0	~	7.	9.	७.	1 (ې د	ָ וְיִּ	6	<u>م</u>	ţ.	; (ņσ	တ	٠ 6	<u>.</u>	m.	<u>.</u> כ	2 1	ن	!	1			
ç	, ,	6.	1	თ	! !	80	8		; <u>U</u>	ת מ	വ	្ស	ស	ດ	o O	. (n c	ו מ	CI	0	ı	, (0 (.	9	6	თ		ומ	o.	ı			? 1 ? !	
1		10	0	0		ស	ស	,	1 6	2 4	0	0	4	4	4	, ,	.	. .	7 5	~	ı			. (o	ιo	(0.1	ıc.	1 14		ıΩ	ı	1	1 Q		
u u	1	. 6	4	4		4	4																							9			1 4	: :	
•		, u	Э.	e.	! !	4	4	1	! <		4	₹	4	ທ	'n,	۱.	ກ່ມ	, ¦	4	4	ļ	; ,	· <	4	4	4.	m m	; ;	,	ი	1	1	. 4	; ;	
ţ	• 1	5.0			1 1				1							1						1			٠.	-		•	. 1		ŧ	1	. 4		
Ç	- 1	6.0			: 1				ŧ			•			•			- 1			t							•				1	1 1	1	
:		6.			1 1		•	•										. 1																. !	
Ş	- 1	6.5					-	-	1					•		1						t									1	8.4			
WEEK	1 1	5.6						•	,																							-	_		
1631	1	. 47	4.	4.4	4 C	0	o.	0.	, (i c	. ~	2	۲.	თ.	თ.	; (n c	אַ יַּת	~	.7	.7	! 0	ه م	. ω	80.	œ. ۱	ن ن) i	6	o.	0 0		1 5	
•	- !	0	0.	0	၁ ၈		6	<u>م</u>	י ר		, ო	е.	ო.	o.	0	; (<u>ء</u> د	ب ي ج	φ	9	œ.	1 (, c	0	0	01	ru r	ប្រ	? !	5	8	<u>ه</u> د	ώα) !	
Ú	-	3 -			m +-		_	_		י כי		6	<u>ب</u>		-	, ,		- "		(0	(0	1 4			_	-	os o	7 C	ומ		m				
ט	-				- 1	7	7	-1	i U	מח	ດມຸດ	ເນ	ស	ω	œ	1 (D C	ט מ	ល	ល	ល	1 (שפ	0	9	φ.	4 4	7	1	4	ស				
_	1 1 1	6		۲.	ی .	0	9	(i)	•		4	4	4	7.	۲.	٠. ۱	٠,	- 1	ິທ	ູນ	S.	ល រ			7.	7.	ن ن	٠,	. !	9	ល	ທ່ ເ	ກ່ດ	; !	
			9	<u>ن</u> ر	0	4	4	4.	4	4	4	4	4	œ.	9		، ف	ວ່ ເ	(0	Ġ	9	٠ ن	n o	່ເດ	Ŋ,	ເດ	4.	• •	. !						
·	110	4 . 7		•					•	•			٠	•	•	•	٠	٠													-	4.	٠, ٠		
r	۱ .	2 4 2 8	•	•			•	•						•	•			•																	
•		. 4	•	•	•			•	-			•	•	•	•	•	•	•			•	•	•			•		-				•		•	
•		ာ တ	•	•	•	٠,	•	•	•				•	•	•	•	•	•																	
c	, ;	. r 	- .	- .•	- c	, O	0.	0 0	ې د	oα	. .	80.	ω.	ო.	ლ 1	ი ი			, m	(ი	ი.	ლ (oα	. ω	æ.	φ.	4.	٠, ٦	•	4	o.	ص ص	ກອ	. o.	
	1							• •	•	•	•	•	•	. ,	3 .	u, (٠, ٠	٠, ٣	, 6,		٠,	.,	•	7	7	7	7	7 '	, ,	4	7		. ·	7	
wω>	· :	ΞΞ	Σ	Σ:	ΣΣ	Σ	Σ	Σ:	ΣΞ	EΞ	Σ	Σ	Σ	Σ	Σ	Σ:	Σ:	Σ 3	Σ	Σ	Σ	Σ:	ΕZ	Ξ	Σ	Σ	Σ:	Σ	E 2	Ξ	Σ	Σ:	٤ ٤	Ξ	
+ a a a a a a	. .	ប្រ	ស	ល	ល ស	ល	ស	ល	ប	ם מ	ທ	ស	ល	ស	រ ព	រ ល	ກເ	ນ ນ	ល	ស	מו	ល រ	ט מ	ល	ß	ស្រ	ល រ	រ ព	ט ה	ល	വ	ហ	ប្រ	ល	
SHEAT SO		641	4	♥,	77	4	4	∢ 1	ກະ	ດແ	າເດ	ເນ	D	ഹ	1 0	រ ល	n (D C	တ	· co	9	(0 (oα	10	O	<u>~ 1</u>	~ !	~ r			\sim	0 0	7 C	9	

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; t=35.0 mg/kg/day RDX; t=175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3,5-TRINITXO-1.3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

	C/ I	444441411000010110000000011110000010001
	23	44444141 00000 01 0000000 1 100000 000 001 1
	C: 1	444440101100000101100000001111440010041411
	61	
	17	44444111144441011000000111111111111111
	I	444440 0 1 1 0 0 0 0 0 1 0 1 1 0 0 0 0 0
	13	4444414 4444 6 6 6 6 6 6 6
	- 1	444440101144441411440000011110044144414
	=	4444000 1444410 10000000 1 4477 774 47 47 47 47
		444441411444416116000000111144888188841411
WEEK	- 1	4444414110000101100000001111004414401011
TEST	1	444440001 0000010 00004444 1 1 4400 100000 1
	7	44444000114444101000444441111000001000000
	1	44448881 0.000 0.00000000 1 14488 8888 8 8886 1 1 1 1 1 1 1 1 1
	S	44444777 เพษพพ. พ. พ. พ. พ. พ. พ. พ. พ. พ. พ. พ. พ.
	1	44444000 10000 41444444 111 1 1 1 1 1
	6	44444444444444444444444444444444444444
	1	44444444440000000000000000000000000000
	-	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
	-	44446666666666666666666666666666666666
	7	44444666660000000000444440000000000000
		ΣΣΣΣυμμαμαμαμαμαμαμαμαμαμαμαμαμαμαμαμαμα
Φ E O		០០ ១០០០ - ១០ - ០០ - ១០ - ១០ - ១០ - ១០
4 → Z	o · į	833 833 833 833 833 833 833 833 833 833

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

1

6.1	3.7			• 1	: ! : !	. a		3.9	- 1	•				1	•	ŧ					1			• 1	•
(5) (4)	4.0	1	. 1	. 1	1 1	• 1			3	1				. 1		1		•			1	1		. 1	
N 1	6.1.			- 1	1 1		• •		1	1				. :		1		•			ł		4 4		
62	9 1 1	ဖွဲ့ဖွဲ့	- 1	- ;	; ;		2		ł	ļ	. 4 .	4.4	4	4 :	o.	; C	0	4.	4.4	7	;	! !		. !	۲.
17	4.1	44	بوب	9	!!	4	1 4	3.7	ì	1 :	- ຕ	n r) ()	် က ၊	m	. (*) (D	2	0 C	0		: 1	១៤) I	ស
15	0 }	00	1.1			6.	6.	9 :	;	1 (9 %	ú.	. ~	۲. ا	ω.	ļα	. e.	5	্ খ	₹.	į	; ,	សួស	? ;	ъ.
: 	8 : 1		01			6	ເກ		1	1 6					9										
i	ស់រ	ကက		6 .	, .	е 6	. 6	CD I	1	1 0		е с		က ၊ က ၊	ස	ı L	מנ	e		n m	,	, (- 1	7
	e ; ;	ကက	(C)	es i		က	l m	က၊	,	, (24	4 4	4	4 1	e	1 6	n	က	ממ	(C)	1	i (ח ת	9 1	3
1	7 3.	CC CC	, to ,	. n	1 1	9	ı (G	(O (C	1		010 24	10 10 4 4	. 4	4 1	. m	: 6		ເດ	ო) (C)		1 (en e	 	-
¥ - 1		ოლ	4.4	4	! !	m,	, e		1	: 6	, u				က်	ŀc	n	က်	o o	, (n)	,	,	4 4	; ;	4
₹	4 4 !			(C)	; ;	7.		m m	1	;		<u>ب</u> د		9	θ.	; c	, _{(,}	<u>რ</u>	ი ო	, m	}	;	4 4	. !	4
11	444				. , ,	•			٠ ١	•				•		1			•		1	1	•		•
	0 0 0					•					. 1	J 1	1			u		-	•		ı	•	٠	٠ ١	•
· 1	0 0 0 0 0			က (၁)	. 1 1							•		•		1		•			1	1	4 4 G. C		
1	ស ស ស ល ល ល						1 .											•			1	4			•
1	ស ស ស ស ស ស											•				1		•				1		- 1	•
	4 4 4 8 8 8 .				• 1	•			٠.	•				•		•		•					•		
	7.50																					•	•		
-	0 0 0 0 0 0 0 0	n n .	: = =	্ৰ ৰ	. –	 .	 	úc		2	۲. نا د	7	. ^.	۲.	4 4	4.4	. .	8	۰,	. ~	2	۲.	۲.	- 1-	
-	က် ကဲ ကဲ	ဖွေဖ	i i i	isis	iúc	ici	u u	۲.		.,	r. 19.	ب ب	စ္ ဖ	9	, ci	ų, c	, ci	<u>ه</u>	ص 0	ຸດ	G)	න _.	ص 0	ກຸດ	, o,
2	8. 7. 8. 7.	ထဆ	ة خ د	. 4 4		. 1-, 1	٠.٠	4.4	4	4	4 rů	មា	ເພ	ស្ន	pœ	α, α	0 00	ب	o u	ی د	Ŀ	_	٠. r		. 7.
	សលស	លេល	បសថ	មេល	9 69 6	o co	യ യ	y Q	ဖ	9	ល ល	សម	വാ	ល	ດເດ	ហេ	. ທ	5	ហ	מונ	2	9	9	ນ ແ	ဖ
ωш×	<u> </u>	F F 1	. L. L		. 11. 1	∟ 1 4. (և և	11.11	. "	L .	<u>ı. ı.</u>	ניבונ	LL	ı <u>r</u> (ı u	LL L	LL	щ	T I	. L	_	u.	L L	ı u	. 11
0 K O D J	ឧឧឧ	សល	ນເນ	មល	וחות	വ	លល	ហប	ា ភេ	വ	ល ល	លរ	ດທ	លេរ	ກເນ	ហ	ក ភេ	ស	លផ	າເກ	ស	S.	ب ا	ე IC	ល
< - 2 0 ·	711			- - c	v (N (V (V)	\sim	N C	4 C	N.	ကက	m (າຕ	CD (ກຕ	C (9 40	₹	~ ~	7	~	₹	せて	ರ ಶ	(1)

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group 1

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

25	0110101011
23	0110141411
2	0 10 4 4 1
	0 1 10 10 10 10 10 10 10 10 10 10 10 10
47	
75	
<u>.</u>	
.	3 3 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1
=	1
ō	1 2 1 1 0 0 2 1 2 1 1
WEEK 9	0.0000000000000000000000000000000000000
1ES1 8	
~	0110000011
υ	0110000011
ល	01100000
4	
ю	414440001
0	
-	
ī	44444000000
C)	4444444444
w ш ×	; ; ; ; ; <u>, , , , , , , , , , , , , , , , , ,</u>
	ា ជា ជា ជា ជា ជា ជា ជា ជា ជា ជា ជា ជា ជា
dZμΣdη ζΟ	8843 8443 8443 8443 8443 8443 8443 8443

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXH II TR Group 1

4ZHZ4J

	65	1		•	1	•	•	•	•	4.7	٠	•	•	•	1	ı	*	•	•	•	•	1			•		•	•	•		•	•		•	•		1		4.6		
		!			1	٠			•				٠.	•	1	1				•		1				1	9.						•				1	5. T	. 1 1	ري -	ب. ب
	61	1 1	•	•	ı	•	•								1	1	•	•									•		•	٠	ъ.	ب -	IJ. ~	ى -					4.7		
	59	! !	•	•		•	•			4.7							•	•		•	•		•	•	•	1		•	•				•				1	•	4.5	•	•
	57	•	٠	•	1	•	•		•	•		٠.	•	•	ŧ	1	•	•	•	•	•	i				1		-	٠.	٠.				•	•				4.9	•	
	55	•		•	1	•	٠	•	٠	•	•		•	٠	1	1			•	•				•		•		•	•	•		•	•	•	•		1	•	۵. د	•	•
	53	•	•	•	•	•	•	•	•	•		•	•		•	1	•	•		•	•	٠	•	•	•		•	•	•	•	٠	•	٠	•		•	1	•	4.7		
	51	4.1																																			1		4.6		
	49				٠	•	٠	٠		٠	•		•	•	•	ŧ	٠	•	•	•	•	•				-			•	•		٠.	•	٠.	-	٠.			9		•
WEEK	47	•	٠	•	٠	•		٠	•	•	•	٠	•	٠		•	٠	٠	•	٠	•	•	•	•	٠	٠	•	٠	•	٠	٠	•	٠	٠	•	•		•	4.6	•	•
TEST	45	4	4.	•	•		•		•	-		•		•	•	•	•	•		•	•		•	•	•			-	•	•	•	•						•	4.9	•	
	43	4.2			•	•	•	•	•	•		•	•	•	•	•	•	•	•	•	•	•	•		•	•				•	•	•	•	•	•	•		•			•
	41	4.2					•	•	•		-	•	•	•		•		•	•			•	•		•	٠		•	•	٠	-	•			•	•	ŧ		5.0	•	•
	39		•		•	•	•	•	•	•	•	•	•	•	•	•	•		•				•				5,9	•		•	•						- 1		л 1.	- -	ى -
	37		•	•		•	•		•			•		-	•	-		×	•			•			•	•	4.8			•	•	•	•	-	•		1		4.8	•	•
	35		-	•							•		•		•	•			•		-		-		•			•		•	٠				-				5.0		
	33	•	•		•	•		٠	٠				•	•		•	•	•		•		•		•	-			•	•	•				-			- 1		5.1		
	31		•	•	•	٠	•	٠	•	•	•	•	•	•	•	•	•	•	•	٠	•	•	•	•		•		•	•			-		-	٠		•		4.4		4.
	29		•	•	•	•	•	•				•		٠		•	•	•							•			•											5.1		
	27	4.7	4.7	4.7	4.7	4.7	4.4	4.4	4.4	4.4	4.4	4.7	4.7	4.7	4.7	4.7	4.7	4.7	4.7	4.7	4.7	4.7	4.7	4.7	4.7	4.7	5.5	ກ ນ	5.5	5.5	5.5	5.2	5.2	5.5	5.2	5.2	5	5.4	5.4	5.4	ъ.
υп	× .	Σ	Σ	Σ	Σ	₹.	Σ	Z	Σ	Σ	×	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Z	Ξ	×	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Z	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ
202	ا ۵۰	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		-	-	-	-	-	-	-		-	-	-	-	-	-	- -	•	-	•	-	-	-	-	•	-
z	.		7	e	4	ល	9	7	80	· σ	9	=	7	5	7	15	16	11	48	6	20	2	22	23	24	25	56	27	28	53	30	3	32	33	34	35	36	37	38	39	40

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX TR Group

TWENTY FOUR MONTH CHRONIC TOXICITY CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIA; (NE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

	65	4.8	•	•	•	•	٠	•	1	•	٠	4. D	٠	٠	٠	٠	٠		1	5.2	٠	t	ı	•		•	•			•	•						ı	0.6		0 1		
	64	8.4	•	•		٠	٠	1	1	•	٠			٠	٠	٠	•		1			t	ı	•	•	•		٠	•			•			•		t		4 4 O 0	- 1		
	61		•	•	•	٠	٠			•	•			•	•	•	٠		ı	5,0	•		1	•		٠	٠	•	•		•	•	•	•	•	-	1	•	4. 0.	5 ! C !		
	59	ري د			٠				1	4.	٠		•	4.7	•	4.7	٠	!	ŧ	5.3	•	1 1	 	6.4	•	•		•	٠	٠	٠	4 .	٠	•	•	•	1			. :		
	57		9 10	ى تەر	9 i	9	4,3	1	1 1			4.9								5.5																				3.7		
	55		•		٠	٠	•	•	,	•	٠		•		٠	•	٠	1	1	5.6	٠	1	1	•	•		•	•	•	٠	٠	•		•		•	ŀ	•	4.	1 4		
	53	4 . R: 1		٠	٠			•	•			٠			•		•	•	•	•	•	•	٠		•	•		٠	•	٠	٠	•				•		•	•	4 4 0 0	•	
	51	មា	-	•	•	٠	•	•	٠	٠	•	•	٠	•	٠	•	•	•	•	•	•	•	•	•	•	•	٠	•	•	٠	•	٠	•	٠	•	٠	•	•	•	ლ ი დ ი	•	
	49	4.7	•		٠	•	٠	•	٠	•	•	٠	•		•	٠	٠		-	•	•	•	•	•	٠	٠	•	•	•	•	•	٠	•	٠	•	٠	٠	•		4.4		
WEEK	4	4	٠	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	٠	•	٠		•	-	•	•	•	6 c	•	
TEST	101	9	•	•	•	•	٠	-	•	•	•	•	•		٠	•	•	•	,	•	•		•	•	•	•	•	-	•	•	•	٠	•	•	•	•	•	•	•	ი ი ი ი	-	
	43	•	•	•	٠	•	٠	•	•	•	•	•	•	•	•	•	•	•	•		4.3	•	•	•	•			•	•	•	•	•	-	•	•	•	•			4 4		
	41	80		•	٠	•		•		•	•	•	•	•	٠	•		•	•	•	•	•	•	-	•	•	•	٠	•	٠	٠	٠	•	•	٠	•	•	•	٠	ი ი ი	•	
	39	ທ		•		•	•		•						•			•										•	•	•	•					٠.		•		6,0	•	
	37	4.9	•	•	•				~	4.	4.1	5.2	5.2	5.2	5.2	5.2	6.4	4.9	6.4	9	9	4.8	4 0	4	4.8	4.8	4	4	4.7	4.7	4.7	4.4	4.	4.4	4.4	4.4		-	•	က (က (•	
	35	.5				•			•		•	•	•	•	٠		•						•		•		•		٠		•	•	•	٠	٠		٠	•	•	ი ი ი	•	
	ကြ	4	-	٠		•	-	٠	-			•	•	•	•	٠	٠		,								٠	•		•	٠	•	•	•	•					2. E	•	
	i	4 9	•	•	•	٠.			4	4	4	- 1	1		ŧ	- 1	•			•						•	-		•		-	•			•				•	9.6	*	
	29	4	•		•		•											•										•			•	•								4.8		4
	27			5. 1			•						•									•						•		-			•	•	•	•				3.7		co:
νı	ж		Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	×	Σ	Σ	Σ	Σ	Σ	Ξ	2	: ≥	2	Ξ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	<u>_</u>	LL.	u	اسا	_	FOO!
α O :	ه د	-	-	-	_		-	-	-	-	-	-	-	-	-	-	-	-	-		-	-	-		-	-	-	-	-	-	-	-	-	-	-	•	_	-	-	₩.	-	-;:
z	0	41	42	43	44	45	46	47	48	4	200	, L	52	6.0	54	55	26	57	α V	ָ מַ	ç	-	6	9 6	64	65	99	67	68	69	70	7.1	72	73	74	75	16	11	78	79	80	

*Food spilled

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX;

4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

8 1	44444 00 000 0 000 00 000 000	
6.4	44444 44 44444 44444 44440 00000 Lee 6222 1223 1233 12	
6 1	လယ္လယ္လ နန္နန္နက္လည္လ နည္တတ္တည္ လြတ္လည္လ လက္လက္လ ႏုိင္ငံ ႏုိင္ငံတိတ္တည္ ႏုိင္ငံတည္တည္သည္ ႏုိင္ငံတြင္တြင္း အသိသည္သည္ ႏုိင္ငံတြင္းသည္။ အသိသည္သည္။ အသိသည္	
න භ		
57	က်က်လည်း ကို လုံးလုံးလုံးလုံးလုံးလုံးလုံးလုံးလုံးလုံး	
នទ		
හ ය		
យ		
4	44444666666444446666666666666666666666	
ш	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	, , , , , , , , , , , , , , , , , , ,
ដា ។		
7		
33		
37	ららららなアファファンスススススの日日日日ファファファン	r.r.r.m.m.m.m.m.o.o.o.o.o
Ö	$\begin{array}{c} \mathbf{a} \\ \mathbf{c} \\ $	4440000000000000
င	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	ာ သင်းသံက်က်က်က ထုံစပ်စပ်စပ်စ
.		ត់ ស ស ស ស ស ស ស ស ស ស ស ស ស ស ស ស ស ស ស
б С	444444444 0000000000000000000000000000	ω
27		စ်စ်စ်စ်စ်စ်စ်စ်စ်စ်ပင်ငံ
wm×		
⊢ α 0α0⊃α		
es co co co co co co co co co co co co co	8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	100 100 100 111 112 113 114 116 116 116

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX TR Group 1

	65	6.6 6.0				•				•	•	•	•	•	•	٠ ١		•	•	•		•	•	٠	٠			•		•	٠	•	•		
	64	6.6		•			•			•	•	•	•	,	•	. 1			•	•				٠	•	•		•	•	•	•	•	•	•	
	6.1	4	7		. ~	_				80	ω	8	: ::::::::::::::::::::::::::::::::::::	20 20	ο α	1	æ	Ü		ه د		o o	တေ	ח כ	ກ່ວ) (L	y (g	9		ဖ	œ		. .		
	1	88	e	m m	n	က (n :	າຕ	1	4	4	4	< (יז כי	י כי) I	r)	n	n c		າຕ	m	ကျ	י מ	יט פי	4	4	4		4	4	ব '	4 <		
	à		•	•		•	•	•		•	•	•	•	•		٠ ۱		•	٠	٠		•		•					1		٠	•	•		
	57	9.6	•	•		•	•	•	٠,	•	٠	•	•	•	•	٠ ١	•	•	•	٠			•	٠	•	•			- 1	•	•	•	•	٠.	•
	55	ດ ທີ່ທີ່				٠	٠			•		•	•	•	•	٠,		•	•	•	•	•	•	•		•	•		ı	•	•	•	•		
	53	4.4		e e		•		•			•	•	•	•	•	•		•	•	•		•	•	•	•	•	•			•	•	٠	•	•	•
	į				٠.	•	•			•	•	•	•	•				•	•	•			•	-	•	•			•	•	•	٠	•		
	49	010		•		•	•	•	٠.		٠	•	•	•	•	•			•	•		٠.	•	•	•		•		•		•	•	٠	•	•
Ä		8 80					ω (8	0	~	~	0 (, 0	_	.	_ ,		· 6 0	6	ω (x c	o -				_	e	e .	ი (ოო	
¥ E	5	n n					n (יז ני	4	7	4	4	4	4 4		1 4	4	e	es i	ო :	9 C	(m	က	m i	m c	2 4	. 4	4	4	4	4	4	ᢦ •	4 4	
TES	4 1	00		•	•	•	•	•	•		٠		•		•			•		٠	•		٠		•		•				٠.		٠		•
	43	(C) (C)		•			•			•	•	•	•	•	•		•		٠	•	•		3.1								٠	٠	-	4 4 6 6	
	₹ 1	00		•		•		•			•	•	•	•	•				•	•			•		-		•	٠.			•	٠	•	4 4 4 4	•
	39	m m		•		-	•	•	٠.			•	•	•	•	•	-	-	-	٠			•	•	•	•	•				٠	•		•	•
	į	មាល				•	•	•			•	•	•		٠	•			•	•	•			٠	•	•						٠	•	•	•
	35	ω α	.	ထွင	٥ c	. 7	7	ú.	ų	-	- ,	- .	Ξ.	۲. ۱	- •	- !-		. ن	9.	9	o o	. m	۳.	ر .	რ () (f	e e	n	7	7	.7	r r	-
	6			. .	- 4	-	₹.	.		. ~	7	7	7	~ 1	- 1																			о r	
	8 1	0 0	ຕ		າຕ	(F)	(C)	n n	3 4	4	4	4	4	က ⁽	m (*	** **	** -**	* •	×									
	33			•	•		•		. 4	4	4	•	4	•	•	•	•			•			- 1	ì		1		•						•	
	29			ლ 	•		•	•	١.	!	1	1	;	•	•	•		•	•	•	-						•					•	•		. "
	27	6. 6.					•	•	•				•	•	•	•	•		•		-			•			•	•	•				•	•	. 1
v	ш×	T D	. u .	LL (ı u	. u.	u.	ı. ı	LL	. 11	·	Œ	u.	ĮŁ.	u. t	ı L	LL	. L	ட	LL.	ıı, u	. u .	ı	ıL	1 4. 1	ı. :	ΣΞ	E Z	Σ	Σ	Σ	Σ	Σ	¥ 3	E ,
⊢ α 0α0	20					-	-	. .		-	-								-	-			-	-	-	- (N (40		1 64	7	8	7	00	4
Z FPZHZP	0	121	123	124	125	127	128	129	3 4	132	133	ve.	135	136	137	800	140	7	142	143	144	146	147	148	149	120	C 0 1	10.4	15.4	155	156	157	158	159	2

1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX**Feeder weight inadvertently was not recorded *Food spilled TR Group

4

TWENTY FOUR MONTH CHRONIC TOXICIFY/CARCINOSENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

ល					1444R			8 1 3 0 0 1 1
8	1			1		, w w w w w w w w w w w w w w w w w w w		1
7	0.00			;				11 1 -
		. 1		1		រល់ល់ល់ល់ល់ សង្គ រល់ល់ល់ល់ង់ 4 4 4 .		1 1 1 .
57	0,00	ျက်မ	. 9 0	00012		ຸດຄຸດຄຸດຄຸດຄຸດ ກຸດຕຸດຕຸດຕຸດ ກຸດຕຸດຕຸດຕຸດຕຸດ	+ + +	
		. ! - !!	7 7 7	4441-		ာကကကက ထာထားထား	& & ! O ! !	מועמוו מועטוו מועטוו
ញ ម			ဝ်ဝဝက်	ល់លំលំលំព	င်းက်က်က် က	0 8 8 8 8 6 6 6	۲. ۲. ۵ ۵ ۱ ۱ ۱ ۵	o
τι +-	m m m	်ထံထံပော်င	ာတ္တတ္∽		44446		· · · 4 4 .	4 00 0
	000	່ພ່ພ່າບໍ່ຖ	ပ်ညက်ည်ဆေ	က်ထံထံထံက	စ်ကာက်က်က	0 to 10 to 4 4 4 4 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7		r: 22 2
WEEK 47	9000	်ုက္က ဖ (ခဲ့ ကဲ့ ကဲ့ ကဲ့ ယ	ល់ល់ល់លំព	ប់សំសំសំសំ	14444000 0000000000	0044114	٠ ١ ١ ١ ١ ١ ١ ١ ١ ١ ١ ١ ١ ١ ١ ١ ١ ١ ١ ١
12 12	် ၈၈ ၈	၈၈၈င်	0000	· · · · · ·	ည်လက်လုံလုံ	വവവയയയയ	1 1	waaa la
	000	004				ज्ञ ज ज ज ज च च	440011	ش هن ده ا ه
		0	ó o ó ó u	ပ်ပပ်ပ် ပ		4444000	00	ا ا ا ا ا ا ا ا
Ş	ស្រល់ផ	រុលសុខព	, , , , , , , , , , , , , , , , , , ,		សំសំសំសំ សំ	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	000011:	១៧ មា ប្រ
27	1 4 5 7	. 4 4 0 0	တ္တတ္တ-		444441		រោយ ខេត្ត 🚶	# 0 0 0 1 0
វេ	រូបបរ	ល្លល់	യവവവവ	ស ភ ភ ភ ភ ភ	00000 4444	. ជ	ិ ១ ១ ១ ១ ១ ១ ១ ១ ១ ១ ១ ១ ១ ១ ១ ១ ១ ១ ១	
ç	ម្រាល ! !		 	44444	លលលលល 4 4 4 4 4 1	00000000	001 4400 i i i	
•	88	0 8 8 + 3 4 4 IU 1	מיינת	44444	44441	លលលលលល បុល្យល្លេស 4 4 4	4400:0:	044414 044414
0	ព្រះបា	ותממה	រោមបាមបា			00000444 vwwwwa44	4400፡፡ መ	
	្រ ព្រះស្រ	ាលល្ ល់	លលលល 4	4444	44441	ນ ພ ທ ພ ພ ພ ພ ພ ທ ທ ທ ຫ ທ 4 4 4	यययय। य	444414
r	ເນີນ ໄ	் ம் ம் ம்	ສຳນີ່ດຳນຳດຳ	4444	यं यं यं यं यं।	********	mm4414	4444
	1					~~~~~~~		!
47 50	161	164 165 166	167 168 169 170	173	176 177 178 179 180	181 182 183 184 186 187	189 190 192 193	195 196 198 198 200

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX*Food spilled

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

	65	4	٠	٠	•	•	•		4.8	1	•	٠	•	1			t	٠	1		•	1	•	•	•	•	1	1	٠	٠	•	٠	•	٠	-		٠	•	3.9	1	•	
	64		•	•	٠	•	•	•	•	1	•	•	•	1	٠	•	t	•	1	•		1	٠	٠	•	•	ı		•	٠	٠	٠	•	•	•	١	٠		4.	t	. .	
	6 +	•	•	•	•	•	•	•	•	1	•	•	•	•		•		•	1		•			•	٠	•	1		•	•	•	•		•		ŧ	•	•	3.7	ı	•	
	59	5.8	•		•		•		5.4	1	•	•	•	1		•	1		1		•	ı		٠	•		,		•			٠		•		•	•	•		!	4.	
	57		•	•	•	•	•		•		•	٠	•	ı		-	1	-	ŧ		•	•		•	•	•	ı	1	•	•			•				•	٠	3.9		•	
	55		٠	•	•	٠	•		•	1	•	•	•	1				•	1		•	•	•		•	•	•	1	•	•	•	٠	٠	•	•	1	•	٠	ი ი	1		
	53		•	•	•	•		•	•		•	٠	•	•	•		٠	-	٠	•	•	•	•	٠	•	•		٠	•		٠	•	•	•		٠		•	3.4	•	•	
	5.1	5 0	•	•		•	•		•		•		•						•			•				•			•	•		•	٠			٠	•		3 9			
	49																																						3.7			
WEEK	47		•	•	٠			*		•	•	•	•	•		•	-	•		•	•			•		•			•	•	•	•					•		3 2			
TEST W	45	5.6	•					•			•	•	•				•		•			•		•		•		•	•	•	•		•							•	•	
	43	5.3	•	•	•			٠		•	•	•	•	•	•	•	•		-	•	•	•	•	٠	•		•	•		•	4	•		•								
	1 4	•									•	•	•	•				•								•	٠	•		-	•		٠		•	•		٠	2.9			
	39	5.4	•	•							•		•	•	•	•	•				٠	•							•	•	٠	•							3 5			
	37	5	ĸ.	ت	ت	ت	ဗ	<u>ب</u>	က	٣.	၈	6.	6.	6.	6.	6.	6	6.	6	6.	6	7	7	~	7	~	.7	۲.	٠.	۲.	۲.	ល	ıs.	ıs.	R.	r,	ı.	5	r.	5	ت	
	35	ı		•	•					•	•	•		•		•	•	•	٠	٠	•	•		•			•			•	•	•	•		•		•		3.8	•	•	
	33	4.9	•	•						•	•	•	•	•	•						•	•		•	•			•		٠		•	•						3.1		3.1	
	1		8	۲,	۲,	7.	æ	80.	∞.	ω.	₩.	₩.	80.	ω.	ω.	ω.	7	.7	.7	۲.	.7	<u>б</u>	o o	6.	6.	<u>ە</u> .	o.	o.	0	0.	0	ص	<u>ر</u>	က	e.	τ.	6.	6	· 6.	Ø	တ	
	29	5 7	•	•						•	•		•		•	-	•		•	•			•	•	•	•	•	•	٠					٠					300			
	27		<u>ب</u>	ღ.	<u>د</u> .	ღ.	6:	<u>ه</u>	6.	6.	<u>و</u>	ω.	8.	₽.	ω.	ω.	4	4	4.	4.	4	۲.	.7	7	۲.	.7	₩.	ω.	ω.	ω.	€.	о О	ق	о О	6	σ	~	. 2		8	.5	
v	ш×	! ! !																																								
0 M D	⊃ •	2	8	8	8	0	~	8	7	8	8	0	8	7	~	~		0	~	8	~	2	8	7	8	8	~	7	7	7	8	۰	٥	8	0	0	~	0	~	8	^	
a ~ Z	ο .	201	0	0	0	ಂ	0	0	0	0	-	-	-	*	-	~	-	_	_	-	C	~	C	3	C	~	2	S	2	~	G	က	6	က	က	C.	(7)	ന	238	က	4	

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TR Group 1

ស		
64		
6		
ຫ		
57		6. 6. 4. 4.
ю С	$\begin{bmatrix} c c c c c c c c c c c c c c c c c c c$	3.7
r.		
9		
WEEK 47	cccccccccccccccccccccccccccccccccccc	3.7
TEST	$\begin{bmatrix} \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega$	
	$\begin{array}{c} \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega$	
4	$\begin{array}{c} \text{ www.} \\ w$	
o r		•
	00000044444000000000000000000444144444000	•
c u		
ç		
č		
	$\sum_{i=1}^{n} \alpha \alpha \alpha \alpha \alpha \alpha \alpha \alpha \alpha \alpha \alpha \alpha \alpha \alpha \alpha \alpha \alpha \alpha \alpha$	
ΩШ>	< ***********************************	u u
0 & O ⊃ O		0.0
4 7 Z O		~ œ

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; $t_0 = 35.0 \text{ mg/kg/day RDX}$; $t_0 = 175/100 \text{ mg/kg/day RDX}$

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MQUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (9/day)

ន ម !	4444466 666666 44 4460000 1000 104444400 00000000 0000000 11111111111111	
64	4444400	
i 1 1 10	, α α α α α α α α ι α α α α α α ι α α α ι α α α ι α α α ι α α α α ι α α α ι α α α ι α α α ι α α α α ι α α α α ι !	
ရ ရ (၁)	4444469 9666999 44 446888 888	1 2 2 2 1
52		1
ហេរ		
53 53		
67		
m 4		1
EST 45	$\begin{array}{c} \begin{array}{c} \text{constant} \\ \text{constant} \\ \text{constant} \\ \end{array}$	
4		1 2 1
n		
37	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} $	
38		7 7 1
6		1
က		1
		5.1
27	WWW.WW.WW.WW.WW.WW.WW.WW.WW.WW.WW.WW.WW	
υш×		
⊢α Ωαο⊃σ		ოოოო
42μΣ4⊐ ZO·	2822 2822 2822 2822 2822 2822 2822 282	317 318 319 320

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group

(

٩

٩

ឆ្នេ រ ម រ		1			44444441141444
6 1 4 4		1			444444441 N N N N N N N N N N N N N N N N N
- 6		1	1		4444400001141444 800000044441101000
ច (ជ. (វ.					444448881 8 888 CCCC 4444 1 1 1 1 1 1 1 1
57					444448881181888 8.888824441141444
រ ស ស					4444400001141444 @ @ @ @ @ O O O I I @ I @ @ @
5 3					4444444444444
بر 1					4444444444444
₹ 1					44444444444444 8.88888000000//////
田 田 4 1					44444 W W W W W 44444 w w w w w w w w w w w w w w w w w w w
in 42					0.0.0.0.0.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4
•					44444444444444
~					4444444444444
39					44444000000044444
37	លសាលាលាល ៖	44444 600000 600000		nn n44444	4444 100000044444 00000000000000000000000000
35	44444				44444444444444444444444444444444444444
33					
15		44441 1444444		44 4000000 00 0 + + + + + +	
59		0	00000	44 44444 	
7.2					
w w ×	EEEE		EZZZZZ	Z Z Z Z Z Z Z Z Z	
⊢¤ @¤o⊃₫	00000		, n n n n n		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
dΣμΣdη ZO·					348 348 348 350 351 352 353 355 355 355 356 356 356

RDX; 3 = 7.0 mg/kg/day mg/kg/day RDX = 1.5 mg/kg/day RDX; /day RDX; 5 = 175/100 35.0 mg/kg/day RDX; ~ Control; Ħ H Group TR

91	$\frac{4}{1444} \frac{1444}{160} \frac{1}{160} $	4.2
O I		•
6	4 4 4 4 M M M M M M M M M M M M M M M	4.5
ហូរ	w w w w w w w w w o o a a a a a a a a a a a a a a a a	
57		•
ו חו	N N N N N N N N N N N N N N N N N N	
រ ល	NNRNNNNNNNNN	•
រ ល	$\begin{array}{c} 4 & 4 & 4 & 4 & 4 & 0 & 0 & 0 & 0 & 0 &$	
41	4 4 4 4 4 6 10 10 10 10 10 10 10 10 10 10 10 10 10	
E 4.	4444488888	•
E 4 1	$\frac{4}{4}\frac{4}\frac$	•
4 1	. rv rv rv rv rv rv r 4 + 4 + 4 + 4 + 4 + 4 + 4 + 4 + 4 + 4	•
4 (4 4 4 4 4 4 4 4 4 4 4 1 4 4 4 6 6 6 6 6	•
က ၊	44444444 NNNUUUUUU444444000UUUUUUUUU4444 0000000000	
37	$\begin{array}{c} 1 \\ 444444441 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ $	
(C)	1 4 4 4 4 4 8 8 8 8 9 9 9 7 9 7 1 4 4 4 4 4 9 9 9 9 9 9 9 9 9 9 9 9 9 9	•
က :	444444444	
က၊		
6	$\begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	
27	$\begin{bmatrix} 1 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\$	•
νшх	EXEXXXXXXXXXXX	IL.
⊢ α 0α0⊃α		က
ZHZ41 ZO·	361 361 362 363 363 363 363 363 373 373 373 374 375 375 375 375 375 375 375 375 375 375	400

1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; $\frac{1}{4}$ = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX TR Group

(

۷Z

⊢ α

4 Z H Z 4

	ဖ	0.00							•		•								•						1 1	•	1
		0.4			• ;				•						. 1			•	•		•			•	1 1		1
			ည်က လ တြင်	, e. e.) W	9 0 0	9 0	က က မ မ	3.6	4	4.1	1 7	7.5	4 4	1	4.0	ກຸດ	3.9	ი ი ი	ກ ຫ ກ ຫ	3.9	ი ი ი	ກຸຕ	4.6	1 	4.6	: : :
	59	3.7														•		•	•	٠.	•	•	•	•	1 1	5.1	
	57	3.7			• 1				•	٠.	•		•			•		•	•		•	•		•			i i
	TU.	0.00 1			٠ ١								•			•					•	•			1 1	4.0	! !
	53	44.							•		•		•		•	•		•	•		•	•		•	1		•
	വ	8.60				• •			•							•			•			•			ı		
	-	9.6																									
VEEK	47	3.7	•						•		•		•			-					•	•		•	1		
rest (45	 000 000		• •												•		•	•		•			-	;		•
	43	0.00							•		•								•			-			!		
	41	44.																									
	39	3.7							•		-								•	ກ ຕ ໝຸ ໝຸ					1		
	37	3.6										•		က ထ ထ		-		•	•		•	•		•	1		•
	35	335							•																1		
	ຕ	3.7						٠.	•		•	•					٠.		•			•			1	•	•
	31	3.6	က က တ တ ပ	3 65 c		. r. u	. 4 . 5	4 4 ro ro	2.5	. r.	3.7	. c	3.4	0 0 7 0	9.6	3.4	က က က	3.8	3.8	9 . 9 .	3.7	3.7	, r	5.1	"	. . .	
	53	3.7							•		•	•		•		-	٠,		•						•		•
	27	3.6									•			• .		•							٠.		•		•
v	ъ×	-	և և ւ	. H. U		- 44 10	··	ji U.	il i	L UL	14.	և ե	. њ	LL LL	. u.	u. i	<u></u>	Ŀ	L .	u u	t.	استا	ı u	u.	LL L	LL	<u>. </u>
φας) D Q	00	იი		າຕເ	າຕເ	იო	ოო	m r	າ ຕ	က	ო ო	ю (ကက	ო	ල (ო ო	6	ლ (ოო	က	ტ (ი ი	6	ი ი	າຕ	n
2 د،	: o ·	401	404	40s 406	408	244	412	4 4 4 4	415	416	418	4 19	421	422 423	424	425	426	428	429	430 431	432	433	435 435	436	437	439	440

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX TR Group 1

TWENLY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day) TWENTY FOUR
HEXAHYDRO-1,3,
INDIVID

THE TANK THE PARTY OF THE PARTY

*Food spilled TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; $t_0 = 35.0 \text{ mg/kg/day RDX}$; $t_0 = 175/100 \text{ mg/kg/day RDX}$

⊢ ∝

C P K H & P

⊢ α

< Z - ∑

	65	44444444444444101000010000 000000000000	
	64		0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	61		
	59	wwww.44444441441w.ww.41444 www.w.c	
	57	r r r r r r r r r r r r r r r r r r r	
	55	wwwwwwwwwwwa44444	0-10110001000
	53	ϕ ϕ ϕ ϕ ϕ ϕ ϕ ϕ ϕ ϕ	000000
	£	υ ω ω α α α α α α α α α α α α α α α α α	000000000000000000000000000000000000000
	49	៰៰៰៰៰ <i>៴៴៴៴៴៴៴៴៴៴៴</i> ៰៰៰៰៰៰៰៰៰៰៰៰៰៰៰៰៰៰៰៰៰	
7			
7. E.F.	2 2	ααααα CCOOO00000000000000000000000000000	
+ -	-		
	4	លុសលក្ខភ <u>ុក្ខុក្</u> មស្លេលលុសល្លេលលេល	
	4	a a a a a a a a a a a a a n n n n n n n	
	39	លេខ ទេខ ៤ ៤ ៤ ៤ ៤ ៤ ៤ ៤ ៤ ៤ ៤ ៤ ៤ ៤ ៤ ៤ ៤ ៤ ៤	
	37	, , , , , , , , , , , , , , , , , , ,	
	35	លេខ ខេឌ្ឌ	
	33	a a a a a a a a a a a a a a a a a a a	
	3.1	υυνυνυς ς 4 4 4 4 4 4 4 μνυνυνιν 4 4 4 4 4 4 6 6 6 6 6 6 6 6 6 6 6 6 6	
	29	44444444444444444444444444444444444444	
	27	44444444444444444444444444444444444444	
ι	лшх	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	E X X X X X X X X X X X X X X X X X X X
υα (v < v < v < v < v < v < v < v < v < v <	1 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
2 د ۲	Z O ·	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	000 000 000 000 000 000 000 000 000 00

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXIJ 11 Group TR

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

0 × 0

	65) (1			œ̈́				<u>ත</u>						œ	œ	ဖ	ဖ	i	ø.	9	س	e O	e,	o.	m i	ស	ស្រ	ທ	សូ	ıs.	! !	بو	œ.	ဖ	9	!	r.	ស	, r	្រ	?	
	u	1 1	•	ເນ	ល	ı	က	ო	n	n	က	m	m	•																				m	n	က	i	က	ຕ	n) (T		
	64		1		5.3	1	•	•	•	•	•		٠		٠	٠	٠	•		•	•	9.0	٠	•	٠	•		•		•	•	1	٠	٠	٠	•		•			•	•	
		1 1	1	5.7	5.7	1	3.8	3.8	3.8	3.8	9. 8	0.4	4 0	 	0.	0.4	3.6	3.6	1	3.6	3.6	4.0	4 0	4.0	0.	0.	ლ ლ	<u>ო</u>	ი ი	ლ ლ	3.3	!	4.	4.1	4	7	1	3.7	3.7	3.7			
	59	1 1	- 1		5.6	1			•	•	•		•			•			ı	•	•			•	•	•	•	•		•	٠	1	•	٠		٠	1	•		•	•	•	
				9	9	:	80	8	œ.	80.	ω.	0	0	ļ	0	0	∞.	æ,	:	80.	₩.	.7	.7	. 7	. 7	.7	თ.	<u>م</u>	თ.	σ.	o.	1	o.	<u></u> ق	<u>ෙ</u>	<u></u>	1	.2	2		, ,	Y.	
	ស	! ! ! !			5																										o o	ı											
	ល	!!	:	r.	ທ	ì	ю	e e	က်	ю	e,	က်	က်	!	რ	ю	<u>د</u>	რ	ļ	ė	ю	က်	რ	რ	ю	რ	ი	က	e,	က်	e.	!	m m	ო	რ	ю С	1	4	4			4	
		1 1			8																								•	3.7	•	•					•			•	•		
	51				6.1	1							•											•		•					•		•		•	•							
	49	!	ŀ		5 7	, i		1.1	4.1						٠.	•						3.8		•	•		•					•			•					٠	•		
X.	47	!	ŧ		_				•		•	•	•	•	•	•		•	•		•		•	•	•		•		•		•	•	•		•				•		•	-	
ST WEEK	ນ	1		Ī	2																	7 3																		, c	· •	າ 	
15	4	1 1		•	ئى				•		•				•	•	•				•	რ	•		•	•	•	٠		٠	•	•			•	•			•	; <	• •	4	
		1 1			S IS		C C		•			•	٠,	•	•	٠,		٠				3.6		-	•									•						-	٠		
		1 1			ت دي																	3.8									•							•		•	•		
	38				7																	4.0																					
																						S.														•		•			•	•	
		1 11		Ī) (C) ග																					
	n	ł			, ru																																						
	33	1 10			יש ני מיני																									•		•							•		٠		
	3	1 (٠						•				•			•			•	•	•	• •			•					•		•		•		•	•	-	٠	٠		•	
	29	1			. 4 ປະທາ																				•							•					•			•	•	•	
	27	!	٠, ٥		, c	· c	<u>,</u> r-	. ^		٠,		-	-	-	-	-	· e) C				9 19		9	بع	9			. 7		. 7	7	7	4	٧	. 4	. 0	ņ. 0	ņ. c	n e	ۍ ا	6.	
۲ō.	ıu ×	1			าแ																																						
	 ⊃a	1			: <																																						į
z	0	1 1 1	- 20	222	573		320	200	200	975	230	331	532	100	755	23.5	900	127	2 0	000	200	141	242	143	544	545	346	547	548	549	550	55.5	75.2	1 1 1 1 1 1	יונ ער גע	י ע טוי	2 11	000	700	558	559	05	

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; $t_{\rm H}$ = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

0

(3)

0

4

٩

(

TW-NTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAH'DRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MDUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

000 0 0 4 1 1 4 4 0 1 0 0 0 0 0 0 0 0 0
444 40 004 4440 000
0001371177010000000000
444 40 000 0004444
ရေမေရ မေရ မေရ မေရ မေရ မေရ မေရ မေရ မေရ မေ
000000044444444444444 0000000000000000
, w w w w w w w w w w w w w w w w w w w
000000044444444400000 0444444+++++00000+++++
000000000000000000000000000000000000000
> 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
, , , , , , , , , , , , , , , , , , ,
0 0 0 0 0 0 0 0 0 0 0 0 4 4 4 4 4 4 4 4
94444466666666666666666666666666666666
00000000000000000000000000000000000000
00000000000000000044444 00000000000000
, , , , , , , , , , , , , , , , , , ,
1 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 5
0.00
,

*Feeder weight was inadvertently not weighed TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; $t_{\rm H}=35.0$ mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGEMICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3+; MOUSE INDIVIDUAL FOOD SONSUMPTION MEASUREMENTS (g/day)

9	7.6	1 1 4 1	4.4	0.11	: : :	6.11	1 1 1	4.3	4441	4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
49	11 3	4.8	1.6	0.11		4 1 1 1	1 1 1	0:11	8.4.8	7.11.18.188
19		. 1 80 .	4.8	4 1 - 1		4 1 4 1 6 1 1 6 1 1 6 1 1	1 1 1	6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	8.1.1.8 5.7.7.1.1.9
										4
										41110100 0.1110100
										41110100
	[i									
			16.1	** 1 1		mm: 1		~ ~ · + ·		4 1 1 1 4 4 4 4 4
	 44'-2	1641	141	411	141	चच । ४	91091	ומוט	ល្ល4 (4 1 4 4 4 4 4 4 4 1 1 1 1 1
	• • •									4 1 1 1 4 4 4 4 6 6 1 1 1 1 1 1 1 1 1 1
T WEEK	6.4 6.5 7.5	4 7 4 7	4.7	6.1	4.2	44 1 1		4.3	444	4 1 1 4 4 4 4 4 4 4 7 7 7 7 7 7 7 7 7 7
구 E S .		• •	1 . 1	. ! !				• • • •		4 1 . 1 4 4 4 4 4 8 8 8 8 8 8 8 8 8 8 8 8 8 8
£ 6	4.7		4 . 8	4.4	4.6	4 4 . 6		5.1	4.3	4 1 1 1 4 4 4 4 4 4 1 1 1 1 1 1 1 1 1 1
4	8 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	, 7 4	1 4 1	4.4	4 2	24 1 1 2 2 1 1 1 1		5.5	444	4 1 4 4 4 4 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6
39	0.4 4	4.7	4 7	8 : :	1 4 1	44 I R	5.1.	4.4	4.4	4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
37	0.00	4.7	4.7	4.6	4.2	4417	5 1 0 1		8	4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
35	2 4 1 4 8 8 1 8		1 1	1 3			1	· t		4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
33	00.0) . 8 & . !	4.8	7 ! !	4.6	9.4.6	ກ ກ ຕ ເ ເ ພ ພ ເ ເ	6.3	4.4	4 4 4 4 4 4 6 6 1
£		7.4	4.7	0, I I	4.7	4 4 1 C	7777	2 1 4	444 444	1 1 0 0 0 0 0
29	្រ ព្រលៈ ជ	וְטּאִינ	ļ 9 [<u></u>	ا ريا ا ريا	ម ព្រំ	!	- ; 6	000	စ ုံ ဖွဲ့ ဖွဲ့ ဖွဲ့ ဖွဲ့ ဖွဲ့ ဖွဲ့ ဖွဲ့ ဖွဲ့
27)	15:1	ත <u> </u>	4	44 10	္ မွ ဖ ဖ _{ွဲ့ ရ}	δ † 4.	444	u114444
	44,4	1441	,4,	அப்ப	। इत्र	4414	4441	414	14441	E E E E E E E E E E E E E E E E E E E
⊢¤ ©¤⊙⊃¢	ព្រលិល ព្រំ	រាមស្រ	លលល	លលា	ហលព	ស្រួស្រួ	ឧភាពល	លេលលេល	រាលលាលា	លក្ខាលាណាណា
AZHZAJ ZO ·	602 603 603	605 606 607 607	609 610 611	512 613 614	615 616 917	618 620	622 622 622 622	625 625 627	629 630 631	633 635 635 635 633 633 633

= Control: 2 - 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 25.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group 1

TOTAL CONTROL OF THE SECOND SE

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE B6C3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

ن م

< Z - 2 < J

The control of the co

	65	1	4.6	1	1	; !	1	4.	!	;	!	73	4.5	4.5	4 ت	4.5	5.6	1 1	1	5.6	5.6	1	5.4	1 	į	:	! !	1	!	1 1 5	!] 	! !	თ დ	1 1 1	ი ი	4.7		4.7	!!	!	
	64	!	4.6	Į	1	:	1	4.6	;	i i	!	4 ت	5.5	4.5	4 5	4.5	6.7	1	:	6.7	6.7	1	5.3	1	1 4	! !	1	; ;	1	! ! !	 - 	1) 	ო		ر ن	4.4		4.4	1 1	1 1 1	
	61	1 1 5	٠. ون) 	1	! !	! !	4.7	 	1	1	4.9	6.4	9.4	6.9	6.9	7.0	!	1	7.0	7.0	1	5.6	;	1	1	:	1	1 1	5	1	! !	† 1	4. ن	\$ 1	4.3	4.4	i	4.4	! ! !	1 1	
	59	!	n C	! !	i i	!	!!	5.0	 	1 +	1	4.8	4.8	4.8	4.8	4.8	6.5	! !	1	6.5	6.5	; ;	ე. გ	1	t 6 1	6 1 1	1	1	:	1	!	!	ł	0.4	1 1	0.4	4 6		4.6	!	1	
	57	1	9.9	1	1	} ! !	l l	4.6	1	!	1 1	4.6	4.6	4.6	4.6	4.6	6.3	!!	1	6.3	6.3	} ! !	5.6	1	 	i	1	1	!	1 5	1	; !	1 1	3.6) i	3.6	4.6	1	4.6	1 1 1	1	
	55	† ;		i i	!	1	ŧ ţ	5.4	1 1	1	1 1	4.3	4.3	4.3	4.3	4.3	0.9	1	: :	0.0	0.9	1	5.6	1 1	!	1	ŧ !	;	; ; !	1 í	1	1	1	ი ი	! !	ი ი	9.	1	4.6	1	ł }	
	53	1	4.7	5 1 4	! !	1 1	! !	ъ. Т	! !	!	 	4.3	4.3	4.3	4.3	4.3	5.0	5.0	1	5.0	5.0	l I f	5.7	1	 	! !	1	1 1	4.3	1	<u>f</u> 1	4.6) 	4 6	! !	4.6	4.4	1 1	4.4	 - -	[[
	5.1	! !	4.6	ì	1	! i	1	ი 4	1 1	!	1 1	4.5	4.5	4.5	4.5	4 .S	5.5	5.5	1	5 2	5.2	1	η, Ο	! !	1 1	1 1 1	:	1	4.9	1 1	:	4	l f i	4.2	! ! !	4.2	4.8	1	4.8	1	!	
	49	1	5.7	1	† ;	1	1	го —	1	1	i i	4.5	4.5	4	4.5	4.5	5.3	5.3	i 1	5.3	5.3	1	5.7	1	!	1	:	!	5.3	t (! !	ი ი	í	ტ ტ	1	3.9	7.	;	4	!	:	> 0
WEEK	47	1	4.4	1 1	1	1 1	:	4.9	;	1	1	4.4	4.4	4.4	4.4	4.4	5.4	5.4	1	5.4	5.4	!	5.6	:	1	! !	1	į	4.9	1	1	ი ი	!	9.0	! !	9.6	4,8	!	4.8	:	1	
TEST	45	1	5	: :	1	:	1	4.7	:	1	! !	4.6	4.6	4.6	4.6	4.6	5	5.5	; ; ;	ຣີ	ស	į	5.9	1	!	1	1 1 1	1	4.7	;	\$ 1 1	0.4	! !	4.0	1 1	0.4	4.5	1	4 3	1	1 1	5
	45	:	4.7	1	1	:	:	4.7	1	!	1	4.5	4.5	4.5	4.5	4.5	5.7	5.7	1 1	5.7	5.7	1 1	5.3	1	1	1	1	:	5.3	!	!	3	t 1		1	3 7	4.6	!	4.6	[;]	:	1
	41	ž ;	4 9	; 	1	1	1	4 7	1	!	1	4.4	4.4	4.4	4.4	4.4	5,4	5.4	i ! }	5.4	5.4	1 1	5.0	!!	:	1	1	1	5.0	1	;	3.7	!	3.7	1 1	3.7	4.2	1 1	4.2	!	1	ſ
	39	1	4.9	1	•	1	!	5 3	1	1 1 1	! !	4.6	4.6	4.6	4.6	4.6	5,3	5.3	1	5	5.3	:	5.6	-	1	; ;	:	1 1	5.0	! !	!	9. 8.	1	3 8	1	3.8	۵. ۲	1	4.1	[t 1	6
	3;	1	9.9	1	!	:	1 1	4.7	!	1 1 1	1	4.5	4.5	٦. ت	4.5	4.5	6.8	6.8	1 1	8.9	6.8	1	5.6	!	1	1	1	\$ 1 1	5.0	1 1	!	4.2	1	4.2	1	4.2	4.8	1	4.8	1 1	; ! !	•
	35		4 6	!	1	• •	1	5.3	;	:	1	4 7	4.7	4.7	4.7	4.7	5.1	5.	1	5	5		6.3		1	1	1	1	4.9	1 1 1	1	3.5	! ! !	3.5	1	5	4.5	!	4 5	!	:	ı
	33	1 1 1	5.6	5 5 1	1	<i>i</i> :	1	4.7	3 1 1) 	1	4.4	4.4	4.4	4.4	4.4	ເນ	5	1	5.3	t)	1	5.1	1	:	1	!	t E J	9.	1	1	3.6	1	3.6	1	3.6	4.4	‡ !	4.	;	!	,
	31	!!	4.9	1 1	1	i i	1	7	!	1	1	4.8	4.8	4.8	4.8	4.8	5.2	2.5	;	5.2	5.2		4.0	4.0	1	1 1	;	3.4	3.4	1	!	3.5	;	3.5	1 1	3.5	4.9	;	4.9	1 1 1	!	•
	29		6.9	1	1	1	1	4	1	1	1	4.0	4.0	0.4	0.4	0.4	2	5.0	1	5.0	5.0	1	5.	5.	1	:	1	4.8	4.8	1	1	3.6	! !	3.6	1	3.6	4.2	!	4.2	!	;	•
	27	1	9.3	! !	;	1 2	1	5.7	1		1	•	4.3	•	•		6.4	6		6.	9	1	2	5.4	:	!	i		4.8	i	1	3. 8.	1 3 1	დ. დ	i i i	3.8	4.6	ł	4.6	;	1 - 1	
ហ	. × i	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Z	Σ	¥	Σ	æ	Σ	3.	Σ	Σ	Σ	Σ	Σ	æ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	۱.,	Ŀ.	ıL	ŧ.	u.	,
× c :	ا ۵۰	ស	ιΩ	ល	ß	ល	ល	ល	'n	ស	Ŋ	ı,	រ	ស	S	ເນ	. . 0	ı,	ı,	i.	U)	ហ	מו	വ	ស	ល	S	ស	Ç,	ល	ហ	IJ	r	រប	Ŀλ	J.	ເນ	ស្រ	ល	ស	ស	ŀ
z	٠ . ا	941	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	929	61.7	99	662	663	664	665	999	667	899	699	670	671	672	673	674	675	676	611	678	619	680	

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3.5-FRINITRO-1.3.5-TRIAZINE(RDX) IN THE B6C3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

		65	g.	ص ص	n (, 10 10 10 10 10 10 10 10 10 10 10 10 10	l 	1	1	;	4.3	4.3	3.7	3,7	3.7	3.7	1	! !	1 2	!	5.0	ъ О	4 3	! !	!!	1	5.5	4.7	1) ; i] 	1	!	! !	1	! ; f	! !	1 1 1	1	t t t	: : :	1
		64	3.7	 	. t	۵.	1 2 2	1	į	1	4.0	4.0	0.	4.0	0.	4.0	1	1	1	1	5.	ა -	4.4	 	!	!	4.4	4.	1	! ! !	! ! !	 	!!	!) 	i i	1	1	-	1 1 1	: i	;
		61	3.8	დ ი დ ი	ກຸເ	χ. :	i 1	1	1	!	4.1	4.1	ю 8	හ ල	ω ω	3.8	1	1 1 1	;	1	4.2	4.2	5.5	 	! !	1	4 . 5	4.7	!	1	!!!	! !	:	i i	! !	! !	1	i i	1	:	I	:
		59	3.5	ເກີດ ເກີນ	ກເ	n	1 1	1 [! !	1 !	3.9	9 9	3.7	3.7	3.7	3.7	1 1	* 2	5	: :	4.1	4.1	4.5	!	! ;	!	4.5	ы 	1 1	† !	!!!	1	 	! !	1 1	; !	!!!	į į	! !	!	! !	!
		57	4.1			1 . 1] 	!!!	ł 1	1	4.2	4.2	3.6	3.6	ი 9.6	9.0	!			1 1	4 0	4.0	4.4	1	! !	1	4.4	5.6	1	! !	1 1 1		! ! !	1	1 1	!!!	;		! !	!	1	: !
		55	3.1	- ·	- ·	3.1	: :	1 1 1	!	1 ! !	4.9	4.9	3.4	3.4	3.4	3.4	1	; ;	!!!	1 1	3.4	3.4	4.3	!!	5 7 1	!	4.3	4.7		!	!!		1 1	!	1 1	[; ;	i ! !	1 1	!!!	!	[! !
		53	3.8	20 (.	x 0	,	ı																										! !	1	0.	0.4	:	4.0		0.4	:
		51	3 7	n 1	- t	٠ •		# !			~	~	₹	₹ .	₹	₹†					0	_	_	_			0	~											4.6			
		49	3.4																																							
	WEEK	47																																		æ.		(3.6	!	بى	:
	TEST W	45																																		о О		!	r.	! :		
	•	!	~																													1	60			m	σ.		3.8 4		8.	!
		41	9.	ب ع	t,	S					ي	CC	ເດ		ເດ	ıΩ			,																				4.0 3			
		ļ	3.3	m d		5	i	1	,	: 	0	0	10	(C	(O	G		,	,		(0	"0	-	_			_	"		!	!	1	- .	1	!	- .	-	!	۵.	1	₹.	!
		37	0	0 0	۰ د	0														,	ល	נט	4	4	,	,	4	.C	,	1	٠	1	4	•	•	4	4	•	4.1 4	1	4	•
		35	3.4 4	-	-	-																																				
				<u> </u>	٠.	_					_	_	٥,	21	٥.	۵1					_	.,	_	_			_	_					_			_	_		_		_	
		1 1 1	3.6 4.0																																							
		6																																								
		7																															7						2 3.7			
	(A II	1 × 1 × 1	(C)																														რ	۱	1	რ	က်		4	1	4	!
ت ت		ام																																							-	
ب ۱	zc	; ; ;	681	682	683	584	685	686	687	683	689	069	691	£69	693	694	695	969	697	698	669	700	101	702	703	704	705	902	707	108	109	7 10	7:1	712	713	714	7 15	716	717	7.18	719	720

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; $\frac{1}{4}$ = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

(

4

٨

٩

4

⊢ α

∀ Z H ∑ ∢

5 %

⊢ ≃

	99	1 1	1	4.2	1	4.2	! !	i	† } 	1	4.3	3.7	3.7	3.7	3.7	1	1	3.4	1	(3) 4	3.4	!	1	4.7	1 1	!!	1	თ დ	ი ი	;	; ;	
	64	1	1	4.4	1	4.4	1	ŧ ŧ	} { 1	1	ъ.	ດ ເກ	က က	3.5	ი ა	1 1	1	o.	1	0.4	0.4	1 1	f 1	4°.3	1	! ! !	i !	4.4	4.	1 2	; ! ;	
	61	1 1	1	4.2	1	4.2	1	ł	i i	! !	4.7	ເນ ເກ	ი ი	3	3.5	! !	!!!	3.7	1	3.7	3.7	! !	!	٧ ۲	1	!	1	4.3	4.3	! !	1	
	59	!	:	4 2	1	4.5	3.9	£	1	; !	3.9	9. 6.	3.9	ი ი	3.9	!!!	1	3.7	!	3.7	3.7	1	1	4.7	! !	1	1	4 ئ	4.5	1 1	i i t	
	57	1	1 1	. .	i i	7.	4.3	1	!!	[]	4 .3	3.7	3.7	3.7	3.7	1 4	!!	3.8	1 1	3.8 8.	3.8 8.E	;	1	4.6	# 1 1	! !	1	ი. წ	3.9	! !	! !	
	55	1	1 1	4.3	1	4.3	4.3	i t	† 2	! !	4.3	3.7	3.7	3.7	3.7	: :	1	ე. მ.	;	თ. დ	ი ი	! !	i i	4.3	1 1	<u> </u>	 	4	4.3	į ; !	i i i	
	53	1 1	!!	40	1 1	0	3.9	!	1	1 1	3.9	3.9	ე ი	9 6	9.6	3.9	!!	3.4	1	3.4	3.4	4.2	4.2	4.2	! !	1 1	! !	3,5	3.5	1	3,5	
	5.1	! !]	40	: 1	4.0	₹ 7	!	1 1	!!	4.4	3.8	3.8	3.8	3.8	3.8	1	3.8	t t	3.8	3.8	3.7	3.7	3.7	! !	1 1	!!!	4.1	4.1	1	4.1	
	49	t t	1	- ~	•	-	3	:	!!!	1 1	8.7	3.6	3.6	3.6	3.6	3.6	1 !!	3.2	! !	3.2	3.2	3.6	3.6	3.6		[]	1	3.3	3.3	; ;	3.3	
WEEK	47	1	:	 		 -	د بر	;	: ;	i i	٠. ت	3.2	3.2	3.2	3.2	3.2	!!	4.0		0.4	0.4	3.9	3.9	3.9	: :	;	1 .	3.6	3.6	:	3.6	
TS. L	45			· -		· -	- -		; !									3.7											4.0		0.	
_	43			6	•	٠ .	ry 		,	,	វេ	9	9	9	9	9	į	7	1	4	4	ဖ	ဖ	9	ı	!	ı	80	8		8.	
	! !	i	•	9		۳ د	ر. س	•	;	i	3	2	2	3	3	3		3.								i	i	0	3.	;	9	
	41	į	i	4	,	7	n	1	1	i	.; m	ю С	6	က	.; m	۳ ۳	į	3.7	i	m	Ю	3.	ص ۳.	3.	į	1	į	9.	3.	ì	3.0	
	39		:	♥ ♥	,	7	4.7	1	1	i	4.7	3.8	3.8	8	3.8	3.8	1 1	9.0	1 1	3.9	ල ල	3.7	3.7	3.7	1	1	1 1	3.5	3.5	1	ນ ນ	
	37	! ! !	!!	4.2	1	4	~	1 +	1	!	•	•			•	3.6	1	4.0	1 1 1	4.0	0.	3	က ထ	3.8	! !	1	1 5 I	0.	4.0	1	4.0	
	35	# # 	1	3.6	;	დ დ	٠	:	1	1 4 1	3.8	3.7	3.7	3.7	3.7	3.7	1 1	3.6			3.6					!!	!	3.6	3.6	!	3.6	
	33	1 1	1	3.9	1	3.9	3.8	!	t 1 1	1	3.8	3.8	3.8	3.8	3.8	3.8	i !	3.8	1	3.8	3.8	3.6	3.6	9 E	! !	I I	!	3.7	3.7		3.7	
	31	1 1	1 1 1	3.7	i I	3.7	4 0	1	! ! !	! !	4.0	3 6	3.6	3.6	3.6	3.6	!!	0.4	1 1	0.	0.4	3.5	3.5	3.5	:	[[1	3.8	3.8	1 1	3.8	
	59		!	3.6	:	3 0	_ ღ	1 1	! ! !	111	 	3.6	3.6	3.6	3.6	3.6	1 1	3.4		3.4	3.4	3.0	3.0	3.0	:	3 1 1	1	3.2	3.2	1	3.2	
	27		1 1 1	g. 6	į	9 6 6	3.8	1	:	1111	3.8	3.7	3.7	3.7	3.7	3.7	1 1	3.5	1 1	3.5	3.5	3.5	3.5	3.5	!	1	,	3.4	3.4	1	3.4	
ω ir	×	L	_	<u>.</u>	!	L	L	LL.	L	L	u.	Ľ	11.	ш	ш	11	Ŀ	u.	Ŀ	ĸ	ш	Li.	Li.	u.	L.	LL.	Ľ	ц.	Ľ,	۱.	u.	
0 =	ه د	ູ່ເລ	ស	ល	ស	ເນ	ญ	ស	ນ	ហ	ស	ß	ល	ស	ស	īŪ	ເດ	ស	ល	ນ	ស	ស	ស	ស	ស	ሪን	ሪን	ស	ប	ស	ស	
zc	, .	721	122	723	124	725	126	127	128	129	130	131	132	133	734	735	36	137	738	139	740	741	142	743	744	745	746	147	748	149	750	

3 = 7.0 mg/kg/day RDX;35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX * Control; 2 = 1.5 mg/kg/day RDX; Group 1 4

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

1 0 1 1 1 4 0 1 1 1 1 1 1 1 1 1 1 1 1 1		4 4 4 4 4 4
±03		
101	4 4 4 4 4 4 4 4 4	
		4 4 4 4 4 4
76	4 4 4 4 4 4 4 4 4 4 4	
98	4 4 4 4 4 4 4 4 4 4	4 4 4 6 6 6
က I		
ග 1		
68	:	•
E C	4 4 4 4 4 4 4 4 4 4 4 4	0.00
LL CC (
αc i		
c		
7	4 4 4 4 4 4 4	
7.7		•
	44 44 44 44 44 44 1 44 44 44 44 44 44 44 44 1 4	4 4 4 4 4 4
. 73		4 4 4 6 6 6
69		
67		
νω×	2222222222222222222222222222222222222	ΣΣΣ
⊢ α 0α0⊃¢	 ***********************************	
	- 4 6 4 7 9 4 5 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	38 39 40

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group 1

Ü

3

⊢ ∝

	104			٠		٠	•		ា	- 1				•	•	•	•		4.4	ı	- 1	•		: 1	ı	1	!	1	ł	1	•	•	•	•	ı		Į.	•	•	1		4.4	1	! !	
	103	} 	ď	, (5	ი ღ	9.9	5.6	1 1	i	ţ	ָ פּיני	0.0	7	7	4.	4.	4.1	4.2	1 1	1	,	, ,	7	i i	! !	1	1	1	1	4	4.	4	4.	! !	ы О	! !	5.0	5.0	1	4.4	4.4	;	;	
	101		,		4.	4.4	4.4	0.9	1 1	1		, ,	١٠		4.7	4.7	4.7	4.7	4.6	1	1	4		ę. 0.	t 7 1	1 1 1	1	1	1	1 1 1	4.4	4.4	4.	4.4	1	5.0	1	5.0	5.0	;	4.6	4.6	1	1 1	
	66				٠				. ,	- (1	•		٠	•			•	4.6	٠	1		٠		ı	į I	1	!!!	1	1			•	•	1	•		•				3,5		ı	
		•		٠		•				- 1		•	•	•	•				4.5		,		٠	•	ı	1	•	ŧ	•		•	•	•	•	ı	•		•	•	ŧ	•	3.7	•	٠,	
		1 1 1 1	p (5	9.4	4.6	4.6	6	; i	1	: (9 (9	5.1	ა -	5.1	5.1	5.	4.3		! !	•		£. 5	1	!	1	! !	3.1	:	4 .5	5.5	5.5	4.5	1	4.7	1	4.7				3 6			
	66	1							. 1		1				•			,	4.3	. 1	į		٠	•	1		•	1	•	•	•	4.2	•	•	•	•	٠	•				, e	•		
	6	1 (4.3	4.3	4.3	ر د) i		;		5	4. ق	4.9	4.9	6.7	0.4	4.6	• 1			5 ·	9.6	1	1	1 1	1 1	6.1	:	0.	4.0	4.0	4.0	!	4.7	1	4.7	4.7		7	-			
	88		_	_																		1											•	•						, ,		4		. 1	
3 11 11	87	1			-	4.	7	. r.	- :	i i	i (5.2	2.5	4.2	4 2	4.2	4.2	2.2	4) (: ! ! 1		4.	2.4	1	1	 	1	4.7	:	4.3	4.3	4.3	4.3	4.1	4.	1 1	4.1	. 4	: :	ď	9 0) G) I	
	85									i	ı		٠							. 1		1		•					•	1	-			•						. ;			-		
	83		۵ ·	7.3	4.3	4.3	7	. 0	1	:	1	4.9	4 9.	4.3	4.3	4 ن	4.3	. 4	. 4	•) 	!!	9. 6	4.6	! !	! !	1	4.7	4.7	1 1	4.4	4.4	4.4	4.4	5.1	5.1	1	ι. -	•	. ;	0	9 W) t) i	
	8										•									. :	1		•	-			ı								•				•	. 1		;	•	. ,	
										١	1	•				•		•	•	•	•	1	٠	4.4		1		•		- 1		•	•	•	•			•				. r		1	
	77	1	÷	4.6	9.4	4 ب			0.	1 1	1	4 ت	4.5	₹ ₹	4.4	4	7 7	. 4	, ,	3.	} 1 1	! !	4	4.3	! !	1	4.1	4.1		- 1										. 1	1	5.6		- 1	1
	75		4 G	4 0	6.43	6		o (5	: !	l l	4.0	4	4.0	4	4	4				} } 	!!!	4	4.0	1 1	1	4.1	4	4.	1	5.5	5.	4.5	5	2.2	4	. 4		, ,			ю с п с	ი ი ი	0	1 1
	73																	-			1																	•			ı		٠		i
	7.1	•					_	4													1															•	•	•				۵. 4.			
		1																			•	•																				9.7			,
	37								-	•	ŧ			•			•	•	•					-				•			•		•	•	•	•	•	•	•	•		ص د د		•	1
	νш×		Σ	Σ	Σ	2	: :	Σ:	Σ	Σ	Σ	Σ	Σ	Σ	2	2	2	Ξ:	ξ:	Σ	Σ	Σ	Σ	Z	Σ	Σ	Ξ	: 3	. ₹	2	Ξ	2	2	2	2	2	2	ξ 2	ε:	Σt	- 1	1 . (٠.		.
ပ ထ	0 ⊃ 4	-	-	-	-					-	-	-	-	-		- +	- •	- ,		-	-	-	-	-	-	-			- 🕶						-		- •		- •			.			-
<u>د</u> ۷	z o		7	42	7	7	; <u>!</u>	۲. د د	46	47	48	49	50	, C	. c	1 C	3 4	ה ה	22	56	57	28	59	9		62	9 0	200	, L	9 4	200	- a	0 0	9 6	7	- 6	7 '		÷ !	c i	9/	77	200	S (O _K

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; μ = 35.0 mg/kg/day RDX; μ = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BEC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

			_				_		_	_		_	_	_	_	_				_					_								_	_			_	_	_			_	
		104	•			•					1							•						•		•										1			•		•		
		103	3.8	٠	•								٠				1	•					. 1	- 1		•	٠,					1	•	•		1			•		1	•	
		101	~	7	4.	2	4.2			4.1	1 1	7	4.2	4.2	4.2	4.2	1	4.	4	4		-	. !	! ;	r C		. 1	ď	9 6	6.6	3.9	1	4.4	4.4	1	1 1	4.4	4.4	4.4	4.4	1	4	
		66	3.9	က က	თ ი	တ ₍	ი ი			- -	1	4.	0.	4.0	0.4	4.0	1	3.9	3.9) C	σ 	, c	; 1 · 1	1	0	, ,		-	. 4	4.	4.1	1 1	•	٠	ſ	1	٠	•	•	4.2	1		
		97	4.0				٠	2	٠		1		•	•		•			•					- 1			٠ ;				•		٠	•	1	ı	٠	-		4.0	1	4 0	
		95	4.1	٦.	7 .	-	7	: :	0.	0.	i 1 1	0	0.	4.0	0.4	4.0	1 1	3.9	9.0	ο • e	6	; 5 (f)	1 1	! !	-	- -		7	, r	3.7	3.7	i i	4.6	4.6	1	1 !	4 6	3.9	3.9	3.9] []	3.9	
		93	3.8	•				:	•	-				•		•	•				•	•	. 1	. 1		•						•		•		ı	٠		•	•			
		_ O _ 1	3 7								1	•		•			1						. 1	1		•			-		•	1			-	1		•		•	ı		
		89	3.6											•			•						. 1				!!					1	٠.			1	٠.		•		1		
	WEEK	87	3 5				•	1	٠				•	•		•	•			•	•					•	•	•	-			1				•		•			1	•	
	TEST V	85	3 6					,	•		1						- 1						. 1												- 1					•	1		
		83								-	ì			•	•	•				•	•		٠ ١	1	•	•	٠	•	•		٠.		•	•	1	•							
		∞ 1	3.7						٠	•	1	٠	•	-		•	1				٠	٠	- 1	ı	•	٠	•	•	•			ŧ					•	•				•	
		_	3.2					!			1					٠.	,										•					1			1						1		
		-	3 2				•		•		•												. 1	1											1						1	•	
			E							٠	1	-	•	•								•	• }	ı		•	•	•	•		•	i				•							
		7	3.5											٠.	-	٠,			_																		٠.				ŧ		
		7.1	3 8					i			1										-			1														٠.					
		ဗ	i 🗢								1			•					•	•	-	•	•	ŀ						•											- 1	٠	7
		67	3.6	•				1	•	•	ŧ	•	•	•		٠.				•	•	•	•	1	•	•	•			•											- 1	•	
	νL	×	! ! ! ! !	ننا	L	L	Ŀ	ı.	ıL	u.	Ŀ	u.	u.	LL.	L	. 4	ı.	. 4	. L	. L		LL		ı. ı	L (_ 1	_ 1	L L	. U	L	. u.		£i.	u	IJ.	u,	ш,	ı.	. 44	Ľ	۱Ł	L.	7
ဖြင့	× 0 =	٥۵		-	-	-	-	-	-	-	-	-	-	-	-					- •	- •	- •									٠ -	-	· -	-	-	-	-	-		-	-	-	-
ل ۵	zc	,	8 1	82	83	84	85	86	87	88	83	90	91	92	6	7	, u	0 0	0 0	2 0	2 0	5 6	3 3	101	102	103	104	2 C	106	2 0	60.0	0,		112	113	1.	5	116	117	118	119	120	

*Food spilled TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

0

G

Ø

٩

٩

١

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BEC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

a billion of the control of the cont

The second of the second secon

A P P P P P P P P P P P P P P P P P
X X X X Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
0.00 0.00
Omx rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr
Nm×

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINGGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRC-1.3.5-TRIAZINE(RDX) IN THE B6C3F1 MQUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

TEST WEEK

S

5 2 0 ⊃

104	4.4	4.	!	1	1	4.	1 1	1	} 	4.4	4.9	4.9	1	1	1 1	1	1	1 1	4.4	4.4	! !	и Э	t 1	5.3	1 1	ì t 1	9.4	9.4	9.	9.	 	! !	 	1 1	1	-	5.5	5.2	! ! !	!!	
103	4.0	٠.	1	1 1 1	:	4.	! !	! !	! ! !	. .	4.	¥.	} }	!!!	1 t	i 1 1	1 1	1	4.4	4.4	1 !	4.6	! ! !	4.6	! ! !	1	4.6	9.	4.6	4.6	1 1	1	t I I	1	1 1	l 1	4.1	4.	i i i	} { 1	
101	4.3	4 ن	1	1	1	4.8	۳. ۳.	5 E 1	!	4.8	5.4	5.4	5.4	!	1	1	1 1	!	6.4	6.4	1	5.	!	5.	1 1 1	1	5.0	2,0	ις Ο	2.0	: 1 1	1	1	1 1	 	1	4.6	4.6	! !	!	
66	4.5	4 3	1 1	1	1	6.4	۵. و	} ! !	:	4.9	4.9	4.9	4. 9.	!	! !	6.4	1	;	4.9	4.9	1	6.5	1	4.9	1 1	!	4.6	4.6	9.4	9.4	1	! }	1	l !	1	1	4.6	4.6	1 1	! !	
97	4.6	4.6	i 1	! !	1 1	4.7	4.7	! !	1 5	4.7	4.9	4.9	6.9	1 1	1 	6.9	4.9	:	6.9	4.9	1 1	5.1	!!!	ъ. Т	; 1	1	4.8	4.8	8.	Δ. 80.	!!] } {	1	!	!!!	! !	4.8	4.8	1	i i	
95	4 2	4.2	1	1 1	;	4.9	٠ ت	! !	1 1	6.4	4.4	4 4	4.4	4.4	1	5.0	5.0	1	5.0	ر. ٥.	5.4	5.4	1	5.4	t t	: !	4.8	4.8	4.8	8.8	! ! !	; ; ì	! !	!	! ! !	1 1 F	4.3	4.3	1 1	I I	
63	4.5	4 ئ	; [:	f f I	4 0	ە 0	!	1 1	4 9	9.	6.9	6.9	4.9	1	ტ დ.	6.	t 1	4.9	4.9	ა დ	5.6	1 1 1	5.6	!!	i i 1	5.0	5 0	S.0	г О	1 1	1	1 1	1	1 1	1 	٠.	4.4	1 1	1 1	
9.6		د ش	! !	! ; ;	t 1	<u>ئ</u> ھ	4.8	l ł	1 1	4.8	5. -	5.1	5.1	ى 	1	4.7	4.7	3 1 1	4.7	4.7	5.1	5.1	1 3 1	ъ. Т	1	1	5.4	4.	ъ.	5.4	1 1	! !	:	1 1	! !	i i	5.6	5.6	!	1	
89	4 2	4.2	1	! !	i i	0 0	4 0	1	!	6.9	5.5	5.3	5.2	5.5	1	4.5	4.5	1 1 1	4.5	4.5	5.5	5.5	! !	5.2	1	1 1	5.1	5.1	5.1	5. T	!	1 1	!!!	i i	1 1	1	4.4	4.4	!	1	
83		4.	1 1	i i i	!	4 8	4.8	1 1	!	4.8	5.2	5.2	5.2	5.2	1	4.4	4.4	(4.4	4.4	5.3	5.3	i 1	5.3	1	1	5.1	ъ.	ე.	5. T	1	1 1 1	! !	;	1	;	5.0	5.0	!!!!	5,0	
85		ママ		i I	1	-	5.1	1 1	f 1	5.1	4.7	4.7	4.7	4 7	l !	4.7	4.7	1 1	4.7	4.7	4.6	4 6	1	4	4.6	4.9	4.9	6.	4.9	4.9	1 4 1	1	t t	1	!	; ;	გ ი	5.9	1	9. 9.	
83	4 4	4.1	!	: !	1	4 7	4.7	1	!	4.7	4.6	4 6	4.6	4.6	\$ 	6.3	4.3	1	4.3	6.4	4.7	4.7	1 1	4.7	4.7	5 13	5.5	ი ი	5.5	ນ ນ	1	1	† ! !	1	1	i	5.1	ъ.	1	5.1	
8	13	6,2	:	1		5.2	5.2	!	:	5.2		4.5	4.5	4.5	1 1	5.5	4.5	4.5	4.5	4.5	6.4	6.9	1	4.9	4.9	4.7	4.7	4.7	4.7	4.7	1	1 1 1	t 1	1 1	!	1	5.7	5.7	1 1	5.7	
79			!	:			•		1		•	•	-	4.7			•			•		4.7	1	4.7	4.7		4.5				1	1	1	!	1	1 1		5.6	1	5.6	
7.7	1 .	•	1 1	1		•	•	•	- 1					•	ŧ	•		•			•			•	•	٠		•	•	•	ı	1	l 1	1	1	1		6.6	ı	6.4	
75	. 6 E	6 6	6		6 6	7	4 6	! !	1	4.6	4.4	4.4	4.6	4 4	1	4 .5	រភ	4.5	4.5	4 5	4.4	4 4	4.4	4.4	4.4	5.4	5.4	5.4	5.4	5.4	1	6.4	1 i	1	!	i i	4.6	9.4	1	9.4	
73	4.3		43	ŀ			•	!	ŀ	•	•	4 9	•		1	•	•	•	•	•	•	4.7	•			•	٠		•	•	ı	7 3		1	1			5.3			
7.1	4 5			1			•	1	ı			•	•	•			•				•	7 .5				•			•		1		ı	- 1		1	- 1	5.0	- 1	•	
69	4 4	7	₹ ₹	; ; ;	7	5.5	5.5	; ; ;	1 1	5 5	5.	5.	5			•					•	5.2				٠					- 1		ŧ	ı	1 1	:	7 2	5.7			
	4.5	•	4.5	ŧ	•	-			•			•	•		:	•					•	5.5	•		•			•		•	1				1			. 2		4.2	
ш×	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Z	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Ξ	Σ	Σ	Z	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Ξ	Σ	Σ	
⊃ c	2	7	٥	~	8	٥,	8	c	7	2	2	7	7	0	~	8	8	~	. 0	0	8	8	C	~	6	C	6	8	8	7	2	8	~	8	0	2	0	2 (7	~	6	
0	161	162	163	164	165	166	167	158	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/lg/day RDX; 5 = 175/100 mg/kg/day RDX II

٥

0

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINGSENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

0	1	00444		1 - 1 -		1.11	
103	44.2	44444	5.0	5.1	144 1 9 9 0 0 0 0	1011444411411411	
101					1 1	D 4444 4 D	
60	1		1		1	1 4 1 4 4 4 4 1 1 1 1 1 1 1 1 1 1 1 1 1	
16	0.4	2 4 4 4 4 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9	8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	5.0 1.0 1.0	144144	1 4 1 4 4 4 4 1 1 4 1 1 7 1 1 1 1 1 1 1	
95	4.6	4 4 4 4 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	5.2	2.1.4	1 4 4 1 R R 1 0 0 1 E C 1 0 0 1 E C	M	
o	6.6	00///	r-∞.∞.¦	ဆဆ ု တ	וְסִּפִּוְמִמִּ	M	
	. 7 . 7	~ ~ 0 0 0 0	000	က က မ က က မ က က မ	1991	N	
9	α α α		r.e.e. !	ω. ω. · · · · · · · · · · · · · · · · ·	166100	00::000::::::::::::::::::::::::::::::::	
ш с	ឧស្	22777	r.00	0016	1 6 6 1 6 6	001100001012211 0011444111100010	
EST W	cc cc cc	α α εύ εύ ευ έ	ဆ ဖ်ဖ ရှ	ه ه ا پ	1001		
-			7 67 67 1	m m 1 4	, 44 , 8, 8,		
	1 4 4 4	च च च च ।	4 10 10 1	מים מים	144144	6 4	
			4 10 10 1	אוממ ד	144144	44 0000 00 00 00 00 00 00	
	1 4 4 4	0 C 0 0 0 0 1	. 0000 i	0010	1001	:ImmpOOIOImmoIm	
,	444		4441	4414	44 44	44	
	1 4 4 4	44000	ומהטמו	ם וממ	144144	441 www.ww.ww.ww.w.w.w.w.w.w.w.w.w.w.w.w.	
73	4 4 4	4 4 0 0 0 j	່ດກ່ວງ	ເຄົ້າ 4.	44144	44:1000000101000010	
1,7	444	< < < < < d <	444	4414	144144	44 44444 4 6 6 6 6 6 6	
69	1 .		1			44 444 W W W W W W W W W W W W W	
19			1		1	44	
	; ;					2	
02 F>Z~Z:	001	004 005 007 008	80-55	15 10 10 10 10 10 10 10 10 10 10 10 10 10	25 + 26 23 2 + 26 23 2 + 26	22 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	
	1000	<i>000000</i>	40000	10000	000000		

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDY; 5 = 175/100 mg/kg/day RDX11 K TR Group

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

104		
103		
	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	
റെ≀	1000004	
97		
36		
93		
σ. :		
83		
±		
EST 85		
83		
ec :		
7.9	 	
7.7		
75		•
73		
_		•
69		
67		_
νш×		ı
64024	*	-
47 SO	2422 2442 2442 2442 2443 2443 2443 2443	

Q

٨

٩

٥

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; $t_1 = 35.0 \text{ mg/kg/day RDX}$; $t_2 = 175/100 \text{ mg/kg/day RDX}$

**Feeder weight was inadvertently not recorded

⊢ ≃

42 H \ 2 4 J

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MFASUREMENTS (g/dav)

104	Dι	3,8	,	٠	•	•				- 1	•				ı		•	ļ				1		1	•	•	1 1							- 1				ı	
Ç		3.2	1 ·	3.5	დ (ю (າ ຕ ຍ ຜ	; ;	3.6	1	9. 8.	3.8	3.8	! } !	i i	l l	4	 	 		9 ·	5. 4 5. 0) i	1	က က (5.3	i (? !	4 7	7	4.7	1 5	1	1	4.4	4,4) 	
Ş) i	3.9	i		•		•	. ,		•	•			1	1	1	٠			•	•			- 1	•		1 1	ı	. 1		•			- 1	•	6.1	6.1	i i	
Ö	9 1 1 1	4.1	1 1 1	-	4.	- (. i	4.2	4.5	3.7	3.7	3.7	1	! ! !	! !	4.8	1 1	1	Δ, 8, 6	0 i	2 C		1	0.9	0.9) i	α	. α	8.	1	I I }	5.0	5.0	20	i !	
97		4. ئ	! !	ح ت	4 ، تن ا	د د د د		· ;	4.1		3.8	3.8	3,8	3.8	1	t 1 1	6.9	!	F 1	4 . ون	գ. Ն լ	4 - ชัก	. 4 . n	1	ရ. ရ	က တ (ກ ເ	י נו	9 1	6	9	9	1	; ;	5.2	5.2	ŭ.2	; 1	
	ו מ	3.5	ŧ				•	٠ ;		٠,			•	•	1	•	•	1	1	٠	•	•			•	•	.		1	1			1	t	•			ī	
c	1 32	3.8	i ;	3.8	တေ	က •			4.1	4.1	4.0	4.0	4.0	4.0	!	4.5 5	4.5			. d.	8.4	4 4 2 0	. 4 . 8	1	5 10 10	ព្រ	 				7	4.4	1 1	1	5.0	20	5.0	! !	
ō	ו מ	3.7		•											1			,		•	•					•				1	1	1	1	- 1				ŧ	
Ö	80	3 8	3.8	ဆ	ස ස ද	α (m (င် ရေ	: :	3.6	3.6	3.6	3.6	3.6	3.6	1 1	3.9	3.9	:	ი ი	ი. ი.				!	5.2	10 I	2	; c	3		. o	0.00	0.0	!!	5.2	5.2	5.2	1 t	
FEK 27		7	. 7	7	٠,	~ (ဆ်ထ	3 1	œ	ω.	7	7	~	7	; ;	7	۲.	!	7	7	ω, α	æ, s	بم	!	<u>ه</u>	ص •	<u>ت</u>		ָה מ	ָ ו	. ע	ی د	· ·	1	7	. 7	.7	; ;	
*	001	6 6	6:	c	С (c (ກເ	• ‡	6	, o	-	-	-	-	!	6.	б .	1	б .	ص ا	ស រ	ប់ព	ກຸເກ	1	ღ.	<u>ر</u>			? ;) C	0		0.	c	¢.	! •	
ς α	1 0	ល	ស	ıc.	សុ	ភ (<u>ئ</u> د	: !	o,		9.	9.	ဖ	9.	1	<u>б</u>	<u>.</u> ق	:	6	ص •	-	- . •			-	- , .	-	, -	- I		٠,		. 7.	1	6.	<u>ත</u>		; i	
α		S.	2	۳	ព្រ	ر ا	တ္ဖ) ! • 1	G	9	٧.	4.	4.	₹.	!	4.	4.	!	4.	4.	، ب	ب ب	ی و	: !	80.	ω,	ສ.	! (o i		•	, c	0	. !	-	- .	- ,	ı 1	
0	9 1	.8	ထ	œ	د د	cc i	- 1	٠ :	7	. 7.	ت	ı.	ស	ت	:	œ.	9.	1	9.	9	- .	- •		1	7	. 7		! !	-	: 0	9 0	ņσ	. 0		0	o.	o.	,	
	1	- 3	-	-	 .	 .	7 <	7.	7	4	₹.	₹.	4	7	i	6.	თ	1 1	<u>.</u>	ත _ු	٠, ١	4,0	i c	1 1	ស់	ស់	s.	! L	C	ı r	٠,	. ^			0.	0.	0	1	
n T		8 3									. ~	2		8	i	ລ		ı	ល	ស្គ	~	ο,			ນ	ហ				1 (ស		
ç	2 1	!					ი ი დ დ		u	ຸດ	ı.	ល	ເດ	ī	1	_	-		_	-	60 (10 L			4	4	-		.	, -	- •			. (0	. 10	9	, 6 d		
•		6 3							۳. ن) E	7 3	7 3	7 3	7 3	1	8	8 4	1	8 4	8:4	ខា	ពេ	ល		8 4	8	γ. 4	. •	2 0		00	o a	ຸພ	8	8				
	ה ו נ		-					o i	ď	. e	. E	8	8	8	1	5	5	1	5	5 3	ខា	ស រ ស រ	ນຄ	: :	1 4	4	4	. •	7			: ¬	4	. O	0 0		0 4		
1		7 4.							۲.		e e	B	3	5	1	6 4	6 4	1	5	4	נטו			. 1	3	S.	3		Ωŧ	ກະ	טמ	า เ	00	in.	มเ	വ	5	1	
י שיט	9 1		င	რ	က	က	e c	; ;	۲,	'n		'n	ю	e,	;	Ŋ.	ις.	1	۳.	ъ	ເກ :	LL	n n	· ;	4	4	4	;	4 1	υ. Γ		ນ ທ	່ທ	4	4	4	4	i i	-
⊬α 6 π ο⊃0	1	; 																																					•
		28																																					
																																							2

%Food spilled
TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX;
4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

																																					_				
	104	1	4.7	1	1	4.7	1	4.6	1	7.6	4	4	4.	4.		4	4.4		4.4	1	1	3.8	9	3.8	1 (0	4 . R i	4. U.	4 . U r	4 . U I	4 ·	4.	1 1	7			4 5		1 4	. 1	
	103	1	9.4	!	! !	6.9	1 1		1	4.7	7			T .	, .	7	4.2	; ;	4.2	ı	1	٠	0	•	4	٠	6. G		•	•	٠	•	ŧ	4	1				1 d	1 :	
	101	l i	بر -	! ! !	'	٠. -	1	4.9	1 1	9.	ه. ن	0.0	٠ ١	о. С	(0.	4.4	1	4.4	i 1	!!	4.7	7	4.7	1 	4.7	 	4 . ن	4 . T	<u>ຈ</u> . ບໍ່ເ	4 i	ນ ເ 4 .	υ r	4.	t l	! (5.0	י ני	0 0	; ;	
	66	;		 			l 1	4.8) ! !	8	Δ. Θ.	6.8	φ. α.	φ.	1 (8.	2.0	1	5.0	# E	1 	•			1		4 . ق	٠	•	•			٠	•	1	•	4.7	ı	7 7	; ;	
	97	;	5.0	0.0	L :	0.8	ì 1	4.8	! !	4.8	4.8	8.	8.	8.	:	م	4.9	I I I	თ ₹	1 1 1	£ 1	4.5	4 .5	4.5	1 1	4.5	4.8	8.	8.6	φ. φ.	φ. Θ.	ກຸ	ກ ເ	р. Э	1 1 1	; (o S	1 U	ນ ນຸດ) !	
	95	4	•	4.4	1	4.4	1	-	1	4.8						8.8	8.8	1 1	4.8	1	:	4.6	4.6	4.6	1 .		4.7				٠	٠	•		ı	í	٠	! (<u>ب</u> و و	- 1	
	ග 1	5.0	•	5.0	í	•			1			•	•		1	٠		i	4.8	•			•			•	4.8	٠	•			•	•	•		1	9.4	1	2	4 4 0 0	
	91	"	4.6	4.6	:	9	:	4.6	!!	4.6	4.6	9.	9	9		9.	4.	!!!	5.4	1 1	!!	4.6	4.6	4.6	:	4.6	4.7	7	7.7	4.7	7.7	5.4	ر ا م	5.4	!!!		٠	:		5 K	•
	89	.7	7.		!		:	9.	,	9		9	ဖ	ဖ		ၒ	o.		<u>ق</u>		ŧ	ı۵	r.		:	ıs.	ີ ຫຼ	<u>.</u>	ත _.	<u>.</u>	o.	0.	0	0	1	! í		1		0 00	
¥	87	ဖ	9.	ဖ	E I	9.	!	ص	!	<u>.</u> د	e	٠.7	_	. 7	!	۲.	۲.	!	٠.		1	ü	'n	7	!	~	د	س	e e	n.	e.	0	0	o,	:	1	٠ بى	· ! (ن بي	ی ہ	,
TEST WEEK	ت ا	8	æ	8 4						7 4							7 4		•	!		4	4	4	,	4	.7 4	7		7		N	0	8	1		0		-	90	
Ŧ	80	4	4	4	i	4	i	4	¦	4	₹	4	4	4	i	4	₹	i	4	i	ì	4	4	4	1	4			₹.	4	4	ໝ່	ល	ហ	i	i		۱,	บุก	ព្រ	•
	83	4		4.2	ŧ	•	;		;		4.3				1			3	4.8	1	1	4.4	4.4	4.4	1		4.3										4.8	ı		φ α	•
	8		•	4.3	•		i		1	-			•						4.3	:	1				1		4.6			٠		•	•		1	1		; -	១៤)
	7		•	4 2					1	4.7	4.7			٠	1	•	7.7			t i	1				ı		4.7		•	٠	•		•		1	1	4 6	ŧ		2 4 5 4	•
	77	4 0		-	•	-		•	1		٠				1	•	٠		•	1	•	•	•	•	1		•	•	•	•	٠	•	•	-	1	1	•	ţ	٠	ر د د	•
	75	4.1					ı								1		•	1	-	1	•				ŧ		٠	•			•	٠		•	1	1	•	ı	٠	7.5	
		١.	4.1	4.1	4.1	4.1	; ;	4.6	4 6	4.6	4.6	9.	4.9	4.9	:	4.9	7 8	t !	7.8	;	7.8	4.2	4.2	4.2	4.2	4.2	4 2	4.2	4.2	4.2	4.2	4.7	4.7	4.7	!	1 1	4.1	!	4 ·	4 4	- -
	~	4.5		•	٠	•	Í	•	•	•	-	٠	•	•	•		•	1		- 1	•		•	•	•	•	•		•	•		•	•	•	1	1	•	ı	•	•	
	မ	4.8		•	•	•					•		•	•	1	•	•	1		•		•	•	•		•	•		•	•	•			٠		1		•	•	٠	•
	29	3.9	၈	<u>ත</u>	о	б .	!	.7	7	.7	. 7	4.	₽.	4.	1	4.	-	í	-	;	•-		2	7.	٠,	8	r.	<u>د</u> .	ъ.	ស	ı.	.7	۲.	۲.	!	1 1	r	1	ខេ	សក	?
υ. : α α :		!																																							
- 		\$ •																																							
, Z	ο .	32.1	322	325	324	325	326	327	328	328	330	331	335	333	334	335	336	337	338	338	340	341	342	34.	344	345	346	347	348	346	320	35	357	380	354	355	326	32.	328	326	Ś

0

9

٩

٥

0

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

H H

TR Group 1

G ~ ∝

104	4.4		1	4.4	5.7	1	1			1		•	1	•			1	•				•		•	•	1	1		. 1		4		•
103	4.3	, ,	1	•	. 4 . 5		1	ı	. i		•		1			1	1				1	•				•	1	-			3.7	1	
101	5.1	1	1	5.1	6 7		1 t	י י עי		 	5.3	5.3	4.4	7 •	4.4	1 1	1	6.3	4 4 	6.4	1 1	0.0	2 !	5.0	4.3	6.9	: !	4 . w.	4 . ن د	4.6	4.6	1 .	ه. و
o 1	4.6	1 1					1	1		i		•				•		•			•								٠ ١			1	
o 1	5.3	ı		•			1	٠	٠ 1		•	•	•	•			•	•			ı	•	. 1	٠	•	•	•	•	٠ ١			1	•
95	- 1	! ; ! •	1	- ,			۲. ۱	۲. ۱	. !	ŀ	ır.	ເດ	φ.		ο ω	;	<u>.</u> ق	တ (ກຸອ	. o.	1 1	m. r	; ¦	۳.	<u>ه</u>	<u>ი</u>	<u>ඉ</u>	ص 0	י ויי	7	2	1 (Ŋ.
O O	4 1	; ;		₹ (. 7	7	ه نی	0 ;	!	œ.	ω.	თ. ი	n c	ກຸດກຸ	:	80.	ω.	æ.α	œί		4.	ŧ ¦	4.	∞.	æ	ထ	œ (Σ	0	0	1 '	0
	2 .	: ; } :	:	ú,	xα	8.	ω,	ش ر	? ¦	1	ო.	က္	<u>ه</u> د	n o	n 0.	1	9.	9.	<u>ه</u> به	9.		က္ဖ	?	€.	<u>ئ</u>	<u>ق</u>	თ :	<u>ه</u> :	ו יי	0	0	;	o,
c		; :	;	ល់	ល	្រេ	ល់	ស្ត	\	!	7	7	<u>ق</u> د	ກຸດ	ກຸດ	1	8	æ. :	ας α		.7	۲.	· ;	7.	ri.	rij :	សុ	សៈ	ا ا	α,	ε α.	1 1	æ.
8.7	.2 4	, ,	. ~	с.		·	-	- . (0 1	!	9.	9.	- . •	-, -	- -	I	.7	٠.	٠,	. ~	4.	4.	. !	۲.	o.	c)	б (ص	ָּרָ הַ	ω,	ε.	1 1	∞.
EST W	8 4	, α	. æ	හ _.	ب ان در		e.	m u	n 1	1 1	s.	ស	0.0	o c	90		8.	c	ص. «		-	-	- 1	-	o)	6.	<u>ن</u>	و	י ע	-	-	1	- .
83		! "	: 4	7 :	ខាធ	10	ri J	ເກີກ	G	;	r.	ທ.	0,0	<u>ې</u> د	90		<u>.</u>	<u>ق</u>	თ. <u>"</u>	, o.	<u>ن</u>	ທຸເ	: מ	מ	۲-	۲.	۲.	۲.	· !	រប	្រ	1 1	•
	6				១១		ו מש	ស ៤	ו ת	1	6	ົ	છ (60	~			60	ထေးရ	DΙ	80									
	5. 4				4 4	4	4	₹ ₹	ŧ 1	1	4	8 4	ខេត	ים מ ים מ	າຕ		က					~ 1		~						ı uc	ي د		9.
-	.7 4		• ••	7 4	ពេយ	่งเ	5	ល ខ	ים זו	,	9	9 4	ω. (, e		6	8	0.0	4 (4	4	e .	ופ	9	ıΩ	rc	מו	ن م	n	· m	9 6	1	
	5 4			~	₹ 1.	₹	4	4 4	3 :	•	4	4	e (rs (າຕ) [4	4	4 4	4	က	m (וכי	n	.;n	က	n	(r)		ייי) M	1	
n	0	1 7	4	4	4 4	8	8 4	8 (7 1	1	3 4	3 4	e .	m .	უ რ		9	ю :0:	e e	າຕ	6 3	ი ი	ופ	9	5	5	ຄ	ດ ເຄ	υ	. 6	30	1	က
-	5 5	; ư				0	0 4	0 (.	1	0	0 5	0	00	o c) ;	7 3	7 3	7.4	- -	8	8	וכי	8	6	o	9	С	n	٠.		1	
თ	1 4.	i =		_	ωα	າເດ	8 5	ຜເ	ומ	1	5	5	4	.	. 4	. 1	8	8	c o o	າຕ	7 3	7	ا رم ا	3	۔	- 3	3	~	e -	1 6	٠,	1	m
9	5 6.	ו נו	9 9	છ	4.4	4	4	۲.	ດ :	1	S.	S.	ю (რ ი		(n	က	ю	ი ი		б.	რ (n 1	Ċ.	4	4	4	4	₹.	4	4	1	4
9	4	; ; <	: «	4	e 9	4	4	4.1	. !	1	5	IJ.	ю·	m (, m	6	က	e c		6	က်	, i	C	m	ю	ю	რ	Э.	. 6		;	က်
>	/ t 1				æ 2																												
	361	~ ~	2 4	ıΩ	(C F	- 60	60	٥.	- 0	u m	•	ıc	ဖ	· (э		-	C)	e •	. 10	10	~	m c	. C		~	6	~	ເກເ	٥ ٨	- 00	6	0

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

₹	アフェフフのの: ローフ・アファファファファーナー サーフ・ロロのの日のフェーフ・	
Ģ	44 44 44 44 1 44 44 1 44 44 1 44 44 1 44 44	
0		
101		
66		
o	44 44 44 1 4 66 10 64 44 44 44 44 44 44 47 1 10 1 1 1 1 1 1 1 1	
ស	0.0 0.0.44 40.0.0.0.0444 4444 44444 0.0.0.0.0.0 0.1.0.0.0.0.0 0.1.0.0.0.0.0 0.1.0.0.0.0.0 0.1.0.0.0.0.0 0.1.0.0.0.0.0 0.1.0.0.0.0.0 0.1.0.0.0.0.0 0.1.0.0.0.0.0 0.1.0.0.0.0.0.0 0.1.0.0.0.0.0.0 0.1.0.0.0.0.0.0 0.1.0.0.0.0.0.0 0.1.0.0.0.0.0.0 0.1.0.0.0.0.0.0 0.1.0.0.0.0.0.0 0.1.0.0.0.0.0.0.0.0 0.1.0.0.0.0.0.0.0 0.1.0.0.0.0.0.0.0.0 0.1.0.0.0.0.0.0.0.0.0.0.0 0.1.0.0.0.0.0.0.0.0.0.0.0 0.1.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0 0.1.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0	
o,	www.www.www.www.a44 4444 40000 000000000000000000000000	
5		
	44 4444 44000000000 0444 400000000	
w œ	00 00 44 44 40 00 00 00	:
EST	cc cccc cccccccccccc c444 40000000000	•
		
©	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
7	00000000 000000000000 0444 444444000004 14 4 4 4 4 4 4 4 4	
7.7		•
		,
7.1		
9	$\begin{array}{cccccccccccccccccccccccccccccccccccc$:
	CARCACIO COCACACIONO COCACACIONO COCACACIONO COCACACIONO COCACACACIONO COCACACACACACACACACACACACACACACACACACA	ı
on in be		٠,
⊢α ७αο⊃α		, (
:H\$<1 Z0	1 7 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	:

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group 1

(

٩

٩

٥

٥

٥

٠,

Ŷ

۷ Z

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINGGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MQUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

		04	!!!	•		. 1			•	•	•	•	•	1		1				4	4	:	1	•		4 4 U R			1	,	1	٠			- 1		!	4	
						. 1				•	•	1	•	: (9.6	[]			. 4	. 4	4	!	;	4	1 1	4 4 UR	5.4	4.5	:	!!	! !	4. G.	4	; -	- 1	} !	:	4.	
		101	1 1	4	•	1	1		•	•	٠	ı	•	ı	•	,	•		•	•		1	1	•	•	4 4 Ծ R		•	i	:	1	•			- 1	1 4 9	1	4.6	
		66	# 	ი ი	ກ ເ	ر ا ا	0	0.4	0.4	4.0	4.0		4 0	! !	0.	1 5	9 (; e	, c	4.5	1 1 1	: : :	4 ت	: :	۸. ۷	4.7	4.7	ļ }	:	1 .	4 . 0 .	י פיל	, 4) - -	:	} 	4.6	
		97		4.0	0.4	4.0	2 2	4.4	4.4	4.4	4.4	3,7	3.7	, 1 , 1	3.7	: 0	4 4 D.C	2 ¢	קילי	. 6	4.7	;	! : 1 1	4.7	: (e 4	9.4	4.6	; !	!	1 1	2.5	טיי	, o) !		1 1	9.	
		95	 	0.4	0 (0.1	י ט י ר	9.0	3.6	3.6	3.6	8.0	ස ස	1 1	3. B	! (4 • O (4 4 5 6) C	0.0		1	1 1	4.5	! :	- ;-	7.4	4.7	! !	ŧ :	1 1	8.0	2	0 5	T !		!	۵. د	
		93		0.	o o	o ;	. ^		.7	.7	۲.	<u>.</u>	- .	;	- -		- ·	- 4			. ب	!	:	· o	j (יי פי	, m	n	!	1	!	0.	ې د	, ,	: ;	[!		
		91		<u>ت</u>	<u>ن</u> د	m	, α	, æ	8	∞.	ω.	ςγ	ņ	; '	Ċ	· .	ΰΓ	ប់ព	. ព	, ru	۶ ح	:	ļ	4.	; (0 u	9	9.	!	n.	; ;	ı.	v n) t	:	į	!	4.	
		∞ :		۲.	۱ م	_	i C	0	0.	0.	0.	0.	0.	1 '	o.	; (∞ِ د	χ. c	0 0	, «	, ω	ŧ	ε.	ω.	; i	vi n	. 10	ī.	į	۲,	۲.	ς.	ŊC	. o	, œ	: ŧ	1	ω,	
	я Х		; ; ; ; ;	Φ		Τ.	. u	ຸເດ	ı.	т.	ıs.	<u>.</u>	<u>ن</u>	: '	o;	: (n. i			, 6	, m	!	e.	<u>ب</u>	, ·	•	4	4	;	۲.	٠.	۲.	٠.	• •	. 7		!		
	EST WEI	នទ	1 1																							٠. 4 د												7	
	-	ć.	; ; ; ; ; ; ;	5	47 ·	4		. 4	~	4	4	4	о 4	,	9	1 1	13 F	υr 4.	ט מ	. 4	00	1	0	0		4 <	9 0	6	3	۰ د	₹	⋖7	O (. .	. w		1	₹	
			# 1 # # 	က									c	•	က	ι '	4 ,	4 4	* *	7	מני	• 1	មា	n.	1 '	* *	7	4	1	ស			ກເ	0.4	1 4	٠,	١		
			; ; ; ; ;	₹	- .	·	٠,	י ה	(C)	<u>ლ</u>	e.	4	4	ŀ	4	; ,	٠,	4.	1 4	. 4	4	;	4	4	۱.	ਚ ਵ	4	4	1	Ŋ.	ທ	ហ	ທີ່ເ	ព	ດທ	. [İ	S.	
			₹ 	4 0	4 ·	٥ ۸	, c	9 0	6	ი ი	3.9	4.	4.1	1	4.	: 1	ص ص		, c	n σ	. 4	1	7 0	4.6	! .	۷	1 4	4.	ŧ •	4.7	4.7	4,7	- 1	- (2 4		;	4.5	
			! ! ! ! . ! .	3.6	3.6	ပ က	1 6		3.7	3.7	3.7	4.0	4.0	; ! !	4.0	! !	4.2	2.5	4 4	. d	4 4	1	4.4	4.4	1 1	4 4 0 0	. 4 . c	4	1	4.6	4.6	4.6	9.4	. s	4	: : :	!!!	4.	
		75	; ; ; ; ;	3.4	ю т	٠ ۲	; r	, r	. 7	3.7	3.7	3.4	3.4	;	3.4	!	0.	4 . O (. 4 . 0	. 4	1	4.7	4.7		- ·		· •	1	4.4	4.4	4.4	e .	4 4	4 4 5 6) j	!	4.3	
				3.6	9.6	၁	: ני יר	່ດ	9 6	ი გ	3.5	4.1	4.	† †	4.	1 1	4 . U :	4 .		4 <	. 4 . 6	1	4 6	4.6	!	4 4	. 4 . c	. 4	t f	4.9	6.4	4.9	6 4	on (4 4 0. 0) ;	1 1	4.9	
		7.1	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	4.0	0.4	6.0	: (. 4 . C	2.0	0.4	4.0	4.1	4.	i s l	4.	1	4	4.	υ r	יי קיי	. 4		4.5	4 3	1	4 4 0 0	. v	6.6	1 1	5.4	5.4	5.4	ນ ເ 4.	4.0	4 4 D C	: :	!	4.9	
		9	!				ı	•			•	•	•		•	ı	•		•	•	•	٠,		•					•		٠			٠		٠.	- 1		
		29	1 1 1 1	3.8	3.8	3.8	; (ი ო	0 60	3.8	3.8	4.	4.1	!	4.1	1	9.	9.4	4 . ت	9 4	. 4 6	2	4.6	4.6	1			3.7	1	5.0	5.0	5.0	0,1	, 5 7	4 4 5 5) ! ! !	!	4.0	
	S	ш×	 u	14.	<u>.</u>	L 1	L. I	. .	نا ـ	. 11	u	Æ	Z	Σ	Σ	Σ	Z	Σ:	Σ:	ΣΞ	EZ	Σ	Σ	Σ	Σ	Σ:	E 3	ΞΞ	Σ	Œ	Σ	Σ	Σ:	Σ	ΣΣ	: E	Σ	æ	
⊢ α	2 0	⊃ a	1 0	C	က	ю.	თ (י ר) (T) რ	ღ	4	4	4	4	4	4	4	4 .	4 4	7 7	7	4	4	4	77 •	3 <	1 4	4	7	7	7	₹ .	4 '	c c	14	~	4	
∢Z∺∑<∴	z	.	441	*	4	4	7	* ~	7	7	S	S	S	S	'n	S	ທ	S I	n t	S G	ט פ	y O	ဗ	9	9	9	ט פ	ာ တ	-	~	7	7	~ 1	~ :	- 1			8	

TR Group 1 = Control; 2 = 1.5 mg/kg/day R0X; 3 = 7.0 mg/kg/day R0X; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEYAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MDUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

2 H Z < 2	+¤ ©¤																					
zs	0 :	(/) u										⊢	WEEK									
o • ˈ	2 0	٧ يا	ဖ	ဖ	7.1	73	75	F- 1	79	8	∞ ≀	85	87		on ₁	93	95	97	66	101	:03	104
	4	1	4	ı I	5.3	6.9	9.4	4.9	4.7	5.1	4.7	.		~	4.5	4 ت	4.4	4.8	4.4	4.6	7	
2	~	Σ	•	ı	!	;	1 5 1		•	1		1	3	3 (1 1	1	1 1		1 1	1 ,	1 9	1 (1 4
ي د ا	₹.	Σ			ر ا ا	بر ون	÷ . د د							4 + 10 11	•	ជា ។ ព្រះ	ए र •; र	1 4	4.4	7. T	4 4 W C	4 4 W (
484	٠,	Σ:			က ((၁)	ი ი •	ۍ د د			 ::				 		4 - ບິກ	2 T	\$ °	4.5	יי פיע	4 ¢	; c
32.5	۲ ٦	£ 2	•		r ~	. ~	: - : :			. ć				ಕ		: 4 .0	: 4 : 3	. 4 . R	5.5	. n	. 7.	, 4 , 0
487	*	Σ	٠		. 6 0	7	. 			٠ د				٠. ت		4.9	4.6	4.5	5.5	5,1	4.7	4.6
488	4	Σ	•		æ ~	4 7	4 9			÷				ນ:		4.9	4.6	4 . ت	1	!	1	t ;
489	Ţ	Σ	•	•	4 8	4.7	6.4	•	•	4.9				5.5		6.4 0.	ه. ۵	. S	1 1	1 4	! ! ! .	1 4
490	7	Σ		•	4.8	4.7	4.9		•	6. 6.		•		5.5		6.4 0.0	4.6	4. ت	ນ ທ	5.1	4.7	9.6
٠, ç,	۷,	Σ:	•	•	4 . R: 1	٠,	4.	٠		6. A				0 C	•	4 4 8 a	ין נ	י ני ני	ין פ	1 -	() 	1 1
265	. .	2 2	• 1	• 1	G. 1	9 1	- 1			9.19	. 1	٠,		Y		0 i	2 1	. !	0 1	- I	1	
4 4 2 6 2 6	3 13	ΕΞ	1	1	. A	7 7	7			6				4.2		4.8	5.0	5.1	!	1	!	1
967	. 4	=	•	•	. 4 . 13	4.	4			9.4				4.2		4.8	0,0	٦. ٦.	3.9	4.4	4.4	4.7
496	4	Σ			1	1	! !	- 1	٠.	1	١			1 1	1	: :	! ! ;	! !	i 1 1		t 1 t	!!
497	7	Σ	•	•	ξ. Ο	4 0	4 ن	•		ъ.		•		4.9	٠.	4.3	4.:	4.1	4.3	1 1 1	!	
498	4	Σ	1	•	1	! !	i i	ı		1	ŧ	1	t	1 1		1	: : :	!	, !	1	! !	! !
439	11	Σ			5.0	6.3	4 . 6 .	•	•	ا دیا -			•	6.0	•		; •	1 7	: C	S	1 7	1 (
00°	4 •	Σ;	•	•	0 1	ر د د	4 n دن د	•	•			•		4 4 20 14	•	4 п Д 4	4.	r, 7	. t . i	. i	4 I	1 2
Š. 5	4 <	٤٤			D . C	. i	7 1	. ,		- 1 - 1	. 1	. 1		. !		† ! ? !		r 1	!	i 1	ì	i l
202	1 4	EΞ			6	5.4	5.2	•		5.1			- 1	1	1	1 1	† †	1 1	1	1	1 1	1
504	4	2			9.	5.4	2	•		5.1		•	·	1 1		1 1	1 1	1 1	\$!	-	1	1
505	•;	Σ	•		9. 0	5.4	5.5	•	•	5.1	•		•	4.7	•	5.4	ત્ર 	4,4	4.7	4 . Q !	6.6	2.9
906	4	Σ:	•	•	ъ.	4	4.3 E.	•	•	4 3				4.5	•	- 1	4.6	4.5	6.1	4 . ت ا	. 1	4.1
507	4 4	ΣΣ	1		l 1 1 l	! ! ' ! } !	1 i 1 i 1 i		, ,	! ! ! !	1 1	1 1	1	1 1			1	1	1 1	1		
202	4	2			£.	6,4	6.3	٠.		4.5				4.5		4.1	4.6	4.5	4.9	4.5		4.4
12 15 15	4	×			5	6.9	4.3			4.5				4.5		4.1	1	t 1 1	: 1 1	1 1	1	1
51	4	Σ			5.3	5.1	4.8	•		4.8			-	5.0	•	5.5	s.0	5.5	5.0	0.9	•	9. 6.
512	4	Σ	1		!	:	;	1		! !	ı	ı	1	:		L	1	! !	1	l l	1	i 1
513	4	ž	ı	1	!	! ! !	1 1	ı	٠	\$ (!	í		t	1 (1	L	! (! L	! (i (1	! (
5:4	4	Σ	•		ы С	-	Δ. Θ.	•		4.8		٠	•	0 i		ນ ນັ້ນ	ນ ເ ວຸເ	ຄຸເ	υ r Ο c	٠ د د	•	ກຸດ
ស ស	4,	∑ :	•		5.3		α, α		•	2 . 2 .	•			0 4 0 4		ກຸແ) a	טית ט'כ	ກ ແ ວ ~	ם סיכ	•	, 4 y y
516	٠.	Σ;	•	•	4.	5.	o. 1		. :	2 i	. (. ;		- !	. 1) !	0 1		- i) i	. 1) ; ; ;
22.7	. •	Σ:	ł	ŧ	! .	1 T		ι	1			†		7 7	i	L C	α •	ני	ı.	r.		2
ນ ກ ກົ <u>ດ</u>	. T	ΣΞ	•	•	: 7	ນ R.	2 T	7.7		2 4 0 60		. T.		4.7		ы О. С	1.4 5.8	20.5	. r.	20.0	0.0	. S.
ה ה ה	•	: 2	•	•			. 4	-	•	. α				7		0	8.	5.0	5.1	5.0		4.5
>	,	E	•	•	:		, :		•	:					•	, ,			ı			

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; $\theta = 35.0$ mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

(2)

0

٣

نځ

ټ

< Z

Ç		4
103		4.2
101		4.3
66		4.3
76		4.6
95		4.1
93		4 1
± 6		1 4
6:8		4.0
EST W		, ~
83		. 0
	$\begin{array}{cccccccccccccccccccccccccccccccccccc$: 0
σ,		,
ស	: י . ט ' י ' ' ו ' ו ו ט ט ט ט ט ט ט ט ט ' מ מ מ מ מ ' מ מ מ ' מ מ מ מ	100
		m m
-		
თ		
-		
FR GROUP	 	च च
HEAN ZO .		559 560

<u></u>

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX TR Group

A STATE OF THE PROPERTY OF THE

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3.5-TRINITRO-1,3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

	⊢ జ లజ	х ш х	4	4 4	44	14	୯ ୯	44	æ 4	4 4	া ব ব	**	578 4 F	: 4 ·	4 4	4 4	া ব	4 4	**	4 4	4.	7 7	4 4		~ ~
		7.	. 6.	9.1	9.	. .	4.4. 0.00	4 4 6 6	44		. <i>L</i> . a)	e e e e e e e e e e e e e e e e e e e	 		; 0	0.0	!!	0.	0.4		<u>4</u> 4	4.0	n m	ص در
		۲-	.6 3.	9. 1	.6 3.	.9	ო ო ი ო	6. 6. 6. 6.	(n) (n)	900) (ი. ი.ი.	; .	 		.4	1 1	4.	4 0 4 0			6.4	ထားတ	8 8 4 4
HE.		,	9.	m	e ;	က က	, ,	ຕ່ ຕ່	m m				900	, ,	ກ່ ຕ	10	4	! ;	4	4 W	: 1 6	ກ ຕ	m r	ກ່ຕົ	m m
TWENTY KAHYDRO IN		75								•								1 1							
. 3 . 1		77	2	~ ;	6. 1	0.	00	00	8 8	, cc c	, e, c) <u> </u> (000	်က	به به	; 4	9 09	1 !	9	9. ^.	. 1	· r	טי	១ ភេ	ល់ស
NTH CHE TRINITE		79	10.	٠. ا	ហ	<u>ग</u>	4 4 .	4.4	ဖဏ္	. w w) ; (; - , t		1 1		: :	7	ري -		ບໍ່ເນັ	rv a	0 ec	ထင္
RONIC 1 RO-1.3. CONSUM		81	4.	4	A :		œ φ. 	ක් ක් ක්	0.0	000	. O. a	· · ·		, r- 1	· [-	1 6	. e.	; ;	6.	ოო) () ()	, e	0.4	n m	မ . မ .
OXICITY 5-TRIAZ PIION P	;			N	e: !	;	-		<u>ن</u> ب		90.			٠,٠	٠٠.	<u>.</u> .	. 60	: :	œ.	8. 1.	ļ t		٠. ۵	و بی	က် က
MONTH CHRONIC TOXICITY/CARCINGGENY .S-TRINITRO-1,3,5-TRIAZINE(RDX) IN DUAL FOOD CONSUMPTION MEASUREMENTS		ST WEE	[6 :	; ;		ი ი ი ი	44	4 4	46				, w	10	. e	: :	3.	 			9.6		e e
NOGENIC K) IN T			(1 °	T. I.	æ 1	. (- -	66) M M		 		ממי	10			က၊	ოო	1 (າຕ	n r	9 6 6 9 6 6 9 6 6	ო ო
ICITY STUDY THE BGC3F1 (g/day)		6	. , \	7 1	Z 1	' (თ თ ⊦	ოო	44	प्र	. 4 W	1 (က က က က က) m	מפי	16	ເທ		ເດເ	ນ 4	! ~	44	46	າຕເ	ი ი
DY OF F1 MOUS		93	; ; ; ; ; ; ; ;	4.6 6.1	4.6	1 (9 9 9	ი ი ი	4 4 8 8	4 4	8.18		! ! ! ! ! !	0.4	4 4	1 4	4.	1 1 1 1 1 1	1 .	. B.	1 0	ນ ເວ ເນ ເວ	ອ ເ ເ	9 6 6	တ တ တ
ñ		တ	, ,		. 1	- 1			٠.		4 K	. 1				1		1 1	1						
		97	 - 	~ ;	- ;	: 1	- ·	- +.							າຕ	1 6	· -	1 1	1 .	_ 4			4		
		99	' (8.1	8.1	; ,	a 4 . u w i	4 4. u w	o. o.	იი			n en e n en e	9 60 6	, o.	10	4.	 ! !		4 4		* 4	* -		
-		-	1	₹ 1	8 I 4 I		ഗതാ	n n n n	ი ი ი ი	തെ	. CO 1		6. 6. 7. 4. 4	 	າຕ	10	an O	, , , ,	1 (ւ 24	1 !	. R	20 C		e e 00
		6	!	- ,	- 1	, ,	n m 1	m m	60 60	mm	. m .		200	10.5	0 10	. 10				~ ~	1	. ~	~ ~	+ +++	* *

RDX; Control: 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXĦ Group TR

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RCX) IN THE BGG3F1 MOUSE INDIVIDUAL FOOD CONSUMPTION MEASUREMENTS (g/day)

104	1 5 6 1	1	1	4.6	1 1 1	; ;	! ! ! !	1	2		4.0	1	1	1	! ! !	! .	4 ئ			1	† 1	1	4.6	! !	1 1				!	4.6	!!!	1	i !	: :		4,3	
103	[1	1 1	4.4	1	!	! ! ! !		0) !	4.1	1	j L	j ! 1	! !	; ;	4	! ! ! !		:	1 1	!	4.7	-	1	;	. d	1 :	1 1	4.6	:	1	1 1	 	7	4.3	
101	! ! !	i	1	5.7	1	i i	; ; ; ;	1 1	7	: ;	4.4	1	i i	!) 	!!	4.7	1		!	1	1	5.1	1	1	; (!!	6.4	1	; !	1	! !	. 4	5.4	
66	1 1 1	1	1	6.1	1	1	! ! ! !	1 1	ָ ער		4.4	! !	1 1	! ! !	i i	! .	9. 6	i			1 1	!	4.7	i	! !	1 .	n 0		!!	5.0	1	!	t []	!	י ד	4.6	
76		1 1	l !	5.7	t 1	1		: I	6 7) 1	4.3	1	! !	!	1	ļ,	4.		! ! ! !	! !	1	1 1	5. ↑	1 1	i !	! 4	φ. α) i	!	5.7	1 1	!	1	1	O	6.4	
95			:	4.7	1 1	1 (3.6		י י י) ! ; !	4.0	; ;	1 1	1 2 1	! }	: (6.3	i ;		1 1		1	4.7	1 !	;	! !	- 1-	- ! - ! - !	1	5.0	1	! !	1	1	, +	. T.	
e S			1 1	5.6	: :	1 1	3.6		י י י) ! 	4 ع	;	1 1 1	1	1		0.4	i :	! ! ! !	: :	1	1 1	4.3	! ! !	!	: 1	4 د ان ا	? !	;	5.3	1	ł ! !	<u> </u>	;		5.1	
3.6	; ; ; ; ; ;		1 3	5.1	!	1 .	4.4	1 : 1	! ?	; ; ; ;	4.3	;	1 1	:	* *	L (ი ი	; !	9 1 1	: ! : !	1	1 1	4.7	1 1	\$ 1 1	1 1	4 4 U N		1	5.3	i i	: :	:	! !	; (°	. 4 . 6.	
6 B	;) ! ! !	1 1 1	4.9	i i	* :	- ·	,	: -	- I	4.0	!	1	!!!	;		0	† 1	2 ; 1 ;		: :	[1 1	4.6	:	! !	1 (9· 4 0· 4	. i		6.	: :	!	: :	6.0	; (0.9	;
	1																																			6.3	
3	1																																			. 4 . 8	;
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	: :	,																										: :								
				۳.																																5.4	,
79	1		•	-																																5.7	
	1						ď																4.0			:		ດ	: I) ;		:	ئ	E	ດມຸດ	
ស	1 1 1	: :		σ			37				~	ı					0						æ				~ .	·	- ;	-	. ,		:	. 7	1 5	5.7	•
73	1	! !	. !				4 د د																3.7											7	1 1	٠٠.	
7.	1 1 1 5 2	1 1					4 6 4																											-		4 4 U IU	
69	1	! !		-	• •	;					0												5.3				m (T. (٠.	_			ı		. ,	ກຄຸ	
49	1 1 1 1 1	1 :	! !	-) 1	1	ь. Б	1	į (ָרָר. פַּרָר	σ))	1 1	:	;								6			;	6 (ופ		ı U) I		1		. (. r.	
νш×	1	•	• 1	י ע		1	4	1	, ,	マ 1		1	1	1	'	•										1	4	4 ,	₫ :		; '	:	ı	ស		E ZE	
⊢ α 0α0⊃α	1	ស ព	ט ט	n u	מני	ស	ស	יט	ហ	ກພ	ם מ	ល	r,	ເດ	ល	Ω	ស	ហ	ស រ	ហ	ກ	ព	, ru	ល	Ŋ	ស	ស រ	ກເ	ប ព	១៥) W	ស	ស	ល	លេ	o ro	
42HE<7 20 ·	1 1	904 904	200	500	605	609	607	608	609	9		613	614	6 15	616	617	618	619	620	621	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	5 7 5 5	625	626	627	628	629	630	631	22.5	634	635	636	637	638	640	

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BEC3F1 MOUSE INDIVIDUAL FOUS CONSUMPTION MFASUREMENTS (g/day)

	104	1	ις. -	: ! !	i	! !	1	4.0	t 1	1 1 1	į Į	7	2	4.2	4	4.2	 	! !	1	4 (S)	4 0	! !	ი ი	1 1	! !	1	!	1	!!	1	!	1	1 .	6.	1	6.0	4.4	!	4.4	1	
	ţ03	1 1 1	5.	1	1	1 1	1 6 3	4.	1	1	: !	.4 (C)	6.3	φ.	5.3	4.3	1	1 1	; ;	0.	4.0	;	5.4	1	!	!	1	1	1	1	1	1 1 1	! !	ω. ω.	1	დ დ	4.4	1 1	4.4	1 1	
	201	!	0.9	1	i l i	1 1	1	4.6	1 1	t 1	1 1	7	4.7	7 7	4.1	4.7	\$ 6 1	t i	 	9.	6,4	1 1	6.7	1	1	! ! !	l !	1	1	i I I	[]]	t t	1 1	4.2	t I	4.2	9.4	1 .	4.6	i	
	৮৫	1 1 1	6.3	1 1	!	1	i i	6.	! !	! !	l l	4.7	4.7	4.7	7.7	4.7	l 1 1	1 1	1	-	5.1	t 1 t	. 1	1 1	1	1 	! !	1 1	t 1	t i	1	\$ 	1 '	4.2	1 1	4.2	4.2	1 '	4.2	i [
	97	1 1	5.6	: 1 t	1	1 1 1	!	4.7	1 1 1	1	1	4.6	4.6	9.4	9.4	9.6	i i	!	1	ى -	-	1 1	6.4	1	1	1	1] 1 1	! !	1	1	1	!	4.2	1	4.2	4.7	1 1	4.7	 } 	
	95		5.3	1 ;	ł	1	k L 1	4.6	i i	1	1 1	6.4	۵. ف	6.4	9. 9.	9.) 	1	1	T	ъ -	!!	5. 9.	! \$ 1	1	l l	1	1 1	1	1	1 2 1	1 t	t :	4.1	l ; i	4.4	4.8	1 1	4.8	! !	
	93) ; ; ; ; ;	5.3	1	1 5 t	!	1	4.6	1 1	1 1	1	4.6	4.6	9.6	4.6	9.	1	1	! !	ນ ນ	ນ ໝ	1	. 6		1	!	1 !	1	Į Į	!	l 	!!	1 1	ი ი	1	ე ი	٠ ت	1 .	7	1	
	91	; ; ; ; ;	5.0	;	1	! !	-	7	1 1	! ! !	1	4.6	9.6	4.6	9.6	4.6	ł !	1	1 1	4.9	6.	1	9.6	1	! !	!	! !	1	1	;	1	1	1 5	6.3	1	4 ن	4.2		4.2	1	
	88	 	4.9	:		! ; 1	1	4.6	1 1	; ;	:	4.7	4.7	4.7	4.7	4.7	9.9		1	9.9	9.9	:	5.4	!	1 1	1	1	1	1	!	! !	1	1 1 1	7.	1	4.1	4 6	1 1	9.4	1 1	
WEEK	87	 	4 6) 1	1 1	1 ;	: 1	4.3	!	!	1 5	4 .5	4 .5	4 ت	3.5	. 5 . 5	5.4	:	1 1	ช. 4	5.4	:	5.6	! !	1	ŀ	1	:	:	l l	: !	1 1 1	! !	თ დ	1	9 6	4.5	i i t	4.5	L	
TEST	85	! ! ! ! ! !	4.3	:	!	} ! 1	:	7.7	1 1	t 1	!	4.7	7.4	4.7	4 7	7.7	9.73	! !	1	6.2	6.2	1	2	1	!	i	1	1	!	!!!	1 1	!	l I	ი ი	: !	3.9	4 3	!	4.3	;	
	83		9. 6.	1 2	1	1	:	4.0	1	! !	i i 1	7.5	4 3	5	4.S	4 تن	6.1] ! 	1 l	- 0	6.1	1 1	4.7	1 1 1	1 1	1 1	} 1	1	1	t I I	! !	! ! !	1	3,6	 	3.6	4.3	!	4.3	1 1	
	81	1 1 1 1 1 1	4.6	1	1 1	;	;	43	1	!	! !	4.5	4.5	4.5	4. N	5	5.2	! !	1	5.2	5.2] 1	5.3	! !	1 1 1	1	ł !	t ! !	1] } }	1	i i) 	ი ი	1	9.6	4	;	4.4	1 1	
	62		4	1	1 1	1 1	! !	4.4	1	:	1	4.5	4 3	5	4 .5	7.5	5. 12.	:	1	ຸນ	5. 5	!	9.0	 	1	1	 	 	1	! !	!	! !	1 1	4.0	ŧ !	4.0	4.3	! ! !	6.7		
	11		4.1	2 1 1	1	;	!	4.0	! ! !	1	;	6.4	4.3	4.3	4 G	6.4	ب -)) (1	-	ы Т	1 1 1	4.7	! !	!	 	t L	!	; !	1	:	!!	:	3.7	!	3.7	- .	; !		: : : :	
	75	! ! ! ! ! !	4.0	! ! !	;) 	1	3.7	1 1	l I i	1	4.2	4.2	4	4.2	4.2	5.2	!	1	5.5	5.2	1	4.6	l l	1	!	 	1 1) ; !	1	1	1	!!!	3.4	!!!	დ 7	4.1	1 1	-	! !	
	73	 - 	3 7	! !	:	1	í 1	~	!	1 1	:	4.4	4.4	4.4	4.4	4.4	6.1	! ! [1	9	6.1	; 1	4.4	1 1	1 1	!	i i	1 1	!	1 1	!	!	1	3.9	3 1 1	9. 6.	3.9	1 1	3 3	i i	
	7.1	! - 	5.0	t :	1	1 i	:	4.4	1	1	1	4 4	4.4	4.4	4.4	4.4	5.6	1	1	5.6	5.6	1 1 1	5.0	1	!!!!	! ! !	!	1	1 1	1	; ! !	t I I	:	ი. ნ	1	ნ წ	7	1	4.4	! ! ! !	
	69	 	7	1	1	1 1	1	4.7	1	i	!!	4.9	6.4	4.9	6.4	4 0	6.2	!	1 1	6.2	6.2	1	5.4	1	l 	1 1	1	1 5 7	l l t	1 t	:	!	1 † 1	4.	1	4.1	3.9	1	3	! [! !	
	67	! ! ! ! ! ! ! !	4.9	1	:	1 1	;	4.3	!	1	:	4.3	4.3	4.3	4 6	4.3	5.7	:	[5.7	5.7	1	4.7	1	1	1	!!	i i i	1	1	1	!	t I	3.6	!	3.6	4.5	:	4.5	; i	
S)	u×		Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	<u>.</u>	L	L 1	_ u	
0	⊃ ¢		ស	ស	ณ	រប	r	S	ເນ	ស	S	บ	ប	ល	ហ	ĸ.	ស	Ŋ	ນ	ល	ស	r.	ស	S.	വ	ស	ល	ល	ស	ស	ស	Ŋ	ស	ប	ល	ស	ស	ស	ហេរ	ពមា	}
Z	o ·	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	629	099	661	662	663	664	665	999	667	668	699	670	671	672	673	674	675	616	677	678	680)

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

(

0

(2)

0

٩

3

Ğ

⊢ α

೮ 🛛

401		თ (ი () i	1	-	!!!	4.		, to	3,5	3.5	l l	:	1		2 6	; ;	1	!	1 3	4 6		1	!	1	; ;	1		1	;	1	;	1	!!!
103	1 1	0.0	0.0	2 :	!	! !	1	4.1		ດເດ	3.5	3.5	1	1	1			- ! - !	1	1	;	4 4 5 4		1	:) (1	: :	! !	1	;	 	!	! !	1
101		4. 0.	0.0	5 !	t I	1	1	4.6	! C	9 69	3.8	3.8	1	1	1 1			9 60	1) 	1 6	2 c	· 1	1	1	1 1	i i	i !	! ! ! !	1	1 1	!!!	i i	1 1))
66		9.0	თ. დ. ი) 	; ;	t i t	1 1	4.7	: (0.0	0.	4.0	! !	1	! 6		ים מים	, 4 , 10		1	! !	. v) - -	1	1	1	\$ # 1	- - -		;	!	1	1	!	!
76	i ; ; ; ; 1	2.5	4.2	4 I	; £ ;	i t	1	6.3	, ,	, r	3.7	3.7	:	1 1	1	: (D 0	5.6) <u> </u>	1 1	; ;	7 5	; ;	i i	:	1	1 1 1	: ! !	:	t t	1	 	1	!	! !
99.2	3.7	3.7	 	· !	1 1	! !	t i	5.6	; (0 00	3.8	3.8	:	! ! !	!	, , , ,		. 4		l l	: .	4 <) i	ŧ !	1 1	1	!	ί ί ί	 	1 1	1 1	i i	1 1	-	:
693	3 2	3.2	e :	. !	1	!!	1 1	7.4	1 (ກ ຫ ຕ	9.6	3.9	! !	i !	;	1 (5) O	. 6	1 1	;	1 .	4.4)	\$! !	} ! !	!	i) 1	! !	1 I	!	1	\$ \$ 1) 		1
6	3.5	က (ຕ ທີ່ເ	 	1 1	1 1	{	5.3	0	ກຸດ	Б	3.9	:]	! ! !	1 (ب ب ب	0.4	· !	!	; ;	4 ¢	2 1	! ! 1	! !	! !	! : (1 1		1	1	[!	!	1 1	i i i
68 8	3.2	3.2	ი :	5 !	1 1 1	1	1	4.6	: L	ກ ຕ ດ ເຄ		3.5	!!	; i	! !	: (n c	, o)	1	(n <	7 I) †	1	:	i 1	!	; ; ; ;	į	!	;	!	1	:
¥ E E E K 8 7	3.5	ස 1	က က (5 i	1	:	;	5.7	; 6	າ ຕ ຕ	9.0	3.3	1 1	1	1 1 1	: :	ص ص	, T	1 1	! !	! :	4.4) ! ! !	1	1	1 1	1 ! !	!	; ;	1	1) ! !	1	! !	:
TEST	3.4	ත :	ი (5	:	!	:	0.9	; ;	ာ (C		3.6	!	1	! !	1 1	4 t	. 4 . 10	1 1	!	: !	4.4 5.4	. !		1 !	!	1	;	!!!			1	;	1	; ;
83	5.4	С 4	4.6	÷ ;	1	1 1	! ! !	3.7	: (9 W	9.6	3 6	;	i ! !	1		თ ი ი	ກ	1 (!	1 (o () ! !	! !	! ! !	1		1	ł 1		:	! ! !	1	1	; ;
α 1-α	3 7	3 7		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	1	1 1	1	3.7	;	2) C	9.6	3.4	1 1	\$ 2 7	1		2 7 0 0	4 4 5 +		! !	;	4 . - (?!	1	1 1	! !	1	1	1 1 4			t 1	1 1	1	!
62	933	G 6	ი :	m ;	1	} ;	ž I	3.6	9.6		3.7	3,7	1	!	1	t .	4 4 6 0	7 -	. 1	1 1	;	- (. i	! !	! !	1	:	1 1 1	1 1	1 1	: 1 !	1	1	;	t ! !
77	3,1	3 +	د .	- ;	t t	1 1	1	3.7	. 7 1	ກິດ	, to	3.5	! !	1	:	!	ი ი 4 4	, d		1		4.6	. !	!	1 1	!	; ;	; 1 1	1		! ! ! !	1	;	1 1 1	!!!
75	3.4	3 4	۳ ا	6	!	5 ! !	: -	3.6	က က		, c	3.2	!	! ! !	!	1 1	က (က (, , ,	. !	1	!	ლ (n :	1 1	1 1	:	:	f L T	-	! ! ! !		1 1	;	;	:
73	3.2	3 2	3 5	G :	i ! !	ł 1	:	0.4	0.4		, c	3.5	;	1) ! !	;	ю (2 c	1 · i	1 ,	{	3.5	. i	!!	i	:	! !	1 1	;		: :	1		:	1 2
7.4	3.4	3 4	ъ Ф	e :		1	1	4.2	4	ب م د) (C	9.6	!	:	1	! !	4.		; ;	1	1 1	. .	. I	1		1	1	1	1				!	1 1	:
69	3 5	3.5	3	က ၊ က ၊	;	į	!	4.1	7	ω c 4 ∠	1 T	3.4	! ! !	1	1		တ က (5 c	: !	!	!	4 ·		1 1	1	i i	ļ	:	1	I I I	f 1		:	!!!	! ! }
67	3.1	3.1	ლ -	5 1	1	į	1	3,3	ი ი	w r	. 6	3.	i i	ļ	! ! !	 	က (က (ω < υ (N	1	1	4 . G 1		1 1	:	1 1 1	1 1	! ! }) 1 1	;	1 1	1 1	1	i i	
wm×	ļ	u.	<u>. </u>	L 14	·	. 14	ų.	ш	L.	L L	L L	. 4	u.	v.	u.	L.	LL I	ı u	u	ı.	u.	tt. I	L L	. LL	u.	Ľ.	Ŀ	u.	u. L	ı. i	L	ц	. 4	u.	tı.
+ α ω α ο ⊃ ¢	្រុ	ເນ	Ŋ	೮ಚ	េះ	ល	ស	ស	ល	រ ប) ស	, 1 0	ຜ	ហ	ល	ព	មា	ល ព	າທ	ស	ų,	រស (ល	ហ	ល	10	เบ	Ŋ	ហ	ກເ	ល	กษา	ຸເຄ	ស	Ŋ
∢∑⊣∑∢ 」 ZC ·	681	682	683	684 202	288	687	688	689	280	694	200	694	695	969	697	698	609 609	9 5	102	703	704	705	702	708	109	710	711	712	713	41.4	715	717	7 18	719	720

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TO THE REPORT OF THE PROPERTY

TWENTY FOUR MONTH CHRONIC TOXICITY/CAF : STUDY OF HEXAHYDRO-1,3 5-TRINITRO-1,3,5-TRIV: KD. MOUSE INDIVIDUAL FOOD COMSUMPTION MEASUREMENTS (g/day) 294

	104	:	i i	5	; ,	U	t !	1 1	: :		6, (9	ი ი	ი დ	3.0	1	1	1	1		, 1	2	1	1 .	?	;		 	! (5.C	1 1	
	103	1 1	1 	о С	; (n	\$ 		l l		. 4 . 6	დ 4.	3. 4	3.4	3.4	! !	1	1	į	,	· ·		1 1 1	! ,	-	1	!	1	O 6	9.0 0.0	i i	l l
	101	i t	1	4.	ļ :	- -	; !		l l	!	4.4	4	4.	4.	4.4	i	;	1	1 5	,		4	!]	! (1) 1 1	1 †		O (0.4	l 1	l i
	66	: :	1	4.0	! !	4.4	!	:	!	1	9.6	ი ი	ი. წ	3.9	3.9	1	1	1 1				4.4	1	1 (4. D	1 1 1	1 -	. (ص ص	ი ი	1	i !
	44	t 1	;	4.4	·	4.4]] 	t B ł	t !	t i	6.9	ე ი	3.9	3.9	3.9	1 1	1	!!!		,	4 ·	4.1	! !	! (9.	1 5	1 1 1		7	4.4	i t	l l
	95	: :	!	4.6	: :	4.6	† ?	! :	l t	f 	4.4	9.0	3.9	ი. წ	3.9	:	1 2	; !	,		n (g.	5 1 1	!	4.1	1	!	1 ·	4	4.1	!	!
	33	1 1 1	: :	6 7		4.9	! ! !	! !	! !	1 1	4	3. 8.	Э. В.	3.8	3. B.	! !	:	·		: (N (3.2	1 1	1 1	£.3	1 1	1	i :	٠. ت	4.5	! ! !	i i
	6	; ; ;	1	ე დ	!!;	<u>ဖ</u>	:	• •	} !	6 1 1	4.4	3.6	3.6	3.6	3.6	! !	1	7		! `	4.6	3 4	:	1	4.4	!	!	1	4.6	4.6	! ! ;	: t
	89	. I	1	ි ර	1 1	r ւ.	† •	} *	: !	} !	۳ 9	3.4	3.4	3.4	3.4	1 1	!	,		. (ص ص	3.3	# # #	1	4.4	1	!	:	3.8	3.8	f !	
WE.	87	;	•	, ,	:	۳ ج	•) ! ;	{ { }	4.4	3.4	3.4	3.4	3.4	1	1 1	u	o . o	! ! ! !	3.5	3,5	1 1	: :	. .	!	! !	1 1	4.1	4.1	\$ 8 1	
TEST W	85		1 ;	4.6	:	م. م.	1		1 .		4.1	s S	3 5	3.5	13	:	! ! !	c	٠ ٠	!!	3.8	3.8	! !	!	4.6	:	!!!	 	5.0	5.0	i :	1 1
	83		1 1 1	3.8		α c				!!	4.4	ъ С	3.1	3.1	-	1 1	1		٥.٥	1	3.8	3.8	! ! !	1	3.9	1 1		!!!	3.8	3.8	i I t	i
	81	; ; ; ; ;	1 1 1	3 7	;	~ ~	i		;					3.4			1		3.	1 1	3.4	3.4	!	:	4.3	:	1 1	:	4.4	4	! ! !	
	79	; ! ! ! ! !		-	:	- 7		:	;	1 1 1	4.1	3.4	4.6	4	4	. 1			æ. 	! ! !	2.8	2.8			4.4	1	!)]]	3.8	3.8	} !	;
		: : : : ! !	!!!	3 6	1 1	3 6	:																	1	•-	1		: :	4.1	4.1	:	! !
		; ; ; ; ; ; ; ;																														
		; ; ; ; ; ; ; ; ; ;																														
		; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;																														
		1 1 1																														
		: :																														
S	ш×	•																														
) ~ O	⊃ •		ะ) V	ល	ري د	ڻ ان	៤.	ស	ĸ	រ ពេ	ម	ט כ	กม	ם מ	וח	ភ រ	ın.	ស	ເດ	ស	ស	ı Kı	ເທ	R	ស	ຜ	ī.	ស	ល	ខ	ស
, S	o ·	721	723	703	724	725	726	727	728	720	730	4.5	- 0	1 0	5 t	7.44	735	736	737	738	739	7.40	741	742	743	744	745	746	747	748	749	750

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group 1

C. P Z H Z >

TWENTY FOUR MONTH CHRONIC FOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-IRINJTRO-1,3,5-IRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL HEMATOLOGY VALUES - TEST WFFK 14

Z x x v \-00 3 x v	000000000000000000000000000000000000000
omex cu>a	000000000000000000000000000000000000000
ಬಡ€% ಬರಱ	000-0000-000000000000000000000000000000
SOS %380	0-00000
८७६% देन	
▼ 2 ш ⊃- % 3 &∪	
- x Zud- %3mu	. < < < < < < < < < < < < < < < < < <
33 / O + + + + + + + + + + + + + + + + + +	1331 1331 1336 1336 1338 1473 1438 1472 1438 1472 1438 1438 1438 1438 1438 1438 1438 1438
x 010 b-t-	33 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
≅ ∪I c ⊽	$\begin{array}{c} . \\ . \\ . \\ . \\ . \\ . \\ . \\ . \\ . \\ . $
≥ ∪> ⊐ £	. xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Ξυ⊢ ⅓	$\frac{4}{4} \frac{1}$
-5~5 BUE	$\begin{array}{c} \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot $
∝ ⊗ ∨ × − ° ∨ ₹ E ° °	0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
≱æ∪ x −ő ∨∈E [®]	$\begin{array}{c} \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots $
wπ×	· · Z Z Z Z Z Z Z L L L L L L L L Z Z Z Z
⊢ α ଓ ଘଟ⊅∟	
<2+2<- 20	22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 23.00 23.00 23.00 23.00

*Instrument malfunction TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

CONTRACTOR OF THE PROPERTY OF

OF.	MOUSE	
TWENTY FOUR MONTH CHRONIC 10XICITY/CARCINGGENICITY STUDY OF	HEXAHYDRO-1,3,5-TRINITRO-1,3,5-FRIAZINETRDX) IN THE BGGSF1 MOUSE	INDIVIDUAL HEMATOLOGY VALUES TEST WEEK 14

Zαπυ \-00 ≯mυ	000000000000000000000000000000000000000	
B < VC %3BC	000000000000000000000000000000000000000	
₽₽	00000-000000000000000000000000000000000	
ZOZ %3œc	000000000	
_> Z %3mC	6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
₹ Zw⊃- %3@U		
HE ZLD- X380		
> -C /EE	833 1152 862 1033 10	
Σ 020 5 √5-		
סם בטפ	C	
× 0> 5 €	. 444444444444444444444444444444444444	
IO- ×	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	
דטעס ס/ד-		1 4
ano x -c ∕ se	10 25 20 10 20 20 20 20 20 20 20 20 20 20 20 20 20	m 1 f
Bac x +C ∕EE	$\begin{array}{c} \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot $	400
νm×	· \$2\$\$\$\$\$\$\$\$\underleber\$\t\$\$\$\$\$\$\$\underleber\$\ ;	-
- a 6 a 6 D c	. aaaaaaaaaaaaaaaaaa	•]:
<2-2<- 20		

*Instrument malfunction TR Group 1 = Control; $2 = 1.5 \, \mathrm{mg/kg/day} \, \mathrm{RDX}$; $4 = 35.0 \, \mathrm{mg/kg/day} \, \mathrm{RDX}$; $5 = 175/100 \, \mathrm{mg/kg/day} \, \mathrm{RDX}$

@

9

0

•

9

٩

I

TWENTY FOUR MONTH CHRONIC FOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINF(RDX) IN THE RGC3F1 MOUSE INDIVIDUAL HEMATOLOGY VALUES - 1FST WEEK 14

NEBC)	_	-	0	c	:	3	8 2	ا ن	(٠ (0	0	0	0	C	0	0	o ,	0	٥ :	> (0 (0	٥ (0	0	0	0 (၁
	83	<	S	c	•	2	3	ထ	C		o	0	0	0	0	0	0	0	0	0	0 1	0 (0 (۰ د	۰ د	0	0	0	0 1	0
		w	0	s	ī	:	3	జ	د		0	c	0	0	c	0	0	0	0	0	٥	0	0	o ·	-	0	0	0	٥ ا	0
		Σ	С	z	;	75	3	c	ပ		c	C	-	-	0	0	0	0	0	ဂ	0	0		0	0	0	0	0	0	c
		ب	>	Σ		۶,	3	Œ	ပ		æ	87	9/	5.9	37	3 S	84	68	82	83	32	87	7.1	88	83	ສຄ	82	1.1	35	20
Σ	z	: _	⊃	-		*	3	œ	د	:	5	<u>.</u>	23	38	16	-	16	32	<u>8</u>	-	68	-	28	12	ξ,	15	15	23	œ	£0
⊷ Σ	z	։ սւ	ח	-		*:	3	ಜ	ပ	•	С	٤	c	c	C ⁱ	0	С	၁	0	0	С	0	С	0	C	c	c	0	0	С
c	>	:		ć	2	_	ε	E			1102	878	1052	067	1122	10.19	1109	1406	828	784	52.1	91¢	1049	1592	1230	730	954	716	1016	1020
	Σ	ن :	=	L		5	\	τ	_		38 8	15 7	31 B	7 pt	39.2	38 4	37 1	39 0	35 6	37 6	36 3	37.0	É	36.7	39.2	40.7	40 4	18 0	36.4	36.2
				Σ	ပ	Ξ		c	Ξ											17.4										
				Σ	ပ	>		=	E		<u>د</u>	11	5.	4.7	-	11	46	47	48	46	47	46	46	48	46	16	46	<u>۱</u> 6	48	17
		Ξ	: 0	-		%														48 4										
	2	. c	: <u>a</u>		5	```	. च	_												17.9										
ಜಙ೮	;	,	-	- c	e :	\	. =	E	~	1										10.48										
3 ഇ∪	:	>	-	- ć	8	`	É	: 8	د	1 1 1 1 1 1	~	50	, c	, œ	· α	ពេ	ο (C	. 4	· &	6 7	55.2	8. 6.	7 2	6.3	** ! !	4	7 4	5 7	4	7 0
							v) <u>u</u>	. ×	1 1	٤.,	Σ	: \$	Σ.	: 3	: 2	2	Σ.	Σ	Σ		i.	L	L.	ـــا	· i	ٺ	. 14.	. L	L.
		۰	- c	Ľ	g	~	· c	=	ے ہ	;	-	· L	ť	נו	, r	្រ	ı,	ı,	: 17	ម	ı,	'n	ß	ı,	ស	េ	T.	r C	េស	ស
	< ∶	z •	- 2	ξ <	- ۱	Ī	z	: =	;	,	Con	613	41.0	622	828	0.00	023	647	5.00	675	676	678	681	689	069	69	769	701	730	733

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX*Instrument malfunction

//day RDX; 3 = 7.0 mg/kg/day RDX; = 175/100 mg/kg/day RDXControl; 2 = 1.5 mg/kg/day RDX; 'n 35.0 mg/kg/day RDX; function mal 11 11 nsirument Group 1 -7 ۲. ج ÷:

Û

0

٣

3

(2)

0

٨

TWENTY FOUR KONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRU-1,3,5 IRINITRO-1,3,5-TRIAZINF(RDX) IN 14E BGC3F1 MOUSE INPIVIDUAL HEMATOLOGY VALUES - 1FST WEEK 26

Z α m ∪	000-00000000000000000000000000000000000
r <vo %3*bu<="" th=""><th>000000000000000000000000000000000000000</th></vo>	000000000000000000000000000000000000000
uoo %≥mu	000000000040000000000000000000000000
ZOZ X3EU	00-00-00000-000000000000-000
しいめど ぱんし	7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7
Z Zwコ- %38C	28 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3
	20-0-00-0000000000000000000000000000000
	15.748 15.748 15.748 16.744 16.741 16.751
20 E O E O E O E O E O E O E O E O E O E	- 68 - 68 - 69 - 68 - 68 - 68 - 68 - 68
MA COM	- OB 8 - O 8 8 - C 8 8 6 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
## 	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$
10 F %	/ x 0 0 2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
בטש ס⁄ס-	- 6000000000000000000000000000000000000
22 > + C	255 275 277 277 277 277 277 278 289 291 291 291 292 293 293 294 295 296 296 297 297 297 297 297 297 297 297 297 297
≯EU > -C \EE	101 102 103 103 103 103 103 103 103 103
νшх	* * * * * * * * * * * * * * * * * * *
- a caba	
<z-x<- th="" zc="" ·<=""><th>7.91 7.92 7.93 7.93 7.93 7.93 7.93 7.93 800 800 800 800 800 800 800 800 800 80</th></z-x<->	7.91 7.92 7.93 7.93 7.93 7.93 7.93 7.93 800 800 800 800 800 800 800 800 800 80

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX;
4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

N K W C		\	-	0 (0	3	₹ (r	C		0	0	0	0	0	0	0	0 ()	0 (0 0) C	> <	> 0	0 (0 (> (0 (> (>
	ಹ	<	ທ	0	3	۲.	₹ (20	ပ	; ; ; ; ; ;	0	0	0	0	0	o ·	0	0	0	0 (> (> 0	> 0	5 (0	0 (o (0 (٥ (o
		w	С	S	;	٤:	3 :	œ	ပ		0	0	0	c	-	-	0	0	,	0	0 (0	> (٥ (0	0	0	0 (0 (0
		Σ	0	z	;	× :	3 ∶	8	U		0	0	¢	-	_	-	-	0	0	0	0 (0 ()	0	C	0	0	0	8 .	
		ك	>	Σ	;	× :	3	Œ	ပ		73	80	82	አብ	73	79	73	98	-	78	76	7.5	e (92	88	80	35	94	82	19
Σ	z	ıι	>	- -	,	, ·	3	œ	U	;	21	20	18	Ę	, ,	19	96	"	2	22	24	28	2.7	œ	2	20	ω	Ç	91	20
- Σ	z	; <u>t.</u>	Ξ	-		*	3	œ	ر	,	С	٤	ε	င	С	0	C	С	8	0	0	0	a	c	0	0	0	0	0	0
c	>		-	cັ	77.	_	=	ຮ໌	c.			0051	1080	12.61	6,01	1305	1701	1.136	1837	1556	950	1754	1205	1085	806	1182	1002	1332	926	1105
	Σ	٤	Ξ	Ü		b	`	τ	-		0 11	c C.	o or	1 07	6 01	10 A	39 65	36 7	38 1	39.4	39.2	40 6	40.0	40.9	410	38 0	41.4	41.2	41.1	40.4
				Z	ပ	=		2	. 5		۲ ۲	: #			۳. ۳.	18	18 5	176	17.8	18 0	17.9	18.2	18 8	19.1	19.0	18	19 8	19 3	19.4	18.8 8
				Σ	C	>		=	Ę	τ,	15,	1.7	1.1	52	 		<u>-</u>	, 81,	<u>ه</u>	91,	45	44.4	47	5	16	48	43	47	7	91,
		=	: c) 		75				,	100																	42.9	•	
		: 0	7 c	:	5	_	τ	~									,				•		•				•	17 1		
~ & 	;	y	-	- 0	٥	\	E	5	e E										_									90.6		
≱ထပ	:	x	-	- 0	m	`	£	Ę	۳:		r c	101	2 2	. 0	, c		. 6	- α - σ	15 15 15 15 15 15 15 15 15 15 15 15 15 1	8.7	12.4	8.7	င တ	0.0	9	7 5	9	6.7	<u>ဝ</u>	9.0
							v	٠.	: ×		2	Ξ	2	: 2	E 2	Σ	.	Σ	Σ	Ξ	Σ	Σ	ji.	ш	. L.	. 14	. 1	. u.	. اس	. L
			- £	¥	c	~	0	=	٦ (ם נ	า น	טנ	÷ £	ני	ť	ı U	ប	, tu	េហ	z,	ນ	ហ	, LC	מי	ហ	ល	: 10	ម
	< ;	2 •	- 2	₹ <	- ۱		Z	: c			600	מיט	6000	000	000	97.8	200	מר מ	500	840	644	999	841	744	844	704	846	708	848	989

Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXtı tı Group

③

٩

٩

٩

E.

3

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRD 1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL HEMATOLOGY VALUES - 1FS: WEEK 53

Z¤¤∪	000000000000000000000000000000000000000
ರ≪ ಇ೦ %ತಾಣರ	000000000000000000000000000000000000000
naak san	0
ZCZ %3mu	# # # # # # # # # # # # # # # # # # #
טאצא אירר	# # # # # # # # # # # # # # # # # # #
OBEK HCME Z	
-5 Zub- %360	***************************************
C > -C	4 - 1 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2
ನ∪ದಲ ರ∿೪-	23 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Συπ αδ	
∑ ∪> 3£	
10- %	
≖ 0≝ 5 ∕5-	$\begin{array}{c} 1 \\ 1 \\ 1 \\ 2 \\ 2 \\ 3 \\ 3 \\ 4 \\ 3 \\ 4 \\ 3 \\ 4 \\ 3 \\ 4 \\ 3 \\ 4 \\ 3 \\ 4 \\ 3 \\ 4 \\ 3 \\ 4 \\ 3 \\ 4 \\ 3 \\ 4 \\ 4$
α α Ο → + Ο / ε ε ε ε ε ε ε ε ε ε ε ε ε ε ε ε ε ε	20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
3800 x +0 √ E E	
игх	. ZZZZZZZZZz
+ a a a c ⊃ c	
<2-2<- ZC	25 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2

*Clotted TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; $t_0 = 35.0 \, \text{mg/kg/day}$ RDX; $t_0 = 175/100 \, \text{mg/kg/day}$ RDX

Company Comp	#S :							!			
88 8 8 9 9 1 1 2 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	:		TWENTY FOUR HEXAHYDRO-1.3. INDI	MONTH CHRC	NIC TOXICIT 1.3,5 TRIA ATOLOGY VAL	Y/CARCINOGEN 71NF(RDX) IN JFS - TFSI W	HCTTY STUR THE RECOL EEK 53	Y OF 1 MOUSE			
H. W. W. W. W. W. W. W. W. W. W. W. W. W.	:	ကလေးပ				- د ت	⊢ Σ	Σ			-2400
88 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	:	x - C	3 G H	Σ	\$ U I (> - 6	Z - D -		ΣCZ	шOи	
877 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	•		×	د> 5 5	σ\τ- υπ ασ	, EE	光蓮四に		%ತ∞೮	%ತ∞೮	
86 4 2 0 644 2 0 0 76 3 4 2 0 86 3 4 1 0 88 2 0 0 0 81 3 2 0 0 83 1 2 0 0 84 1 2 0 0 84 1 2 0 0 85 2 1 0 0 87 3 2 0 0 87 7 3 2 0 0 88 3 3 2 0 0 88 3 4 1 0 0 0 88 3 6 0 0 0 0 0 89 5 1 0 0 0 0 0 0 89 5 1 0 0 0 0 0 0 0 0		7 9 45	16 1 41 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	, T. 17	1 30 6		; c c	:		0	! ! !
64 2 75 4 7 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		4 05 48 48 48 48 48 48 48 48 48 48 48 48 48	13 s 10 c 14 c 29 c 15 4 2 2 c 15 2 2 c 15 2 2 c 15 2 2 c 15 2 2 2 c 15 2 2 c 15 2 2 c 15 2 2 c 15 2 2 2 c 15 2 2 2 c 15 2 2 2 c 15 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	41 16	2 37 2	8.12 154	; c c		: ए (4	.00	
36 3 88 4 1 0 88 2 0 0 91 3 2 0 88 2 0 0 89 0 1 0 94 1 2 0 83 1 2 0 84 1 2 0 85 2 0 0 86 3 0 0 87 4 1 0 88 3 0 0 88 3 0 0 88 3 0 0 88 3 0 0 88 3 0 0 88 3 0 0 88 3 0 0 88 3 0 0 88 3 0 0 88 3 0 0 88 3 0 0 88 0		5 6.57	11.5 31.3 15.9 41.1	46 17	6 37.2 0 38.8	1030 1005	00		7.4	o-	
889 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		6 9 15 7 8 95	15 6 42 5 15 4 39 6	46 17	1 36.9 2 39.3	964 1006	00		೧೯	o	
88 8 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		3 8 98 3 8.91	15 5 39 4 14.9 39 1	44 16	39.8	7.14	000		- 00	-00	
89 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		7 9 33 0 64 0 46	16 1 45 6 17 1 44 8 17 1 43 0	46 17	38.6	767 767 832	200		o a -	00	
84 1 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		3 10 16 10 06	17.0 44 4 16.9 43.7	44 16	.8 39.0 .8 39.0	821	.00		0-	-0	
853 6 2 2 8 8 8 8 9 1 1 2 2 0 0 8 8 8 9 9 3 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		9 10.21	15 G 40.0 17 5 45 8	45 17	2 39.5 2 38.4	811 864	00		- m	00	
83		8 9 89 3 10.06	16.3 43.2 17.0 44.0	44 44 16	8 37.8	802 6 <i>7</i> 8	000		o - •	n v .	
833 3 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		1 9 59 3 9 15	16 6 43 5 15 8 40.3	45 17	. 4 33 4 39 6 6 6	738	000		- ~ r	- c	
85 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		8 8 83	16 4 42.9 14.6 38 1	43 43 64	. 6 38.8 8.8	1374	000		v m r) N •	
859 2 7 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9		7 8 64 7 9 17	148 396 153 401	44 16	7 38.6	890 890) C (n — (-0-	
75 7 3 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9		5 9.84 1 8.80	16 6 44 7 15 1 39 6	45 17	97.6 2 38.6	966 962	၁င		N 60 I	-01	
75 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		8 8 91 3 9 97	td 4 37.9	43 (6	2 38 4	1040	50			m O	
87 5 1 0 79 5 2 1 0 88 6 0 0 86 3 0 0 91 2 1 0 87 10 0 0		5 9 39	16 1 40 9	44 17	2 39 8	1078	00		r 0	00	
79 5 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		9 48	16 2 41 7	7	2 39 2	890	00		ស្ត	• •	
86 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		6 9 98 2 9 98	16 8 44 9 16 9 46 0	45 46 17	37.0	856	00		ប្រ	- ~ (
91 2 1 0 93 1 0 0 82 10 0 0 88 2 0 0		6 9 41 3 10 16	16 8 44 6 17.0 46 2	17 17	8 37 6 8 37 1	8 9 4 4	. c		စက	00	
82 (0 0 0 88 2 0 0		6 9 40 4 8 84	16,6 43.7	46 17	38.0	763 738	ဝင		~ -	- c	
		50 00 00 00 00 00 00 00 00 00 00 00 00 0	17 2 43 0	17	40 A 80 A 80 A 80 A 80 A 80 A 80 A 80 A	926	00		ō,	00	

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDR'-1.3,5-IRINITRO-1.3,5-IRIAZINF(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL HEMATOLOGY VALUES - 1FST WFEK 53

Z x m ∪	000000000000000000
m< vc %3*m∪	000000000000000000000000000000000000000
ಗರಿಣ ಕೃಷ್ಣ ಬರೆಗ	0000000000000
ΣCZ %ತ¤೮೮	₩
~≻≅ %3ŒU	881 881 882 883 884 884 884 884 886 881 881 881 881 881 881 881
ጀ Ζኰጋ- 光端임ህ	£8 & e e E 0 7 £ £ 2 0 5 4 ± 1 0 2 8 8 8 e e e
+₹ Zub+ %360	000000000000000000000000000000000000000
> -C > E E	17271 1160 680 1172 1178 1228 830 830 11150 1100 11
	33 6 6 3 3 4 4 4 6 6 6 6 6 6 6 6 6 6 6 6
מם בטפ	7.7.8.7.7.7.8.9.9.7.7.7.7.7.7.7.7.7.7.7.
£ ∪ > ≳ E	6 6 6 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
20- %	8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
בטב פּגִּד-	2 75 12 75 75 75 75 75 75 75 75 75 75 75 75 75
ααυ > -0 ∕εε °	8 58 95 77 67 77 67 77 67 67 67 67 67 67 67 67
3	0011000 0011000 000000 000000 000000 000000 000000
wex	2222222222
68005	. មាលជាលាលបាលជាបាលជាបាលបាលបាលបាលបាលបាលបាលបាលបាលបាលបាលបាលបាល
<z∺≅<∴ th="" zc="" ·<=""><th>606 606 623 623 623 638 671 702 714 715 715 717 717 715</th></z∺≅<∴>	606 606 623 623 623 638 671 702 714 715 715 717 717 715

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX;
4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

Z∝m∪ ~~00 3m∪	000000000000000000000000000000000000000
makk conba	000000000000000000000000000000000000000
mov ×≯¤∵	000000000000000000000000000000000000000
SOZ X3BU	200-6-0000004-000000400-0-000
טמצא צאנ	88 88 83 77 73 86 86 86 73 86 73 86 73 86 74 75 86 87 73 87 73 87 73 87 73 87 73 87 73 87 73 87 73 87 74 87 75 87 75 87 75 87 75 87 75 75 75 75 75 75 75 75 75 75 75 75 75
\$ Z#D- %3EC	
⊬Σ ZLD- `3ΩU	
E UEO <i>5</i> \7-	
Συπ Δσ	0 - 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Σ∪> ⊃ €	: :
I U - %	0 4 4 7 7 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
רס∕ס שטב	$\begin{array}{c} \vdots \\ continuous continuou$
αωυ γ - C / E E	######################################
3mc y +c ∕ee	
νæ×	* * * * * * * * * * * * * * * * * * *
~Z-∑<- ZC	233 253 253 253 253 253 254 255 255 255 255 255 255 255 255 255
•	

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; t_1 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

0

_

0

(3)

٧

Ō

۳

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXALIYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN HIE BGC3F1 MOUSE INDIVIDUAL HEMATOLOGY VALUES - TEST WEEK 79

Ζαω ί		
m < ∨ O × ≯ m (000000000000000000000000000000000000000	
#Ov %3€;	0-0000000000000000-00000-0000000	
\$CZ %3¤¢	00-8-04+0004000004-00-0-40-00006-04	
ንመቋን መላጉ	2	
Σ Z∟⊃⊢ %3α¢)	
- Z Z L D - % 3 E (' 	
€ J + Y + C	766 820 831 754 850 736 736 1098 450 858 878 878 878 870 870 870 692 1071 731 731 730 731	
≅ ∪⊒∪ 5 \₹.	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	:
∑ IUZ	+	
∑ (> ∃	~ o o o o o o o o o o o o o o o o o o o	
= 0 - ×	4 4 4 4 4 8 8 4 4 4 4 8 4 4 4 4 4 4 4 8 8 4 8 8 4 8 4 4 4 4 8 8 4 8 8 4 8 4 4 4 4 8 8 8 8 8 8 4 8 4 8	
-5/d 20I	$\begin{array}{c} \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots \\ \vdots $	
ಜಙ೧ x ~Ç ∕ ∈ ೯	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
3 m ∪ x - c	8 G 0 0 0 5 G 5 G 9 F 10 0 0 10 0 0 4 0 G 5 F 10 F 15 5 F 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
សច	×	٠ ,
- 2 5 5 5 5	-	
< Z ~ ∑ < ~ Z C	306 308 310 310 310 310 310 310 310 310 310 310	?

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kq/day RDX; 5 = 175/100 mg/kg/day RDX TR Group 1 :

20 000	\ +	00) 3	ድ 123	ن ا	0	0 (> c	0	0	0	0	00	0	0	C	0	0	0	0	00	0 0	> C	0	0		0	> c	0	0	0	0	~ (5 C) c	o c	0	0	00	>
	⊠ < ⊄	00	*3	≥ ∞	ا ا ا ا	0	0 (0	0	c	0	0	00	0	o	c	0	O	0	0	00	0	0	0	0	0	0	> C	0	0	0	0	0 (0	> 0	o	0	0	00	>
	w C	s vs	* 3	≥ 12	O I	0	0	00	c	••	0	- (0 () c	v C	c	0	0	0	0	00	> c) C	0	0	-	0 (00	0	-	0	0	0 (o •	- c	o C	0	0	00	>
	ΣC	Z	*3	± £3	ن	0	- (7 4	• 0	4	4	- (0 4	* 5	. 0	ı C	0	-	-	0	- (n (> -	-	-	ស	0 (-	0	0	4	ი -	- (> -			- 0	0	00	÷
	ح لــ	Σ	٤%	≈ ∞	ပ	7.5	68) (86	63	69	980	- t	. 65	80	83	84	68	75	16	ი ი ს ს	000	# C	77	84		74	, 69	63	83	73	87	0 0) ti	C &	្ត	50.0	8.7	88 76	:
Σ	2 4 5	_	* 3	= E	: ا ا	25	<u>C</u> :	9 E	7	33	2.7	- 1	n •	- 00) C	1.	16	31	24	24	ეც 3 •	- u	<u> </u>	22	13	53	20	37	37	16	23	0 :	٠ ت (<u> </u>	<u>.</u>	2 7	. 4	13	C 7 C	į.
– 2	Z L D	-	⊱3	= ಜ	ט :	С	c :	c	c	С	0	0 :	0 0	> c	c	0	0	0	0	0	00	> c) C	0	0	0	0 () C	: 0	0	c	0	c	0	00) C	0	0	c c	;
C	>	03	∖ 8	£	· ·	159	758	7.67	270	7.1.7	557	61.	- 000	295	273	193	394	643	418	389	657	227	340	1680	731	578	624	380 080	801	980	1.19	356	220	5 7 S	0,77	91.5	733	699	. 169 181	
	E UI	C	ر م	פּ	-																																		38.0 38.0	
		Σ ()	=	c	: : :	0 /1	c -	: c	-	ς.	۱۳	٠. (ى د	· α	. ~	~	۲۷	œ	~	٥,		, IC	9 (2)	0	ස	9		. ~	8	æ	œ	ا ق	۰. ۰	o <	· c) m	. ~		17 6 17 6	1
		Σ ∪	>	=	e, ; €		<u>.</u> .	היי	7	÷	<u></u>		7 -	47	47	46	47	47	48	46	o u	. 4	9 9	44	44	643	46	. 4 . 6	47	47	7	96.) (1)		, f	á	17	35	ر د د	2
	Ξυ	-	%		*																																		27 24 0	
	<u> ಇ</u> ೧೮	5	`~ で	· -		16.0	Ľ.						•		•		•				14 14 15	•						•											15.9 16.19	. 1
& & O	× -	ငိ	∖ £	ີ ≣ິ	; ;																																		9 57	, .
≯ to ∪	× -	ر ک	<u> </u>	E	1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	7.9	- 2 - 2	- 10			ص	~ <		1 m							တဏ						9 1		6										ນ ຄ ທະນ	1 = [.on
			u.	: س اد	× :	Σ	ΣΣ	Ξ	Σ	Σ	Σ:	Σ:	E 2	: L.	<u>ا</u>	L.	L	L	-	ı. ı	_ u	. L.	. Σ	Σ	Σ	Σ:	Σ 2	Ξ	Σ	Σ	Σ۱	<u>.</u> .		- 1-	. اــ		L	<u>.</u> .	ـ ك	roup
	⊢ ≃	ပ	~ C	: - :	: :	-			-	-	 .			-	-	-	-	-	-			٠ -	- 0	8	7	7	r> c	۰,	2	7	٠,	24 (у с	10	, C	~	~	۰ د	·	TR G
<	Z ⊷ ∑	ند >	z	0		- (29	38	44	5	23	3 20	2.5	82	6	94	97	86	901	600) e	137	153	159	166	180	282	202	205	207	2.15	243	0 th C	26.4	265	266	268	279	300	!

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; $\frac{1}{4}$ = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINF(RDX) IN THE 86C3F1 MOUSE INDIVIDUAL HEMATOLOGY VALUES - TEST WEEK 105

	2 % B C	· \-	00	3	ကားပ ရ	0	00	0	00	0	0	ى د	0	-	0 () C	0	00	00	0	0 0	00	0	00	0	0 0	00	0	0	0 0	5 C	0	00	> 0	c	
		8 ∢ ∨	0	% 3	ထပ	0	00	0	00	0	0	0 0	00	0	00) C	0	00	o c	0	0 (00	0	00	0	0 (o c	0	O	0 (> C) O	0 (> ¢	, c	
		э C	ν	*3	ရာပ	0	o -	- 0	۰ م	- 0	0	0 (0	0	- (o c	0	0	o -	-	0	~ C	. ~	c c	0	٥,	n C	0	-	0 (> -	. 0	- (> C	c	
		æc	z	% 3	ရာပ	0	0-	. ,	۰	- 0	6	0 (00	-	7	o -	- 0	ימ	4 C	0	ဖ ဖ	~ ~	-	O 17	, 	 ·	(°	· –	4	(n d	N 4	r 0	۷,	- c) ~	
		< ك	· Σ	% ≯	ထေးပ	26	36 81	83	- c	-	28	75	0 6	8 1	77	- u	67	3.	68 78	74	29	65 67	69	89 0 5.3	33	80	6. 4 6. 4	86	81	88	υ - 5) α	7.	77	£ =	78	
s.	Σ	Z w =	-	£ %	ထားပ	7.4	بن م	ွှဲဖ	ត (5 5 0	40	25	္ ၈	\$	8 9	2 <u>c</u>	3 5	99	28	23	65	Q 6	28	71	90	2 :	۳ <u>- ۲</u>		14	σ.	7	. 62	ن :	٠ <i>٥</i> ر	Œ	
W X	- ₹	ZLI	- -	% 3		: : c	0:) C	0 (0	0	0 (0 0	0	0	0 0	0	0	c c	0	C:	00	0	cc	0	0	0:	0	0	0 :	00	0	C.	o c	> c	;
2 - 2	c	· -	- °	`\ =		385	1324	534	50,6	618 18	487	57.8 6.0	642 392	41.1	150	1920 1920 1930	530	7:4-1	483	329	875	568	763	981	642	336	7.1.1	100 100 100 100	7	488	5 E	200 200	907	4 12 7.85	410	•
JGY VALUE		∑ ∪ ⊒	E C	6/	、モー	33.4	•	36 6 36					•					*			•	•														•
DUAL HEMATOLOGY			ΣC	~ ==	נס			5 2 5 0 0	•											17.6		•					<u>e</u> :							120	17 A	
NOINION			Συ	; >	е Э Е	65	د :	70	. is	د کر ات	46	50	44	20	£.	. .	÷ ÷	50	<u>-</u> -	46	9	55 54 54	45		ŞŞ			ડ ઉ	46	45	<u>ج</u> ج	τ α	7	ដ ឃុំ ឃុំ	19	
Z		Ξ (۔ ر	%		56.9																													5 ¢	•
		ΙO	r (ז ∕ τ		8 1		 												*	•	•	•	•								•				
	മെന	×	- c _o	∖ ε	e e ^m	4 09					•	•		•						,	•		•	•												
	3 > 10 U	×	- o ^e	∼ E	: ະ	14 0		0.0		•				•					•			•										•				
				U	o ⊫ ×	` æ	₹ :	E S	Σ	ΣΞ	Ξ	Σ	Σ:	- 1-	. ۱	L :	. .		i 1		Σ	Σ:	€ ≨	Σ	ξ Σ	Σ	Σ	Σ۷	L L.	<u>. </u>	<u>د</u> ا			L L		
		~ z ~ :			20	329 3		5.43 5.43 5.43																												
						: m	C	r. r	i m		. m	n	m (שיי ני	इ	-	ς :	. 4	7	~ ~	. 4	4,	7 7	7	c .	. 73	r.	ហ ប	ດທ	ຜ	ម (. ហ	. IS	មា រ	្រ	

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

	Z & & O	`	-0	0	3	8	: ن	0	0	01	0	0 (۰ ۵	0 (٥,	0 (٥ (> (۰ د	- (> (> (0 (٥ (٥,	۵ (0
		83 K	s o	, ,	€ 3€	e	ن	٥	0	0	0	0	۰,	0	٥,	0 (0	5 ()	٥ (> (٥ (0	0 (0 (0 (0
		w	Oν	; >	₹ 3	۳	: ن :	C	ო	0	C	С	0	o ·	, . ,	٥-	- (> (٥ (٥ (> •	0 (<u>ر</u>	0 :	0	0	0
		Σ	cz	: >	€ 3	ಜ	ن	0	-	0	0	0	0	0	0	0 (m (Ν.	- 1	0 (>	01	S.	0	o ·	₹ '	-
យ		نـ	≻ \$: }	€ 3	œ	ပ	83	7.1	37	92	97	78	82	23	7.1	7.7	/ R	83	73	19	87	88	83	78	80	88
TUDY OF	¥	z w	⊐⊢		£ 35	æ	ပ	17	23	63	S	24	22	.	7	00.0	֓֞֞֞֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֡֓֓֓֓֓֓֡֓֞֞֓֡֡֞֜֞֡֓֡֓֞֜֜֓֡֡֡֜	(9	27	33	-	7	17	22	16	Ξ
JICTIV SI JITTE BEC JEFK 105	- Σ	ZĽ	ɔ -	. ;	: ≥	22	Ŀ	с	c	ο	0	c	0	0	0	C ·	0:	0	0	0	0	0	0	0	0	0	С
NNTH CHRGNIC 10XICITY/CARCINUGENICITY STUDY TRIGHTRO-1,3,5 (RTAZINETBX) IN THE BECSET DUAL HEMATOLOGY VALUES TEST WEEK 10S	د ــ -	ν.	- c	m ;	、 €	£	er;	5-19	173	217	961	7.13	736	916	457	575	7.43	553	609	539	193	อรอ	407	419	679	355	392
RIAZINE VALUFS		ΣU	= 0)	5 ∕	. T:	_	38 .1	0 88	30.6					97.9			36.4	33.2	17.2	0 0	110	87.8	38 G	88.8	37.4	38.2
NEW CHRONIC TOX PRIGITRO-1,3,5 DUAL HEMATOLOGY			2	: c :	=	٤	٦		~		ಬ	ي	₹.	c	60	છ	œ	(0	ဖ	æ	~	9	œ	ထ	9	5.0	₹.
ONTH CHR - TRIGITE IDUAL HE			2	: O :	>	=	e. E	1 51	- -			•	45	_	_	_	-		•	•	_		-	-	455	_	45
TWENTY LOUR MONI HEXANYORO-1,3,5-TH INDIVIDE		Ξ	: ပ -	- :	: ζ			a: er	2 2	٠ ئ	3	1 7									•					1.9	
TWENT HEXANYON		ΞŒ) eg	σ.	٠. ٦	:		6C 6	c	_	က	~	Ţ	_	r,	ත	ç,	ဖ	٠.	ပ	က		0.	6:	က	4	æ
	& B U	y	- (۰ °	\ 2	. 5	٣	65																		40 15	
	≱က္ပ	x		°,				8 : 0	٠. د	35	-	۳	6	~	C		~	ល	2	n	ν,	8	ស	c	ပ	-	0
		•	•					6			-					ເກ	7	4	9	7	7	4	TO.	4	e	7	w
		-	- cz	C:			ے	1																		ນ	
	•	: Z +	٤٠	< _	2	2 0	;	612	629	633	689	647	651	6112	654	9660	675	81.9	682	683	692	694	307	730	733	731	2.13

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5 FRIAZINF(RDY) IN THE BGC3F1 MOUSE INDIVIDUAL CLINICAL CHEMISTRY VALUES + 11S1 WEFK 14

80 L G / B L P	- w 0 0 w 0 v - v - v - v 0 0 w v 4 w w 4 - w w w w 0 w - 0 v w - w w w w 4 v -	1.6
רס אם אם בט ד∼		
OIO_ EO\T-	125 125 126 127 127 127 127 127 127 127 127 127 127	102
∀ ∃# 5/7-	 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
- 525 5/5-	ι η το το το το το το το το το το το το το	
- 2 - 8 5 ~ て -	102 103 104 105 106 107 107 107 108 108 109 109 109 109 109 109 109 109 109 109	7.4
NGC2/-	25	28
α ສ.' Ευ∕τ-	7	. D
v_⊃ s5∕v-	126 126 127 127 127 128 129 129 129 129 129 129 129 129 129 129	167
νг×	 - XXXXXXXXXXXXXCCCCCCCCCCCCCXXXXXXXXXXX	i
⊢ α ७α ० ⊃೭		· ~
<2-2<- ZC	8 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	275

= Control; $2 = 1.5 \text{ mg/k}_3/\text{day RDX}$; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5 TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL CLINICAL CHEMISTRY VALUES TEST WEEK 14

30 L G / B L >		
0-10 B 5\-P-		
CTOP EDVE		
< -> & -> & -> & -> & -> & -> & -> & ->	$\begin{bmatrix} 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 $	
- 280 5/5-	$ \begin{array}{c} \alpha & \alpha & \alpha & \alpha & \alpha & \alpha & \alpha & \alpha & \alpha & \alpha $. Yda wch/
-な~び Eぴ\て-		7// 5 2 -
wez=	: - = = = = = = = = = = = = = = = = = = =	7 32 000
ממצ במעד-	- 	/1
	13.5 13.5 12.9 12.9 12.9 12.9 13.3 13.3 13.3 13.3 13.3 13.3 13.3 13	
		,
- 2 - 2 - 2 O	2000 0000	ì

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

IMENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINF(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL CLINICAL CHEMISTRY VALUES - 1FS1 WEFK 14

30 T G / 30 F A		
-3/8 GOLO	200777999999999999999999999999999999999	
0101 E0/0-	138 120 120 120 120 120 120 120 120 120 120	
-מ/מ ארא		
+ ccc 6/7-		
- 2 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5	255 82 82 83 83 83 83 84 85 86 86 86 86 86 86 86 86 86 86 86 86 86	
wce=>-		•
出口之 きかへてー	: - 00	2
רבט במ∕ד−	144 145 163 163 163 163 163 163 163 163 163 163	?
2∈0×0 ×− 2∈0×0 ×−	. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	-
<z≒≅<≟ th="" z≎<=""><th>6019 6019 6019 6019 6019 6019 6019 6019</th><th></th></z≒≅<≟>	6019 6019 6019 6019 6019 6019 6019 6019	

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MON-H CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXALYORO-1,3,5-TRINITRO 1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL CLINICAL CHEMISTRY VALUES + 1FS1 WFFK 26

a O r o / a r >		
רט אטרט−		
∪ = 0 = 5 \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	13.4 15.3 15.4 15.5 15.5 15.5 15.5 15.5 15.5 15.5	
マーピ サ〜モー	, and the L V V the the the the the the the the the the	
- 585 5/5-	ស្តិនក្នុង - ក្រុង មិន្តិ មិន្តិ - ក្រុង មិន្តិ -	
⊢なー の w♡^♡−		
NOTH - 1/-		
בטב בט/י-		
७~ □ ६ठ \ र −	25	4 ()
wω×	. 22222222222	
- ∝ 6×6⊃€		
<2~~~ ZC ·	751 751 751 752 753 753 753 753 753 753 754 775 777 777 778 783 783 783	

*Blood quantity not sufficient TR Group 1 = Control; $2 = 1.5 \, \text{mg/kg/day RDX}$; $4 = 35.0 \, \text{mg/kg/day RDX}$; $5 = 175/100 \, \text{mg/kg/day RDX}$

9

0

٨

6

Û

Ğ

IMENTY FOUR MONTH CHRONIC FOXICITY/CARC, MENICITY STUDY OF HEXALPYDRO-1,9,5-TRINITRO-1,9,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL CLINICAL CHEMISTRY VALUES - ITST WEEK 26

The State of the S

3 O C S ∕ S C C S	
574 30℃	
OIOJ EDNO-	109 109 109 109 109 109 109 109 109 109
くつら ケンケー	$\begin{array}{c} \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot $
- 686 6/5-	ບຸກຄຸນວາດດານຄຸດຄຸນຄຸດຄຸດຄຸດຄຸດຄຸດຄຸດຄຸດຄຸດຄຸດຄຸດຄຸດຄຸດຄຸດຄ
- なーじ - さへで-	25
roz=\-	. 81080007601104001007141870286080874468
בטע פטעט-	11 12 13 14 15 16 17 18 18 18 18 18 18 18 18 18 18
ピーコ きひへてー	000 000 000 000 000 000 000 000 000 00
	; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
< 2 - 2 < 2 D C	2492 7992 7992 7992 7992 7995 7995 7995 8905 8909 8909 8909 8909 8909 8913 8913 8920 8920 8933 8920 8933 8944 895 895 895 895 895 895 895 895

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; t=35.0 mg/kg/day RDX; t=175/100 mg/kg/day RDX

A CONTROL OF THE PROPERTY OF T

FWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXALIYDRO-1,3,5-IRINITRO-1,3,5-TRIAZINF(RDX) IN THE BGG3F1 MOUSE INDIVIDUAL CLINICAL CHIMISTRY VALUES - 1151 WER 26

8 J B / C J D B	1	24
-ק/ס מסרט	***********	
Offc』 Eの/で-	170 170 136 136 163 163 164	660 160 160 160 160 160 161 161
- דייס מר>	- 60 € € 6 € 6 € 6 € 6 € 6 € 6 € 6 € 6 €	:
- 202 5/5-	* TCJ-67	
- ぴ / ぴ - ぴ - ぴ -	7. % 17.6 17.9 17.9 9.1	115 115 115 137 137 140 160 160 161 161 163
vca=/-	# # # # # # # # # # # # # # # # # # #	[<u> </u>
#SZ E D\U-		5 8 7 5 7 7 5 5 5 5 5 5 5 5 5 5 5 5 5 5
0-B E5\7-	1. 2. 1. 2.	104 104 172 172 173 173 173 178 178 178
<i>v</i> , ∟ ×	22222 2	:
⊢ α 0¤0Dc	មិ ស្សាយ មេសា	ានាង ខាង ខាង ខាង ខាង ខាង ខាង ខាង ខាង ខាង ខាង ខាង ខាង ខាង ខាង ខាង
<2+2<- 20 ·	628 648 669 834 670 836	833 833 833 833 833 834 744 744 703 804 886 886

*Blood quantity not sufficient TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; $\frac{4}{7}$ = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

6

(a)

٩

Ť,

1WENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-FRINTIRO-1,3,5-FRIAZINF(ROX) IN 1HE BEG3F1 MOUSE INDIVIOUAL OF INICAL CHEMISTRY VALUES - 1FST WFFK 53

Additional desired desired and the second of

4 18∕6198	O4r04r00+0000000000000000000000000000000	
- קיע אסרה	00000000000000000000000000000000000000	
∪ ∓ ο⊒ ε 5 ∕ο−	201	
< ~ u	$\begin{array}{c} \omega \omega \omega \omega \omega \omega \omega \omega \omega \omega $	
→ £ & C	、 らすちらちららられるのちちらちららちちららなる。	
⊢ α+6 €6/5-		
va∈= ===/=	· <u></u>	
&⊃Z E &\ ~ ~	. = = = = = = = = = = = = = = = = = =	
C_3 50\T-	130 130 130 130 130 130 130 130 130 130	
vs us x		
- 8 68626		, -
<2-\$<- ZC		•

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; h=35.0 mg/kg/day RUX; 5 = 175/100 mg/kg/day RDX

THE STATE OF THE PROPERTY OF T

IWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUPY OF HEXARYDRO-1,3,5-TRINITRO 1,3,5-TRIAZINITROX) IN THE BECSET MOUSE INDIVIDUAL CLINICAL CHEMISTRY VALUES - IFST WEFK 53

**************************************		1.6
o ~ o ~ o ~ o ~		2.0
-ס/מפ עסנט	126 127 127 127 127 127 127 128 128 128 129 129 129 129 129 129 129 129 129 129	143
マンエ ケンケー	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
- 440 V\T-	$\begin{array}{c} (a + a + a + a + a + a + a + a + a + a $	
-E-6 82/1-		129
NCT1/	######################################	36
₩ ⊃Z	£ 6 7 % 7 7 6 4 8 0 8 6 4 7 4 9 6 8 8 8 8 9 9 9 8 9 8 9 9 9 8 9 9 9 9	. 5 5 5 8
	133 134 135 137 137 138 138 138 139 139 139 139 130 130 130 130 130 130 130 130 130 130	130
∿	·	. L
∵ α 0α0⊃α	$\frac{1}{2}$ unuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuu	:খেড
<2-E<- ZC	103 309 309 309 309 309 309 408 408 419 419 419 419 419 419 419 419 419 419	588 592

Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX TR

Q

@

٥

< 10 / C 10 B	4 w 4 w v m o w u v n v v v v o o o o o
רט אסרט−	00000000000000000000000000000000000000
ひぜひ_ ミガヘヤー	133 131 136 139 170 171 171 171 171 160 202 202 203 203 160 160 160 170
くり ロンロー	
- 545 5/1-	$\begin{array}{c} & \\ & \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ $
- なーピ ミガヘマー	7.4 170 170 120 120 128 173 173 173 162 163 163 163 163 202 85 85 85 85 85 85
υςς− +3∕-	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
מאצ בס/ד-	
じごコ ミケヘモー	120 133 133 133 130 130 130 130 130
υ ⊢ ×	
+	: សេសស្គសស្គសស្គសស្គសស្គសស្គ
<2-2<- 20	602 606 616 621 623 623 627 638 657 711 714 715 717 717 719

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; t_1 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

ed lessesses escapadad escapadad escapadad escapada escapadad escapadad escapadad escapadad escapadad escapada

IWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXALHYDRO-1,3,5 TRINITRO 1,3,5-TRIAZINF(RCX) IN THE BEC3FT MOUSE INDIVIDUAL CLINICAL CHEMISTRY VALUES - TEST WEEK 79

מטר ה/מר א	- m 4 4 0 0 in 0 in m in L 4 w w is 0 in 4 0 4 0 L in m in L in in in in in in in in in in in in in	
רט מס∟ט ריס -		2.1
しばひょ mg\ヷ゠	273 131 131 126 126 127 123 134 140 150 150 150 150 150 150 150 150 150 15	97 115 86
	$\begin{array}{c} \text{c} \\ $	
- 574 377 -	น ส ก ก	
⊢α⊣೮ ΞԾ∕∇−		855 146 179
νυ <u>ε</u>	- ' x - z - z - z - z - z - z - z - z - z -	90 17 17 150
ピンZ ミガヘてー	់ - "	20 13 13 13 13 13 13 13 13 13 13 13 13 13
ピーコ ミケヘて~	15.5 15.5 15.5 15.5 15.5 15.5 15.5 15.5	119
νων 	1	
< X - X < 3 Z C	7 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	•

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

S

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXALIYORO 1.3.5 TRITITIRO 1.3.5 TRIAZINERDY) IN THE BGC3F1 MOUSE INDIVIDUAL CLINICAL CHEMISTRY VALUES TEST WEEK 79

 מסרמ/מרא 	4/	
,	40-10-00-00-00-00-00-00-00-00-00-00-00-00	
רכבט רכבט	23	
י-פיעס שר>	$\begin{array}{c} ω ω ω ω ω ω ω ω ω ω	
- בצם ס/ד-	- απου α ει ει ει ει ει ει ει ει ει ει ει ει ει	
בסיים בסיים ב	221 888 800 110 120 120 120 120 120 120 120 120 1	;
~845×-		
CDZ EDVD-		
	$\begin{bmatrix} Cuu \mathsf$	
<2-E<- ZC ·	302 302 303 313 313 313 313 313 314 313 314 401 401 403 403 403 403 403 403 403 403 403 403	•

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX TR Group 1

ACOCKI, II KASAMARIA WARAATAA KASAMAA KASAMAA WAXAA WA

3 = 7.0 mg/kg/day RDX; mg/kg/day RDX Jay RDX; 175/100 ma/kg/day 11 5 RDX; = 1.5 35.0 mg/kg/day Control; 2 11 II Group 3

0

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5 TRINITRO 1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL CLINICAL CHEMISTRY VALUES - TEST WEFK 105

4 1 8 / 0	- C E		· -	1.2	1.6	ا . ت		÷ -			5.0	٠. د	æ	و 	۷ 	۰ د	 	9.	1.8	8.	- u	- -	. 3	÷.		٠ د) e			5.0	2.1	6	- ⋅	9.	, c) «	
ഗചറജ ത	~ □ ~ :			٠.		2.4																		•	•	•											
UIO. 80	~ P -	- 1 1 - 1	76	25	134	129	118	122		2-1-8	117	83	125	130	/ L -	n r	291	116	167	=	125	125	145	122	218	125	113	127	135	121	66	143	117	230	101	101	
מ ארא	n∕ ⊽ -) (C)	3.4	3.6	4.0	ກເ	ים מ	ა ი ი 4	33	2.2	က က	ပ က	s •	. .		3.6	2.8	3.0	د. د.	 	. n	3.5	6. 6.	ਚ (ਲ.¢	ى ە ە	0 0	. 4	. 6	3 6	1 17	3.8	3.7	C (ສຸດ	5
ERO 5	î ~ ₹ -		~ E			ဝ																						-									7
⊢≃⊢ ሮ ≘ 5	ı ∼ ε •	- ! !	99	47	117	239	54	160	× 1	131	155	961	162	87	176	21.5	5 to 5	177	231	61	180	82	145	127	78	31.	167	4.50 0.00	5 6	 	139	222	231	178	128	131	÷.c.
<i>თ</i> ლ <u>ლ</u> —	. : < .	-	د 5	ξ.	25	52	26.1	23	8.6	X 2	20	. E	20	25	ភ :	æ ;	30	200	33	25	<u>8</u>	8 C	36	30	282	£	38	ဂ (ာ ရ	36	9 6	25	28	23	20	σ.	o.
#32 E C	ァ 〜 で・	- ;	73	, c	5 2	2.2	61	6	20		<u> </u>	5	91	1.1	21	ភ្	₹ ₹	. 0	25	19	20	æ .	5 5	ē	1.7	20	22	2.	ច្ច រួ	~ ~		2.5	Ē	18	12		2
೮೨၁ ಕ	७		105	13d	13.5	133	76	158	505	157	2.5	106	134	126	1.19	95	060	100	116	100	133	134	24.5	167	83	162	130	134	140	627	2 t	130	121	122	112	5 .	146
	S) EL	; ; ×	∑ ∶	ΣΞ	Z 2	ΞΣ	Σ	Σ	Σ	Σ:	Ē L	۔ د	۔۔	L	L	<u>.</u> .	∟ ⊾			. ≊	Σ	Σ:	ΣZ	Ξ	Σ	≨	Σ	Σ	L. 1	- L			۔ ا۔	_	<u>ا</u>	_ .	-
⊢ ლ	x c ɔ	٠,	c	n r	י ני	း က	n	က	က	ი ი	י ר	n	· г	၉	က	ල I	ო ი	י כ	ים מ	· 	~	۲.	. .	. 4	7	7	4	~	₹,	٠,		7 75	•	7	4	~	.
< Z H \ \ \ \ \	zc	1 4 1	329	336	2 4 4 4 4	348	356	959	361	367	700	397	410	418	429	131	432	436	447	458	161	16.1	466	473	495	514	516	520	544	223 100	353 27	578 878	579	580	582	586	166

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5 IRINITRO-1,3,5 IRIAZINETRBX) IN THE BEC3F1 MOUSE INDIVIDUAL CLINICAL CHEMISTRY VALUES - 1FST WEEK 105

8 / B / C / B / C / B / C / C / C / C / C	0.4-40400000000000000000000000000000000	
-4 /0 more	νν 4 ν α α α α α α α α α α α α α α α α α	
במיסם בסיסרן	720 501 106 106 106 106 107 108 108 108 108 108 108 108 108 108 108	
A 18 0/6-		
- cac 5/5-	6 1 6 2 6 2 6 2 6 2 6 2 6 2 6 2 6 2 6 2	XOX
	106 118 35 160 197 127 127 127 129 100 100 108 108 108 138 134 134 134 134 134 134	mg/kg/day_RDX
60F3/-		5 = 175/100
m D Z ミグへでー!	25 81 82 00 00 00 00 00 00 00 00 00 00 00 00 00	35.0 mg/kg/day RDX; 5
פט בטעד-	t	ı u
ωπχ		t dnoun ut
+		_
	6212 6233 633 633 633 631 682 682 682 683 734 734 734	

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINGGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL ORGAN WEIGHTS (g) - TEST WEEK 26

\$ 0 Z 4 D W	10	٠,	. 0	١٥.	2	C	0.56	7	2		1		[1 1 1 1	1 1	1	1	1 1	'n	ų,	, c	0.25	Ġ	?	Ġ	ci (i	į	t ! t	i		1	;	1 1 5	1	
ひで 1 mm Z i	; 0	•	_	· C	0					•		•	•	•	•	•			•	•	•		0.0			•	•			•	•	•	•				60 0	
고 i > 다 &		•	•	•					•	•	•	•	2.09	•	1.56	3 (1)	500	1.56	-	•	1.73	-	2.01		1.67	•	•	.60	1.69	20.1	1.76	50. +	- C	332	1.58	1.63	1.38	
⊼ ⊷ O S m ≻ ω	נונו	י ר		٧			ο.	9	ഗ	ı.	۵.	٧.	ល់	<u>ن</u> (i, i	د	; (7	4.	۲.	ល រ	ח נ	0.63	. ب	ır.	۲.	۲.	φ.	۲.	۲.	ਹ, '	4.	: 7	. "	~	4	. r.	/ba/day BDX.
I m < C +	•	- -	٠,	٠,		10	: -	٠,	~	Ξ.	Ξ.	Τ.	Ξ.	_	Ξ.	Ξ,			Τ.	7		,	- e		Ξ.	Ξ.	~	S	Τ.		<u> </u>	٦.					: -	0 0 7 1 6 . 200
nα<-2				•							•	•	•		•	•		•			•	•	0 0 4 4 4 8 4 8		•	•	•	•	•	•		•		•	•		0.44	
#OC> 3+																•						•	34.8 24.8								•						28.6	•
4 Z H Z 4 J Z C		- •			- +			- +			-	1 1	3		* -					. ~	2 2	2	٠ ، ر	, ,	, ,	2	3 2	2	1 2	2	2	. 2	2.0	0 F	, (v C	790 2 -	

1/day RDX; 3 = 7.0 mg/kg/day RDX; = 175/100 mg/kg/day RDX Control; 2 = 1.5 mg/kg/day RDX; 35.0 mg/kg/day RDX; 5 = 175/100 $\mathfrak{k}=\mathfrak{h}$ Group TR

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL ORGAN WEIGHTS (9) - FEST WEEK 26

0 0 Z < 0 W	10	. 6	3	0.26	٠,	3	3	úι	. !		; ; ;	† } I	1 1 1		1	1 1	-	ç, c	. c	7 0	3	4	0.22	. ~	7	1	!!!	1 1	:	1 (1 1	! ! ! !	1 1	1	
Smmrs	1			0.44																		•	•			•	•	•	•	•	•	•		•	
	1			1.68	•				•	1.64	1.43	1.42	1.72	7.7	63	1,33	•	•		•			69 . 69	•		1.66	1.70	1.66	1.84	50	20. 1	 		1 46) r -
X - 5 Z r > v				0 53														•		-				•								•	•		
# u v v H	:			C 3											0.13								•							•	٠	,			
Ωα< Σ				0 47																								•			•		•	•	•
800× 3+				36.0							٠																								
αu×		E 2	E	Σ:	2 2	: E	Σ	Σ	Σ:	⊥ U	. i.		L.	u.	. (_ 44		Σ	Σ	Σ:	εΣ	Ξ	Σ	Σ:	٤٤	Ē LL	. u .	Ľ.	u.	L.	u.	LL:	ti. I	u. 1	-
+a @ac⊃a	. 1 (ח מ	ာက	က	n (1	၁၈	က	င	ကျ	n r	י ר	ာက	ဇ	က	က (י ר	ာက	4	4	٠,	† 5	4	4	4 ,	3 5	. 4	4	4	4	4	7	4	۲.	÷ .	₹
42H24J ZO ·	- i (320	792	793	795	707	798	799	800	301 801	700	804	805	806	807	200	8 10	513	811	812	2 c 2 c	8 15	316	8 18	5 C	224	822	823	824	825	826	827	828	829	3 2 2 3

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group 1

Ġ

ँ

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3.5-TRINITRO-1,3.5-TRIAZINE(RDX) IN THF B6C3F1 MOUSE INDIVIDUAL DRGAM WEIGHTS (g) - TEST WEEK 26

ωσ ⊐≡πΣ ασ Σασω	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	0.09 0.09 0.00 0.00
> m &	2.2 - 2.2 5. + 2.2 5.2 5. + + + 4.2 6.2 6.4 5.2 6.4 5.2 6.2 6.4 5.2 6.2 6.2 6.2 6.2 6.2 6.2 6.2 6.2 6.2 6	
X = O Z m > w	0.78 0 64 0 77 0 71 0 71 0 74 0 75 0 75 0 75 0 75 0 75 0 75 0 75	
Ξυ<α +	0.000000000000000000000000000000000000	
æα<-Z	00 00 00 00 00 00 00 00 00 00 00 00 00	0 0 0 0 47 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
₩ 0 @ ≻ ≥ ⊢	33 33 34 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	26.4 22.9 25.7 30.1
νш×	**************************************	
+ 2 C C C C S → 2 C C C C C C C C C C C C C C C C C C	6666 6666 6666 6666 6666 6666 6666 6666 6666	

1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group

THE PROPERTY OF THE PROPERTY O

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE 86C3F1 MOUSE INDIVIDUAL ORGAN WEIGHTS (g) - TEST WEEK 53

00Z<00		0.240										1	1 1 1	i } •	; ;	1 t 1	1 1 1	1 1	1	i		, c	3 c	24	0.282	.2	5	27	4	7	1 1	1			3 1	1 1	1 1	4 6 1	!	
N C T m m Z		0 162	•		•					•		•						•			•					•	•													
~ H ≻ ⊞ &		٠,	•	•	1.985	•	•		•	•	•	•	•		•	•	•	•	1.694	1.323	200:	269.1		100 +	2.581	•	•	•	•	•	4 500	•	7.0.1	2007.	. 433	44.	1.451	1.000	1 445	
XμOZm≻ν		•	•			•	•	•	٠		•	•	•		٠	•	•		•		•	٠		•	0.920			٠	•	٠		•	•			•	•			•
∓₩∀⊻⊢		0.197		-	•	•	•		•	•	٠				•		•	•	•	•	•	•	•	•	0.289	-	•		•	•	•	•		•		•	•	•		•
& α < ∽ Z			4	₹.	₹.	ς.	₹.	₹.	₹	₹.	₹.	ئ رن	<u>ن</u> ک	۲.	ເນ	ın.	₹.	₹.	4	ഥ .	? '	ς.	٦,	₹. ₹	; ~	ͺͺͺͺ	۲.	4	ı.	4 1	ນໍ .	T 1	ο,	٠,	उ १	\$ T	٠.	: <	: `	;
800≻ ≯ ⊢	1	7	ر. ديا	.	9		ເດ	œ.	<u>.</u> :	ဖ	60	છ	છ	თ	6	'n	ς.	ó	e.	N		Ω	ما	o c	43. n		4	٠,	Š	ი. თ.:	· 1	ο.	2 1	· .	. •	. .			n • c	
⊢¤ ७¤๐⊃• %±×	1	Σ.	Σ	Σ.	∑	₹ -	Ξ.	Z	₹.	×	Σ -	. .	<u>т</u>												E E															
∢Z∺£∢IJ ZO	1 1	7	14	2.1	25	47	418	57	58	6.1	62	9/	80	86	83	98	101	1.0	119	131	139	154	164	168	6/1	195	209	213	216	218	227	7.35	239	241	255	253	- 001	230	000	067

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX TR Group

()

TWENTY FOUR MONTH CHECNIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE 86C3F1 MOUSE INDIVIDUAL ORGAN WEIGHTS (g) - TFST WEEK 53

© O Z ⊲ O w	00000000000000000000000000000000000000	t 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
ひでします	0.093 0.093 0.093 0.103 0.	
→ ~ > ≡ &	2. 22.2 2.	1.820 1.928 1.930
X ← C S m ≻ w	0.643 0.643 0.630 0.630 0.573 0.738 0.738 0.738 0.738 0.733 0.733 0.733 0.725 0.725 0.	
I ₩ < α ⊢	0.210 0.223 0.199 0.197 0.197 0.174 0.174 0.178 0.205 0.205 0.205 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.177 0.176 0.177 0.176 0.177 0.176	
Ωα<- Ζ	0.467 0.454 0.454 0.455 0.493 0.493 0.493 0.493 0.508 0.509 0.493 0.486 0.486 0.486 0.497 0.503 0.497 0.503 0.497 0.503 0.493 0.493 0.493 0.503 0.493 0.503 0.493 0.503 0.493 0.503 0.493 0.503 0.493 0.503 0.493 0.503 0.493 0.503 0.493 0.503 0.493 0.503 0.493 0.503 0.493 0.503 0.493 0.503 0.653 0.793 0.	
₩ ○○ > 3	35 4 36 5 37 5 37 5 37 5 37 5 37 5 37 5 37 5 40 6 40 7 7 6 40 7 7 6 40 8	
	305 305 305 307 307 307 307 307 307 307 307 307 408 307 408 309 408 309 408 309 408 408 408 408 408 408 408 408 408 408	

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group 1

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3,5-TRINITRO-1.3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL ORGAN WEIGHTS (g) - 1EST WEEK 53

0 0 Z < 0 W	0.231	0.209	0.222	0.247	0.220	0.00	7.7.	200	0.228	0.224	!!!	! !	1 1 1	t 1 1	!!	:	1 1 1	1 1	!	!	
ωσ ¬ m m S	0.127			0.083																	
א ה < ∼ ר	2.113	2.169	2.212	1 802							2,155										
X ≒ O Z ₩ ≻ W	0.839	0.836	0.855	0 550	0.693	187 0	0.793	0.901	0.999	0.788	0.493	0.565	0.490	0.545	0.435	0.507	0.346	0.477	0.473	0.488	
Iω<α⊢	0.225			0.179																	
ωα< -Ζ	0 473			0 489																	
₩ O O > - > - > - +	,			30 8			٠	•	•			•			•	•		•	•		
+α ©αο⊃α ν⊔×) 			S.																	
<z \$="" -="" <="" c<="" j="" th="" z=""><th>602</th><th>909</th><th>616</th><th>621</th><th>623</th><th>627</th><th>638</th><th>657</th><th>668</th><th>67.1</th><th>702</th><th>711</th><th>714</th><th>715</th><th>717</th><th>7 19</th><th>735</th><th>741</th><th>742</th><th>750</th><th></th></z>	602	909	616	621	623	627	638	657	668	67.1	702	711	714	715	717	7 19	735	741	742	750	

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

,

(

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BACGF1 MOUSE INDIVIDUAL ORGAN WEIGHTS (g) - TEST WEEK 105-106

00Z<00	1 2	2.5	2	20	7	. 22	<u>ښ</u> د	, ,	i٦	3		•	•	•		•		0.273	•	•		•		•			2.5	,,	, ,		2		22	61.		•
να – ω ω z	-	5		•		•				•							•	0.095						•	•	•	•	•	•	•						
→ → > tu ⊠																		2.065																		1.898
X 2 Z F > N	1							•	•	•				•	•		•	0.759		•					•		•	•	•		•		•			•
I. ພ < 22 ⊢	,					•				•		•			•			0.216				٠			•				•	٠			•			
ಏ ଫ < ⊷ Z	•		•		•	•		•			•		•	•			•	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		•	•	•	•		•	•		•			•	•		•	•	
W C V > 3 F																		35.7 37.8																		
ζшχ	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	ΣΞ	Σ.	2	ξ Σ	Σ	æ	Σ	≨ :	Σ:	ξŞ	ΞΞ	Σ	Σ.	Σ	¥	Σ:	Z 3	: 5	Σ	Σ	Σ	ε :	Ξ Σ	Σ	Σ	æ	Z	Z	Σ	Σ:	٤۶	E 3	Σ	Z	Σ
0_0_	1 1 1 1	~ .	9 1		0 57	0	11 1	12 1	17 1	22 1	2.4	27	28	29 1	30 1	31 1	32 1	34	37	38 1	39 1	40	22	7 -	. TU	9	6	0	_	~ :	m ·	.	0 0	60	, J~	68 1
	ı																	ĺ									•					-	Ĩ	_	-	

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINGGENICITY STUDY OF HEXAHYDRD-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGU3F1 MOUSE INDIVICUAL ORGAN WEIGHTS (g) - TEST WEEK 105-106

0 D Z < D 30	0.208				1	1 1 1	† 	I 1	ı	1 1	1 1	1 1	1 1	1	1 1	f 1 1	\$ \$ 1	1 1	1 1	ł ł	1 ! !	} (! !	!	1 1		i i	1 1 2		1 1 ,	i i] 	t t	1 1 1	1 4	1 t [1 1		
N G J E L Z	 0.136	0. 110	0.457	0.120	0 124	0 259 0 110	(3. 176 0. 23.	0.22.0	6.710	5.5		0.402	0.138	0.175	0.677	0.200	0.176	0.216	0.197	0.280	0.323	0.482	6.00.00 0.00.00	0.225	0.224	0.113	0.174	0.194	0.464	0.377	0.129	0.194	0 220	0.986	0.271	0.283	200	C. 193	
¬ H > m &																								2.294														200	
wiΩ Ζ ┗ ≻ w																																							2
I w e α ⊢															-									0.177															1
ω α<~Ζ	٥													•	•			•						0.538						•		•							•
800≻ ≯ ⊢								_																29.8				. ,	,								-		
.π α α α α α α α α α α α α α α α α α α α									<u>.</u>		L.	<u>.</u>	<u>.</u>	L . ←										.														<u>.</u>	
42+ 2 4	ç	20	2.2	7 ₹	7.7	7.8	χ,	82	83	8,1	85	8.7	88	20	66	32	ල .	2) (4 (9 6	, a	8 2	103	50	90;	107	2 5				116	117	411	001	122	123	124	127	129	

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group 1

G

@

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL ORGAN WEIGHTS (g) - TEST WEEK 105-106

0 C Z < D v	0.202 0.183 0.204 0.183 0.202 0.183 0.202 0.183 0.202 0.183 0.203 0.003	
να¬шшZ	0.157 0.157 0.157 0.237 0.125 0.125 0.125 0.125 0.134 0.132 0.132 0.138 0.138 0.138 0.138 0.146 0.165 0.176 0.176 0.176 0.176 0.176 0.176 0.176 0.177 0.177	
א ה < ∼ ר	1. 745 1. 745 1. 955 1. 955 1. 955 1. 955 1. 955 1. 962 2. 280 2. 280 2. 280 1. 962 1. 962 2. 280 2. 280 3. 687 2. 280 1. 962 2. 967 2. 967 2. 967 2. 967 2. 967 2. 967 2. 967 2. 967 2. 967 3. 687 4. 985 5. 967 6. 985 6. 985 6. 985 6. 985 6. 985 6. 985 6. 985 6. 985 6. 987	
X O S m ≻ ω	0. 490 0. 490 0. 502 0. 483 0. 483 0. 483 0. 542 0. 564 0. 565 0. 656 0. 656 0. 656 0. 772 0. 772 0. 772 0. 772 0. 773 0. 774 0. 775 0. 775 0. 775 0. 775 0. 775 0. 775 0. 775 0. 775 0. 775 0. 775 0. 775 0. 775 0. 775 0. 775 0. 775 0. 775 0. 775 0. 777 0. 778	-
エレくなト	0 184 0 175 0 175 0 173 0 173 0 157 0 189 0 189 0 189 0 189 0 189 0 189 0 189 0 224 0 234 0 234 0 235	
ພ ≃ < ⊢ Z	0 542 0 511 0 511 0 511 0 511 0 511 0 511 0 511 0 511 0 511 0 511 0 511 0 511 0 512 0 65 0 65 0 70	•
800≻ ≯⊢	25 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	
+ & & & & O D Ø	- C C C C C C C C C C C C C C C C C C C	· m

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL ORGAN WEIGHTS (g) - TEST WEEK 105-106

5	cz	٩	C	ı vo	1	0.171	Τ.					0.012	•		•			•	0. 196	1	!!!	1 1 1	!!!	! !	1 1	1 !	1 1	1 1 1	1 1	1 1	1 1	I I I	1 1 1	!!!	1 1 1	!!!	1 1	1 1	!!!!	!!!!	1	111	1 1	1 1 1	\$ 8 1	;;	
v	ىـ ە	ı tu	i tu	: 2		0.102																																							0.268		
	 ⊶	• >	·u	ם ח		•																																									
x	C 2	2 4	≾ با	- u	· · · · · · · · · · · · · · · · · · ·	0 641	0.552	0.525	0 628	752 0		0 661	99/ 0	0.757	0.694	0 732	0.614	0.759	0.681	0.476	0.529	0.595	0.585	0.000	0.440	0 498	0 526	0 0 C	0.521	0 12 C	0.618	0.427	0.614	0.645	0.753	0.574	0.577	0 494	0.660	0.431	0.580	708	0.133) (0 0	0 00	786 O
	Σu	◄ ين	ς (Ϋ́																					0.138						•							•	•	•	•				0.163		0.165
	ec 6	χ.	۷ -	- ;																																									0 473		
& ⊂	o e :	>		3								.12 1													-					-				•							•		-	•	27.5	•	
			ဟ	ų.	×		ε:	ε:	Σ:	Σ	Σ	Σ	Ξ	Σ	Σ	Σ	.	: 2	: :	Ēι	. L	<u>.</u> 1	L. 1	اخا	11.	.	ı. I	ا بد	L 1	ı. ı	<u>.</u> 1	T F	٠. ١	Lu	. u	LU	L 1.	. l	L l	i.	LL I	L	i _	L	ـنا	خا	u
⊢ α	ၒ	~	c	⊃	۵	!	` (S (~	۰	2	٥	٥.	٥	^		; c	۰,	٠,	٧ (N C	~	C: ·	~	8	8	7	7	8	۰ ،	2	~ c	× 0	ν c	٠ ٢	٧ (V (N (N (?	8	0	0	2	٥.	0	c
: 2 <	ب ۲		z	c			000	90:	207	900	2.10	211	2.15	217	219	220	000	,,,,	2 2 2	077	877	229	230	231	234	237	243	244	245	247	248	249	220	707	000	200	200	260	261	263	264	265	996	267	268	270	27.0

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/cay RDXTR Group

(3)

٩

٨

0

4

٥

٧

Ġ

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL DRGAN WEIGHTS (g) - TEST WEEK 105-106

0 0 Z 4 0 0	0.233 0.234 0.234 0.234 0.234 0.234 0.236 0.234 0.236 0.236 0.236 0.237 0.236 0.237 0.236 0.237	
νc ¬ m m Z	0.585 0.208 0.108 0.108 0.138 0.139 0.155 0.	
-1 > :0 &	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	1 731 2.124 2.830
X ~ C Z U > v	0. 458 0. 575 0. 578 0. 578 0. 578 0. 527 0. 527 0. 527 0. 527 0. 527 0. 527 0. 527 0. 527 0. 528 0. 527 0. 528 0. 527 0. 528 0. 527 0. 528 0. 528 0. 527 0. 528 0.	
Iω∢α⊢	0.255 0.255	
& ~ < ~ Z	0.532 0.532 0.533 0.5332 0	48 00 69
800≻ 3 ⊢	8.50 8.50	0.00
⊢ α α α α α σ σ σ		ღღი
	2744 2744 2744 2744 2744 2744 2744 2744	342

TR Group 1 = Control; $2 = 1.5 \, \text{mg/kg/day RDX}$; $3 = 7.0 \, \text{mg/kg/day RDX}$; $4 = 35.0 \, \text{mg/kg/day RDX}$; $5 = 175/100 \, \text{mg/kg/day RDX}$

TWENIY FOUR MONTH CHRONIC TOXICITY/CARCINUGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL ORGAN WEIGHTS (g) - TEST WEEK 105-106

00240V	0. 1839 0. 1839 0. 1946 0. 1946 0. 1947 0. 194	
i	0.099 0.099 0.134 0.266 0.232 0.233 0.238 0.238 0.091 0.173 0.174	
しょ > 部 仅	2.232 2.232 2.241	
ス ᠳ ℧ ℧ Ⅲ ≻ ℆	0.636 0.636 0.747 0.786 0.747	
	0 203 0 233 0 233 0 233 198 0 233 0 221 0 221 0 225 0	
	0.488 0.400 0.500 0.	
800≻ ≯ ⊢	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	
νш×	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z r r r r	
	0.00	

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; 4 = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

@

< 2

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINDGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL ORGAN WEIGHTS (g) - TEST WEEK 105-106

νσ ¬ ω μ Σ		•	•		•	•	•								•	•	•	•		•	•	•	•	•	.575	.097	087 0.	. 111	.176 0.	. 137 0.	.575	.173 0.	.094	.141	.334	. 102	0.128)
א ה < ייר א ה		1.765	1.770	1.659	3.243	2.126	735	1.932	2.630	950.4	1.733	2.647	1.164	2.841	2 071	2.194	2.016	2.119	2.226	7.554 1004	2.30%	2.732	2.166	2.863	2.351	2 040	1.997	2.014	2.326	2.311	2.931	2.132	1.824	2.362	3 321	2 333	2.272	: !
$X \mapsto C \subseteq m \succ \alpha$		0.454								•	•					•		•	•	•	•	٠	•	•		•					•	•	•	•	•	•	0.739	•
ጀመ ሩ α⊢		٠		•	•	٠		•			•				•	•		•	•	•		•		•	•		•		•	•		•	•	•			0 250	•
ໝ ଫ < ⊷ Z	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1						•				•		,						•	-		•	•		•		•	•	•			•		•	•	•	0.522	
₩ □Ω> 3 +	- ¦	រេ	8	о О	8	ق		ლ	~	ກເ	כי	۲ ۳	o c	· -	Ö	_	ю Э	ö	_ل ى .	4.1		- c	ໝ	8	<u>.</u>	٠. ٥	οα	,	ω.	6	₹	੍ਹ. ਚ	œ	Ċ	0	(.) ·	34.2	0
+ ₩ ₩ ₩ ₩ ₩ ₩ ₩ ₩ ₩ ₩ ₩ ₩ ₩ ₩ ₩ ₩ ₩ ₩ ₩	1																																				X 2	
	. !	15	16	18	20	2.1	22	23	25	26		9 0	9.5	. 6	33	34	35	36	39	42	٠ ۲	\$ F	48	49	20	2.2	5 to 10	57	28	60	90	51	64	99	67	89	469	2

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group

0 O Z < a v	0.210 0.205 0.206	20.	23.5	0.185 0.185	35.5		0.204			0.232		! !	1 1	6 1 1 1 1 1	1	!	t 1 1 1 1 1	t t	1	1 1 1	!	1 1	1	!!!	
N σ ¬ m m Z	0 127 0 093 0.098																								
J H > W &	2.630 2.742 2.067																								
$X \vdash O S \oplus > \emptyset$	0.730 0.840 0.743																								2,00
Iω≺α⊢	0 194 0 230 0 219	0 268 0 230 0 230	0 245																			ο.	٠.	, o	
ω ư < ⊢ Z		0 408																							
∞ □C> 3⊢	34 8	39.4 36.6																•							
⊢к скс⊐ч ∾≖×	X X																								
<z-\$<j th="" zo.<=""><th>474</th><th>481</th><th>483 486 486</th><th>487 490</th><th>495 500</th><th>505 506</th><th>509</th><th>515</th><th>5 15 5 16</th><th>57 t8</th><th>5,20</th><th>52.7 52.8</th><th>529</th><th>53.1 53.1</th><th>532</th><th>93.4 53.7</th><th>539</th><th>540</th><th>54.4 4.2</th><th>545 544</th><th>543</th><th>549</th><th>55 55 55 55 55 55 55 55 55 55 55 55 55</th><th>557</th><th></th></z-\$<j>	474	481	483 486 486	487 490	495 500	505 506	509	515	5 15 5 16	57 t8	5,20	52.7 52.8	529	53.1 53.1	532	93.4 53.7	539	540	54.4 4.2	545 544	543	549	55 55 55 55 55 55 55 55 55 55 55 55 55	557	

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 0.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDXTR Group

Ü

TWENTY FOUR MONTH CHRONIC TOXICITY/CARCINGGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL ORGAN WEIGHTS (9) - TEST WEEK 105-106

& O Z < O W	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 1	1	1	!	1	1 1	t ? 1	f ;	! !	; t	1	!	1 1	1	;	•	1	!	1 1	1 1	1	!	1		0.185										0.205			0 184	
ωσ┐m m Z	1		•	•	•		•	•	0.405		•		•		•	•	•		•				•	•	•	•	•	٠	•		•	•	•	٠	•			•	•	•
א⊞מיר		•	•	•	•	•	•	•	2.272	•	•	•	•		•	•	•	•	•	•	• •	•	•		•		•	•	•	•	•	•	•	•	•	•	4	ထ္	۲.	₹.
X ™ O Z ⊕ ≻ N		•	•	•	•	•	•		0.604	•	•		•		•	•	•	•	•	•			•		•		•	•	•	•	•	•	•	•	•			0.882	£.	67
I m < α⊢									0.220									•							•							•			•					
							•		0 402	•	•		•							•		•			•		•		•	•		•					•	57.		48
$\omega \cup \omega \times \mathcal{F}$				٠.			٠.		39.2																											٠.				
νп×	1																																							
- 0 C C C C C C C C C C C C C C C C C C	1																																							

CONTRACTOR OF THE PROPERTY OF

TR Group

= Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

TWENTY FOUR MONTH CHRONIC TOXICITY/CAPCINDGENICITY STUDY OF HEXAHYDRO-1.3.5-TRINITRO-1.3.5-TRIAZINE(RDX) IN THE BGC3F1 MOUSE INDIVIDUAL ORGAN WEIGHTS (g) - IEST WEEK 105-106

Ø ⊖ Z < ⊖ W	0.201	0.120	0.211	0.230	0.215	1	t :	5 1 ! 5	i i	1 1 1	!!!	1 1	1 ! !	1 1 1	1 1 1 1	t 1	;	ŧ !		1 1	1 t	1 1	1 1	:	4 - 1	1 1	1 :	1 1	l] }
NernmmS	0.097	0.143	0.068	0.072	0.101	0 194	0.176	0.170	797	0.140	0.140	0.148	0.170	0.206	2.663	0.103	0.137	0.190	0.178	0.467	0.182	0.145	1.220	0.297	0.245	0.158	0 171	0 209	0.143
とまくまれ	3.648	5.806	2.290	1.989	2 305	1.801	2.773	0.870	27.67.5	2.259	1.761	2.017	2.487	2.647	5.471	1.788	2.504	2 285	1.761	2.483	•	•	4.996	1.693	4.904	2.294	1 833	2.441	1.615
X⊶ΩZω≻ທ	0.833	0.714	1,050	0 891	0.970	0.486	0.618	0.483	0.623	0.447	0.467	0.530	0.493	0.598	0.608	0.429	0.640	0.528	0 406	0.537	0.459	0.526	0.546	0.434	0.496	0.524	0 420	0.533	0.390
∷ ω < α −	0.200	0.281																											
Ωα<⊢2	0.493	0.487	0.495					•		0.460						•			•	•		•	•	•		•			
800> 3-	1 .	31.6	, io	5	7.	œ	42.4	· (უ ი	34.4		o	8	<u>.</u>	8	8	Б.	~	8	ö	ö	6	ιc)	80	03	ω.	7	7.	24.1
ω ⊏ ×	: : : : : : : :	ΣΣ	: Σ	Σ	¥	u.	i. 1	ا سم	ى ب	ı. LL	. ts.	. Ա.	u.	i.	LL.	ı	u.	Ľ.	u.	u.	ш	ij.	L	u.	ų.	Ľ.	Įį.	L	և
- X < 1 \ X O .	655 5																												

TR Group 1 = Control; 2 = 1.5 mg/kg/day RDX; 3 = 7.0 mg/kg/day RDX; h = 35.0 mg/kg/day RDX; 5 = 175/100 mg/kg/day RDX

(2)

APPENDIX VII
CHLORTETRACYCLINE CONTENT OF 5002

CHLORTETRACYCLINE CONTENT OF 5002

ANALYTICAL RESULTS (ppm)

	SAMPLE	IDENTI	FICATIO	NO
SOURCE OF ANALYSIS	<u>A</u>	B	<u>c</u>	D
TEI ANALYTICAL, INC.*			9.9	
TEl ANALYTICAL, INC.*	12	9.9	7.7	10.2
SCIENTIFIC ASSOCIATES**	1.76	1.72	1.20	1.64
WOODSEN-TENENT LABS, INC**	ND	ND	ND	ND
HARRIS TARS. INC **	<0.05	<0.05	<0.05	20 05

Sample A = Lot No. Sept.18.81

Sample B = Lot No. Dec.10.31 Sample C = Lot No. March.24.82 (Original lot)

Sample D = Lot No. Sept.10.82

ND = None Detected

Note: The manufacturer's specification states absence of antibiotics and hormones in the "certified feed".

^{*} Method: Snell and Snell, Colorimetric method of analysis. Vol IV AAA, pg. 184

^{**}Nethod: AOAC, XIII, pg. 722-723, paragraph 42.211-42.214; Detection limit >0.1 ppm

APPENDIX VIII

NITRATE, NITRITE AND MERCURY CONTENT OF 5002

PERFORMED BY TRACE ELEMENTS, INC.

NITRATE, NITRITE, AND MERCURY CONTENT OF 5002

LOT NUMBER	MITRATES(ug/g)	NITRITES(ug/g)	MERCURY(ug/g)
OCT 29-801N	5.6	0.4	0.06
NOV 19-802K	3.4	<0.1	0.05
DEC 02-801G	1.1	<0.1	0.04
JAN 08-811J	14	<0.1	0.04
JAN 15-812E	32	<0.1	0.02
FEB 03-811B	9.2	<0.1	0.04
JAN 21-811N	32	<0.1	0.11
MARCH 05-811A		<0.1	0.14
MARCH 17-811M	<3	<0.1	0.02
APRIL 30-811D	<3	0.3	0.0:
MAY 13-812K	15.3	0.2	<0.06
JUNE 01-812D	<2.0	0.6	<0.1
AUG 04-811T	28	0.5	0.03
SEPT 18-811A	<2.0	<0.1	0.05
OCT 07-811J	6.3	0.2	0.15
NOV 12-811G	16	0.4	<0.02
DEC 10-811A	1 2		0.09
JAN 22-821K	1 4	<0.2	<0.05
FEB 09-821C	7.2	0.4	0.05
MARCH 24-822G	19.0	0.24	<0.05
MAY 12-822F	16.4	0.1	<0.05
JUNE 04-821K	17.0	0.1	<0.05
JULY 29-821G	11.8	0.1	0.06
SEPT 10-822J	5.0	0.1	0.2
OCT 20-822L	4.7	0.1	0.2
NOV 23-821M	15.4	0.2	0.05

APPENDIX IX
CHICAGO WATER CHEMICAL ANALYSIS

	CITY OF	CHICAG	CHICAGO	NOISI	DEPARTMENT OF	WATER WATER P	PURIFICATION	BUREAU OF	WATER	OPERATIONS	
SAMPL	SAMPLES COLLECTED Fot. 3	73 E.	100	OMPPEHENSIVE	٦	DNAL		8	ANALYSIS COMPLETED	ETED Mach 30	28 63, 0
		₽CB	CANINGSTAC	STORFT	жоот.	WATER DIST	RICT	CENTRAL	AND NOR	H WATER	RICTS
	PARAMETER	렃	57	NUMBER	RAW CRIB	SITE	SAMFLES	RAW CRIB	OMP	OSITE SAMPLE	
1640	TEMOCOATUBE	2)61	00	01000		00.16.1	NIS I RIBUTION	,	OUTEE	CEN. DISTA.	E C
TURBIDITY			R ₹U.	000076	5.0	0.15	0.20	0.50	6.27	0.28	0.30
THRE, MOLD	ODOR,	r.	T.O M.	98000	Ŕ	జ్ఞ	జ	20.	3	2	<u>ਲ</u>
THRES	OLD	3	TON.		•	H	×	ı	X	*	2
COLOR		13	STING 42-19	08000	2	0	0		0	0	0
		6.5-6.5	STD. UNITS	00400	6.3	2.0	6.3	2.0	4.0	9.5	9.6
<u> </u>	ALVALINITY PRIM.		£0303	00413	201	115	2 2	2 1	-11	- 417	- 41
١٥	ALTERNATION OF THE	350	2000	2000	0.8	144	28	U EZ	¥ 72	7,4	2 72
<u> </u>	SI CALLO	250	000	0000	10.5	511	11.0	6.6	0 0	10.5	00
٦_	FLUORIDE	2	J 14	05600	0.16	8	80	0. k	26 C	200	20.0
ـــــ	PHOSPHATE, TOTAL		P.0.4	00650	9.0	0.02	20.0	20.0	10.0	0.0	0.0
	PHOSPHATE, DISSOLVED		POS	00653	0.03	0.0	0.01	0.01	<0.01	0.01	<0.0>
ر د د	SILICA		\$102	00956	6.0	-:-	 	0.	1.2	1.2	6.3
نبا	CALCIUM		Ca	91600	. 38	13	0h	9	3	=	9
	MAGNESIUM		PMg.	00927	7 01	01	0.	0,	0,1	0	0
A:	POTASSIUM		×	00937	6,1	1:7	2.0	a .	- 5	9.1	1.5
	SODIUM		20	00929	5.2	5.2	5.2	6'8	8.8	8.8	4.8
~	RESIDUE, TOYAL		TOT. SOLIDS	00200	2	221		3	169	2	157
ع الخ	RESIDUE, FILTRABLE	8	0158 501.108	00313	1/8	7/1	761	100	6 17	3 5	101
٠.	VOEW DEMAND CHEMICAL			2000	2 2	2.0	200	15.11	7.7	6.3	9.3
	NITROGEN AMMONIA .		*	0000	0.9	(0.0)	<0.0>	9.0	<0.01	0.0	0.05
	•	01/1	2	00630	0.77	0.76	92.0	0.22	0.25	0.25	0.24
Ē	NITROGEN, ORGANIC		2	00605	0.09	0.10	0.08	0.10	0°0	O.08	0,10
لب	CYANIDE	70	CR	00720	Z00.05	ZDO:00	<0.00	<0.002	<0.002	40.002	<0.02
5	FOAMING AGENTS	0.5	MBAS	38260	B.6	<0.05	χ.0, δ	<0.05	ζη,05	<0.05	6.8
<u>기</u>	HARDNESS		C 000	00600	98	雪	# # # # # # # # # # # # # # # # # # #		jai	#	193
	7			0.00	Olo	2.20	ex.	ol>	301	180	Ĭ.
1	TOPINO S	0		2000	2			17	, i	200	72
٠.	PADITA	200		01002	, X	18		33	X)	, K	K,
-	BORON	200	8	01022	90	5	*	0	0	0	5
٠.	CADMIUM	0	CA	01027	₽	₽	₹	₽	Ş	₹	₽
<u>.</u>	CHROMIUM	30	ပ်	01034	⊽	₹	₹	>.	()	</td <td>۲)</td>	۲)
<u> </u>	COBALT		တိ	01037	Þ	<1	\	</td <td>١></td> <td>\</td> <td>7</td>	١>	\	7
ш	COPPER	2000	رم	01042	2	₽	>	₽	Ś	>	2
	IRON, TOTAL	800	• 5	01045	S	9	9	0I>	g);	0	Sig
	LEAD	င္တ	Pb	01051	9	>	>	>	>		3,
	LITHIUM		L.(01152	2		3	2	7	7	
	MERCURY	200	2 2	7 1900	Ø.01	16.0	0.0	(0.0)	<0.01	<0.01	(0.0)
1.	NICKEL		Z	01067	₽	1>	⊽	₽	₽	>	<۱
ـــا	STRONTIUM		Sr	01082	691	<u>6</u>	150	130	150	130	(30
ш		2000	u Z	01092	3	4	01	5	Þ	6	10
_4	PHENOL-LIKE SUBSTANCES	-	PHENOL	32730	>	₹	⊽	7	77	>	\$
<u>م</u> ا	SILVER	30	Ag	01077	₽		₽		- 28	2	4
2010	I SELENIUM		Se AFTA Pe/	01145	0	M 0 1 11 2 1	4 - NAW - N	11 11 1 1 0 1 1	13	18	- G
SATUR	ATION JNDEX		(1)		-0.03	-1%	+0.13	9.0	+0.13	+0.77	+0.13
	9	١	,			·				1.	
	2. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	4		- <u> </u>	6320 aco. 10	Del 1 /	-		Hilli (Tautourathe	un Hal	1
MCV 3. 6	CHIEF WATER CHEMIST O			910	I., WATER PURIF	DIR., WATER PURIFICATION LABORATORIE	TORIES	Ē	ENGINEER OF WA	TER PURIFICAT	NO

APPENDIX X

OPHTHALMOLOGY NARRATIVE REPORT

REVISION TO THE FINAL OPHTHALMOLOGY REPORT

of Twenty-Four Month Chronic Toxicity-Carcinogenicity Study of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) in B6C3F1 Hybrid Mice

A reanalysis of incidences of cataracts was carried out at the suggestion of the draft final report reviewers. Animals that were used for orbital blood collection were eliminated from the statistical analysis. As a result of it the significant increase of cataracts for male mice receiving 175/100 mg/kg/day was no longer apperent. (See Table 31 and 31a.)

STUDY NUMBER: L6121-7 TEST ARTICLE: RDX SPECIES: MOUSE

KEY NOTE: Animals used for orbital bleeding were indicated on the ophthalmic incidence data sheets by the letters "L" or "R" when it was known which eye was used for orbital sinus bleeding. The letter "U" indicated that the animals were either bled from both eyes or the eye used was not known.

SUMMARY OF OPHTHALMIC FINDINGS

Ocular conjunctivitis, discharge, and corneal scarring were observed in all test groups throughout the study and probably were a result of chronic external irritation from normal sources.

Throughout the study, a number of animals which were bled from the orbital sinus demonstrated cataracts, phthisis, enophthalmia, iritis, synechia, iris prolapse, and retinal vascular attenuation. Ocular trauma or penetration could have been responsible for the aforementioned abnormalities. Prominent lens nuclei (nuclear sclerosis) and suture lines, vitreal strands, and vitreal precipitates on the posterior lens capsule (posterior capsular opacities/cataracts - "PC") are normal aging changes that were observed in all groups, especially at Test Week 103.

At Test Week 25, one animal (601) was observed to have vitreal hemorrhage present, which was resolved by Test Week 51. At Test Week 78, findings of note were orbital masses (#387, 403) and dilated retinal vessels (#504, 566). At Test Week 103, there was an overall increased incidence in cataracts observed. Many of these cataracts were associated with aging and vitreal precipitates adhering to the posterior lens capsule. A statistically significant increase in the incidence of cataracts was seen for 175/100 mg/kg/day males but not for the females, although a dose response relationship was not apparent. At Test Week 103, it was not possible to dilate the pupils of one animal with miosis (#55) in order to evaluate the deep structures of the eyes. The orbital mass in animal #387 was still observed. With the possible exception of cataracts, all of the aforementioned observations occurred randomly with respect to control and treatment groups, and were not considered to be treatment-related.

C. Sue West, D.V.M.
Diplomate, American College
of Veterinary Ophthalmologists

Date 3-12-84

SEASO . HEREOCCUSIA ... LEGISCOCCUSIONINES COCCUSIONINES C

itudy Number L6121-7 est Article RDX pecies: B6C3F1 Mice

			OPHT	HALMIC IN	OPHTHALMIC INCIDENCE TABLE	ш				
			ns	MMARY -	SUMMARY - TEST WEEK 51					
					2000	(Rep/37/64) \$480	a.l			
			ΣΙ	Males				Famales	5 2	
	0]	7 1	32 0	00175.11	୍	7	0,1	22.0	
Ocular Dischange	6773	1771	ia ia	9.76	81.73	0775	6770	0/74	0/74	6/41
Conjunctivitis	0/73	0/71	1772	07.70	0738	07.70	6773	0/74	0/74	0/41
Phthys1s	0/73	0/71	0/72	0//0	95/0	0/75	1/73	1/74	0/74	1/41
Enophthelmia	6770	1/71	2/72	0//0	ac/2	6773	1/73	1/74	0/74	0/41
Corneal Scar	3/73	1/71	1772	2/70	2/38	0/75	2/73	2/74	6/74	3/41
Anterior Synechia	1/73	3/71	1/72	1/70	3/38	0/75	1/73	1/74	0/74	2/41
Posterior Synechia	2/73	3/71	1/72	1/70	0/38	0/75	2/73	0/74	0/74	0/41
Gataract	1/73	2/71	0/72	1/70	1/38	0/75	2/73	1/74	0/74	0/41
Inte Prolapse	1/73	0/71	9/72	0770	95/0	0/75	0/73	6/74	6/74	;; ;;
Bled - Orbital Sinus	20/73	18/71	20/72	19,76	86/8!	20/75	16/73	20/74	20174	25/41

@

OPHTHALMIC INCIDENCE TABLE SUMHARY - TEST WEEK 23

Dose (mg/kg/day)

							;			
				Male				1		
LEGION	c							S T PEL	3	
			7 0	0.55	125/100	9 %	1	7 0	25. 2	125/100
Orași an artistă										
egrecosiu Testos	0/84	1/83	2/84	0,784	•					
Conjunctivitis	0/84		Ċ		*6/1	0/83	0/83	0/85	0/83	0, 49
Enophthalmsa	0/84		, (i	0/94	0/34	0/83	0/63	0/83	0/83	0/49
Corneal Scar	2/84	20.0		0/84	2/34	0/83	1/85	0/85	0/R3	0/49
Anterior Synachia	1/84			2/84	2/34	0/83	2/83	2/83	0/83	3/49
Posterior Synechia	0/84			0/84	1/34	68/0	0/83	0/85	0/85	2/49
Cateract	0/84	0/83	0/84	984	0/34		1/89	0/83	0/83	0/49
Vitreal Hemorrhage	0/84	0/83	0/84		1/34		2/83	1/83	0/83	0/49
Bled - Orbital Sinus	20/84	20/83	20/R4	* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0/54	0/83	6870	0/83	0/85	1/49
) }		*0/0*	20/83	20/83	20/85	20/83	20/49

OPHTHALMIC INCIDENCE TABLE SUMMARY - TEST WEEK 78

Dose (mg/bg/day)

				Males				Females		
<u>LESION</u>	0 0	c	7 0	35 0	173/100	0 0	1	7.0	0	175/100
Ocular Discharge	90/0	1/37	2/38	0/54	1/25	0/63	07.60	1/63	0/61	0/30
Conjunctivitis	6670	0/57	1758	0/34	0/53	0/63	07/0	0/63	0/61	0/30
Phthys:s	0758	0/57	0/58	0/54	0/25	6/63	1760	1763	19/0	1/30
Enophthalmia	86/0	1/37	2/38	6/34	1/25	6/63	07.40	67/0	0/61	0/30
Keratitis	92/0	0/57	0/58	0/54	0/25	69/0	07/0	1763	0/61	06/0
Corneal Scar	4/58	2/37	2/38	2/34	1/25	64/0	1760	2/63	19/0	1/30
Anterior Synechia	9670	4/37	0/38	1/34	2/23	64/0	07.60	1763	0/61	0/30
Posterior Synechia	1/38	3/37	1/58	1/34	0/23	69/0	1760	69/0	19/0	06/0
Cataract	2/58	3/57	0/58	1/54	2/25	67/0	1760	69/0	19/0	0/30
Retinal Hemorrhage	1758	0/57	0/38	0/54	0/25	6470	07/60	64/0	0/61	07.30
Retinal Vascular Attenuation	92/0	1/57	82/0	0/34	0/23	6/63	0760	69/0	1761	07:30
Dilated Retinal Vessels	95/0	0/57	82/0	1/54	0/25	6/63	0760	0763	1/01	37.30
Orbital Mass	93.0	0/57	95.70	0/34	0/25	0/63	07.40	2/63	0/4:	3
Bled - Orbical Sinus	17758	18/87	20/58	17/54	16/25	19763	16/60	20/63	19/81	19, 30

@

٩

6

٥

٧

Study Number L4621-7 Test Article. HDX Species: B&C3F1 Mice

OPHTHALMIC INCIDENCE TABLE SUMMARY - TEST WEEK 103

Dose (my, 19/day)

			Males	51				Famelus		
NOISET	0	0	2 0	33 0	0017421	0	1	0	33 0	175,100
Ocular Discharje	0/47	1/42	1/42	9270	27/0	0/51	0/46	0/54	0.46	92/0
Buphthalmia/Erophthalmia	0/49	0/42	1/40	82/0	22/0	15/0	0/46	0/54	0/46	92/0
Phthysis	0/49	1/42	1/42	95/0	0/55	1/51	1/46	1/54	0/46	1/26
Enophthelmia	0/49	1/42	2/42	96/0	0/22	16/0	0/46	9070	0/46	0/26
Corneal Scar	4/49	0/42	3/42	2/38	3/22	2/21	95/4	9/34	1/46	1/26
Iritis/Anterior Uveitis Miosis	1/49	0/42	0/42	86/0	0/25	0/31	0/46	0/34	0/46	0/28
Anterior Synechia	1/49	2/42	0/42	1/38	2/25	1/21	3.46	1/34	0/46	0/26
Posterior Surschis	0/49	2/42	1/42	1/38	0/22	0/31	0/45	1/54	0/46	92/0
Prominent Lens Nucleus	0/49	0/42	0/42	92/0	0/22	0/51	0/46	1/34	0/46	92/0
Catarant	4/49	7/42	1/42	4/20	6/22	3/31	2/44	9/34	0/46	1/20
Vitreal Strands	0/49	0/42	0/42	92/0	0/22	2/51	0/46	0/34	0/46	0/20
Retinal Vascular Attenuation	1/49	1/42	2/42	92/0	22/0	0/51	0/46	0/54	1/46	92/0
Orbital Mass	0/49	0/42	0/42	96/0	0/22	0731	0/46	1/54	0/46	92/0
Bled - Orbital Sinus	19/49	20/42	16/42	12/38	14/22	17/51	18/46	17754	18/45	15/25

APPENDIX XI
PATHOLOGY NARRATIVE REPORT

REVISIONS TO THE FINAL PATHOLOGY REPORT

9

of Twenty-Four Month Chronic Toxicity-Carcinogenicity Study of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) in B6C3F1 Hybrid Mice

A reanalysis of histopatology data was carried out at the suggestion of the draft final report reviewers. The statistical significance resulted in changes of certain pathology findings. These changes are reported in the following revisions and are noted by underlining.

Histopathology

TWENTY-FOUR MONTH TERMINAL SACRIFICE

- o Microscopic examination of tissues from mice after the terminal sacrifice did not reveal stastically significant compound induced testicular degeneration at the 35 and 175/100 mg/kg/day dose levels (Table 44).
- o The statistically significant increase of the hepatocellular carcinomas was not observed in female mice (Tables 45 and 46).
- o Historical control data from the National Toxicology Program (NTP Pulletin No. 10) were also included in the analysis as the female concurrent control group demonstrated a low incidence of liver tumes. On reanalysis female mice receiving 35 mg/kg/day did not show a significant increase in hepatocarcinomas (Table 46).
- o The incidence of alveolar/bronchial carcinoma in male mice was not statistically significant at the 175/100 mg/kg/day dose level (Table 44).

SUMMARY AND CONCLUSIONS

- o Microscopic examination revealed a statistically significant increased incidence of combined hepatocellular adenomas and carcinomas in female mice for 7.0, 35.0 and 175/100 mg/kg/day dose levels which was a possible carcinogenic effect of RDX in the B6C3F1 strain when treated for twenty-four months.
- o In male mice testicular degeneration was considered to be induced by RDX at the 35 and 175/100 mg/kg/day dose levels, although the increased incidences were not statistically significant.
- o The occurence of combined alveolar-brorchial carcinoma/adenoma in male mice was not statistically significant at any dose level.

However, incidences of alveolar/bronchial carcinomas for male mice receiving 175/100 mg/kg/day were increased.

FINAL PATHOLOGY REPORT

of Twenty-four Month Chronic Toxicity-Carcinogenicity Study of Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) in B6C3F1 Hybrid Mice

March 25, 1984

IITRI Project Number L6121 Study Number 7

QUALITY ASSURANCE STATEMENT L6121 SN 7

Necropsy and histology procedures were inspected on January 1, August 4, and November 11, 1981; February 10, April 21, and November 29, 1982; and January 26, February 8, April 25 and May, 19, 1983. Draft Pathology Reports were audited January 21, May 3, and August 19 and 20, 1982; January 12 to 17, and October 6, 1983; and January 12 to 18, February 29 to March 2 and March 28 to 30, 1984. Inspections and audits were performed by Josephine M. Reed and Julie McPhilips. The study was found to meet Life Sciences Quality Assurance criteria. Specimens and raw data generated during the study will be retained in the IITRI Life Sciences Archives as specified in standard operating procedures.

Josephine M. Reed

Supervisor, Quality Assurance

TABLE OF CONTENTS

MATERIAL	AND METHODS	601			
1.	Gross Pathology	601			
2.	Histopathology	602			
PATHOLOGY RESULTS 6					
1.	Gross Observations	_			
	Six Month Observations	603			
2.	Histopathology	604			
	Six Month Interim Sacrifice	604			
3.	Summary and Conclusions	605			
PATHOLOGY APPENDIX I:					
Six	Month Interim Sacrifice	808			
	A Gross Pathology Table I	6 28 6 67			
PATHOLOGY APPENDIX II:					
Twe	lve Month Interim Sacrifice	673			
	A Gross Pathology Table II B Histopathology Incidence Tables C Incidence Comparison Tables	690			
PATHOLOG	Y APPENDIX III:	725			
Twenty-four Month Terminal Sacrifice					
	A Gross Pathology Table III A, III B	. 771 1153			

NAMES OF THE PROPERTY OF THE P

TABLE OF CONTENTS (Continued)

PATHOLOGY	APP:	ENDIX IV:	2		
Stati	isti	cal Evaluation	2		
	1.	Statistical Evaluation of Histopathologic Lesions MALE B6C3F1 HYBRID MOUSE - Table IV	2		
	2.	Statistical Evaluation of Histopathologic Lesions FEMALE B6C3F1 HYBRID MCUSE - Table V			
	3.	Statistical Evaluation of Histopathologic Lesions MALE B6C3F1 HYBRID MOUSE (LIVER, Adenoma and Carcinoma) - Table VI	8		
PATHOLOGY	APP	ENDIX V: 118	9		
Addendum - Histopathology Report - Lung Sections From 1.5. 7.0 and 35.0 mg/kg/day Dose Groups					

FINAL PATHOLOGY REPORT of Twenty-four Month Chronic Toxicity-Carcinogenicity Study of Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) in B6C3F1 Hybrid Mice

MATERIAL AND METHODS

In accordance with the amended experimental protocol gross and histopathologic examinations were performed on organs and tissues of B6C3F1 hybrid mice for IITRI Project L6121, Study Number 7.

The mice were divided into five groups, each consisting of 85 males and 85 females. Four of the five groups were each treated with different doses of HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE (RDX) for twenty-four months. The mice of the fifth group did not receive RDX and did serve as a control group. The group number, treatment, number of mice per group, and the corresponding dose levels are outlined below.

Treatment Group	Treatment	Number of Males	Number of Females	Dose Level mg/kg/day
I	-	85	85	0.0
II	RDX	85	85	1.5
III	RDX	85	85	7.0
IV	RDX	85	85	35.0
V	RDX	85	85	175.0/1.00*

^{*} Due to high mortality, dose level of 175 mg/kg was reduced for both sexes to 100 mg/kg, commencing on 4/20/81 (Week 11 of the Study).

In accordance with the experimental design, 10 mice per sex, per dose level were sacrificed after six months and twelve months of the study. All surviving mice were sacrificed after twenty-four months of the study.

1. Gross Pathology All mice were anesthetized by carbon dioxide inhalation and exanguinated from the orbital sinus or abominal aorta. Mice that died or were sacrificed moribund were also necropsied. At necropsy thoracic, abdominal, and cranial cavities of each mouse were opened and organs were examined and collected in buffered neutral 10% formalin. The lungs were fixed by intratracheal perfusion of formalin. Eyes were fixed in 3% glutaraldehyde, testes were fixed in Bouin's solution for 24 hours, and then placed in 70% ethanol before processing. The brain, heart, kidneys, liver, spleen, testes were weighed at necropsy before fixation except for spontaneous deaths and moribund sacrifices.

The following tissues were collected.

```
ovaries
    *brain (frontal, parietal, cerebellar) *pancreas
     *cecum
                                              pituitary
     *colon
                                              *prostate
    costobrondial junction, rib
                                              rectum
     *duodenum
                                             salivary gland
     *epididymes
                                              seminal vesicles
     *esophagus
                                             sciatic nerve
     *eye and optic nerves
                                              *skin/mammary gland
     gall ladder
                                             *spinal cord (cerival, thoracic,
     *heart
                                              lumbar)
     *ileum
                                              *spleen
     *ieiunum
                                              *sternum with marrow
     *kidneys
                                              *stomach
     *larvnx
                                              testes
     *liver
                                              thymus
     *lungs with mainstem bronchi
                                              *thyroids/parathyroids
     lymph nodes:
                                              *trachea
      mandibular
                                              *uterus
      *mesenteric
                                              *urinary bladder
     muscle, skeletal
                                              bone marrow smear
     nasal turbinates
                                              *tissue masses
and any other tissues with *gross lesions.
```

2. Histopathology Tissues marked with an asterisk from control and high dose level(175/100 mg/kg) were paraffin embedded, sectioned at 5 μ , stained with hematoxylin and eosin and examined microscopically. The liver, brain, spinal cord, kidneys, heart, spleen, gonads, lungs, gross lesions and tissue masses were examined microscopically for all remaining test mice.

The grading system and abbreviations used in the tables are as follows.

Grade 1 = minimal severity
Grade 2 = mild severity
Grade 3 = moderate severity
Grade 4 = marked severity
N = Within Normal Limits
M = Tissue Not Present
- = Tissue Not Applicable
P = Lesion Present, No Grade

Ś

PATHOLOGY RESULTS

1. Gross Observations A summary of gross observations is presented by group and sex for Six Month Interim Sacrifice, Pathology Appendix I - Table I; Twelve Month Interim Sacrifice, Pathology Appendix II - Table II; and Twenty-Four Month Terminal Sacrifice, Pathology Appendix III - Tables IIIA and IIIE.

SIX MONTH OBSERVATIONS - TABLE I

There was fighting among the male mice, especially at the 175/100 mg/kg/day dosage level. This fighting induced damage to external genitalia and induced skin lesions. These lesions were considered to be only secondary to the compound administration. Crusty and dark red skin was observed at these fighting wounds.

Thirty male and 36 female mice that died during the first six months of the study at the 175/100 mg/kg/day dose level had dark red mottled lungs, dark red spleen and dark red liver. Distended with red, yellow and brown fluid urinary bladder was observed in 14/39 male mice at the 175/100 mg/kg/day dose level. These lesions observed at necropsy were considered to be induced by the RDX administration.

TWELVE MONTH OBSERVATIONS - TABLE II

Mice that died or were sacrificed moribund between six and twelve months and all mice that were sacrificed at twelve month interim period and were treated with RDX did not have lesions observed at necropsy in greater frequency than those observed in the control group.

TWENTY-FOUR MONTH TERMINAL SACRIFICE - TABLE III A, III B

Lesions observed at necropsy in mice that died spontaneously or those sacrificed as moribund between twelve and twenty-four months are present in Fathology Appendix III in Tables IIIA and IIIB. Mice which were treated with RDX when compared with the control group, appear to have higher incidences of liver nodules or masses and enlarged livers than the control group.

Gross observations at terminal sacrifice are presented in Table III B. Lesions observed at necropsy in female mice as liver nodules or masses appear to occur in higher incidences in RDX treated female mice which was probably related to the compound administration.

All other lesions observed at necropsy at six month interim sacrifices, twelve month sacrifice and in mice that were sacrificed at the twenty-four month of the study and all mice that died spontaneously or were sacrificed as moribund during the study were considered to be spontaneously occurring inflammatory, degenerative and/or neoplastic lesions which are commonly observed in this strain of mice and were considered to be unrelated to the administration of RDX.

SIX MONTH INTERIM SACRIFICE

Microscopic examination of tissues from mice sacrificed after six months, mice that died spontaneously or were sacrificed moribund during this study period, revealed renal tubular cytoplasmic vacuolization in male mice at all dose levels. Renal tubular cytoplasmic vacuolization was seen in one control mouse, 10 mice receiving 1.5 mg/kg/day, 12 mice receiving 7.0 mg/kg/day, 11 mice receiving 35.0 mg/kg/day and 12 mice receiving 175/100 mg/kg/day. In this lesion, single or multiple sharply delineated cytoplasmic vacuoles were found in renal tubular epithelium. Renal tubular cytoplasmic vacuolization was considered to be compoundinduced at six month interim sacrifice but was not considered to be RDX-induced at the twelve month interim sacrifice and at the twenty-four month terminal sacrifice. There was excessive fighting in male mice causing cutaneous trauma and an increased incidence of dermatitis in male mice. This increased incidence of skin lesions is a secondary compound effect.

TWELVE MONTH INTERIM SACRIFICE

No compound-related microscopic lesions were observed in male and female mice sacrificed after twelve months of the study, mice that died spontaneously nor in mice which were sacrificed moribund. The increased incidence of dermal lesions reflects compound-induced behavioral changes (fighting wounds) rather than specific effects on the skin as a target organ.

TWENTY-FOUR MONTH TERMINAL SACRIFICE

Microscopic examination of tissues from mice after the terminal sacrifice revealed statistically significant (at p < 0.05) compound-induced testicular degeneration at the 35 and 175/100 mg/kg/day dose level (Pathology Appendix IV - Table IV). There was necrosis of germinal epithelium, interstitial fibrosis and aspermia in male mice. The statistically significant increase of the hepatocellular adenoma/carcinoma was observed in female mice at the 7.1, 35, and 175/100 mg/kg/day dose level (Pathology Appendix IV - Tables V and VI). Chronic dermatitis observed in male mice was a compound-induced hyperesthesia and fight-induced dermal lesion.

Historical control data from the National Toxicology Program (NTP Bulletin #10) were therefore included in the analyses as the female concurrent control group demonstrated a low incidence of liver tumors. When this was performed (Pathology Appendix IV - Table VI) female mice receiving 35 mg/kg/day still showed a significant increase in hepatocarcinomas. A p value of ≈ 0.09 was, however, seen for 175/100 mg/kg/day-treated females when compared to historical controls. The small number of surviving animals in this high dose group (31) compared to 60-65 for the other groups may have contributed to this statistic as the actual incidence (9.7%) was greater than that seen at 35 mg/kg/day (9.4%). When combined adenoma/carcinoma data were analyzed, statistically significant increases were observed for both 35 and 175,100 mg/kg/day females compared to either concurrent or historical control data. This was apparent even though concurrent controls had a significantly lower incidence than historical controls. The data therefore suggest that RDX is a suspect carcinogen.

The incidence of alveolar/bronchiolar carcinoma in male mice (Pathology Appendix IV - Table IV) was statistically significant only at the 175/100 mg/kg/day dose level.

All other lesions observed microscopically in tissues from the twenty-four month chronic toxicity/carcinogenicity study of KEXAHYDRO-1,3,5-TRINITRO-1,2,5-TRIAZINE (RDX) were considered spontaneous, naturally occuring degenerative, inflammatory and/or neoplastic diseases which commonly occur in an aging mouse population of the B6C3F1 strain (see References 1 and 2).

SUMMARY AND CONCLUSIONS

CLANTAL CALCAL C

Gross lesions observed at six months of the study for the 175/100 mg/kg/day dosage level as red lungs, dark red spleen, dark red liver, distended with red fluid urinary bladder were considered to be induced by RDX. Compound-related lesions observed in kidneys for male mice as renal tubular cytoplasmic vacuolization (Six Month Interim Report) at all dosage levels was not observed in male mice at the Twelve Month nor the Twenty-four Month Histopathologic Examination at any dosage level. Increased incidence of dermatitis in male mice was considered to be a secondary compound effect.

No compound-related gross nor histopathologic lesions were observed at the Twelve Month Interim Sacrifice. The increased incidence of dermal lesions during this study period reflect compound-induced behavioral changes (fighting wounds) rather than specific effects on the skin as a target organ.

Lesions observed at necropsy at the terminal sacrifice for female mice as liver nodules and masses were considered to be compound-induced. Microscopic examination revealed statistically significant increased incidence of hepatocellular adenomas and carcinomas in female mice for 7.0, 35.0, and 175/100 mg/kg/day dose levels which was a carcinogenic effect of RDX in the B6C3F1 strain when treated for twenty-four months. In male mice testicular degeneration was considered to be induced by RDX at the 35 and 175/100 mg/kg/day dosage levels. The occurrence of combined alveolar-bronchial carcinoma/adenoma in male mice was statistically significant (at p < 0.05) only at the 175/100 mg/kg/day dose level.

On the basis of compound-induced histopathologic lesions observed in this study, no effect levels for RDX in B6C3F1 Hybrid Mice were 7.0~mg/kg/day for male mice and 1.5~mg/kg/day dose level for female mice.

Vladislava S. Rac, D.V.M., M.S.

Head, Pathology Pathology Section Life Sciences Pass

Life Sciences Research

DISTRIBUTION LIST

25	copies	Commander ATTN: SGRD-UBG U.S. Army Medical Bioengineering Research and Development Laboratory Fort Detrick, Frederick, MD 21701-5010
4	copies	Commander U.S. Army Medical Research and Development Command ATTN: SGRD-RMS Fort Detrick, Frederick, MD 21701-5012
12	copies	Defense Technical Information Center (DTIC) ATTN: DTIC-DDAC Cameron Station Alexandria, VA 22304-6145
1	сору	Dean School of Medicine Uniformed Services University of the Health Sciences 4301 Jones Bridge Road Bethesda, MD 20814-4799
1	сору	Commandant Academy of Health Sciences, U.S. Army ATTN: AHS-CDM Fort Sam Houston, TX 78234-6100
1	сору	Commander U.S. Army Medical Bioengineering Research and Development Laboratory ATTN: SGRD-UBD-A/Librarian Fort Detrick, Frederick, MD 21701-5010